Drug,Indication,TA_ID,Search_Term,SNOMEDCode,SNOMEDDescription,CleanedDrugName,PrimaryDirectorate,AllDirectorates
ABATACEPT,Psoriatic arthritis after DMARDs,TA568,psoriatic arthritis,156370009,Psoriatic arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ABATACEPT,Psoriatic arthritis after DMARDs,TA568,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ABATACEPT,Psoriatic arthritis after DMARDs,TA568,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ABATACEPT,Psoriatic arthritis after DMARDs,TA568,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ABATACEPT,Psoriatic arthritis after DMARDs,TA568,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ABATACEPT,Psoriatic arthritis after DMARDs,TA568,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT,Rheumatoid arthritis,TA141,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),"Rheumatoid arthritis that has responded inadequately to one or more conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA234,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT IN COMBINATION WITH METHOTREXATE (2ND LINE),Treatment of moderate to severe active rheumatoid arthritis after one or more conventional non-biological disease-modifying anti-rheumatic drugs including methotrexate,TA280,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATACEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ABATECEPT,Treating juvenile idiopathic arthritis,TA373,juvenile idiopathic arthritis,410798004,Oligoarticular juvenile idiopathic arthritis,ABATECEPT,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS
ABATECEPT,Treating juvenile idiopathic arthritis,TA373,juvenile idiopathic arthritis,16044751000119106,"Juvenile idiopathic arthritis, polyarthritis",ABATECEPT,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS
ABCIXIMAB,Acute coronary syndromes,TA047,acute coronary syndrome,837091000000100,H/O acute coronary syndrome,ABCIXIMAB,CARDIOLOGY,CARDIOLOGY
ABCIXIMAB (INTRAVENOUS),Acute coronary syndromes,TA012,acute coronary syndrome,837091000000100,H/O acute coronary syndrome,ABCIXIMAB,CARDIOLOGY,CARDIOLOGY
ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,134405005,Suspected breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,160287004,FH: Breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,268547008,Screening for breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,429740004,Family history of breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,706970001,TNBC - Triple-negative breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,94361000000105,Breast cancer detected by national screening programme,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,838351000000107,Education about risk of breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,874291000000100,QCancer breast cancer risk,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA579,breast cancer,1035841000000108,Lymphoedema following breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,134405005,Suspected breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,160287004,FH: Breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,268547008,Screening for breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,429740004,Family history of breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,706970001,TNBC - Triple-negative breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,94361000000105,Breast cancer detected by national screening programme,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,838351000000107,Education about risk of breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,874291000000100,QCancer breast cancer risk,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB,"Hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as initial endocrine-based therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist",TA563,breast cancer,1035841000000108,Lymphoedema following breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,134405005,Suspected breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,160287004,FH: Breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,hormone receptor,237521008,Hypothyroidism due to thyroid stimulating hormone receptor blocking antibody,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,268547008,Screening for breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,hormone receptor,417742002,Hormone receptor positive tumour,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,429740004,Family history of breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,hormone receptor,438628005,Hormone receptor negative tumour,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,706970001,TNBC - Triple-negative breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,94361000000105,Breast cancer detected by national screening programme,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,hormone receptor,310871000000100,Tumour hormone receptor status,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,838351000000107,Education about risk of breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,874291000000100,QCancer breast cancer risk,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH ENDOCRINE THERAPY,"Adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence",TA810,breast cancer,1035841000000108,Lymphoedema following breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,134405005,Suspected breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,160287004,FH: Breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,268547008,Screening for breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,429740004,Family history of breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,706970001,TNBC - Triple-negative breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,94361000000105,Breast cancer detected by national screening programme,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,838351000000107,Education about risk of breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,874291000000100,QCancer breast cancer risk,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABEMACICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA725,breast cancer,1035841000000108,Lymphoedema following breast cancer,ABEMACICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ABIRATERONE,Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer,TA721,prostate cancer,315268008,Suspected prostate cancer,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE,Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer,TA721,prostate cancer,428262008,H/O: prostate cancer,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE,Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer,TA721,prostate cancer,698470001,Advice given about prostate cancer screening,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE,Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer,TA721,prostate cancer,712837004,Active surveillance of prostate cancer,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE,Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer,TA721,prostate cancer,720007002,Prostate cancer care review,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE,Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer,TA721,prostate cancer,31011000119107,Prostate cancer screening declined,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE,Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer,TA721,prostate cancer,874211000000109,QCancer prostate cancer risk,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE,Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer,TA721,prostate cancer,878401000000104,No FH of prostate cancer,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE,Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer,TA721,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE,Newly diagnosed high-risk hormone-sensitive metastatic prostate cancer,TA721,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE),Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen,TA259,prostate cancer,315268008,Suspected prostate cancer,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE),Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen,TA259,prostate cancer,428262008,H/O: prostate cancer,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE),Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen,TA259,prostate cancer,698470001,Advice given about prostate cancer screening,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE),Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen,TA259,prostate cancer,712837004,Active surveillance of prostate cancer,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE),Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen,TA259,prostate cancer,720007002,Prostate cancer care review,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE),Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen,TA259,prostate cancer,31011000119107,Prostate cancer screening declined,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE),Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen,TA259,prostate cancer,874211000000109,QCancer prostate cancer risk,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE),Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen,TA259,prostate cancer,878401000000104,No FH of prostate cancer,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE),Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen,TA259,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE IN COMBINATION WITH PREDNISOLONE OR PREDNISONE (2ND LINE),Treatment of castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen,TA259,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy,TA387,prostate cancer,315268008,Suspected prostate cancer,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy,TA387,prostate cancer,428262008,H/O: prostate cancer,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy,TA387,prostate cancer,698470001,Advice given about prostate cancer screening,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy,TA387,prostate cancer,712837004,Active surveillance of prostate cancer,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy,TA387,prostate cancer,720007002,Prostate cancer care review,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy,TA387,prostate cancer,31011000119107,Prostate cancer screening declined,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy,TA387,prostate cancer,874211000000109,QCancer prostate cancer risk,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy,TA387,prostate cancer,878401000000104,No FH of prostate cancer,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy,TA387,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABIRATERONE IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy,TA387,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,ABIRATERONE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ABROCITINIB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
ABROCITINIB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238543002,Discoid atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
ABROCITINIB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
ABROCITINIB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238545009,Follicular atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
ABROCITINIB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
ABROCITINIB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
ACALABRUTINIB,Chronic lymphocytic leukaemia,TA689,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,ACALABRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
ACALABRUTINIB,Chronic lymphocytic leukaemia,TA689,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,ACALABRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
ACALABRUTINIB,Chronic lymphocytic leukaemia,TA689,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,ACALABRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
ACALABRUTINIB,Chronic lymphocytic leukaemia,TA689,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,ACALABRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
ACALABRUTINIB,Chronic lymphocytic leukaemia,TA689,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,ACALABRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
ACALABRUTINIB,Chronic lymphocytic leukaemia,TA689,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,ACALABRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
ACALABRUTINIB,Chronic lymphocytic leukaemia,TA689,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,ACALABRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
ACALABRUTINIB,Chronic lymphocytic leukaemia,TA689,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,ACALABRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
ADALIMUMAB,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,162930007,On examination - ankylosing spondylitis chest deformity,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ADALIMUMAB,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,239805001,Juvenile ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ADALIMUMAB,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,239810002,Ankylosing spondylitis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ADALIMUMAB,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,239811003,Ankylosing spondylitis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ADALIMUMAB,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,394990003,Family history: Ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ADALIMUMAB,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,429712009,Bath Ankylosing Spondylitis Disease Activity Index,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ADALIMUMAB,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,441562009,Bath Ankylosing Spondylitis Disease Activity Index score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ADALIMUMAB,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,441680005,BASFI (Bath Ankylosing Spondylitis Functional Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ADALIMUMAB,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,441930001,BASMI (Bath Ankylosing Spondylitis Metrology Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ADALIMUMAB,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,axial spondyloarthritis,723116002,Axial spondyloarthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,4927003,Acute anterior uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,11226001,Fuchs uveitis syndrome,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,43363007,Posterior uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,75614007,Panuveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,89114005,Infectious anterior uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,95707009,Phacotoxic uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,267619000,Non-infectious anterior uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,312922007,Uveitis related cystoid macular oedema,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,314029000,Tuberculous uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,314030005,Post-traumatic uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,314033007,Secondary open-angle glaucoma with uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,314493000,Postoperative uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,370506009,Keratouveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,398155003,Chronic anterior uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,410494003,Phacoantigenic uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,410692006,Anterior uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
ADALIMUMAB,Non-infectious uveitis,TA460,uveitis,342151000119100,Acute anterior uveitis of left eye,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
ADALIMUMAB,Plaque psoriasis,TA146,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),ADALIMUMAB,DERMATOLOGY,DERMATOLOGY
ADALIMUMAB,Plaque psoriasis,TA146,plaque psoriasis,402307000,Chronic large plaque psoriasis,ADALIMUMAB,DERMATOLOGY,DERMATOLOGY
ADALIMUMAB,Plaque psoriasis,TA146,plaque psoriasis,402310007,Chronic stable plaque psoriasis,ADALIMUMAB,DERMATOLOGY,DERMATOLOGY
ADALIMUMAB,Plaque psoriasis in children and young people,TA455,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),ADALIMUMAB,DERMATOLOGY,DERMATOLOGY
ADALIMUMAB,Plaque psoriasis in children and young people,TA455,plaque psoriasis,402307000,Chronic large plaque psoriasis,ADALIMUMAB,DERMATOLOGY,DERMATOLOGY
ADALIMUMAB,Plaque psoriasis in children and young people,TA455,plaque psoriasis,402310007,Chronic stable plaque psoriasis,ADALIMUMAB,DERMATOLOGY,DERMATOLOGY
ADALIMUMAB,Psoriatic arthritis,TA125,psoriatic arthritis,156370009,Psoriatic arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ADALIMUMAB,Psoriatic arthritis,TA199,psoriatic arthritis,156370009,Psoriatic arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ADALIMUMAB,Psoriatic arthritis,TA125,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ADALIMUMAB,Psoriatic arthritis,TA199,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ADALIMUMAB,Psoriatic arthritis,TA125,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ADALIMUMAB,Psoriatic arthritis,TA199,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ADALIMUMAB,Psoriatic arthritis,TA125,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ADALIMUMAB,Psoriatic arthritis,TA199,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ADALIMUMAB,Psoriatic arthritis,TA125,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ADALIMUMAB,Psoriatic arthritis,TA199,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ADALIMUMAB,Psoriatic arthritis,TA125,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ADALIMUMAB,Psoriatic arthritis,TA199,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB,Severe active Crohn's disease (adults),TA187,crohn's disease,196578009,Oral Crohn's disease,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
ADALIMUMAB,Severe active Crohn's disease (adults),TA187,crohn's disease,196578009,Oral Crohn's disease,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
ADALIMUMAB,Severe active Crohn's disease (adults),TA187,crohn's disease,273364009,Crohn's Disease Activity Index,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
ADALIMUMAB,Severe active Crohn's disease (adults),TA187,crohn's disease,273364009,Crohn's Disease Activity Index,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
ADALIMUMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,162930007,On examination - ankylosing spondylitis chest deformity,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ADALIMUMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,239805001,Juvenile ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ADALIMUMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,239810002,Ankylosing spondylitis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ADALIMUMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,239811003,Ankylosing spondylitis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ADALIMUMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,394990003,Family history: Ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ADALIMUMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,429712009,Bath Ankylosing Spondylitis Disease Activity Index,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ADALIMUMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,441562009,Bath Ankylosing Spondylitis Disease Activity Index score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ADALIMUMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,441680005,BASFI (Bath Ankylosing Spondylitis Functional Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ADALIMUMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,441930001,BASMI (Bath Ankylosing Spondylitis Metrology Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ADALIMUMAB,Treating juvenile idiopathic arthritis,TA373,juvenile idiopathic arthritis,410798004,Oligoarticular juvenile idiopathic arthritis,ABATECEPT,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS
ADALIMUMAB,Treating juvenile idiopathic arthritis,TA373,juvenile idiopathic arthritis,16044751000119106,"Juvenile idiopathic arthritis, polyarthritis",ABATECEPT,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS
ADALIMUMAB,Treatment of moderate to severe ulcerative colitis,TA262,ulcerative colitis,64766004,UC - ulcerative colitis,ADALIMUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
ADALIMUMAB,Treatment of moderate to severe ulcerative colitis,TA262,ulcerative colitis,160383003,FH: Ulcerative colitis,ADALIMUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
ADALIMUMAB,Treatment of moderate to severe ulcerative colitis,TA262,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,ADALIMUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
ADALIMUMAB,Treatment of moderate to severe ulcerative colitis,TA262,ulcerative colitis,275129008,Family history of ulcerative colitis,ADALIMUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
ADALIMUMAB,Treatment of moderate to severe ulcerative colitis,TA262,ulcerative colitis,275549008,History of ulcerative colitis,ADALIMUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
ADALIMUMAB,Treatment of moderate to severe ulcerative colitis,TA262,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,ADALIMUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
ADALIMUMAB,Treatment of moderate to severe ulcerative colitis,TA262,ulcerative colitis,445243001,Left sided ulcerative colitis,ADALIMUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
ADALIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,64766004,UC - ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
ADALIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,160383003,FH: Ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
ADALIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
ADALIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,275129008,Family history of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
ADALIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,275549008,History of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
ADALIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
ADALIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,445243001,Left sided ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADALIMUMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,16584000,Administration of vaccine product containing only Hepatitis B virus antigen,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,17627009,Hepatitis B e antigen Ab,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,22290004,Hepatitis B virus surface antigen,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,47758006,Hepatitis B surface antigen level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,61977001,Chronic viral hepatitis B,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,76795007,Acute hepatitis B,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,81665004,Hepatitis B virus,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,82409003,Hepatitis B core antigen Ab,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,82645009,Hepatitis B virus surface antigen Ab,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,116800003,Hepatitis B Virus immune globulin administration,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,122450004,Hepatitis B virus antibody,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,161638000,Hepatitis B Occupational risk,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,165806002,Hepatitis B surface antigen positive,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,165807006,Hepatitis Be antigen present,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,165808001,Hepatitis B non-immune,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,170370000,First hepatitis B immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,170371001,Administration of second dose of hepatitis B vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,170372008,Third hepatitis B immunisation,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,170373003,Hepatitis B booster vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,170374009,Fourth hepatitis B immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,170375005,Administration of fifth dose of hepatitis B vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,170436000,Administration of third dose of vaccine product containing only Hepatitis A and Hepatitis B virus antigens,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,170542003,Requires course of hepatitis B vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,171122006,Hepatitis B screening,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,171123001,Hepatitis B screening required,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,186626002,Acute hepatitis B with delta-agent (coinfection) without hepatic coma,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,192723002,Post hepatitis B vaccination encephalitis,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,235871004,Hepatitis B carrier,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,268504008,Anti-hepatitis B immunoglobulin given,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,271511000,Hepatitis B immune,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,278969009,Hepatitis B status,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,293110008,Adverse reaction to component of vaccine product containing Hepatitis B virus antigen,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,294637001,Hepatitis B immunoglobulin allergy,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,294646007,Hepatitis B vaccine allergy,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,303233001,Antigen of Hepatitis B virus,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,313234004,Hepatitis B antibody present,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,406010001,Hepatitis B surface antigen not detected,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,408778004,Hepatitis B vaccination declined,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,416923003,Sixth hepatitis B immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,425569004,Hepatitis B immunization recommended,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,426519003,History of two doses hepatitis B vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,426980004,History of one dose of hepatitis B vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,427390007,History of hepatitis B vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,429203008,History of three hepatitis B vaccinations,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,429721005,History of hepatitis B,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,698604002,Hepatitis B outbreak education,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,699037006,Hepatitis B vaccination contraindicated,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,707287001,Hepatitis B vaccination not indicated,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,736687002,Hepatitis B core antibody detected,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,736693005,Hepatitis B core antibody negative,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,736699009,Requires hepatitis B booster,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,198041000000109,Hepatitis B vaccination refused,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,201591000000101,Advice on hepatitis B vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,202271000000108,Hepatitis B screening declined,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,204681000000104,Hepatitis B screening counselling,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,221021000000103,Hepatitis B treatment drugs Band 1,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,356121000000100,Hepatitis B screening positive,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,362851000000109,Hepatitis B screening negative,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,835791000000107,Hepatitis B vaccination invitation,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,835811000000108,Hepatitis B vaccination invitation first letter,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,835831000000100,Hepatitis B vaccination invitation second letter,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,835851000000107,Hepatitis B vaccination invitation third letter,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,835871000000103,Hepatitis B vaccination verbal invitation,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,839711000000101,Hepatitis B vaccination not offered,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,846421000000105,Hepatitis B screening not offered,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,865061000000108,First hepatitis B junior vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,865081000000104,Second hepatitis B junior vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,865101000000105,Third hepatitis B junior vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,865121000000101,Fourth hepatitis B junior vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,991971000000109,Hepatitis B immunity test,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,991981000000106,Hepatitis B core antigen test,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,991991000000108,Hepatitis B e antigen test,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,995941000000101,Anti HBc (hepatitis B core) IgG level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1008441000000106,Hepatitis B deoxyribonucleic acid detection assay,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1008791000000106,HBsAg (hepatitis B surface antigen) antibody level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1009271000000109,Hepatitis B screening test,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1014201000000102,Hepatitis B surface antibody level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1014211000000100,Hepatitis B surface antigen level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1014231000000108,Hepatitis B core antibody level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1014241000000104,Hepatitis B e antibody level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1028341000000105,Hepatitis B antigen screening,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1037211000000101,First hepatitis B vaccination given by other healthcare provider,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1037231000000109,Second hepatitis B vaccination given by other healthcare provider,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1060591000000103,Hepatitis B resolved,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1091701000000105,At risk of hepatitis B infection,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,1107691000000105,Hepatitis B screening offered,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL,Hepatitis B (chronic),TA096,hepatitis b,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,16584000,Administration of vaccine product containing only Hepatitis B virus antigen,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,17627009,Hepatitis B e antigen Ab,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,22290004,Hepatitis B virus surface antigen,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,47758006,Hepatitis B surface antigen level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,61977001,Chronic viral hepatitis B,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,76795007,Acute hepatitis B,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,81665004,Hepatitis B virus,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,82409003,Hepatitis B core antigen Ab,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,82645009,Hepatitis B virus surface antigen Ab,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,116800003,Hepatitis B Virus immune globulin administration,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,122450004,Hepatitis B virus antibody,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,161638000,Hepatitis B Occupational risk,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,165806002,Hepatitis B surface antigen positive,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,165807006,Hepatitis Be antigen present,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,165808001,Hepatitis B non-immune,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,170370000,First hepatitis B immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,170371001,Administration of second dose of hepatitis B vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,170372008,Third hepatitis B immunisation,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,170373003,Hepatitis B booster vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,170374009,Fourth hepatitis B immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,170375005,Administration of fifth dose of hepatitis B vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,170436000,Administration of third dose of vaccine product containing only Hepatitis A and Hepatitis B virus antigens,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,170542003,Requires course of hepatitis B vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,171122006,Hepatitis B screening,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,171123001,Hepatitis B screening required,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,186626002,Acute hepatitis B with delta-agent (coinfection) without hepatic coma,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,192723002,Post hepatitis B vaccination encephalitis,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,235871004,Hepatitis B carrier,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,268504008,Anti-hepatitis B immunoglobulin given,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,271511000,Hepatitis B immune,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,278969009,Hepatitis B status,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,293110008,Adverse reaction to component of vaccine product containing Hepatitis B virus antigen,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,294637001,Hepatitis B immunoglobulin allergy,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,294646007,Hepatitis B vaccine allergy,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,303233001,Antigen of Hepatitis B virus,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,313234004,Hepatitis B antibody present,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,406010001,Hepatitis B surface antigen not detected,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,408778004,Hepatitis B vaccination declined,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,416923003,Sixth hepatitis B immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,425569004,Hepatitis B immunization recommended,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,426519003,History of two doses hepatitis B vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,426980004,History of one dose of hepatitis B vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,427390007,History of hepatitis B vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,429203008,History of three hepatitis B vaccinations,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,429721005,History of hepatitis B,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,698604002,Hepatitis B outbreak education,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,699037006,Hepatitis B vaccination contraindicated,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,707287001,Hepatitis B vaccination not indicated,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,736687002,Hepatitis B core antibody detected,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,736693005,Hepatitis B core antibody negative,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,736699009,Requires hepatitis B booster,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,198041000000109,Hepatitis B vaccination refused,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,201591000000101,Advice on hepatitis B vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,202271000000108,Hepatitis B screening declined,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,204681000000104,Hepatitis B screening counselling,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,221021000000103,Hepatitis B treatment drugs Band 1,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,356121000000100,Hepatitis B screening positive,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,362851000000109,Hepatitis B screening negative,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,835791000000107,Hepatitis B vaccination invitation,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,835811000000108,Hepatitis B vaccination invitation first letter,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,835831000000100,Hepatitis B vaccination invitation second letter,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,835851000000107,Hepatitis B vaccination invitation third letter,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,835871000000103,Hepatitis B vaccination verbal invitation,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,839711000000101,Hepatitis B vaccination not offered,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,846421000000105,Hepatitis B screening not offered,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,865061000000108,First hepatitis B junior vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,865081000000104,Second hepatitis B junior vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,865101000000105,Third hepatitis B junior vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,865121000000101,Fourth hepatitis B junior vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,991971000000109,Hepatitis B immunity test,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,991981000000106,Hepatitis B core antigen test,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,991991000000108,Hepatitis B e antigen test,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,995941000000101,Anti HBc (hepatitis B core) IgG level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1008441000000106,Hepatitis B deoxyribonucleic acid detection assay,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1008791000000106,HBsAg (hepatitis B surface antigen) antibody level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1009271000000109,Hepatitis B screening test,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1014201000000102,Hepatitis B surface antibody level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1014211000000100,Hepatitis B surface antigen level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1014231000000108,Hepatitis B core antibody level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1014241000000104,Hepatitis B e antibody level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1028341000000105,Hepatitis B antigen screening,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1037211000000101,First hepatitis B vaccination given by other healthcare provider,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1037231000000109,Second hepatitis B vaccination given by other healthcare provider,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1060591000000103,Hepatitis B resolved,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1091701000000105,At risk of hepatitis B infection,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,1107691000000105,Hepatitis B screening offered,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ADEFOVIR DIPIVOXIL IN COMBINATION WITH LAMIVUDINE,Hepatitis B (chronic),TA096,hepatitis b,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,162573006,Suspected lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,254637007,Non-small cell lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,275981009,Lung cancer screening,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,429011007,Family history of lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,877691000000107,No FH of lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Advanced squamous non-small-cell lung cancer after platinum-based chemotherapy,TA444,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,162573006,Suspected lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,254637007,Non-small cell lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,275981009,Lung cancer screening,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,429011007,Family history of lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,877691000000107,No FH of lung cancer,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFATINIB,Epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer,TA310,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",AFATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AFLIBERCEPT,Choroidal neovascularisation,TA486,choroidal neovascularisation,733124000,Myopic choroidal neovascularisation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT,Choroidal neovascularisation,TA486,choroidal neovascularisation,380621000000102,Subfoveal choroidal neovascularisation drugs Band 1,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,macular oedema,37231002,Macular oedema,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,retinal vein occlusion,232038007,Central retinal vein occlusion with neovascularization,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,macular oedema,232039004,Central retinal vein occlusion with macular oedema,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,retinal vein occlusion,232042005,Macular edema due to juvenile central retinal vein occlusion,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,macular oedema,232045007,Macular oedema due to hemispheric retinal vein occlusion,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,retinal vein occlusion,232045007,Macular oedema due to hemispheric retinal vein occlusion,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,macular oedema,312911008,CSME - clinically significant macular oedema,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,macular oedema,312912001,Macular oedema due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,macular oedema,312920004,Postoperative cystoid macular oedema,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,macular oedema,312921000,Autosomal dominant cystoid macular oedema,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,macular oedema,312922007,Uveitis related cystoid macular oedema,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,macular oedema,769218003,Macular oedema of left eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,macular oedema,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT,Treating visual impairment caused by macular oedema after branch retinal vein occlusion,TA409,macular oedema,895021000000102,Macular oedema drugs Band 1,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,macular oedema,37231002,Macular oedema,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,retinal vein occlusion,232038007,Central retinal vein occlusion with neovascularization,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,macular oedema,232039004,Central retinal vein occlusion with macular oedema,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,retinal vein occlusion,232042005,Macular edema due to juvenile central retinal vein occlusion,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,macular oedema,232045007,Macular oedema due to hemispheric retinal vein occlusion,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,retinal vein occlusion,232045007,Macular oedema due to hemispheric retinal vein occlusion,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,macular oedema,312911008,CSME - clinically significant macular oedema,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,macular oedema,312912001,Macular oedema due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,macular oedema,312920004,Postoperative cystoid macular oedema,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,macular oedema,312921000,Autosomal dominant cystoid macular oedema,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,macular oedema,312922007,Uveitis related cystoid macular oedema,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,macular oedema,769218003,Macular oedema of left eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,macular oedema,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT SOLUTION FOR INJECTION,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA305,macular oedema,895021000000102,Macular oedema drugs Band 1,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT SOLUTION FOR INJECTION,Wet age‑related macular degeneration,TA294,macular degeneration,70099003,Familial juvenile macular degeneration syndrome,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT SOLUTION FOR INJECTION,Wet age‑related macular degeneration,TA294,macular degeneration,193384000,Senile macular degeneration,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT SOLUTION FOR INJECTION,Wet age‑related macular degeneration,TA294,macular degeneration,267718000,Age-related macular degeneration,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT SOLUTION FOR INJECTION,Wet age‑related macular degeneration,TA294,macular degeneration,312898002,Myopic macular degeneration,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT SOLUTION FOR INJECTION,Wet age‑related macular degeneration,TA294,macular degeneration,314427006,Drusen plus pigment change stage macular degeneration,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AFLIBERCEPT SOLUTION FOR INJECTION,Wet age‑related macular degeneration,TA294,macular degeneration,1296526000,Disciform macular degeneration,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
AGOMELATINE,Major depressive episodes,TA231,major depressive episodes,191610000,"Recurrent major depressive episodes, mild",AGOMELATINE,MENTAL HEALTH,MENTAL HEALTH
AGOMELATINE,Major depressive episodes,TA231,major depressive episodes,191611001,"Recurrent major depressive episodes, moderate",AGOMELATINE,MENTAL HEALTH,MENTAL HEALTH
AGOMELATINE,Major depressive episodes,TA231,major depressive episodes,191613003,"Recurrent major depressive episodes, severe, with psychosis",AGOMELATINE,MENTAL HEALTH,MENTAL HEALTH
AGOMELATINE,Major depressive episodes,TA231,major depressive episodes,268621008,Recurrent major depressive episodes,AGOMELATINE,MENTAL HEALTH,MENTAL HEALTH
AGOMELATINE,Major depressive episodes,TA231,major depressive episodes,755331000000108,"Recurrent major depressive episodes, severe, with psychosis, psychosis in remission",AGOMELATINE,MENTAL HEALTH,MENTAL HEALTH
AGOMELATINE,Major depressive episodes,TA231,major depressive episodes,764611000000100,"Recurrent major depressive episodes, severe",AGOMELATINE,MENTAL HEALTH,MENTAL HEALTH
AGOMELATINE,Major depressive episodes,TA231,major depressive episodes,764691000000109,"Recurrent major depressive episodes, in partial remission",AGOMELATINE,MENTAL HEALTH,MENTAL HEALTH
ALCLOMETASONE DIPROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
ALCLOMETASONE DIPROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
ALCLOMETASONE DIPROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
ALCLOMETASONE DIPROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
ALCLOMETASONE DIPROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
ALCLOMETASONE DIPROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,162573006,Suspected lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,254637007,Non-small cell lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,275981009,Lung cancer screening,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,429011007,Family history of lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,877691000000107,No FH of lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Non-small-cell lung cancer,TA536,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,162573006,Suspected lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,254637007,Non-small cell lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,275981009,Lung cancer screening,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,429011007,Family history of lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,877691000000107,No FH of lung cancer,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALECTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA438,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ALECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,24700007,Multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,160337009,Family history of multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,192926004,Brain stem multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,192928003,Generalised multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,428700003,Primary progressive multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,438511000,Benign multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,700409000,Suspected multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,198491000000106,Multiple sclerosis review,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,515931000000104,Multiple sclerosis review declined,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALEMTUZUMAB,Relapsing-remitting multiple sclerosis,TA312,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,ALEMTUZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALENDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ALIROCUMAB,Treating primary hypercholesterolaemia and mixed dyslipidaemia,TA393,primary hypercholesterolaemia,238076009,Primary hypercholesterolaemia,ALIROCUMAB,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
ALITRETINOIN,Severe chronic hand eczema,TA177,hand eczema,238556009,Psoriasiform hand eczema,ALITRETINOIN,DERMATOLOGY,DERMATOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,134405005,Suspected breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,160287004,FH: Breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,268547008,Screening for breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,429740004,Family history of breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,706970001,TNBC - Triple-negative breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,94361000000105,Breast cancer detected by national screening programme,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,838351000000107,Education about risk of breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,874291000000100,QCancer breast cancer risk,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer",TA816,breast cancer,1035841000000108,Lymphoedema following breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,134405005,Suspected breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,160287004,FH: Breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,268547008,Screening for breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,429740004,Family history of breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,706970001,TNBC - Triple-negative breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,94361000000105,Breast cancer detected by national screening programme,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,838351000000107,Education about risk of breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,874291000000100,QCancer breast cancer risk,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALPELISIB WITH FULVESTRANT,"Hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer",TA652,breast cancer,1035841000000108,Lymphoedema following breast cancer,ALPELISIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ALTEPLASE,Ischaemic stroke (acute),TA122,ischaemic stroke,422504002,Ischaemic stroke,ALTEPLASE,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
ALTEPLASE,Ischaemic stroke (acute),TA264,ischaemic stroke,422504002,Ischaemic stroke,ALTEPLASE,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
ALTEPLASE,Ischaemic stroke (acute),TA122,ischaemic stroke,788880006,Cerebral ischaemic stroke due to dissection of artery,ALTEPLASE,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
ALTEPLASE,Ischaemic stroke (acute),TA264,ischaemic stroke,788880006,Cerebral ischaemic stroke due to dissection of artery,ALTEPLASE,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,1755008,Healed myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,15990001,Acute myocardial infarction of posterolateral wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,22298006,MI - myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,41380003,Radioisotope scan for myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,52035003,Acute anteroapical myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,54329005,Acute anterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,57054005,Acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,58612006,Acute myocardial infarction of lateral wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,62695002,Acute anteroseptal myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,65547006,Acute inferolateral myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,66189004,Postmyocardial infarction syndrome,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,70211005,Acute anterolateral myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,73795002,Acute myocardial infarction of diaphragmatic wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,76593002,Acute myocardial infarction of inferoposterior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,79009004,Acute myocardial infarction of septum,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,129574000,Postoperative myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,160361002,FH: ischemic heart disease (& [myocardial infarction] or [coronary thrombosis]),ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,164866006,Electrocardiogram: no myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,164867002,Electrocardiographic old myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,194809007,Acute myocardial infarction of atrium,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,194821006,Aborted myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,194856005,Subsequent myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,194857001,Subsequent myocardial infarction of anterior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,194858006,Subsequent myocardial infarction of inferior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,194862000,Hemopericardium due to and following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,194863005,Atrial septal defect due to and following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,194865003,Rupture of cardiac wall without haemopericardium as current complication following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,194868001,"Thrombosis of atrium, auricular appendage, and ventricle due to and following acute myocardial infarction",ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,233838001,Acute posterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,233839009,Old anterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,233840006,Old inferior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,233841005,Old lateral myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,233842003,Old posterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,233843008,Silent myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,233847009,Cardiac rupture due to and following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,233885007,Pericarditis following myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,266288001,Myocardial infarction (& [acute]) or coronary thrombosis,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,266897007,Family history of myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,275122004,Family history: Myocardial infarction at less than 60,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,275123009,Family history: Myocardial infarction at greater than 60,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,304914007,Acute Q wave myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,308065005,History of myocardial infarction in last year,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,311793000,Postoperative transmural myocardial infarction of inferior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,311796008,Postoperative subendocardial myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,314207007,Non-Q wave myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,315619001,"Family history of myocardial infarction in male relative of first degree, age known",ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,315620007,"Family history of myocardial infarction in male relative of first degree, age unknown",ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,315621006,"Family history of myocardial infarction in female relative of first degree, age known",ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,315622004,"Family history of myocardial infarction in female relative of first degree, age unknown",ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,394710008,First myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,399211009,Previous myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,401303003,STEMI - ST elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,401314000,Acute non-ST segment elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,698593009,History of non-ST segment elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,703164000,Acute anterior ST segment elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,703213009,Acute STEMI (ST elevation myocardial infarction) of inferior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,827164008,Delayed postmyocardial infarction syndrome,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,879955009,MINOCA - myocardial infarction with non-obstructive coronary artery,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,515711000000105,Family history of myocardial infarction in second degree relative less than 50 years,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,515741000000106,Family history of myocardial infarction in first degree relative less than 60 years,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,715971000000103,Excepted from myocardial infarction quality indicators - informed dissent,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,715981000000101,Excepted from myocardial infarction quality indicators - patient unsuitable,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,717541000000106,Exception reporting - myocardial infarction quality indicators,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,883961000000109,Thrombolysis In Myocardial Infarction risk score for unstable angina or non-ST-segment-elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,12238111000119106,Acute ST segment elevation myocardial infarction of inferolateral wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
ALTEPLASE,Myocardial infarction,TA052,myocardial infarction,16837681000119104,Myocardial infarction due to demand ischaemia,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,6142004,Influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,24662006,Influenza caused by Influenza B virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,41269000,Influenzal bronchopneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,44470000,Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,46233009,Influenza virus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,51593004,Haemophilus parainfluenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,64917006,Pneumonia due to parainfluenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,70036007,Haemophilus influenzae pneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,74644004,Influenza with encephalopathy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,89117003,Parainfluenza virus type 4,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,91428005,Haemophilus influenzae infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,95891005,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,120753009,Influenza A virus antibody,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,120843002,Influenza B virus Ab,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,120975003,Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,127787002,Haemophilus influenzae type b immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,170343007,First Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,170345000,Third Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,171272004,No consent - influenza immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,171282003,Influenza immunization advised at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,171290003,Influenza vaccination consent given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,171291004,No consent for Haemophilus influenzae type b immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,185900003,Has influenza vaccination at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,185901004,Has influenza vaccination at surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,185902006,Has influenza vaccination at hospital,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,185903001,Needs influenza immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,192721000,Post influenza vaccination encephalitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,194946005,Acute myocarditis - influenzal,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,195726000,Acute parainfluenza virus bronchitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,195878008,Pneumonia and influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,195923003,Influenza with laryngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,195924009,Influenza with pharyngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,195929004,Influenza with gastrointestinal tract involvement,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,195931008,Influenza like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,266393000,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,268561003,Influenza immunization advised in surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,275983007,Influenza immunisation advised,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,291749008,Influenza vaccine poisoning,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,293112000,Influenza split virion vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,293113005,Influenza surface antigen vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,294647003,Allergy to influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,294648008,Allergy to influenza split virion vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,294649000,Allergy to influenza surface antigen vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,294664000,Haemophilus influenzae type b vaccine allergy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,308532005,Influenza vaccination status,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,309789002,Encephalitis caused by Influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,315640000,Influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,315641001,Influenza vaccination invitation letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,390796006,Influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,396425006,FLU - Influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,407479009,Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,407480007,Influenza B virus(B/Lee/40),AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,407489008,Human parainfluenza virus 1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,407491000,Parainfluenza virus type 2,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,407493002,Human parainfluenza virus 3,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,407498006,Human parainfluenza viruses,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,407573008,Influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,414496007,Influenza vaccination telephone invite,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,416928007,Has influenza vaccination at work,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,441043003,Influenza A virus subtype H1 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,441049004,Influenza A virus subtype H3 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,441343005,Influenza A virus subtype H5 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,441344004,Human parainfluenza virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,441345003,Influenza B virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,442438000,Influenza caused by Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,442696006,Influenza A (H1N1) swine flu,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,444426005,Swine influenza contact,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,473169009,History of influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,698353005,Requires influenza virus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,709410003,Hib (Haemophilus influenzae type b) infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,711330007,Influenza A virus subtype H1N1 detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,711334003,Influenza A virus H1N1 subtype not detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,736818002,Influenza vaccination requested,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,737041000,Influenza immunisation telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,787016008,Administration of influenza vaccine via nasal route,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,73701000119109,Vaccination for influenza given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,135221000119101,Influenza A H1N1 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,199331000000106,Did not attend influenza vaccination appointment,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,200481000000107,Influenza vaccination invitation first letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,200491000000109,Influenza vaccination invitation second letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,200501000000103,Influenza vaccination invitation third letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,201391000000106,Booster influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,202301000000106,First pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,202311000000108,Second pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,380271000000101,Consent given for pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,380381000000108,Pandemic influenza vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,380631000000100,Pandemic influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,380801000000105,Pandemic influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,506751000000104,Possible influenza A virus H1N1 subtype,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,516101000000103,No response to influenza vaccination invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,540151000000108,Pneumonia or influenza NOS,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,761311000000109,Influenza vaccination verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,777791000000102,Influenza vaccination invitation first text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,822851000000102,Seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,822931000000100,Seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,822951000000107,Seasonal influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,822971000000103,Seasonal influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,822991000000104,Consent given for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,844941000000103,Influenza vaccination invitation email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,844961000000102,Influenza vaccination invitation first email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,844981000000106,Influenza vaccination invitation second email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,845001000000101,Influenza vaccination invitation third email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,860151000000103,Influenza vaccination first verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,860171000000107,Influenza vaccination second verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,860211000000105,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,860291000000101,Influenza vaccination third verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,868241000000109,Administration of intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,868491000000103,No consent for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,871521000000104,First intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,871541000000106,Second intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,871751000000104,Administration of first intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,871781000000105,Administration of second intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,873681000000101,Provision of information about seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,913961000000102,Education about influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,932221000000103,At risk of influenza related complication,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,935351000000106,Long term indication for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,955641000000103,Influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,996211000000100,Influenza (A and B) serology,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,996761000000106,Haemophilus influenzae B IgG level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1001341000000106,Influenza A antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1001351000000109,Influenza B antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1005101000000108,Parainfluenza virus antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1005111000000105,Parainfluenza type 3 antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1008771000000107,Haemophilus influenzae B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1014261000000103,Influenza A antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1014271000000105,Influenza B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1020381000000100,Parainfluenza virus antigen assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1033051000000101,Influenza due to zoonotic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1033071000000105,Influenza due to pandemic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1033091000000109,Influenza due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1095821000000105,Influenza vaccination first telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1095831000000107,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1095841000000103,Influenza vaccination third telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1239861000000100,Seasonal influenza vaccination given in school,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (post-exposure prophylaxis),TA158,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,6142004,Influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,24662006,Influenza caused by Influenza B virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,41269000,Influenzal bronchopneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,44470000,Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,46233009,Influenza virus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,51593004,Haemophilus parainfluenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,64917006,Pneumonia due to parainfluenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,70036007,Haemophilus influenzae pneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,74644004,Influenza with encephalopathy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,89117003,Parainfluenza virus type 4,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,91428005,Haemophilus influenzae infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,95891005,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,120753009,Influenza A virus antibody,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,120843002,Influenza B virus Ab,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,120975003,Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,127787002,Haemophilus influenzae type b immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,170343007,First Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,170345000,Third Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,171272004,No consent - influenza immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,171282003,Influenza immunization advised at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,171290003,Influenza vaccination consent given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,171291004,No consent for Haemophilus influenzae type b immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,185900003,Has influenza vaccination at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,185901004,Has influenza vaccination at surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,185902006,Has influenza vaccination at hospital,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,185903001,Needs influenza immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,192721000,Post influenza vaccination encephalitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,194946005,Acute myocarditis - influenzal,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,195726000,Acute parainfluenza virus bronchitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,195878008,Pneumonia and influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,195923003,Influenza with laryngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,195924009,Influenza with pharyngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,195929004,Influenza with gastrointestinal tract involvement,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,195931008,Influenza like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,266393000,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,268561003,Influenza immunization advised in surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,275983007,Influenza immunisation advised,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,291749008,Influenza vaccine poisoning,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,293112000,Influenza split virion vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,293113005,Influenza surface antigen vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,294647003,Allergy to influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,294648008,Allergy to influenza split virion vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,294649000,Allergy to influenza surface antigen vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,294664000,Haemophilus influenzae type b vaccine allergy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,308532005,Influenza vaccination status,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,309789002,Encephalitis caused by Influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,315640000,Influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,315641001,Influenza vaccination invitation letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,390796006,Influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,396425006,FLU - Influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,407479009,Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,407480007,Influenza B virus(B/Lee/40),AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,407489008,Human parainfluenza virus 1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,407491000,Parainfluenza virus type 2,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,407493002,Human parainfluenza virus 3,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,407498006,Human parainfluenza viruses,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,407573008,Influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,414496007,Influenza vaccination telephone invite,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,416928007,Has influenza vaccination at work,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,441043003,Influenza A virus subtype H1 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,441049004,Influenza A virus subtype H3 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,441343005,Influenza A virus subtype H5 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,441344004,Human parainfluenza virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,441345003,Influenza B virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,442438000,Influenza caused by Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,442696006,Influenza A (H1N1) swine flu,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,444426005,Swine influenza contact,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,473169009,History of influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,698353005,Requires influenza virus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,709410003,Hib (Haemophilus influenzae type b) infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,711330007,Influenza A virus subtype H1N1 detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,711334003,Influenza A virus H1N1 subtype not detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,736818002,Influenza vaccination requested,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,737041000,Influenza immunisation telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,787016008,Administration of influenza vaccine via nasal route,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,73701000119109,Vaccination for influenza given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,135221000119101,Influenza A H1N1 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,199331000000106,Did not attend influenza vaccination appointment,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,200481000000107,Influenza vaccination invitation first letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,200491000000109,Influenza vaccination invitation second letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,200501000000103,Influenza vaccination invitation third letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,201391000000106,Booster influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,202301000000106,First pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,202311000000108,Second pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,380271000000101,Consent given for pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,380381000000108,Pandemic influenza vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,380631000000100,Pandemic influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,380801000000105,Pandemic influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,506751000000104,Possible influenza A virus H1N1 subtype,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,516101000000103,No response to influenza vaccination invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,540151000000108,Pneumonia or influenza NOS,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,761311000000109,Influenza vaccination verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,777791000000102,Influenza vaccination invitation first text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,822851000000102,Seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,822931000000100,Seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,822951000000107,Seasonal influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,822971000000103,Seasonal influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,822991000000104,Consent given for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,844941000000103,Influenza vaccination invitation email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,844961000000102,Influenza vaccination invitation first email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,844981000000106,Influenza vaccination invitation second email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,845001000000101,Influenza vaccination invitation third email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,860151000000103,Influenza vaccination first verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,860171000000107,Influenza vaccination second verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,860211000000105,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,860291000000101,Influenza vaccination third verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,868241000000109,Administration of intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,868491000000103,No consent for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,871521000000104,First intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,871541000000106,Second intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,871751000000104,Administration of first intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,871781000000105,Administration of second intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,873681000000101,Provision of information about seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,913961000000102,Education about influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,932221000000103,At risk of influenza related complication,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,935351000000106,Long term indication for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,955641000000103,Influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,996211000000100,Influenza (A and B) serology,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,996761000000106,Haemophilus influenzae B IgG level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1001341000000106,Influenza A antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1001351000000109,Influenza B antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1005101000000108,Parainfluenza virus antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1005111000000105,Parainfluenza type 3 antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1008771000000107,Haemophilus influenzae B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1014261000000103,Influenza A antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1014271000000105,Influenza B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1020381000000100,Parainfluenza virus antigen assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1033051000000101,Influenza due to zoonotic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1033071000000105,Influenza due to pandemic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1033091000000109,Influenza due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1095821000000105,Influenza vaccination first telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1095831000000107,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1095841000000103,Influenza vaccination third telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1239861000000100,Seasonal influenza vaccination given in school,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (prevention),TA067,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,6142004,Influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,6142004,Influenza,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,24662006,Influenza caused by Influenza B virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,24662006,Influenza caused by Influenza B virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,41269000,Influenzal bronchopneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,41269000,Influenzal bronchopneumonia,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,44470000,Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,44470000,Haemophilus influenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,46233009,Influenza virus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,46233009,Influenza virus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,51593004,Haemophilus parainfluenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,51593004,Haemophilus parainfluenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,64917006,Pneumonia due to parainfluenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,64917006,Pneumonia due to parainfluenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,70036007,Haemophilus influenzae pneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,70036007,Haemophilus influenzae pneumonia,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,74644004,Influenza with encephalopathy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,74644004,Influenza with encephalopathy,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,89117003,Parainfluenza virus type 4,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,89117003,Parainfluenza virus type 4,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,91428005,Haemophilus influenzae infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,91428005,Haemophilus influenzae infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,95891005,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,95891005,Influenza-like illness,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,120753009,Influenza A virus antibody,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,120753009,Influenza A virus antibody,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,120843002,Influenza B virus Ab,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,120843002,Influenza B virus Ab,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,120975003,Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,120975003,Haemophilus influenzae type b antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,127787002,Haemophilus influenzae type b immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,127787002,Haemophilus influenzae type b immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,170343007,First Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,170343007,First Haemophilus influenzae type b vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,170345000,Third Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,170345000,Third Haemophilus influenzae type b vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,171272004,No consent - influenza immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,171272004,No consent - influenza immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,171282003,Influenza immunization advised at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,171282003,Influenza immunization advised at home,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,171290003,Influenza vaccination consent given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,171290003,Influenza vaccination consent given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,171291004,No consent for Haemophilus influenzae type b immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,171291004,No consent for Haemophilus influenzae type b immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,185900003,Has influenza vaccination at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,185900003,Has influenza vaccination at home,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,185901004,Has influenza vaccination at surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,185901004,Has influenza vaccination at surgery,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,185902006,Has influenza vaccination at hospital,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,185902006,Has influenza vaccination at hospital,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,185903001,Needs influenza immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,185903001,Needs influenza immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,192721000,Post influenza vaccination encephalitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,192721000,Post influenza vaccination encephalitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,194946005,Acute myocarditis - influenzal,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,194946005,Acute myocarditis - influenzal,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,195726000,Acute parainfluenza virus bronchitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,195726000,Acute parainfluenza virus bronchitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,195878008,Pneumonia and influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,195878008,Pneumonia and influenza,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,195923003,Influenza with laryngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,195923003,Influenza with laryngitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,195924009,Influenza with pharyngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,195924009,Influenza with pharyngitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,195929004,Influenza with gastrointestinal tract involvement,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,195929004,Influenza with gastrointestinal tract involvement,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,195931008,Influenza like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,195931008,Influenza like illness,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,266393000,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,266393000,Influenza-like illness,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,268561003,Influenza immunization advised in surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,268561003,Influenza immunization advised in surgery,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,275983007,Influenza immunisation advised,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,275983007,Influenza immunisation advised,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,291749008,Influenza vaccine poisoning,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,291749008,Influenza vaccine poisoning,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,293112000,Influenza split virion vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,293112000,Influenza split virion vaccine adverse reaction,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,293113005,Influenza surface antigen vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,293113005,Influenza surface antigen vaccine adverse reaction,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,294647003,Allergy to influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,294647003,Allergy to influenza vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,294648008,Allergy to influenza split virion vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,294648008,Allergy to influenza split virion vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,294649000,Allergy to influenza surface antigen vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,294649000,Allergy to influenza surface antigen vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,294664000,Haemophilus influenzae type b vaccine allergy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,294664000,Haemophilus influenzae type b vaccine allergy,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,308532005,Influenza vaccination status,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,308532005,Influenza vaccination status,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,309789002,Encephalitis caused by Influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,309789002,Encephalitis caused by Influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,315640000,Influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,315640000,Influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,315641001,Influenza vaccination invitation letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,315641001,Influenza vaccination invitation letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,390796006,Influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,390796006,Influenza vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,396425006,FLU - Influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,396425006,FLU - Influenza vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,407479009,Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,407479009,Influenza A virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,407480007,Influenza B virus(B/Lee/40),AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,407480007,Influenza B virus(B/Lee/40),ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,407489008,Human parainfluenza virus 1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,407489008,Human parainfluenza virus 1,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,407491000,Parainfluenza virus type 2,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,407491000,Parainfluenza virus type 2,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,407493002,Human parainfluenza virus 3,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,407493002,Human parainfluenza virus 3,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,407498006,Human parainfluenza viruses,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,407498006,Human parainfluenza viruses,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,407573008,Influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,407573008,Influenza vaccination not indicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,414496007,Influenza vaccination telephone invite,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,414496007,Influenza vaccination telephone invite,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,416928007,Has influenza vaccination at work,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,416928007,Has influenza vaccination at work,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,441043003,Influenza A virus subtype H1 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,441043003,Influenza A virus subtype H1 present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,441049004,Influenza A virus subtype H3 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,441049004,Influenza A virus subtype H3 present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,441343005,Influenza A virus subtype H5 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,441343005,Influenza A virus subtype H5 present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,441344004,Human parainfluenza virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,441344004,Human parainfluenza virus present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,441345003,Influenza B virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,441345003,Influenza B virus present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,442438000,Influenza caused by Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,442438000,Influenza caused by Influenza A virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,442696006,Influenza A (H1N1) swine flu,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,442696006,Influenza A (H1N1) swine flu,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,444426005,Swine influenza contact,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,444426005,Swine influenza contact,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,473169009,History of influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,473169009,History of influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,698353005,Requires influenza virus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,698353005,Requires influenza virus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,709410003,Hib (Haemophilus influenzae type b) infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,709410003,Hib (Haemophilus influenzae type b) infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,711330007,Influenza A virus subtype H1N1 detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,711330007,Influenza A virus subtype H1N1 detected,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,711334003,Influenza A virus H1N1 subtype not detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,711334003,Influenza A virus H1N1 subtype not detected,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,736818002,Influenza vaccination requested,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,736818002,Influenza vaccination requested,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,737041000,Influenza immunisation telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,737041000,Influenza immunisation telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,787016008,Administration of influenza vaccine via nasal route,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,787016008,Administration of influenza vaccine via nasal route,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,73701000119109,Vaccination for influenza given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,73701000119109,Vaccination for influenza given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,135221000119101,Influenza A H1N1 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,135221000119101,Influenza A H1N1 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,199331000000106,Did not attend influenza vaccination appointment,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,199331000000106,Did not attend influenza vaccination appointment,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,200481000000107,Influenza vaccination invitation first letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,200481000000107,Influenza vaccination invitation first letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,200491000000109,Influenza vaccination invitation second letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,200491000000109,Influenza vaccination invitation second letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,200501000000103,Influenza vaccination invitation third letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,200501000000103,Influenza vaccination invitation third letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,201391000000106,Booster influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,201391000000106,Booster influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,202301000000106,First pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,202301000000106,First pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,202311000000108,Second pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,202311000000108,Second pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,380271000000101,Consent given for pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,380271000000101,Consent given for pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,380381000000108,Pandemic influenza vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,380381000000108,Pandemic influenza vaccination refused,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,380631000000100,Pandemic influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,380631000000100,Pandemic influenza vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,380801000000105,Pandemic influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,380801000000105,Pandemic influenza vaccination not indicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,506751000000104,Possible influenza A virus H1N1 subtype,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,506751000000104,Possible influenza A virus H1N1 subtype,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,516101000000103,No response to influenza vaccination invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,516101000000103,No response to influenza vaccination invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,540151000000108,Pneumonia or influenza NOS,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,540151000000108,Pneumonia or influenza NOS,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,761311000000109,Influenza vaccination verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,761311000000109,Influenza vaccination verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,777791000000102,Influenza vaccination invitation first text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,777791000000102,Influenza vaccination invitation first text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,822851000000102,Seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,822851000000102,Seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,822931000000100,Seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,822931000000100,Seasonal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,822951000000107,Seasonal influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,822951000000107,Seasonal influenza vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,822971000000103,Seasonal influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,822971000000103,Seasonal influenza vaccination not indicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,822991000000104,Consent given for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,822991000000104,Consent given for seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,844941000000103,Influenza vaccination invitation email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,844941000000103,Influenza vaccination invitation email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,844961000000102,Influenza vaccination invitation first email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,844961000000102,Influenza vaccination invitation first email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,844981000000106,Influenza vaccination invitation second email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,844981000000106,Influenza vaccination invitation second email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,845001000000101,Influenza vaccination invitation third email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,845001000000101,Influenza vaccination invitation third email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,860151000000103,Influenza vaccination first verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,860151000000103,Influenza vaccination first verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,860171000000107,Influenza vaccination second verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,860171000000107,Influenza vaccination second verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,860211000000105,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,860211000000105,Influenza vaccination second telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,860291000000101,Influenza vaccination third verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,860291000000101,Influenza vaccination third verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,868241000000109,Administration of intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,868241000000109,Administration of intranasal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,868491000000103,No consent for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,868491000000103,No consent for seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,871521000000104,First intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,871521000000104,First intranasal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,871541000000106,Second intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,871541000000106,Second intranasal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,871751000000104,Administration of first intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,871751000000104,Administration of first intranasal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,871781000000105,Administration of second intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,871781000000105,Administration of second intranasal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,873681000000101,Provision of information about seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,873681000000101,Provision of information about seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,913961000000102,Education about influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,913961000000102,Education about influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,932221000000103,At risk of influenza related complication,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,932221000000103,At risk of influenza related complication,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,935351000000106,Long term indication for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,935351000000106,Long term indication for seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,955641000000103,Influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,955641000000103,Influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,996211000000100,Influenza (A and B) serology,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,996211000000100,Influenza (A and B) serology,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,996761000000106,Haemophilus influenzae B IgG level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,996761000000106,Haemophilus influenzae B IgG level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1001341000000106,Influenza A antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1001341000000106,Influenza A antigen level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1001351000000109,Influenza B antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1001351000000109,Influenza B antigen level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1005101000000108,Parainfluenza virus antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1005101000000108,Parainfluenza virus antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1005111000000105,Parainfluenza type 3 antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1005111000000105,Parainfluenza type 3 antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1008771000000107,Haemophilus influenzae B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1008771000000107,Haemophilus influenzae B antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1014261000000103,Influenza A antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1014261000000103,Influenza A antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1014271000000105,Influenza B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1014271000000105,Influenza B antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1020381000000100,Parainfluenza virus antigen assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1020381000000100,Parainfluenza virus antigen assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1033051000000101,Influenza due to zoonotic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1033051000000101,Influenza due to zoonotic influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1033071000000105,Influenza due to pandemic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1033071000000105,Influenza due to pandemic influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1033091000000109,Influenza due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1033091000000109,Influenza due to seasonal influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1095821000000105,Influenza vaccination first telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1095821000000105,Influenza vaccination first telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1095831000000107,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1095831000000107,Influenza vaccination second telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1095841000000103,Influenza vaccination third telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1095841000000103,Influenza vaccination third telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1239861000000100,Seasonal influenza vaccination given in school,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1239861000000100,Seasonal influenza vaccination given in school,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA058,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMANTADINE,Influenza (treatment),TA168,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,4926007,Schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,12939007,Chronic disorganized schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,31373002,Hebephrenic schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,31658008,Chronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,35252006,Disorganised schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,39610001,Undifferentiated schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,58214004,Schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,63181006,"Paranoid schizophrenia, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,64905009,Paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,79866005,Subchronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,83746006,Chronic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,111482003,Subchronic schizophrenia with acute exacerbations,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,111483008,"Schizophrenia, catatonic, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,111484002,Undifferentiated schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,160328009,Family history of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,161103001,Schizophrenia association member,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,161468000,History of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,191527001,Simple schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,191531007,Acute exacerbation of chronic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,191548004,Chronic catatonic schizophrenia with acute exacerbation,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,191554003,Acute exacerbation of subchronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,191555002,Acute exacerbation of chronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,191559008,Latent schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,191565008,Latent schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,191567000,Schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,191570001,Chronic schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,191572009,Acute exacerbation of chronic schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,191574005,"Schizophrenia, schizoaffective, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,247804008,Prodromal schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,274952002,Borderline schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,278853003,Acute schizophrenia-like psychotic disorder,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,444180005,History of schizophrenia in child of subject,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,712824002,Acute polymorphic psychotic disorder without symptoms of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,712850003,Acute polymorphic psychotic disorder with symptoms of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,200951000000109,"Psychosis, schizophrenia and bipolar affective disorder resolved",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,285521000000103,Schizophrenia resolved,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,417601000000102,"[X]Schizophrenia, schizotypal and delusional disorders",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,443791000000100,[X]Pseudopsychopathic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,1062101000000104,Schizophrenia TOM (Therapy Outcome Measure) activity score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,1062121000000108,Schizophrenia TOM (Therapy Outcome Measure) impairment score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,1062131000000105,Schizophrenia TOM (Therapy Outcome Measure) participation score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMISULPRIDE,Schizophrenia,TA043,schizophrenia,1062141000000101,Schizophrenia TOM (Therapy Outcome Measure) wellbeing score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,162573006,Suspected lung cancer,AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,254637007,Non-small cell lung cancer,AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,275981009,Lung cancer screening,AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,429011007,Family history of lung cancer,AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,877691000000107,No FH of lung cancer,AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
AMIVANTAMAB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA850,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",AMIVANTAMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANAKINRA,Rheumatoid arthritis,TA072,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ANAKINRA,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ANASTROZOLE,Breast cancer (early),TA112,breast cancer,134405005,Suspected breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ANASTROZOLE,Breast cancer (early),TA112,breast cancer,160287004,FH: Breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ANASTROZOLE,Breast cancer (early),TA112,breast cancer,268547008,Screening for breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ANASTROZOLE,Breast cancer (early),TA112,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ANASTROZOLE,Breast cancer (early),TA112,breast cancer,429740004,Family history of breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ANASTROZOLE,Breast cancer (early),TA112,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ANASTROZOLE,Breast cancer (early),TA112,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ANASTROZOLE,Breast cancer (early),TA112,breast cancer,706970001,TNBC - Triple-negative breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ANASTROZOLE,Breast cancer (early),TA112,breast cancer,94361000000105,Breast cancer detected by national screening programme,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ANASTROZOLE,Breast cancer (early),TA112,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ANASTROZOLE,Breast cancer (early),TA112,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ANASTROZOLE,Breast cancer (early),TA112,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ANASTROZOLE,Breast cancer (early),TA112,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ANASTROZOLE,Breast cancer (early),TA112,breast cancer,838351000000107,Education about risk of breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ANASTROZOLE,Breast cancer (early),TA112,breast cancer,874291000000100,QCancer breast cancer risk,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ANASTROZOLE,Breast cancer (early),TA112,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ANASTROZOLE,Breast cancer (early),TA112,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ANASTROZOLE,Breast cancer (early),TA112,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ANASTROZOLE,Breast cancer (early),TA112,breast cancer,1035841000000108,Lymphoedema following breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,apixaban,985211000000107,Apixaban adverse reaction,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY
ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,apixaban,985211000000107,Apixaban adverse reaction,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY
ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,rivaroxaban,985231000000104,Rivaroxaban adverse reaction,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY
ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,rivaroxaban,985231000000104,Rivaroxaban adverse reaction,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY
ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,rivaroxaban,985251000000106,Allergy to rivaroxaban,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY
ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,rivaroxaban,985251000000106,Allergy to rivaroxaban,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY
ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,rivaroxaban,985311000000102,Rivaroxaban declined,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY
ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,rivaroxaban,985311000000102,Rivaroxaban declined,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY
ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,apixaban,985331000000105,Apixaban not tolerated,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY
ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,apixaban,985331000000105,Apixaban not tolerated,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY
ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,rivaroxaban,985351000000103,Rivaroxaban not tolerated,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY
ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,rivaroxaban,985351000000103,Rivaroxaban not tolerated,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY
ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,apixaban,985631000000101,Apixaban contraindicated,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY
ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,apixaban,985631000000101,Apixaban contraindicated,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY
ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,rivaroxaban,985661000000106,Rivaroxaban contraindicated,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY
ANDEXANET ALFA,Reversing anticoagulation from apixaban or rivaroxaban,TA697,rivaroxaban,985661000000106,Rivaroxaban contraindicated,ANDEXANET,CARDIOLOGY,CARDIOLOGY|CLINICAL HAEMATOLOGY
ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,4676006,"Systemic lupus erythematosus glomerulonephritis syndrome, World Health Organization class II",ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,36402006,"Systemic lupus erythematosus glomerulonephritis syndrome, World Health Organization class IV",ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,73286009,"Systemic lupus erythematosus glomerulonephritis syndrome, World Health Organization class I",ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,76521009,"Systemic lupus erythematosus glomerulonephritis syndrome, World Health Organization class III",ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,95644001,Cerebral systemic lupus erythematosus,ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,196138005,Lung disease with systemic lupus erythematosus,ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,201436003,Drug-induced systemic lupus erythematosus,ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,230307005,Chorea due to systemic lupus erythematosus,ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,239887007,Systemic lupus erythematosus with organ/system involvement,ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,239889005,Bullous systemic lupus erythematosus,ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,239890001,Systemic lupus erythematosus with multisystem involvement,ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,273863009,Systemic lupus erythematosus disease activity index,ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,307755009,Renal tubulo-interstitial disorder due to systemic lupus erythematosus,ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
ANIFROLUMAB,Active autoantibody-positive systemic lupus erythematosus,TA793,systemic lupus erythematosus,309762007,Systemic lupus erythematosus with pericarditis,ANIFROLUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,High-risk hormone-relapsed non-metastatic prostate cancer,TA740,prostate cancer,315268008,Suspected prostate cancer,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,High-risk hormone-relapsed non-metastatic prostate cancer,TA740,prostate cancer,428262008,H/O: prostate cancer,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,High-risk hormone-relapsed non-metastatic prostate cancer,TA740,prostate cancer,698470001,Advice given about prostate cancer screening,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,High-risk hormone-relapsed non-metastatic prostate cancer,TA740,prostate cancer,712837004,Active surveillance of prostate cancer,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,High-risk hormone-relapsed non-metastatic prostate cancer,TA740,prostate cancer,720007002,Prostate cancer care review,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,High-risk hormone-relapsed non-metastatic prostate cancer,TA740,prostate cancer,31011000119107,Prostate cancer screening declined,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,High-risk hormone-relapsed non-metastatic prostate cancer,TA740,prostate cancer,874211000000109,QCancer prostate cancer risk,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,High-risk hormone-relapsed non-metastatic prostate cancer,TA740,prostate cancer,878401000000104,No FH of prostate cancer,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,High-risk hormone-relapsed non-metastatic prostate cancer,TA740,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,High-risk hormone-relapsed non-metastatic prostate cancer,TA740,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-sensitive metastatic prostate cancer,TA741,prostate cancer,315268008,Suspected prostate cancer,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-sensitive metastatic prostate cancer,TA741,prostate cancer,428262008,H/O: prostate cancer,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-sensitive metastatic prostate cancer,TA741,prostate cancer,698470001,Advice given about prostate cancer screening,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-sensitive metastatic prostate cancer,TA741,prostate cancer,712837004,Active surveillance of prostate cancer,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-sensitive metastatic prostate cancer,TA741,prostate cancer,720007002,Prostate cancer care review,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-sensitive metastatic prostate cancer,TA741,prostate cancer,31011000119107,Prostate cancer screening declined,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-sensitive metastatic prostate cancer,TA741,prostate cancer,874211000000109,QCancer prostate cancer risk,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-sensitive metastatic prostate cancer,TA741,prostate cancer,878401000000104,No FH of prostate cancer,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-sensitive metastatic prostate cancer,TA741,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
APALUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-sensitive metastatic prostate cancer,TA741,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,APALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,2517002,Stroke rehabilitation,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,25133001,Completed stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,28690004,Stroke test,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,39925003,"MELAS - mitochondrial encephalopathy, lactic acidosis and stroke-like episodes",APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,44922000,Bounding pulse with rapid upstroke and descent,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,49436004,Atrial fibrillation,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,90096001,Stroke volume,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,134377004,Atrial fibrillation monitoring,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,135875009,Stroke prevention,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,135877001,Stroke risk,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,160252004,No family history of cardiovascular accident or stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,160271002,No family history of stroke and/or transient ischaemic attack,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,170600009,Stroke monitoring,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,195080001,Atrial fibrillation and flutter,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,195163003,Stroke due to intracerebral haemorrhage,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,195212005,Brainstem stroke syndrome,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,195213000,Cerebellar stroke syndrome,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,212937007,Heat stroke and sunstroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,230690007,Stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,230694003,Total anterior cerebral circulation stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,230695002,Partial anterior cerebral circulation stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,230696001,Posterior cerebral circulation stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,230700009,Pure sensory stroke due to and following lacunar infarction,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,230713003,Stroke of uncertain pathology,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,230714009,Anterior circulation stroke of uncertain pathology,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,230715005,Posterior circulation stroke of uncertain pathology,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,230739000,Spinal cord stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,233911009,Non-rheumatic atrial fibrillation,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,275434003,Stroke in the puerperium,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,276898003,Left ventricular stroke work index,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,277286006,Chronic central post-stroke pain,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,277381004,Stroke index,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,282825002,Intermittent atrial fibrillation,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,297250002,No family history of stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,299403002,Stroke test positive,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,299404008,Stroke test negative,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,300996004,Controlled atrial fibrillation,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,306802002,Referral to stroke service,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,306803007,Admission to stroke unit,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,306808003,Discharge from stroke service,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,306810001,Seen by stroke service,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,308067002,History of stroke in last year,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,309966001,Stroke unit,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,310137004,Stroke service,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,312442005,History of atrial fibrillation,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,371040005,Thrombotic stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,371041009,Embolic stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,412773009,Referral to stroke clinic,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,413119003,Stroke group member,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,413124000,Stroke/transient ischaemic attack referral,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,415628004,Stroke/transient ischaemic attack monitoring first letter,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,415629007,Stroke/transient ischemic attack monitoring second letter,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,415630002,Stroke/transient ischaemic attack monitoring status,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,415631003,Stroke/transient ischemic attack monitoring third letter,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,417059002,Stroke/transient ischemic attack monitoring verbal invitation,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,417506008,Hemorrhagic stroke monitoring,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,417540008,Stroke/transient ischaemic attack monitoring invitation,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,422504002,Ischaemic stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,440028005,Permanent atrial fibrillation,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,440059007,Persistent atrial fibrillation,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,449863006,Insertion of pacemaker for control of atrial fibrillation,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,450743008,NIHSS (National Institutes of Health stroke scale) score,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,699833006,Provision of written information about atrial fibrillation,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,704154001,"HAS-BLED (hypertension, abnormal renal and/or liver function, stroke, bleeding history or predisposition, labile INR (international normalised ratio), elderly over 65, and drugs and/or alcohol concomitantly) score",APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,704180000,"HAS-BLED (hypertension, abnormal renal and/or liver function, stroke, bleeding history or predisposition, labile international normalised ratio, elderly over 65, and drugs and/or alcohol concomitantly) bleeding risk score",APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,706923002,Longstanding persistent atrial fibrillation,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,707514001,Stroke impact scale version 3.0 score,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,719008003,At increased risk of atrial fibrillation,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,722929005,Perinatal arterial ischemic stroke of fetus and/or neonate,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,724424009,Cerebral ischemic stroke due to small artery occlusion,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,736712009,PASS (Postural Assessment Scale for Stroke Patients) score,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,788880006,Cerebral ischaemic stroke due to dissection of artery,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,788884002,Cerebral ischemic stroke due to subarachnoid hemorrhage,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,1010405004,Paroxysmal AF (atrial fibrillation) with RVR (rapid ventricular response),APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,88601000000107,DNA (did not attend) stroke clinic,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,112901000000108,Referral to multidisciplinary stroke function improvement service,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,120041000119109,Atrial fibrillation with rapid ventricular response,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,133111000000106,QOF (Quality and Outcomes Framework) atrial fibrillation quality indicator-related care invitation using preferred method of communication,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,140921000119102,Ischemic stroke without coma,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,143471000000105,QOF (Quality and Outcomes Framework) stroke and transient ischaemic attack quality indicator-related care invitation using preferred method of communication,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,196371000000102,Atrial fibrillation resolved,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,201501000000108,Seen in stroke clinic,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,231231000000107,Delivery of rehabilitation for stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,248411000000105,Atrial fibrillation annual review,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,519751000000106,Stroke 6 month review,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,521411000000106,Did not attend stroke review,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,685631000000102,Stroke and cerebrovascular accident unspecified,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,711411000000101,Atrial fibrillation monitoring invitation,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,713771000000100,Stroke/transient ischaemic attack monitoring administration,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,713801000000102,Atrial fibrillation monitoring administration,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,715941000000109,Excepted from atrial fibrillation quality indicators - patient unsuitable,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,716021000000109,Excepted from stroke quality indicators - informed dissent,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,716181000000109,Atrial fibrillation monitoring third letter,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,716331000000108,Exception reporting - stroke quality indicators,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,716581000000101,Excepted from stroke quality indicators - patient unsuitable,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,716721000000107,Atrial fibrillation monitoring telephone invitation,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,716871000000101,Exception reporting - atrial fibrillation quality indicators,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,716981000000106,Atrial fibrillation monitoring second letter,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,717011000000100,Atrial fibrillation monitoring verbal invite,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,717221000000101,Atrial fibrillation monitoring first letter,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,717241000000108,Stroke/transient ischaemic attack monitoring telephone invitation,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,717381000000109,Excepted from atrial fibrillation quality indicators - informed dissent,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,769211000000103,Suspected stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,810991000000109,Stroke self-management plan review,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,812041000000104,Stroke self-management plan agreed,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,816401000000105,Atrial fibrillation excluded,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,816561000000108,Stroke initial post discharge review,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,842441000000104,Provision of written information about stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,847611000000104,Atrial fibrillation care pathway,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,870631000000105,QStroke 10 year risk of stroke calculator,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,1025021000000107,High risk of atrial fibrillation,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,1062151000000103,Stroke TOM (Therapy Outcome Measure) activity score,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,1062171000000107,Stroke TOM (Therapy Outcome Measure) impairment score,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,1062181000000109,Stroke TOM (Therapy Outcome Measure) participation score,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,1062191000000106,Stroke TOM (Therapy Outcome Measure) wellbeing score,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,1066831000000104,Atrial fibrillation detected,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,1067061000000104,Atrial fibrillation not detected,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,1078001000000105,Haemorrhagic stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,1085311000000106,QStroke risk calculator score,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,atrial fibrillation,1110851000000100,QOF (Quality and Outcomes Framework) atrial fibrillation quality indicator-related care invitation,APIXABAN,CARDIOLOGY,CARDIOLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,1110981000000104,QOF (Quality and Outcomes Framework) stroke and transient ischaemic attack quality indicator-related care invitation,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of stroke and systemic embolism in people with nonvalvular atrial fibrillation,TA275,stroke,16371781000119100,Cerebellar stroke,APIXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
APIXABAN,Prevention of venous thromboembolism after total hip or knee replacement,TA245,venous thromboembolism,443749004,Venous thromboembolism risk assessment,APIXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY
APIXABAN,Prevention of venous thromboembolism after total hip or knee replacement,TA245,venous thromboembolism,699035003,At low risk of venous thromboembolism,APIXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY
APIXABAN,Prevention of venous thromboembolism after total hip or knee replacement,TA245,venous thromboembolism,711293008,At moderate risk of venous thromboembolism,APIXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY
APIXABAN,Prevention of venous thromboembolism after total hip or knee replacement,TA245,venous thromboembolism,711328005,At high risk of venous thromboembolism,APIXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY
APIXABAN,Prevention of venous thromboembolism after total hip or knee replacement,TA245,venous thromboembolism,787331000000107,Venous thromboembolism prevention management,APIXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY
APIXABAN,Prevention of venous thromboembolism after total hip or knee replacement,TA245,venous thromboembolism,844041000000102,Education about risk of venous thromboembolism,APIXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,14534009,Deep vein thrombosis of splenic vein,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,49956009,Antenatal DVT (deep vein thrombosis),APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,56272000,Puerperal DVT (deep vein thrombosis),APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,pulmonary embolism,59282003,Pulmonary embolism,APIXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,128053003,Deep vein thrombosis,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,134399007,Deep vein thrombosis of leg related to air travel,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,161508001,History of DVT (deep vein thrombosis),APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,200232006,Antenatal deep vein thrombosis - delivered,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,200233001,Antenatal deep vein thrombosis with antenatal complication,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,200238005,Postnatal deep vein thrombosis with postnatal complication,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,pulmonary embolism,200284000,Obstetric pulmonary embolism,APIXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,pulmonary embolism,200286003,Obstetric air pulmonary embolism,APIXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,pulmonary embolism,200303005,Obstetric blood-clot pulmonary embolism with antenatal complication,APIXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,213220000,Postoperative deep vein thrombosis,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,225999004,At increased risk of DVT (deep vein thrombosis),APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,pulmonary embolism,233217004,Operation for pulmonary embolism,APIXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,pulmonary embolism,233936003,Acute massive pulmonary embolism,APIXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,pulmonary embolism,233937007,Subacute massive pulmonary embolism,APIXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,234044007,Ileofemoral deep vein thrombosis,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,401186003,Deep vein thrombosis screening,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,413459009,Advised risk of deep vein thrombosis in air travel,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,413956008,Deep vein thrombosis of leg related to intravenous drug use,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,pulmonary embolism,417113001,Suspected PE (pulmonary embolism),APIXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,429053008,Wells deep vein thrombosis clinical probability score,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,pulmonary embolism,430801003,Family history of pulmonary embolism,APIXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,432805000,Suspected deep vein thrombosis,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,pulmonary embolism,438773007,Recurrent pulmonary embolism,APIXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,443210003,Deep vein thrombosis of peroneal vein,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,710167004,Recurrent DVT (deep vein thrombosis),APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,198301000000109,FH: deep vein thrombosis,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,323631000000102,DVT (deep vein thrombosis) prevention,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,492161000000109,Deep vein thrombosis enhanced services administration,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,503421000000105,Deep vein thrombosis enhanced services administration stage 1 service level,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,503451000000100,Deep vein thrombosis enhanced services administration stage 2 service level,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,503481000000106,Deep vein thrombosis enhanced services administration stage 3 service level,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,513251000000101,Low probability of deep vein thrombosis,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,513271000000105,Moderate probability of deep vein thrombosis,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,513291000000109,High probability of deep vein thrombosis,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,869611000000104,On deep vein thrombosis care pathway,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,872221000000109,No history of deep vein thrombosis,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,978421000000101,Unprovoked deep vein thrombosis,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APIXABAN,Treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA341,deep vein thrombosis,978441000000108,Provoked deep vein thrombosis,APIXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
APREMILAST,Moderate to severe plaque psoriasis,TA368,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),APREMILAST,DERMATOLOGY,DERMATOLOGY
APREMILAST,Moderate to severe plaque psoriasis,TA368,plaque psoriasis,402307000,Chronic large plaque psoriasis,APREMILAST,DERMATOLOGY,DERMATOLOGY
APREMILAST,Moderate to severe plaque psoriasis,TA368,plaque psoriasis,402310007,Chronic stable plaque psoriasis,APREMILAST,DERMATOLOGY,DERMATOLOGY
APREMILAST,Treating moderate to severe plaque psoriasis,TA419,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),APREMILAST,DERMATOLOGY,DERMATOLOGY
APREMILAST,Treating moderate to severe plaque psoriasis,TA419,plaque psoriasis,402307000,Chronic large plaque psoriasis,APREMILAST,DERMATOLOGY,DERMATOLOGY
APREMILAST,Treating moderate to severe plaque psoriasis,TA419,plaque psoriasis,402310007,Chronic stable plaque psoriasis,APREMILAST,DERMATOLOGY,DERMATOLOGY
APREMILAST ALONE OR IN COMBINATION WITH DISEASE‑MODIFYING ANTIRHEUMATIC DRUG (DMARD) THERAPY,Treating active psoriatic arthritis,TA372,psoriatic arthritis,156370009,Psoriatic arthritis,APREMILAST,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
APREMILAST ALONE OR IN COMBINATION WITH DISEASE‑MODIFYING ANTIRHEUMATIC DRUG (DMARD) THERAPY,Treating active psoriatic arthritis,TA372,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,APREMILAST,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
APREMILAST ALONE OR IN COMBINATION WITH DISEASE‑MODIFYING ANTIRHEUMATIC DRUG (DMARD) THERAPY,Treating active psoriatic arthritis,TA372,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,APREMILAST,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
APREMILAST ALONE OR IN COMBINATION WITH DISEASE‑MODIFYING ANTIRHEUMATIC DRUG (DMARD) THERAPY,Treating active psoriatic arthritis,TA372,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,APREMILAST,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
APREMILAST ALONE OR IN COMBINATION WITH DISEASE‑MODIFYING ANTIRHEUMATIC DRUG (DMARD) THERAPY,Treating active psoriatic arthritis,TA372,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,APREMILAST,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
APREMILAST ALONE OR IN COMBINATION WITH DISEASE‑MODIFYING ANTIRHEUMATIC DRUG (DMARD) THERAPY,Treating active psoriatic arthritis,TA372,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,APREMILAST,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
"APREMILAST, ALONE OR IN COMBINATION WITH DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS)",Active psoriatic arthritis,TA433,psoriatic arthritis,156370009,Psoriatic arthritis,APREMILAST,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
"APREMILAST, ALONE OR IN COMBINATION WITH DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS)",Active psoriatic arthritis,TA433,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,APREMILAST,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
"APREMILAST, ALONE OR IN COMBINATION WITH DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS)",Active psoriatic arthritis,TA433,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,APREMILAST,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
"APREMILAST, ALONE OR IN COMBINATION WITH DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS)",Active psoriatic arthritis,TA433,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,APREMILAST,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
"APREMILAST, ALONE OR IN COMBINATION WITH DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS)",Active psoriatic arthritis,TA433,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,APREMILAST,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
"APREMILAST, ALONE OR IN COMBINATION WITH DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS)",Active psoriatic arthritis,TA433,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,APREMILAST,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ARIPIPRAZOLE,Moderate to severe manic episodes in adolescents with bipolar I disorder,TA292,manic episode,191583000,"Single manic episode, mild",ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Moderate to severe manic episodes in adolescents with bipolar I disorder,TA292,manic episode,191584006,"Single manic episode, moderate",ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Moderate to severe manic episodes in adolescents with bipolar I disorder,TA292,manic episode,191586008,"Single manic episode, severe, with psychosis",ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Moderate to severe manic episodes in adolescents with bipolar I disorder,TA292,manic episode,191592002,"Recurrent manic episodes, mild",ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Moderate to severe manic episodes in adolescents with bipolar I disorder,TA292,manic episode,191595000,"Recurrent manic episodes, severe, with psychosis",ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Moderate to severe manic episodes in adolescents with bipolar I disorder,TA292,manic episode,191597008,"Recurrent manic episodes, in full remission",ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,4926007,Schizophrenia in remission,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,12939007,Chronic disorganized schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,31373002,Hebephrenic schizophrenia in remission,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,31658008,Chronic paranoid schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,35252006,Disorganised schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,39610001,Undifferentiated schizophrenia in remission,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,58214004,Schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,63181006,"Paranoid schizophrenia, in remission",ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,64905009,Paranoid schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,79866005,Subchronic paranoid schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,83746006,Chronic schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,111482003,Subchronic schizophrenia with acute exacerbations,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,111483008,"Schizophrenia, catatonic, in remission",ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,111484002,Undifferentiated schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,160328009,Family history of schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,161103001,Schizophrenia association member,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,161468000,History of schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,191527001,Simple schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,191531007,Acute exacerbation of chronic schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,191548004,Chronic catatonic schizophrenia with acute exacerbation,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,191554003,Acute exacerbation of subchronic paranoid schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,191555002,Acute exacerbation of chronic paranoid schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,191559008,Latent schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,191565008,Latent schizophrenia in remission,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,191567000,Schizoaffective schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,191570001,Chronic schizoaffective schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,191572009,Acute exacerbation of chronic schizoaffective schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,191574005,"Schizophrenia, schizoaffective, in remission",ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,247804008,Prodromal schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,274952002,Borderline schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,278853003,Acute schizophrenia-like psychotic disorder,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,444180005,History of schizophrenia in child of subject,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,712824002,Acute polymorphic psychotic disorder without symptoms of schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,712850003,Acute polymorphic psychotic disorder with symptoms of schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,200951000000109,"Psychosis, schizophrenia and bipolar affective disorder resolved",ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,285521000000103,Schizophrenia resolved,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,417601000000102,"[X]Schizophrenia, schizotypal and delusional disorders",ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,443791000000100,[X]Pseudopsychopathic schizophrenia,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,1062101000000104,Schizophrenia TOM (Therapy Outcome Measure) activity score,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,1062121000000108,Schizophrenia TOM (Therapy Outcome Measure) impairment score,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,1062131000000105,Schizophrenia TOM (Therapy Outcome Measure) participation score,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARIPIPRAZOLE,Schizophrenia in people aged 15-17 years,TA213,schizophrenia,1062141000000101,Schizophrenia TOM (Therapy Outcome Measure) wellbeing score,ARIPIPRAZOLE,MENTAL HEALTH,MENTAL HEALTH
ARSENIC TRIOXIDE,Acute promyelocytic leukaemia,TA526,acute promyelocytic leukaemia,28950004,Acute promyelocytic leukaemia with,ARSENIC,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
ARSENIC TRIOXIDE,Acute promyelocytic leukaemia,TA526,acute promyelocytic leukaemia,110004001,Acute promyelocytic leukaemia (clinical),ARSENIC,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
ASCIMINIB,Chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors,TA813,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,ASCIMINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
"ATEZOLIZMAB WITH BEVACIZUMAB, PACLITAXEL AND CARBOPLATIN",First-line treatment of metastatic non-squamous non-small cell lung cancer,TA584,non-small cell lung cancer,254637007,Non-small cell lung cancer,ATEZOLIZMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
"ATEZOLIZMAB WITH BEVACIZUMAB, PACLITAXEL AND CARBOPLATIN",First-line treatment of metastatic non-squamous non-small cell lung cancer,TA584,non-small cell lung cancer,723301009,Squamous non-small cell lung cancer,ATEZOLIZMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
"ATEZOLIZMAB WITH BEVACIZUMAB, PACLITAXEL AND CARBOPLATIN",First-line treatment of metastatic non-squamous non-small cell lung cancer,TA584,non-small cell lung cancer,1259727001,Primary non-small cell lung cancer,ATEZOLIZMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
"ATEZOLIZMAB WITH BEVACIZUMAB, PACLITAXEL AND CARBOPLATIN",First-line treatment of metastatic non-squamous non-small cell lung cancer,TA584,non-small cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ATEZOLIZMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,162573006,Suspected lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,254637007,Non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,275981009,Lung cancer screening,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,429011007,Family history of lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,877691000000107,No FH of lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Adjuvant treatment of resected non-small-cell lung cancer,TA823,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,162573006,Suspected lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,254637007,Non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,275981009,Lung cancer screening,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,429011007,Family history of lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,877691000000107,No FH of lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Locally advanced or metastatic non-small-cell lung cancer after chemotherapy,TA520,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,TA525,urothelial carcinoma,12400006,Papillary urothelial carcinoma,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,TA525,urothelial carcinoma,27090000,Urothelial carcinoma,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,TA525,urothelial carcinoma,1259709004,Primary micropapillary urothelial carcinoma,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,162573006,Suspected lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,254637007,Non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,275981009,Lung cancer screening,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,429011007,Family history of lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,877691000000107,No FH of lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB,Untreated advanced non-small-cell lung cancer,TA705,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH BEVACIZUMAB,Advanced or unresectable hepatocellular carcinoma,TA666,hepatocellular carcinoma,15619004,"Hepatocellular carcinoma, fibrolamellar",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH BEVACIZUMAB,Advanced or unresectable hepatocellular carcinoma,TA666,hepatocellular carcinoma,253018005,Fibrolamellar hepatocellular carcinoma,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH BEVACIZUMAB,Advanced or unresectable hepatocellular carcinoma,TA666,hepatocellular carcinoma,990271000000107,Ultrasound scan surveillance of liver for hepatocellular carcinoma,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,162573006,Suspected lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,254637007,Non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,275981009,Lung cancer screening,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,429011007,Family history of lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,723301009,Squamous non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,1259727001,Primary non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,276491000000101,Fast track referral for suspected lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,848881000000108,QCancer lung cancer risk,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,877691000000107,No FH of lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,1771781000000107,Did not attend lung cancer screening,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND ETOPOSIDE,Untreated extensive-stage small-cell lung cancer,TA638,lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,162573006,Suspected lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,254637007,Non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,275981009,Lung cancer screening,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,429011007,Family history of lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,877691000000107,No FH of lung cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH CARBOPLATIN AND NAB-PACLITAXEL,Untreated advanced non-squamous non-small-cell lung cancer,TA618,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,134405005,Suspected breast cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,160287004,FH: Breast cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,268547008,Screening for breast cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,429740004,Family history of breast cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,706970001,TNBC - Triple-negative breast cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,94361000000105,Breast cancer detected by national screening programme,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,838351000000107,Education about risk of breast cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,874291000000100,QCancer breast cancer risk,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ATEZOLIZUMAB WITH NAB-PACLITAXEL,"Untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer",TA639,breast cancer,1035841000000108,Lymphoedema following breast cancer,ATEZOLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,7461003,"Attention deficit hyperactivity disorder, hyperactive impulsive type",ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,31177006,"Attention deficit hyperactivity disorder, combined type",ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,702536007,Stimulant drug therapy for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,702538008,Drug therapy for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,703314001,Non-stimulant drug therapy for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,516401000000106,Attention deficit hyperactivity disorder monitoring invitation first letter,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,516891000000101,Attention deficit hyperactivity disorder monitoring invitation second letter,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,516911000000103,Attention deficit hyperactivity disorder monitoring invitation third letter,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,710071000000106,Attention deficit hyperactivity disorder annual review,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,886371000000105,On drug therapy for ADHD (attention deficit hyperactivity disorder),ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,886391000000109,On stimulant drug therapy for ADHD (attention deficit hyperactivity disorder),ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,886411000000109,On non-stimulant drug therapy for ADHD (attention deficit hyperactivity disorder),ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,1863681000000108,Attention deficit hyperactivity disorder suspected,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,1914891000000100,Diagnostic assessment for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,2427101000000103,Signposting to attention deficit hyperactivity disorder resource,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
ATOMOXETINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,2437121000000109,Referral for diagnostic assessment for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,160270001,No family history of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,161499004,H/O: cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,171405001,Examination for suspected cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,266894000,Family history of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,266995000,History of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,395048001,Cardiovascular disease monitoring not required,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417206009,Cardiovascular disease monitoring,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417287002,Cardiovascular disease interim monitoring,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417322008,Cardiovascular disease annual review,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,429284000,Cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,429785003,Cardiovascular disease health education,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,440358008,Primary prevention of CVD (cardiovascular disease),ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,441829007,Assessment for risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166701000000106,Joint British Societies cardiovascular disease risk,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,302881000000102,Cardiovascular disease annual review declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,383321000000103,Cardiovascular disease risk assessment indicated,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,492581000000108,Cardiovascular disease high risk review declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,492611000000102,Cardiovascular disease high risk review,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,752451000000100,Cardiovascular disease risk assessment by third party,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,837461000000101,High risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,845171000000108,At risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,962871000000107,Aware of overall cardiovascular disease risk,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,990301000000105,Cardiovascular disease risk assessment done,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ATORVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,16434071000119108,At increased risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
AUTOLOGOUS ANTI-CD19-TRANSDUCED CD3+ CELLS,Relapsed or refractory mantle cell lymphoma,TA677,mantle cell lymphoma,74654000,Mantle cell lymphoma,AUTOLOGOUS,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
AUTOLOGOUS ANTI-CD19-TRANSDUCED CD3+ CELLS,Relapsed or refractory mantle cell lymphoma,TA677,mantle cell lymphoma,443487006,Mantle cell lymphoma,AUTOLOGOUS,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
AVACOPAN,Severe active granulomatosis with polyangiitis or microscopic polyangiitis,TA825,granulomatosis with polyangiitis,82275008,EGPA - eosinophilic granulomatosis with polyangiitis,AVACOPAN,RHEUMATOLOGY,RHEUMATOLOGY|THORACIC MEDICINE|NEPHROLOGY
AVACOPAN,Severe active granulomatosis with polyangiitis or microscopic polyangiitis,TA825,granulomatosis with polyangiitis,239935007,Limited granulomatosis with polyangiitis,AVACOPAN,RHEUMATOLOGY,RHEUMATOLOGY|THORACIC MEDICINE|NEPHROLOGY
AVATROMBOPAG,Primary chronic immune thrombocytopenia,TA853,immune thrombocytopenia,2897005,ITP - immune thrombocytopenia,AVATROMBOPAG,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
AVATROMBOPAG,Primary chronic immune thrombocytopenia,TA853,immune thrombocytopenia,128091003,Primary ITP (immune thrombocytopenia),AVATROMBOPAG,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
AVATROMBOPAG,Primary chronic immune thrombocytopenia,TA853,immune thrombocytopenia,240305000,NAIT - neonatal alloimmune thrombocytopenia,AVATROMBOPAG,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
AVATROMBOPAG,Severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure,TA626,chronic liver disease,197279005,Cirrhosis and chronic liver disease,AVATROMBOPAG,GASTROENTEROLOGY,GASTROENTEROLOGY
AVATROMBOPAG,Severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure,TA626,chronic liver disease,197324004,Liver abscess and sequelae of chronic liver disease,AVATROMBOPAG,GASTROENTEROLOGY,GASTROENTEROLOGY
AVATROMBOPAG,Severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure,TA626,chronic liver disease,328383001,Chronic liver disease,AVATROMBOPAG,GASTROENTEROLOGY,GASTROENTEROLOGY
AVELUMAB,Untreated metastatic Merkel cell carcinoma,TA691,merkel cell carcinoma,133871000119103,Merkel cell carcinoma of upper limb,AVELUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
AVELUMAB (FIRST-LINE),Metastatic Merkel cell carcinoma,TA517,merkel cell carcinoma,133871000119103,Merkel cell carcinoma of upper limb,AVELUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
AVELUMAB (SECOND-LINE AND BEYOND TREATMENT),Metastatic Merkel cell carcinoma,TA517,merkel cell carcinoma,133871000119103,Merkel cell carcinoma of upper limb,AVELUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
AVELUMAB WITH AXITINIB FOR UNTREATED ADVANCED RENAL CELL CARCINOMA,Untreated advanced renal cell carcinoma,TA645,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,AVELUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
AVELUMAB WITH AXITINIB FOR UNTREATED ADVANCED RENAL CELL CARCINOMA,Untreated advanced renal cell carcinoma,TA645,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,AVELUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
AVELUMAB WITH AXITINIB FOR UNTREATED ADVANCED RENAL CELL CARCINOMA,Untreated advanced renal cell carcinoma,TA645,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,AVELUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
AVELUMAB WITH AXITINIB FOR UNTREATED ADVANCED RENAL CELL CARCINOMA,Untreated advanced renal cell carcinoma,TA645,renal cell carcinoma,733608000,Papillary renal cell carcinoma,AVELUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
AVELUMAB WITH AXITINIB FOR UNTREATED ADVANCED RENAL CELL CARCINOMA,Untreated advanced renal cell carcinoma,TA645,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,AVELUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
AVELUMAB WITH AXITINIB FOR UNTREATED ADVANCED RENAL CELL CARCINOMA,Untreated advanced renal cell carcinoma,TA645,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,AVELUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
AVELUMAB WITH AXITINIB FOR UNTREATED ADVANCED RENAL CELL CARCINOMA,Untreated advanced renal cell carcinoma,TA645,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,AVELUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
AXICABTAGENE CILOLEUCEL,Diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies,TA559,diffuse large b-cell lymphoma,109969005,Diffuse large B-cell lymphoma,AXICABTAGENE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
AXICABTAGENE CILOLEUCEL,Diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies,TA872,diffuse large b-cell lymphoma,109969005,Diffuse large B-cell lymphoma,AXICABTAGENE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
AXICABTAGENE CILOLEUCEL,Diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies,TA559,diffuse large b-cell lymphoma,847741000000106,Diffuse large B-cell lymphoma,AXICABTAGENE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
AXICABTAGENE CILOLEUCEL,Diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies,TA872,diffuse large b-cell lymphoma,847741000000106,Diffuse large B-cell lymphoma,AXICABTAGENE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
AXITINIB,treating advanced renal cell carcinoma after failure of prior systemic treatment,TA333,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,AXITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
AXITINIB,treating advanced renal cell carcinoma after failure of prior systemic treatment,TA333,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,AXITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
AXITINIB,treating advanced renal cell carcinoma after failure of prior systemic treatment,TA333,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,AXITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
AXITINIB,treating advanced renal cell carcinoma after failure of prior systemic treatment,TA333,renal cell carcinoma,733608000,Papillary renal cell carcinoma,AXITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
AXITINIB,treating advanced renal cell carcinoma after failure of prior systemic treatment,TA333,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,AXITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
AXITINIB,treating advanced renal cell carcinoma after failure of prior systemic treatment,TA333,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,AXITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
AXITINIB,treating advanced renal cell carcinoma after failure of prior systemic treatment,TA333,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,AXITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
AZACITIDINE,"Myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia",TA218,acute myeloid leukaemia,91861009,"Acute myeloid leukaemia, disease",AZACITIDINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
AZACITIDINE,Treating acute myeloid leukaemia with more than 30% bone marrow blasts,TA399,acute myeloid leukaemia,91861009,"Acute myeloid leukaemia, disease",AZACITIDINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,6142004,Influenza,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,24662006,Influenza caused by Influenza B virus,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,41269000,Influenzal bronchopneumonia,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,44470000,Haemophilus influenzae,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,46233009,Influenza virus vaccine,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,51593004,Haemophilus parainfluenzae,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,64917006,Pneumonia due to parainfluenza virus,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,70036007,Haemophilus influenzae pneumonia,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,74644004,Influenza with encephalopathy,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,89117003,Parainfluenza virus type 4,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,91428005,Haemophilus influenzae infection,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,95891005,Influenza-like illness,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,120753009,Influenza A virus antibody,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,120843002,Influenza B virus Ab,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,120975003,Haemophilus influenzae type b antigen,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,127787002,Haemophilus influenzae type b immunisation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,170343007,First Haemophilus influenzae type b vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,170345000,Third Haemophilus influenzae type b vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,171272004,No consent - influenza immunization,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,171282003,Influenza immunization advised at home,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,171290003,Influenza vaccination consent given,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,171291004,No consent for Haemophilus influenzae type b immunization,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,185900003,Has influenza vaccination at home,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,185901004,Has influenza vaccination at surgery,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,185902006,Has influenza vaccination at hospital,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,185903001,Needs influenza immunisation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,192721000,Post influenza vaccination encephalitis,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,194946005,Acute myocarditis - influenzal,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,195726000,Acute parainfluenza virus bronchitis,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,195878008,Pneumonia and influenza,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,195923003,Influenza with laryngitis,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,195924009,Influenza with pharyngitis,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,195929004,Influenza with gastrointestinal tract involvement,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,195931008,Influenza like illness,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,266393000,Influenza-like illness,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,268561003,Influenza immunization advised in surgery,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,275983007,Influenza immunisation advised,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,291749008,Influenza vaccine poisoning,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,293112000,Influenza split virion vaccine adverse reaction,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,293113005,Influenza surface antigen vaccine adverse reaction,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,294647003,Allergy to influenza vaccine,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,294648008,Allergy to influenza split virion vaccine,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,294649000,Allergy to influenza surface antigen vaccine,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,294664000,Haemophilus influenzae type b vaccine allergy,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,308532005,Influenza vaccination status,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,309789002,Encephalitis caused by Influenza virus,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,315640000,Influenza vaccination declined,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,315641001,Influenza vaccination invitation letter sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,390796006,Influenza vaccination contraindicated,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,396425006,FLU - Influenza vaccine,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,407479009,Influenza A virus,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,407480007,Influenza B virus(B/Lee/40),BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,407489008,Human parainfluenza virus 1,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,407491000,Parainfluenza virus type 2,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,407493002,Human parainfluenza virus 3,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,407498006,Human parainfluenza viruses,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,407573008,Influenza vaccination not indicated,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,414496007,Influenza vaccination telephone invite,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,416928007,Has influenza vaccination at work,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,441043003,Influenza A virus subtype H1 present,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,441049004,Influenza A virus subtype H3 present,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,441343005,Influenza A virus subtype H5 present,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,441344004,Human parainfluenza virus present,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,441345003,Influenza B virus present,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,442438000,Influenza caused by Influenza A virus,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,442696006,Influenza A (H1N1) swine flu,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,444426005,Swine influenza contact,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,473169009,History of influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,698353005,Requires influenza virus vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,709410003,Hib (Haemophilus influenzae type b) infection,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,711330007,Influenza A virus subtype H1N1 detected,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,711334003,Influenza A virus H1N1 subtype not detected,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,736818002,Influenza vaccination requested,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,737041000,Influenza immunisation telephone invitation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,787016008,Administration of influenza vaccine via nasal route,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,73701000119109,Vaccination for influenza given,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,135221000119101,Influenza A H1N1 vaccination given,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,199331000000106,Did not attend influenza vaccination appointment,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,200481000000107,Influenza vaccination invitation first letter sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,200491000000109,Influenza vaccination invitation second letter sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,200501000000103,Influenza vaccination invitation third letter sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,201391000000106,Booster influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,202301000000106,First pandemic influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,202311000000108,Second pandemic influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,380271000000101,Consent given for pandemic influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,380381000000108,Pandemic influenza vaccination refused,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,380631000000100,Pandemic influenza vaccination contraindicated,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,380801000000105,Pandemic influenza vaccination not indicated,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,506751000000104,Possible influenza A virus H1N1 subtype,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,516101000000103,No response to influenza vaccination invitation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,540151000000108,Pneumonia or influenza NOS,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,761311000000109,Influenza vaccination verbal invitation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,777791000000102,Influenza vaccination invitation first text message sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,822851000000102,Seasonal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,822931000000100,Seasonal influenza vaccination declined,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,822951000000107,Seasonal influenza vaccination contraindicated,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,822971000000103,Seasonal influenza vaccination not indicated,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,822991000000104,Consent given for seasonal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,844941000000103,Influenza vaccination invitation email,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,844961000000102,Influenza vaccination invitation first email,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,844981000000106,Influenza vaccination invitation second email,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,845001000000101,Influenza vaccination invitation third email,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,860151000000103,Influenza vaccination first verbal invitation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,860171000000107,Influenza vaccination second verbal invitation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,860211000000105,Influenza vaccination second telephone invitation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,860291000000101,Influenza vaccination third verbal invitation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,868241000000109,Administration of intranasal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,868491000000103,No consent for seasonal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,871521000000104,First intranasal influenza vaccination declined,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,871541000000106,Second intranasal influenza vaccination declined,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,871751000000104,Administration of first intranasal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,871781000000105,Administration of second intranasal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,873681000000101,Provision of information about seasonal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,913961000000102,Education about influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,932221000000103,At risk of influenza related complication,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,935351000000106,Long term indication for seasonal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,955641000000103,Influenza vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,996211000000100,Influenza (A and B) serology,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,996761000000106,Haemophilus influenzae B IgG level,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1001341000000106,Influenza A antigen level,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1001351000000109,Influenza B antigen level,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1005101000000108,Parainfluenza virus antibody level,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1005111000000105,Parainfluenza type 3 antibody level,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1008771000000107,Haemophilus influenzae B antibody level,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1014261000000103,Influenza A antibody level,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1014271000000105,Influenza B antibody level,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1020381000000100,Parainfluenza virus antigen assay,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1033051000000101,Influenza due to zoonotic influenza virus,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1033071000000105,Influenza due to pandemic influenza virus,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1033091000000109,Influenza due to seasonal influenza virus,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1095821000000105,Influenza vaccination first telephone invitation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1095831000000107,Influenza vaccination second telephone invitation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1095841000000103,Influenza vaccination third telephone invitation,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1239861000000100,Seasonal influenza vaccination given in school,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BALOXAVIR MARBOXIL,Acute uncomplicated influenza,TA732,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",BALOXAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
BARICITINIB FOR TREATING MODERATE TO SEVERE ATOPIC DERMATITIS,Moderate to severe atopic dermatitis,TA681,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,BARICITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
BARICITINIB FOR TREATING MODERATE TO SEVERE ATOPIC DERMATITIS,Moderate to severe atopic dermatitis,TA681,atopic dermatitis,238543002,Discoid atopic dermatitis,BARICITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
BARICITINIB FOR TREATING MODERATE TO SEVERE ATOPIC DERMATITIS,Moderate to severe atopic dermatitis,TA681,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,BARICITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
BARICITINIB FOR TREATING MODERATE TO SEVERE ATOPIC DERMATITIS,Moderate to severe atopic dermatitis,TA681,atopic dermatitis,238545009,Follicular atopic dermatitis,BARICITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
BARICITINIB FOR TREATING MODERATE TO SEVERE ATOPIC DERMATITIS,Moderate to severe atopic dermatitis,TA681,atopic dermatitis,238546005,Pruriginous atopic dermatitis,BARICITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
BARICITINIB FOR TREATING MODERATE TO SEVERE ATOPIC DERMATITIS,Moderate to severe atopic dermatitis,TA681,atopic dermatitis,584621000000108,Atopic dermatitis NOS,BARICITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,161567008,History of rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,161567008,History of rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,161567008,History of rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BARICITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA466,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,BARICITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
BASILIXIMAB,Kidney transplant in adults,TA481,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BASILIXIMAB,Kidney transplant in adults,TA481,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BASILIXIMAB,Kidney transplant in adults,TA481,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BASILIXIMAB,Kidney transplant in adults,TA481,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BASILIXIMAB,Kidney transplant in adults,TA481,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BASILIXIMAB,Kidney transplant in adults,TA481,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BASILIXIMAB,Kidney transplant in children and young people,TA482,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BASILIXIMAB,Kidney transplant in children and young people,TA482,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BASILIXIMAB,Kidney transplant in children and young people,TA482,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BASILIXIMAB,Kidney transplant in children and young people,TA482,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BASILIXIMAB,Kidney transplant in children and young people,TA482,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BASILIXIMAB,Kidney transplant in children and young people,TA482,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BASILIXIMAB,Renal transplantation - children and adolescents,TA099,renal transplantation,70536003,Renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BASILIXIMAB,Renal transplantation - children and adolescents,TA099,renal transplantation,313030004,Donor renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BASILIXIMAB,Renal transplantation - children and adolescents,TA099,renal transplantation,429451003,Disorder related to renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BECLOMETASONE DIPROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
BECLOMETASONE DIPROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
BECLOMETASONE DIPROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
BECLOMETASONE DIPROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
BECLOMETASONE DIPROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
BECLOMETASONE DIPROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
BELATACEPT,Kidney transplant in adults,TA481,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BELATACEPT,Kidney transplant in adults,TA481,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BELATACEPT,Kidney transplant in adults,TA481,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BELATACEPT,Kidney transplant in adults,TA481,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BELATACEPT,Kidney transplant in adults,TA481,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BELATACEPT,Kidney transplant in adults,TA481,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BELATACEPT,Kidney transplant in children and young people,TA482,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BELATACEPT,Kidney transplant in children and young people,TA482,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BELATACEPT,Kidney transplant in children and young people,TA482,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BELATACEPT,Kidney transplant in children and young people,TA482,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BELATACEPT,Kidney transplant in children and young people,TA482,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BELATACEPT,Kidney transplant in children and young people,TA482,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,4676006,"Systemic lupus erythematosus glomerulonephritis syndrome, World Health Organization class II",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,36402006,"Systemic lupus erythematosus glomerulonephritis syndrome, World Health Organization class IV",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,73286009,"Systemic lupus erythematosus glomerulonephritis syndrome, World Health Organization class I",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,76521009,"Systemic lupus erythematosus glomerulonephritis syndrome, World Health Organization class III",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,95644001,Cerebral systemic lupus erythematosus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,196138005,Lung disease with systemic lupus erythematosus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,201436003,Drug-induced systemic lupus erythematosus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,230307005,Chorea due to systemic lupus erythematosus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,239887007,Systemic lupus erythematosus with organ/system involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,239889005,Bullous systemic lupus erythematosus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,239890001,Systemic lupus erythematosus with multisystem involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,273863009,Systemic lupus erythematosus disease activity index,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,307755009,Renal tubulo-interstitial disorder due to systemic lupus erythematosus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Active autoantibody-positive systemic lupus erythematosus,TA752,systemic lupus erythematosus,309762007,Systemic lupus erythematosus with pericarditis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,4676006,"Systemic lupus erythematosus glomerulonephritis syndrome, World Health Organization class II",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,36402006,"Systemic lupus erythematosus glomerulonephritis syndrome, World Health Organization class IV",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,73286009,"Systemic lupus erythematosus glomerulonephritis syndrome, World Health Organization class I",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,76521009,"Systemic lupus erythematosus glomerulonephritis syndrome, World Health Organization class III",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,95644001,Cerebral systemic lupus erythematosus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,196138005,Lung disease with systemic lupus erythematosus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,201436003,Drug-induced systemic lupus erythematosus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,230307005,Chorea due to systemic lupus erythematosus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,239887007,Systemic lupus erythematosus with organ/system involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,239889005,Bullous systemic lupus erythematosus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,239890001,Systemic lupus erythematosus with multisystem involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,273863009,Systemic lupus erythematosus disease activity index,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,307755009,Renal tubulo-interstitial disorder due to systemic lupus erythematosus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BELIMUMAB,Treating active autoantibody-positive systemic lupus erythematosus,TA397,systemic lupus erythematosus,309762007,Systemic lupus erythematosus with pericarditis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|NEPHROLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,835009,Angioimmunoblastic lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,1929004,"Malignant lymphoma, diffuse",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,19340000,Plasmacytic lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,20776008,Adenolymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,21964009,Lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,21983002,Struma lymphomatosa,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,28054005,Cutaneous lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,28175004,Gastric pseudolymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,30440004,Lymphoma stage I,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,31047003,Lymphomatoid papulosis,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,40411000,"Malignant lymphoma, histiocytic, nodular",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,41529000,"Classical Hodgkin lymphoma, mixed cellularity",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,46732000,"Malignant lymphoma, large cell, cleaved, diffuse",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,51092000,Malignant lymphoma lymphocytic well differentiated diffuse,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,52248008,"Classical Hodgkin lymphoma, nodular sclerosis",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,55020008,"Malignant lymphoma, mixed cell type, follicular",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,55150002,"Malignant lymphoma, nodular",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,56944001,Lymphoma stage III,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,64575004,"Malignant lymphoma, small lymphocytic, diffuse",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,66445009,Lymphoma stage IV,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,70600005,"Hodgkin lymphoma, nodular lymphocyte predominance",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,74654000,Mantle cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,76422004,Lymphoma stage II,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,92814006,B-cell CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma),BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,93191005,Malignant lymphoma of intra-abdominal lymph nodes,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,93192003,Malignant lymphoma of intrapelvic lymph nodes,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,93194002,Malignant lymphoma of lymph nodes of axilla AND/OR upper limb,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,93195001,"Malignant lymphoma of lymph nodes of head, face AND/OR neck",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,93197009,Malignant lymphoma of lymph nodes of multiple sites,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,93198004,Malignant lymphoma of spleen,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,95186006,Nodular lymphoma of intra-abdominal lymph nodes,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,95192000,Nodular lymphoma of lymph nodes of multiple sites,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,95193005,Nodular lymphoma of spleen,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,106252000,Staging classification for lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,109962001,Nonfollicular lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,109966003,"Lymphoma, immunoblastic, high grade",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,109969005,Diffuse large B-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,109975001,T-zone lymphoma (clinical),BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,109976000,Lymphoepithelioid lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,109977009,Peripheral T-cell lymphoma pleomorphic medium and large cell,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,109978004,T-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,109979007,B-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,109988003,True histiocytic lymphoma (clinical),BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,115244002,Malignant lymphoma - category,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,115245001,"Malignant lymphoma, follicular AND/OR nodular",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,118599009,"Lymphoma, Hodgkins",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,118600007,Malignant lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,118601006,Non-Hodgkin lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,118605002,"Hodgkin lymphoma, nodular lymphocyte predominance",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,118609008,Hodgkin mixed cellularity lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,118617000,Burkitt lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,128799007,"Hodgkin lymphoma, lymphocyte-rich",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,128803008,Marginal zone lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,128805001,Angiocentric natural killer cell and T-cell malignant lymphoma nasal type,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,128875000,Primary cutaneous CD30 antigen positive large T-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,128929007,Non-Hodgkin lymphoma - category,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,128930002,Hodgkin lymphoma - category,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,188609000,"Nodular lymphoma of lymph nodes of head, face and neck",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,188612002,Nodular lymphoma of lymph nodes of axilla and upper limb,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,188613007,Nodular lymphoma of lymph nodes of inguinal region and lower limb,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,188674006,Diffuse malignant lymphoma - small non-cleaved cell,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,188675007,"Malignant lymphoma, lymphocytic - poorly differentiated",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,188676008,Malignant lymphoma - mixed lymphocytic-histiocytic,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,189958005,"Lymphomatous tumour, benign",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,189962004,"Malignant lymphoma, stem cell type",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,232075002,Lymphoma of retina,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,236513009,Lymphoma of kidney,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,238994000,Drug-induced pseudolymphomatous eruption,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,239297008,Lymphomatoid granulomatosis of lung,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,239940004,Lymphomatoid granulomatosis,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,240794006,Splenic schistosomal giant cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,254372002,Ann Arbor lymphoma staging system,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,255102004,Intravascular lymphomatosis,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,258279002,Lymphoma staging symptom status values,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,269476000,Nodular lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,274905008,Mantle zone lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,276811008,Gastric lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,276815004,Lymphoma of intestine,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,276836002,Primary cerebral lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277024002,Working formulation of non-Hodgkin lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277551008,Splenic lymphoma with villous lymphocytes,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277570003,Lymphoma with spill,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277613000,Cutaneous peripheral T-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277615007,Low grade B-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277616008,Diffuse low grade B-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277617004,High grade B-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277618009,Nodular malignant lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277623009,Monocytoid B-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277624003,Follicular malignant lymphoma - mixed cell type,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277625002,Follicular malignant lymphoma - small cleaved cell,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277626001,Diffuse high grade B-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277627005,Nodular high grade B-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277637000,Large cell anaplastic lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277641001,Follicular malignant lymphoma - large cell,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277642008,Low grade T-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277643003,High grade T-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277651000,Peripheral T-cell lymphoma - pleomorphic small cell,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277654008,Enteropathy-type T-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,277664004,Malignant lymphoma of testis,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,278051002,Malignant lymphoma of thyroid gland,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,278052009,Malignant lymphoma of breast,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,302841002,Malignant lymphoma - small cell,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,303055001,"Malignant lymphoma, follicular centre cell",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,307623001,Malignant lymphoma - lymphoplasmacytic,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,308121000,Follicular lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,314922006,B-cell lymphoma morphology,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,314923001,Low grade B-cell lymphoma morphology,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,314924007,Follicular low grade B-cell lymphoma morphology,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,314925008,High grade B-cell lymphoma morphology,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,314926009,T-cell lymphoma morphology,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,314929002,Diffuse low grade B-cell lymphoma morphology,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,314934003,Diffuse high grade B-cell lymphoma morphology,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,315264005,Suspected lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,400001003,Primary cutaneous lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,400122007,CTCL - Cutaneous T-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,404111002,Lymphomatoid papulosis-associated mycosis fungoides,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,404140004,SALT type B-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,413537009,Angioimmunoblastic T-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,414166008,Natural Killer cell and T-cell malignant lymphoma nasal type,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,414780005,Mucosa-associated lymphoid tissue lymphoma of orbit,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,420788006,Vitreoretinal lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,426071002,Hodgkin lymphoma in remission,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,427141003,Malignant lymphoma in remission,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,428046009,History of non-Hodgkins lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,433450000,Family history of non-Hodgkin lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,443487006,Mantle cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,444597005,Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of stomach,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,444910004,Primary mediastinal (thymic) large B-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,445269007,Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,445406001,Hepatosplenic T-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,447100004,Marginal zone lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,448211002,Adenolymphoma of parotid gland,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,448212009,Anaplastic lymphoma kinase negative anaplastic large cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,448709005,Non-Hodgkin lymphoma of stomach,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,449074003,Lymphoma of small intestine,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,449220000,Diffuse follicle center lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,450958009,"Malignant lymphoma, diffuse large B-cell, immunoblastic",BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,721555001,Follicular lymphoma of small intestine,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,724648008,Plasmablastic lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,738770003,Anaplastic lymphoma kinase positive anaplastic large cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,762690000,Classical Hodgkin lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,763666008,Splenic marginal zone B-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,830057003,Relapsing classical Hodgkin lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,1148845007,Follicular non-Hodgkin lymphoma grade 3b,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,1148851002,Follicular lymphoma grade IIIa,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,143291000119104,Non-Hodgkin's lymphoma in remission,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,847481000000109,Follicular lymphoma grade 1,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,847631000000107,Follicular lymphoma grade 2,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,847651000000100,Follicular lymphoma grade 3,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,847691000000108,Follicular lymphoma grade 3a,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,847701000000108,Follicular lymphoma grade 3b,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,847741000000106,Diffuse large B-cell lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,878461000000100,No FH of non-Hodgkin lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,1090241000000107,Angioimmunoblastic T-cell lymphoma with dysproteinaemia,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,1091861000000100,Cutaneous follicle centre lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,1091891000000106,B-cell Hodgkin's lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE,Indolent non-Hodgkin's lymphoma that is refractory to rituximab,TA206,lymphoma,1091921000000103,B-cell non-Hodgkin's lymphoma,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BENDAMUSTINE (1ST LINE),Chronic lymphocytic leukaemia (Binet stage B or C),TA216,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
BENDAMUSTINE (1ST LINE),Chronic lymphocytic leukaemia (Binet stage B or C),TA216,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
BENDAMUSTINE (1ST LINE),Chronic lymphocytic leukaemia (Binet stage B or C),TA216,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
BENDAMUSTINE (1ST LINE),Chronic lymphocytic leukaemia (Binet stage B or C),TA216,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,BENDAMUSTINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,12428000,Intrinsic asthma without status asthmaticus,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,31387002,Exercise-induced asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,34015007,Flour asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,56018004,Asthmatic breathing,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,56968009,Asthma caused by wood dust,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,57607007,Industrial asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,63088003,Allergic asthma without status asthmaticus,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,71892000,Cardiac asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,93432008,Drug-induced asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,160377001,Family history of asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,161105008,Asthma society member,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,161527007,History of asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,162660004,Asthma resolved,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170607007,Respiratory disease monitoring (& [asthma] or [chronic]),BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170631002,Asthma disturbing sleep,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170632009,Asthma causing night waking,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170633004,Asthma disturbs sleep weekly,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170634005,Asthma disturbs sleep frequently,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170635006,Asthma not disturbing sleep,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170636007,Asthma never disturbs sleep,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170637003,Asthma limiting activities,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170638008,Asthma not limiting activities,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170642006,Asthma severity,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170647000,Asthma prophylactic medication used,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170655007,Asthma restricts exercise,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170656008,Asthma sometimes restricts exercise,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170657004,Asthma severely restricts exercise,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,170658009,Asthma never restricts exercise,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,171231001,Asthma screening,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,182724005,Further asthma - drug prevention,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,182726007,Asthma control step 0,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,182727003,Asthma control step 1,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,182728008,Asthma control step 2,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,182729000,Asthma control step 3,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,182730005,Asthma control step 4,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,182731009,Asthma control step 5,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,183099005,Asthma leaflet given,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,183478001,Emergency hospital admission for asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,185242005,Seen in asthma clinic,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,185728001,Attends asthma monitoring,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,185730004,Asthma monitor offer default,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,185731000,Asthma monitoring call first letter,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,185732007,Asthma monitoring call second letter,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,185734008,Asthma monitoring call third letter,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,185735009,Asthma monitoring call verbal invite,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,185736005,Asthma monitoring call telephone invite,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,185737001,Asthma monitoring deleted,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,185940009,Patient in asthma study,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,195113008,(Left ventricular: [failure] or [impaired function]) or (cardiac asthma) or (acute pulmonary edema),BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,195949008,Chronic asthmatic bronchitis,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,195967001,Asthmatic,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,195968006,Asthma: [extrinsic - atopic] or [allergic] or [pollen] or [childhood] or [with hay fever],BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,195973000,Late-onset asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,195977004,Mixed asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,195983001,Exercise induced asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,219036002,Adverse reaction to antiasthmatic,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,225057002,Brittle asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,233678006,Childhood asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,233679003,Late-onset asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,233683003,Hay fever with asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,233691007,Eosinophilic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,266361008,Non-allergic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,266396008,Extrinsic asthma - atopy (& pollen),BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,266397004,Intrinsic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,266398009,Asthma attack,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,270442000,Asthma monitoring check done,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,275908000,Asthma monitoring,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,281239006,Asthma attack,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,302220000,Asthma control steps,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,304527002,Acute asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,308500005,Asthma monitoring call,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,308501009,Asthma monitoring status,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,312453004,Asthma - currently active,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,312454005,Asthma - currently dormant,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,366874008,Number of asthma exacerbations in past year,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370202007,Asthma causes daytime symptoms 1 to 2 times per month,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370203002,Asthma causes daytime symptoms 1 to 2 times per week,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370204008,Asthma causes daytime symptoms most days,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370205009,Asthma causes night symptoms 1 to 2 times per month,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370206005,Asthma limits walking on the flat,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370207001,Asthma limits walking up hills or stairs,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370208006,Asthma never causes daytime symptoms,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370218001,Mild asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370219009,Moderate asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370220003,Occasional asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370221004,Severe asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370225008,Asthma treatment compliance unsatisfactory,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,370226009,Asthma treatment compliance satisfactory,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,373899003,Asthma daytime symptoms,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,389145006,Allergic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,390798007,Asthma finding,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,390872009,Change in asthma management plan,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,390877003,Step up change in asthma management plan,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,390878008,Step down change in asthma management plan,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,390921001,Absent from work or school due to asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,390940007,Asthma monitoring due,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,394700004,Asthma annual review,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,394701000,Asthma follow-up,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,394720003,Asthma medication review,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,394967008,Suspected asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,395022009,Nocturnal asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,400987003,Asthma trigger,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,401135008,Health education - asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,401182001,Asthma monitoring by nurse,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,401183006,Asthma monitoring by doctor,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,401193004,Asthma confirmed,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,405944004,Asthmatic bronchitis,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,406162001,Asthma care,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,407674008,Aspirin-induced asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,409663006,Cough variant asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,415265005,Referral to asthma clinic,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,423889005,Non-immunoglobulin E mediated allergic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,424643009,Allergic atopic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,425969006,Acute intermittent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,426656000,Severe persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,426979002,Mild persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,427295004,Moderate persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,427603009,Intermittent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,427679007,Mild intermittent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,442025000,Acute exacerbation of chronic asthmatic bronchitis,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,443117005,Asthma control test score,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,445427006,Seasonal asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,445531003,ACQ - Asthma control questionnaire,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,473391009,Asthma never causes night symptoms,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,698509001,Under care of asthma specialist nurse,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,699191007,Did not attend asthma review,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,702823004,Asthma clinic,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,704008007,No family history of asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,707445000,Acute mild persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,707446004,Acute exacerbation of moderate persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,707447008,Exacerbation of severe persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,707511009,Uncomplicated mild persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,707512002,Uncomplicated moderate persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,707513007,Uncomplicated severe persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,707979007,Acute severe exacerbation of severe persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,707980005,Acute severe exacerbation of moderate persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,707981009,Acute severe exacerbation of mild persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,708038006,Acute exacerbation of asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,708090002,Acute severe exacerbation of asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,708093000,Acute exacerbation of allergic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,708094006,Acute exacerbation of intrinsic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,708095007,Acute severe exacerbation of extrinsic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,708358003,Emergency asthma admission since last encounter,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,708373002,Emergency asthma patient visit since last encounter,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,711442001,Recent asthma management,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,715191006,Telehealth asthma monitoring,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,734346005,Use of asthma symptom diary,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,734904007,Life threatening acute exacerbation of asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,734905008,Moderate acute exacerbation of asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,736056000,Asthma clinical management plan,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,762521001,Acute allergic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,763077003,Asthma Control Questionnaire score,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,763221007,Asthma monitoring declined,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,763695004,Mini Asthma Quality of Life Questionnaire score,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,782520007,Exacerbation of allergic asthma due to infection,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,782559003,Asthma never causes night symptoms,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,401000119107,Asthma with irreversible airway obstruction,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,641000119106,Intermittent asthma well controlled,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,1741000119102,Intermittent asthma uncontrolled,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,72301000119103,Asthma in pregnancy,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,89581000000109,DNA (did not attend) asthma clinic,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,92161000000104,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation using preferred method of communication,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,99031000119107,Acute exacerbation of asthma co-occurrent with allergic rhinitis,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,125011000119100,Mild persistent asthma co-occurrent with allergic rhinitis,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,125021000119107,Intermittent asthma co-occurrent with allergic rhinitis,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,135171000119106,Acute exacerbation of moderate persistent asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,143901000000108,Registration for access to online asthma self-management application,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,143931000000102,Declined to register for access to online asthma self-management application,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,176711000000100,Does not have asthma management plan,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,198971000000102,Asthma outreach clinic,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,201031000000108,Asthma trigger - respiratory infection,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,201041000000104,Asthma trigger - seasonal,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,201051000000101,Asthma trigger - animal,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,201191000000108,Asthma trigger - cold air,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,201201000000105,Asthma trigger - damp,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,201211000000107,Asthma trigger - emotion,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,302331000000106,RCP (Royal College of Physicians) asthma assessment,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,340891000000106,Asthma trigger - airborne dust,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,340901000000107,Asthma trigger - exercise,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,340911000000109,Asthma trigger - pollen,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,340921000000103,Asthma trigger - tobacco smoke,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,340931000000101,Asthma trigger - warm air,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,527171000000103,Patient has a written asthma personal action plan,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,527191000000104,Health education - asthma self management,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,527211000000100,Health education - structured asthma discussion,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,527231000000108,Health education - structured patient focused asthma discussion,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,713701000000108,Asthma monitoring administration,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,713711000000105,Asthma clinic administration,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,715801000000103,Exception reporting - asthma quality indicators,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,716491000000100,Excepted from asthma quality indicators - informed dissent,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,717291000000103,Excepted from asthma quality indicators - patient unsuitable,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,754061000000100,Asthma review using Royal College of Physicians three questions,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,771901000000100,Asthma causes night time symptoms 1 to 2 times per week,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,771941000000102,Asthma causes symptoms most nights,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,771981000000105,Asthma limits activities 1 to 2 times per month,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,772011000000107,Asthma limits activities 1 to 2 times per week,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,772051000000106,Asthma limits activities most days,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,791401000000104,Seen in school asthma clinic,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,810901000000102,Asthma self-management plan review,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,811151000000105,Number of days absent from school due to asthma in past 6 months,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,811921000000103,Asthma self-management plan agreed,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,815631000000106,Asthma trigger - wind,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,818161000000104,Asthma trigger - perfume,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,866881000000101,Chronic asthma with fixed airflow obstruction,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,867171000000106,No asthma trigger identified by subject,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,892301000000100,Asthma management plan declined,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,905301000000103,Childhood Asthma Control Test score,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,928451000000107,Asthma monitoring invitation short message service text message,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,928511000000107,Asthma monitoring invitation email,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,928651000000105,Review of patient at risk of asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,928691000000102,At risk of asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,959401000000101,Asthma monitoring SMS (short message service) text message first invitation,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,959421000000105,Asthma monitoring SMS (short message service) text message second invitation,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,959441000000103,Asthma monitoring SMS (short message service) text message third invitation,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,959901000000107,Asthma action plan,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,966011000000109,At risk of severe asthma exacerbation,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,966031000000101,Severe asthma exacerbation risk assessment,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,1086701000000102,Life threatening acute exacerbation of allergic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,1086711000000100,Life threatening acute exacerbation of non-allergic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,1108701000000106,Excepted from asthma quality indicators - service unavailable,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,1110841000000103,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,10674991000119104,Intermittent allergic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,10675431000119106,Severe persistent allergic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,10675551000119104,Acute severe exacerbation of severe persistent asthma co-occurrent with allergic rhinitis,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,10675871000119106,Mild persistent allergic asthma,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,10675991000119100,Acute severe exacerbation of mild persistent allergic asthma co-occurrent with allergic rhinitis,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,10676031000119106,Mild persistent allergic asthma controlled,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BENRALIZUMAB,Severe eosinophilic asthma,TA565,asthma,10676111000119102,Mild persistent asthma controlled co-occurrent with allergic rhinitis,BENRALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,24700007,Multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,160337009,Family history of multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,192926004,Brain stem multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,192928003,Generalised multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,428700003,Primary progressive multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,438511000,Benign multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,700409000,Suspected multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,198491000000106,Multiple sclerosis review,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,515931000000104,Multiple sclerosis review declined,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETA INTERFERON,Multiple sclerosis,TA032,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
BETAMETHASONE ESTERS (IN GUIDANCE: BETAMETHASONE VALERATE),Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
BETAMETHASONE ESTERS (IN GUIDANCE: BETAMETHASONE VALERATE),Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
BETAMETHASONE ESTERS (IN GUIDANCE: BETAMETHASONE VALERATE),Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
BETAMETHASONE ESTERS (IN GUIDANCE: BETAMETHASONE VALERATE),Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
BETAMETHASONE ESTERS (IN GUIDANCE: BETAMETHASONE VALERATE),Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
BETAMETHASONE ESTERS (IN GUIDANCE: BETAMETHASONE VALERATE),Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,162573006,Suspected lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,254637007,Non-small cell lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,275981009,Lung cancer screening,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,429011007,Family history of lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,877691000000107,No FH of lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB,EGFR mutation-positive non-small-cell lung cancer,TA436,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB,First recurrence of platinum-sensitive advanced ovarian cancer,TA560,ovarian cancer,423274005,Ovarian cancer stage 4,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,First recurrence of platinum-sensitive advanced ovarian cancer,TA560,ovarian cancer,762997004,Suspected ovarian cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,First recurrence of platinum-sensitive advanced ovarian cancer,TA560,ovarian cancer,758821000000106,No family history of ovarian cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,First recurrence of platinum-sensitive advanced ovarian cancer,TA560,ovarian cancer,848891000000105,QCancer ovarian cancer risk,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,8100009,Structure of infundibulum of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,9361007,Downward displacement of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,22611009,Endometriosis of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,25344002,Fimbriectomy of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,25811000,Excision of entire bilateral fallopian tubes,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,29827000,Excision of both fallopian tubes and ovaries,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,32587001,Rupture of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,32987009,Both fallopian tubes,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,38043007,Implantation of prosthesis into fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,41393008,Excision of cyst of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,42618007,Atresia of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,44793005,Excision of lesion of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,46536000,Inflammation of ovary and fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,46946009,Torsion of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,49558004,Fallopian tube tuberculosis,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,56900004,Infarction of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,64233004,Congenital cyst of fimbria of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,78328007,Aspiration of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,78517009,Dilation of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,79586000,Fallopian tube pregnancy,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,85029000,Congenital anomaly of fallopian tubes,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,88157006,Inflammation of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,92100009,Benign neoplasm of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,92591008,Carcinoma in situ of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,118869008,Procedure on fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,120062000,Fallopian tube reconstruction,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,128134005,Fallopian tube disorder,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176936004,Open occlusion of both fallopian tubes,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176937008,Open ligation of both fallopian tubes,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176938003,Open bilateral clipping of fallopian tubes,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176942000,Open ligation of remaining solitary fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176948001,Open ligation of right fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176949009,Open ligation of left fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176965005,Drainage of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176975008,Exploration of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176978005,Endoscopic bilateral cauterisation of fallopian tubes,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176979002,Endoscopic bilateral clipping of fallopian tubes,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176980004,Ligation of fallopian tubes with Fallope ring by endoscopy,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176984008,Endoscopic occlusion of remaining solitary fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176985009,Endoscopic occlusion of right fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,176986005,Endoscopic occlusion of left fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,177002003,Laparoscopy of fallopian tube: [diagnostic NOS] or [NEC],BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,189120005,Benign neoplasm of fallopian tubes and uterine ligaments,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,193331004,Laparoscopy with occlusion of fallopian tube by device,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,198299001,Acquired ovarian and fallopian tube atrophy,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,198305004,Prolapse of ovary and fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,198308002,"Torsion of the ovary, ovarian pedicle or fallopian tube",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,198311001,"Other ovary, fallopian tube and broad ligament disorders",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,198313003,"Ovarian, fallopian tube and broad ligament disorder NOS",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,204826004,Fallopian tube and broad ligament anomalies,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,236927008,Removal of clip from fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,236938008,Laparoscopy of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,237050007,Fimbrial phimosis of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,245482004,Entire left cornu of Fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,262931005,Transection of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,265071006,Open clipping of both fallopian tubes,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,265076001,Open clipping of left fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,266591002,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,266592009,Acquired absence of ovary or fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,271414005,Fallopian tube prosthesis operation,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,271415006,Removal of products of conception from fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,274975009,Open ringing of bilateral fallopian tubes,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,274977001,Unilateral occlusion of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,280504001,Fallopian tube stenosis,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,281258002,LAP DYE - laparoscopic dye test of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,283958000,Hematoma of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,287664005,Ligation of both fallopian tubes,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,287931008,Fallopian tube cornual resection,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,287943009,Insufflation of fallopian tube using saline,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,287944003,Insufflation of fallopian tube using gas,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,288032001,Transection of both fallopian tubes,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,288033006,Unilateral ligation of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,288034000,Unilateral fallopian tube division,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,289832005,Fallopian tube present,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,289833000,Fallopian tube absent,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,292002002,Open unilateral occlusion of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,300020002,Diathermy of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,302954008,Congenital cyst of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,307264000,Remaining fallopian tube removed,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,309290005,Fallopian tube biopsy specimen,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,309500004,Excised uterus and single fallopian tube and ovary sample,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,310808000,Fallopian tube clip,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,369514009,Metastatic malignant neoplasm of left fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,387615001,Removal of gestational sac from fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,387617009,Aspiration of gestational sac from fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,391993002,Reestablishment of continuity of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,392250009,Operation on fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,398319002,Abscess of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,427543006,Recanalisation of fallopian tube,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,609321005,Endoscopic bilateral occlusion of fallopian tubes using intrafallopian implants,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,719447009,Ectopic fallopian tube tissue,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,560681000000101,Reanastomosis of fallopian tube NEC,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,561491000000108,Fallopian tube operations NOS,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB,"Treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer",TA353,fallopian tube,647361000000102,"Ovarian, fallopian tube and broad ligament disorder NOS",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,733608000,Papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,134405005,Suspected breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,160287004,FH: Breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,268547008,Screening for breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,429740004,Family history of breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,431330007,Family history of breast cancer 1 gene mutation,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,431331006,Family history of breast cancer 2 gene mutation,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,706970001,TNBC - Triple-negative breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,94361000000105,Breast cancer detected by national screening programme,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,276341000000100,Fast track referral for suspected breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,838351000000107,Education about risk of breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,874291000000100,QCancer breast cancer risk,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),Metastatic breast cancer,TA147,breast cancer,1035841000000108,Lymphoedema following breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,162573006,Suspected lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,254637007,Non-small cell lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,275981009,Lung cancer screening,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,429011007,Family history of lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,877691000000107,No FH of lung cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB (1ST LINE),"Unresectable advanced, metastatic or recurrent non-small-cell lung cancer",TA148,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH 5-FLUOROURACIL PLUS FOLINIC ACID (WITH OR WITHOUT IRINOTECAN),Colorectal cancer (metastatic),TA118,colorectal cancer,276401000000108,Fast track referral for suspected colorectal cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH 5-FLUOROURACIL PLUS FOLINIC ACID (WITH OR WITHOUT IRINOTECAN),Colorectal cancer (metastatic),TA118,colorectal cancer,382651000000108,Seen in fast track suspected colorectal cancer clinic,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH 5-FLUOROURACIL PLUS FOLINIC ACID (WITH OR WITHOUT IRINOTECAN),Colorectal cancer (metastatic),TA118,colorectal cancer,722731000000100,Colorectal cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH 5-FLUOROURACIL PLUS FOLINIC ACID (WITH OR WITHOUT IRINOTECAN),Colorectal cancer (metastatic),TA118,colorectal cancer,848861000000104,QCancer colorectal cancer risk,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH 5-FLUOROURACIL PLUS FOLINIC ACID (WITH OR WITHOUT IRINOTECAN),Colorectal cancer (metastatic),TA118,colorectal cancer,1034401000000107,Discharge from secondary care colorectal cancer service,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,134405005,Suspected breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,160287004,FH: Breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,268547008,Screening for breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,429740004,Family history of breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,431330007,Family history of breast cancer 1 gene mutation,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,431331006,Family history of breast cancer 2 gene mutation,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,706970001,TNBC - Triple-negative breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,94361000000105,Breast cancer detected by national screening programme,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,276341000000100,Fast track referral for suspected breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,838351000000107,Education about risk of breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,874291000000100,QCancer breast cancer risk,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH A TAXANE (1ST LINE),Metastatic breast cancer,TA214,breast cancer,1035841000000108,Lymphoedema following breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,134405005,Suspected breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,160287004,FH: Breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,268547008,Screening for breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,429740004,Family history of breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,431330007,Family history of breast cancer 1 gene mutation,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,431331006,Family history of breast cancer 2 gene mutation,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,706970001,TNBC - Triple-negative breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,94361000000105,Breast cancer detected by national screening programme,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,276341000000100,Fast track referral for suspected breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,838351000000107,Education about risk of breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,874291000000100,QCancer breast cancer risk,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH CAPECITABINE (1ST LINE),First-line treatment of metastatic breast cancer,TA263,breast cancer,1035841000000108,Lymphoedema following breast cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH GEMCITABINE AND CARBOPLATIN,First recurrence of platinum-sensitive advanced ovarian cancer,TA285,ovarian cancer,423274005,Ovarian cancer stage 4,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH GEMCITABINE AND CARBOPLATIN,First recurrence of platinum-sensitive advanced ovarian cancer,TA285,ovarian cancer,762997004,Suspected ovarian cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH GEMCITABINE AND CARBOPLATIN,First recurrence of platinum-sensitive advanced ovarian cancer,TA285,ovarian cancer,758821000000106,No family history of ovarian cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH GEMCITABINE AND CARBOPLATIN,First recurrence of platinum-sensitive advanced ovarian cancer,TA285,ovarian cancer,848891000000105,QCancer ovarian cancer risk,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN,Advanced ovarian cancer (1st line),TA284,ovarian cancer,423274005,Ovarian cancer stage 4,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN,Advanced ovarian cancer (1st line),TA284,ovarian cancer,762997004,Suspected ovarian cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN,Advanced ovarian cancer (1st line),TA284,ovarian cancer,758821000000106,No family history of ovarian cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BEVACIZUMAB IN COMBINATION WITH PACLITAXEL AND CARBOPLATIN,Advanced ovarian cancer (1st line),TA284,ovarian cancer,848891000000105,QCancer ovarian cancer risk,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
BIMEKIZUMAB,Moderate to severe plaque psoriasis,TA723,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),BIMEKIZUMAB,DERMATOLOGY,DERMATOLOGY
BIMEKIZUMAB,Moderate to severe plaque psoriasis,TA723,plaque psoriasis,402307000,Chronic large plaque psoriasis,BIMEKIZUMAB,DERMATOLOGY,DERMATOLOGY
BIMEKIZUMAB,Moderate to severe plaque psoriasis,TA723,plaque psoriasis,402310007,Chronic stable plaque psoriasis,BIMEKIZUMAB,DERMATOLOGY,DERMATOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,1755008,Healed myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,15990001,Acute myocardial infarction of posterolateral wall,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,22298006,MI - myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,41380003,Radioisotope scan for myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,52035003,Acute anteroapical myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,54329005,Acute anterior myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,57054005,Acute myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,58612006,Acute myocardial infarction of lateral wall,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,62695002,Acute anteroseptal myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,65547006,Acute inferolateral myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,66189004,Postmyocardial infarction syndrome,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,70211005,Acute anterolateral myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,73795002,Acute myocardial infarction of diaphragmatic wall,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,76593002,Acute myocardial infarction of inferoposterior wall,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,79009004,Acute myocardial infarction of septum,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,129574000,Postoperative myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,160361002,FH: ischemic heart disease (& [myocardial infarction] or [coronary thrombosis]),BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,164866006,Electrocardiogram: no myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,164867002,Electrocardiographic old myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,194809007,Acute myocardial infarction of atrium,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,194821006,Aborted myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,194856005,Subsequent myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,194857001,Subsequent myocardial infarction of anterior wall,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,194858006,Subsequent myocardial infarction of inferior wall,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,194862000,Hemopericardium due to and following acute myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,194863005,Atrial septal defect due to and following acute myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,194865003,Rupture of cardiac wall without haemopericardium as current complication following acute myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,194868001,"Thrombosis of atrium, auricular appendage, and ventricle due to and following acute myocardial infarction",BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,233838001,Acute posterior myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,233839009,Old anterior myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,233840006,Old inferior myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,233841005,Old lateral myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,233842003,Old posterior myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,233843008,Silent myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,233847009,Cardiac rupture due to and following acute myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,233885007,Pericarditis following myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,266288001,Myocardial infarction (& [acute]) or coronary thrombosis,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,266897007,Family history of myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,275122004,Family history: Myocardial infarction at less than 60,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,275123009,Family history: Myocardial infarction at greater than 60,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,304914007,Acute Q wave myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,308065005,History of myocardial infarction in last year,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,311793000,Postoperative transmural myocardial infarction of inferior wall,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,311796008,Postoperative subendocardial myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,314207007,Non-Q wave myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,315619001,"Family history of myocardial infarction in male relative of first degree, age known",BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,315620007,"Family history of myocardial infarction in male relative of first degree, age unknown",BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,315621006,"Family history of myocardial infarction in female relative of first degree, age known",BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,315622004,"Family history of myocardial infarction in female relative of first degree, age unknown",BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,394710008,First myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,399211009,Previous myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,401303003,STEMI - ST elevation myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,401314000,Acute non-ST segment elevation myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,698593009,History of non-ST segment elevation myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,703164000,Acute anterior ST segment elevation myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,703213009,Acute STEMI (ST elevation myocardial infarction) of inferior wall,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,827164008,Delayed postmyocardial infarction syndrome,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,879955009,MINOCA - myocardial infarction with non-obstructive coronary artery,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,515711000000105,Family history of myocardial infarction in second degree relative less than 50 years,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,515741000000106,Family history of myocardial infarction in first degree relative less than 60 years,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,715971000000103,Excepted from myocardial infarction quality indicators - informed dissent,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,715981000000101,Excepted from myocardial infarction quality indicators - patient unsuitable,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,717541000000106,Exception reporting - myocardial infarction quality indicators,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,883961000000109,Thrombolysis In Myocardial Infarction risk score for unstable angina or non-ST-segment-elevation myocardial infarction,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,12238111000119106,Acute ST segment elevation myocardial infarction of inferolateral wall,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BIVALIRUDIN IN COMBINATION WITH ASPIRIN AND CLOPIDOGREL,ST-segment-elevation myocardial infarction,TA230,myocardial infarction,16837681000119104,Myocardial infarction due to demand ischaemia,BIVALIRUDIN,CARDIOLOGY,CARDIOLOGY
BLINATUMOMAB,Acute lymphoblastic leukaemia in remission with minimal residual disease activity,TA589,acute lymphoblastic leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,BLINATUMOMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS
BLINATUMOMAB,Acute lymphoblastic leukaemia in remission with minimal residual disease activity,TA589,acute lymphoblastic leukaemia,413440007,Acute lymphoblastic leukaemia - category,BLINATUMOMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS
BLINATUMOMAB,Previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia,TA450,acute lymphoblastic leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,BLINATUMOMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS
BLINATUMOMAB,Previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia,TA450,acute lymphoblastic leukaemia,413440007,Acute lymphoblastic leukaemia - category,BLINATUMOMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS
BLINATUMOMAB,Previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia,TA686,acute lymphoblastic leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,BLINATUMOMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS
BLINATUMOMAB,Previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia,TA686,acute lymphoblastic leukaemia,413440007,Acute lymphoblastic leukaemia - category,BLINATUMOMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,62944002,Hepatitis C virus,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,62944002,Hepatitis C virus,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,72165005,Hepatitis C virus antibody,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,72165005,Hepatitis C virus antibody,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,170489004,Viral hepatitis carrier,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,170489004,Viral hepatitis carrier,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,197344005,Hepatitis caused by adenovirus,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,197344005,Hepatitis caused by adenovirus,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,235872006,Hepatitis C carrier,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,235872006,Hepatitis C carrier,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,278973007,Hepatitis C status,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,278973007,Hepatitis C status,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,278974001,Hepatitis C immune,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,278974001,Hepatitis C immune,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,278975000,Hepatitis C non-immune,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,278975000,Hepatitis C non-immune,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,314706002,Hepatitis C antibody detected,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,314706002,Hepatitis C antibody detected,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,314707006,Hepatitis C antibody test negative,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,314707006,Hepatitis C antibody test negative,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,413107006,Hepatitis C screening,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,413107006,Hepatitis C screening,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,773113008,Acute hepatitis caused by infection,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,773113008,Acute hepatitis caused by infection,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,12891000175105,Hepatitis C screening declined,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,12891000175105,Hepatitis C screening declined,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,200371000000104,Hepatitis C contact,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,200371000000104,Hepatitis C contact,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,201451000000105,Hepatitis C immunisation declined,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,201451000000105,Hepatitis C immunisation declined,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,202281000000105,Hepatitis C screening declined,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,202281000000105,Hepatitis C screening declined,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,204671000000101,Hepatitis C screening counselling,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,204671000000101,Hepatitis C screening counselling,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,304821000000107,Hepatitis C screening not offered,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,304821000000107,Hepatitis C screening not offered,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,362491000000104,Hepatitis C screening negative,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,362491000000104,Hepatitis C screening negative,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,362751000000101,Hepatitis C screening positive,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,362751000000101,Hepatitis C screening positive,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,761381000000102,Hepatitis C resolved,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,761381000000102,Hepatitis C resolved,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,824841000000105,Hepatitis C genotype 1,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,824841000000105,Hepatitis C genotype 1,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,824871000000104,Hepatitis C genotype 3,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,824871000000104,Hepatitis C genotype 3,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,829731000000106,On hepatitis C treatment plan,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,829731000000106,On hepatitis C treatment plan,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,992751000000109,Hepatitis C viral load,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,992751000000109,Hepatitis C viral load,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,992771000000100,Hepatitis C virus genotype,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,992771000000100,Hepatitis C virus genotype,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,996031000000104,Hepatitis C IgG level,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,996031000000104,Hepatitis C IgG level,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,998771000000103,Hepatitis C antibody level,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,998771000000103,Hepatitis C antibody level,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,1001331000000102,Hepatitis C antigen level,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,1001331000000102,Hepatitis C antigen level,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,1008931000000108,Hepatitis C antibody test,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,1008931000000108,Hepatitis C antibody test,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,1107671000000106,Hepatitis C screening offered,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA253,hepatitis c,1107671000000106,Hepatitis C screening offered,BOCEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
BORTEZOMIB,Multiple myeloma,TA129,multiple myeloma,230586003,Neuropathy due to multiple myeloma,BORTEZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BORTEZOMIB,Multiple myeloma,TA129,multiple myeloma,413587002,Smoldering multiple myeloma,BORTEZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BORTEZOMIB,Multiple myeloma,TA129,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,BORTEZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BORTEZOMIB,Multiple myeloma after second or subsequent relapse,TA453,multiple myeloma,230586003,Neuropathy due to multiple myeloma,BORTEZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BORTEZOMIB,Multiple myeloma after second or subsequent relapse,TA453,multiple myeloma,413587002,Smoldering multiple myeloma,BORTEZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BORTEZOMIB,Multiple myeloma after second or subsequent relapse,TA453,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,BORTEZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BORTEZOMIB,Previously untreated mantle cell lymphoma,TA370,mantle cell lymphoma,74654000,Mantle cell lymphoma,BORTEZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BORTEZOMIB,Previously untreated mantle cell lymphoma,TA370,mantle cell lymphoma,443487006,Mantle cell lymphoma,BORTEZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BORTEZOMIB IN COMBINATION WITH AN ALKYLATING AGENT AND A CORTICOSTEROID,Multiple myeloma,TA228,multiple myeloma,230586003,Neuropathy due to multiple myeloma,THALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BORTEZOMIB IN COMBINATION WITH AN ALKYLATING AGENT AND A CORTICOSTEROID,Multiple myeloma,TA228,multiple myeloma,413587002,Smoldering multiple myeloma,THALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BORTEZOMIB IN COMBINATION WITH AN ALKYLATING AGENT AND A CORTICOSTEROID,Multiple myeloma,TA228,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,THALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
"BORTEZOMIB IN COMBINATION WITH DEXAMETHASONE, OR WITH DEXAMETHASONE AND THALIDOMIDE",For induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation,TA311,multiple myeloma,230586003,Neuropathy due to multiple myeloma,BORTEZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
"BORTEZOMIB IN COMBINATION WITH DEXAMETHASONE, OR WITH DEXAMETHASONE AND THALIDOMIDE",For induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation,TA311,multiple myeloma,413587002,Smoldering multiple myeloma,BORTEZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
"BORTEZOMIB IN COMBINATION WITH DEXAMETHASONE, OR WITH DEXAMETHASONE AND THALIDOMIDE",For induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation,TA311,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,BORTEZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BOSUTINIB,Chronic myeloid leukaemia,TA576,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,BOSUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
BOSUTINIB,Previously treated chronic myeloid leukaemia,TA299,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,BOSUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
BOSUTINIB,Previously treated chronic myeloid leukaemia,TA401,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,BOSUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,4473006,Classical migraine,BOTULINUM,NEUROLOGY,NEUROLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,23186000,Menstrual migraine,BOTULINUM,NEUROLOGY,NEUROLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,37796009,Migraine,BOTULINUM,NEUROLOGY,NEUROLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,56097005,Migraine without aura,BOTULINUM,NEUROLOGY,NEUROLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,59292006,Hemiplegic migraine,BOTULINUM,NEUROLOGY,NEUROLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,75879005,Decapitated migraine,BOTULINUM,NEUROLOGY,NEUROLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,79267007,Retinal migraine,BOTULINUM,NEUROLOGY,NEUROLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,83351003,Basilar artery migraine,BOTULINUM,NEUROLOGY,NEUROLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,95655001,Ocular migraine,BOTULINUM,NEUROLOGY,NEUROLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,95656000,Familial hemiplegic migraine,BOTULINUM,NEUROLOGY,NEUROLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,160342001,Family history of migraine,BOTULINUM,NEUROLOGY,NEUROLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,161481007,History of migraine,BOTULINUM,NEUROLOGY,NEUROLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,162040008,Abdominal migraine - symptom,BOTULINUM,NEUROLOGY,NEUROLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,193030005,Migraine variants,BOTULINUM,NEUROLOGY,NEUROLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,193039006,Complex migraine,BOTULINUM,NEUROLOGY,NEUROLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,230462002,Migraine with typical aura,BOTULINUM,NEUROLOGY,NEUROLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,230464001,Sporadic hemiplegic migraine,BOTULINUM,NEUROLOGY,NEUROLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,230465000,Migraine aura without headache,BOTULINUM,NEUROLOGY,NEUROLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,230468003,Migraine with ischaemic complication,BOTULINUM,NEUROLOGY,NEUROLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,232284007,Vestibular migraine,BOTULINUM,NEUROLOGY,NEUROLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,394707001,No history of migraine,BOTULINUM,NEUROLOGY,NEUROLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,408381007,Migraine prophylaxis,BOTULINUM,NEUROLOGY,NEUROLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,427419006,Chronic migraine,BOTULINUM,NEUROLOGY,NEUROLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,608837004,History of migraine with aura,BOTULINUM,NEUROLOGY,NEUROLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,124171000119105,Chronic intractable migraine without aura,BOTULINUM,NEUROLOGY,NEUROLOGY
BOTULINUM TOXIN TYPE A,Prevention of headaches in adults with chronic migraine (defined as headaches on at least 15 days per month of which at least 8 days are with migraine) after 3 prior preventive medicines.,TA260,migraine,781381000000100,Migraine induced by oestrogen contraceptive,BOTULINUM,NEUROLOGY,NEUROLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma,TA524,hodgkin lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma,TA524,hodgkin lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma,TA524,hodgkin lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma,TA524,hodgkin lymphoma,118601006,Non-Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma,TA524,hodgkin lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma,TA524,hodgkin lymphoma,128929007,Non-Hodgkin lymphoma - category,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma,TA524,hodgkin lymphoma,128930002,Hodgkin lymphoma - category,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma,TA524,hodgkin lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma,TA524,hodgkin lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma,TA524,hodgkin lymphoma,433450000,Family history of non-Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma,TA524,hodgkin lymphoma,448709005,Non-Hodgkin lymphoma of stomach,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma,TA524,hodgkin lymphoma,762690000,Classical Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,TA446,hodgkin lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,TA446,hodgkin lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,TA446,hodgkin lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,TA446,hodgkin lymphoma,118601006,Non-Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,TA446,hodgkin lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,TA446,hodgkin lymphoma,128929007,Non-Hodgkin lymphoma - category,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,TA446,hodgkin lymphoma,128930002,Hodgkin lymphoma - category,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,TA446,hodgkin lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,TA446,hodgkin lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,TA446,hodgkin lymphoma,433450000,Family history of non-Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,TA446,hodgkin lymphoma,448709005,Non-Hodgkin lymphoma of stomach,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option,TA446,hodgkin lymphoma,762690000,Classical Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,TA446,hodgkin lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,TA446,hodgkin lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,TA446,hodgkin lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,TA446,hodgkin lymphoma,118601006,Non-Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,TA446,hodgkin lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,TA446,hodgkin lymphoma,128929007,Non-Hodgkin lymphoma - category,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,TA446,hodgkin lymphoma,128930002,Hodgkin lymphoma - category,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,TA446,hodgkin lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,TA446,hodgkin lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,TA446,hodgkin lymphoma,433450000,Family history of non-Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,TA446,hodgkin lymphoma,448709005,Non-Hodgkin lymphoma of stomach,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive Hodgkin lymphoma after autologous stem cell transplant,TA446,hodgkin lymphoma,762690000,Classical Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,CD30-positive cutaneous T-cell lymphoma,TA577,cutaneous t-cell lymphoma,400122007,CTCL - Cutaneous T-cell lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|DERMATOLOGY
BRENTUXIMAB VEDOTIN,Relapsed or refractory systemic anaplastic large cell lymphoma,TA478,anaplastic large cell lymphoma,448212009,Anaplastic lymphoma kinase negative anaplastic large cell lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,Relapsed or refractory systemic anaplastic large cell lymphoma,TA478,anaplastic large cell lymphoma,738770003,Anaplastic lymphoma kinase positive anaplastic large cell lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,Untreated advanced Hodgkin lymphoma,TA594,hodgkin lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,Untreated advanced Hodgkin lymphoma,TA594,hodgkin lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,Untreated advanced Hodgkin lymphoma,TA594,hodgkin lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,Untreated advanced Hodgkin lymphoma,TA594,hodgkin lymphoma,118601006,Non-Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,Untreated advanced Hodgkin lymphoma,TA594,hodgkin lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,Untreated advanced Hodgkin lymphoma,TA594,hodgkin lymphoma,128929007,Non-Hodgkin lymphoma - category,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,Untreated advanced Hodgkin lymphoma,TA594,hodgkin lymphoma,128930002,Hodgkin lymphoma - category,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,Untreated advanced Hodgkin lymphoma,TA594,hodgkin lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,Untreated advanced Hodgkin lymphoma,TA594,hodgkin lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,Untreated advanced Hodgkin lymphoma,TA594,hodgkin lymphoma,433450000,Family history of non-Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,Untreated advanced Hodgkin lymphoma,TA594,hodgkin lymphoma,448709005,Non-Hodgkin lymphoma of stomach,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN,Untreated advanced Hodgkin lymphoma,TA594,hodgkin lymphoma,762690000,Classical Hodgkin lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN IN COMBINATION,Untreated systemic anaplastic large cell lymphoma,TA641,anaplastic large cell lymphoma,448212009,Anaplastic lymphoma kinase negative anaplastic large cell lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRENTUXIMAB VEDOTIN IN COMBINATION,Untreated systemic anaplastic large cell lymphoma,TA641,anaplastic large cell lymphoma,738770003,Anaplastic lymphoma kinase positive anaplastic large cell lymphoma,BRENTUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,162573006,Suspected lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,254637007,Non-small cell lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,275981009,Lung cancer screening,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,429011007,Family history of lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,877691000000107,No FH of lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer after crizotinib,TA571,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,162573006,Suspected lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,254637007,Non-small cell lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,275981009,Lung cancer screening,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,429011007,Family history of lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,877691000000107,No FH of lung cancer,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRIGATINIB,ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor,TA670,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",BRIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
BRODALUMAB,Moderate to severe plaque psoriasis,TA511,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),BRODALUMAB,DERMATOLOGY,DERMATOLOGY
BRODALUMAB,Moderate to severe plaque psoriasis,TA511,plaque psoriasis,402307000,Chronic large plaque psoriasis,BRODALUMAB,DERMATOLOGY,DERMATOLOGY
BRODALUMAB,Moderate to severe plaque psoriasis,TA511,plaque psoriasis,402310007,Chronic stable plaque psoriasis,BRODALUMAB,DERMATOLOGY,DERMATOLOGY
BROLUCIZUMAB,Wet age-related macular degeneration,TA672,macular degeneration,70099003,Familial juvenile macular degeneration syndrome,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
BROLUCIZUMAB,Wet age-related macular degeneration,TA672,macular degeneration,193384000,Senile macular degeneration,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
BROLUCIZUMAB,Wet age-related macular degeneration,TA672,macular degeneration,267718000,Age-related macular degeneration,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
BROLUCIZUMAB,Wet age-related macular degeneration,TA672,macular degeneration,312898002,Myopic macular degeneration,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
BROLUCIZUMAB,Wet age-related macular degeneration,TA672,macular degeneration,314427006,Drusen plus pigment change stage macular degeneration,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
BROLUCIZUMAB,Wet age-related macular degeneration,TA672,macular degeneration,1296526000,Disciform macular degeneration,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,169941005,Maternal drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,228366006,Drug misuse history,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,228371004,Long-term drug misuser,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,228372006,Poly-drug misuser,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,228390007,Frequency of drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,228411009,Time since stopped drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,228413007,Age at starting drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,371435006,History of drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,439213009,Paternal drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,442080007,Drug misuse by mother,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,700187009,Seen in drug misuse clinic,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,712542001,Abstinent from drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,712543006,Abstinent from drug misuse in normal environment,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,712544000,Abstinent from drug misuse in protected environment,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,712545004,Abstinent from drug misuse on maintenance replacement,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,712546003,Abstinent from drug misuse when receiving blocking therapy,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,713070003,Drug misuser in household,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,744857009,Under care of drug misuse service,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,176811000000105,Drug misuse enhanced services administration,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,176831000000102,Drug misuse enhanced service completed,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,362451000000107,Drug misuse assessment declined,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,372511000000103,Shared care drug misuse treatment,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,372541000000102,Drug misuse treatment in primary care,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,383871000000108,Health problem secondary to drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,503771000000102,SMR25a drug misuse initial assessment form,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,503801000000104,SMR25b drug misuse follow up assessment form,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,505091000000102,Declined consent for notification of drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,507041000000101,Name of pharmacy attended due to drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,869161000000106,Drug misuse clinic administration,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPRENORPHINE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,1364721000000101,Date stopped drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,390900001,Smoking cessation milestones,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,395700008,Referral to smoking cessation advisor,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,401068004,Seen by smoking cessation advisor,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,401160008,Smoking cessation programme start date,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,710081004,Smoking cessation therapy,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,713700008,Smoking cessation drug therapy,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,765001003,Monitoring of smoking cessation therapy refused,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,771155005,Brief intervention for smoking cessation,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,1290027009,Consultation for smoking cessation,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,25261000000107,Did not attend smoking cessation clinic,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,200221000000105,Smoking cessation advice provided by community pharmacist,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,201931000000109,Attends practice smoking cessation clinic,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,201941000000100,Attends smoking cessation clinic not at practice,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,374361000000100,Smoking cessation enhanced services administration,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,374391000000106,Smoking cessation enhanced services administration monitoring template completed,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,506491000000102,Brief intervention for smoking cessation,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,527151000000107,Smoking cessation advice declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,712971000000108,Practice based smoking cessation programme start date,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,720401000000103,Smoking cessation,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,750821000000109,Consent given for follow-up evaluation after smoking cessation intervention,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,750851000000104,Consent given for smoking cessation data sharing,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,751101000000101,Declined consent for follow-up evaluation after smoking cessation intervention,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,751661000000106,Declined consent for smoking cessation data sharing,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,755721000000107,Consent given for follow-up by smoking cessation team,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,755741000000100,Declined consent for follow-up by smoking cessation team,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,767641000000109,Referral for smoking cessation service offered,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,768971000000109,Lost to smoking cessation follow-up,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,822591000000108,Smoking cessation drug therapy declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,850331000000104,Smoking cessation 12 week follow-up,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,871641000000105,Referral to smoking cessation service declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,871661000000106,Referral to smoking cessation service,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,966971000000103,Varenicline smoking cessation therapy declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,966991000000104,Varenicline smoking cessation therapy offered,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,1084381000000100,Signposting to smoking cessation service,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,1087441000000106,Smoking cessation programme declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
BUPROPION,Smoking cessation,TA039,smoking cessation,2140191000000108,Referral to Community Pharmacy Smoking Cessation Service,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating hormone-relapsed metastatic prostate cancer treated with docetaxel,TA391,prostate cancer,315268008,Suspected prostate cancer,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating hormone-relapsed metastatic prostate cancer treated with docetaxel,TA391,prostate cancer,428262008,H/O: prostate cancer,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating hormone-relapsed metastatic prostate cancer treated with docetaxel,TA391,prostate cancer,698470001,Advice given about prostate cancer screening,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating hormone-relapsed metastatic prostate cancer treated with docetaxel,TA391,prostate cancer,712837004,Active surveillance of prostate cancer,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating hormone-relapsed metastatic prostate cancer treated with docetaxel,TA391,prostate cancer,720007002,Prostate cancer care review,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating hormone-relapsed metastatic prostate cancer treated with docetaxel,TA391,prostate cancer,31011000119107,Prostate cancer screening declined,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating hormone-relapsed metastatic prostate cancer treated with docetaxel,TA391,prostate cancer,874211000000109,QCancer prostate cancer risk,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating hormone-relapsed metastatic prostate cancer treated with docetaxel,TA391,prostate cancer,878401000000104,No FH of prostate cancer,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating hormone-relapsed metastatic prostate cancer treated with docetaxel,TA391,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treating hormone-relapsed metastatic prostate cancer treated with docetaxel,TA391,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treatment of hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen,TA255,prostate cancer,315268008,Suspected prostate cancer,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treatment of hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen,TA255,prostate cancer,428262008,H/O: prostate cancer,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treatment of hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen,TA255,prostate cancer,698470001,Advice given about prostate cancer screening,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treatment of hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen,TA255,prostate cancer,712837004,Active surveillance of prostate cancer,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treatment of hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen,TA255,prostate cancer,720007002,Prostate cancer care review,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treatment of hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen,TA255,prostate cancer,31011000119107,Prostate cancer screening declined,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treatment of hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen,TA255,prostate cancer,874211000000109,QCancer prostate cancer risk,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treatment of hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen,TA255,prostate cancer,878401000000104,No FH of prostate cancer,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treatment of hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen,TA255,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE,Treatment of hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen,TA255,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,CABAZITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,48943007,Archivist,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,48943007,Archivist,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,161855003,Complaining of shivering,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,201272008,Hives,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,201272008,Hives,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,248456009,Shivering or rigors,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1287783000,HIV-PrEP - Human immunodeficiency virus pre-exposure prophylaxis,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1287783000,HIV-PrEP - Human immunodeficiency virus pre-exposure prophylaxis,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,200901000000108,HIV (human immunodeficiency virus) screening counselling,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,200901000000108,HIV (human immunodeficiency virus) screening counselling,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,768801000000109,HIV (human immunodeficiency virus) test not appropriate,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,928531000000104,Ministry of Defence Personal Medical Record F MED 4 closed and archived,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,928531000000104,Ministry of Defence Personal Medical Record F MED 4 closed and archived,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,970551000000107,Main spoken language Dhivehi,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,970551000000107,Main spoken language Dhivehi,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,992781000000103,HIV (human immunodeficiency virus) screening test,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,992781000000103,HIV (human immunodeficiency virus) screening test,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,998701000000106,HIV (human immunodeficiency virus) viral load,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,998701000000106,HIV (human immunodeficiency virus) viral load,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,998711000000108,HIV (human immunodeficiency virus) p24 antigen level,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,998711000000108,HIV (human immunodeficiency virus) p24 antigen level,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1008351000000102,HIV (human immunodeficiency virus) 1 ribonucleic acid detection assay,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1008351000000102,HIV (human immunodeficiency virus) 1 ribonucleic acid detection assay,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1008801000000105,HIV1 (human immunodeficiency virus 1) antibody level,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1008801000000105,HIV1 (human immunodeficiency virus 1) antibody level,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1008811000000107,HIV2 (human immunodeficiency virus 2) antibody level,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1008811000000107,HIV2 (human immunodeficiency virus 2) antibody level,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1014121000000102,HIV (human immunodeficiency virus) antibody level,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1014121000000102,HIV (human immunodeficiency virus) antibody level,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1014171000000103,HIV (human immunodeficiency virus) antibody/antigen (Duo),CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1014171000000103,HIV (human immunodeficiency virus) antibody/antigen (Duo),CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1020841000000100,HIV (human immunodeficiency virus) serology,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1020841000000100,HIV (human immunodeficiency virus) serology,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1027831000000105,HIV - Human immunodeficiency virus test,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1086581000000100,Daily HIV-PrEP (human immunodeficiency virus pre-exposure prophylaxis) commenced,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1086581000000100,Daily HIV-PrEP (human immunodeficiency virus pre-exposure prophylaxis) commenced,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1086591000000103,Intermittent HIV-PrEP (human immunodeficiency virus pre-exposure prophylaxis) commenced,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1086591000000103,Intermittent HIV-PrEP (human immunodeficiency virus pre-exposure prophylaxis) commenced,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1086721000000106,Daily HIV-PrEP (human immunodeficiency virus pre-exposure prophylaxis),CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1086721000000106,Daily HIV-PrEP (human immunodeficiency virus pre-exposure prophylaxis),CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1086731000000108,Event-based HIV-PrEP (human immunodeficiency virus pre-exposure prophylaxis),CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1086731000000108,Event-based HIV-PrEP (human immunodeficiency virus pre-exposure prophylaxis),CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1086751000000101,HIV (human immunodeficiency virus) test declined,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOTEGRAVIR  WITH RILPIVIRINE,Treating HIV-1,TA757,hiv,1086751000000101,HIV (human immunodeficiency virus) test declined,CABOTEGRAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES
CABOZANTINIB,Medullary thyroid cancer,TA516,thyroid cancer,94098005,Primary malignant neoplasm of thyroid gland,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY
CABOZANTINIB,Medullary thyroid cancer,TA516,thyroid cancer,363478007,Malignant tumour of thyroid gland,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY
CABOZANTINIB,Previously treated advanced hepatocellular carcinoma,TA582,hepatocellular carcinoma,15619004,"Hepatocellular carcinoma, fibrolamellar",CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
CABOZANTINIB,Previously treated advanced hepatocellular carcinoma,TA849,hepatocellular carcinoma,15619004,"Hepatocellular carcinoma, fibrolamellar",CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
CABOZANTINIB,Previously treated advanced hepatocellular carcinoma,TA582,hepatocellular carcinoma,253018005,Fibrolamellar hepatocellular carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
CABOZANTINIB,Previously treated advanced hepatocellular carcinoma,TA849,hepatocellular carcinoma,253018005,Fibrolamellar hepatocellular carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
CABOZANTINIB,Previously treated advanced hepatocellular carcinoma,TA582,hepatocellular carcinoma,990271000000107,Ultrasound scan surveillance of liver for hepatocellular carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
CABOZANTINIB,Previously treated advanced hepatocellular carcinoma,TA849,hepatocellular carcinoma,990271000000107,Ultrasound scan surveillance of liver for hepatocellular carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
CABOZANTINIB,Previously treated advanced renal cell carcinoma,TA463,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABOZANTINIB,Previously treated advanced renal cell carcinoma,TA463,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABOZANTINIB,Previously treated advanced renal cell carcinoma,TA463,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABOZANTINIB,Previously treated advanced renal cell carcinoma,TA463,renal cell carcinoma,733608000,Papillary renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABOZANTINIB,Previously treated advanced renal cell carcinoma,TA463,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABOZANTINIB,Previously treated advanced renal cell carcinoma,TA463,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABOZANTINIB,Previously treated advanced renal cell carcinoma,TA463,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABOZANTINIB,Untreated advanced renal cell carcinoma,TA542,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABOZANTINIB,Untreated advanced renal cell carcinoma,TA542,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABOZANTINIB,Untreated advanced renal cell carcinoma,TA542,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABOZANTINIB,Untreated advanced renal cell carcinoma,TA542,renal cell carcinoma,733608000,Papillary renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABOZANTINIB,Untreated advanced renal cell carcinoma,TA542,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABOZANTINIB,Untreated advanced renal cell carcinoma,TA542,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CABOZANTINIB,Untreated advanced renal cell carcinoma,TA542,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,CABOZANTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA315,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN (DUAL THERAPY),Type 2 diabetes,TA315,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA/THIAZOLIDINEDIONE (TRIPLE THERAPY),Type 2 diabetes,TA315,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,9386003,Gouty neuritis,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,14763005,Gouty tophus of pinna,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,24595009,Idiopathic gout,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,27277001,Tophus of heart co-occurrent and due to gout,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,43193009,Gouty iritis,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,48440001,Gouty arthropathy,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,67148009,Arthritis of great toe due to gout,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,90560007,Gout,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,160308005,Family history: Gout,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,161451004,History of gout,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,170730005,Gout monitoring,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,170731009,Initial gout assessment,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,170732002,Follow-up gout assessment,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,170733007,Joints gout affected,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,170735000,Date gout treatment started,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,170736004,Date of last gout attack,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,170737008,Gout associated problem,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,170738003,Gout drug side effect,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,170739006,Gout treatment changed,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,170740008,Date gout treatment stopped,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,171190009,Gout screening,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,190828008,Gouty arthropathy,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,190829000,Gouty nephropathy,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,190842000,Chronic tophaceous gout of hand,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,200983001,Parapsoriasis en gouttes,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,201663006,Articular gout of shoulder region,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,201666003,Gouty arthritis of hand,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,201667007,Gouty arthritis of pelvic region and thigh,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,201669005,Gouty arthritis of ankle and/or foot,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,201670006,Articular gout of multiple joints,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,230312006,Aicardi Goutieres syndrome,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,239843003,Secondary gout,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,239844009,Gout secondary to renal impairment,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,239845005,Gout secondary to drug,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,239848007,Gouty bursitis,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,243859006,Gout monitoring status,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,268142006,Pseudogout,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,281362006,Gouty tophus of bursa,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,281363001,Tophus of tendon co-occurrent and due to gout,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,281364007,Gouty tophus of olecranon bursa,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,281365008,Gouty tophus of prepatellar bursa,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,292671009,Drug for the treatment of gout adverse reaction,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,402469004,Gouty tophus,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,428839004,Articular gout of toe,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,770924008,Gout attack,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,427211000000108,[V]Screening for gout,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,924311000000106,Acute exacerbation of gout,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Gouty arthritis attacks,TA281,gout,1033961000000104,Gouty tophi of toe,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CANAKINUMAB,Systemic juvenile idiopathic arthritis,TA302,juvenile idiopathic arthritis,410798004,Oligoarticular juvenile idiopathic arthritis,CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS
CANAKINUMAB,Systemic juvenile idiopathic arthritis,TA302,juvenile idiopathic arthritis,16044751000119106,"Juvenile idiopathic arthritis, polyarthritis",CANAKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS
CANNABIDIOL,Treating seizures caused by tuberous sclerosis complex,TA873,tuberous sclerosis,36025004,Fibrous skin tumor of tuberous sclerosis,CANNABIDIOL,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CANNABIDIOL,Treating seizures caused by tuberous sclerosis complex,TA873,tuberous sclerosis,417001009,Family history of tuberous sclerosis,CANNABIDIOL,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CANNABIDIOL WITH CLOBAZAM,Seizures associated with Dravet syndrome,TA614,dravet syndrome,230437002,Dravet Syndrome,CANNABIDIOL,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CANNABIDIOL WITH CLOBAZAM,Seizures associated with Lennox–Gastaut syndrome,TA615,seizures,407618000,1 to 12 seizures a year,CANNABIDIOL,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CANNABIDIOL WITH CLOBAZAM,Seizures associated with Lennox–Gastaut syndrome,TA615,seizures,407620002,1 to 7 seizures a week,CANNABIDIOL,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CANNABIDIOL WITH CLOBAZAM,Seizures associated with Lennox–Gastaut syndrome,TA615,seizures,407622005,Many seizures a day,CANNABIDIOL,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CANNABIDIOL WITH CLOBAZAM,Seizures associated with Lennox–Gastaut syndrome,TA615,seizures,699688008,Genetic epilepsy with febrile seizures plus,CANNABIDIOL,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CANNABIDIOL WITH CLOBAZAM,Seizures associated with Lennox–Gastaut syndrome,TA615,seizures,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,CANNABIDIOL,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,134405005,Suspected breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,160287004,FH: Breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,268547008,Screening for breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,429740004,Family history of breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,431330007,Family history of breast cancer 1 gene mutation,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,431331006,Family history of breast cancer 2 gene mutation,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,706970001,TNBC - Triple-negative breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,94361000000105,Breast cancer detected by national screening programme,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,276341000000100,Fast track referral for suspected breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,838351000000107,Education about risk of breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,874291000000100,QCancer breast cancer risk,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
CAPECITABINE,Breast cancer (locally advanced or metastatic),TA062,breast cancer,1035841000000108,Lymphoedema following breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
CAPECITABINE,Colorectal cancer,TA061,colorectal cancer,276401000000108,Fast track referral for suspected colorectal cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
CAPECITABINE,Colorectal cancer,TA061,colorectal cancer,382651000000108,Seen in fast track suspected colorectal cancer clinic,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
CAPECITABINE,Colorectal cancer,TA061,colorectal cancer,722731000000100,Colorectal cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
CAPECITABINE,Colorectal cancer,TA061,colorectal cancer,848861000000104,QCancer colorectal cancer risk,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
CAPECITABINE,Colorectal cancer,TA061,colorectal cancer,1034401000000107,Discharge from secondary care colorectal cancer service,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
CAPECITABINE (1ST LINE),Inoperable advanced gastric cancer,TA191,gastric cancer,276809004,Early gastric cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
CAPECITABINE (1ST LINE),Inoperable advanced gastric cancer,TA191,gastric cancer,276810009,Late gastric cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
CAPECITABINE (ADJUVANT),Colon cancer,TA100,colon cancer,275978004,Screening for colon cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
CAPECITABINE (ADJUVANT),Colon cancer,TA100,colon cancer,315058005,Hereditary nonpolyposis colon cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,134405005,Suspected breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,160287004,FH: Breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,268547008,Screening for breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,429740004,Family history of breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,431330007,Family history of breast cancer 1 gene mutation,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,431331006,Family history of breast cancer 2 gene mutation,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,706970001,TNBC - Triple-negative breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,94361000000105,Breast cancer detected by national screening programme,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,276341000000100,Fast track referral for suspected breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,838351000000107,Education about risk of breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,874291000000100,QCancer breast cancer risk,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"CAPECITABINE, PLUS DOCETAXEL",Breast cancer (locally advanced or metastatic),TA062,breast cancer,1035841000000108,Lymphoedema following breast cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
CAPLACIZUMAB,Acute acquired thrombotic thrombocytopenic purpura,TA667,thrombotic thrombocytopenic purpura,78129009,TTP - thrombotic thrombocytopenic purpura,CAPLACIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
CARFILZOMIB FOR PREVIOUSLY TREATED MULTIPLE MYELOMA,Previously treated multiple myeloma,TA657,multiple myeloma,230586003,Neuropathy due to multiple myeloma,CARFILZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CARFILZOMIB FOR PREVIOUSLY TREATED MULTIPLE MYELOMA,Previously treated multiple myeloma,TA657,multiple myeloma,413587002,Smoldering multiple myeloma,CARFILZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CARFILZOMIB FOR PREVIOUSLY TREATED MULTIPLE MYELOMA,Previously treated multiple myeloma,TA657,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,CARFILZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CARFILZOMIB IN COMBINATION WITH DEXAMETHASONE,Previously treated multiple myeloma,TA457,multiple myeloma,230586003,Neuropathy due to multiple myeloma,CARFILZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CARFILZOMIB IN COMBINATION WITH DEXAMETHASONE,Previously treated multiple myeloma,TA457,multiple myeloma,413587002,Smoldering multiple myeloma,CARFILZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CARFILZOMIB IN COMBINATION WITH DEXAMETHASONE,Previously treated multiple myeloma,TA457,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,CARFILZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CARFILZOMIB WITH DARATUMUMAB AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA841,multiple myeloma,230586003,Neuropathy due to multiple myeloma,CARFILZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CARFILZOMIB WITH DARATUMUMAB AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA841,multiple myeloma,413587002,Smoldering multiple myeloma,CARFILZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CARFILZOMIB WITH DARATUMUMAB AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA841,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,CARFILZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CARFILZOMIB WITH DEXAMETHASONE AND LENALIDOMIDE,Previously treated multiple myeloma,TA695,multiple myeloma,230586003,Neuropathy due to multiple myeloma,CARFILZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CARFILZOMIB WITH DEXAMETHASONE AND LENALIDOMIDE,Previously treated multiple myeloma,TA695,multiple myeloma,413587002,Smoldering multiple myeloma,CARFILZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CARFILZOMIB WITH DEXAMETHASONE AND LENALIDOMIDE,Previously treated multiple myeloma,TA695,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,CARFILZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,803009,Paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,3102004,"Oligodendroglioma, anaplastic",CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,9903002,"Paraganglioma, malignant",CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,26138003,Gliomatosis cerebri,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,31794002,Sympathetic paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,32037004,Jugular paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,72787006,Gangliocytic paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,73348003,Oligodendroglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,74532006,"Glioma, malignant",CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,89880005,Ganglioglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,107694002,"Paraganglioma, benign",CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,115222007,Paraganglioma AND/OR glomus tumor,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,115240006,Glioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,253029009,Gangliocytic paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,253031000,Tympanic paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,254940005,Oligodendroglioma of brain,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,254947008,Glioma of spinal cord,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,254976006,Optic nerve glioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,276826005,Malignant glioma of brain,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,276827001,Malignant glioma of spinal cord,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,302833002,Paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,307649006,Microglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,307829004,Excision of nasal glioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,443565000,Oligodendroglioma - category,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
CARMUSTINE IMPLANTS,Glioma (newly diagnosed),TA121,glioma,443936004,Oligodendroglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,22193007,Osteoarthritis of joint of hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,33952002,Localised osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,37895003,Osteoarthritis of first carpometacarpal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,82300000,Osteoarthritis of ankle and/or foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,160414002,Family history: Osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,161567008,History of rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,161568003,History of osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201819000,Generalised osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201821005,(Heberdens' nodes) or (Bouchards' nodes) or (generalized osteoarthritis of the hand),CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201831003,"Localized, primary osteoarthritis of the shoulder region",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201835007,"Localized, primary osteoarthritis of the pelvic region and thigh",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201837004,"Localised, primary osteoarthritis of the ankle and foot",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201849003,"Localised, secondary osteoarthritis of the shoulder region",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201852006,"Localised, secondary osteoarthritis of the hand",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201855008,"Localized, secondary osteoarthritis of the ankle and/or foot",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201889009,"Osteoarthritis NOS, of the upper arm",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201890000,Wrist osteoarthritis NOS,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201891001,Thumb osteoarthritis NOS,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201892008,Osteoarthritis NOS: [pelvic region and/or thigh] or [hip],CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201893003,Knee osteoarthritis NOS,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201894009,"Osteoarthritis NOS, of ankle and foot",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,202655008,Osteoarthritis of spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239863005,Osteoarthritis of spinal facet joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239866002,Osteoarthritis of elbow,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239868001,Osteoarthritis of finger,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239874001,Osteoarthritis of ankle,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239877008,Osteoarthritis of first MTPJ (metatarsophalangeal joint),CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239878003,Osteoarthritis of toe joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,267889007,Generalized osteoarthritis of the hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,267890003,"Localised, secondary osteoarthritis of the pelvic region and thigh",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,267891004,"Localized osteoarthritis, unspecified, of the pelvic region and thigh",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,268054009,Osteoarthritis of multiple joints,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,313257005,"Localized, primary osteoarthritis of the wrist",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,313258000,"Localised, primary osteoarthritis of toe",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,313259008,"Localized, primary osteoarthritis of elbow",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,373623009,Osteoarthritis of glenohumeral joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,394991004,Flare of osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,443524000,Secondary osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,446165001,HOOS - hip disability and osteoarthritis outcome score,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,450521003,Osteoarthritis of patellofemoral joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,700324005,Osteoarthritis of talonavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,782845000,Knee Injury and Osteoarthritis Outcome Score,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1162304008,Oligoarticular osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343601009,OA (osteoarthritis) of spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343603007,Osteoarthritis of thoracic spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343604001,Cervical osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343605000,Osteoarthritis of lumbar spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,230771000000108,Delivery of rehabilitation for osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,323301000119109,Osteoarthritis of left knee joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,323311000119107,Osteoarthritis of right hip joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,637091000000105,"Osteoarthritis NOS, of the lower leg",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,666441000000103,"Osteoarthritis NOS, of shoulder region",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,666451000000100,"Osteoarthritis NOS, other specified site",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,805881000000109,Exception reporting - osteoarthritis quality indicators,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,805901000000107,Excepted from osteoarthritis quality indicators - patient unsuitable,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,805921000000103,Excepted from osteoarthritis quality indicators - informed dissent,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,850791000000102,Osteoarthritis of sternoclavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CELECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,10288008,Squamous cell carcinoma - spindle cell,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,12478003,Microinvasive squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,18048008,"Squamous cell carcinoma, keratinising",CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,35718007,"Squamous cell carcinoma, small cell, nonkeratinizing",CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,37304002,Mixed basal-squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,39056008,Papillary squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,59529006,Squamous cell carcinoma in situ,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,64204000,Metastatic squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,65692009,Polypoid squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,85956000,Pseudoglandular squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,89906000,Verrucous SCC (squamous cell carcinoma),CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,231830001,Squamous cell carcinoma in situ of eyelid,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,231831002,Squamous cell carcinoma of eyelid,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,254620000,Squamous cell carcinoma of trachea,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,254634000,Squamous cell carcinoma of lung,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,254652000,Clear cell squamous cell carcinoma of skin,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,254654004,Acantholytic squamous cell carcinoma of skin,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,254886006,Squamous cell carcinoma of cervix,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,255003007,Squamous cell carcinoma of conjunctiva,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,255071008,Squamous cell carcinoma of lip,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,255111004,Squamous cell carcinoma of urinary bladder,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,276804009,Squamous cell carcinoma of esophagus,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,276860003,Squamous cell carcinoma of scrotum,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,276952000,Squamous cell carcinoma of tongue,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,276953005,Squamous cell carcinoma of gingiva,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,276954004,Squamous cell carcinoma of floor of mouth,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,276962007,Squamous cell carcinoma of palate,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,285307007,Squamous cell carcinoma of skin of upper lip,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,285308002,Squamous cell carcinoma of skin of lower lip,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,285309005,Squamous cell carcinoma of skin of cheek,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,300987004,Disseminated squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,307502000,Squamous cell carcinoma of mouth,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,313353007,Squamous cell carcinoma of bronchus in left lower lobe,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,313354001,Squamous cell carcinoma of bronchus in left upper lobe,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,313355000,Squamous cell carcinoma of bronchus in right lower lobe,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,313356004,Squamous cell carcinoma of bronchus of middle lobe of right lung,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,313357008,Squamous cell carcinoma of bronchus in right upper lobe,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,400066006,Intraepithelial squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,400155002,Squamous cell carcinoma - category,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,402815007,Squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,402816008,Squamous cell carcinoma of anogenital area,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,403901001,Acantholytic squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,403904009,Verrucous squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,403906006,Metastatic squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,408649007,Squamous cell carcinoma of pharynx,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,422599000,Squamous cell carcinoma of back,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,423700001,Squamous cell carcinoma of auricle,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,698011002,Keratinizing squamous cell carcinoma of nasopharynx,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,700193001,Family history of squamous cell carcinoma of skin,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,707388009,Primary squamous cell carcinoma of trachea,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,707429002,Overlapping squamous cell carcinoma of larynx,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,707576008,Primary squamous cell carcinoma of subglottis,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,707581004,Primary papillary squamous cell carcinoma of oropharynx,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,707662004,Primary basaloid squamous cell carcinoma of larynx,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,716659002,Squamous cell carcinoma of head and neck,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,719052006,Recurrent SCC (squamous cell carcinoma),CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,721618006,Primary squamous cell carcinoma of upper third of esophagus,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,722530005,Primary squamous cell carcinoma of adenoid,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,722542000,Primary squamous cell carcinoma of anal canal,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,722672002,Primary squamous cell carcinoma of root of tongue,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,722673007,Primary squamous cell carcinoma of lingual tonsil,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,722674001,Primary squamous cell carcinoma of parotid gland,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,723182009,Primary squamous cell carcinoma of nasal cavity,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,723265000,Primary squamous cell carcinoma of anus,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,733343005,Primary squamous cell carcinoma of oral cavity,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,1254755004,Metastatic basosquamous cell carcinoma of skin,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,1255632004,Spindle cell squamous cell carcinoma of larynx,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,18121000119104,Primary squamous cell carcinoma of palatine tonsil,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,78461000119105,Metastatic squamous cell carcinoma of skin,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,91271000119101,Metastatic squamous cell carcinoma of bone,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,105041000119109,Metastatic squamous cell carcinoma to lung,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,688851000119108,Primary squamous cell carcinoma of glans penis,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,689361000119108,Primary squamous cell carcinoma of tonsillar fossa,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,878441000000101,No FH of squamous cell carcinoma of skin,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,1014611000000103,Squamous cell carcinoma antigen level,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,1082071000119102,Primary squamous cell carcinoma of left ear,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Advanced cutaneous squamous cell carcinoma,TA802,squamous cell carcinoma,12240991000119102,Squamous cell carcinoma of right lung,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,10288008,Squamous cell carcinoma - spindle cell,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,12478003,Microinvasive squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,18048008,"Squamous cell carcinoma, keratinising",CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,35718007,"Squamous cell carcinoma, small cell, nonkeratinizing",CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,37304002,Mixed basal-squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,39056008,Papillary squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,59529006,Squamous cell carcinoma in situ,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,64204000,Metastatic squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,65692009,Polypoid squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,85956000,Pseudoglandular squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,89906000,Verrucous SCC (squamous cell carcinoma),CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,231830001,Squamous cell carcinoma in situ of eyelid,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,231831002,Squamous cell carcinoma of eyelid,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,254620000,Squamous cell carcinoma of trachea,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,254634000,Squamous cell carcinoma of lung,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,254652000,Clear cell squamous cell carcinoma of skin,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,254654004,Acantholytic squamous cell carcinoma of skin,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,254886006,Squamous cell carcinoma of cervix,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,255003007,Squamous cell carcinoma of conjunctiva,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,255071008,Squamous cell carcinoma of lip,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,255111004,Squamous cell carcinoma of urinary bladder,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,276804009,Squamous cell carcinoma of esophagus,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,276860003,Squamous cell carcinoma of scrotum,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,276952000,Squamous cell carcinoma of tongue,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,276953005,Squamous cell carcinoma of gingiva,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,276954004,Squamous cell carcinoma of floor of mouth,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,276962007,Squamous cell carcinoma of palate,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,285307007,Squamous cell carcinoma of skin of upper lip,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,285308002,Squamous cell carcinoma of skin of lower lip,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,285309005,Squamous cell carcinoma of skin of cheek,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,300987004,Disseminated squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,307502000,Squamous cell carcinoma of mouth,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,313353007,Squamous cell carcinoma of bronchus in left lower lobe,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,313354001,Squamous cell carcinoma of bronchus in left upper lobe,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,313355000,Squamous cell carcinoma of bronchus in right lower lobe,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,313356004,Squamous cell carcinoma of bronchus of middle lobe of right lung,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,313357008,Squamous cell carcinoma of bronchus in right upper lobe,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,400066006,Intraepithelial squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,400155002,Squamous cell carcinoma - category,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,402815007,Squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,402816008,Squamous cell carcinoma of anogenital area,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,403901001,Acantholytic squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,403904009,Verrucous squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,403906006,Metastatic squamous cell carcinoma,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,408649007,Squamous cell carcinoma of pharynx,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,422599000,Squamous cell carcinoma of back,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,423700001,Squamous cell carcinoma of auricle,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,698011002,Keratinizing squamous cell carcinoma of nasopharynx,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,700193001,Family history of squamous cell carcinoma of skin,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,707388009,Primary squamous cell carcinoma of trachea,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,707429002,Overlapping squamous cell carcinoma of larynx,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,707576008,Primary squamous cell carcinoma of subglottis,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,707581004,Primary papillary squamous cell carcinoma of oropharynx,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,707662004,Primary basaloid squamous cell carcinoma of larynx,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,716659002,Squamous cell carcinoma of head and neck,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,719052006,Recurrent SCC (squamous cell carcinoma),CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,721618006,Primary squamous cell carcinoma of upper third of esophagus,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,722530005,Primary squamous cell carcinoma of adenoid,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,722542000,Primary squamous cell carcinoma of anal canal,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,722672002,Primary squamous cell carcinoma of root of tongue,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,722673007,Primary squamous cell carcinoma of lingual tonsil,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,722674001,Primary squamous cell carcinoma of parotid gland,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,723182009,Primary squamous cell carcinoma of nasal cavity,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,723265000,Primary squamous cell carcinoma of anus,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,733343005,Primary squamous cell carcinoma of oral cavity,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,1254755004,Metastatic basosquamous cell carcinoma of skin,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,1255632004,Spindle cell squamous cell carcinoma of larynx,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,18121000119104,Primary squamous cell carcinoma of palatine tonsil,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,78461000119105,Metastatic squamous cell carcinoma of skin,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,91271000119101,Metastatic squamous cell carcinoma of bone,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,105041000119109,Metastatic squamous cell carcinoma to lung,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,688851000119108,Primary squamous cell carcinoma of glans penis,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,689361000119108,Primary squamous cell carcinoma of tonsillar fossa,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,878441000000101,No FH of squamous cell carcinoma of skin,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,1014611000000103,Squamous cell carcinoma antigen level,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,1082071000119102,Primary squamous cell carcinoma of left ear,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Metastatic or locally advanced cutaneous squamous cell carcinoma,TA592,squamous cell carcinoma,12240991000119102,Squamous cell carcinoma of right lung,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,162573006,Suspected lung cancer,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,254637007,Non-small cell lung cancer,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,275981009,Lung cancer screening,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,429011007,Family history of lung cancer,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,877691000000107,No FH of lung cancer,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CEMIPLIMAB,Untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer,TA848,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",CEMIPLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,6204001,Juvenile myoclonic epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,16873003,Musicogenic epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,19598007,Generalized epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,36803009,IGE - idiopathic generalized epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,38281008,Self-limited neonatal epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,50866000,CAE - childhood absence epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,65120008,Generalised convulsive epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,71831005,Secondary generalised epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,79745005,Sensory-induced epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,84757009,Epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,95208000,Photic epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,160341008,Family history of epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,161480008,History of epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,162658001,Epilepsy resolved,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,170702005,Epilepsy monitoring,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,170703000,Initial epilepsy assessment,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,170704006,Follow-up epilepsy assessment,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,170706008,Epilepsy associated problems,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,170709001,Epilepsy drug side effect,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,170710006,Epilepsy treatment changed,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,170711005,Epilepsy treatment started,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,170712003,Epilepsy treatment stopped,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,192979009,Generalized non-convulsive epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,192990004,Myoclonic epilepsy in infancy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,192999003,Partial epilepsy with impairment of consciousness,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,193000002,Temporal lobe epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,193002005,Psychosensory epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,193007004,Focal epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,193008009,Somatosensory epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,193009001,Partial epilepsy with autonomic symptoms,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,193011005,Unilateral epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,193021002,Running epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230381009,Localization-related epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230382002,Benign frontal epilepsy of childhood,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230384001,Benign atypical partial epilepsy in childhood,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230386004,Benign occipital epilepsy of childhood,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230388003,Late onset occipital epilepsy of childhood,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230390002,Localisation-related symptomatic epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230393000,Lateral temporal lobe epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230394006,Frontal lobe epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230403005,Parietal lobe epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230404004,Occipital lobe epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230408001,Localisation-related cryptogenic epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230412007,Myoclonic epilepsy of early childhood,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230413002,JAE - juvenile absence epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230415009,Cryptogenic generalised epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230422001,Epilepsy with myoclonic absence,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230428002,Idiopathic myoclonic epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230430000,Symptomatic myoclonic epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230438007,Aphasia co-occurrent with epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230440002,Secondary reading epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230441003,Drug-induced epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230444006,Catamenial epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230450001,Eating epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230452009,Toothbrushing epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,230454005,Bathing epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,243857008,Epilepsy monitoring status,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,267581004,Progressive myoclonic epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,278510009,Localisation-related idiopathic epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,307356008,Motor epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,314827004,Epilepsy control good,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,314828009,Epilepsy control poor,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,352818000,Grand mal epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,361123003,Psychomotor epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,361268000,Alcohol-induced epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,401062003,Epilepsy medication review,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,401178003,Epilepsy care arrangement,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,407616001,Epilepsy severity,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,407623000,Emergency epilepsy treatment since last appointment,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,407625007,Suspected epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,407627004,Epilepsy confirmed,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,413101007,Stress-induced epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,414113005,Epilepsy leaflet given,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,414860000,No epilepsy drug side effects,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,416090009,Epilepsy monitoring verbal invite,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,417568007,Epilepsy monitoring call,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,429279006,Seen in epilepsy clinic,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,719425009,Sudden unexpected death in epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,1260117009,Combined focal and generalized epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,1260407007,Genetic generalised epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,88491000000102,Epilepsy limits activities,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,93141000000105,Epilepsy restricts employment,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,93151000000108,Epilepsy prevents employment,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,93211000000101,Epilepsy does not limit activities,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,108211000000104,Epilepsy impairs education,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,109121000000109,Epilepsy society member,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,116401000119105,Recurrent complex partial epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,202061000000107,Epilepsy monitoring call first letter,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,202071000000100,Epilepsy monitoring call second letter,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,202081000000103,Epilepsy monitoring call third letter,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,509341000000107,Petit-mal epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,711501000000104,Epilepsy screening invitation,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,715091000000100,Epilepsy screening administration,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,715791000000102,Epilepsy screening second invitation,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,716011000000103,Epilepsy screening first invitation,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,716811000000106,Epilepsy screening third invitation,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,809381000000103,Referral for epilepsy review,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,809551000000103,Referral to epilepsy clinic,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,810161000000101,Epilepsy monitoring in secondary care,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,811411000000104,Under care of epilepsy specialist nurse,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,840261000000103,Epilepsy management plan given,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,850201000000104,Epilepsy annual review,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,865371000000104,No history of epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,876461000000101,No FH of epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,892181000000107,Referral to epilepsy service,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CENOBAMATE,Focal onset seizures in epilepsy,TA753,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,CENOBAMATE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,162573006,Suspected lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,254637007,Non-small cell lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,275981009,Lung cancer screening,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,429011007,Family history of lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,877691000000107,No FH of lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer,TA395,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,162573006,Suspected lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,254637007,Non-small cell lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,275981009,Lung cancer screening,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,429011007,Family history of lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,877691000000107,No FH of lung cancer,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERITINIB,Untreated ALK-positive non-small-cell lung cancer,TA500,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",CERITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,161567008,History of rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB (SUBCUTANEOUS INJECTION),Rheumatoid arthritis,TA186,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,162930007,On examination - ankylosing spondylitis chest deformity,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CERTOLIZUMAB PEGOL,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,239805001,Juvenile ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CERTOLIZUMAB PEGOL,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,239810002,Ankylosing spondylitis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CERTOLIZUMAB PEGOL,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,239811003,Ankylosing spondylitis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CERTOLIZUMAB PEGOL,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,394990003,Family history: Ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CERTOLIZUMAB PEGOL,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,429712009,Bath Ankylosing Spondylitis Disease Activity Index,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CERTOLIZUMAB PEGOL,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,441562009,Bath Ankylosing Spondylitis Disease Activity Index score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CERTOLIZUMAB PEGOL,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,441680005,BASFI (Bath Ankylosing Spondylitis Functional Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CERTOLIZUMAB PEGOL,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,ankylosing spondylitis,441930001,BASMI (Bath Ankylosing Spondylitis Metrology Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CERTOLIZUMAB PEGOL,Ankylosing spondylitis and non-radiographic axial spondyloarthritis,TA383,axial spondyloarthritis,723116002,Axial spondyloarthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
CERTOLIZUMAB PEGOL,Moderate to severe plaque psoriasis,TA574,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),CERTOLIZUMAB,DERMATOLOGY,DERMATOLOGY
CERTOLIZUMAB PEGOL,Moderate to severe plaque psoriasis,TA574,plaque psoriasis,402307000,Chronic large plaque psoriasis,CERTOLIZUMAB,DERMATOLOGY,DERMATOLOGY
CERTOLIZUMAB PEGOL,Moderate to severe plaque psoriasis,TA574,plaque psoriasis,402310007,Chronic stable plaque psoriasis,CERTOLIZUMAB,DERMATOLOGY,DERMATOLOGY
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
"CERTOLIZUMAB PEGOL ALONE, OR IN COMBINATION WITH METHOTREXATE",Psoriatic arthritis after inadequate response to DMARDs,TA445,psoriatic arthritis,156370009,Psoriatic arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
"CERTOLIZUMAB PEGOL ALONE, OR IN COMBINATION WITH METHOTREXATE",Psoriatic arthritis after inadequate response to DMARDs,TA445,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
"CERTOLIZUMAB PEGOL ALONE, OR IN COMBINATION WITH METHOTREXATE",Psoriatic arthritis after inadequate response to DMARDs,TA445,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
"CERTOLIZUMAB PEGOL ALONE, OR IN COMBINATION WITH METHOTREXATE",Psoriatic arthritis after inadequate response to DMARDs,TA445,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
"CERTOLIZUMAB PEGOL ALONE, OR IN COMBINATION WITH METHOTREXATE",Psoriatic arthritis after inadequate response to DMARDs,TA445,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
"CERTOLIZUMAB PEGOL ALONE, OR IN COMBINATION WITH METHOTREXATE",Psoriatic arthritis after inadequate response to DMARDs,TA445,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,161567008,History of rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,161567008,History of rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CERTOLIZUMAB PEGOL MONOTHERAPY,Rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor,TA415,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,10288008,Squamous cell carcinoma - spindle cell,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,12478003,Microinvasive squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,18048008,"Squamous cell carcinoma, keratinising",CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,28899001,Squamous cell epithelioma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,35718007,"Squamous cell carcinoma, small cell, nonkeratinizing",CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,37304002,Mixed basal-squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,39056008,Papillary squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,59529006,Squamous cell carcinoma in situ,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,64204000,Metastatic squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,65692009,Polypoid squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,85956000,Pseudoglandular squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,89906000,Verrucous SCC (squamous cell carcinoma),CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,90121000,"Inverted papilloma, squamous cell",CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,107692003,Mixed squamous cell and glandular papilloma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,118286007,Squamous cell neoplasm,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,231825000,Squamous cell papilloma of eyelid,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,231830001,Squamous cell carcinoma in situ of eyelid,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,231831002,Squamous cell carcinoma of eyelid,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,252994001,Benign squamous cell tumour,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,254620000,Squamous cell carcinoma of trachea,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,254634000,Squamous cell carcinoma of lung,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,254652000,Clear cell squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,254654004,Acantholytic squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,254661000,Squamous cell papilloma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,254886006,Squamous cell carcinoma of cervix,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,255003007,Squamous cell carcinoma of conjunctiva,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,255071008,Squamous cell carcinoma of lip,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,255111004,Squamous cell carcinoma of urinary bladder,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,276804009,Squamous cell carcinoma of esophagus,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,276860003,Squamous cell carcinoma of scrotum,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,276878008,Squamous cell hyperplasia of vulva,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,276952000,Squamous cell carcinoma of tongue,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,276953005,Squamous cell carcinoma of gingiva,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,276954004,Squamous cell carcinoma of floor of mouth,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,276962007,Squamous cell carcinoma of palate,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,285307007,Squamous cell carcinoma of skin of upper lip,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,285308002,Squamous cell carcinoma of skin of lower lip,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,285309005,Squamous cell carcinoma of skin of cheek,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,300987004,Disseminated squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,307502000,Squamous cell carcinoma of mouth,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,313353007,Squamous cell carcinoma of bronchus in left lower lobe,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,313354001,Squamous cell carcinoma of bronchus in left upper lobe,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,313355000,Squamous cell carcinoma of bronchus in right lower lobe,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,313356004,Squamous cell carcinoma of bronchus of middle lobe of right lung,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,313357008,Squamous cell carcinoma of bronchus in right upper lobe,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,400066006,Intraepithelial squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,400155002,Squamous cell carcinoma - category,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,402815007,Squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,402816008,Squamous cell carcinoma of anogenital area,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,403901001,Acantholytic squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,403904009,Verrucous squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,403906006,Metastatic squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,405822008,"Cancer of the larynx, squamous cell",CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,408649007,Squamous cell carcinoma of pharynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,422599000,Squamous cell carcinoma of back,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,423700001,Squamous cell carcinoma of auricle,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,698011002,Keratinizing squamous cell carcinoma of nasopharynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,700193001,Family history of squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,700399008,Cervical smear - borderline change in squamous cells,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,707388009,Primary squamous cell carcinoma of trachea,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,707429002,Overlapping squamous cell carcinoma of larynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,707576008,Primary squamous cell carcinoma of subglottis,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,707581004,Primary papillary squamous cell carcinoma of oropharynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,707662004,Primary basaloid squamous cell carcinoma of larynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,716659002,Squamous cell carcinoma of head and neck,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,719052006,Recurrent SCC (squamous cell carcinoma),CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,721618006,Primary squamous cell carcinoma of upper third of esophagus,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,722530005,Primary squamous cell carcinoma of adenoid,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,722542000,Primary squamous cell carcinoma of anal canal,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,722672002,Primary squamous cell carcinoma of root of tongue,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,722673007,Primary squamous cell carcinoma of lingual tonsil,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,722674001,Primary squamous cell carcinoma of parotid gland,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,723182009,Primary squamous cell carcinoma of nasal cavity,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,723265000,Primary squamous cell carcinoma of anus,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,733343005,Primary squamous cell carcinoma of oral cavity,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,1254755004,Metastatic basosquamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,1255632004,Spindle cell squamous cell carcinoma of larynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,18121000119104,Primary squamous cell carcinoma of palatine tonsil,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,78461000119105,Metastatic squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,91271000119101,Metastatic squamous cell carcinoma of bone,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,105041000119109,Metastatic squamous cell carcinoma to lung,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,470781000000106,[M]Papillary &/or squamous cell neoplasms,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,688851000119108,Primary squamous cell carcinoma of glans penis,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,689361000119108,Primary squamous cell carcinoma of tonsillar fossa,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,878441000000101,No FH of squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,1014611000000103,Squamous cell carcinoma antigen level,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,1082071000119102,Primary squamous cell carcinoma of left ear,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Locally advanced squamous cell cancer of the head and neck,TA145,squamous cell,12240991000119102,Squamous cell carcinoma of right lung,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,10288008,Squamous cell carcinoma - spindle cell,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,12478003,Microinvasive squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,18048008,"Squamous cell carcinoma, keratinising",CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,28899001,Squamous cell epithelioma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,35718007,"Squamous cell carcinoma, small cell, nonkeratinizing",CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,37304002,Mixed basal-squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,39056008,Papillary squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,59529006,Squamous cell carcinoma in situ,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,64204000,Metastatic squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,65692009,Polypoid squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,85956000,Pseudoglandular squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,89906000,Verrucous SCC (squamous cell carcinoma),CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,90121000,"Inverted papilloma, squamous cell",CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,107692003,Mixed squamous cell and glandular papilloma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,118286007,Squamous cell neoplasm,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,231825000,Squamous cell papilloma of eyelid,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,231830001,Squamous cell carcinoma in situ of eyelid,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,231831002,Squamous cell carcinoma of eyelid,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,252994001,Benign squamous cell tumour,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,254620000,Squamous cell carcinoma of trachea,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,254634000,Squamous cell carcinoma of lung,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,254652000,Clear cell squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,254654004,Acantholytic squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,254661000,Squamous cell papilloma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,254886006,Squamous cell carcinoma of cervix,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,255003007,Squamous cell carcinoma of conjunctiva,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,255071008,Squamous cell carcinoma of lip,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,255111004,Squamous cell carcinoma of urinary bladder,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,276804009,Squamous cell carcinoma of esophagus,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,276860003,Squamous cell carcinoma of scrotum,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,276878008,Squamous cell hyperplasia of vulva,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,276952000,Squamous cell carcinoma of tongue,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,276953005,Squamous cell carcinoma of gingiva,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,276954004,Squamous cell carcinoma of floor of mouth,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,276962007,Squamous cell carcinoma of palate,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,285307007,Squamous cell carcinoma of skin of upper lip,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,285308002,Squamous cell carcinoma of skin of lower lip,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,285309005,Squamous cell carcinoma of skin of cheek,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,300987004,Disseminated squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,307502000,Squamous cell carcinoma of mouth,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,313353007,Squamous cell carcinoma of bronchus in left lower lobe,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,313354001,Squamous cell carcinoma of bronchus in left upper lobe,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,313355000,Squamous cell carcinoma of bronchus in right lower lobe,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,313356004,Squamous cell carcinoma of bronchus of middle lobe of right lung,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,313357008,Squamous cell carcinoma of bronchus in right upper lobe,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,400066006,Intraepithelial squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,400155002,Squamous cell carcinoma - category,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,402815007,Squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,402816008,Squamous cell carcinoma of anogenital area,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,403901001,Acantholytic squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,403904009,Verrucous squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,403906006,Metastatic squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,405822008,"Cancer of the larynx, squamous cell",CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,408649007,Squamous cell carcinoma of pharynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,422599000,Squamous cell carcinoma of back,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,423700001,Squamous cell carcinoma of auricle,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,698011002,Keratinizing squamous cell carcinoma of nasopharynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,700193001,Family history of squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,700399008,Cervical smear - borderline change in squamous cells,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,707388009,Primary squamous cell carcinoma of trachea,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,707429002,Overlapping squamous cell carcinoma of larynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,707576008,Primary squamous cell carcinoma of subglottis,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,707581004,Primary papillary squamous cell carcinoma of oropharynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,707662004,Primary basaloid squamous cell carcinoma of larynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,716659002,Squamous cell carcinoma of head and neck,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,719052006,Recurrent SCC (squamous cell carcinoma),CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,721618006,Primary squamous cell carcinoma of upper third of esophagus,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,722530005,Primary squamous cell carcinoma of adenoid,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,722542000,Primary squamous cell carcinoma of anal canal,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,722672002,Primary squamous cell carcinoma of root of tongue,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,722673007,Primary squamous cell carcinoma of lingual tonsil,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,722674001,Primary squamous cell carcinoma of parotid gland,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,723182009,Primary squamous cell carcinoma of nasal cavity,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,723265000,Primary squamous cell carcinoma of anus,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,733343005,Primary squamous cell carcinoma of oral cavity,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,1254755004,Metastatic basosquamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,1255632004,Spindle cell squamous cell carcinoma of larynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,18121000119104,Primary squamous cell carcinoma of palatine tonsil,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,78461000119105,Metastatic squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,91271000119101,Metastatic squamous cell carcinoma of bone,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,105041000119109,Metastatic squamous cell carcinoma to lung,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,470781000000106,[M]Papillary &/or squamous cell neoplasms,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,688851000119108,Primary squamous cell carcinoma of glans penis,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,689361000119108,Primary squamous cell carcinoma of tonsillar fossa,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,878441000000101,No FH of squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,1014611000000103,Squamous cell carcinoma antigen level,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,1082071000119102,Primary squamous cell carcinoma of left ear,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB,Recurrent  and/or metastatic squamous cell cancer of the head and neck,TA172,squamous cell,12240991000119102,Squamous cell carcinoma of right lung,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH IRINOTECAN,Colorectal cancer (metastatic),TA118,colorectal cancer,276401000000108,Fast track referral for suspected colorectal cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH IRINOTECAN,Colorectal cancer (metastatic),TA118,colorectal cancer,382651000000108,Seen in fast track suspected colorectal cancer clinic,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH IRINOTECAN,Colorectal cancer (metastatic),TA118,colorectal cancer,722731000000100,Colorectal cancer,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH IRINOTECAN,Colorectal cancer (metastatic),TA118,colorectal cancer,848861000000104,QCancer colorectal cancer risk,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH IRINOTECAN,Colorectal cancer (metastatic),TA118,colorectal cancer,1034401000000107,Discharge from secondary care colorectal cancer service,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,10288008,Squamous cell carcinoma - spindle cell,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,12478003,Microinvasive squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,18048008,"Squamous cell carcinoma, keratinising",CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,28899001,Squamous cell epithelioma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,35718007,"Squamous cell carcinoma, small cell, nonkeratinizing",CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,37304002,Mixed basal-squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,39056008,Papillary squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,59529006,Squamous cell carcinoma in situ,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,64204000,Metastatic squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,65692009,Polypoid squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,85956000,Pseudoglandular squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,89906000,Verrucous SCC (squamous cell carcinoma),CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,90121000,"Inverted papilloma, squamous cell",CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,107692003,Mixed squamous cell and glandular papilloma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,118286007,Squamous cell neoplasm,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,231825000,Squamous cell papilloma of eyelid,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,231830001,Squamous cell carcinoma in situ of eyelid,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,231831002,Squamous cell carcinoma of eyelid,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,252994001,Benign squamous cell tumour,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,254620000,Squamous cell carcinoma of trachea,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,254634000,Squamous cell carcinoma of lung,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,254652000,Clear cell squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,254654004,Acantholytic squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,254661000,Squamous cell papilloma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,254886006,Squamous cell carcinoma of cervix,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,255003007,Squamous cell carcinoma of conjunctiva,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,255071008,Squamous cell carcinoma of lip,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,255111004,Squamous cell carcinoma of urinary bladder,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,276804009,Squamous cell carcinoma of esophagus,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,276860003,Squamous cell carcinoma of scrotum,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,276878008,Squamous cell hyperplasia of vulva,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,276952000,Squamous cell carcinoma of tongue,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,276953005,Squamous cell carcinoma of gingiva,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,276954004,Squamous cell carcinoma of floor of mouth,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,276962007,Squamous cell carcinoma of palate,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,285307007,Squamous cell carcinoma of skin of upper lip,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,285308002,Squamous cell carcinoma of skin of lower lip,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,285309005,Squamous cell carcinoma of skin of cheek,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,300987004,Disseminated squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,307502000,Squamous cell carcinoma of mouth,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,313353007,Squamous cell carcinoma of bronchus in left lower lobe,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,313354001,Squamous cell carcinoma of bronchus in left upper lobe,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,313355000,Squamous cell carcinoma of bronchus in right lower lobe,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,313356004,Squamous cell carcinoma of bronchus of middle lobe of right lung,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,313357008,Squamous cell carcinoma of bronchus in right upper lobe,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,400066006,Intraepithelial squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,400155002,Squamous cell carcinoma - category,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,402815007,Squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,402816008,Squamous cell carcinoma of anogenital area,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,403901001,Acantholytic squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,403904009,Verrucous squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,403906006,Metastatic squamous cell carcinoma,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,405822008,"Cancer of the larynx, squamous cell",CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,408649007,Squamous cell carcinoma of pharynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,422599000,Squamous cell carcinoma of back,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,423700001,Squamous cell carcinoma of auricle,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,698011002,Keratinizing squamous cell carcinoma of nasopharynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,700193001,Family history of squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,700399008,Cervical smear - borderline change in squamous cells,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,707388009,Primary squamous cell carcinoma of trachea,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,707429002,Overlapping squamous cell carcinoma of larynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,707576008,Primary squamous cell carcinoma of subglottis,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,707581004,Primary papillary squamous cell carcinoma of oropharynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,707662004,Primary basaloid squamous cell carcinoma of larynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,716659002,Squamous cell carcinoma of head and neck,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,719052006,Recurrent SCC (squamous cell carcinoma),CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,721618006,Primary squamous cell carcinoma of upper third of esophagus,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,722530005,Primary squamous cell carcinoma of adenoid,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,722542000,Primary squamous cell carcinoma of anal canal,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,722672002,Primary squamous cell carcinoma of root of tongue,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,722673007,Primary squamous cell carcinoma of lingual tonsil,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,722674001,Primary squamous cell carcinoma of parotid gland,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,723182009,Primary squamous cell carcinoma of nasal cavity,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,723265000,Primary squamous cell carcinoma of anus,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,733343005,Primary squamous cell carcinoma of oral cavity,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,1254755004,Metastatic basosquamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,1255632004,Spindle cell squamous cell carcinoma of larynx,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,18121000119104,Primary squamous cell carcinoma of palatine tonsil,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,78461000119105,Metastatic squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,91271000119101,Metastatic squamous cell carcinoma of bone,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,105041000119109,Metastatic squamous cell carcinoma to lung,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,470781000000106,[M]Papillary &/or squamous cell neoplasms,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,688851000119108,Primary squamous cell carcinoma of glans penis,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,689361000119108,Primary squamous cell carcinoma of tonsillar fossa,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,878441000000101,No FH of squamous cell carcinoma of skin,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,1014611000000103,Squamous cell carcinoma antigen level,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,1082071000119102,Primary squamous cell carcinoma of left ear,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CETUXIMAB IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY,Recurrent or metastatic squamous cell cancer of the head and neck,TA473,squamous cell,12240991000119102,Squamous cell carcinoma of right lung,CETUXIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
CHLORMETHINE GEL,Mycosis fungoides-type cutaneous T-cell lymphoma,TA720,cutaneous t-cell lymphoma,400122007,CTCL - Cutaneous T-cell lymphoma,CHLORMETHINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|DERMATOLOGY
CICLOSPORIN,Treating dry eye disease that has not improved despite treatment with artificial tears,TA369,dry eye,162290004,Dry eyes,CICLOSPORIN,OPHTHALMOLOGY,OPHTHALMOLOGY
CICLOSPORIN,Treating dry eye disease that has not improved despite treatment with artificial tears,TA369,dry eye,164742009,Dry eye test,CICLOSPORIN,OPHTHALMOLOGY,OPHTHALMOLOGY
CICLOSPORIN,Treating dry eye disease that has not improved despite treatment with artificial tears,TA369,dry eye,340951000119104,Left dry eye syndrome,CICLOSPORIN,OPHTHALMOLOGY,OPHTHALMOLOGY
CILOSTAZOL,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,822611000000100,Exception reporting - peripheral arterial disease quality indicators,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CILOSTAZOL,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,822641000000104,Excepted from peripheral arterial disease quality indicators - patient unsuitable,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CILOSTAZOL,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,822671000000105,Excepted from peripheral arterial disease quality indicators - informed dissent,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CILOSTAZOL,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,968121000000103,Peripheral arterial disease screening,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CINACALCET,Hyperparathyroidism (refractory),TA117,hyperparathyroidism,36348003,Primary hyperparathyroidism,CINACALCET,ENDOCRINOLOGY,ENDOCRINOLOGY
CINACALCET,Hyperparathyroidism (refractory),TA117,hyperparathyroidism,66999008,Hyperparathyroidism,CINACALCET,ENDOCRINOLOGY,ENDOCRINOLOGY
CINACALCET,Hyperparathyroidism (refractory),TA117,hyperparathyroidism,78200003,Tertiary hyperparathyroidism,CINACALCET,ENDOCRINOLOGY,ENDOCRINOLOGY
CINACALCET,Hyperparathyroidism (refractory),TA117,hyperparathyroidism,91478007,Secondary hyperparathyroidism,CINACALCET,ENDOCRINOLOGY,ENDOCRINOLOGY
CINACALCET,Hyperparathyroidism (refractory),TA117,hyperparathyroidism,203471008,Brown tumour of hyperparathyroidism,CINACALCET,ENDOCRINOLOGY,ENDOCRINOLOGY
CINACALCET,Hyperparathyroidism (refractory),TA117,hyperparathyroidism,237653008,Familial hyperparathyroidism,CINACALCET,ENDOCRINOLOGY,ENDOCRINOLOGY
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,24700007,Multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,160337009,Family history of multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,192926004,Brain stem multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,192928003,Generalised multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,428700003,Primary progressive multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,438511000,Benign multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,700409000,Suspected multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,198491000000106,Multiple sclerosis review,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,515931000000104,Multiple sclerosis review declined,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE,Relapsing–remitting multiple sclerosis,TA616,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,24700007,Multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,160337009,Family history of multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,192926004,Brain stem multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,192928003,Generalised multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,428700003,Primary progressive multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,438511000,Benign multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,700409000,Suspected multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,198491000000106,Multiple sclerosis review,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,515931000000104,Multiple sclerosis review declined,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLADRIBINE TABLETS,Relapsing–remitting multiple sclerosis,TA493,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,CLADRIBINE,NEUROLOGY,NEUROLOGY|REHABILITATION
CLOBETASOL PROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
CLOBETASOL PROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
CLOBETASOL PROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
CLOBETASOL PROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
CLOBETASOL PROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
CLOBETASOL PROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
CLOBETASONE BUTYRATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
CLOBETASONE BUTYRATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
CLOBETASONE BUTYRATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
CLOBETASONE BUTYRATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
CLOBETASONE BUTYRATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
CLOBETASONE BUTYRATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
CLOPIDOGREL,Acute coronary syndromes,TA080,acute coronary syndrome,837091000000100,H/O acute coronary syndrome,CLOPIDOGREL,CARDIOLOGY,CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,62914000,Cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,62914000,Cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,62914000,Cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,72092001,Arteriosclerotic vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,72092001,Arteriosclerotic vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,72092001,Arteriosclerotic vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,123799005,Hypertension due to renovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,123799005,Hypertension due to renovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,123799005,Hypertension due to renovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,127014009,Diabetic peripheral vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,127014009,Diabetic peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,127014009,Diabetic peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,134379001,Peripheral vascular disease monitoring,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,134379001,Peripheral vascular disease monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,134379001,Peripheral vascular disease monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,160270001,No family history of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,160270001,No family history of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,160270001,No family history of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,161499004,H/O: cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,161499004,H/O: cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,161499004,H/O: cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,171405001,Examination for suspected cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,171405001,Examination for suspected cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,171405001,Examination for suspected cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,192813004,Cerebral degeneration due to cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,192813004,Cerebral degeneration due to cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,192813004,Cerebral degeneration due to cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,195239002,Late effects of cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,195239002,Late effects of cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,195239002,Late effects of cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,195293004,(Peripheral vascular disease (& [ischemic] or [other])) or (ischemia of legs) or (peripheral ischemia),MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,195293004,(Peripheral vascular disease (& [ischemic] or [other])) or (ischemia of legs) or (peripheral ischemia),CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,195293004,(Peripheral vascular disease (& [ischemic] or [other])) or (ischemia of legs) or (peripheral ischemia),CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,198057005,Male genital organ vascular diseases,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,198057005,Male genital organ vascular diseases,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,198057005,Male genital organ vascular diseases,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,230738008,Asymptomatic cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,230738008,Asymptomatic cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,230738008,Asymptomatic cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,233845001,Coronary microvascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,233845001,Coronary microvascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,233845001,Coronary microvascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,266320008,Peripheral vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,266320008,Peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,266320008,Peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,266894000,Family history of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,266894000,Family history of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,266894000,Family history of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,266995000,History of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,266995000,History of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,266995000,History of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,275509000,Infective vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,275509000,Infective vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,275509000,Infective vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,302909007,Diffuse cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,302909007,Diffuse cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,302909007,Diffuse cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,308064009,History of cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,308064009,History of cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,308064009,History of cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,308071004,History of peripheral vascular disease procedure,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,308071004,History of peripheral vascular disease procedure,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,308071004,History of peripheral vascular disease procedure,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,395048001,Cardiovascular disease monitoring not required,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,395048001,Cardiovascular disease monitoring not required,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,395048001,Cardiovascular disease monitoring not required,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,400047006,PVD - peripheral vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,400047006,PVD - peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,400047006,PVD - peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,413988000,Did not attend peripheral vascular disease clinic,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,413988000,Did not attend peripheral vascular disease clinic,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,413988000,Did not attend peripheral vascular disease clinic,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,417206009,Cardiovascular disease monitoring,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,417206009,Cardiovascular disease monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,417206009,Cardiovascular disease monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,417287002,Cardiovascular disease interim monitoring,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,417287002,Cardiovascular disease interim monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,417287002,Cardiovascular disease interim monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,417322008,Cardiovascular disease annual review,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,417322008,Cardiovascular disease annual review,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,417322008,Cardiovascular disease annual review,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,429284000,Cardiovascular disease risk assessment declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,429284000,Cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,429284000,Cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,429785003,Cardiovascular disease health education,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,429785003,Cardiovascular disease health education,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,429785003,Cardiovascular disease health education,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,438370008,Vascular disease risk assessment declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,438370008,Vascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,438370008,Vascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,440358008,Primary prevention of CVD (cardiovascular disease),MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,440358008,Primary prevention of CVD (cardiovascular disease),CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,440358008,Primary prevention of CVD (cardiovascular disease),CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,440401008,Vascular disease risk assessment,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,440401008,Vascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,440401008,Vascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,441829007,Assessment for risk of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,441829007,Assessment for risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,441829007,Assessment for risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,443929000,Small vessel cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,443929000,Small vessel cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,443929000,Small vessel cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,473109007,History of peripheral vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,473109007,History of peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,473109007,History of peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,166701000000106,Joint British Societies cardiovascular disease risk,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,166701000000106,Joint British Societies cardiovascular disease risk,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,166701000000106,Joint British Societies cardiovascular disease risk,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,205001000000100,Suspected cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,205001000000100,Suspected cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,205001000000100,Suspected cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,302881000000102,Cardiovascular disease annual review declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,302881000000102,Cardiovascular disease annual review declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,302881000000102,Cardiovascular disease annual review declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,375421000000101,Vascular disease risk assessment invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,375421000000101,Vascular disease risk assessment invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,375421000000101,Vascular disease risk assessment invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,375511000000106,Vascular disease risk assessment first letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,375511000000106,Vascular disease risk assessment first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,375511000000106,Vascular disease risk assessment first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,375541000000107,Vascular disease risk assessment second letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,375541000000107,Vascular disease risk assessment second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,375541000000107,Vascular disease risk assessment second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,375571000000101,Vascular disease risk assessment third letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,375571000000101,Vascular disease risk assessment third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,375571000000101,Vascular disease risk assessment third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,376591000000106,Peripheral vascular disease monitoring invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,376591000000106,Peripheral vascular disease monitoring invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,376591000000106,Peripheral vascular disease monitoring invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,376621000000109,Peripheral vascular disease monitoring first letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,376621000000109,Peripheral vascular disease monitoring first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,376621000000109,Peripheral vascular disease monitoring first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,383321000000103,Cardiovascular disease risk assessment indicated,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,383321000000103,Cardiovascular disease risk assessment indicated,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,383321000000103,Cardiovascular disease risk assessment indicated,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,492581000000108,Cardiovascular disease high risk review declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,492581000000108,Cardiovascular disease high risk review declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,492581000000108,Cardiovascular disease high risk review declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,492611000000102,Cardiovascular disease high risk review,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,492611000000102,Cardiovascular disease high risk review,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,492611000000102,Cardiovascular disease high risk review,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,646351000000103,Peripheral vascular disease NOS,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,646351000000103,Peripheral vascular disease NOS,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,646351000000103,Peripheral vascular disease NOS,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,660711000000109,Arteriosclerotic vascular disease NOS,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,660711000000109,Arteriosclerotic vascular disease NOS,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,660711000000109,Arteriosclerotic vascular disease NOS,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,752451000000100,Cardiovascular disease risk assessment by third party,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,752451000000100,Cardiovascular disease risk assessment by third party,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,752451000000100,Cardiovascular disease risk assessment by third party,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,810681000000101,Coronary microvascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,810681000000101,Coronary microvascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,810681000000101,Coronary microvascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,837461000000101,High risk of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,837461000000101,High risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,837461000000101,High risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,845171000000108,At risk of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,845171000000108,At risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,845171000000108,At risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,858191000000103,FH: peripheral vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,858191000000103,FH: peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,858191000000103,FH: peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,863151000000105,Peripheral vascular disease monitoring second letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,863151000000105,Peripheral vascular disease monitoring second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,863151000000105,Peripheral vascular disease monitoring second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,863161000000108,Peripheral vascular disease monitoring third letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,863161000000108,Peripheral vascular disease monitoring third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,863161000000108,Peripheral vascular disease monitoring third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,863171000000101,Peripheral vascular disease monitoring verbal invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,863171000000101,Peripheral vascular disease monitoring verbal invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,863171000000101,Peripheral vascular disease monitoring verbal invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,863181000000104,Peripheral vascular disease monitoring telephone invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,863181000000104,Peripheral vascular disease monitoring telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,863181000000104,Peripheral vascular disease monitoring telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,865391000000100,No peripheral vascular disease symptoms,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,865391000000100,No peripheral vascular disease symptoms,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,865391000000100,No peripheral vascular disease symptoms,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,962871000000107,Aware of overall cardiovascular disease risk,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,962871000000107,Aware of overall cardiovascular disease risk,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,962871000000107,Aware of overall cardiovascular disease risk,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,990301000000105,Cardiovascular disease risk assessment done,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,990301000000105,Cardiovascular disease risk assessment done,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,990301000000105,Cardiovascular disease risk assessment done,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA090,vascular disease,16434071000119108,At increased risk of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,16434071000119108,At increased risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
CLOPIDOGREL,Vascular disease,TA210,vascular disease,16434071000119108,At increased risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,915007,Malignant melanoma in junctional naevus,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,1556006,Clark melanoma level 4,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,2092003,Malignant melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,2142002,Nodular melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,16974005,"Acral lentiginous melanoma, malignant",COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,21119008,Benign melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,21165006,Clark melanoma level 3,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,37138001,Epithelioid cell melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,39896009,"Malignant melanoma, regressing",COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,44474009,Lentigo maligna melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,50542000,Clark melanoma level 2,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,50813003,Spitz melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,51757004,"Desmoplastic melanoma, amelanotic",COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,55320002,Superficial spreading melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,68827007,Spindle cell melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,70594002,Amelanotic melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,77986002,Melanoma in situ,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93209006,Malignant melanoma of perianal skin,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93214005,Malignant melanoma of skin of back,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93217003,Malignant melanoma of skin of cheek,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93220006,Malignant melanoma of skin of ear,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93221005,Malignant melanoma of skin of elbow,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93223008,Malignant melanoma of eyebrow,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93225001,Malignant melanoma of skin of face,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93227009,Malignant melanoma of skin of foot,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93228004,Malignant melanoma of skin of forearm,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93642000,Malignant melanoma of skin of neck,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93643005,Malignant melanoma of external surface of nose,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93646002,Malignant melanoma of skin of scalp,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93647006,Malignant melanoma of skin of shoulder,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93651008,Malignant melanoma of skin of trunk,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93653006,Malignant melanoma of skin of upper limb,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93654000,Malignant melanoma of skin of wrist,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,93655004,MM (malignant melanoma) of skin,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,106243009,Breslow depth staging for melanoma of skin,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,109266006,Melanoma in situ of skin,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,109270003,Melanoma in situ of face,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,109272006,Melanoma in situ of lip,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,109276009,Melanoma in situ of scalp,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,109278005,Melanoma in situ of ear,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,109282007,Melanoma in situ of neck,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,109284008,Melanoma in situ of trunk,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,109290007,Melanoma in situ of upper limb,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,109294003,Melanoma in situ of lower limb,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,127330008,Melanoma in situ by body site (clinical),COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,161432005,History of malignant melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,177281002,Excision of melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188030005,Malignant melanoma of lip,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188033007,Malignant melanoma of auricle (ear),COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188034001,Malignant melanoma of external auditory meatus,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188038003,Malignant melanoma of chin,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188040008,Malignant melanoma of forehead,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188042000,Malignant melanoma of temple,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188044004,Malignant melanoma of scalp and/or neck,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188045003,Malignant melanoma of scalp,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188046002,Malignant melanoma of neck,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188049009,Malignant melanoma of axilla,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188050009,Malignant melanoma of breast,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188051008,Malignant melanoma of buttock,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188052001,Malignant melanoma of groin,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188054000,Malignant melanoma of perineum,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188055004,Malignant melanoma of umbilicus,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188060000,Malignant melanoma of shoulder,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188061001,Malignant melanoma of upper arm,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188062008,Malignant melanoma of forearm,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188063003,Malignant melanoma of hand,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188064009,Malignant melanoma of finger,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188065005,Malignant melanoma of thumb,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188067002,Malignant melanoma of lower limb and hip,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188068007,Malignant melanoma of hip,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188069004,Malignant melanoma of thigh,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188070003,Malignant melanoma of knee,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188071004,Malignant melanoma of popliteal fossa area,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188072006,Malignant melanoma of lower leg,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188073001,Malignant melanoma of ankle,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188074007,Malignant melanoma of heel,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188075008,Malignant melanoma of foot,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188076009,Malignant melanoma of toe,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,188077000,Malignant melanoma of great toe,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,189758001,Melanoma in situ,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,231834005,Malignant melanoma of eyelid,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,254731001,Nodular melanoma of skin,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,254732008,Acral lentiginous melanoma of skin,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,254896002,Malignant melanoma of vulva,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,255004001,Malignant melanoma of conjunctiva,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,255012009,Malignant melanoma of iris,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,255015006,Malignant melanoma of ciliary body,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,255021005,Malignant melanoma of choroid,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,269578002,Malignant melanoma of head and neck,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,269579005,Malignant melanoma of trunk,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,269580008,Malignant melanoma of upper limb,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,269581007,Malignant melanoma of lower limb,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,274087000,MM (malignant melanoma) of eye,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,276751004,Amelanotic melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,276821000,Malignant melanoma of anus,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,276822007,Malignant melanoma of rectum,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,302837001,Lentigo maligna melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,310498001,Malignant melanoma of back,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,312941005,Melanoma associated retinopathy,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,313248004,Malignant melanoma of chest wall,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,314976006,Local recurrence of malignant melanoma of skin,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,314987003,Metastasis from malignant melanoma of skin,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,315036008,Melanoma in situ of back of hand,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,315230006,Melanoma in situ of back,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,372158004,"Malignant melanoma, metastatic",COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,427858005,Family history of malignant melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,443493003,Metastatic malignant melanoma,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,449636007,Malignant melanoma of skin of lower leg,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,449637003,Malignant melanoma of skin of upper arm,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,698040004,Malignant melanoma of nasal cavity,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,1197324006,Metastatic malignant melanoma to skin,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,351961000119109,Malignant melanoma of skin of right arm,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,352211000119108,Malignant melanoma of skin of left ear,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,546881000000105,Malignant melanoma of skin NOS,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,956331000000107,Malignant melanoma stage IA,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,956351000000100,Malignant melanoma stage IB,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,956371000000109,Malignant melanoma stage IIA,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,956391000000108,Malignant melanoma stage IIB,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,956451000000107,Malignant melanoma stage IIIB,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,956471000000103,Malignant melanoma stage IIIC,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,956511000000107,Malignant melanoma stage IV M1a,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,956551000000106,Malignant melanoma stage IV M1c,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,1080941000119109,Malignant melanoma of left choroid,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COBIMETINIB IN COMBINATION WITH VEMURAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma,TA414,melanoma,1080981000119104,Malignant melanoma of right choroid,COBIMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,86555001,Cystic fibrosis of the lung,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,160309002,Family history of cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,171191008,Cystic fibrosis screening,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,235978006,Cystic fibrosis of pancreas,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,427022004,Liver disease due to cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,428273001,Cystic fibrosis not suspected,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,428301001,Suspected cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,428841003,Cystic fibrosis screening declined,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,441520002,Carrier of cystic fibrosis gene mutation,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,698529000,Seen in cystic fibrosis clinic,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,302651000000109,Cystic fibrosis carrier comment,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,302771000000109,Cystic fibrosis not screened for or screening incomplete,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,384341000000107,Cystic fibrosis repeat screening with further sample required,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,384401000000104,Cystic fibrosis not suspected and other disorders follow up required,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,515611000000104,Cystic fibrosis monitoring,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,515631000000107,Cystic fibrosis annual review,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,526071000000104,Arthropathy in cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,526091000000100,Cystic fibrosis with distal intestinal obstruction syndrome,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,776981000000103,Cirrhosis associated with cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,859041000000103,Exacerbation of cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947031000000109,"Cystic fibrosis screening declined, no history of being screened",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947041000000100,"Cystic fibrosis screening declined, screened in UK (as reported by parents) with no evidence of result",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947061000000104,"Cystic fibrosis screening declined, screened outside UK with evidence of result",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947081000000108,"Cystic fibrosis screening declined, screened outside UK with no evidence of result",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947101000000102,"Cystic fibrosis screening, too young for reliable screening",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947121000000106,"Cystic fibrosis screening,sample taken too soon after blood transfusion (less than 72 hours)",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947141000000104,"Cystic fibrosis screening, insufficient sample",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947161000000103,"Cystic fibrosis screening, unsuitable sample (blood quality): incorrect blood application",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947181000000107,"Cystic fibrosis screening, unsuitable sample (blood quality): compressed/damaged",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947201000000106,"Cystic fibrosis screening, unsuitable sample: day 0 and day 5 on same card",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947221000000102,"Cystic fibrosis screening, unsuitable sample: possible faecal contamination",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947241000000109,"Cystic fibrosis screening, unsuitable sample: NHS number missing/not accurately recorded",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947281000000101,"Cystic fibrosis screening, unsuitable sample: date of sample missing/not accurately recorded",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947301000000100,"Cystic fibrosis screening, unsuitable sample: date of birth not accurately matched",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947321000000109,"Cystic fibrosis screening, unsuitable sample: expired card used",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947341000000102,"Cystic fibrosis screening, unsuitable sample: more than 14 days in transit, too old for analysis",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947361000000101,"Cystic fibrosis screening, unsuitable sample: damaged in transit",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947381000000105,"Cystic fibrosis screening, inconclusive result",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947401000000105,"Cystic fibrosis not screened for or screening incomplete: more than 8 weeks, too old for screening",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947491000000103,"Cystic fibrosis not screened for or screening incomplete, moved out of area",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947511000000106,"Cystic fibrosis not screened for or screening incomplete, not contactable, reasonable efforts made",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947551000000105,"Cystic fibrosis not screened for or screening incomplete, not required, previous valid result",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,1015871000000108,Cystic fibrosis screening test,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
COLISTIMETHATE SODIUM,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,1028351000000108,Cystic fibrosis screening,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,46635009,T1DM - type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,290002008,Unstable type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,420825003,Gangrene due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,420868002,Disorder due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,429094000,Dietary advice for type 1 diabetes,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,444073006,Uncontrolled type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,703137001,Type 1 diabetes mellitus in remission,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 1 diabetes,TA057,type 1 diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP THERAPY'),Type 2 diabetes,TA057,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,46635009,T1DM - type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,290002008,Unstable type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,420825003,Gangrene due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,420868002,Disorder due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,429094000,Dietary advice for type 1 diabetes,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,444073006,Uncontrolled type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,703137001,Type 1 diabetes mellitus in remission,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII OR ‘INSULIN PUMP’) THERAPY,Type 1 diabetes,TA151,type 1 diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,CONTINUOUS,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
CRISABOROLE,Mild to moderate atopic dermatitis in people 2 years and older,TA701,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,CRISABOROLE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
CRISABOROLE,Mild to moderate atopic dermatitis in people 2 years and older,TA701,atopic dermatitis,238543002,Discoid atopic dermatitis,CRISABOROLE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
CRISABOROLE,Mild to moderate atopic dermatitis in people 2 years and older,TA701,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,CRISABOROLE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
CRISABOROLE,Mild to moderate atopic dermatitis in people 2 years and older,TA701,atopic dermatitis,238545009,Follicular atopic dermatitis,CRISABOROLE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
CRISABOROLE,Mild to moderate atopic dermatitis in people 2 years and older,TA701,atopic dermatitis,238546005,Pruriginous atopic dermatitis,CRISABOROLE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
CRISABOROLE,Mild to moderate atopic dermatitis in people 2 years and older,TA701,atopic dermatitis,584621000000108,Atopic dermatitis NOS,CRISABOROLE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
CRIZANLIZUMAB,Preventing sickle cell crises in sickle cell disease,TA743,sickle cell disease,193370005,Proliferative retinopathy due to sickle cell disease,CRIZANLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS
CRIZANLIZUMAB,Preventing sickle cell crises in sickle cell disease,TA743,sickle cell disease,416180004,Sickle cell disease without crisis,CRIZANLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS
CRIZANLIZUMAB,Preventing sickle cell crises in sickle cell disease,TA743,sickle cell disease,442186003,Screening for sickle cell disease,CRIZANLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS
CRIZANLIZUMAB,Preventing sickle cell crises in sickle cell disease,TA743,sickle cell disease,473131004,Suspected sickle cell disease,CRIZANLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS
CRIZANLIZUMAB,Preventing sickle cell crises in sickle cell disease,TA743,sickle cell disease,473132006,Sickle cell disease not suspected,CRIZANLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS
CRIZANLIZUMAB,Preventing sickle cell crises in sickle cell disease,TA743,sickle cell disease,991891000000102,Sickle cell disease screening test,CRIZANLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS
CRIZANLIZUMAB,Preventing sickle cell crises in sickle cell disease,TA743,sickle cell disease,1027811000000102,Sickle cell disease screening,CRIZANLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS
CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,162573006,Suspected lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,254637007,Non-small cell lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,275981009,Lung cancer screening,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,429011007,Family history of lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,877691000000107,No FH of lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA422,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,835009,Angioimmunoblastic lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,1929004,"Malignant lymphoma, diffuse",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,19340000,Plasmacytic lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,20776008,Adenolymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,21964009,Lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,21983002,Struma lymphomatosa,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,28054005,Cutaneous lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,28175004,Gastric pseudolymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,30440004,Lymphoma stage I,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,31047003,Lymphomatoid papulosis,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,40411000,"Malignant lymphoma, histiocytic, nodular",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,41529000,"Classical Hodgkin lymphoma, mixed cellularity",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,46732000,"Malignant lymphoma, large cell, cleaved, diffuse",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,51092000,Malignant lymphoma lymphocytic well differentiated diffuse,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,52248008,"Classical Hodgkin lymphoma, nodular sclerosis",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,55020008,"Malignant lymphoma, mixed cell type, follicular",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,55150002,"Malignant lymphoma, nodular",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,56944001,Lymphoma stage III,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,64575004,"Malignant lymphoma, small lymphocytic, diffuse",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,66445009,Lymphoma stage IV,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,70600005,"Hodgkin lymphoma, nodular lymphocyte predominance",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,74654000,Mantle cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,76422004,Lymphoma stage II,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,92814006,B-cell CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma),CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,93191005,Malignant lymphoma of intra-abdominal lymph nodes,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,93192003,Malignant lymphoma of intrapelvic lymph nodes,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,93194002,Malignant lymphoma of lymph nodes of axilla AND/OR upper limb,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,93195001,"Malignant lymphoma of lymph nodes of head, face AND/OR neck",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,93197009,Malignant lymphoma of lymph nodes of multiple sites,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,93198004,Malignant lymphoma of spleen,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,95186006,Nodular lymphoma of intra-abdominal lymph nodes,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,95192000,Nodular lymphoma of lymph nodes of multiple sites,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,95193005,Nodular lymphoma of spleen,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,106252000,Staging classification for lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,109962001,Nonfollicular lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,109966003,"Lymphoma, immunoblastic, high grade",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,109969005,Diffuse large B-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,109975001,T-zone lymphoma (clinical),CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,109976000,Lymphoepithelioid lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,109977009,Peripheral T-cell lymphoma pleomorphic medium and large cell,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,109978004,T-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,109979007,B-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,109988003,True histiocytic lymphoma (clinical),CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,115244002,Malignant lymphoma - category,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,115245001,"Malignant lymphoma, follicular AND/OR nodular",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,118599009,"Lymphoma, Hodgkins",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,118600007,Malignant lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,118601006,Non-Hodgkin lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,118605002,"Hodgkin lymphoma, nodular lymphocyte predominance",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,118609008,Hodgkin mixed cellularity lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,118617000,Burkitt lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,128799007,"Hodgkin lymphoma, lymphocyte-rich",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,128803008,Marginal zone lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,128805001,Angiocentric natural killer cell and T-cell malignant lymphoma nasal type,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,128875000,Primary cutaneous CD30 antigen positive large T-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,128929007,Non-Hodgkin lymphoma - category,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,128930002,Hodgkin lymphoma - category,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,162573006,Suspected lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,188609000,"Nodular lymphoma of lymph nodes of head, face and neck",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,188612002,Nodular lymphoma of lymph nodes of axilla and upper limb,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,188613007,Nodular lymphoma of lymph nodes of inguinal region and lower limb,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,188674006,Diffuse malignant lymphoma - small non-cleaved cell,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,188675007,"Malignant lymphoma, lymphocytic - poorly differentiated",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,188676008,Malignant lymphoma - mixed lymphocytic-histiocytic,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,189958005,"Lymphomatous tumour, benign",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,189962004,"Malignant lymphoma, stem cell type",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,232075002,Lymphoma of retina,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,236513009,Lymphoma of kidney,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,238994000,Drug-induced pseudolymphomatous eruption,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,239297008,Lymphomatoid granulomatosis of lung,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,239940004,Lymphomatoid granulomatosis,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,240794006,Splenic schistosomal giant cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,254372002,Ann Arbor lymphoma staging system,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,254637007,Non-small cell lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,255102004,Intravascular lymphomatosis,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,258279002,Lymphoma staging symptom status values,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,269476000,Nodular lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,274905008,Mantle zone lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,275981009,Lung cancer screening,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,276811008,Gastric lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,276815004,Lymphoma of intestine,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,276836002,Primary cerebral lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277024002,Working formulation of non-Hodgkin lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277551008,Splenic lymphoma with villous lymphocytes,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277570003,Lymphoma with spill,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277613000,Cutaneous peripheral T-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277615007,Low grade B-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277616008,Diffuse low grade B-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277617004,High grade B-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277618009,Nodular malignant lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277623009,Monocytoid B-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277624003,Follicular malignant lymphoma - mixed cell type,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277625002,Follicular malignant lymphoma - small cleaved cell,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277626001,Diffuse high grade B-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277627005,Nodular high grade B-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277637000,Large cell anaplastic lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277641001,Follicular malignant lymphoma - large cell,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277642008,Low grade T-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277643003,High grade T-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277651000,Peripheral T-cell lymphoma - pleomorphic small cell,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277654008,Enteropathy-type T-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,277664004,Malignant lymphoma of testis,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,278051002,Malignant lymphoma of thyroid gland,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,278052009,Malignant lymphoma of breast,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,302841002,Malignant lymphoma - small cell,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,303055001,"Malignant lymphoma, follicular centre cell",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,307623001,Malignant lymphoma - lymphoplasmacytic,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,308121000,Follicular lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,314922006,B-cell lymphoma morphology,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,314923001,Low grade B-cell lymphoma morphology,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,314924007,Follicular low grade B-cell lymphoma morphology,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,314925008,High grade B-cell lymphoma morphology,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,314926009,T-cell lymphoma morphology,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,314929002,Diffuse low grade B-cell lymphoma morphology,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,314934003,Diffuse high grade B-cell lymphoma morphology,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,315264005,Suspected lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,400001003,Primary cutaneous lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,400122007,CTCL - Cutaneous T-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,404111002,Lymphomatoid papulosis-associated mycosis fungoides,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,404140004,SALT type B-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,413537009,Angioimmunoblastic T-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,414166008,Natural Killer cell and T-cell malignant lymphoma nasal type,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,414780005,Mucosa-associated lymphoid tissue lymphoma of orbit,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,420788006,Vitreoretinal lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,426071002,Hodgkin lymphoma in remission,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,427141003,Malignant lymphoma in remission,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,428046009,History of non-Hodgkins lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,429011007,Family history of lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,433450000,Family history of non-Hodgkin lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,443487006,Mantle cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,444597005,Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of stomach,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,444910004,Primary mediastinal (thymic) large B-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,445269007,Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,445406001,Hepatosplenic T-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,447100004,Marginal zone lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,448211002,Adenolymphoma of parotid gland,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,448212009,Anaplastic lymphoma kinase negative anaplastic large cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,448709005,Non-Hodgkin lymphoma of stomach,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,449074003,Lymphoma of small intestine,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,449220000,Diffuse follicle center lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,450958009,"Malignant lymphoma, diffuse large B-cell, immunoblastic",CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,721555001,Follicular lymphoma of small intestine,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,724648008,Plasmablastic lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,738770003,Anaplastic lymphoma kinase positive anaplastic large cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,762690000,Classical Hodgkin lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,763666008,Splenic marginal zone B-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,830057003,Relapsing classical Hodgkin lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,1148845007,Follicular non-Hodgkin lymphoma grade 3b,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,1148851002,Follicular lymphoma grade IIIa,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,143291000119104,Non-Hodgkin's lymphoma in remission,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,847481000000109,Follicular lymphoma grade 1,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,847631000000107,Follicular lymphoma grade 2,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,847651000000100,Follicular lymphoma grade 3,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,847691000000108,Follicular lymphoma grade 3a,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,847701000000108,Follicular lymphoma grade 3b,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,847741000000106,Diffuse large B-cell lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,877691000000107,No FH of lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,878461000000100,No FH of non-Hodgkin lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,1090241000000107,Angioimmunoblastic T-cell lymphoma with dysproteinaemia,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,1091861000000100,Cutaneous follicle centre lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,1091891000000106,B-cell Hodgkin's lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,lymphoma,1091921000000103,B-cell non-Hodgkin's lymphoma,CRIZOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene,TA296,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,162573006,Suspected lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,254637007,Non-small cell lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,275981009,Lung cancer screening,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,429011007,Family history of lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,877691000000107,No FH of lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,ROS1-positive advanced non-small-cell lung cancer,TA529,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,162573006,Suspected lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,254637007,Non-small cell lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,275981009,Lung cancer screening,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,429011007,Family history of lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,877691000000107,No FH of lung cancer,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
CRIZOTINIB,Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer,TA406,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",CRIZOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,2517002,Stroke rehabilitation,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,25133001,Completed stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,28690004,Stroke test,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,39925003,"MELAS - mitochondrial encephalopathy, lactic acidosis and stroke-like episodes",DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,44922000,Bounding pulse with rapid upstroke and descent,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,49436004,Atrial fibrillation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,90096001,Stroke volume,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,134377004,Atrial fibrillation monitoring,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,135875009,Stroke prevention,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,135877001,Stroke risk,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,160252004,No family history of cardiovascular accident or stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,160271002,No family history of stroke and/or transient ischaemic attack,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,170600009,Stroke monitoring,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,195080001,Atrial fibrillation and flutter,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,195163003,Stroke due to intracerebral haemorrhage,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,195212005,Brainstem stroke syndrome,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,195213000,Cerebellar stroke syndrome,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,212937007,Heat stroke and sunstroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,230690007,Stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,230694003,Total anterior cerebral circulation stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,230695002,Partial anterior cerebral circulation stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,230696001,Posterior cerebral circulation stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,230700009,Pure sensory stroke due to and following lacunar infarction,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,230713003,Stroke of uncertain pathology,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,230714009,Anterior circulation stroke of uncertain pathology,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,230715005,Posterior circulation stroke of uncertain pathology,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,230739000,Spinal cord stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,233911009,Non-rheumatic atrial fibrillation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,275434003,Stroke in the puerperium,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,276898003,Left ventricular stroke work index,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,277286006,Chronic central post-stroke pain,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,277381004,Stroke index,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,282825002,Intermittent atrial fibrillation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,297250002,No family history of stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,299403002,Stroke test positive,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,299404008,Stroke test negative,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,300996004,Controlled atrial fibrillation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,306802002,Referral to stroke service,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,306803007,Admission to stroke unit,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,306808003,Discharge from stroke service,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,306810001,Seen by stroke service,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,308067002,History of stroke in last year,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,309966001,Stroke unit,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,310137004,Stroke service,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,312442005,History of atrial fibrillation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,371040005,Thrombotic stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,371041009,Embolic stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,412773009,Referral to stroke clinic,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,413119003,Stroke group member,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,413124000,Stroke/transient ischaemic attack referral,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,415628004,Stroke/transient ischaemic attack monitoring first letter,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,415629007,Stroke/transient ischemic attack monitoring second letter,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,415630002,Stroke/transient ischaemic attack monitoring status,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,415631003,Stroke/transient ischemic attack monitoring third letter,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,417059002,Stroke/transient ischemic attack monitoring verbal invitation,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,417506008,Hemorrhagic stroke monitoring,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,417540008,Stroke/transient ischaemic attack monitoring invitation,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,422504002,Ischaemic stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,440028005,Permanent atrial fibrillation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,440059007,Persistent atrial fibrillation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,449863006,Insertion of pacemaker for control of atrial fibrillation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,450743008,NIHSS (National Institutes of Health stroke scale) score,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,699833006,Provision of written information about atrial fibrillation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,704154001,"HAS-BLED (hypertension, abnormal renal and/or liver function, stroke, bleeding history or predisposition, labile INR (international normalised ratio), elderly over 65, and drugs and/or alcohol concomitantly) score",DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,704180000,"HAS-BLED (hypertension, abnormal renal and/or liver function, stroke, bleeding history or predisposition, labile international normalised ratio, elderly over 65, and drugs and/or alcohol concomitantly) bleeding risk score",DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,706923002,Longstanding persistent atrial fibrillation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,707514001,Stroke impact scale version 3.0 score,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,719008003,At increased risk of atrial fibrillation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,722929005,Perinatal arterial ischemic stroke of fetus and/or neonate,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,724424009,Cerebral ischemic stroke due to small artery occlusion,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,736712009,PASS (Postural Assessment Scale for Stroke Patients) score,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,788880006,Cerebral ischaemic stroke due to dissection of artery,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,788884002,Cerebral ischemic stroke due to subarachnoid hemorrhage,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,1010405004,Paroxysmal AF (atrial fibrillation) with RVR (rapid ventricular response),DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,88601000000107,DNA (did not attend) stroke clinic,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,112901000000108,Referral to multidisciplinary stroke function improvement service,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,120041000119109,Atrial fibrillation with rapid ventricular response,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,133111000000106,QOF (Quality and Outcomes Framework) atrial fibrillation quality indicator-related care invitation using preferred method of communication,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,140921000119102,Ischemic stroke without coma,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,143471000000105,QOF (Quality and Outcomes Framework) stroke and transient ischaemic attack quality indicator-related care invitation using preferred method of communication,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,196371000000102,Atrial fibrillation resolved,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,201501000000108,Seen in stroke clinic,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,231231000000107,Delivery of rehabilitation for stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,248411000000105,Atrial fibrillation annual review,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,519751000000106,Stroke 6 month review,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,521411000000106,Did not attend stroke review,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,685631000000102,Stroke and cerebrovascular accident unspecified,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,711411000000101,Atrial fibrillation monitoring invitation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,713771000000100,Stroke/transient ischaemic attack monitoring administration,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,713801000000102,Atrial fibrillation monitoring administration,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,715941000000109,Excepted from atrial fibrillation quality indicators - patient unsuitable,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,716021000000109,Excepted from stroke quality indicators - informed dissent,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,716181000000109,Atrial fibrillation monitoring third letter,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,716331000000108,Exception reporting - stroke quality indicators,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,716581000000101,Excepted from stroke quality indicators - patient unsuitable,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,716721000000107,Atrial fibrillation monitoring telephone invitation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,716871000000101,Exception reporting - atrial fibrillation quality indicators,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,716981000000106,Atrial fibrillation monitoring second letter,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,717011000000100,Atrial fibrillation monitoring verbal invite,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,717221000000101,Atrial fibrillation monitoring first letter,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,717241000000108,Stroke/transient ischaemic attack monitoring telephone invitation,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,717381000000109,Excepted from atrial fibrillation quality indicators - informed dissent,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,769211000000103,Suspected stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,810991000000109,Stroke self-management plan review,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,812041000000104,Stroke self-management plan agreed,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,816401000000105,Atrial fibrillation excluded,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,816561000000108,Stroke initial post discharge review,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,842441000000104,Provision of written information about stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,847611000000104,Atrial fibrillation care pathway,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,870631000000105,QStroke 10 year risk of stroke calculator,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,1025021000000107,High risk of atrial fibrillation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,1062151000000103,Stroke TOM (Therapy Outcome Measure) activity score,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,1062171000000107,Stroke TOM (Therapy Outcome Measure) impairment score,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,1062181000000109,Stroke TOM (Therapy Outcome Measure) participation score,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,1062191000000106,Stroke TOM (Therapy Outcome Measure) wellbeing score,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,1066831000000104,Atrial fibrillation detected,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,1067061000000104,Atrial fibrillation not detected,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,1078001000000105,Haemorrhagic stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,1085311000000106,QStroke risk calculator score,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,atrial fibrillation,1110851000000100,QOF (Quality and Outcomes Framework) atrial fibrillation quality indicator-related care invitation,DABIGATRAN,CARDIOLOGY,CARDIOLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,1110981000000104,QOF (Quality and Outcomes Framework) stroke and transient ischaemic attack quality indicator-related care invitation,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Prevention of stroke and systemic embolism in atrial fibrillation,TA249,stroke,16371781000119100,Cerebellar stroke,DABIGATRAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
DABIGATRAN ETEXILATE,Venous thromboembolism after hip or knee replacement surgery,TA157,venous thromboembolism,443749004,Venous thromboembolism risk assessment,DABIGATRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY
DABIGATRAN ETEXILATE,Venous thromboembolism after hip or knee replacement surgery,TA157,venous thromboembolism,699035003,At low risk of venous thromboembolism,DABIGATRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY
DABIGATRAN ETEXILATE,Venous thromboembolism after hip or knee replacement surgery,TA157,venous thromboembolism,711293008,At moderate risk of venous thromboembolism,DABIGATRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY
DABIGATRAN ETEXILATE,Venous thromboembolism after hip or knee replacement surgery,TA157,venous thromboembolism,711328005,At high risk of venous thromboembolism,DABIGATRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY
DABIGATRAN ETEXILATE,Venous thromboembolism after hip or knee replacement surgery,TA157,venous thromboembolism,787331000000107,Venous thromboembolism prevention management,DABIGATRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY
DABIGATRAN ETEXILATE,Venous thromboembolism after hip or knee replacement surgery,TA157,venous thromboembolism,844041000000102,Education about risk of venous thromboembolism,DABIGATRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,14534009,Deep vein thrombosis of splenic vein,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,49956009,Antenatal DVT (deep vein thrombosis),DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,56272000,Puerperal DVT (deep vein thrombosis),DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,pulmonary embolism,59282003,Pulmonary embolism,DABIGATRAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,128053003,Deep vein thrombosis,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,134399007,Deep vein thrombosis of leg related to air travel,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,161508001,History of DVT (deep vein thrombosis),DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,200232006,Antenatal deep vein thrombosis - delivered,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,200233001,Antenatal deep vein thrombosis with antenatal complication,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,200238005,Postnatal deep vein thrombosis with postnatal complication,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,pulmonary embolism,200284000,Obstetric pulmonary embolism,DABIGATRAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,pulmonary embolism,200286003,Obstetric air pulmonary embolism,DABIGATRAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,pulmonary embolism,200303005,Obstetric blood-clot pulmonary embolism with antenatal complication,DABIGATRAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,213220000,Postoperative deep vein thrombosis,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,225999004,At increased risk of DVT (deep vein thrombosis),DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,pulmonary embolism,233217004,Operation for pulmonary embolism,DABIGATRAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,pulmonary embolism,233936003,Acute massive pulmonary embolism,DABIGATRAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,pulmonary embolism,233937007,Subacute massive pulmonary embolism,DABIGATRAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,234044007,Ileofemoral deep vein thrombosis,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,401186003,Deep vein thrombosis screening,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,413459009,Advised risk of deep vein thrombosis in air travel,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,413956008,Deep vein thrombosis of leg related to intravenous drug use,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,pulmonary embolism,417113001,Suspected PE (pulmonary embolism),DABIGATRAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,429053008,Wells deep vein thrombosis clinical probability score,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,pulmonary embolism,430801003,Family history of pulmonary embolism,DABIGATRAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,432805000,Suspected deep vein thrombosis,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,pulmonary embolism,438773007,Recurrent pulmonary embolism,DABIGATRAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,443210003,Deep vein thrombosis of peroneal vein,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,710167004,Recurrent DVT (deep vein thrombosis),DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,198301000000109,FH: deep vein thrombosis,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,323631000000102,DVT (deep vein thrombosis) prevention,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,492161000000109,Deep vein thrombosis enhanced services administration,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,503421000000105,Deep vein thrombosis enhanced services administration stage 1 service level,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,503451000000100,Deep vein thrombosis enhanced services administration stage 2 service level,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,503481000000106,Deep vein thrombosis enhanced services administration stage 3 service level,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,513251000000101,Low probability of deep vein thrombosis,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,513271000000105,Moderate probability of deep vein thrombosis,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,513291000000109,High probability of deep vein thrombosis,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,869611000000104,On deep vein thrombosis care pathway,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,872221000000109,No history of deep vein thrombosis,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,978421000000101,Unprovoked deep vein thrombosis,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABIGATRAN ETEXILATE,treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism,TA327,deep vein thrombosis,978441000000108,Provoked deep vein thrombosis,DABIGATRAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,162573006,Suspected lung cancer,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,254637007,Non-small cell lung cancer,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,275981009,Lung cancer screening,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,429011007,Family history of lung cancer,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,877691000000107,No FH of lung cancer,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DABRAFENIB,Advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer,TA564,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,915007,Malignant melanoma in junctional naevus,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,1556006,Clark melanoma level 4,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,2092003,Malignant melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,2142002,Nodular melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,16974005,"Acral lentiginous melanoma, malignant",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,21119008,Benign melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,21165006,Clark melanoma level 3,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,37138001,Epithelioid cell melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,39896009,"Malignant melanoma, regressing",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,44474009,Lentigo maligna melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,50542000,Clark melanoma level 2,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,50813003,Spitz melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,51757004,"Desmoplastic melanoma, amelanotic",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,55320002,Superficial spreading melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,68827007,Spindle cell melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,70594002,Amelanotic melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,77986002,Melanoma in situ,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93209006,Malignant melanoma of perianal skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93214005,Malignant melanoma of skin of back,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93217003,Malignant melanoma of skin of cheek,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93220006,Malignant melanoma of skin of ear,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93221005,Malignant melanoma of skin of elbow,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93223008,Malignant melanoma of eyebrow,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93225001,Malignant melanoma of skin of face,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93227009,Malignant melanoma of skin of foot,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93228004,Malignant melanoma of skin of forearm,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93642000,Malignant melanoma of skin of neck,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93643005,Malignant melanoma of external surface of nose,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93646002,Malignant melanoma of skin of scalp,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93647006,Malignant melanoma of skin of shoulder,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93651008,Malignant melanoma of skin of trunk,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93653006,Malignant melanoma of skin of upper limb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93654000,Malignant melanoma of skin of wrist,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,93655004,MM (malignant melanoma) of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,106243009,Breslow depth staging for melanoma of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,109266006,Melanoma in situ of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,109270003,Melanoma in situ of face,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,109272006,Melanoma in situ of lip,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,109276009,Melanoma in situ of scalp,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,109278005,Melanoma in situ of ear,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,109282007,Melanoma in situ of neck,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,109284008,Melanoma in situ of trunk,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,109290007,Melanoma in situ of upper limb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,109294003,Melanoma in situ of lower limb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,127330008,Melanoma in situ by body site (clinical),DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,161432005,History of malignant melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,177281002,Excision of melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188030005,Malignant melanoma of lip,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188033007,Malignant melanoma of auricle (ear),DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188034001,Malignant melanoma of external auditory meatus,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188038003,Malignant melanoma of chin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188040008,Malignant melanoma of forehead,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188042000,Malignant melanoma of temple,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188044004,Malignant melanoma of scalp and/or neck,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188045003,Malignant melanoma of scalp,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188046002,Malignant melanoma of neck,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188049009,Malignant melanoma of axilla,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188050009,Malignant melanoma of breast,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188051008,Malignant melanoma of buttock,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188052001,Malignant melanoma of groin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188054000,Malignant melanoma of perineum,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188055004,Malignant melanoma of umbilicus,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188060000,Malignant melanoma of shoulder,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188061001,Malignant melanoma of upper arm,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188062008,Malignant melanoma of forearm,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188063003,Malignant melanoma of hand,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188064009,Malignant melanoma of finger,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188065005,Malignant melanoma of thumb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188067002,Malignant melanoma of lower limb and hip,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188068007,Malignant melanoma of hip,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188069004,Malignant melanoma of thigh,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188070003,Malignant melanoma of knee,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188071004,Malignant melanoma of popliteal fossa area,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188072006,Malignant melanoma of lower leg,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188073001,Malignant melanoma of ankle,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188074007,Malignant melanoma of heel,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188075008,Malignant melanoma of foot,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188076009,Malignant melanoma of toe,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,188077000,Malignant melanoma of great toe,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,189758001,Melanoma in situ,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,231834005,Malignant melanoma of eyelid,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,254731001,Nodular melanoma of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,254732008,Acral lentiginous melanoma of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,254896002,Malignant melanoma of vulva,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,255004001,Malignant melanoma of conjunctiva,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,255012009,Malignant melanoma of iris,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,255015006,Malignant melanoma of ciliary body,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,255021005,Malignant melanoma of choroid,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,269578002,Malignant melanoma of head and neck,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,269579005,Malignant melanoma of trunk,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,269580008,Malignant melanoma of upper limb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,269581007,Malignant melanoma of lower limb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,274087000,MM (malignant melanoma) of eye,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,276751004,Amelanotic melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,276821000,Malignant melanoma of anus,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,276822007,Malignant melanoma of rectum,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,302837001,Lentigo maligna melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,310498001,Malignant melanoma of back,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,312941005,Melanoma associated retinopathy,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,313248004,Malignant melanoma of chest wall,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,314976006,Local recurrence of malignant melanoma of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,314987003,Metastasis from malignant melanoma of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,315036008,Melanoma in situ of back of hand,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,315230006,Melanoma in situ of back,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,372158004,"Malignant melanoma, metastatic",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,427858005,Family history of malignant melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,443493003,Metastatic malignant melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,449636007,Malignant melanoma of skin of lower leg,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,449637003,Malignant melanoma of skin of upper arm,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,698040004,Malignant melanoma of nasal cavity,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,1197324006,Metastatic malignant melanoma to skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,351961000119109,Malignant melanoma of skin of right arm,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,352211000119108,Malignant melanoma of skin of left ear,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,546881000000105,Malignant melanoma of skin NOS,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,956331000000107,Malignant melanoma stage IA,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,956351000000100,Malignant melanoma stage IB,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,956371000000109,Malignant melanoma stage IIA,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,956391000000108,Malignant melanoma stage IIB,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,956451000000107,Malignant melanoma stage IIIB,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,956471000000103,Malignant melanoma stage IIIC,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,956511000000107,Malignant melanoma stage IV M1a,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,956551000000106,Malignant melanoma stage IV M1c,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,1080941000119109,Malignant melanoma of left choroid,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB,Unresectable or metastatic BRAF V600 mutation‑positive melanoma,TA321,melanoma,1080981000119104,Malignant melanoma of right choroid,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,915007,Malignant melanoma in junctional naevus,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,1556006,Clark melanoma level 4,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,2092003,Malignant melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,2142002,Nodular melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,16974005,"Acral lentiginous melanoma, malignant",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,21119008,Benign melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,21165006,Clark melanoma level 3,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,37138001,Epithelioid cell melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,39896009,"Malignant melanoma, regressing",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,44474009,Lentigo maligna melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,50542000,Clark melanoma level 2,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,50813003,Spitz melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,51757004,"Desmoplastic melanoma, amelanotic",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,55320002,Superficial spreading melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,68827007,Spindle cell melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,70594002,Amelanotic melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,77986002,Melanoma in situ,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93209006,Malignant melanoma of perianal skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93214005,Malignant melanoma of skin of back,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93217003,Malignant melanoma of skin of cheek,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93220006,Malignant melanoma of skin of ear,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93221005,Malignant melanoma of skin of elbow,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93223008,Malignant melanoma of eyebrow,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93225001,Malignant melanoma of skin of face,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93227009,Malignant melanoma of skin of foot,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93228004,Malignant melanoma of skin of forearm,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93642000,Malignant melanoma of skin of neck,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93643005,Malignant melanoma of external surface of nose,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93646002,Malignant melanoma of skin of scalp,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93647006,Malignant melanoma of skin of shoulder,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93651008,Malignant melanoma of skin of trunk,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93653006,Malignant melanoma of skin of upper limb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93654000,Malignant melanoma of skin of wrist,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,93655004,MM (malignant melanoma) of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,106243009,Breslow depth staging for melanoma of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,109266006,Melanoma in situ of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,109270003,Melanoma in situ of face,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,109272006,Melanoma in situ of lip,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,109276009,Melanoma in situ of scalp,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,109278005,Melanoma in situ of ear,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,109282007,Melanoma in situ of neck,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,109284008,Melanoma in situ of trunk,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,109290007,Melanoma in situ of upper limb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,109294003,Melanoma in situ of lower limb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,127330008,Melanoma in situ by body site (clinical),DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,161432005,History of malignant melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,177281002,Excision of melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188030005,Malignant melanoma of lip,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188033007,Malignant melanoma of auricle (ear),DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188034001,Malignant melanoma of external auditory meatus,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188038003,Malignant melanoma of chin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188040008,Malignant melanoma of forehead,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188042000,Malignant melanoma of temple,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188044004,Malignant melanoma of scalp and/or neck,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188045003,Malignant melanoma of scalp,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188046002,Malignant melanoma of neck,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188049009,Malignant melanoma of axilla,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188050009,Malignant melanoma of breast,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188051008,Malignant melanoma of buttock,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188052001,Malignant melanoma of groin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188054000,Malignant melanoma of perineum,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188055004,Malignant melanoma of umbilicus,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188060000,Malignant melanoma of shoulder,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188061001,Malignant melanoma of upper arm,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188062008,Malignant melanoma of forearm,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188063003,Malignant melanoma of hand,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188064009,Malignant melanoma of finger,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188065005,Malignant melanoma of thumb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188067002,Malignant melanoma of lower limb and hip,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188068007,Malignant melanoma of hip,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188069004,Malignant melanoma of thigh,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188070003,Malignant melanoma of knee,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188071004,Malignant melanoma of popliteal fossa area,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188072006,Malignant melanoma of lower leg,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188073001,Malignant melanoma of ankle,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188074007,Malignant melanoma of heel,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188075008,Malignant melanoma of foot,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188076009,Malignant melanoma of toe,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,188077000,Malignant melanoma of great toe,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,189758001,Melanoma in situ,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,231834005,Malignant melanoma of eyelid,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,254731001,Nodular melanoma of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,254732008,Acral lentiginous melanoma of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,254896002,Malignant melanoma of vulva,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,255004001,Malignant melanoma of conjunctiva,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,255012009,Malignant melanoma of iris,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,255015006,Malignant melanoma of ciliary body,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,255021005,Malignant melanoma of choroid,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,269578002,Malignant melanoma of head and neck,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,269579005,Malignant melanoma of trunk,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,269580008,Malignant melanoma of upper limb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,269581007,Malignant melanoma of lower limb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,274087000,MM (malignant melanoma) of eye,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,276751004,Amelanotic melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,276821000,Malignant melanoma of anus,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,276822007,Malignant melanoma of rectum,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,302837001,Lentigo maligna melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,310498001,Malignant melanoma of back,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,312941005,Melanoma associated retinopathy,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,313248004,Malignant melanoma of chest wall,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,314976006,Local recurrence of malignant melanoma of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,314987003,Metastasis from malignant melanoma of skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,315036008,Melanoma in situ of back of hand,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,315230006,Melanoma in situ of back,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,372158004,"Malignant melanoma, metastatic",DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,427858005,Family history of malignant melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,443493003,Metastatic malignant melanoma,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,449636007,Malignant melanoma of skin of lower leg,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,449637003,Malignant melanoma of skin of upper arm,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,698040004,Malignant melanoma of nasal cavity,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,1197324006,Metastatic malignant melanoma to skin,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,351961000119109,Malignant melanoma of skin of right arm,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,352211000119108,Malignant melanoma of skin of left ear,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,546881000000105,Malignant melanoma of skin NOS,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,956331000000107,Malignant melanoma stage IA,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,956351000000100,Malignant melanoma stage IB,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,956371000000109,Malignant melanoma stage IIA,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,956391000000108,Malignant melanoma stage IIB,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,956451000000107,Malignant melanoma stage IIIB,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,956471000000103,Malignant melanoma stage IIIC,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,956511000000107,Malignant melanoma stage IV M1a,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,956551000000106,Malignant melanoma stage IV M1c,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,1080941000119109,Malignant melanoma of left choroid,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DABRAFENIB WITH TRAMETINIB,Resected BRAF V600 mutation-positive melanoma,TA544,melanoma,1080981000119104,Malignant melanoma of right choroid,DABRAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,62944002,Hepatitis C virus,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,62944002,Hepatitis C virus,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,72165005,Hepatitis C virus antibody,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,72165005,Hepatitis C virus antibody,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,170489004,Viral hepatitis carrier,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,170489004,Viral hepatitis carrier,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,197344005,Hepatitis caused by adenovirus,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,197344005,Hepatitis caused by adenovirus,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,235872006,Hepatitis C carrier,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,235872006,Hepatitis C carrier,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,278973007,Hepatitis C status,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,278973007,Hepatitis C status,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,278974001,Hepatitis C immune,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,278974001,Hepatitis C immune,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,278975000,Hepatitis C non-immune,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,278975000,Hepatitis C non-immune,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,314706002,Hepatitis C antibody detected,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,314706002,Hepatitis C antibody detected,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,314707006,Hepatitis C antibody test negative,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,314707006,Hepatitis C antibody test negative,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,413107006,Hepatitis C screening,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,413107006,Hepatitis C screening,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,773113008,Acute hepatitis caused by infection,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,773113008,Acute hepatitis caused by infection,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,12891000175105,Hepatitis C screening declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,12891000175105,Hepatitis C screening declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,200371000000104,Hepatitis C contact,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,200371000000104,Hepatitis C contact,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,201451000000105,Hepatitis C immunisation declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,201451000000105,Hepatitis C immunisation declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,202281000000105,Hepatitis C screening declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,202281000000105,Hepatitis C screening declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,204671000000101,Hepatitis C screening counselling,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,204671000000101,Hepatitis C screening counselling,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,304821000000107,Hepatitis C screening not offered,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,304821000000107,Hepatitis C screening not offered,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,362491000000104,Hepatitis C screening negative,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,362491000000104,Hepatitis C screening negative,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,362751000000101,Hepatitis C screening positive,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,362751000000101,Hepatitis C screening positive,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,761381000000102,Hepatitis C resolved,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,761381000000102,Hepatitis C resolved,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,824841000000105,Hepatitis C genotype 1,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,824841000000105,Hepatitis C genotype 1,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,824871000000104,Hepatitis C genotype 3,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,824871000000104,Hepatitis C genotype 3,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,829731000000106,On hepatitis C treatment plan,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,829731000000106,On hepatitis C treatment plan,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,992751000000109,Hepatitis C viral load,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,992751000000109,Hepatitis C viral load,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,992771000000100,Hepatitis C virus genotype,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,992771000000100,Hepatitis C virus genotype,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,996031000000104,Hepatitis C IgG level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,996031000000104,Hepatitis C IgG level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,998771000000103,Hepatitis C antibody level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,998771000000103,Hepatitis C antibody level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1001331000000102,Hepatitis C antigen level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1001331000000102,Hepatitis C antigen level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1008931000000108,Hepatitis C antibody test,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1008931000000108,Hepatitis C antibody test,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1107671000000106,Hepatitis C screening offered,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1107671000000106,Hepatitis C screening offered,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,62944002,Hepatitis C virus,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,62944002,Hepatitis C virus,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,72165005,Hepatitis C virus antibody,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,72165005,Hepatitis C virus antibody,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,170489004,Viral hepatitis carrier,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,170489004,Viral hepatitis carrier,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,197344005,Hepatitis caused by adenovirus,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,197344005,Hepatitis caused by adenovirus,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,235872006,Hepatitis C carrier,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,235872006,Hepatitis C carrier,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,278973007,Hepatitis C status,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,278973007,Hepatitis C status,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,278974001,Hepatitis C immune,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,278974001,Hepatitis C immune,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,278975000,Hepatitis C non-immune,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,278975000,Hepatitis C non-immune,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,314706002,Hepatitis C antibody detected,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,314706002,Hepatitis C antibody detected,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,314707006,Hepatitis C antibody test negative,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,314707006,Hepatitis C antibody test negative,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,413107006,Hepatitis C screening,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,413107006,Hepatitis C screening,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,773113008,Acute hepatitis caused by infection,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,773113008,Acute hepatitis caused by infection,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,12891000175105,Hepatitis C screening declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,12891000175105,Hepatitis C screening declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,200371000000104,Hepatitis C contact,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,200371000000104,Hepatitis C contact,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,201451000000105,Hepatitis C immunisation declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,201451000000105,Hepatitis C immunisation declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,202281000000105,Hepatitis C screening declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,202281000000105,Hepatitis C screening declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,204671000000101,Hepatitis C screening counselling,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,204671000000101,Hepatitis C screening counselling,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,304821000000107,Hepatitis C screening not offered,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,304821000000107,Hepatitis C screening not offered,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,362491000000104,Hepatitis C screening negative,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,362491000000104,Hepatitis C screening negative,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,362751000000101,Hepatitis C screening positive,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,362751000000101,Hepatitis C screening positive,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,761381000000102,Hepatitis C resolved,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,761381000000102,Hepatitis C resolved,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,824841000000105,Hepatitis C genotype 1,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,824841000000105,Hepatitis C genotype 1,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,824871000000104,Hepatitis C genotype 3,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,824871000000104,Hepatitis C genotype 3,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,829731000000106,On hepatitis C treatment plan,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,829731000000106,On hepatitis C treatment plan,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,992751000000109,Hepatitis C viral load,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,992751000000109,Hepatitis C viral load,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,992771000000100,Hepatitis C virus genotype,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,992771000000100,Hepatitis C virus genotype,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,996031000000104,Hepatitis C IgG level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,996031000000104,Hepatitis C IgG level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,998771000000103,Hepatitis C antibody level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,998771000000103,Hepatitis C antibody level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,1001331000000102,Hepatitis C antigen level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,1001331000000102,Hepatitis C antigen level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,1008931000000108,Hepatitis C antibody test,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,1008931000000108,Hepatitis C antibody test,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,1107671000000106,Hepatitis C screening offered,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR,Chronic hepatitis C,TA364,hepatitis c,1107671000000106,Hepatitis C screening offered,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,62944002,Hepatitis C virus,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,62944002,Hepatitis C virus,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,72165005,Hepatitis C virus antibody,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,72165005,Hepatitis C virus antibody,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,170489004,Viral hepatitis carrier,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,170489004,Viral hepatitis carrier,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,197344005,Hepatitis caused by adenovirus,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,197344005,Hepatitis caused by adenovirus,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,235872006,Hepatitis C carrier,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,235872006,Hepatitis C carrier,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,278973007,Hepatitis C status,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,278973007,Hepatitis C status,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,278974001,Hepatitis C immune,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,278974001,Hepatitis C immune,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,278975000,Hepatitis C non-immune,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,278975000,Hepatitis C non-immune,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,314706002,Hepatitis C antibody detected,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,314706002,Hepatitis C antibody detected,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,314707006,Hepatitis C antibody test negative,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,314707006,Hepatitis C antibody test negative,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,413107006,Hepatitis C screening,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,413107006,Hepatitis C screening,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,773113008,Acute hepatitis caused by infection,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,773113008,Acute hepatitis caused by infection,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,12891000175105,Hepatitis C screening declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,12891000175105,Hepatitis C screening declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,200371000000104,Hepatitis C contact,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,200371000000104,Hepatitis C contact,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,201451000000105,Hepatitis C immunisation declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,201451000000105,Hepatitis C immunisation declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,202281000000105,Hepatitis C screening declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,202281000000105,Hepatitis C screening declined,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,204671000000101,Hepatitis C screening counselling,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,204671000000101,Hepatitis C screening counselling,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,304821000000107,Hepatitis C screening not offered,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,304821000000107,Hepatitis C screening not offered,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,362491000000104,Hepatitis C screening negative,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,362491000000104,Hepatitis C screening negative,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,362751000000101,Hepatitis C screening positive,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,362751000000101,Hepatitis C screening positive,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,761381000000102,Hepatitis C resolved,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,761381000000102,Hepatitis C resolved,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,824841000000105,Hepatitis C genotype 1,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,824841000000105,Hepatitis C genotype 1,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,824871000000104,Hepatitis C genotype 3,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,824871000000104,Hepatitis C genotype 3,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,829731000000106,On hepatitis C treatment plan,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,829731000000106,On hepatitis C treatment plan,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,992751000000109,Hepatitis C viral load,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,992751000000109,Hepatitis C viral load,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,992771000000100,Hepatitis C virus genotype,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,992771000000100,Hepatitis C virus genotype,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,996031000000104,Hepatitis C IgG level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,996031000000104,Hepatitis C IgG level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,998771000000103,Hepatitis C antibody level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,998771000000103,Hepatitis C antibody level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1001331000000102,Hepatitis C antigen level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1001331000000102,Hepatitis C antigen level,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1008931000000108,Hepatitis C antibody test,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1008931000000108,Hepatitis C antibody test,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1107671000000106,Hepatitis C screening offered,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLATASVIR PLUS SOFOSBUVIR AND RIBAVIRIN,Chronic hepatitis C,TA364,hepatitis c,1107671000000106,Hepatitis C screening offered,DACLATASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,24700007,Multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,160337009,Family history of multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,192926004,Brain stem multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,192928003,Generalised multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,428700003,Primary progressive multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,438511000,Benign multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,700409000,Suspected multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,198491000000106,Multiple sclerosis review,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,515931000000104,Multiple sclerosis review declined,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Relapsing–remitting multiple sclerosis,TA441,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,DACLIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
DACLIZUMAB,Renal transplantation - children and adolescents,TA099,renal transplantation,70536003,Renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
DACLIZUMAB,Renal transplantation - children and adolescents,TA099,renal transplantation,313030004,Donor renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
DACLIZUMAB,Renal transplantation - children and adolescents,TA099,renal transplantation,429451003,Disorder related to renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,162573006,Suspected lung cancer,DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,254637007,Non-small cell lung cancer,DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,275981009,Lung cancer screening,DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,429011007,Family history of lung cancer,DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,877691000000107,No FH of lung cancer,DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DACOMITINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA595,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",DACOMITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,10335000,Chronic right-sided heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,10633002,Acute congestive heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,36315003,Malignant hypertensive heart disease without congestive heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,48447003,Chronic heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,56675007,Acute heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,77970009,Benign hypertensive heart disease without congestive heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,83105008,Malignant hypertensive heart disease with congestive heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,83291003,Right heart failure due to pulmonary hypertension,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,85232009,Left-sided heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,88805009,Chronic congestive heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,111283005,Chronic left-sided heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,128404006,Right heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,134378009,Congestive heart failure monitoring,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,134440006,Referral to heart failure clinic,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,161505003,History of heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,194779001,Hypertensive heart and renal disease with (congestive) heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,194781004,Hypertensive heart and renal disease with both (congestive) heart failure and renal failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,233924009,Heart failure as a complication of care,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,266308000,Right heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,309634009,History of heart failure in last year,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,314206003,Refractory heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,367363000,Right heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,390868005,Heart failure screen,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,390884006,Heart failure follow-up,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,390885007,Heart failure annual review,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,394887005,Suspected heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,394927007,Heart failure excluded,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,395105005,Heart failure confirmed,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,416683003,Emergency hospital admission for heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,416717003,Seen in heart failure clinic,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,417146007,Referral to heart failure nurse,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,417359009,Seen by community heart failure nurse,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,423475008,Heart failure education,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,424404003,Decompensated chronic heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,426263006,Congestive heart failure due to left ventricular systolic dysfunction,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,426611007,Congestive heart failure due to valvular disease,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,429959009,Family history of heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,441530006,Chronic diastolic heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,446221000,HFpEF - heart failure with preserved ejection fraction,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,473226007,Heart failure medication review,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,703272007,HFrEF - heart failure with reduced ejection fraction,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,703275009,Heart failure with reduced ejection fraction due to cardiomyopathy,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,704095000,Referral to heart failure exercise programme,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,704096004,Referral to heart failure exercise programme not indicated,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,704097008,Referral to heart failure exercise program declined,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,735984001,Heart failure self management plan,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,788950000,HFmEF - heart failure with mid range ejection fraction,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,1296659009,Acute on chronic heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,96311000119109,Exacerbation of congestive heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,143411000000100,QOF (Quality and Outcomes Framework) heart failure quality indicator-related care invitation using preferred method of communication,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,200171000000102,Referred by heart failure nurse specialist,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,200201000000101,Discharge from practice nurse heart failure clinic,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,200361000000106,Did not attend practice nurse heart failure clinic,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,202231000000106,Heart failure review completed,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,203791000000106,Referred to heart failure education group,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,247361000000100,Heart failure 6 month review,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,248571000000104,Did not attend heart failure clinic,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,374231000000104,High risk of heart failure screening invitation,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,521691000000100,Heart failure resolved,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,711461000000104,Heart failure monitoring invitation,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,713791000000101,Heart failure monitoring administration,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,715951000000107,Exception reporting - heart failure quality indicators,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,716621000000101,Heart failure monitoring third letter,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,716971000000109,Heart failure monitoring first letter,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,717191000000108,Heart failure monitoring second letter,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,717481000000104,Excepted from heart failure quality indicators - patient unsuitable,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,717491000000102,Excepted from heart failure quality indicators - informed dissent,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,717501000000108,Heart failure monitoring verbal invitation,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,717531000000102,Heart failure monitoring telephone invitation,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,760361000000100,Fast track heart failure referral for transthoracic two dimensional echocardiogram,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,763641000000102,Referral to heart failure education group declined,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,765661000000102,Discharge from heart failure nurse service,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,781051000000108,Has heart failure management plan,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,789621000000105,Preferred place of care for next exacerbation of heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,810971000000105,Heart failure self-management plan review,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,812001000000102,Heart failure self-management plan agreed,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,813991000000101,Education about deteriorating heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,835981000000108,Rehabilitation for heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,851071000000108,Heart failure initial assessment,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,851521000000102,Heart failure clinical pathway,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,871681000000102,Heart failure monitoring,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,872361000000105,Discussion about heart failure care plan,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,873881000000100,Referral to rapid access heart failure clinic,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,915571000000102,On optimal heart failure therapy,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,961881000000101,Provision of information about heart failure,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,1108711000000108,Excepted from heart failure quality indicators - service unavailable,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA679,heart failure,1110931000000103,QOF (Quality and Outcomes Framework) heart failure quality indicator-related care invitation,DAPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,171234009,Chronic kidney disease screening,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,431855005,Chronic kidney disease stage 1,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,431856006,Chronic kidney disease stage 2,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,431857002,Chronic kidney disease stage 4,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,433144002,Chronic kidney disease stage 3,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,433146000,Chronic kidney disease stage 5,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,472953006,H/O chronic kidney disease,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,698463001,At increased risk of chronic kidney disease,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,700378005,Chronic kidney disease stage 3A,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,700379002,Chronic kidney disease stage 3B,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,709044004,Chronic kidney disease,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,714152005,Chronic kidney disease 5d,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,248721000000108,Chronic kidney disease monitoring,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,249171000000102,Chronic kidney disease annual review,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,249311000000109,Predicted stage chronic kidney disease,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,298141000000107,Did not attend chronic kidney disease monitoring clinic,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324121000000109,CKD (chronic kidney disease stage) 1 with proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324151000000104,CKD (chronic kidney disease) stage 1 without proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324181000000105,CKD (chronic kidney disease) stage 2 with proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324211000000106,CKD (chronic kidney disease) stage 2 without proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324251000000105,CKD (chronic kidney disease) stage 3 with proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324281000000104,CKD (chronic kidney disease) stage 3 without proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324311000000101,CKD (chronic kidney disease) stage 3A with proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324341000000100,CKD (chronic kidney disease) stage 3A without proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324371000000106,CKD (chronic kidney disease) stage 3B with proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324411000000105,CKD (chronic kidney disease) stage 3B without proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324441000000106,CKD (chronic kidney disease) stage 4 with proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324471000000100,CKD (chronic kidney disease) stage 4 without proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324501000000107,CKD (chronic kidney disease) stage 5 with proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,324541000000105,CKD (chronic kidney disease) stage 5 without proteinuria,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,711421000000107,Chronic kidney disease monitoring invitation,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,713811000000100,Chronic kidney disease monitoring administration,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,716651000000106,Chronic kidney disease monitoring first letter,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,716881000000104,Excepted from chronic kidney disease quality indicators - informed dissent,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,716891000000102,Excepted from chronic kidney disease quality indicators - patient unsuitable,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,717231000000104,Chronic kidney disease monitoring verbal invite,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,717361000000100,Exception reporting - chronic kidney disease quality indicators,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,717461000000108,Chronic kidney disease monitoring third letter,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,717511000000105,Chronic kidney disease monitoring telephone invite,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,717751000000104,Chronic kidney disease monitoring second letter,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,811021000000104,Chronic kidney disease self-management plan review,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,811941000000105,Chronic kidney disease self-management plan agreed,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,857971000000104,Estimated glomerular filtration rate using Chronic Kidney Disease Epidemiology Collaboration formula,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,903261000000109,Chronic kidney disease laboratory study,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,939211000000104,Chronic kidney disease resolved,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,949401000000103,Chronic kidney disease with glomerular filtration rate category G1 and albuminuria category A1,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,949421000000107,Chronic kidney disease with glomerular filtration rate category G1 and albuminuria category A2,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,949481000000108,CKD G1A3 - chronic kidney disease with glomerular filtration rate category G1 and albuminuria category A3,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,949521000000108,CKD G2A1 - chronic kidney disease with glomerular filtration rate category G2 and albuminuria category A1,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,949561000000100,Chronic kidney disease with glomerular filtration rate category G2 and albuminuria category A2,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,949621000000109,CKD G2A3 - chronic kidney disease with glomerular filtration rate category G2 and albuminuria category A3,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,949881000000106,CKD G3aA1 - chronic kidney disease with glomerular filtration rate category G3a and albuminuria category A1,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,949901000000109,CKD G3aA2 - chronic kidney disease with glomerular filtration rate category G3a and albuminuria category A2,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,949921000000100,Chronic kidney disease with glomerular filtration rate category G3a and albuminuria category A3,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,950061000000103,Chronic kidney disease with glomerular filtration rate category G3b and albuminuria category A1,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,950081000000107,CKD G3bA2 - chronic kidney disease with glomerular filtration rate category G3b and albuminuria category A2,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,950101000000101,CKD G3bA3 - chronic kidney disease with glomerular filtration rate category G3b and albuminuria category A3,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,950181000000106,CKD G4A1 - chronic kidney disease with glomerular filtration rate category G4 and albuminuria category A1,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,950211000000107,CKD G4A2 - chronic kidney disease with glomerular filtration rate category G4 and albuminuria category A2,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,950231000000104,CKD G4A3 - chronic kidney disease with glomerular filtration rate category G4 and albuminuria category A3,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,950251000000106,CKD G5A1 - chronic kidney disease with glomerular filtration rate category G5 and albuminuria category A1,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,950291000000103,Chronic kidney disease with glomerular filtration rate category G5 and albuminuria category A2,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,950311000000102,Chronic kidney disease with glomerular filtration rate category G5 and albuminuria category A3,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,1011481000000105,Estimated glomerular filtration rate using creatinine Chronic Kidney Disease Epidemiology Collaboration equation per 1.73 square metres,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN,Chronic kidney disease,TA775,chronic kidney disease,1011491000000107,Estimated glomerular filtration rate using cystatin C Chronic Kidney Disease Epidemiology Collaboration equation per 1.73 square metres,DAPAGLIFLOZIN,NEPHROLOGY,NEPHROLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA288,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA,Type 2 diabetes,TA288,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATIN WITH METFORMIN AND A SULFONYLUREA,Treating type 2 diabetes,TA418,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA288,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,46635009,T1DM - type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,290002008,Unstable type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,420825003,Gangrene due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,420868002,Disorder due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,429094000,Dietary advice for type 1 diabetes,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,444073006,Uncontrolled type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,703137001,Type 1 diabetes mellitus in remission,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DAPAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA597,type 1 diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,DAPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
DARATUMUMAB,Multiple myeloma,TA573,multiple myeloma,230586003,Neuropathy due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DARATUMUMAB,Multiple myeloma,TA573,multiple myeloma,413587002,Smoldering multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DARATUMUMAB,Multiple myeloma,TA573,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DARATUMUMAB,Relapsed or refractory multiple myeloma,TA454,multiple myeloma,230586003,Neuropathy due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DARATUMUMAB,Relapsed or refractory multiple myeloma,TA454,multiple myeloma,413587002,Smoldering multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DARATUMUMAB,Relapsed or refractory multiple myeloma,TA454,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DARATUMUMAB IN COMBINATION,Multiple myeloma when a stem cell transplant is suitable,TA763,multiple myeloma,230586003,Neuropathy due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DARATUMUMAB IN COMBINATION,Multiple myeloma when a stem cell transplant is suitable,TA763,multiple myeloma,413587002,Smoldering multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DARATUMUMAB IN COMBINATION,Multiple myeloma when a stem cell transplant is suitable,TA763,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DARATUMUMAB MONOTHERAPY,Relapsed and refractory multiple myeloma,TA510,multiple myeloma,230586003,Neuropathy due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DARATUMUMAB MONOTHERAPY,Relapsed and refractory multiple myeloma,TA510,multiple myeloma,413587002,Smoldering multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DARATUMUMAB MONOTHERAPY,Relapsed and refractory multiple myeloma,TA510,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DARATUMUMAB MONOTHERAPY FOR TREATING RELAPSED AND REFRACTORY MULTIPLE MYELOMA,Relapsed and refractory multiple myeloma,TA783,multiple myeloma,230586003,Neuropathy due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DARATUMUMAB MONOTHERAPY FOR TREATING RELAPSED AND REFRACTORY MULTIPLE MYELOMA,Relapsed and refractory multiple myeloma,TA783,multiple myeloma,413587002,Smoldering multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DARATUMUMAB MONOTHERAPY FOR TREATING RELAPSED AND REFRACTORY MULTIPLE MYELOMA,Relapsed and refractory multiple myeloma,TA783,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
"DARATUMUMAB WITH BORTEZOMIB, MELPHALAN AND PREDNISONE",Untreated multiple myeloma,TA771,multiple myeloma,230586003,Neuropathy due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
"DARATUMUMAB WITH BORTEZOMIB, MELPHALAN AND PREDNISONE",Untreated multiple myeloma,TA771,multiple myeloma,413587002,Smoldering multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
"DARATUMUMAB WITH BORTEZOMIB, MELPHALAN AND PREDNISONE",Untreated multiple myeloma,TA771,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE,Untreated multiple myeloma,TA634,multiple myeloma,230586003,Neuropathy due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE,Untreated multiple myeloma,TA634,multiple myeloma,413587002,Smoldering multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE,Untreated multiple myeloma,TA634,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DARATUMUMAB WITH POMALIDOMIDE AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA726,multiple myeloma,230586003,Neuropathy due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DARATUMUMAB WITH POMALIDOMIDE AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA726,multiple myeloma,413587002,Smoldering multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DARATUMUMAB WITH POMALIDOMIDE AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA726,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,DARATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DAROLUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-relapsed non-metastatic prostate cancer,TA660,prostate cancer,315268008,Suspected prostate cancer,DAROLUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DAROLUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-relapsed non-metastatic prostate cancer,TA660,prostate cancer,428262008,H/O: prostate cancer,DAROLUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DAROLUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-relapsed non-metastatic prostate cancer,TA660,prostate cancer,698470001,Advice given about prostate cancer screening,DAROLUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DAROLUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-relapsed non-metastatic prostate cancer,TA660,prostate cancer,712837004,Active surveillance of prostate cancer,DAROLUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DAROLUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-relapsed non-metastatic prostate cancer,TA660,prostate cancer,720007002,Prostate cancer care review,DAROLUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DAROLUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-relapsed non-metastatic prostate cancer,TA660,prostate cancer,31011000119107,Prostate cancer screening declined,DAROLUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DAROLUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-relapsed non-metastatic prostate cancer,TA660,prostate cancer,874211000000109,QCancer prostate cancer risk,DAROLUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DAROLUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-relapsed non-metastatic prostate cancer,TA660,prostate cancer,878401000000104,No FH of prostate cancer,DAROLUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DAROLUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-relapsed non-metastatic prostate cancer,TA660,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,DAROLUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DAROLUTAMIDE WITH ANDROGEN DEPRIVATION THERAPY,Hormone-relapsed non-metastatic prostate cancer,TA660,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,DAROLUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DASATINIB,Philadelphia-chromosome-positive acute lymphoblastic leukaemia,TA714,acute lymphoblastic leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,DASATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS
DASATINIB,Philadelphia-chromosome-positive acute lymphoblastic leukaemia,TA714,acute lymphoblastic leukaemia,413440007,Acute lymphoblastic leukaemia - category,DASATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS
DASATINIB,Treatment of chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia,TA251,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,STANDARD-DOSE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
DASATINIB,Untreated chronic myeloid leukaemia,TA426,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,DASATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
DASITINIB,Treating imatinib-resistant or intolerant chronic myeloid leukaemia,TA425,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,DASITINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
DECITABINE,Acute myeloid leukaemia,TA270,acute myeloid leukaemia,91861009,"Acute myeloid leukaemia, disease",DECITABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DECITABINE,Untreated acute myeloid leukaemia,TA548,acute myeloid leukaemia,91861009,"Acute myeloid leukaemia, disease",DECITABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DEGARELIX,Advanced hormone-dependent prostate cancer,TA404,prostate cancer,315268008,Suspected prostate cancer,DEGARELIX,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DEGARELIX,Advanced hormone-dependent prostate cancer,TA404,prostate cancer,428262008,H/O: prostate cancer,DEGARELIX,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DEGARELIX,Advanced hormone-dependent prostate cancer,TA404,prostate cancer,698470001,Advice given about prostate cancer screening,DEGARELIX,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DEGARELIX,Advanced hormone-dependent prostate cancer,TA404,prostate cancer,712837004,Active surveillance of prostate cancer,DEGARELIX,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DEGARELIX,Advanced hormone-dependent prostate cancer,TA404,prostate cancer,720007002,Prostate cancer care review,DEGARELIX,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DEGARELIX,Advanced hormone-dependent prostate cancer,TA404,prostate cancer,31011000119107,Prostate cancer screening declined,DEGARELIX,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DEGARELIX,Advanced hormone-dependent prostate cancer,TA404,prostate cancer,874211000000109,QCancer prostate cancer risk,DEGARELIX,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DEGARELIX,Advanced hormone-dependent prostate cancer,TA404,prostate cancer,878401000000104,No FH of prostate cancer,DEGARELIX,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DEGARELIX,Advanced hormone-dependent prostate cancer,TA404,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,DEGARELIX,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DEGARELIX,Advanced hormone-dependent prostate cancer,TA404,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,DEGARELIX,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,14651005,Drug-induced osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,18040001,Age-related osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,64859006,Osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,102447009,Postmenopausal osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,160313009,Family history of osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,203429007,Idiopathic generalised osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,203433000,Postoophorectomy osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,203435007,Localized osteoporosis - Lequesne,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,203437004,Osteoporosis in endocrine disorders,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,203438009,Osteoporosis of spine,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,240157009,Secondary generalised osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,240158004,Regional migrating osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,240159007,Transient osteoporosis of hip,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,240162005,Secondary localized osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,268028001,Localised disuse osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,276661002,Primary osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,281387004,Regional osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,300004007,Screening for osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,309745002,Osteoporosis localized to spine,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,310251007,No family history: Osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,313423004,At increased risk of osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,390833005,Osteoporosis caused by corticosteroid,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391003008,Osteoporosis monitoring administration,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391004002,Attends osteoporosis monitoring,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391006000,Osteoporosis monitoring default,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391007009,Osteoporosis monitoring first letter,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391008004,Osteoporosis monitoring second letter,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391012005,Osteoporosis monitoring deleted,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391013000,Osteoporosis monitoring check done,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391014006,Osteoporosis risk assessment done,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391015007,Osteoporosis risk assessment declined,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391016008,Osteoporosis risk assessment defaulted,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391017004,Osteoporosis monitoring,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391018009,Initial osteoporosis assessment,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391019001,Follow-up osteoporosis assessment,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391020007,Osteoporosis treatment started,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391021006,Osteoporosis treatment stopped,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391022004,Osteoporosis treatment changed,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391023009,Osteoporosis - no treatment,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391024003,Osteoporosis - dietary advice,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391025002,Osteoporosis - dietary assessment,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391026001,Osteoporosis - exercise advice,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391027005,Osteoporosis - falls prevention,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391028000,Osteoporosis - treatment response,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391033001,Refer to osteoporosis specialist,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391037000,Seen in osteoporosis clinic,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,394936006,Health education - osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,412717001,Referral to osteoporosis clinic,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,473120007,History of osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,763322002,Osteoporosis monitoring refused,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,278781000000105,Osteoporosis treatment not indicated,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,505141000000108,Osteoporosis enhanced services administration,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,711341000000106,Osteoporosis resolved,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (primary prevention),TA204,osteoporosis,965871000000101,Osteoporosis medication compliance review,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,14651005,Drug-induced osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,18040001,Age-related osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,64859006,Osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,102447009,Postmenopausal osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,160313009,Family history of osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,203429007,Idiopathic generalised osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,203433000,Postoophorectomy osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,203435007,Localized osteoporosis - Lequesne,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,203437004,Osteoporosis in endocrine disorders,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,203438009,Osteoporosis of spine,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,240157009,Secondary generalised osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,240158004,Regional migrating osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,240159007,Transient osteoporosis of hip,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,240162005,Secondary localized osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,268028001,Localised disuse osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,276661002,Primary osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,281387004,Regional osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,300004007,Screening for osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,309745002,Osteoporosis localized to spine,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,310251007,No family history: Osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,313423004,At increased risk of osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,390833005,Osteoporosis caused by corticosteroid,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391003008,Osteoporosis monitoring administration,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391004002,Attends osteoporosis monitoring,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391006000,Osteoporosis monitoring default,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391007009,Osteoporosis monitoring first letter,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391008004,Osteoporosis monitoring second letter,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391012005,Osteoporosis monitoring deleted,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391013000,Osteoporosis monitoring check done,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391014006,Osteoporosis risk assessment done,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391015007,Osteoporosis risk assessment declined,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391016008,Osteoporosis risk assessment defaulted,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391017004,Osteoporosis monitoring,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391018009,Initial osteoporosis assessment,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391019001,Follow-up osteoporosis assessment,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391020007,Osteoporosis treatment started,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391021006,Osteoporosis treatment stopped,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391022004,Osteoporosis treatment changed,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391023009,Osteoporosis - no treatment,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391024003,Osteoporosis - dietary advice,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391025002,Osteoporosis - dietary assessment,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391026001,Osteoporosis - exercise advice,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391027005,Osteoporosis - falls prevention,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391028000,Osteoporosis - treatment response,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391033001,Refer to osteoporosis specialist,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391037000,Seen in osteoporosis clinic,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,394936006,Health education - osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,412717001,Referral to osteoporosis clinic,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,473120007,History of osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,763322002,Osteoporosis monitoring refused,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,278781000000105,Osteoporosis treatment not indicated,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,505141000000108,Osteoporosis enhanced services administration,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,711341000000106,Osteoporosis resolved,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA204,osteoporosis,965871000000101,Osteoporosis medication compliance review,DENOSUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
DENOSUMAB,Preventing skeletal-related events in multiple myeloma,TA549,multiple myeloma,230586003,Neuropathy due to multiple myeloma,DENOSUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DENOSUMAB,Preventing skeletal-related events in multiple myeloma,TA549,multiple myeloma,413587002,Smoldering multiple myeloma,DENOSUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DENOSUMAB,Preventing skeletal-related events in multiple myeloma,TA549,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,DENOSUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,134405005,Suspected breast cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,160287004,FH: Breast cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,268547008,Screening for breast cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,429740004,Family history of breast cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,431330007,Family history of breast cancer 1 gene mutation,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,431331006,Family history of breast cancer 2 gene mutation,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,706970001,TNBC - Triple-negative breast cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,94361000000105,Breast cancer detected by national screening programme,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,276341000000100,Fast track referral for suspected breast cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,838351000000107,Education about risk of breast cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,874291000000100,QCancer breast cancer risk,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from breast cancer and from solid tumours other than prostate,TA265,breast cancer,1035841000000108,Lymphoedema following breast cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from prostate cancer,TA265,prostate cancer,315268008,Suspected prostate cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from prostate cancer,TA265,prostate cancer,428262008,H/O: prostate cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from prostate cancer,TA265,prostate cancer,698470001,Advice given about prostate cancer screening,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from prostate cancer,TA265,prostate cancer,712837004,Active surveillance of prostate cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from prostate cancer,TA265,prostate cancer,720007002,Prostate cancer care review,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from prostate cancer,TA265,prostate cancer,31011000119107,Prostate cancer screening declined,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from prostate cancer,TA265,prostate cancer,874211000000109,QCancer prostate cancer risk,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from prostate cancer,TA265,prostate cancer,878401000000104,No FH of prostate cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from prostate cancer,TA265,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DENOSUMAB,Prevention of skeletal-related events in adults with bone metastases from prostate cancer,TA265,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DENOSUMAB,Therapy-induced bone loss in non-metastatic prostate cancer,TA194,prostate cancer,315268008,Suspected prostate cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DENOSUMAB,Therapy-induced bone loss in non-metastatic prostate cancer,TA194,prostate cancer,428262008,H/O: prostate cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DENOSUMAB,Therapy-induced bone loss in non-metastatic prostate cancer,TA194,prostate cancer,698470001,Advice given about prostate cancer screening,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DENOSUMAB,Therapy-induced bone loss in non-metastatic prostate cancer,TA194,prostate cancer,712837004,Active surveillance of prostate cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DENOSUMAB,Therapy-induced bone loss in non-metastatic prostate cancer,TA194,prostate cancer,720007002,Prostate cancer care review,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DENOSUMAB,Therapy-induced bone loss in non-metastatic prostate cancer,TA194,prostate cancer,31011000119107,Prostate cancer screening declined,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DENOSUMAB,Therapy-induced bone loss in non-metastatic prostate cancer,TA194,prostate cancer,874211000000109,QCancer prostate cancer risk,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DENOSUMAB,Therapy-induced bone loss in non-metastatic prostate cancer,TA194,prostate cancer,878401000000104,No FH of prostate cancer,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DENOSUMAB,Therapy-induced bone loss in non-metastatic prostate cancer,TA194,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DENOSUMAB,Therapy-induced bone loss in non-metastatic prostate cancer,TA194,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,DENOSUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DESOXIMETASONE (OLD NAME: DESOXYMETHASONE),Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
DESOXIMETASONE (OLD NAME: DESOXYMETHASONE),Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
DESOXIMETASONE (OLD NAME: DESOXYMETHASONE),Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
DESOXIMETASONE (OLD NAME: DESOXYMETHASONE),Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
DESOXIMETASONE (OLD NAME: DESOXYMETHASONE),Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
DESOXIMETASONE (OLD NAME: DESOXYMETHASONE),Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Macular oedema caused following central retinal vein occlusion,TA229,retinal vein occlusion,232038007,Central retinal vein occlusion with neovascularization,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Macular oedema caused following central retinal vein occlusion,TA229,retinal vein occlusion,232042005,Macular edema due to juvenile central retinal vein occlusion,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Macular oedema caused following central retinal vein occlusion,TA229,retinal vein occlusion,232045007,Macular oedema due to hemispheric retinal vein occlusion,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Macular oedema following branch retinal vein occlusion,TA229,retinal vein occlusion,232038007,Central retinal vein occlusion with neovascularization,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Macular oedema following branch retinal vein occlusion,TA229,retinal vein occlusion,232042005,Macular edema due to juvenile central retinal vein occlusion,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Macular oedema following branch retinal vein occlusion,TA229,retinal vein occlusion,232045007,Macular oedema due to hemispheric retinal vein occlusion,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,4927003,Acute anterior uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,11226001,Fuchs uveitis syndrome,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,43363007,Posterior uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,75614007,Panuveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,89114005,Infectious anterior uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,95707009,Phacotoxic uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,267619000,Non-infectious anterior uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,312922007,Uveitis related cystoid macular oedema,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,314029000,Tuberculous uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,314030005,Post-traumatic uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,314033007,Secondary open-angle glaucoma with uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,314493000,Postoperative uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,370506009,Keratouveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,398155003,Chronic anterior uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,410494003,Phacoantigenic uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,410692006,Anterior uveitis,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Non-infectious uveitis,TA460,uveitis,342151000119100,Acute anterior uveitis of left eye,ADALIMUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,7461003,"Attention deficit hyperactivity disorder, hyperactive impulsive type",ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,31177006,"Attention deficit hyperactivity disorder, combined type",ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,702536007,Stimulant drug therapy for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,702538008,Drug therapy for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,703314001,Non-stimulant drug therapy for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,516401000000106,Attention deficit hyperactivity disorder monitoring invitation first letter,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,516891000000101,Attention deficit hyperactivity disorder monitoring invitation second letter,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,516911000000103,Attention deficit hyperactivity disorder monitoring invitation third letter,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,710071000000106,Attention deficit hyperactivity disorder annual review,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,886371000000105,On drug therapy for ADHD (attention deficit hyperactivity disorder),ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,886391000000109,On stimulant drug therapy for ADHD (attention deficit hyperactivity disorder),ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,886411000000109,On non-stimulant drug therapy for ADHD (attention deficit hyperactivity disorder),ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,1863681000000108,Attention deficit hyperactivity disorder suspected,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,1914891000000100,Diagnostic assessment for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,2427101000000103,Signposting to attention deficit hyperactivity disorder resource,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
DEXAMFETAMINE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,2437121000000109,Referral for diagnostic assessment for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
DIFLUCORTOLONE VALERATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
DIFLUCORTOLONE VALERATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
DIFLUCORTOLONE VALERATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
DIFLUCORTOLONE VALERATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
DIFLUCORTOLONE VALERATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
DIFLUCORTOLONE VALERATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,24700007,Multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,160337009,Family history of multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,192926004,Brain stem multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,192928003,Generalised multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,428700003,Primary progressive multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,438511000,Benign multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,700409000,Suspected multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,198491000000106,Multiple sclerosis review,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,515931000000104,Multiple sclerosis review declined,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIMETHYL FUMARATE,Relapsing-remitting multiple sclerosis,TA320,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,DIMETHYL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,24700007,Multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,160337009,Family history of multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,192926004,Brain stem multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,192928003,Generalised multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,428700003,Primary progressive multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,438511000,Benign multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,700409000,Suspected multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,198491000000106,Multiple sclerosis review,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,515931000000104,Multiple sclerosis review declined,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DIROXIMEL FUMARATE,Relapsing–remitting multiple sclerosis,TA794,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,DIROXIMEL,NEUROLOGY,NEUROLOGY|REHABILITATION
DOCETAXEL,Advanced breast cancer,TA006,breast cancer,134405005,Suspected breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL,Advanced breast cancer,TA006,breast cancer,160287004,FH: Breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL,Advanced breast cancer,TA006,breast cancer,268547008,Screening for breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL,Advanced breast cancer,TA006,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL,Advanced breast cancer,TA006,breast cancer,429740004,Family history of breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL,Advanced breast cancer,TA006,breast cancer,431330007,Family history of breast cancer 1 gene mutation,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL,Advanced breast cancer,TA006,breast cancer,431331006,Family history of breast cancer 2 gene mutation,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL,Advanced breast cancer,TA006,breast cancer,706970001,TNBC - Triple-negative breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL,Advanced breast cancer,TA006,breast cancer,94361000000105,Breast cancer detected by national screening programme,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL,Advanced breast cancer,TA006,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL,Advanced breast cancer,TA006,breast cancer,276341000000100,Fast track referral for suspected breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL,Advanced breast cancer,TA006,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL,Advanced breast cancer,TA006,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL,Advanced breast cancer,TA006,breast cancer,838351000000107,Education about risk of breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL,Advanced breast cancer,TA006,breast cancer,874291000000100,QCancer breast cancer risk,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL,Advanced breast cancer,TA006,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL,Advanced breast cancer,TA006,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL,Advanced breast cancer,TA006,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL,Advanced breast cancer,TA006,breast cancer,1035841000000108,Lymphoedema following breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL,Prostate cancer (hormone-refractory),TA101,prostate cancer,315268008,Suspected prostate cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DOCETAXEL,Prostate cancer (hormone-refractory),TA101,prostate cancer,428262008,H/O: prostate cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DOCETAXEL,Prostate cancer (hormone-refractory),TA101,prostate cancer,698470001,Advice given about prostate cancer screening,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DOCETAXEL,Prostate cancer (hormone-refractory),TA101,prostate cancer,712837004,Active surveillance of prostate cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DOCETAXEL,Prostate cancer (hormone-refractory),TA101,prostate cancer,720007002,Prostate cancer care review,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DOCETAXEL,Prostate cancer (hormone-refractory),TA101,prostate cancer,31011000119107,Prostate cancer screening declined,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DOCETAXEL,Prostate cancer (hormone-refractory),TA101,prostate cancer,874211000000109,QCancer prostate cancer risk,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DOCETAXEL,Prostate cancer (hormone-refractory),TA101,prostate cancer,878401000000104,No FH of prostate cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DOCETAXEL,Prostate cancer (hormone-refractory),TA101,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DOCETAXEL,Prostate cancer (hormone-refractory),TA101,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,134405005,Suspected breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,160287004,FH: Breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,268547008,Screening for breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,429740004,Family history of breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,431330007,Family history of breast cancer 1 gene mutation,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,431331006,Family history of breast cancer 2 gene mutation,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,706970001,TNBC - Triple-negative breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,94361000000105,Breast cancer detected by national screening programme,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,276341000000100,Fast track referral for suspected breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,838351000000107,Education about risk of breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,874291000000100,QCancer breast cancer risk,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,1035841000000108,Lymphoedema following breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL (2ND LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,254637007,Non-small cell lung cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DOCETAXEL (2ND LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,723301009,Squamous non-small cell lung cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DOCETAXEL (2ND LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,1259727001,Primary non-small cell lung cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DOCETAXEL (2ND LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,134405005,Suspected breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,160287004,FH: Breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,268547008,Screening for breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,429740004,Family history of breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,431330007,Family history of breast cancer 1 gene mutation,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,431331006,Family history of breast cancer 2 gene mutation,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,706970001,TNBC - Triple-negative breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,94361000000105,Breast cancer detected by national screening programme,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,276341000000100,Fast track referral for suspected breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,838351000000107,Education about risk of breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,874291000000100,QCancer breast cancer risk,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL IN COMBINATION WITH AN ANTHRACYCLINE (1ST LINE),Advanced breast cancer,TA030,breast cancer,1035841000000108,Lymphoedema following breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,134405005,Suspected breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,160287004,FH: Breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,268547008,Screening for breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,429740004,Family history of breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,431330007,Family history of breast cancer 1 gene mutation,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,431331006,Family history of breast cancer 2 gene mutation,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,706970001,TNBC - Triple-negative breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,94361000000105,Breast cancer detected by national screening programme,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,276341000000100,Fast track referral for suspected breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,838351000000107,Education about risk of breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,874291000000100,QCancer breast cancer risk,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DOCETAXEL WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE (THE TAC REGIMEN),Breast cancer (early),TA109,breast cancer,1035841000000108,Lymphoedema following breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
DONEPEZIL,Alzheimer's disease,TA019,alzheimer's disease,273269001,ADAS - Alzheimer's Disease Assessment Scale,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
DONEPEZIL,Alzheimer's disease,TA111,alzheimer's disease,273269001,ADAS - Alzheimer's Disease Assessment Scale,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
DONEPEZIL,Alzheimer's disease,TA019,alzheimer's disease,416780008,Dementia in Alzheimer's disease with early onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
DONEPEZIL,Alzheimer's disease,TA111,alzheimer's disease,416780008,Dementia in Alzheimer's disease with early onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
DONEPEZIL,Alzheimer's disease,TA019,alzheimer's disease,416975007,Alzheimer's disease with late onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
DONEPEZIL,Alzheimer's disease,TA111,alzheimer's disease,416975007,Alzheimer's disease with late onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
DONEPEZIL,Alzheimer's disease,TA019,alzheimer's disease,142011000119109,Alzheimer's disease co-occurrent with delirium,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
DONEPEZIL,Alzheimer's disease,TA111,alzheimer's disease,142011000119109,Alzheimer's disease co-occurrent with delirium,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
DONEPEZIL,Alzheimer's disease (mild to moderate),TA217,alzheimer's disease,273269001,ADAS - Alzheimer's Disease Assessment Scale,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
DONEPEZIL,Alzheimer's disease (mild to moderate),TA217,alzheimer's disease,416780008,Dementia in Alzheimer's disease with early onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
DONEPEZIL,Alzheimer's disease (mild to moderate),TA217,alzheimer's disease,416975007,Alzheimer's disease with late onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
DONEPEZIL,Alzheimer's disease (mild to moderate),TA217,alzheimer's disease,142011000119109,Alzheimer's disease co-occurrent with delirium,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
DOSTARLIMAB,Previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency,TA779,endometrial cancer,315267003,Suspected endometrial cancer,DOSTARLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
DOSTARLIMAB,Previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency,TA779,endometrial cancer,874231000000101,QCancer endometrial cancer risk,DOSTARLIMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,49436004,Atrial fibrillation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,134377004,Atrial fibrillation monitoring,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,195080001,Atrial fibrillation and flutter,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,233911009,Non-rheumatic atrial fibrillation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,282825002,Intermittent atrial fibrillation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,300996004,Controlled atrial fibrillation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,312442005,History of atrial fibrillation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,440028005,Permanent atrial fibrillation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,440059007,Persistent atrial fibrillation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,449863006,Insertion of pacemaker for control of atrial fibrillation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,699833006,Provision of written information about atrial fibrillation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,706923002,Longstanding persistent atrial fibrillation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,719008003,At increased risk of atrial fibrillation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,1010405004,Paroxysmal AF (atrial fibrillation) with RVR (rapid ventricular response),DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,120041000119109,Atrial fibrillation with rapid ventricular response,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,133111000000106,QOF (Quality and Outcomes Framework) atrial fibrillation quality indicator-related care invitation using preferred method of communication,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,196371000000102,Atrial fibrillation resolved,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,248411000000105,Atrial fibrillation annual review,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,711411000000101,Atrial fibrillation monitoring invitation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,713801000000102,Atrial fibrillation monitoring administration,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,715941000000109,Excepted from atrial fibrillation quality indicators - patient unsuitable,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,716181000000109,Atrial fibrillation monitoring third letter,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,716721000000107,Atrial fibrillation monitoring telephone invitation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,716871000000101,Exception reporting - atrial fibrillation quality indicators,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,716981000000106,Atrial fibrillation monitoring second letter,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,717011000000100,Atrial fibrillation monitoring verbal invite,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,717221000000101,Atrial fibrillation monitoring first letter,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,717381000000109,Excepted from atrial fibrillation quality indicators - informed dissent,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,816401000000105,Atrial fibrillation excluded,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,847611000000104,Atrial fibrillation care pathway,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,1025021000000107,High risk of atrial fibrillation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,1066831000000104,Atrial fibrillation detected,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,1067061000000104,Atrial fibrillation not detected,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DRONEDARONE (2ND LINE),Non-permanent atrial fibrillation,TA197,atrial fibrillation,1110851000000100,QOF (Quality and Outcomes Framework) atrial fibrillation quality indicator-related care invitation,DRONEDARONE,CARDIOLOGY,CARDIOLOGY
DROTRECOGIN,Sepsis (severe),TA084,sepsis,1089000,Intrauterine fetal sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,25042006,Tracheostomy sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,67465009,Spontaneous abortion with sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,76571007,Sepsis-associated hypotension,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,91302008,Sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,206376005,Sepsis of the newborn,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,206378006,Sepsis of newborn caused by Staphylococcus aureus,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,206379003,Sepsis of newborn caused by Escherichia coli,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,206380000,Sepsis of newborn caused by anaerobes,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,233812001,Sepsis-associated lung injury,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,235657005,Sepsis-related gastritis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,238151006,Sepsis-associated organ dysfunction,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,275827007,Maintaining asepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,276229008,Sepsis-associated gastrointestinal haemorrhage,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,276669000,Bacterial sepsis of newborn,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,276678006,Umbilical sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,308887002,Postprocedural intra-abdominal sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,310669007,Sepsis due to enterococcus,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,443980004,Neutropenic sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,447841007,Sepsis caused by Candida,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,447843005,Severe sepsis with acute organ dysfunction caused by anaerobic bacteria,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,447894003,Severe sepsis with acute organ dysfunction caused by Staphylococcus,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,447899008,Sepsis caused by Escherichia coli,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,448417001,Sepsis caused by Staphylococcus aureus,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,448418006,Severe sepsis with acute organ dysfunction caused by Streptococcus,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,448419003,Severe sepsis with acute organ dysfunction caused by Group B streptococcus,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,448421008,Severe sepsis with acute organ dysfunction caused by Pneumococcus,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,448784003,Sepsis due to herpes simplex,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,448813005,Severe sepsis with acute organ dysfunction caused by Pseudomonas,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,449082003,Severe sepsis with acute organ dysfunction caused by Gram-negative bacteria,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,449083008,Severe sepsis with acute organ dysfunction caused by Salmonella,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,449335002,Listerial sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,449504009,Severe sepsis with acute organ dysfunction caused by Group A streptococcus,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,449505005,Severe sepsis with acute organ dysfunction caused by coagulase negative Staphylococcus,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,609485004,Induced termination of pregnancy complicated by sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,698819004,Postoperative sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,721104000,Sepsis due to urinary tract infection,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,870441004,Screening for sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,870588003,Sepsis due to disease caused by severe acute respiratory syndrome coronavirus 2,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,750511000000101,Biliary sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,859701000000104,Suspected sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,944061000000108,Neonatal sepsis due to Streptococcus,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,944071000000101,Neonatal sepsis due to Staphylococcus,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DROTRECOGIN,Sepsis (severe),TA084,sepsis,957431000000102,Red flag sepsis,DROTRECOGIN,INFECTIOUS DISEASES,INFECTIOUS DISEASES|CRITICAL CARE MEDICINE
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,12428000,Intrinsic asthma without status asthmaticus,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,31387002,Exercise-induced asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,34015007,Flour asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,56018004,Asthmatic breathing,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,56968009,Asthma caused by wood dust,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,57607007,Industrial asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,63088003,Allergic asthma without status asthmaticus,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,71892000,Cardiac asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,93432008,Drug-induced asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,160377001,Family history of asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,161105008,Asthma society member,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,161527007,History of asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,162660004,Asthma resolved,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170607007,Respiratory disease monitoring (& [asthma] or [chronic]),DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170631002,Asthma disturbing sleep,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170632009,Asthma causing night waking,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170633004,Asthma disturbs sleep weekly,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170634005,Asthma disturbs sleep frequently,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170635006,Asthma not disturbing sleep,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170636007,Asthma never disturbs sleep,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170637003,Asthma limiting activities,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170638008,Asthma not limiting activities,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170642006,Asthma severity,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170647000,Asthma prophylactic medication used,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170655007,Asthma restricts exercise,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170656008,Asthma sometimes restricts exercise,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170657004,Asthma severely restricts exercise,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,170658009,Asthma never restricts exercise,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,171231001,Asthma screening,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,182724005,Further asthma - drug prevention,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,182726007,Asthma control step 0,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,182727003,Asthma control step 1,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,182728008,Asthma control step 2,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,182729000,Asthma control step 3,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,182730005,Asthma control step 4,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,182731009,Asthma control step 5,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,183099005,Asthma leaflet given,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,183478001,Emergency hospital admission for asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,185242005,Seen in asthma clinic,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,185728001,Attends asthma monitoring,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,185730004,Asthma monitor offer default,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,185731000,Asthma monitoring call first letter,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,185732007,Asthma monitoring call second letter,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,185734008,Asthma monitoring call third letter,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,185735009,Asthma monitoring call verbal invite,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,185736005,Asthma monitoring call telephone invite,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,185737001,Asthma monitoring deleted,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,185940009,Patient in asthma study,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,195113008,(Left ventricular: [failure] or [impaired function]) or (cardiac asthma) or (acute pulmonary edema),DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,195949008,Chronic asthmatic bronchitis,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,195967001,Asthmatic,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,195968006,Asthma: [extrinsic - atopic] or [allergic] or [pollen] or [childhood] or [with hay fever],DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,195973000,Late-onset asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,195977004,Mixed asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,195983001,Exercise induced asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,219036002,Adverse reaction to antiasthmatic,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,225057002,Brittle asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,233678006,Childhood asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,233679003,Late-onset asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,233683003,Hay fever with asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,233691007,Eosinophilic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,266361008,Non-allergic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,266396008,Extrinsic asthma - atopy (& pollen),DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,266397004,Intrinsic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,266398009,Asthma attack,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,270442000,Asthma monitoring check done,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,275908000,Asthma monitoring,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,281239006,Asthma attack,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,302220000,Asthma control steps,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,304527002,Acute asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,308500005,Asthma monitoring call,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,308501009,Asthma monitoring status,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,312453004,Asthma - currently active,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,312454005,Asthma - currently dormant,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,366874008,Number of asthma exacerbations in past year,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370202007,Asthma causes daytime symptoms 1 to 2 times per month,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370203002,Asthma causes daytime symptoms 1 to 2 times per week,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370204008,Asthma causes daytime symptoms most days,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370205009,Asthma causes night symptoms 1 to 2 times per month,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370206005,Asthma limits walking on the flat,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370207001,Asthma limits walking up hills or stairs,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370208006,Asthma never causes daytime symptoms,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370218001,Mild asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370219009,Moderate asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370220003,Occasional asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370221004,Severe asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370225008,Asthma treatment compliance unsatisfactory,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,370226009,Asthma treatment compliance satisfactory,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,373899003,Asthma daytime symptoms,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,389145006,Allergic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,390798007,Asthma finding,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,390872009,Change in asthma management plan,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,390877003,Step up change in asthma management plan,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,390878008,Step down change in asthma management plan,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,390921001,Absent from work or school due to asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,390940007,Asthma monitoring due,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,394700004,Asthma annual review,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,394701000,Asthma follow-up,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,394720003,Asthma medication review,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,394967008,Suspected asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,395022009,Nocturnal asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,400987003,Asthma trigger,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,401135008,Health education - asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,401182001,Asthma monitoring by nurse,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,401183006,Asthma monitoring by doctor,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,401193004,Asthma confirmed,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,405944004,Asthmatic bronchitis,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,406162001,Asthma care,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,407674008,Aspirin-induced asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,409663006,Cough variant asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,415265005,Referral to asthma clinic,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,423889005,Non-immunoglobulin E mediated allergic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,424643009,Allergic atopic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,425969006,Acute intermittent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,426656000,Severe persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,426979002,Mild persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,427295004,Moderate persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,427603009,Intermittent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,427679007,Mild intermittent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,442025000,Acute exacerbation of chronic asthmatic bronchitis,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,443117005,Asthma control test score,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,445427006,Seasonal asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,445531003,ACQ - Asthma control questionnaire,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,473391009,Asthma never causes night symptoms,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,698509001,Under care of asthma specialist nurse,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,699191007,Did not attend asthma review,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,702823004,Asthma clinic,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,704008007,No family history of asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,707445000,Acute mild persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,707446004,Acute exacerbation of moderate persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,707447008,Exacerbation of severe persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,707511009,Uncomplicated mild persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,707512002,Uncomplicated moderate persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,707513007,Uncomplicated severe persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,707979007,Acute severe exacerbation of severe persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,707980005,Acute severe exacerbation of moderate persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,707981009,Acute severe exacerbation of mild persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,708038006,Acute exacerbation of asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,708090002,Acute severe exacerbation of asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,708093000,Acute exacerbation of allergic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,708094006,Acute exacerbation of intrinsic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,708095007,Acute severe exacerbation of extrinsic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,708358003,Emergency asthma admission since last encounter,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,708373002,Emergency asthma patient visit since last encounter,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,711442001,Recent asthma management,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,715191006,Telehealth asthma monitoring,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,734346005,Use of asthma symptom diary,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,734904007,Life threatening acute exacerbation of asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,734905008,Moderate acute exacerbation of asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,736056000,Asthma clinical management plan,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,762521001,Acute allergic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,763077003,Asthma Control Questionnaire score,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,763221007,Asthma monitoring declined,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,763695004,Mini Asthma Quality of Life Questionnaire score,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,782520007,Exacerbation of allergic asthma due to infection,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,782559003,Asthma never causes night symptoms,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,401000119107,Asthma with irreversible airway obstruction,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,641000119106,Intermittent asthma well controlled,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,1741000119102,Intermittent asthma uncontrolled,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,72301000119103,Asthma in pregnancy,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,89581000000109,DNA (did not attend) asthma clinic,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,92161000000104,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation using preferred method of communication,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,99031000119107,Acute exacerbation of asthma co-occurrent with allergic rhinitis,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,125011000119100,Mild persistent asthma co-occurrent with allergic rhinitis,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,125021000119107,Intermittent asthma co-occurrent with allergic rhinitis,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,135171000119106,Acute exacerbation of moderate persistent asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,143901000000108,Registration for access to online asthma self-management application,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,143931000000102,Declined to register for access to online asthma self-management application,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,176711000000100,Does not have asthma management plan,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,198971000000102,Asthma outreach clinic,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,201031000000108,Asthma trigger - respiratory infection,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,201041000000104,Asthma trigger - seasonal,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,201051000000101,Asthma trigger - animal,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,201191000000108,Asthma trigger - cold air,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,201201000000105,Asthma trigger - damp,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,201211000000107,Asthma trigger - emotion,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,302331000000106,RCP (Royal College of Physicians) asthma assessment,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,340891000000106,Asthma trigger - airborne dust,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,340901000000107,Asthma trigger - exercise,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,340911000000109,Asthma trigger - pollen,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,340921000000103,Asthma trigger - tobacco smoke,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,340931000000101,Asthma trigger - warm air,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,527171000000103,Patient has a written asthma personal action plan,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,527191000000104,Health education - asthma self management,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,527211000000100,Health education - structured asthma discussion,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,527231000000108,Health education - structured patient focused asthma discussion,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,713701000000108,Asthma monitoring administration,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,713711000000105,Asthma clinic administration,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,715801000000103,Exception reporting - asthma quality indicators,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,716491000000100,Excepted from asthma quality indicators - informed dissent,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,717291000000103,Excepted from asthma quality indicators - patient unsuitable,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,754061000000100,Asthma review using Royal College of Physicians three questions,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,771901000000100,Asthma causes night time symptoms 1 to 2 times per week,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,771941000000102,Asthma causes symptoms most nights,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,771981000000105,Asthma limits activities 1 to 2 times per month,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,772011000000107,Asthma limits activities 1 to 2 times per week,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,772051000000106,Asthma limits activities most days,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,791401000000104,Seen in school asthma clinic,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,810901000000102,Asthma self-management plan review,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,811151000000105,Number of days absent from school due to asthma in past 6 months,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,811921000000103,Asthma self-management plan agreed,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,815631000000106,Asthma trigger - wind,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,818161000000104,Asthma trigger - perfume,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,866881000000101,Chronic asthma with fixed airflow obstruction,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,867171000000106,No asthma trigger identified by subject,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,892301000000100,Asthma management plan declined,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,905301000000103,Childhood Asthma Control Test score,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,928451000000107,Asthma monitoring invitation short message service text message,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,928511000000107,Asthma monitoring invitation email,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,928651000000105,Review of patient at risk of asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,928691000000102,At risk of asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,959401000000101,Asthma monitoring SMS (short message service) text message first invitation,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,959421000000105,Asthma monitoring SMS (short message service) text message second invitation,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,959441000000103,Asthma monitoring SMS (short message service) text message third invitation,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,959901000000107,Asthma action plan,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,966011000000109,At risk of severe asthma exacerbation,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,966031000000101,Severe asthma exacerbation risk assessment,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,1086701000000102,Life threatening acute exacerbation of allergic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,1086711000000100,Life threatening acute exacerbation of non-allergic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,1108701000000106,Excepted from asthma quality indicators - service unavailable,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,1110841000000103,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,10674991000119104,Intermittent allergic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,10675431000119106,Severe persistent allergic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,10675551000119104,Acute severe exacerbation of severe persistent asthma co-occurrent with allergic rhinitis,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,10675871000119106,Mild persistent allergic asthma,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,10675991000119100,Acute severe exacerbation of mild persistent allergic asthma co-occurrent with allergic rhinitis,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,10676031000119106,Mild persistent allergic asthma controlled,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe asthma with type 2 inflammation,TA751,asthma,10676111000119102,Mild persistent asthma controlled co-occurrent with allergic rhinitis,DUPILUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
DUPILUMAB,Severe atopic dermatitis,TA534,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,DUPILUMAB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
DUPILUMAB,Severe atopic dermatitis,TA534,atopic dermatitis,238543002,Discoid atopic dermatitis,DUPILUMAB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
DUPILUMAB,Severe atopic dermatitis,TA534,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,DUPILUMAB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
DUPILUMAB,Severe atopic dermatitis,TA534,atopic dermatitis,238545009,Follicular atopic dermatitis,DUPILUMAB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
DUPILUMAB,Severe atopic dermatitis,TA534,atopic dermatitis,238546005,Pruriginous atopic dermatitis,DUPILUMAB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
DUPILUMAB,Severe atopic dermatitis,TA534,atopic dermatitis,584621000000108,Atopic dermatitis NOS,DUPILUMAB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,162573006,Suspected lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,254637007,Non-small cell lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,275981009,Lung cancer screening,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,429011007,Family history of lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,877691000000107,No FH of lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA578,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,162573006,Suspected lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,254637007,Non-small cell lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,275981009,Lung cancer screening,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,429011007,Family history of lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,877691000000107,No FH of lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB,Maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation,TA798,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,162573006,Suspected lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,254637007,Non-small cell lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,275981009,Lung cancer screening,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,429011007,Family history of lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,723301009,Squamous non-small cell lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,1259727001,Primary non-small cell lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,276491000000101,Fast track referral for suspected lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,848881000000108,QCancer lung cancer risk,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,877691000000107,No FH of lung cancer,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,1771781000000107,Did not attend lung cancer screening,DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DURVALUMAB IN COMBINATION,Untreated extensive-stage small-cell lung cancer,TA662,lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",DURVALUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
DUVELISIB,Relapsed follicular lymphoma after 2 or more systemic therapies,TA717,follicular lymphoma,109962001,Nonfollicular lymphoma,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DUVELISIB,Relapsed follicular lymphoma after 2 or more systemic therapies,TA717,follicular lymphoma,308121000,Follicular lymphoma,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DUVELISIB,Relapsed follicular lymphoma after 2 or more systemic therapies,TA717,follicular lymphoma,721555001,Follicular lymphoma of small intestine,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DUVELISIB,Relapsed follicular lymphoma after 2 or more systemic therapies,TA717,follicular lymphoma,1148851002,Follicular lymphoma grade IIIa,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DUVELISIB,Relapsed follicular lymphoma after 2 or more systemic therapies,TA717,follicular lymphoma,847481000000109,Follicular lymphoma grade 1,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DUVELISIB,Relapsed follicular lymphoma after 2 or more systemic therapies,TA717,follicular lymphoma,847631000000107,Follicular lymphoma grade 2,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DUVELISIB,Relapsed follicular lymphoma after 2 or more systemic therapies,TA717,follicular lymphoma,847651000000100,Follicular lymphoma grade 3,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DUVELISIB,Relapsed follicular lymphoma after 2 or more systemic therapies,TA717,follicular lymphoma,847691000000108,Follicular lymphoma grade 3a,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DUVELISIB,Relapsed follicular lymphoma after 2 or more systemic therapies,TA717,follicular lymphoma,847701000000108,Follicular lymphoma grade 3b,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
DUVELISIB,Relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments,TA811,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
DUVELISIB,Relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments,TA811,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
DUVELISIB,Relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments,TA811,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
DUVELISIB,Relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments,TA811,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,DUVELISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,2517002,Stroke rehabilitation,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,25133001,Completed stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,28690004,Stroke test,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,39925003,"MELAS - mitochondrial encephalopathy, lactic acidosis and stroke-like episodes",EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,44922000,Bounding pulse with rapid upstroke and descent,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,49436004,Atrial fibrillation,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,90096001,Stroke volume,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,134377004,Atrial fibrillation monitoring,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,135875009,Stroke prevention,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,135877001,Stroke risk,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,160252004,No family history of cardiovascular accident or stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,160271002,No family history of stroke and/or transient ischaemic attack,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,170600009,Stroke monitoring,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,195080001,Atrial fibrillation and flutter,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,195163003,Stroke due to intracerebral haemorrhage,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,195212005,Brainstem stroke syndrome,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,195213000,Cerebellar stroke syndrome,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,212937007,Heat stroke and sunstroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,230690007,Stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,230694003,Total anterior cerebral circulation stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,230695002,Partial anterior cerebral circulation stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,230696001,Posterior cerebral circulation stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,230700009,Pure sensory stroke due to and following lacunar infarction,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,230713003,Stroke of uncertain pathology,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,230714009,Anterior circulation stroke of uncertain pathology,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,230715005,Posterior circulation stroke of uncertain pathology,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,230739000,Spinal cord stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,233911009,Non-rheumatic atrial fibrillation,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,275434003,Stroke in the puerperium,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,276898003,Left ventricular stroke work index,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,277286006,Chronic central post-stroke pain,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,277381004,Stroke index,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,282825002,Intermittent atrial fibrillation,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,297250002,No family history of stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,299403002,Stroke test positive,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,299404008,Stroke test negative,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,300996004,Controlled atrial fibrillation,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,306802002,Referral to stroke service,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,306803007,Admission to stroke unit,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,306808003,Discharge from stroke service,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,306810001,Seen by stroke service,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,308067002,History of stroke in last year,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,309966001,Stroke unit,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,310137004,Stroke service,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,312442005,History of atrial fibrillation,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,371040005,Thrombotic stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,371041009,Embolic stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,412773009,Referral to stroke clinic,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,413119003,Stroke group member,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,413124000,Stroke/transient ischaemic attack referral,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,415628004,Stroke/transient ischaemic attack monitoring first letter,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,415629007,Stroke/transient ischemic attack monitoring second letter,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,415630002,Stroke/transient ischaemic attack monitoring status,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,415631003,Stroke/transient ischemic attack monitoring third letter,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,417059002,Stroke/transient ischemic attack monitoring verbal invitation,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,417506008,Hemorrhagic stroke monitoring,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,417540008,Stroke/transient ischaemic attack monitoring invitation,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,422504002,Ischaemic stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,440028005,Permanent atrial fibrillation,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,440059007,Persistent atrial fibrillation,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,449863006,Insertion of pacemaker for control of atrial fibrillation,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,450743008,NIHSS (National Institutes of Health stroke scale) score,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,699833006,Provision of written information about atrial fibrillation,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,704154001,"HAS-BLED (hypertension, abnormal renal and/or liver function, stroke, bleeding history or predisposition, labile INR (international normalised ratio), elderly over 65, and drugs and/or alcohol concomitantly) score",EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,704180000,"HAS-BLED (hypertension, abnormal renal and/or liver function, stroke, bleeding history or predisposition, labile international normalised ratio, elderly over 65, and drugs and/or alcohol concomitantly) bleeding risk score",EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,706923002,Longstanding persistent atrial fibrillation,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,707514001,Stroke impact scale version 3.0 score,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,719008003,At increased risk of atrial fibrillation,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,722929005,Perinatal arterial ischemic stroke of fetus and/or neonate,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,724424009,Cerebral ischemic stroke due to small artery occlusion,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,736712009,PASS (Postural Assessment Scale for Stroke Patients) score,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,788880006,Cerebral ischaemic stroke due to dissection of artery,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,788884002,Cerebral ischemic stroke due to subarachnoid hemorrhage,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,1010405004,Paroxysmal AF (atrial fibrillation) with RVR (rapid ventricular response),EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,88601000000107,DNA (did not attend) stroke clinic,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,112901000000108,Referral to multidisciplinary stroke function improvement service,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,120041000119109,Atrial fibrillation with rapid ventricular response,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,133111000000106,QOF (Quality and Outcomes Framework) atrial fibrillation quality indicator-related care invitation using preferred method of communication,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,140921000119102,Ischemic stroke without coma,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,143471000000105,QOF (Quality and Outcomes Framework) stroke and transient ischaemic attack quality indicator-related care invitation using preferred method of communication,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,196371000000102,Atrial fibrillation resolved,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,201501000000108,Seen in stroke clinic,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,231231000000107,Delivery of rehabilitation for stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,248411000000105,Atrial fibrillation annual review,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,519751000000106,Stroke 6 month review,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,521411000000106,Did not attend stroke review,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,685631000000102,Stroke and cerebrovascular accident unspecified,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,711411000000101,Atrial fibrillation monitoring invitation,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,713771000000100,Stroke/transient ischaemic attack monitoring administration,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,713801000000102,Atrial fibrillation monitoring administration,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,715941000000109,Excepted from atrial fibrillation quality indicators - patient unsuitable,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,716021000000109,Excepted from stroke quality indicators - informed dissent,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,716181000000109,Atrial fibrillation monitoring third letter,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,716331000000108,Exception reporting - stroke quality indicators,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,716581000000101,Excepted from stroke quality indicators - patient unsuitable,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,716721000000107,Atrial fibrillation monitoring telephone invitation,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,716871000000101,Exception reporting - atrial fibrillation quality indicators,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,716981000000106,Atrial fibrillation monitoring second letter,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,717011000000100,Atrial fibrillation monitoring verbal invite,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,717221000000101,Atrial fibrillation monitoring first letter,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,717241000000108,Stroke/transient ischaemic attack monitoring telephone invitation,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,717381000000109,Excepted from atrial fibrillation quality indicators - informed dissent,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,769211000000103,Suspected stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,810991000000109,Stroke self-management plan review,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,812041000000104,Stroke self-management plan agreed,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,816401000000105,Atrial fibrillation excluded,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,816561000000108,Stroke initial post discharge review,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,842441000000104,Provision of written information about stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,847611000000104,Atrial fibrillation care pathway,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,870631000000105,QStroke 10 year risk of stroke calculator,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,1025021000000107,High risk of atrial fibrillation,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,1062151000000103,Stroke TOM (Therapy Outcome Measure) activity score,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,1062171000000107,Stroke TOM (Therapy Outcome Measure) impairment score,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,1062181000000109,Stroke TOM (Therapy Outcome Measure) participation score,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,1062191000000106,Stroke TOM (Therapy Outcome Measure) wellbeing score,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,1066831000000104,Atrial fibrillation detected,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,1067061000000104,Atrial fibrillation not detected,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,1078001000000105,Haemorrhagic stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,1085311000000106,QStroke risk calculator score,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,atrial fibrillation,1110851000000100,QOF (Quality and Outcomes Framework) atrial fibrillation quality indicator-related care invitation,EDOXABAN,CARDIOLOGY,CARDIOLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,1110981000000104,QOF (Quality and Outcomes Framework) stroke and transient ischaemic attack quality indicator-related care invitation,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation,TA355,stroke,16371781000119100,Cerebellar stroke,EDOXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,14534009,Deep vein thrombosis of splenic vein,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,49956009,Antenatal DVT (deep vein thrombosis),EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,56272000,Puerperal DVT (deep vein thrombosis),EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,pulmonary embolism,59282003,Pulmonary embolism,EDOXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,128053003,Deep vein thrombosis,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,134399007,Deep vein thrombosis of leg related to air travel,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,161508001,History of DVT (deep vein thrombosis),EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,200232006,Antenatal deep vein thrombosis - delivered,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,200233001,Antenatal deep vein thrombosis with antenatal complication,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,200238005,Postnatal deep vein thrombosis with postnatal complication,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,pulmonary embolism,200284000,Obstetric pulmonary embolism,EDOXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,pulmonary embolism,200286003,Obstetric air pulmonary embolism,EDOXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,pulmonary embolism,200303005,Obstetric blood-clot pulmonary embolism with antenatal complication,EDOXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,213220000,Postoperative deep vein thrombosis,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,225999004,At increased risk of DVT (deep vein thrombosis),EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,pulmonary embolism,233217004,Operation for pulmonary embolism,EDOXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,pulmonary embolism,233936003,Acute massive pulmonary embolism,EDOXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,pulmonary embolism,233937007,Subacute massive pulmonary embolism,EDOXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,234044007,Ileofemoral deep vein thrombosis,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,401186003,Deep vein thrombosis screening,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,413459009,Advised risk of deep vein thrombosis in air travel,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,413956008,Deep vein thrombosis of leg related to intravenous drug use,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,pulmonary embolism,417113001,Suspected PE (pulmonary embolism),EDOXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,429053008,Wells deep vein thrombosis clinical probability score,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,pulmonary embolism,430801003,Family history of pulmonary embolism,EDOXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,432805000,Suspected deep vein thrombosis,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,pulmonary embolism,438773007,Recurrent pulmonary embolism,EDOXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,443210003,Deep vein thrombosis of peroneal vein,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,710167004,Recurrent DVT (deep vein thrombosis),EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,198301000000109,FH: deep vein thrombosis,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,323631000000102,DVT (deep vein thrombosis) prevention,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,492161000000109,Deep vein thrombosis enhanced services administration,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,503421000000105,Deep vein thrombosis enhanced services administration stage 1 service level,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,503451000000100,Deep vein thrombosis enhanced services administration stage 2 service level,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,503481000000106,Deep vein thrombosis enhanced services administration stage 3 service level,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,513251000000101,Low probability of deep vein thrombosis,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,513271000000105,Moderate probability of deep vein thrombosis,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,513291000000109,High probability of deep vein thrombosis,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,869611000000104,On deep vein thrombosis care pathway,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,872221000000109,No history of deep vein thrombosis,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,978421000000101,Unprovoked deep vein thrombosis,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EDOXABAN,Treating and preventing deep vein thrombosis and pulmonary embolism,TA354,deep vein thrombosis,978441000000108,Provoked deep vein thrombosis,EDOXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,9014002,Psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,16341002,Parapsoriasis lichenoides,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,25847004,Sebopsoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,37042000,Guttate psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,38360005,Acute generalized pustular psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,81271001,Localised pustular psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,88233000,Parapsoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,160408009,Family history: Psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,161562002,History of psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,200962007,Psoriasis annularis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,200963002,Psoriasis circinata,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,200964008,Psoriasis diffusa,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,200965009,Discoid psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,200966005,Psoriasis geographica,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,200967001,Psoriasis gyrata,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,200968006,Psoriasis inveterata,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,200969003,Ostraceous psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,200970002,Psoriasis palmaris,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,200971003,Psoriasis plantaris,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,200972005,Psoriasis punctata,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,200973000,Pustular psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,200974006,Psoriasis universalis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,200977004,Exfoliative psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,200982006,Parapsoriasis herpetiformis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,200983001,Parapsoriasis en gouttes,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,200984007,Parapsoriasis papulata,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,200985008,Parapsoriasis varioliformis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,238600001,Inverse psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,238601002,Unstable psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,238602009,Eczematous psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,238603004,Eczematised psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,238608008,Psoriasis of scalp,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,238609000,Kobner psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,238612002,Acute generalized pustular psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,238614001,Pustular psoriasis in children,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,238617008,Circinate and annular pustular psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,239803008,Juvenile psoriatic arthritis with psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,267851002,Parapsoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,402307000,Chronic large plaque psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,402310007,Chronic stable plaque psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,430543001,Family history of psoriasis with psoriatic arthritis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,845091000000108,Education for psoriasis care,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,866311000000102,PASI - psoriasis area and severity index,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,866341000000101,PASI (psoriasis area and severity index) score,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
EFALUZIMAB,Psoriasis,TA103,psoriasis,1853821000000104,Psoriasis Epidemiology Screening Tool total score,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,62944002,Hepatitis C virus,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,62944002,Hepatitis C virus,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,72165005,Hepatitis C virus antibody,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,72165005,Hepatitis C virus antibody,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,170489004,Viral hepatitis carrier,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,170489004,Viral hepatitis carrier,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,197344005,Hepatitis caused by adenovirus,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,197344005,Hepatitis caused by adenovirus,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,235872006,Hepatitis C carrier,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,235872006,Hepatitis C carrier,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,278973007,Hepatitis C status,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,278973007,Hepatitis C status,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,278974001,Hepatitis C immune,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,278974001,Hepatitis C immune,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,278975000,Hepatitis C non-immune,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,278975000,Hepatitis C non-immune,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,314706002,Hepatitis C antibody detected,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,314706002,Hepatitis C antibody detected,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,314707006,Hepatitis C antibody test negative,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,314707006,Hepatitis C antibody test negative,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,413107006,Hepatitis C screening,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,413107006,Hepatitis C screening,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,773113008,Acute hepatitis caused by infection,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,773113008,Acute hepatitis caused by infection,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,12891000175105,Hepatitis C screening declined,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,12891000175105,Hepatitis C screening declined,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,200371000000104,Hepatitis C contact,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,200371000000104,Hepatitis C contact,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,201451000000105,Hepatitis C immunisation declined,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,201451000000105,Hepatitis C immunisation declined,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,202281000000105,Hepatitis C screening declined,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,202281000000105,Hepatitis C screening declined,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,204671000000101,Hepatitis C screening counselling,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,204671000000101,Hepatitis C screening counselling,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,304821000000107,Hepatitis C screening not offered,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,304821000000107,Hepatitis C screening not offered,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,362491000000104,Hepatitis C screening negative,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,362491000000104,Hepatitis C screening negative,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,362751000000101,Hepatitis C screening positive,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,362751000000101,Hepatitis C screening positive,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,761381000000102,Hepatitis C resolved,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,761381000000102,Hepatitis C resolved,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,824841000000105,Hepatitis C genotype 1,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,824841000000105,Hepatitis C genotype 1,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,824871000000104,Hepatitis C genotype 3,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,824871000000104,Hepatitis C genotype 3,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,829731000000106,On hepatitis C treatment plan,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,829731000000106,On hepatitis C treatment plan,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,992751000000109,Hepatitis C viral load,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,992751000000109,Hepatitis C viral load,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,992771000000100,Hepatitis C virus genotype,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,992771000000100,Hepatitis C virus genotype,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,996031000000104,Hepatitis C IgG level,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,996031000000104,Hepatitis C IgG level,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,998771000000103,Hepatitis C antibody level,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,998771000000103,Hepatitis C antibody level,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,1001331000000102,Hepatitis C antigen level,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,1001331000000102,Hepatitis C antigen level,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,1008931000000108,Hepatitis C antibody test,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,1008931000000108,Hepatitis C antibody test,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,1107671000000106,Hepatitis C screening offered,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELBASVIR–GRAZOPREVIR,Chronic hepatitis C,TA413,hepatitis c,1107671000000106,Hepatitis C screening offered,ELBASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
ELOTUZUMAB,Previously treated multiple myeloma,TA434,multiple myeloma,230586003,Neuropathy due to multiple myeloma,ELOTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
ELOTUZUMAB,Previously treated multiple myeloma,TA434,multiple myeloma,413587002,Smoldering multiple myeloma,ELOTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
ELOTUZUMAB,Previously treated multiple myeloma,TA434,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ELOTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
ELTROMBOPAG,Chronic immune (idiopathic) thrombocytopenic purpura,TA205,thrombocytopenic purpura,78129009,TTP - thrombotic thrombocytopenic purpura,ELTROMBOPAG,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
ELTROMBOPAG,Chronic immune (idiopathic) thrombocytopenic purpura,TA293,thrombocytopenic purpura,78129009,TTP - thrombotic thrombocytopenic purpura,ELTROMBOPAG,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
ELTROMBOPAG,Chronic immune (idiopathic) thrombocytopenic purpura,TA205,thrombocytopenic purpura,234493006,Non-thrombocytopenic purpura,ELTROMBOPAG,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
ELTROMBOPAG,Chronic immune (idiopathic) thrombocytopenic purpura,TA293,thrombocytopenic purpura,234493006,Non-thrombocytopenic purpura,ELTROMBOPAG,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
ELTROMBOPAG,Chronic immune (idiopathic) thrombocytopenic purpura,TA205,thrombocytopenic purpura,234494000,Primary non-thrombocytopenic purpura,ELTROMBOPAG,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
ELTROMBOPAG,Chronic immune (idiopathic) thrombocytopenic purpura,TA293,thrombocytopenic purpura,234494000,Primary non-thrombocytopenic purpura,ELTROMBOPAG,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
ELTROMBOPAG,Chronic immune (idiopathic) thrombocytopenic purpura,TA205,thrombocytopenic purpura,302873008,Thrombocytopenic purpura,ELTROMBOPAG,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
ELTROMBOPAG,Chronic immune (idiopathic) thrombocytopenic purpura,TA293,thrombocytopenic purpura,302873008,Thrombocytopenic purpura,ELTROMBOPAG,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
ELTROMBOPAG,Treating severe aplastic anaemia refractory to immunosuppressive therapy,TA382,aplastic anaemia,191256002,Idiopathic aplastic anaemia,ELTROMBOPAG,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
ELUXADOLINE,Irritable bowel syndrome with diarrhoea,TA471,irritable bowel syndrome,197125005,Irritable bowel syndrome with diarrhea,ELUXADOLINE,GASTROENTEROLOGY,GASTROENTEROLOGY
ELUXADOLINE,Irritable bowel syndrome with diarrhoea,TA471,irritable bowel syndrome,440544005,Irritable bowel syndrome characterized by alternating bowel habit,ELUXADOLINE,GASTROENTEROLOGY,GASTROENTEROLOGY
ELUXADOLINE,Irritable bowel syndrome with diarrhoea,TA471,irritable bowel syndrome,70871000119100,H/O irritable bowel syndrome,ELUXADOLINE,GASTROENTEROLOGY,GASTROENTEROLOGY
ELUXADOLINE,Irritable bowel syndrome with diarrhoea,TA471,irritable bowel syndrome,817511000000108,Management of irritable bowel syndrome,ELUXADOLINE,GASTROENTEROLOGY,GASTROENTEROLOGY
ELUXADOLINE,Irritable bowel syndrome with diarrhoea,TA471,irritable bowel syndrome,1083671000000108,Irritable Bowel Syndrome - Symptom Severity Scale score,ELUXADOLINE,GASTROENTEROLOGY,GASTROENTEROLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,10335000,Chronic right-sided heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,10633002,Acute congestive heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,36315003,Malignant hypertensive heart disease without congestive heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,48447003,Chronic heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,56675007,Acute heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,77970009,Benign hypertensive heart disease without congestive heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,83105008,Malignant hypertensive heart disease with congestive heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,83291003,Right heart failure due to pulmonary hypertension,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,85232009,Left-sided heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,88805009,Chronic congestive heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,111283005,Chronic left-sided heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,128404006,Right heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,134378009,Congestive heart failure monitoring,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,134440006,Referral to heart failure clinic,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,161505003,History of heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,194779001,Hypertensive heart and renal disease with (congestive) heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,194781004,Hypertensive heart and renal disease with both (congestive) heart failure and renal failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,233924009,Heart failure as a complication of care,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,266308000,Right heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,309634009,History of heart failure in last year,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,314206003,Refractory heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,367363000,Right heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,390868005,Heart failure screen,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,390884006,Heart failure follow-up,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,390885007,Heart failure annual review,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,394887005,Suspected heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,394927007,Heart failure excluded,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,395105005,Heart failure confirmed,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,416683003,Emergency hospital admission for heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,416717003,Seen in heart failure clinic,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,417146007,Referral to heart failure nurse,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,417359009,Seen by community heart failure nurse,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,423475008,Heart failure education,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,424404003,Decompensated chronic heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,426263006,Congestive heart failure due to left ventricular systolic dysfunction,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,426611007,Congestive heart failure due to valvular disease,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,429959009,Family history of heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,441530006,Chronic diastolic heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,446221000,HFpEF - heart failure with preserved ejection fraction,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,473226007,Heart failure medication review,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,703272007,HFrEF - heart failure with reduced ejection fraction,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,703275009,Heart failure with reduced ejection fraction due to cardiomyopathy,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,704095000,Referral to heart failure exercise programme,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,704096004,Referral to heart failure exercise programme not indicated,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,704097008,Referral to heart failure exercise program declined,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,735984001,Heart failure self management plan,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,788950000,HFmEF - heart failure with mid range ejection fraction,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,1296659009,Acute on chronic heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,96311000119109,Exacerbation of congestive heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,143411000000100,QOF (Quality and Outcomes Framework) heart failure quality indicator-related care invitation using preferred method of communication,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,200171000000102,Referred by heart failure nurse specialist,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,200201000000101,Discharge from practice nurse heart failure clinic,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,200361000000106,Did not attend practice nurse heart failure clinic,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,202231000000106,Heart failure review completed,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,203791000000106,Referred to heart failure education group,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,247361000000100,Heart failure 6 month review,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,248571000000104,Did not attend heart failure clinic,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,374231000000104,High risk of heart failure screening invitation,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,521691000000100,Heart failure resolved,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,711461000000104,Heart failure monitoring invitation,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,713791000000101,Heart failure monitoring administration,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,715951000000107,Exception reporting - heart failure quality indicators,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,716621000000101,Heart failure monitoring third letter,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,716971000000109,Heart failure monitoring first letter,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,717191000000108,Heart failure monitoring second letter,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,717481000000104,Excepted from heart failure quality indicators - patient unsuitable,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,717491000000102,Excepted from heart failure quality indicators - informed dissent,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,717501000000108,Heart failure monitoring verbal invitation,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,717531000000102,Heart failure monitoring telephone invitation,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,760361000000100,Fast track heart failure referral for transthoracic two dimensional echocardiogram,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,763641000000102,Referral to heart failure education group declined,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,765661000000102,Discharge from heart failure nurse service,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,781051000000108,Has heart failure management plan,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,789621000000105,Preferred place of care for next exacerbation of heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,810971000000105,Heart failure self-management plan review,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,812001000000102,Heart failure self-management plan agreed,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,813991000000101,Education about deteriorating heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,835981000000108,Rehabilitation for heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,851071000000108,Heart failure initial assessment,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,851521000000102,Heart failure clinical pathway,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,871681000000102,Heart failure monitoring,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,872361000000105,Discussion about heart failure care plan,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,873881000000100,Referral to rapid access heart failure clinic,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,915571000000102,On optimal heart failure therapy,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,961881000000101,Provision of information about heart failure,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,1108711000000108,Excepted from heart failure quality indicators - service unavailable,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN,Chronic heart failure with reduced ejection fraction,TA773,heart failure,1110931000000103,QOF (Quality and Outcomes Framework) heart failure quality indicator-related care invitation,EMPAGLIFLOZIN,CARDIOLOGY,CARDIOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A DUAL THERAPY REGIMEN IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA336,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN A TRIPLE THERAPY REGIMEN IN COMBINATION WITH METFORMIN AND EITHER A SULFONYLUREA OR A THIAZOLIDINEDIONE,Type 2 diabetes,TA336,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN IN COMBINATION WITH INSULIN WITH OR WITHOUT OTHER ANTIDIABETIC DRUGS,Type 2 diabetes,TA336,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,EMPAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EMPAGLIFLOZIN MONOTHERAPY,Treating type 2 diabetes,TA390,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,CANAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,915007,Malignant melanoma in junctional naevus,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,1556006,Clark melanoma level 4,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,2092003,Malignant melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,2142002,Nodular melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,16974005,"Acral lentiginous melanoma, malignant",ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,21119008,Benign melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,21165006,Clark melanoma level 3,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,37138001,Epithelioid cell melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,39896009,"Malignant melanoma, regressing",ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,44474009,Lentigo maligna melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,50542000,Clark melanoma level 2,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,50813003,Spitz melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,51757004,"Desmoplastic melanoma, amelanotic",ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,55320002,Superficial spreading melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,68827007,Spindle cell melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,70594002,Amelanotic melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,77986002,Melanoma in situ,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93209006,Malignant melanoma of perianal skin,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93214005,Malignant melanoma of skin of back,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93217003,Malignant melanoma of skin of cheek,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93220006,Malignant melanoma of skin of ear,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93221005,Malignant melanoma of skin of elbow,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93223008,Malignant melanoma of eyebrow,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93225001,Malignant melanoma of skin of face,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93227009,Malignant melanoma of skin of foot,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93228004,Malignant melanoma of skin of forearm,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93642000,Malignant melanoma of skin of neck,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93643005,Malignant melanoma of external surface of nose,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93646002,Malignant melanoma of skin of scalp,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93647006,Malignant melanoma of skin of shoulder,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93651008,Malignant melanoma of skin of trunk,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93653006,Malignant melanoma of skin of upper limb,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93654000,Malignant melanoma of skin of wrist,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,93655004,MM (malignant melanoma) of skin,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,106243009,Breslow depth staging for melanoma of skin,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,109266006,Melanoma in situ of skin,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,109270003,Melanoma in situ of face,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,109272006,Melanoma in situ of lip,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,109276009,Melanoma in situ of scalp,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,109278005,Melanoma in situ of ear,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,109282007,Melanoma in situ of neck,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,109284008,Melanoma in situ of trunk,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,109290007,Melanoma in situ of upper limb,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,109294003,Melanoma in situ of lower limb,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,127330008,Melanoma in situ by body site (clinical),ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,161432005,History of malignant melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,177281002,Excision of melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188030005,Malignant melanoma of lip,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188033007,Malignant melanoma of auricle (ear),ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188034001,Malignant melanoma of external auditory meatus,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188038003,Malignant melanoma of chin,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188040008,Malignant melanoma of forehead,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188042000,Malignant melanoma of temple,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188044004,Malignant melanoma of scalp and/or neck,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188045003,Malignant melanoma of scalp,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188046002,Malignant melanoma of neck,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188049009,Malignant melanoma of axilla,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188050009,Malignant melanoma of breast,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188051008,Malignant melanoma of buttock,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188052001,Malignant melanoma of groin,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188054000,Malignant melanoma of perineum,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188055004,Malignant melanoma of umbilicus,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188060000,Malignant melanoma of shoulder,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188061001,Malignant melanoma of upper arm,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188062008,Malignant melanoma of forearm,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188063003,Malignant melanoma of hand,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188064009,Malignant melanoma of finger,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188065005,Malignant melanoma of thumb,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188067002,Malignant melanoma of lower limb and hip,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188068007,Malignant melanoma of hip,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188069004,Malignant melanoma of thigh,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188070003,Malignant melanoma of knee,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188071004,Malignant melanoma of popliteal fossa area,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188072006,Malignant melanoma of lower leg,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188073001,Malignant melanoma of ankle,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188074007,Malignant melanoma of heel,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188075008,Malignant melanoma of foot,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188076009,Malignant melanoma of toe,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,188077000,Malignant melanoma of great toe,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,189758001,Melanoma in situ,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,231834005,Malignant melanoma of eyelid,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,254731001,Nodular melanoma of skin,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,254732008,Acral lentiginous melanoma of skin,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,254896002,Malignant melanoma of vulva,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,255004001,Malignant melanoma of conjunctiva,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,255012009,Malignant melanoma of iris,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,255015006,Malignant melanoma of ciliary body,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,255021005,Malignant melanoma of choroid,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,269578002,Malignant melanoma of head and neck,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,269579005,Malignant melanoma of trunk,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,269580008,Malignant melanoma of upper limb,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,269581007,Malignant melanoma of lower limb,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,274087000,MM (malignant melanoma) of eye,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,276751004,Amelanotic melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,276821000,Malignant melanoma of anus,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,276822007,Malignant melanoma of rectum,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,302837001,Lentigo maligna melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,310498001,Malignant melanoma of back,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,312941005,Melanoma associated retinopathy,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,313248004,Malignant melanoma of chest wall,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,314976006,Local recurrence of malignant melanoma of skin,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,314987003,Metastasis from malignant melanoma of skin,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,315036008,Melanoma in situ of back of hand,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,315230006,Melanoma in situ of back,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,372158004,"Malignant melanoma, metastatic",ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,427858005,Family history of malignant melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,443493003,Metastatic malignant melanoma,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,449636007,Malignant melanoma of skin of lower leg,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,449637003,Malignant melanoma of skin of upper arm,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,698040004,Malignant melanoma of nasal cavity,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,1197324006,Metastatic malignant melanoma to skin,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,351961000119109,Malignant melanoma of skin of right arm,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,352211000119108,Malignant melanoma of skin of left ear,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,546881000000105,Malignant melanoma of skin NOS,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,956331000000107,Malignant melanoma stage IA,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,956351000000100,Malignant melanoma stage IB,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,956371000000109,Malignant melanoma stage IIA,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,956391000000108,Malignant melanoma stage IIB,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,956451000000107,Malignant melanoma stage IIIB,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,956471000000103,Malignant melanoma stage IIIC,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,956511000000107,Malignant melanoma stage IV M1a,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,956551000000106,Malignant melanoma stage IV M1c,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,1080941000119109,Malignant melanoma of left choroid,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENCORAFENIB,Unresectable or metastatic BRAF V600 mutation-positive melanoma in adults,TA562,melanoma,1080981000119104,Malignant melanoma of right choroid,ENCORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,162573006,Suspected lung cancer,ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,254637007,Non-small cell lung cancer,ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,275981009,Lung cancer screening,ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,429011007,Family history of lung cancer,ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,877691000000107,No FH of lung cancer,ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ENTRECTINIB,ROS1-positive advanced non-small-cell lung cancer,TA643,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ENTRECTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ENZALUTAMIDE,Hormone-relapsed non-metastatic prostate cancer,TA580,prostate cancer,315268008,Suspected prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Hormone-relapsed non-metastatic prostate cancer,TA580,prostate cancer,428262008,H/O: prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Hormone-relapsed non-metastatic prostate cancer,TA580,prostate cancer,698470001,Advice given about prostate cancer screening,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Hormone-relapsed non-metastatic prostate cancer,TA580,prostate cancer,712837004,Active surveillance of prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Hormone-relapsed non-metastatic prostate cancer,TA580,prostate cancer,720007002,Prostate cancer care review,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Hormone-relapsed non-metastatic prostate cancer,TA580,prostate cancer,31011000119107,Prostate cancer screening declined,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Hormone-relapsed non-metastatic prostate cancer,TA580,prostate cancer,874211000000109,QCancer prostate cancer risk,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Hormone-relapsed non-metastatic prostate cancer,TA580,prostate cancer,878401000000104,No FH of prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Hormone-relapsed non-metastatic prostate cancer,TA580,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Hormone-relapsed non-metastatic prostate cancer,TA580,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Hormone-sensitive metastatic prostate cancer,TA712,prostate cancer,315268008,Suspected prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Hormone-sensitive metastatic prostate cancer,TA712,prostate cancer,428262008,H/O: prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Hormone-sensitive metastatic prostate cancer,TA712,prostate cancer,698470001,Advice given about prostate cancer screening,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Hormone-sensitive metastatic prostate cancer,TA712,prostate cancer,712837004,Active surveillance of prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Hormone-sensitive metastatic prostate cancer,TA712,prostate cancer,720007002,Prostate cancer care review,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Hormone-sensitive metastatic prostate cancer,TA712,prostate cancer,31011000119107,Prostate cancer screening declined,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Hormone-sensitive metastatic prostate cancer,TA712,prostate cancer,874211000000109,QCancer prostate cancer risk,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Hormone-sensitive metastatic prostate cancer,TA712,prostate cancer,878401000000104,No FH of prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Hormone-sensitive metastatic prostate cancer,TA712,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Hormone-sensitive metastatic prostate cancer,TA712,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Metastatic hormone-relapsed prostate cancer,TA316,prostate cancer,315268008,Suspected prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Metastatic hormone-relapsed prostate cancer,TA316,prostate cancer,428262008,H/O: prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Metastatic hormone-relapsed prostate cancer,TA316,prostate cancer,698470001,Advice given about prostate cancer screening,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Metastatic hormone-relapsed prostate cancer,TA316,prostate cancer,712837004,Active surveillance of prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Metastatic hormone-relapsed prostate cancer,TA316,prostate cancer,720007002,Prostate cancer care review,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Metastatic hormone-relapsed prostate cancer,TA316,prostate cancer,31011000119107,Prostate cancer screening declined,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Metastatic hormone-relapsed prostate cancer,TA316,prostate cancer,874211000000109,QCancer prostate cancer risk,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Metastatic hormone-relapsed prostate cancer,TA316,prostate cancer,878401000000104,No FH of prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Metastatic hormone-relapsed prostate cancer,TA316,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Metastatic hormone-relapsed prostate cancer,TA316,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,TA377,prostate cancer,315268008,Suspected prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,TA377,prostate cancer,428262008,H/O: prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,TA377,prostate cancer,698470001,Advice given about prostate cancer screening,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,TA377,prostate cancer,712837004,Active surveillance of prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,TA377,prostate cancer,720007002,Prostate cancer care review,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,TA377,prostate cancer,31011000119107,Prostate cancer screening declined,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,TA377,prostate cancer,874211000000109,QCancer prostate cancer risk,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,TA377,prostate cancer,878401000000104,No FH of prostate cancer,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,TA377,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
ENZALUTAMIDE,Treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated,TA377,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,ENZALUTAMIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
EPTIFIBATIDE (INTRAVENOUS),Acute coronary syndromes,TA012,acute coronary syndrome,837091000000100,H/O acute coronary syndrome,ABCIXIMAB,CARDIOLOGY,CARDIOLOGY
EPTIFIBITIDE,Acute coronary syndromes,TA047,acute coronary syndrome,837091000000100,H/O acute coronary syndrome,ABCIXIMAB,CARDIOLOGY,CARDIOLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,4473006,Classical migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,23186000,Menstrual migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,37796009,Migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,56097005,Migraine without aura,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,59292006,Hemiplegic migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,75879005,Decapitated migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,79267007,Retinal migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,83351003,Basilar artery migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,95655001,Ocular migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,95656000,Familial hemiplegic migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,160342001,Family history of migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,161481007,History of migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,162040008,Abdominal migraine - symptom,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,193030005,Migraine variants,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,193039006,Complex migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,230462002,Migraine with typical aura,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,230464001,Sporadic hemiplegic migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,230465000,Migraine aura without headache,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,230468003,Migraine with ischaemic complication,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,232284007,Vestibular migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,394707001,No history of migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,408381007,Migraine prophylaxis,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,427419006,Chronic migraine,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,608837004,History of migraine with aura,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,124171000119105,Chronic intractable migraine without aura,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
EPTINEZUMAB,Preventing migraine,TA871,migraine,781381000000100,Migraine induced by oestrogen contraceptive,EPTINEZUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,4473006,Classical migraine,ERENUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,23186000,Menstrual migraine,ERENUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,37796009,Migraine,ERENUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,56097005,Migraine without aura,ERENUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,59292006,Hemiplegic migraine,ERENUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,75879005,Decapitated migraine,ERENUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,79267007,Retinal migraine,ERENUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,83351003,Basilar artery migraine,ERENUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,95655001,Ocular migraine,ERENUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,95656000,Familial hemiplegic migraine,ERENUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,160342001,Family history of migraine,ERENUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,161481007,History of migraine,ERENUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,162040008,Abdominal migraine - symptom,ERENUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,193030005,Migraine variants,ERENUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,193039006,Complex migraine,ERENUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,230462002,Migraine with typical aura,ERENUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,230464001,Sporadic hemiplegic migraine,ERENUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,230465000,Migraine aura without headache,ERENUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,230468003,Migraine with ischaemic complication,ERENUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,232284007,Vestibular migraine,ERENUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,394707001,No history of migraine,ERENUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,408381007,Migraine prophylaxis,ERENUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,427419006,Chronic migraine,ERENUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,608837004,History of migraine with aura,ERENUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,124171000119105,Chronic intractable migraine without aura,ERENUMAB,NEUROLOGY,NEUROLOGY
ERENUMAB,Migraine,TA682,migraine,781381000000100,Migraine induced by oestrogen contraceptive,ERENUMAB,NEUROLOGY,NEUROLOGY
ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,134405005,Suspected breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,160287004,FH: Breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,268547008,Screening for breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,429740004,Family history of breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,706970001,TNBC - Triple-negative breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,94361000000105,Breast cancer detected by national screening programme,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,838351000000107,Education about risk of breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,874291000000100,QCancer breast cancer risk,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Locally advanced or metastatic breast cancer after 1 chemotherapy regimen,TA515,breast cancer,1035841000000108,Lymphoedema following breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,134405005,Suspected breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,160287004,FH: Breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,268547008,Screening for breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,429740004,Family history of breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,706970001,TNBC - Triple-negative breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,94361000000105,Breast cancer detected by national screening programme,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,838351000000107,Education about risk of breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,874291000000100,QCancer breast cancer risk,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens,TA423,breast cancer,1035841000000108,Lymphoedema following breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,134405005,Suspected breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,160287004,FH: Breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,268547008,Screening for breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,429740004,Family history of breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,706970001,TNBC - Triple-negative breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,94361000000105,Breast cancer detected by national screening programme,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,838351000000107,Education about risk of breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,874291000000100,QCancer breast cancer risk,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERIBULIN,Treatment of locally advanced or metastatic breast cancer that has progressed after at least two chemotherapy regimens for advanced disease,TA250,breast cancer,1035841000000108,Lymphoedema following breast cancer,ERIBULIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,162573006,Suspected lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,254637007,Non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,275981009,Lung cancer screening,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,429011007,Family history of lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,877691000000107,No FH of lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,162573006,Suspected lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,254637007,Non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,275981009,Lung cancer screening,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,429011007,Family history of lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,877691000000107,No FH of lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (1ST LINE MAINTENANCE TREATMENT),Advanced or metastatic non-small-cell lung cancer (which is stable after platinum-based first-line chemotherapy),TA227,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (1ST LINE),Treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small cell lung cancer,TA258,non-small cell lung cancer,254637007,Non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (1ST LINE),Treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small cell lung cancer,TA258,non-small cell lung cancer,723301009,Squamous non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (1ST LINE),Treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small cell lung cancer,TA258,non-small cell lung cancer,1259727001,Primary non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (1ST LINE),Treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small cell lung cancer,TA258,non-small cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,162573006,Suspected lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,254637007,Non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,275981009,Lung cancer screening,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,429011007,Family history of lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,877691000000107,No FH of lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS SUITABLE),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,162573006,Suspected lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,254637007,Non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,275981009,Lung cancer screening,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,429011007,Family history of lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,877691000000107,No FH of lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERLOTINIB (2ND-LINE TREATMENT IN PATIENTS FOR WHOM DOCETAXEL IS UNSUITABLE; OR AS A 3RD-LINE TREATMENT AFTER DOCETAXEL THERAPY),Non-small-cell lung cancer,TA162,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes,TA572,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,2751001,Fibrocalculous pancreatic diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,4855003,Retinopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,5368009,Drug-induced diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,5969009,Diabetes mellitus associated with genetic syndrome,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,6143009,Diabetes mellitus education,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,8801005,Secondary diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,9414007,Latent diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,11530004,Brittle diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,11687002,GDM - gestational diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,15771004,Diabetes insipidus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,21584002,Maternal diabetes syndrome,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,25093002,Disorder of eye due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,25412000,Microaneurysm of retinal artery due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,26298008,Ketoacidotic coma due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,39058009,Lumbosacral radiculoplexus neuropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,43959009,Cataract of eye due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,44054006,T2DM - diabetes mellitus type 2,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,46635009,T1DM - type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,48951005,Bullous disease due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,49455004,Polyneuropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,49817004,Neonatal diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,50620007,Autonomic neuropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,51002006,Pancreatogenic type 3c diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,59276001,Proliferative retinopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,61165007,Adiuretin-resistant diabetes insipidus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,62260007,Pretibial pigmental patches due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,70694009,"DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, deafness) syndrome",ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,73211009,Diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,74627003,Complication due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,75524006,MRDM - malnutrition related diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,111552007,Diabetes mellitus without complication,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,111556005,Ketoacidosis without coma due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,126534007,Mixed sensorimotor polyneuropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,127012008,Lipodystrophic diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,127013003,Disorder of kidney due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,160274005,No family history of diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,160303001,Family history of diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,160402005,Family history: Diabetes in pregnancy,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,161445009,History of diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,161641009,At increased risk of diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,166928007,Glucose tolerance test indicates diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,170745003,Diet controlled diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,170752001,Has seen dietitian - diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,170753006,Understands diet - diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,170766006,Loss of hypoglycaemic warning due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,170774007,Diabetes: practice program,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,170775008,Diabetes: shared care program,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,171183004,Diabetes mellitus screening,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,185753003,Attends diabetes monitoring,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,185754009,Diabetes monitoring declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,185755005,Diabetes monitoring default,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,185756006,Diabetes monitoring first letter,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,185757002,Diabetes monitoring second letter,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,185758007,Diabetes monitoring third letter,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,185759004,Diabetes monitoring verbal invite,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,185760009,Diabetes monitoring telephone invite,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,185761008,Diabetes monitoring deleted,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190323008,Non-insulin dependent diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190349003,Diabetes mellitus with neuropathy,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190354007,Diabetes with gangrene,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190368000,Insulin-dependent diabetes mellitus with ulcer,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190372001,Insulin-dependent diabetes maturity onset,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190388001,Type 2 diabetes mellitus with multiple complications,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190389009,Type 2 diabetes mellitus with ulcer,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190406000,Ketoacidosis due to malnutrition related diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190411003,Multiple complications due to malnutrition related diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190412005,Malnutrition-related diabetes mellitus without complications,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190416008,Steroid-induced diabetes mellitus without complication,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190447002,Steroid-induced diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,190484000,Diabetes insipidus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,193141005,Mononeuritis multiplex due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,193183000,Acute painful neuropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,193184006,Chronic painful neuropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,193185007,Asymptomatic neuropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,193349004,Preproliferative retinopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,193350004,Advanced maculopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,193489006,Iritis due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,197605007,Nephrotic syndrome due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,199223000,"Diabetes mellitus during pregnancy, childbirth and the puerperium",ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,199225007,Diabetes mellitus during pregnancy - baby delivered,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,199226008,Diabetes mellitus in the puerperium - baby delivered during current episode of care,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,199227004,Diabetes mellitus during pregnancy - baby not yet delivered,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,199230006,Pre-existing type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,200687002,Cellulitis of foot due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,201250006,Ischemic ulcer of foot due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,201251005,Neuropathic ulcer of foot due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,201723002,Cheiroarthropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,201724008,Neuropathic arthropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,230572002,Neuropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,230574001,Acute painful polyneuropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,230575000,Chronic painful polyneuropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,230577008,Mononeuropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,230579006,Thoracic radiculopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,232020009,Disorder of macula due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,232021008,Proliferative retinopathy with optic disc neovascularization due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,232022001,Proliferative retinopathy with neovascularisation elsewhere than the optic disc due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,232023006,Traction detachment of retina due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,236499007,Microalbuminuric nephropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,236500003,Proteinuric nephropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,237599002,Insulin treated type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,237601000,Secondary endocrine diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,237604008,MODY2 (maturity onset diabetes of the young type 2),ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,237606005,Insulin receptor defect with insulin-resistant diabetes mellitus and acanthosis nigricans,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,237618001,Congenital insulin-dependent diabetes mellitus with fatal secretory diarrhea,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,237619009,Maternally-inherited diabetes and hearing loss,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,237620003,Abnormal metabolic state due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,237621004,Severe hyperglycemia due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,237627000,Pregnancy and type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,237632004,Hypoglycemic event due to diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,237633009,Hypoglycaemia due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,237635002,Nocturnal hypoglycemia due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,238981002,Disorder of soft tissue due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,238982009,Dermopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,238983004,Thick skin syndrome due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,267471001,Diabetes + eye manifestation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,268519009,Diabetes mellitus uncontrolled,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,270445003,Diabetes monitoring check done,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,273411009,Diabetes clinic satisfaction questionnaire,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,273412002,Diabetes treatment satisfaction questionnaire,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,273413007,Diabetes wellbeing questionnaire,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,284350006,Diabetes mellitus diet education,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,290002008,Unstable type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,303059007,Postpancreatectomy diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,304752002,Perceived control of insulin-dependent diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,308505000,Diabetes monitoring call,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,309417009,Diabetes dietitian,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,309426007,Glomerulopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,309593006,Education score - diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,309596003,Retinal abnormality - non-diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,309598002,Foot abnormality - non-diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,309635005,History of admission in last year for diabetes foot problem,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,310425007,Diabetes monitoring invitation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,310505005,Hyperosmolar non-ketotic state due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,311782002,Advanced retinal disease due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,312856000,Referral to diabetes nurse,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,312888008,Attending diabetes clinic,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,312903003,Mild nonproliferative retinopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,312904009,Moderate nonproliferative retinopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,312905005,Severe nonproliferative retinopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,312909004,Proliferative retinopathy with iris neovascularisation due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,312910009,Vitreous hemorrhage due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,312912001,Macular oedema due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,313435000,Insulin-dependent diabetes without complication,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,313436004,Type II diabetes mellitus without complication,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,314010006,Diffuse exudative maculopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,314011005,Focal exudative maculopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,314014002,Ischemic maculopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,314015001,Mixed maculopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,314537004,Optic papillopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,314771006,Insulin dependent diabetes mellitus with hypoglycemic coma,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,315051004,Diabetes resolved,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,315216001,Diabetes mellitus excluded,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,361216007,Femoral mononeuropathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,371087003,Ulcer of foot due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,385805005,Health education - diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,390834004,Nonproliferative retinopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,394725008,Diabetes medication review,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,395123002,Urine screening test for diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,398140007,Post hypoglycaemic hyperglycaemia due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,399868002,Intraretinal microvascular anomaly due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,399871005,Visually threatening retinopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,405749004,Newly diagnosed diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,407569005,Patient on maximal tolerated therapy for diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,408290003,Diabetes key contact,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,408392008,Under care of diabetes specialist nurse,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,408540003,Diabetes mellitus induced by non-steroid drugs,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,413180006,Pan retinal photocoagulation for diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,413597006,Attended diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,414229005,Family/carer attended diabetes structured education program,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,414230000,Family/carer referral to diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,415269004,Referral to diabetes preconception counselling clinic,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,415270003,Referral to diabetes structured education program,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,415744000,Transition of diabetes care options discussed,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,416554009,Seen in community diabetes specialist clinic,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,416855002,Family history of diabetes mellitus in first degree relative,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,417467000,Discharged from care of diabetes specialist nurse,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,419100001,Infection of foot due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,420422005,Ketoacidosis due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,420756003,Cataract of eye due to diabetes mellitus type 2,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,420825003,Gangrene due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,420868002,Disorder due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421631007,Gangrene due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421895002,Peripheral vascular disorder due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421920002,Cataract of eye due to diabetes mellitus type 1,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,422014003,Disorder due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,422088007,Disorder of nervous system due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,422126006,Hyperosmolar coma due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,422183001,Skin ulcer due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,422275004,Gangrene due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,426875007,Latent autoimmune diabetes mellitus in adult,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,428274007,Dietary advice for type II diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,429094000,Dietary advice for type 1 diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,430678008,Family history of diabetes mellitus type 1,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,430679000,Family history of diabetes mellitus type 2,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,439051004,Dietary advice for gestational diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,441656006,Hyperglycaemic crisis due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,443694000,Uncontrolled type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,444073006,Uncontrolled type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,444094009,History of diabetes mellitus in child of subject,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,472969004,H/O diabetes mellitus type 2,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,472970003,H/O diabetes mellitus type 1,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,472971004,Past pregnancy history of gestational diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,473127005,Suspected diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,609561005,MODY - maturity onset diabetes of young,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,609572000,HNF1B (HNF1 homeobox B) monogenic diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,698610002,Education about self management of diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,699826006,Lifestyle education regarding risk of diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,700414001,Education about diabetes and driving,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,703040004,Agreeing on diabetes care plan,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,703136005,Diabetes mellitus in remission,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,703137001,Type 1 diabetes mellitus in remission,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,703138006,Type 2 diabetes mellitus in remission,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,704408003,Invitation for diabetes screening,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,705072004,Diabetes monitoring invitation by short message service text messaging,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,714628002,Prediabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,715159005,Referral to diabetes service,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,715759002,Provision of written information about diabetes and hypertension,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,715879000,Provision of written information about diabetes and high cholesterol,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,719943000,Provision of written information about diabetes and high haemoglobin A1c level,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,720504004,Not suitable for Diabetes Education and Self Management for Ongoing and Newly Diagnosed program,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,720685006,Seen by diabetes specialist nurse,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,720724003,Has diabetes identity card,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,724136006,Mastopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,735199000,History of diabetes related lower limb amputation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,735985000,Diabetes self management plan,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,736284000,Diabetes clinical management plan,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,762291006,Syndrome of infant of mother with gestational diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,762489000,Acute complication due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,763117005,FINDRISC (Finnish Diabetes Risk Score) score,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,763782001,Provision of patient held diabetes record declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,765147009,Diabetes Treatment Satisfaction Questionnaire status version score,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,768794008,Cataract of bilateral eyes due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,769182000,Preproliferative retinopathy of left eye due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,769218003,Macular oedema of left eye due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,769222008,Clinically significant macular edema of left eye due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,769244003,Disorder of right macula due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,769245002,Disorder of left macula due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,770096002,Erectile dysfunction due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,816177009,Nonproliferative retinopathy of left eye due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,816178004,Nonproliferative retinopathy of right eye due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,816961009,Stable treated proliferative retinopathy of right eye due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,816962002,Stable treated proliferative retinopathy of left eye due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,860709007,No disorder of macula of left eye due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,860710002,No maculopathy of right eye due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,860712005,Disorder of macula of both eyes due to diabetes mellitus present,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,878859007,Self management of diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,890171006,KPD - ketosis-prone diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,897238003,Diabetes management using closed-loop delivery system,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1196922005,Neovascular glaucoma due to type II diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1196923000,Neovascular glaucoma due to type I diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1258872006,Family referred to diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1258873001,Caregiver referred to diabetes structured education program,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1268646002,Gestational diabetes mellitus screening,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1296758008,Diabetes insipidus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1306699009,Stable treated proliferative retinopathy due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,701000119103,Mixed hyperlipidaemia due to type II diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,24451000000107,Diabetes: shared care in pregnancy - diabetologist and obstetrician,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,40801000119106,Gestational diabetes mellitus complicating pregnancy,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,113131000000107,Informed consent for diabetes national audit,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,113141000000103,Informed dissent for diabetes national audit,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,143401000000102,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation using preferred method of communication,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,143911000000105,Registration for access to online diabetes self-management application,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,143941000000106,Declined to register for access to online diabetes self-management application,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,199481000000100,Diabetes monitoring lower risk albumin excretion,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,199491000000103,Diabetes monitoring higher risk albumin excretion,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,276651000000107,Attended DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,279291000000109,Diabetes type 1 review,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,279321000000104,Diabetes type II review,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,279521000000108,Referral to community diabetes specialist nurse,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,300641000000105,Seen by general practitioner with special interest in diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306401000000106,Attended XPERT (expert patient education versus routine treatment) diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306441000000109,Attended DAFNE (dose adjustment for normal eating) diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306471000000103,DAFNE (dose adjustment for normal eating) diabetes structured education programme completed,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306501000000105,DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme completed,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306531000000104,XPERT (expert patient education versus routine treatment) diabetes structured education programme completed,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306591000000103,Diabetes structured education programme declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306701000000102,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306741000000104,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) diabetes structured programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306771000000105,Referral to XPERT (expert patient education versus routine treatment) diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306861000000107,Did not attend diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306931000000106,Did not complete diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306961000000101,Did not complete DAFNE (dose adjustment for normal eating) diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,306991000000107,Did not complete DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,307021000000105,Did not complete XPERT diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,307141000000102,Did not attend DAFNE (dose adjustment for normal eating) diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,307171000000108,Did not attend DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,307201000000109,Did not attend XPERT (expert patient education versus routine treatment) diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,334711000000100,Referral to diabetes special interest general practitioner,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,335621000000101,Maternally inherited diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,344061000000104,Referral to children's diabetes nurse specialist,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,368711000119106,Mild nonproliferative retinopathy due to secondary diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,385041000000108,Diabetes mellitus with multiple complications,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,385051000000106,Pre-existing diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,494961000000102,Discharged from diabetes shared care programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,512561000000108,Unsuitable for diabetes year of care programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,512581000000104,Declined consent for diabetes year of care programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,532411000000102,"Diabetes mellitus, adult onset, with no mention of complication",ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,658011000000104,Diabetes mellitus with other specified manifestation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,658061000000102,Diabetes mellitus NOS with other specified manifestation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,713671000000109,Diabetes monitoring administration,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,713691000000108,Diabetes clinic administration,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,715111000000105,Diabetes screening administration,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,716031000000106,Excepted from diabetes quality indicators - informed dissent,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,716911000000104,Exception reporting - diabetes quality indicators,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,717421000000100,Excepted from diabetes quality indicators - patient unsuitable,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,750721000000102,Excepted from diabetes quality indicators: service unavailable,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,754461000000105,Referral to type I diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,755491000000100,Diabetes structured education programme completed,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,762811000000109,DNA (did not attend) diabetes foot screening,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,764921000000102,Gestational diabetes information leaflet given,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,771571000000102,H/O: secondary diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,781161000000107,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,787061000000100,Diabetes care plan declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,810961000000103,Diabetes self-management plan review,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,811391000000104,Referral to community diabetes service,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,811981000000102,Diabetes self-management plan agreed,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,816711000000104,Gestational diabetes mellitus annual review,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,819301000000105,Diabetes monitoring injection site check declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,819331000000104,Diabetes monitoring injection site not checked,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,828901000000109,Endocrinology and diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,829521000000104,Provision of diabetes clinical summary,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,837491000000107,High risk of diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,838731000000104,Referral to community diabetes specialist nurse declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,841221000000102,Referral to community diabetes clinic,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,850581000000106,High risk of diabetes mellitus annual review,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,851501000000106,Diabetes clinical pathway,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,851991000000108,Diabetes quality of life questionnaire score,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,857921000000103,Provision of written information about diabetes and driving,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,858301000000107,Pre-diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,860981000000106,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,863501000000102,QDiabetes risk calculator,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,863521000000106,QDiabetes risk calculator score,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,867891000000101,Erectile dysfunction due to diabetes mellitus,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,876381000000100,Conversion to insulin by diabetes specialist nurse,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,885931000000100,Diabetes structured education programme not available,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,887861000000105,Diabetes Year of Care annual review,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,909421000000102,DDS2 (Diabetes Distress Scale 2) score,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,909441000000109,DDS17 - Diabetes Distress Scale 17,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,910931000000101,DDS17 (Diabetes Distress Scale 17) score,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,923461000000103,Lifestyle education for diabetes,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,927821000000100,Discharge from secondary care diabetes service,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,956781000000107,Joint consultation with practice nurse and community diabetes specialist nurse,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,956921000000109,Joint consultation with General Practitioner and community diabetes specialist nurse,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,961931000000109,Diabetes education care plan,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,977201000000107,Recommendation to self-refer for diabetes structured education,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1019431000000105,HbA1c level (Diabetes Control and Complications Trial aligned),ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1019551000000104,HbA1 level (Diabetes Control and Complications Trial aligned),ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1024551000000109,Under care of hospital-based diabetes specialist nurse,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1024571000000100,Under care of community-based diabetes specialist nurse,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1024941000000100,NHS Diabetes Prevention Programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1025211000000108,NHS Diabetes Prevention Programme not completed,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1025251000000107,NHS Diabetes Prevention Programme completed,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1025271000000103,NHS Diabetes Prevention Programme started,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1025301000000100,Referral to NHS Diabetes Prevention Programme declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1025321000000109,Referral to NHS Diabetes Prevention Programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1025601000000108,Leicester Diabetes Risk Score,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1054221000000100,Seen in hospital diabetes antenatal clinic,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1065461000000102,Type II diabetes mellitus risk assessment invitation first letter,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1065491000000108,Type II diabetes mellitus risk assessment verbal invitation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1065501000000102,Type II diabetes mellitus risk assessment telephone invitation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1066911000000100,Diabetes monitoring SMS (short message service) text message first invitation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1066921000000106,Diabetes monitoring SMS (short message service) text message second invitation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1066931000000108,Diabetes monitoring SMS (short message service) text message third invitation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1083111000000108,Diabetes monitoring invitation email,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1084661000000103,Diabetes UK Diabetes Risk Score,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1087971000000105,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) score",ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1089101000000109,UKPDS (United Kingdom Prospective Diabetes Study) risk engine score,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1090701000000104,NHS Diabetes Prevention Programme invitation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1092721000000109,Signposting to Diabetes UK,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1092731000000106,Signposting to Diabetes UK Learning Zone,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1097131000000105,Remote diabetes structured education and support programme commenced,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1097141000000101,Remote diabetes structured education and support programme completed,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1098011000000102,Did not commence remote structured diabetes education and support programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1103691000000102,Diabetes structured education programme offered,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1108731000000100,Referral to online diabetes structured education programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1108741000000109,Referral to HeLP-Diabetes (Healthy Living for People with Diabetes) online self-management programme,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1110921000000100,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1362341000000103,Diabetes care plan,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ERTUGLIFLOZIN,Type 2 diabetes mellitus,TA583,diabetes,12275391000119108,Diabetes screening declined,ERTUGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,2694001,Leucoerythroblastic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,4854004,Acquired haemolytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,5315003,HNSHA (hereditary nonspherocytic haemolytic anaemia) due to increased adenosine deaminase activity,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,28975000,Congenital aplastic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,30575002,Fanconi anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,41841004,Sideroblastic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,45828008,"Anaemia in mother complicating pregnancy, childbirth AND/OR puerperium",ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,48983004,X-linked sideroblastic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,49708008,Anaemia of chronic renal failure,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,52951008,CDA - congenital dyserythropoietic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,53743006,Anaemia following foetal blood loss,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,55907008,Idiopathic acquired aplastic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,55995005,Congenital spherocytic haemolytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,56921004,Perinatal jaundice due to hereditary haemolytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,61261009,Haemolytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,63565007,Congenital anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,74703006,PK (pyruvate kinase) deficiency haemolytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,81711008,Haemolytic anaemia caused by drugs,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,83414005,Macrocytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,85649008,Folate deficiency anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,87522002,Chlorotic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,90414007,Chronic acquired pure red cell anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,161457000,History of anaemia vitamin B12 deficient,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,161458005,History of haemolytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,164139008,On examination - anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,171201007,Anaemia screening,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,189509003,"Refractory anaemia without sideroblasts, so stated",ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191125001,Deficiency anaemiasm (& [asiderotic] or [sideropenic]),ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191127009,Iron deficiency anaemia due to blood loss,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191142007,Vitamin B12 deficiency anaemia due to malabsorption with proteinuria,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191147001,Anaemia: [folate-deficiency or megaloblastic due to dietary causes] or [goat's milk],ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191150003,Folate deficiency anaemia due to liver disorders,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191154007,Combined B12 and folate deficiency anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191210005,Primary cold-type haemolytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191217008,Mechanical haemolytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191218003,Toxic haemolytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191248000,Aplastic anaemia caused by toxic cause,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191251007,Transient hypoplastic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191256002,Idiopathic aplastic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,191277004,Normocytic anaemia due to unspecified cause,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,199244000,Anaemia during pregnancy - baby delivered,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,206434001,Late anaemia of newborn due to isoimmunisation,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,234339009,Macrocytosis - no anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,234340006,Iron deficiency without anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,234347009,Anaemia of systemic disease,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,234349007,Microcytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,234360003,Vegan anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,234402007,Chronic non-spherocytic haemolytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,266888008,Family history: Anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,267513007,Deficiency anaemias,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,267553005,Microcytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,267554004,Deficiency anaemias excl. iron,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,271737000,Anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,275538002,History of anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,276578004,Physiological anaemia of infancy,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,300980002,Normocytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,307726001,Anaemia in ovarian carcinoma,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,309742004,Drug-induced autoimmune haemolytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,310647000,Anaemia secondary to renal failure,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,413533008,Anaemia due to chronic blood loss,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,413603009,Autoimmune haemolytic anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,417425009,Sickle cell anaemia with crisis,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,441482006,History of sickle cell anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,221241000000101,Hypoplastic haemolytic and renal anaemia drugs Band 2,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,389601000000102,[X]Anaemia in other chronic diseases classified elsewhere,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,421261000000104,"[X]Vitamin B12, folic acid and other anti-megaloblastic anaemia preparations causing adverse effects in therapeutic use",ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,579711000000100,Other specified megaloblastic anaemia NEC,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,668381000000100,Anaemia unspecified,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,820601000000103,Refractory anaemia with multilineage dysplasia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIESIS-STIMULATING AGENTS (EPOETIN ALFA, BETA, THETA AND ZETA, AND DARBEPOETIN ALFA)",Treating anaemia in people with cancer having chemotherapy,TA323,anaemia,866381000000109,Recurrent anaemia,ERYTHROPOIESIS-STIMULATING,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,2694001,Leucoerythroblastic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,4854004,Acquired haemolytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,5315003,HNSHA (hereditary nonspherocytic haemolytic anaemia) due to increased adenosine deaminase activity,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,28975000,Congenital aplastic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,30575002,Fanconi anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,41841004,Sideroblastic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,45828008,"Anaemia in mother complicating pregnancy, childbirth AND/OR puerperium",ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,48983004,X-linked sideroblastic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,49708008,Anaemia of chronic renal failure,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,52951008,CDA - congenital dyserythropoietic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,53743006,Anaemia following foetal blood loss,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,55907008,Idiopathic acquired aplastic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,55995005,Congenital spherocytic haemolytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,56921004,Perinatal jaundice due to hereditary haemolytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,61261009,Haemolytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,63565007,Congenital anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,74703006,PK (pyruvate kinase) deficiency haemolytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,81711008,Haemolytic anaemia caused by drugs,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,83414005,Macrocytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,85649008,Folate deficiency anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,87522002,Chlorotic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,90414007,Chronic acquired pure red cell anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,161457000,History of anaemia vitamin B12 deficient,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,161458005,History of haemolytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,164139008,On examination - anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,171201007,Anaemia screening,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,189509003,"Refractory anaemia without sideroblasts, so stated",ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191125001,Deficiency anaemiasm (& [asiderotic] or [sideropenic]),ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191127009,Iron deficiency anaemia due to blood loss,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191142007,Vitamin B12 deficiency anaemia due to malabsorption with proteinuria,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191147001,Anaemia: [folate-deficiency or megaloblastic due to dietary causes] or [goat's milk],ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191150003,Folate deficiency anaemia due to liver disorders,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191154007,Combined B12 and folate deficiency anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191210005,Primary cold-type haemolytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191217008,Mechanical haemolytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191218003,Toxic haemolytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191248000,Aplastic anaemia caused by toxic cause,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191251007,Transient hypoplastic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191256002,Idiopathic aplastic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,191277004,Normocytic anaemia due to unspecified cause,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,199244000,Anaemia during pregnancy - baby delivered,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,206434001,Late anaemia of newborn due to isoimmunisation,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,234339009,Macrocytosis - no anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,234340006,Iron deficiency without anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,234347009,Anaemia of systemic disease,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,234349007,Microcytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,234360003,Vegan anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,234402007,Chronic non-spherocytic haemolytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,266888008,Family history: Anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,267513007,Deficiency anaemias,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,267553005,Microcytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,267554004,Deficiency anaemias excl. iron,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,271737000,Anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,275538002,History of anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,276578004,Physiological anaemia of infancy,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,300980002,Normocytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,307726001,Anaemia in ovarian carcinoma,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,309742004,Drug-induced autoimmune haemolytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,310647000,Anaemia secondary to renal failure,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,413533008,Anaemia due to chronic blood loss,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,413603009,Autoimmune haemolytic anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,417425009,Sickle cell anaemia with crisis,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,441482006,History of sickle cell anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,221241000000101,Hypoplastic haemolytic and renal anaemia drugs Band 2,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,389601000000102,[X]Anaemia in other chronic diseases classified elsewhere,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,421261000000104,"[X]Vitamin B12, folic acid and other anti-megaloblastic anaemia preparations causing adverse effects in therapeutic use",ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,579711000000100,Other specified megaloblastic anaemia NEC,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,668381000000100,Anaemia unspecified,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,820601000000103,Refractory anaemia with multilineage dysplasia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
"ERYTHROPOIETIN ANALOGUES (EPOETIN ALPHA, EPOETIN BETA, DARBEPOETIN)",Cancer treatment-induced anaemia,TA142,anaemia,866381000000109,Recurrent anaemia,ERYTHROPOIETIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|GENERAL MEDICINE
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,832007,Moderate major depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,15639000,"Moderate major depression, single episode",ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,18818009,Moderate recurrent major depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,19527009,"Major depression, single episode, in full remission",ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,26141007,ST segment depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,28475009,Severe recurrent major depression with psychotic features,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,33135002,Recurrent major depression in partial remission,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,36474008,Severe recurrent major depression without psychotic features,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,36923009,"Major depression, single episode",ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,39540007,Congenital depression in skull,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,40379007,Mild recurrent major depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,46244001,Recurrent major depression in complete remission,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,58703003,Postpartum depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,70747007,"Major depression single episode, in partial remission",ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,73867007,Psychotic depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,75084000,Severe major depression without psychotic features,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,76441001,"Severe major depression, single episode, without psychotic features",ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,79298009,"Mild major depression, single episode",ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,82218004,Postoperative depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,83458005,Agitated depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,87227007,Cerebral depression in newborn,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,87414006,Reactive depression (situational),ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,87512008,Mild major depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,160329001,Family history of depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,160403000,Family history: Puerperal depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,161104007,Manic-depression association member,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,171207006,Depression screening,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,191455000,Presenile dementia with depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,191459006,Senile dementia with depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,191466007,Arteriosclerotic dementia with depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,191599006,Endogenous depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,191616006,Recurrent depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,191627008,"Bipolar affective disorder, current episode depression",ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,191676002,Psychotic reactive depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,191740008,Neurotic depression reactive type,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,192079006,Postviral depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,192080009,Chronic depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,231485007,Post-schizophrenic depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,231499006,Endogenous depression first episode,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,231500002,Masked depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,231504006,Anxiety depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,233928007,Myocardial depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,237350002,Severe postnatal depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,247802007,Depression worse later in day,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,251245007,PR depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,255339005,Depression - motion,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,263923006,Vasodepression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,268753005,Depression - postnatal,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,273306008,Beck depression inventory,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,273333007,Brief depression rating scale,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,273362008,Child depression scale,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,273402009,Depression anxiety scale,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,273403004,Depression self rating scale,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,273441006,EPDS - Edinburgh postnatal depression scale,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,273481004,Geriatric depression score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,273503001,HAMD - Hamilton rating scale for depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,273524006,Hospital anxiety and depression scale,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,274948002,Endogenous depression - recurrent,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,300706003,Endogenous depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,310495003,[X]Mild depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,310496002,Moderate depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,310497006,Severe depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,395072006,Postnatal depression counseling,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,401174001,Depression management program,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,401319005,Hospital Anxiety and Depression scale: anxiety score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,401320004,Hospital Anxiety and Depression scale: depression score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,413169006,On depression register,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,413170007,Removed from depression register,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,413972000,Depression annual review,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,413973005,Depression interim review,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,413974004,Depression medication review,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,416619008,Depression anxiety stress scales anxiety score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,416954004,Depression anxiety stress scales depression score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,425402008,GDS - Geriatric depression score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,444949001,GDS (geriatric depression scale) 4 item score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,445064009,GDS (geriatric depression scale) original long form score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,445676008,Assessment using GDS (geriatric depression scale) short form,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,446053003,BDI (Beck depression inventory) score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,446087008,Montgomery-Asberg depression rating scale,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,449413009,Decline in Edinburgh postnatal depression scale score at 8 months,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,450320001,EPDS (Edinburgh postnatal depression scale) score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,450714000,Severe major depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,473126001,Suspected depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,698569004,Postnatal depression not discussed,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,700143000,No history of depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,715252007,Depression screening using Patient Health Questionnaire Nine Item score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718316006,BASDEC (Brief Assessment Schedule Depression Cards) score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718366000,Beck Depression Inventory II score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718655001,Revised Children's Anxiety and Depression Scale Major Depressive Disorder score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718656000,RCADS (Revised Children's Anxiety and Depression Scale) generalized anxiety score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718657009,RCADS (Revised Children's Anxiety and Depression Scale) Obsessive Compulsive Disorder subscale score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718658004,RCADS (Revised Children's Anxiety and Depression Scale) Panic Disorder subscale score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718660002,Revised Children's Anxiety and Depression Scale social phobia score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718661003,Revised Children's Anxiety and Depression Scale total anxiety score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718662005,Revised Children's Anxiety and Depression Scale total anxiety and depression score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718666008,Revised Children's Anxiety and Depression Scale Parent Version generalized anxiety score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718668009,RCADS (Revised Children's Anxiety and Depression Scale) Parent Version Panic Disorder subscale score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718669001,RCADS (Revised Children's Anxiety and Depression Scale) Parent Version separation anxiety score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718670000,Revised Children's Anxiety and Depression Scale Parent Version social phobia score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718671001,RCADS (Revised Children's Anxiety and Depression Scale) Parent Version total anxiety score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718672008,RCADS (Revised Children's Anxiety and Depression Scale) Parent Version total anxiety and depression score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,718738005,Revised Children's Anxiety and Depression Scale,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,720453001,Moderately severe major depression single episode,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,720834000,Depression screening declined,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,761880008,HAM-D (Hamilton Rating Scale for Depression) score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,763265004,Montgomery-Asberg Depression Rating Scale score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,765176007,Psychosis and severe depression co-occurrent and due to bipolar affective disorder,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,788120007,Antenatal depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,870191006,Follow up for depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1153570009,Treatment resistant depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,251000119105,"Severe major depression, single episode",ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,281000119103,Severe recurrent major depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,10211000132109,Perinatal depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,104851000119103,Postpartum major depression in remission,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,112001000119100,Positive screening for depression on Patient Health Questionnaire 9,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,112011000119102,Negative screening for depression on Patient Health Questionnaire 9,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,143391000000100,QOF (Quality and Outcomes Framework) depression quality indicator-related care invitation using preferred method of communication,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,149631000000108,Digital cognitive behavioural therapy for depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,166291000000108,Depression enhanced services administration,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,166481000000107,Depression enhanced service completed,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,196381000000100,Depression resolved,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,199111000000100,Referral for guided self-help for depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,200971000000100,Depression screening using questions,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,206341000000108,Discussion about maternal wellbeing - postnatal depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,248641000000109,BASDEC - Brief Assessment Schedule Depression Cards,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,286711000000107,Counseling for depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,311611000000104,History of postnatal depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,361761000000106,On full dose long term treatment for depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,713831000000108,Depression monitoring administration,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,715831000000109,Excepted from depression quality indicators - informed dissent,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,716421000000103,Depression monitoring telephone invitation,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,716681000000100,Depression monitoring second letter,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,716831000000103,Excepted from depression quality indicators - patient unsuitable,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,716961000000102,Depression monitoring third letter,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,717211000000107,Depression monitoring first letter,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,717261000000109,Depression monitoring verbal invitation,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,792491000000100,Assessment using Whooley depression screen,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,803351000000106,Whooley depression screen score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,814191000000100,Referral to postnatal depression group,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,821611000000108,EQ-5D-5L (EuroQol five dimension five level) anxiety depression score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,883491000000106,Did not attend depression review,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,933441000000101,Referral for guided self-help for depression declined,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,987331000000104,Current View Provisional Problem Description item 9 score - depression/low mood,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,988671000000106,HADS (Hospital Anxiety and Depression Scale) declined,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1038261000000100,Maternal postnatal depression,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1057351000000106,Signposting to depression self-help group,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1083051000000106,Depression monitoring invitation email,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1083071000000102,Depression monitoring invitation SMS (short message service) text message,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1086661000000108,"Reactive depression, prolonged single episode",ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1089511000000100,Recurrent depression with current severe episode and psychotic features,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1110911000000106,QOF (Quality and Outcomes Framework) depression quality indicator-related care invitation,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1364401000000101,RCADS-P (Revised Children's Anxiety and Depression Scale Parent Version) Major Depression T-score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1364411000000104,Revised Children's Anxiety and Depression Scale Parent Version Generalized Anxiety T-score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1364421000000105,Revised Children's Anxiety and Depression Scale Parent Version Obsessive-Compulsive T-score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1364431000000107,Revised Children's Anxiety and Depression Scale Parent Version Panic Disorder T-score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1364441000000103,RCADS-P (Revised Children's Anxiety and Depression Scale Parent Version) Separation Anxiety T-score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1364451000000100,RCADS-P (Revised Children's Anxiety and Depression Scale Parent Version) Social Phobia T-score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1364461000000102,RCADS (Revised Children's Anxiety and Depression Scale) Major Depression T-score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1364481000000106,RCADS (Revised Children's Anxiety and Depression Scale) Obsessive-Compulsive T-score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1364491000000108,Revised Children's Anxiety and Depression Scale Panic Disorder T-score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1364501000000102,Revised Children's Anxiety and Depression Scale Separation Anxiety T-score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1364511000000100,Revised Children's Anxiety and Depression Scale Social Phobia T-score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1854961000000104,Revised Children's Anxiety and Depression Scale-25 Parent Version Total Depression score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ESKETAMINE NASAL SPRAY,Treatment-resistant depression,TA854,depression,1976801000000106,Revised Children's Anxiety and Depression Scale Total Anxiety and Depression T-score,ESKETAMINE,MENTAL HEALTH,MENTAL HEALTH
ETANERCEPT,Ankylosing spondylitis,TA383,ankylosing spondylitis,162930007,On examination - ankylosing spondylitis chest deformity,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Ankylosing spondylitis,TA383,ankylosing spondylitis,239805001,Juvenile ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Ankylosing spondylitis,TA383,ankylosing spondylitis,239810002,Ankylosing spondylitis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Ankylosing spondylitis,TA383,ankylosing spondylitis,239811003,Ankylosing spondylitis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Ankylosing spondylitis,TA383,ankylosing spondylitis,394990003,Family history: Ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Ankylosing spondylitis,TA383,ankylosing spondylitis,429712009,Bath Ankylosing Spondylitis Disease Activity Index,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Ankylosing spondylitis,TA383,ankylosing spondylitis,441562009,Bath Ankylosing Spondylitis Disease Activity Index score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Ankylosing spondylitis,TA383,ankylosing spondylitis,441680005,BASFI (Bath Ankylosing Spondylitis Functional Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Ankylosing spondylitis,TA383,ankylosing spondylitis,441930001,BASMI (Bath Ankylosing Spondylitis Metrology Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,602001,Epidemic polyarthritis and exanthema,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,3723001,Inflammatory arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,9350004,Arthritis due to inflammatory bowel disease,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,9467007,Meningococcal arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,11939005,Acute arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,14175009,Arthritis due to rheumatic fever,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,16935003,Allergic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,19431000,Infective arthritis caused by Rubella virus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,19514005,Arthritis mutilans,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,20358003,Septic arthritis of ankle,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,22193007,Osteoarthritis of joint of hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,28880005,Rheumatoid arthritis with carditis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,33937009,Arthritis in Lyme disease,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,33952002,Localised osteoarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,34934005,Septic arthritis of multiple sites,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,35908007,Chronic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,36678001,Septic arthritis of shoulder region,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,37895003,Osteoarthritis of first carpometacarpal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,39838007,Ochronotic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,48245008,Bacterial arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,50921008,Periarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,51646002,Streptococcal arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,61112000,Septic arthritis of hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,61126009,Infective arthritis of multiple sites,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,65323003,Senile arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,67148009,Arthritis of great toe due to gout,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,67224007,Reactive arthritis triad,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,71299003,Salmonella arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,74391003,Pauciarticular onset juvenile chronic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,75822003,Acute juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,77888002,Menopausal arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,80813006,Haemophilic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,82300000,Osteoarthritis of ankle and/or foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,84172003,Spondarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,111242007,Periarthritis of wrist,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,156370009,Psoriatic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,160413008,Family history: Rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,160414002,Family history: Osteoarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,161567008,History of rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,161568003,History of osteoarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,171238007,Arthritis screening,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,171239004,Rheum arthritis screening test,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,190920002,Hyperuricemia without signs of inflammatory arthritis and tophaceous disease,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,193250002,Myopathy due to rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201466005,Staphylococcal arthritis and polyarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201467001,Pneumococcal arthritis and polyarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201500003,Reactive arthritis of joint of hand due to and following dysentery,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201504007,Reactive arthritis of joint of multiple sites due to and following dysentery,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201558003,Reactive arthritis of glenohumeral joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201559006,Reactive arthritis of sternoclavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201560001,Reactive arthritis of acromioclavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201561002,Reactive arthritis of joint of elbow,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201564005,Reactive arthritis of metacarpophalangeal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201567003,Reactive arthritis of joint of hip,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201568008,Reactive arthritis of sacroiliac joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201569000,Reactive arthritis of joint of knee,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201571000,Reactive arthritis of joint of ankle,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201572007,Reactive arthritis of subtalar joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201573002,Reactive arthritis of talonavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201575009,Reactive arthritis of first metatarsophalangeal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201576005,Reactive arthritis of lesser metatarsophalangeal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201577001,Reactive arthritis of interphalangeal joint of toe,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201666003,Gouty arthritis of hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201667007,Gouty arthritis of pelvic region and thigh,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201669005,Gouty arthritis of ankle and/or foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201752004,"Arthritis associated with other disease, knee",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201764007,Rheumatoid arthritis of cervical spine,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201766009,Rheumatoid arthritis of shoulder,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201769002,Rheumatoid arthritis of elbow,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201771002,Rheumatoid arthritis of wrist,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201775006,Rheumatoid arthritis of hip,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201777003,Rheumatoid arthritis of knee,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201779000,Rheumatoid arthritis of ankle,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201780002,Rheumatoid arthritis of subtalar joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201791009,Flare of rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201805000,Juvenile arthritis in Crohn disease,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201819000,Generalised osteoarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201821005,(Heberdens' nodes) or (Bouchards' nodes) or (generalized osteoarthritis of the hand),ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201831003,"Localized, primary osteoarthritis of the shoulder region",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201835007,"Localized, primary osteoarthritis of the pelvic region and thigh",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201837004,"Localised, primary osteoarthritis of the ankle and foot",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201849003,"Localised, secondary osteoarthritis of the shoulder region",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201852006,"Localised, secondary osteoarthritis of the hand",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201855008,"Localized, secondary osteoarthritis of the ankle and/or foot",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201889009,"Osteoarthritis NOS, of the upper arm",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201890000,Wrist osteoarthritis NOS,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201891001,Thumb osteoarthritis NOS,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201892008,Osteoarthritis NOS: [pelvic region and/or thigh] or [hip],ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201893003,Knee osteoarthritis NOS,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201894009,"Osteoarthritis NOS, of ankle and foot",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201964002,Allergic arthritis of the shoulder region,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201967009,Allergic arthritis of the hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201970008,Allergic arthritis of the ankle and foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201972000,Allergic arthritis of multiple sites,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201977006,Climacteric arthritis of the shoulder region,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201980007,Climacteric arthritis of the hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201983009,Climacteric arthritis of the ankle and foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,201985002,Climacteric arthritis of multiple sites,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,202031002,Generalised arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,202033004,Unspecified monoarthritis (& [coxitis]),ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,202046009,Arthritis secondary to malignancy,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,202655008,Osteoarthritis of spine,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,236690002,Urethritis due to reactive arthritis triad,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,236744002,Circinate balanitis co-occurrent with reactive arthritis triad,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,237876008,Arthritis secondary to amyloidosis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239777004,Septic arthritis of knee,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239778009,Septic arthritis of wrist,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239779001,Septic arthritis of elbow,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239780003,Infective arthritis caused by virus,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239783001,Arthritis occurring after infection,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239785008,Reactive arthritis due to and following dysentery,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239787000,Post-tuberculous reactive arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239791005,Seropositive rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239792003,Seronegative rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239796000,Juvenile arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239797009,Early onset pauciarticular chronic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239799007,Early onset polyarticular juvenile chronic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239802003,Juvenile psoriatic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239807009,Juvenile reactive arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239808004,Juvenile reactive arthritis triad,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239809007,Juvenile arthritis of inflammatory bowel disease,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239814006,Seronegative arthritis secondary to inflammatory bowel disease,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239819001,Undifferentiated oligoarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239820007,Undifferentiated monoarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239821006,Secondary inflammatory arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239828000,Basic calcium phosphate arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239831004,Calcific periarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239834007,Pyrophosphate arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239835008,Idiopathic pyrophosphate arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239836009,Secondary pyrophosphate arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239842008,Monosodium urate arthritis and periarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239849004,Intra-articular steroid-induced arthritis and periarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239851000,Cholesterol-related arthritis and periarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239863005,Osteoarthritis of spinal facet joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239866002,Osteoarthritis of elbow,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239868001,Osteoarthritis of finger,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239874001,Osteoarthritis of ankle,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239877008,Osteoarthritis of first MTPJ (metatarsophalangeal joint),ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,239878003,Osteoarthritis of toe joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,267878000,Septic arthritis of upper arm,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,267879008,Pyogenic arthritis of the forearm,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,267880006,Septic arthritis of the pelvic region and thigh,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,267881005,Septic arthritis of lower leg,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,267882003,Septic arthritis of the ankle and/or foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,267889007,Generalized osteoarthritis of the hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,267890003,"Localised, secondary osteoarthritis of the pelvic region and thigh",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,267891004,"Localized osteoarthritis, unspecified, of the pelvic region and thigh",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,268054009,Osteoarthritis of multiple joints,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,274135002,Arthritis/arthrosis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,275134007,Family history: Arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,275554004,History of arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,275902004,Rheumatoid arthritis monitoring,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,275920008,Arthritis monitoring,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,276653007,Parvovirus arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,287006005,Rheumatoid arthritis of multiple joints,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,287007001,Rheumatoid arthritis of hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,300028009,Drainage of septic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,308143008,Seropositive erosive rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,313257005,"Localized, primary osteoarthritis of the wrist",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,313258000,"Localised, primary osteoarthritis of toe",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,313259008,"Localized, primary osteoarthritis of elbow",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,361198004,Arthritis secondary to sarcoidosis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,371081002,Arthritis of knee,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,372939007,Pyogenic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,372941008,Septic arthritis of hip,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,373623009,Osteoarthritis of glenohumeral joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,394991004,Flare of osteoarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,396234004,Septic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,399112009,Seronegative arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,399114005,Duplay's periarthritis syndrome,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,399923009,Rheumatoid arthritis with arteritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,400054000,Rheumatoid arthritis with vasculitis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,410502007,Juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,410793008,Chronic arthritis of juvenile onset,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,410795001,Juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,410797009,"Juvenile chronic arthritis, polyarticular seronegative",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,410798004,Oligoarticular juvenile idiopathic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,416956002,Undifferentiated inflammatory polyarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,417180005,Undifferentiated inflammatory arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,417373000,Inflammatory polyarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,422565003,Post-infective polyarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,423515003,Post-infective arthritis of joint of foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,429192004,Rheumatoid arthritis of foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,429459001,Arthritis of acromioclavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,430543001,Family history of psoriasis with psoriatic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,431956005,Suspected inflammatory arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,439656005,Arthritis of elbow,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,443524000,Secondary osteoarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,446165001,HOOS - hip disability and osteoarthritis outcome score,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,446478005,AIMS (arthritis impact measurement scale) score,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,448394006,Arthritis of foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,450521003,Osteoarthritis of patellofemoral joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,698475006,Monoarthritis of hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,699462004,Monoarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,700324005,Osteoarthritis of talonavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,723116002,Axial spondyloarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,724606001,Peripheral spondyloarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,735599007,Rheumatoid arthritis with erosion of joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,782845000,Knee Injury and Osteoarthritis Outcome Score,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1162304008,Oligoarticular osteoarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1303835007,Arthritis of shoulder region joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1343601009,OA (osteoarthritis) of spine,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1343603007,Osteoarthritis of thoracic spine,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1343604001,Cervical osteoarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1343605000,Osteoarthritis of lumbar spine,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1771000119109,Arthritis of wrist,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,6011000119108,Transient arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,143441000119108,Rheumatoid arthritis in remission,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,230771000000108,Delivery of rehabilitation for osteoarthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,323301000119109,Osteoarthritis of left knee joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,323311000119107,Osteoarthritis of right hip joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,637091000000105,"Osteoarthritis NOS, of the lower leg",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,666441000000103,"Osteoarthritis NOS, of shoulder region",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,666451000000100,"Osteoarthritis NOS, other specified site",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,805881000000109,Exception reporting - osteoarthritis quality indicators,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,805901000000107,Excepted from osteoarthritis quality indicators - patient unsuitable,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,805921000000103,Excepted from osteoarthritis quality indicators - informed dissent,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,847261000000104,Rheumatoid arthritis annual review,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,850791000000102,Osteoarthritis of sternoclavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1016811000000108,Rheumatoid arthritis screening test,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1029271000000101,Rheumatoid arthritis latex test,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1073781000119104,Rheumatoid arthritis of right foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1073791000119101,Rheumatoid arthritis of right hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1074801000119103,Arthritis of carpometacarpal joint of left thumb,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1074881000119106,Arthritis of left ankle,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,12236561000119100,Arthritis of finger of left hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,12236601000119100,Arthritis of finger of right hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Arthritis (juvenile idiopathic),TA035,arthritis,16044751000119106,"Juvenile idiopathic arthritis, polyarthritis",ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Plaque psoriasis in children and young people,TA455,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),ADALIMUMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Plaque psoriasis in children and young people,TA455,plaque psoriasis,402307000,Chronic large plaque psoriasis,ADALIMUMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Plaque psoriasis in children and young people,TA455,plaque psoriasis,402310007,Chronic stable plaque psoriasis,ADALIMUMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,9014002,Psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,16341002,Parapsoriasis lichenoides,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,25847004,Sebopsoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,37042000,Guttate psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,38360005,Acute generalized pustular psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,81271001,Localised pustular psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,88233000,Parapsoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,160408009,Family history: Psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,161562002,History of psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,200962007,Psoriasis annularis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,200963002,Psoriasis circinata,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,200964008,Psoriasis diffusa,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,200965009,Discoid psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,200966005,Psoriasis geographica,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,200967001,Psoriasis gyrata,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,200968006,Psoriasis inveterata,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,200969003,Ostraceous psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,200970002,Psoriasis palmaris,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,200971003,Psoriasis plantaris,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,200972005,Psoriasis punctata,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,200973000,Pustular psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,200974006,Psoriasis universalis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,200977004,Exfoliative psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,200982006,Parapsoriasis herpetiformis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,200983001,Parapsoriasis en gouttes,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,200984007,Parapsoriasis papulata,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,200985008,Parapsoriasis varioliformis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,238600001,Inverse psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,238601002,Unstable psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,238602009,Eczematous psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,238603004,Eczematised psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,238608008,Psoriasis of scalp,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,238609000,Kobner psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,238612002,Acute generalized pustular psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,238614001,Pustular psoriasis in children,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,238617008,Circinate and annular pustular psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,239803008,Juvenile psoriatic arthritis with psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,267851002,Parapsoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,402307000,Chronic large plaque psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,402310007,Chronic stable plaque psoriasis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,430543001,Family history of psoriasis with psoriatic arthritis,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,845091000000108,Education for psoriasis care,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,866311000000102,PASI - psoriasis area and severity index,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,866341000000101,PASI (psoriasis area and severity index) score,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriasis,TA103,psoriasis,1853821000000104,Psoriasis Epidemiology Screening Tool total score,EFALUZIMAB,DERMATOLOGY,DERMATOLOGY
ETANERCEPT,Psoriatic arthritis,TA104,psoriatic arthritis,156370009,Psoriatic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ETANERCEPT,Psoriatic arthritis,TA199,psoriatic arthritis,156370009,Psoriatic arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ETANERCEPT,Psoriatic arthritis,TA104,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ETANERCEPT,Psoriatic arthritis,TA199,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ETANERCEPT,Psoriatic arthritis,TA104,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ETANERCEPT,Psoriatic arthritis,TA199,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ETANERCEPT,Psoriatic arthritis,TA104,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ETANERCEPT,Psoriatic arthritis,TA199,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ETANERCEPT,Psoriatic arthritis,TA104,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ETANERCEPT,Psoriatic arthritis,TA199,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ETANERCEPT,Psoriatic arthritis,TA104,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ETANERCEPT,Psoriatic arthritis,TA199,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis,TA036,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,162930007,On examination - ankylosing spondylitis chest deformity,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,239805001,Juvenile ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,239810002,Ankylosing spondylitis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,239811003,Ankylosing spondylitis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,394990003,Family history: Ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,429712009,Bath Ankylosing Spondylitis Disease Activity Index,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,441562009,Bath Ankylosing Spondylitis Disease Activity Index score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,441680005,BASFI (Bath Ankylosing Spondylitis Functional Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,441930001,BASMI (Bath Ankylosing Spondylitis Metrology Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
ETANERCEPT,Treating juvenile idiopathic arthritis,TA373,juvenile idiopathic arthritis,410798004,Oligoarticular juvenile idiopathic arthritis,ABATECEPT,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS
ETANERCEPT,Treating juvenile idiopathic arthritis,TA373,juvenile idiopathic arthritis,16044751000119106,"Juvenile idiopathic arthritis, polyarthritis",ABATECEPT,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT MONOTHERAPY (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETANERCEPT WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETELCALCETIDE,Secondary hyperparathyroidism,TA448,hyperparathyroidism,36348003,Primary hyperparathyroidism,ETELCALCETIDE,ENDOCRINOLOGY,ENDOCRINOLOGY
ETELCALCETIDE,Secondary hyperparathyroidism,TA448,hyperparathyroidism,66999008,Hyperparathyroidism,ETELCALCETIDE,ENDOCRINOLOGY,ENDOCRINOLOGY
ETELCALCETIDE,Secondary hyperparathyroidism,TA448,hyperparathyroidism,78200003,Tertiary hyperparathyroidism,ETELCALCETIDE,ENDOCRINOLOGY,ENDOCRINOLOGY
ETELCALCETIDE,Secondary hyperparathyroidism,TA448,hyperparathyroidism,91478007,Secondary hyperparathyroidism,ETELCALCETIDE,ENDOCRINOLOGY,ENDOCRINOLOGY
ETELCALCETIDE,Secondary hyperparathyroidism,TA448,hyperparathyroidism,203471008,Brown tumour of hyperparathyroidism,ETELCALCETIDE,ENDOCRINOLOGY,ENDOCRINOLOGY
ETELCALCETIDE,Secondary hyperparathyroidism,TA448,hyperparathyroidism,237653008,Familial hyperparathyroidism,ETELCALCETIDE,ENDOCRINOLOGY,ENDOCRINOLOGY
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETIDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,22193007,Osteoarthritis of joint of hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,33952002,Localised osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,37895003,Osteoarthritis of first carpometacarpal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,82300000,Osteoarthritis of ankle and/or foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,160414002,Family history: Osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,161567008,History of rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,161568003,History of osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201819000,Generalised osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201821005,(Heberdens' nodes) or (Bouchards' nodes) or (generalized osteoarthritis of the hand),CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201831003,"Localized, primary osteoarthritis of the shoulder region",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201835007,"Localized, primary osteoarthritis of the pelvic region and thigh",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201837004,"Localised, primary osteoarthritis of the ankle and foot",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201849003,"Localised, secondary osteoarthritis of the shoulder region",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201852006,"Localised, secondary osteoarthritis of the hand",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201855008,"Localized, secondary osteoarthritis of the ankle and/or foot",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201889009,"Osteoarthritis NOS, of the upper arm",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201890000,Wrist osteoarthritis NOS,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201891001,Thumb osteoarthritis NOS,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201892008,Osteoarthritis NOS: [pelvic region and/or thigh] or [hip],CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201893003,Knee osteoarthritis NOS,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201894009,"Osteoarthritis NOS, of ankle and foot",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,202655008,Osteoarthritis of spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239863005,Osteoarthritis of spinal facet joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239866002,Osteoarthritis of elbow,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239868001,Osteoarthritis of finger,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239874001,Osteoarthritis of ankle,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239877008,Osteoarthritis of first MTPJ (metatarsophalangeal joint),CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239878003,Osteoarthritis of toe joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,267889007,Generalized osteoarthritis of the hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,267890003,"Localised, secondary osteoarthritis of the pelvic region and thigh",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,267891004,"Localized osteoarthritis, unspecified, of the pelvic region and thigh",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,268054009,Osteoarthritis of multiple joints,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,313257005,"Localized, primary osteoarthritis of the wrist",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,313258000,"Localised, primary osteoarthritis of toe",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,313259008,"Localized, primary osteoarthritis of elbow",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,373623009,Osteoarthritis of glenohumeral joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,394991004,Flare of osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,443524000,Secondary osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,446165001,HOOS - hip disability and osteoarthritis outcome score,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,450521003,Osteoarthritis of patellofemoral joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,700324005,Osteoarthritis of talonavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,782845000,Knee Injury and Osteoarthritis Outcome Score,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1162304008,Oligoarticular osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343601009,OA (osteoarthritis) of spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343603007,Osteoarthritis of thoracic spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343604001,Cervical osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343605000,Osteoarthritis of lumbar spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,230771000000108,Delivery of rehabilitation for osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,323301000119109,Osteoarthritis of left knee joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,323311000119107,Osteoarthritis of right hip joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,637091000000105,"Osteoarthritis NOS, of the lower leg",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,666441000000103,"Osteoarthritis NOS, of shoulder region",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,666451000000100,"Osteoarthritis NOS, other specified site",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,805881000000109,Exception reporting - osteoarthritis quality indicators,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,805901000000107,Excepted from osteoarthritis quality indicators - patient unsuitable,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,805921000000103,Excepted from osteoarthritis quality indicators - informed dissent,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,850791000000102,Osteoarthritis of sternoclavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ETODOLAC,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
EVEROLIMUS,Advanced renal cell carcinoma (2nd line),TA219,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
EVEROLIMUS,Advanced renal cell carcinoma (2nd line),TA219,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
EVEROLIMUS,Advanced renal cell carcinoma (2nd line),TA219,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
EVEROLIMUS,Advanced renal cell carcinoma (2nd line),TA219,renal cell carcinoma,733608000,Papillary renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
EVEROLIMUS,Advanced renal cell carcinoma (2nd line),TA219,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
EVEROLIMUS,Advanced renal cell carcinoma (2nd line),TA219,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
EVEROLIMUS,Advanced renal cell carcinoma (2nd line),TA219,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
EVEROLIMUS,Advanced renal cell carcinoma after previous treatment,TA432,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
EVEROLIMUS,Advanced renal cell carcinoma after previous treatment,TA432,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
EVEROLIMUS,Advanced renal cell carcinoma after previous treatment,TA432,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
EVEROLIMUS,Advanced renal cell carcinoma after previous treatment,TA432,renal cell carcinoma,733608000,Papillary renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
EVEROLIMUS,Advanced renal cell carcinoma after previous treatment,TA432,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
EVEROLIMUS,Advanced renal cell carcinoma after previous treatment,TA432,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
EVEROLIMUS,Advanced renal cell carcinoma after previous treatment,TA432,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
EVEROLIMUS,Kidney transplant in adults,TA481,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
EVEROLIMUS,Kidney transplant in adults,TA481,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
EVEROLIMUS,Kidney transplant in adults,TA481,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
EVEROLIMUS,Kidney transplant in adults,TA481,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
EVEROLIMUS,Kidney transplant in adults,TA481,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
EVEROLIMUS,Kidney transplant in adults,TA481,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
EVEROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
EVEROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
EVEROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
EVEROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
EVEROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
EVEROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
EVEROLIMUS,Unresectable or metastatic neuroendocrine tumours in people with progressive disease,TA449,neuroendocrine tumour,48554007,Enterochromaffin cell neuroendocrine tumour,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY
EVEROLIMUS,Unresectable or metastatic neuroendocrine tumours in people with progressive disease,TA449,neuroendocrine tumour,60346004,Non-functioning pancreatic neuroendocrine tumour,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY
EVEROLIMUS,Unresectable or metastatic neuroendocrine tumours in people with progressive disease,TA449,neuroendocrine tumour,707594002,Bronchial neuroendocrine tumour,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY
EVEROLIMUS,Unresectable or metastatic neuroendocrine tumours in people with progressive disease,TA449,neuroendocrine tumour,1287573002,Well-differentiated neuroendocrine tumour of bronchus,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY
EVEROLIMUS,Unresectable or metastatic neuroendocrine tumours in people with progressive disease,TA449,neuroendocrine tumour,1290068000,Well-differentiated neuroendocrine tumour of rectum,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,134405005,Suspected breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,160287004,FH: Breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,268547008,Screening for breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,429740004,Family history of breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,431330007,Family history of breast cancer 1 gene mutation,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,431331006,Family history of breast cancer 2 gene mutation,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,706970001,TNBC - Triple-negative breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,94361000000105,Breast cancer detected by national screening programme,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,276341000000100,Fast track referral for suspected breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,838351000000107,Education about risk of breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,874291000000100,QCancer breast cancer risk,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy,TA295,breast cancer,1035841000000108,Lymphoedema following breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,134405005,Suspected breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,160287004,FH: Breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,268547008,Screening for breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,429740004,Family history of breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,431330007,Family history of breast cancer 1 gene mutation,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,431331006,Family history of breast cancer 2 gene mutation,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,706970001,TNBC - Triple-negative breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,94361000000105,Breast cancer detected by national screening programme,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,276341000000100,Fast track referral for suspected breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,838351000000107,Education about risk of breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,874291000000100,QCancer breast cancer risk,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVEROLIMUS IN COMBINATION WITH EXEMESTANE,Treating advanced breast cancer after endocrine therapy,TA421,breast cancer,1035841000000108,Lymphoedema following breast cancer,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EVOLOCUMAB,Treating primary hypercholesterolaemia and mixed dyslipidaemia,TA394,primary hypercholesterolaemia,238076009,Primary hypercholesterolaemia,EVOLOCUMAB,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EXEMESTANE,Breast cancer (early),TA112,breast cancer,134405005,Suspected breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EXEMESTANE,Breast cancer (early),TA112,breast cancer,160287004,FH: Breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EXEMESTANE,Breast cancer (early),TA112,breast cancer,268547008,Screening for breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EXEMESTANE,Breast cancer (early),TA112,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EXEMESTANE,Breast cancer (early),TA112,breast cancer,429740004,Family history of breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EXEMESTANE,Breast cancer (early),TA112,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EXEMESTANE,Breast cancer (early),TA112,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EXEMESTANE,Breast cancer (early),TA112,breast cancer,706970001,TNBC - Triple-negative breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EXEMESTANE,Breast cancer (early),TA112,breast cancer,94361000000105,Breast cancer detected by national screening programme,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EXEMESTANE,Breast cancer (early),TA112,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EXEMESTANE,Breast cancer (early),TA112,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EXEMESTANE,Breast cancer (early),TA112,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EXEMESTANE,Breast cancer (early),TA112,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EXEMESTANE,Breast cancer (early),TA112,breast cancer,838351000000107,Education about risk of breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EXEMESTANE,Breast cancer (early),TA112,breast cancer,874291000000100,QCancer breast cancer risk,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EXEMESTANE,Breast cancer (early),TA112,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EXEMESTANE,Breast cancer (early),TA112,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EXEMESTANE,Breast cancer (early),TA112,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
EXEMESTANE,Breast cancer (early),TA112,breast cancer,1035841000000108,Lymphoedema following breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR METFORMIN AND A THIAZOLIDINEDIONE (TRIPLE THERAPY REGIMEN)",Treatment of type 2 diabetes,TA248,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EXENATIDE PROLONGED-RELEASE SUSPENSION FOR INJECTION IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA (DUAL THERAPY REGIMEN),Treatment of type 2 diabetes,TA248,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,EXENATIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,13644009,Hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,160314003,Family history: Hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,238076009,Primary hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,238079002,Familial hypercholesterolaemia - heterozygous,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,238081000,Familial hypercholesterolaemia due to genetic defect of apolipoprotein B-100,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,267432004,Pure hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,267500001,Hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,398036000,Familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,403831006,Familial hypercholesterolaemia due to genetic defect of apolipoprotein B,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,767133009,Compound heterozygous familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,149601000000102,Simon Broome diagnostic criteria for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,149611000000100,Simon Broome diagnostic criteria for familial hypercholesterolaemia result,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,163841000237109,Familial hypercholesterolaemia comprehensive genetic test result,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,163851000237107,Familial hypercholesterolaemia targeted genetic test result,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,204931000237105,Genetic variant causing familial hypercholesterolaemia not detected,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,513831000000107,Possible heterozygous familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,519851000000103,Assessment using Simon Broome diagnostic criteria for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,804641000000101,Dietary surveillance in hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,858671000000107,No FH of hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,867261000000106,Probable familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,872541000000104,Dutch Lipid Clinic Network diagnostic criteria for familial hypercholesterolaemia score,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,925211000000100,Familial hypercholesterolaemia targeted genetic test,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,925221000000106,Familial hypercholesterolaemia comprehensive genetic test,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,1326181000000100,Assessment for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,1326191000000103,Referral for assessment for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,1363961000000109,H/O secondary hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE (IN COMBINATION WITH A STATIN),Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,1365251000000103,Referral for assessment for familial hypercholesterolaemia refused,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,13644009,Hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,160314003,Family history: Hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,238076009,Primary hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,238079002,Familial hypercholesterolaemia - heterozygous,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,238081000,Familial hypercholesterolaemia due to genetic defect of apolipoprotein B-100,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,267432004,Pure hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,267500001,Hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,398036000,Familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,403831006,Familial hypercholesterolaemia due to genetic defect of apolipoprotein B,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,767133009,Compound heterozygous familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,149601000000102,Simon Broome diagnostic criteria for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,149611000000100,Simon Broome diagnostic criteria for familial hypercholesterolaemia result,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,163841000237109,Familial hypercholesterolaemia comprehensive genetic test result,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,163851000237107,Familial hypercholesterolaemia targeted genetic test result,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,204931000237105,Genetic variant causing familial hypercholesterolaemia not detected,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,513831000000107,Possible heterozygous familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,519851000000103,Assessment using Simon Broome diagnostic criteria for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,804641000000101,Dietary surveillance in hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,858671000000107,No FH of hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,867261000000106,Probable familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,872541000000104,Dutch Lipid Clinic Network diagnostic criteria for familial hypercholesterolaemia score,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,925211000000100,Familial hypercholesterolaemia targeted genetic test,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,925221000000106,Familial hypercholesterolaemia comprehensive genetic test,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,1326181000000100,Assessment for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,1326191000000103,Referral for assessment for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,1363961000000109,H/O secondary hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE CO‑ADMINISTERED WITH INITIAL STATIN THERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,1365251000000103,Referral for assessment for familial hypercholesterolaemia refused,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,13644009,Hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,160314003,Family history: Hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,238076009,Primary hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,238079002,Familial hypercholesterolaemia - heterozygous,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,238081000,Familial hypercholesterolaemia due to genetic defect of apolipoprotein B-100,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,267432004,Pure hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,267500001,Hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,398036000,Familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,403831006,Familial hypercholesterolaemia due to genetic defect of apolipoprotein B,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,767133009,Compound heterozygous familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,149601000000102,Simon Broome diagnostic criteria for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,149611000000100,Simon Broome diagnostic criteria for familial hypercholesterolaemia result,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,163841000237109,Familial hypercholesterolaemia comprehensive genetic test result,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,163851000237107,Familial hypercholesterolaemia targeted genetic test result,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,204931000237105,Genetic variant causing familial hypercholesterolaemia not detected,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,513831000000107,Possible heterozygous familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,519851000000103,Assessment using Simon Broome diagnostic criteria for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,804641000000101,Dietary surveillance in hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,858671000000107,No FH of hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,867261000000106,Probable familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,872541000000104,Dutch Lipid Clinic Network diagnostic criteria for familial hypercholesterolaemia score,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,925211000000100,Familial hypercholesterolaemia targeted genetic test,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,925221000000106,Familial hypercholesterolaemia comprehensive genetic test,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,1326181000000100,Assessment for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,1326191000000103,Referral for assessment for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,1363961000000109,H/O secondary hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Primary (heterozygous-familial and non-familial) hypercholesterolaemia,TA132,hypercholesterolaemia,1365251000000103,Referral for assessment for familial hypercholesterolaemia refused,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,13644009,Hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,160314003,Family history: Hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,238076009,Primary hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,238079002,Familial hypercholesterolaemia - heterozygous,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,238081000,Familial hypercholesterolaemia due to genetic defect of apolipoprotein B-100,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,267432004,Pure hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,267500001,Hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,398036000,Familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,403831006,Familial hypercholesterolaemia due to genetic defect of apolipoprotein B,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,767133009,Compound heterozygous familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,149601000000102,Simon Broome diagnostic criteria for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,149611000000100,Simon Broome diagnostic criteria for familial hypercholesterolaemia result,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,163841000237109,Familial hypercholesterolaemia comprehensive genetic test result,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,163851000237107,Familial hypercholesterolaemia targeted genetic test result,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,204931000237105,Genetic variant causing familial hypercholesterolaemia not detected,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,513831000000107,Possible heterozygous familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,519851000000103,Assessment using Simon Broome diagnostic criteria for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,804641000000101,Dietary surveillance in hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,858671000000107,No FH of hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,867261000000106,Probable familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,872541000000104,Dutch Lipid Clinic Network diagnostic criteria for familial hypercholesterolaemia score,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,925211000000100,Familial hypercholesterolaemia targeted genetic test,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,925221000000106,Familial hypercholesterolaemia comprehensive genetic test,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,1326181000000100,Assessment for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,1326191000000103,Referral for assessment for familial hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,1363961000000109,H/O secondary hypercholesterolaemia,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
EZETIMIBE MONOTHERAPY,Treating primary heterozygous-familial and non-familial hypercholesterolaemia,TA385,hypercholesterolaemia,1365251000000103,Referral for assessment for familial hypercholesterolaemia refused,EZETIMIBE,CARDIOLOGY,CARDIOLOGY|ENDOCRINOLOGY|CHEMICAL PATHOLOGY
FARICIMAB,Wet age-related macular degeneration,TA800,macular degeneration,70099003,Familial juvenile macular degeneration syndrome,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
FARICIMAB,Wet age-related macular degeneration,TA800,macular degeneration,193384000,Senile macular degeneration,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
FARICIMAB,Wet age-related macular degeneration,TA800,macular degeneration,267718000,Age-related macular degeneration,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
FARICIMAB,Wet age-related macular degeneration,TA800,macular degeneration,312898002,Myopic macular degeneration,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
FARICIMAB,Wet age-related macular degeneration,TA800,macular degeneration,314427006,Drusen plus pigment change stage macular degeneration,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
FARICIMAB,Wet age-related macular degeneration,TA800,macular degeneration,1296526000,Disciform macular degeneration,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,9386003,Gouty neuritis,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,14763005,Gouty tophus of pinna,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,24595009,Idiopathic gout,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,27277001,Tophus of heart co-occurrent and due to gout,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,43193009,Gouty iritis,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,48440001,Gouty arthropathy,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,67148009,Arthritis of great toe due to gout,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,90560007,Gout,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,160308005,Family history: Gout,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,161451004,History of gout,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,170730005,Gout monitoring,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,170731009,Initial gout assessment,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,170732002,Follow-up gout assessment,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,170733007,Joints gout affected,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,170735000,Date gout treatment started,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,170736004,Date of last gout attack,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,170737008,Gout associated problem,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,170738003,Gout drug side effect,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,170739006,Gout treatment changed,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,170740008,Date gout treatment stopped,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,171190009,Gout screening,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,190828008,Gouty arthropathy,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,190829000,Gouty nephropathy,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,190842000,Chronic tophaceous gout of hand,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,200983001,Parapsoriasis en gouttes,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,201663006,Articular gout of shoulder region,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,201666003,Gouty arthritis of hand,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,201667007,Gouty arthritis of pelvic region and thigh,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,201669005,Gouty arthritis of ankle and/or foot,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,201670006,Articular gout of multiple joints,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,230312006,Aicardi Goutieres syndrome,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,239843003,Secondary gout,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,239844009,Gout secondary to renal impairment,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,239845005,Gout secondary to drug,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,239848007,Gouty bursitis,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,243859006,Gout monitoring status,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,268142006,Pseudogout,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,281362006,Gouty tophus of bursa,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,281363001,Tophus of tendon co-occurrent and due to gout,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,281364007,Gouty tophus of olecranon bursa,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,281365008,Gouty tophus of prepatellar bursa,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,292671009,Drug for the treatment of gout adverse reaction,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,402469004,Gouty tophus,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,428839004,Articular gout of toe,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,770924008,Gout attack,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,427211000000108,[V]Screening for gout,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,924311000000106,Acute exacerbation of gout,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEBUXOSTAT,Chronic hyperuricaemia (in people with gout),TA164,gout,1033961000000104,Gouty tophi of toe,FEBUXOSTAT,RHEUMATOLOGY,RHEUMATOLOGY
FEDRATINIB,Disease-related splenomegaly or symptoms in myelofibrosis,TA756,myelofibrosis,80570006,Acute panmyelosis with myelofibrosis,FEDRATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
FENFLURAMINE,Treating seizures associated with Dravet syndrome,TA808,dravet syndrome,230437002,Dravet Syndrome,FENFLURAMINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
FILGOTINIB,Moderately to severely active ulcerative colitis,TA792,ulcerative colitis,64766004,UC - ulcerative colitis,FILGOTINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
FILGOTINIB,Moderately to severely active ulcerative colitis,TA792,ulcerative colitis,160383003,FH: Ulcerative colitis,FILGOTINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
FILGOTINIB,Moderately to severely active ulcerative colitis,TA792,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,FILGOTINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
FILGOTINIB,Moderately to severely active ulcerative colitis,TA792,ulcerative colitis,275129008,Family history of ulcerative colitis,FILGOTINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
FILGOTINIB,Moderately to severely active ulcerative colitis,TA792,ulcerative colitis,275549008,History of ulcerative colitis,FILGOTINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
FILGOTINIB,Moderately to severely active ulcerative colitis,TA792,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,FILGOTINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
FILGOTINIB,Moderately to severely active ulcerative colitis,TA792,ulcerative colitis,445243001,Left sided ulcerative colitis,FILGOTINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,161567008,History of rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,161567008,History of rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,161567008,History of rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA676,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,161567008,History of rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FILGOTINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA676,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,FILGOTINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINERENONE,Treating chronic kidney disease in type 2 diabetes,TA877,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,FINERENONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,24700007,Multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,160337009,Family history of multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,192926004,Brain stem multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,192928003,Generalised multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,428700003,Primary progressive multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,438511000,Benign multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,700409000,Suspected multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,198491000000106,Multiple sclerosis review,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,515931000000104,Multiple sclerosis review declined,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FINGOLIMOD,Treatment of highly active relapsing-remitting multiple sclerosis,TA254,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,FINGOLIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,17788007,Acute non-lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,22197008,Burkitt cell leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,24072005,Blast cell leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,28950004,Acute promyelocytic leukaemia with,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,32280000,Lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,37810007,Monocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,69077002,Acute basophilic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,87163000,Leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,91857003,Acute lymphoid leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,91861009,"Acute myeloid leukaemia, disease",FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,92811003,Chronic leukaemia in remission,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,92812005,"Chronic leukaemia, disease",FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,92817004,Chronic myeloid leukaemia in remission,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,93142004,Leukaemia in remission,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,110002002,Mast cell leukaemia (clinical),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,110004001,Acute promyelocytic leukaemia (clinical),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,110006004,Prolymphocytic leukaemia (clinical),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,128831004,Chronic myelomonocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,128922003,"Plasma cell leukaemia, morphology",FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,128931003,Leukaemia - category,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,128933000,Chronic leukaemia - category,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,128935007,Lymphoid leukaemia (category),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,160292002,Family history: leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,161436008,History of leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,188726003,Subacute lymphoid leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,188732008,Myeloid leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,188733003,Chronic eosinophilic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,188734009,Chronic neutrophilic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,188768003,Myelomonocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,190055003,Eosinophilic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,277568007,Hairy cell leukaemia variant,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,277569004,Large granular lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,277571004,Mature B-cell leukaemia Burkitt type,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,277602003,Acute megakaryoblastic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,315262009,Suspected leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,359631009,M0 - Acute myeloblastic leukaemia - undifferentiated,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,413440007,Acute lymphoblastic leukaemia - category,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,449386007,Philadelphia chromosome negative chronic myelogenous leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,634651000000103,Other specified leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE (MONOTHERAPY),Leukaemia (lymphocytic),TA119,leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,17788007,Acute non-lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,22197008,Burkitt cell leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,24072005,Blast cell leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,28950004,Acute promyelocytic leukaemia with,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,32280000,Lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,37810007,Monocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,69077002,Acute basophilic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,87163000,Leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,91857003,Acute lymphoid leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,91861009,"Acute myeloid leukaemia, disease",FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,92811003,Chronic leukaemia in remission,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,92812005,"Chronic leukaemia, disease",FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,92817004,Chronic myeloid leukaemia in remission,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,93142004,Leukaemia in remission,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,110002002,Mast cell leukaemia (clinical),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,110004001,Acute promyelocytic leukaemia (clinical),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,110006004,Prolymphocytic leukaemia (clinical),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,128831004,Chronic myelomonocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,128922003,"Plasma cell leukaemia, morphology",FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,128931003,Leukaemia - category,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,128933000,Chronic leukaemia - category,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,128935007,Lymphoid leukaemia (category),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,160292002,Family history: leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,161436008,History of leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,188726003,Subacute lymphoid leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,188732008,Myeloid leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,188733003,Chronic eosinophilic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,188734009,Chronic neutrophilic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,188768003,Myelomonocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,190055003,Eosinophilic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,277568007,Hairy cell leukaemia variant,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,277569004,Large granular lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,277571004,Mature B-cell leukaemia Burkitt type,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,277602003,Acute megakaryoblastic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,315262009,Suspected leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,359631009,M0 - Acute myeloblastic leukaemia - undifferentiated,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,413440007,Acute lymphoblastic leukaemia - category,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,449386007,Philadelphia chromosome negative chronic myelogenous leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,634651000000103,Other specified leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE -  INTRAVENOUS FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,17788007,Acute non-lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,22197008,Burkitt cell leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,24072005,Blast cell leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,28950004,Acute promyelocytic leukaemia with,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,32280000,Lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,37810007,Monocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,69077002,Acute basophilic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,87163000,Leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,91857003,Acute lymphoid leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,91861009,"Acute myeloid leukaemia, disease",FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,92811003,Chronic leukaemia in remission,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,92812005,"Chronic leukaemia, disease",FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,92817004,Chronic myeloid leukaemia in remission,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,93142004,Leukaemia in remission,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,110002002,Mast cell leukaemia (clinical),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,110004001,Acute promyelocytic leukaemia (clinical),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,110006004,Prolymphocytic leukaemia (clinical),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,128831004,Chronic myelomonocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,128922003,"Plasma cell leukaemia, morphology",FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,128931003,Leukaemia - category,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,128933000,Chronic leukaemia - category,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,128935007,Lymphoid leukaemia (category),FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,160292002,Family history: leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,161436008,History of leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,188726003,Subacute lymphoid leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,188732008,Myeloid leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,188733003,Chronic eosinophilic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,188734009,Chronic neutrophilic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,188768003,Myelomonocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,190055003,Eosinophilic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,277568007,Hairy cell leukaemia variant,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,277569004,Large granular lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,277571004,Mature B-cell leukaemia Burkitt type,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,277602003,Acute megakaryoblastic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,315262009,Suspected leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,359631009,M0 - Acute myeloblastic leukaemia - undifferentiated,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,413440007,Acute lymphoblastic leukaemia - category,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,449386007,Philadelphia chromosome negative chronic myelogenous leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,634651000000103,Other specified leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDARABINE - ORAL FORMULATION (2ND LINE),Leukaemia (B-cell chronic lymphocytic),TA029,leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,FLUDARABINE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
FLUDROXYCORTIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUDROXYCORTIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUDROXYCORTIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUDROXYCORTIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUDROXYCORTIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUDROXYCORTIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUOCINOLONE ACETONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUOCINOLONE ACETONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUOCINOLONE ACETONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUOCINOLONE ACETONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUOCINOLONE ACETONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUOCINOLONE ACETONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,4927003,Acute anterior uveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,11226001,Fuchs uveitis syndrome,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,43363007,Posterior uveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,75614007,Panuveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,89114005,Infectious anterior uveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,95707009,Phacotoxic uveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,267619000,Non-infectious anterior uveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,312922007,Uveitis related cystoid macular oedema,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,314029000,Tuberculous uveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,314030005,Post-traumatic uveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,314033007,Secondary open-angle glaucoma with uveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,314493000,Postoperative uveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,370506009,Keratouveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,398155003,Chronic anterior uveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,410494003,Phacoantigenic uveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,410692006,Anterior uveitis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
FLUOCINOLONE ACETONIDE,Recurrent non-infectious uveitis,TA590,uveitis,342151000119100,Acute anterior uveitis of left eye,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|RHEUMATOLOGY
FLUOCINONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUOCINONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUOCINONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUOCINONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUOCINONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUOCINONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUOCORTOLONE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUOCORTOLONE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUOCORTOLONE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUOCORTOLONE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUOCORTOLONE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUOCORTOLONE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUTICASONE PROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUTICASONE PROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUTICASONE PROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUTICASONE PROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUTICASONE PROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUTICASONE PROPIONATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,160270001,No family history of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,161499004,H/O: cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,171405001,Examination for suspected cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,266894000,Family history of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,266995000,History of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,395048001,Cardiovascular disease monitoring not required,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417206009,Cardiovascular disease monitoring,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417287002,Cardiovascular disease interim monitoring,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417322008,Cardiovascular disease annual review,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,429284000,Cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,429785003,Cardiovascular disease health education,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,440358008,Primary prevention of CVD (cardiovascular disease),ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,441829007,Assessment for risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166701000000106,Joint British Societies cardiovascular disease risk,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,302881000000102,Cardiovascular disease annual review declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,383321000000103,Cardiovascular disease risk assessment indicated,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,492581000000108,Cardiovascular disease high risk review declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,492611000000102,Cardiovascular disease high risk review,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,752451000000100,Cardiovascular disease risk assessment by third party,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,837461000000101,High risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,845171000000108,At risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,962871000000107,Aware of overall cardiovascular disease risk,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,990301000000105,Cardiovascular disease risk assessment done,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FLUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,16434071000119108,At increased risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
FOSTAMATINIB,Refractory chronic immune thrombocytopenia,TA759,immune thrombocytopenia,2897005,ITP - immune thrombocytopenia,FOSTAMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
FOSTAMATINIB,Refractory chronic immune thrombocytopenia,TA835,immune thrombocytopenia,2897005,ITP - immune thrombocytopenia,FOSTAMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
FOSTAMATINIB,Refractory chronic immune thrombocytopenia,TA759,immune thrombocytopenia,128091003,Primary ITP (immune thrombocytopenia),FOSTAMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
FOSTAMATINIB,Refractory chronic immune thrombocytopenia,TA835,immune thrombocytopenia,128091003,Primary ITP (immune thrombocytopenia),FOSTAMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
FOSTAMATINIB,Refractory chronic immune thrombocytopenia,TA759,immune thrombocytopenia,240305000,NAIT - neonatal alloimmune thrombocytopenia,FOSTAMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
FOSTAMATINIB,Refractory chronic immune thrombocytopenia,TA835,immune thrombocytopenia,240305000,NAIT - neonatal alloimmune thrombocytopenia,FOSTAMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,4473006,Classical migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,23186000,Menstrual migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,37796009,Migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,56097005,Migraine without aura,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,59292006,Hemiplegic migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,75879005,Decapitated migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,79267007,Retinal migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,83351003,Basilar artery migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,95655001,Ocular migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,95656000,Familial hemiplegic migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,160342001,Family history of migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,161481007,History of migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,162040008,Abdominal migraine - symptom,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,193030005,Migraine variants,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,193039006,Complex migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,230462002,Migraine with typical aura,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,230464001,Sporadic hemiplegic migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,230465000,Migraine aura without headache,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,230468003,Migraine with ischaemic complication,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,232284007,Vestibular migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,394707001,No history of migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,408381007,Migraine prophylaxis,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,427419006,Chronic migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,608837004,History of migraine with aura,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,124171000119105,Chronic intractable migraine without aura,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Preventing migraine,TA764,migraine,781381000000100,Migraine induced by oestrogen contraceptive,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,4473006,Classical migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,23186000,Menstrual migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,37796009,Migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,56097005,Migraine without aura,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,59292006,Hemiplegic migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,75879005,Decapitated migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,79267007,Retinal migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,83351003,Basilar artery migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,95655001,Ocular migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,95656000,Familial hemiplegic migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,160342001,Family history of migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,161481007,History of migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,162040008,Abdominal migraine - symptom,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,193030005,Migraine variants,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,193039006,Complex migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,230462002,Migraine with typical aura,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,230464001,Sporadic hemiplegic migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,230465000,Migraine aura without headache,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,230468003,Migraine with ischaemic complication,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,232284007,Vestibular migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,394707001,No history of migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,408381007,Migraine prophylaxis,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,427419006,Chronic migraine,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,608837004,History of migraine with aura,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,124171000119105,Chronic intractable migraine without aura,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FREMANEZUMAB,Prophylaxis of migraine in adults who have at least 4 migraine days per month,TA631,migraine,781381000000100,Migraine induced by oestrogen contraceptive,FREMANEZUMAB,NEUROLOGY,NEUROLOGY
FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,134405005,Suspected breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,160287004,FH: Breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,268547008,Screening for breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,429740004,Family history of breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,431330007,Family history of breast cancer 1 gene mutation,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,431331006,Family history of breast cancer 2 gene mutation,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,706970001,TNBC - Triple-negative breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,94361000000105,Breast cancer detected by national screening programme,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,276341000000100,Fast track referral for suspected breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,838351000000107,Education about risk of breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,874291000000100,QCancer breast cancer risk,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Treatment of locally advanced or metastatic breast cancer in postmenopausal women whose cancer has progressed after anti-oestrogen therapy.,TA239,breast cancer,1035841000000108,Lymphoedema following breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,134405005,Suspected breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,160287004,FH: Breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,268547008,Screening for breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,429740004,Family history of breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,431330007,Family history of breast cancer 1 gene mutation,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,431331006,Family history of breast cancer 2 gene mutation,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,706970001,TNBC - Triple-negative breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,94361000000105,Breast cancer detected by national screening programme,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,276341000000100,Fast track referral for suspected breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,838351000000107,Education about risk of breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,874291000000100,QCancer breast cancer risk,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
FULVESTRANT,Untreated locally advanced or metastatic oestrogen-receptor positive breast cancer,TA503,breast cancer,1035841000000108,Lymphoedema following breast cancer,FULVESTRANT,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (adults),TA076,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GABAPENTIN,Epilepsy (children),TA079,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
GALANTAMINE,Alzheimer's disease,TA019,alzheimer's disease,273269001,ADAS - Alzheimer's Disease Assessment Scale,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
GALANTAMINE,Alzheimer's disease,TA111,alzheimer's disease,273269001,ADAS - Alzheimer's Disease Assessment Scale,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
GALANTAMINE,Alzheimer's disease,TA019,alzheimer's disease,416780008,Dementia in Alzheimer's disease with early onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
GALANTAMINE,Alzheimer's disease,TA111,alzheimer's disease,416780008,Dementia in Alzheimer's disease with early onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
GALANTAMINE,Alzheimer's disease,TA019,alzheimer's disease,416975007,Alzheimer's disease with late onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
GALANTAMINE,Alzheimer's disease,TA111,alzheimer's disease,416975007,Alzheimer's disease with late onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
GALANTAMINE,Alzheimer's disease,TA019,alzheimer's disease,142011000119109,Alzheimer's disease co-occurrent with delirium,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
GALANTAMINE,Alzheimer's disease,TA111,alzheimer's disease,142011000119109,Alzheimer's disease co-occurrent with delirium,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
GALANTAMINE,Alzheimer's disease (mild to moderate),TA217,alzheimer's disease,273269001,ADAS - Alzheimer's Disease Assessment Scale,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
GALANTAMINE,Alzheimer's disease (mild to moderate),TA217,alzheimer's disease,416780008,Dementia in Alzheimer's disease with early onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
GALANTAMINE,Alzheimer's disease (mild to moderate),TA217,alzheimer's disease,416975007,Alzheimer's disease with late onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
GALANTAMINE,Alzheimer's disease (mild to moderate),TA217,alzheimer's disease,142011000119109,Alzheimer's disease co-occurrent with delirium,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
GALCANEZUMAB,Preventing migraine,TA659,migraine,4473006,Classical migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GALCANEZUMAB,Preventing migraine,TA659,migraine,23186000,Menstrual migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GALCANEZUMAB,Preventing migraine,TA659,migraine,37796009,Migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GALCANEZUMAB,Preventing migraine,TA659,migraine,56097005,Migraine without aura,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GALCANEZUMAB,Preventing migraine,TA659,migraine,59292006,Hemiplegic migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GALCANEZUMAB,Preventing migraine,TA659,migraine,75879005,Decapitated migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GALCANEZUMAB,Preventing migraine,TA659,migraine,79267007,Retinal migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GALCANEZUMAB,Preventing migraine,TA659,migraine,83351003,Basilar artery migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GALCANEZUMAB,Preventing migraine,TA659,migraine,95655001,Ocular migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GALCANEZUMAB,Preventing migraine,TA659,migraine,95656000,Familial hemiplegic migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GALCANEZUMAB,Preventing migraine,TA659,migraine,160342001,Family history of migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GALCANEZUMAB,Preventing migraine,TA659,migraine,161481007,History of migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GALCANEZUMAB,Preventing migraine,TA659,migraine,162040008,Abdominal migraine - symptom,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GALCANEZUMAB,Preventing migraine,TA659,migraine,193030005,Migraine variants,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GALCANEZUMAB,Preventing migraine,TA659,migraine,193039006,Complex migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GALCANEZUMAB,Preventing migraine,TA659,migraine,230462002,Migraine with typical aura,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GALCANEZUMAB,Preventing migraine,TA659,migraine,230464001,Sporadic hemiplegic migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GALCANEZUMAB,Preventing migraine,TA659,migraine,230465000,Migraine aura without headache,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GALCANEZUMAB,Preventing migraine,TA659,migraine,230468003,Migraine with ischaemic complication,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GALCANEZUMAB,Preventing migraine,TA659,migraine,232284007,Vestibular migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GALCANEZUMAB,Preventing migraine,TA659,migraine,394707001,No history of migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GALCANEZUMAB,Preventing migraine,TA659,migraine,408381007,Migraine prophylaxis,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GALCANEZUMAB,Preventing migraine,TA659,migraine,427419006,Chronic migraine,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GALCANEZUMAB,Preventing migraine,TA659,migraine,608837004,History of migraine with aura,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GALCANEZUMAB,Preventing migraine,TA659,migraine,124171000119105,Chronic intractable migraine without aura,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GALCANEZUMAB,Preventing migraine,TA659,migraine,781381000000100,Migraine induced by oestrogen contraceptive,GALCANEZUMAB,NEUROLOGY,NEUROLOGY
GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,162573006,Suspected lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,254637007,Non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,275981009,Lung cancer screening,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,429011007,Family history of lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,877691000000107,No FH of lung cancer,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB,Treating non-small-cell lung cancer that has progressed after prior chemotherapy,TA374,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ERLOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,162573006,Suspected lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,254637007,Non-small cell lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,275981009,Lung cancer screening,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,429011007,Family history of lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,877691000000107,No FH of lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA192,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,162573006,Suspected lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,254637007,Non-small cell lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,275981009,Lung cancer screening,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,429011007,Family history of lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,723301009,Squamous non-small cell lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,1259727001,Primary non-small cell lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,276491000000101,Fast track referral for suspected lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,848881000000108,QCancer lung cancer risk,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,877691000000107,No FH of lung cancer,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,1771781000000107,Did not attend lung cancer screening,GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEFITINIB (2ND LINE),Locally advanced or metastatic non-small-cell-lung cancer,TA175,lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",GEFITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEMCITABINE,Breast cancer,TA116,breast cancer,134405005,Suspected breast cancer,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
GEMCITABINE,Breast cancer,TA116,breast cancer,160287004,FH: Breast cancer,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
GEMCITABINE,Breast cancer,TA116,breast cancer,268547008,Screening for breast cancer,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
GEMCITABINE,Breast cancer,TA116,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
GEMCITABINE,Breast cancer,TA116,breast cancer,429740004,Family history of breast cancer,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
GEMCITABINE,Breast cancer,TA116,breast cancer,431330007,Family history of breast cancer 1 gene mutation,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
GEMCITABINE,Breast cancer,TA116,breast cancer,431331006,Family history of breast cancer 2 gene mutation,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
GEMCITABINE,Breast cancer,TA116,breast cancer,706970001,TNBC - Triple-negative breast cancer,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
GEMCITABINE,Breast cancer,TA116,breast cancer,94361000000105,Breast cancer detected by national screening programme,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
GEMCITABINE,Breast cancer,TA116,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
GEMCITABINE,Breast cancer,TA116,breast cancer,276341000000100,Fast track referral for suspected breast cancer,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
GEMCITABINE,Breast cancer,TA116,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
GEMCITABINE,Breast cancer,TA116,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
GEMCITABINE,Breast cancer,TA116,breast cancer,838351000000107,Education about risk of breast cancer,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
GEMCITABINE,Breast cancer,TA116,breast cancer,874291000000100,QCancer breast cancer risk,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
GEMCITABINE,Breast cancer,TA116,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
GEMCITABINE,Breast cancer,TA116,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
GEMCITABINE,Breast cancer,TA116,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
GEMCITABINE,Breast cancer,TA116,breast cancer,1035841000000108,Lymphoedema following breast cancer,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
GEMCITABINE (1ST LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,254637007,Non-small cell lung cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEMCITABINE (1ST LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,723301009,Squamous non-small cell lung cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEMCITABINE (1ST LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,1259727001,Primary non-small cell lung cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEMCITABINE (1ST LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
GEMCITABINE (1ST LINE),Pancreatic cancer,TA025,pancreatic cancer,429000004,Family history of pancreatic cancer,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
GEMCITABINE (1ST LINE),Pancreatic cancer,TA025,pancreatic cancer,247591000000101,Suspected pancreatic cancer,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
GEMCITABINE (1ST LINE),Pancreatic cancer,TA025,pancreatic cancer,848901000000106,QCancer pancreatic cancer risk,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
GEMCITABINE (2ND LINE),Pancreatic cancer,TA025,pancreatic cancer,429000004,Family history of pancreatic cancer,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
GEMCITABINE (2ND LINE),Pancreatic cancer,TA025,pancreatic cancer,247591000000101,Suspected pancreatic cancer,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
GEMCITABINE (2ND LINE),Pancreatic cancer,TA025,pancreatic cancer,848901000000106,QCancer pancreatic cancer risk,GEMCITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
GEMCITABINE IN COMBINATION WITH CARBOPLATIN,Treating recurrent ovarian cancer,TA389,ovarian cancer,423274005,Ovarian cancer stage 4,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
GEMCITABINE IN COMBINATION WITH CARBOPLATIN,Treating recurrent ovarian cancer,TA389,ovarian cancer,762997004,Suspected ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
GEMCITABINE IN COMBINATION WITH CARBOPLATIN,Treating recurrent ovarian cancer,TA389,ovarian cancer,758821000000106,No family history of ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
GEMCITABINE IN COMBINATION WITH CARBOPLATIN,Treating recurrent ovarian cancer,TA389,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
GEMTUZUMAB OZOGAMICIN WITH DAUNORUBICIN AND CYTARABINE,Untreated de novo CD33-positive acute myeloid leukaemia except acute promyelocytic leukaemia for patients age 15 years and above,TA545,acute promyelocytic leukaemia,28950004,Acute promyelocytic leukaemia with,GEMTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
GEMTUZUMAB OZOGAMICIN WITH DAUNORUBICIN AND CYTARABINE,Untreated de novo CD33-positive acute myeloid leukaemia except acute promyelocytic leukaemia for patients age 15 years and above,TA545,acute myeloid leukaemia,91861009,"Acute myeloid leukaemia, disease",GEMTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
GEMTUZUMAB OZOGAMICIN WITH DAUNORUBICIN AND CYTARABINE,Untreated de novo CD33-positive acute myeloid leukaemia except acute promyelocytic leukaemia for patients age 15 years and above,TA545,acute promyelocytic leukaemia,110004001,Acute promyelocytic leukaemia (clinical),GEMTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
GILTERITINIB,Relapsed or refractory acute myeloid leukaemia,TA642,acute myeloid leukaemia,91861009,"Acute myeloid leukaemia, disease",GILTERITINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
GLASDEGIB,Untreated acute myeloid leukaemia,TA646,acute myeloid leukaemia,91861009,"Acute myeloid leukaemia, disease",GLASDEGIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,24700007,Multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,24700007,Multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,160337009,Family history of multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,160337009,Family history of multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,192926004,Brain stem multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,192926004,Brain stem multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,192928003,Generalised multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,192928003,Generalised multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,428700003,Primary progressive multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,428700003,Primary progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,438511000,Benign multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,438511000,Benign multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,700409000,Suspected multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,700409000,Suspected multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,198491000000106,Multiple sclerosis review,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,198491000000106,Multiple sclerosis review,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,515931000000104,Multiple sclerosis review declined,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,515931000000104,Multiple sclerosis review declined,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA032,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,BETA,NEUROLOGY,NEUROLOGY|REHABILITATION
GLATIRAMER ACETATE,Multiple sclerosis,TA527,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,62944002,Hepatitis C virus,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,62944002,Hepatitis C virus,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,72165005,Hepatitis C virus antibody,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,72165005,Hepatitis C virus antibody,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,170489004,Viral hepatitis carrier,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,170489004,Viral hepatitis carrier,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,197344005,Hepatitis caused by adenovirus,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,197344005,Hepatitis caused by adenovirus,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,235872006,Hepatitis C carrier,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,235872006,Hepatitis C carrier,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,278973007,Hepatitis C status,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,278973007,Hepatitis C status,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,278974001,Hepatitis C immune,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,278974001,Hepatitis C immune,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,278975000,Hepatitis C non-immune,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,278975000,Hepatitis C non-immune,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,314706002,Hepatitis C antibody detected,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,314706002,Hepatitis C antibody detected,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,314707006,Hepatitis C antibody test negative,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,314707006,Hepatitis C antibody test negative,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,413107006,Hepatitis C screening,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,413107006,Hepatitis C screening,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,773113008,Acute hepatitis caused by infection,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,773113008,Acute hepatitis caused by infection,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,12891000175105,Hepatitis C screening declined,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,12891000175105,Hepatitis C screening declined,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,200371000000104,Hepatitis C contact,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,200371000000104,Hepatitis C contact,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,201451000000105,Hepatitis C immunisation declined,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,201451000000105,Hepatitis C immunisation declined,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,202281000000105,Hepatitis C screening declined,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,202281000000105,Hepatitis C screening declined,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,204671000000101,Hepatitis C screening counselling,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,204671000000101,Hepatitis C screening counselling,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,304821000000107,Hepatitis C screening not offered,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,304821000000107,Hepatitis C screening not offered,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,362491000000104,Hepatitis C screening negative,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,362491000000104,Hepatitis C screening negative,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,362751000000101,Hepatitis C screening positive,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,362751000000101,Hepatitis C screening positive,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,761381000000102,Hepatitis C resolved,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,761381000000102,Hepatitis C resolved,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,824841000000105,Hepatitis C genotype 1,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,824841000000105,Hepatitis C genotype 1,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,824871000000104,Hepatitis C genotype 3,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,824871000000104,Hepatitis C genotype 3,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,829731000000106,On hepatitis C treatment plan,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,829731000000106,On hepatitis C treatment plan,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,992751000000109,Hepatitis C viral load,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,992751000000109,Hepatitis C viral load,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,992771000000100,Hepatitis C virus genotype,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,992771000000100,Hepatitis C virus genotype,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,996031000000104,Hepatitis C IgG level,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,996031000000104,Hepatitis C IgG level,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,998771000000103,Hepatitis C antibody level,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,998771000000103,Hepatitis C antibody level,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,1001331000000102,Hepatitis C antigen level,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,1001331000000102,Hepatitis C antigen level,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,1008931000000108,Hepatitis C antibody test,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,1008931000000108,Hepatitis C antibody test,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,1107671000000106,Hepatitis C screening offered,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GLECAPREVIR–PIBRENTASVIR,Chronic hepatitis C,TA499,hepatitis c,1107671000000106,Hepatitis C screening offered,GLECAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
GOLIMUMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,162930007,On examination - ankylosing spondylitis chest deformity,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
GOLIMUMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,239805001,Juvenile ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
GOLIMUMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,239810002,Ankylosing spondylitis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
GOLIMUMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,239811003,Ankylosing spondylitis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
GOLIMUMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,394990003,Family history: Ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
GOLIMUMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,429712009,Bath Ankylosing Spondylitis Disease Activity Index,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
GOLIMUMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,441562009,Bath Ankylosing Spondylitis Disease Activity Index score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
GOLIMUMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,441680005,BASFI (Bath Ankylosing Spondylitis Functional Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
GOLIMUMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,441930001,BASMI (Bath Ankylosing Spondylitis Metrology Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,161567008,History of rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Methotrexate-naïve rheumatoid arthritis,TA224,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB,Non-radiographic axial spondyloarthritis,TA497,axial spondyloarthritis,723116002,Axial spondyloarthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
GOLIMUMAB,Psoriatic arthritis (active and progressive disease),TA220,psoriatic arthritis,156370009,Psoriatic arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
GOLIMUMAB,Psoriatic arthritis (active and progressive disease),TA220,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
GOLIMUMAB,Psoriatic arthritis (active and progressive disease),TA220,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
GOLIMUMAB,Psoriatic arthritis (active and progressive disease),TA220,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
GOLIMUMAB,Psoriatic arthritis (active and progressive disease),TA220,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
GOLIMUMAB,Psoriatic arthritis (active and progressive disease),TA220,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
GOLIMUMAB,Severe ankylosing spondylitis (adults),TA233,ankylosing spondylitis,162930007,On examination - ankylosing spondylitis chest deformity,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
GOLIMUMAB,Severe ankylosing spondylitis (adults),TA233,ankylosing spondylitis,239805001,Juvenile ankylosing spondylitis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
GOLIMUMAB,Severe ankylosing spondylitis (adults),TA233,ankylosing spondylitis,239810002,Ankylosing spondylitis with organ / system involvement,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
GOLIMUMAB,Severe ankylosing spondylitis (adults),TA233,ankylosing spondylitis,239811003,Ankylosing spondylitis with multisystem involvement,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
GOLIMUMAB,Severe ankylosing spondylitis (adults),TA233,ankylosing spondylitis,394990003,Family history: Ankylosing spondylitis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
GOLIMUMAB,Severe ankylosing spondylitis (adults),TA233,ankylosing spondylitis,429712009,Bath Ankylosing Spondylitis Disease Activity Index,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
GOLIMUMAB,Severe ankylosing spondylitis (adults),TA233,ankylosing spondylitis,441562009,Bath Ankylosing Spondylitis Disease Activity Index score,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
GOLIMUMAB,Severe ankylosing spondylitis (adults),TA233,ankylosing spondylitis,441680005,BASFI (Bath Ankylosing Spondylitis Functional Index) score,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
GOLIMUMAB,Severe ankylosing spondylitis (adults),TA233,ankylosing spondylitis,441930001,BASMI (Bath Ankylosing Spondylitis Metrology Index) score,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
GOLIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,64766004,UC - ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
GOLIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,160383003,FH: Ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
GOLIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
GOLIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,275129008,Family history of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
GOLIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,275549008,History of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
GOLIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
GOLIMUMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,445243001,Left sided ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,161567008,History of rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to conventional disease-modifying anti-rheumatic drugs (DMARDs) only, including methotrexate",TA225,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,161567008,History of rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GOLIMUMAB IN COMBINATION WITH METHOTREXATE,"Rheumatoid arthritis that has responded inadequately to other disease-modifying anti-rheumatic drugs (DMARDs), including a TNF inhibitor",TA225,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,GOLIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
GUSELKUMAB,Active psoriatic arthritis after inadequate response to DMARDs,TA711,psoriatic arthritis,156370009,Psoriatic arthritis,GUSELKUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
GUSELKUMAB,Active psoriatic arthritis after inadequate response to DMARDs,TA815,psoriatic arthritis,156370009,Psoriatic arthritis,GUSELKUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
GUSELKUMAB,Active psoriatic arthritis after inadequate response to DMARDs,TA711,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,GUSELKUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
GUSELKUMAB,Active psoriatic arthritis after inadequate response to DMARDs,TA815,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,GUSELKUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
GUSELKUMAB,Active psoriatic arthritis after inadequate response to DMARDs,TA711,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,GUSELKUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
GUSELKUMAB,Active psoriatic arthritis after inadequate response to DMARDs,TA815,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,GUSELKUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
GUSELKUMAB,Active psoriatic arthritis after inadequate response to DMARDs,TA711,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,GUSELKUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
GUSELKUMAB,Active psoriatic arthritis after inadequate response to DMARDs,TA815,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,GUSELKUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
GUSELKUMAB,Active psoriatic arthritis after inadequate response to DMARDs,TA711,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,GUSELKUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
GUSELKUMAB,Active psoriatic arthritis after inadequate response to DMARDs,TA815,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,GUSELKUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
GUSELKUMAB,Active psoriatic arthritis after inadequate response to DMARDs,TA711,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,GUSELKUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
GUSELKUMAB,Active psoriatic arthritis after inadequate response to DMARDs,TA815,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,GUSELKUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
GUSELKUMAB,Moderate to severe plaque psoriasis,TA521,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),GUSELKUMAB,DERMATOLOGY,DERMATOLOGY
GUSELKUMAB,Moderate to severe plaque psoriasis,TA521,plaque psoriasis,402307000,Chronic large plaque psoriasis,GUSELKUMAB,DERMATOLOGY,DERMATOLOGY
GUSELKUMAB,Moderate to severe plaque psoriasis,TA521,plaque psoriasis,402310007,Chronic stable plaque psoriasis,GUSELKUMAB,DERMATOLOGY,DERMATOLOGY
HALCINONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
HALCINONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
HALCINONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
HALCINONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
HALCINONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
HALCINONIDE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
HIGH-DOSE IMATINIB,Treating imatinib-resistant or intolerant chronic myeloid leukaemia,TA425,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,DASITINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
HYDROCORTISONE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
HYDROCORTISONE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
HYDROCORTISONE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
HYDROCORTISONE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
HYDROCORTISONE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
HYDROCORTISONE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
HYDROCORTISONE BUTYRATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
HYDROCORTISONE BUTYRATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
HYDROCORTISONE BUTYRATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
HYDROCORTISONE BUTYRATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
HYDROCORTISONE BUTYRATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
HYDROCORTISONE BUTYRATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
IBRUTINIB,Relapsed or refractory mantle cell lymphoma,TA502,mantle cell lymphoma,74654000,Mantle cell lymphoma,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IBRUTINIB,Relapsed or refractory mantle cell lymphoma,TA502,mantle cell lymphoma,443487006,Mantle cell lymphoma,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IBRUTINIB,Untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation,TA452,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IBRUTINIB,Untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation,TA452,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IBRUTINIB,Untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation,TA452,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IBRUTINIB,Untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation,TA452,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IBRUTINIB ALONE,Previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation,TA429,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IBRUTINIB ALONE,Previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation,TA429,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IBRUTINIB ALONE,Previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation,TA429,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IBRUTINIB ALONE,Previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation,TA429,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IBRUTINIB WITH BENDAMUSTINE AND RITUXIMAB,Relapsed or refractory chronic lymphocytic leukaemia after systemic therapy,TA437,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IBRUTINIB WITH BENDAMUSTINE AND RITUXIMAB,Relapsed or refractory chronic lymphocytic leukaemia after systemic therapy,TA437,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IBRUTINIB WITH BENDAMUSTINE AND RITUXIMAB,Relapsed or refractory chronic lymphocytic leukaemia after systemic therapy,TA437,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IBRUTINIB WITH BENDAMUSTINE AND RITUXIMAB,Relapsed or refractory chronic lymphocytic leukaemia after systemic therapy,TA437,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IBRUTINIB WITH OBINUTUZUMAB,Untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma,TA702,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IBRUTINIB WITH OBINUTUZUMAB,Untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma,TA702,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IBRUTINIB WITH OBINUTUZUMAB,Untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma,TA702,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IBRUTINIB WITH OBINUTUZUMAB,Untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma,TA702,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IBRUTINIB WITH RITUXIMAB,Untreated chronic lymphocytic leukaemia,TA703,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IBRUTINIB WITH RITUXIMAB,Untreated chronic lymphocytic leukaemia,TA703,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IBRUTINIB WITH RITUXIMAB,Untreated chronic lymphocytic leukaemia,TA703,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IBRUTINIB WITH RITUXIMAB,Untreated chronic lymphocytic leukaemia,TA703,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,IBRUTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IDELALISIB,Refractory follicular lymphoma,TA604,follicular lymphoma,109962001,Nonfollicular lymphoma,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IDELALISIB,Refractory follicular lymphoma,TA604,follicular lymphoma,308121000,Follicular lymphoma,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IDELALISIB,Refractory follicular lymphoma,TA604,follicular lymphoma,721555001,Follicular lymphoma of small intestine,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IDELALISIB,Refractory follicular lymphoma,TA604,follicular lymphoma,1148851002,Follicular lymphoma grade IIIa,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IDELALISIB,Refractory follicular lymphoma,TA604,follicular lymphoma,847481000000109,Follicular lymphoma grade 1,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IDELALISIB,Refractory follicular lymphoma,TA604,follicular lymphoma,847631000000107,Follicular lymphoma grade 2,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IDELALISIB,Refractory follicular lymphoma,TA604,follicular lymphoma,847651000000100,Follicular lymphoma grade 3,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IDELALISIB,Refractory follicular lymphoma,TA604,follicular lymphoma,847691000000108,Follicular lymphoma grade 3a,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IDELALISIB,Refractory follicular lymphoma,TA604,follicular lymphoma,847701000000108,Follicular lymphoma grade 3b,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IDELALISIB,follicular lymphoma that is refractory to 2 prior treatments,TA328,follicular lymphoma,109962001,Nonfollicular lymphoma,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IDELALISIB,follicular lymphoma that is refractory to 2 prior treatments,TA328,follicular lymphoma,308121000,Follicular lymphoma,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IDELALISIB,follicular lymphoma that is refractory to 2 prior treatments,TA328,follicular lymphoma,721555001,Follicular lymphoma of small intestine,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IDELALISIB,follicular lymphoma that is refractory to 2 prior treatments,TA328,follicular lymphoma,1148851002,Follicular lymphoma grade IIIa,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IDELALISIB,follicular lymphoma that is refractory to 2 prior treatments,TA328,follicular lymphoma,847481000000109,Follicular lymphoma grade 1,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IDELALISIB,follicular lymphoma that is refractory to 2 prior treatments,TA328,follicular lymphoma,847631000000107,Follicular lymphoma grade 2,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IDELALISIB,follicular lymphoma that is refractory to 2 prior treatments,TA328,follicular lymphoma,847651000000100,Follicular lymphoma grade 3,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IDELALISIB,follicular lymphoma that is refractory to 2 prior treatments,TA328,follicular lymphoma,847691000000108,Follicular lymphoma grade 3a,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IDELALISIB,follicular lymphoma that is refractory to 2 prior treatments,TA328,follicular lymphoma,847701000000108,Follicular lymphoma grade 3b,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IDELALISIB IN COMBINATION WITH RITUXIMAB,Treating chronic lymphocytic leukaemia,TA359,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IDELALISIB IN COMBINATION WITH RITUXIMAB,Treating chronic lymphocytic leukaemia,TA359,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IDELALISIB IN COMBINATION WITH RITUXIMAB,Treating chronic lymphocytic leukaemia,TA359,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IDELALISIB IN COMBINATION WITH RITUXIMAB,Treating chronic lymphocytic leukaemia,TA359,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IDELALISIB WITH OFATUMUMAB,Chronic lymphocytic leukaemia,TA469,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IDELALISIB WITH OFATUMUMAB,Chronic lymphocytic leukaemia,TA469,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IDELALISIB WITH OFATUMUMAB,Chronic lymphocytic leukaemia,TA469,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IDELALISIB WITH OFATUMUMAB,Chronic lymphocytic leukaemia,TA469,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,IDELALISIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,17788007,Acute non-lymphocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,17788007,Acute non-lymphocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,22197008,Burkitt cell leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,22197008,Burkitt cell leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,24072005,Blast cell leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,24072005,Blast cell leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,28950004,Acute promyelocytic leukaemia with,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,28950004,Acute promyelocytic leukaemia with,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,32280000,Lymphocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,32280000,Lymphocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,37810007,Monocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,37810007,Monocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,69077002,Acute basophilic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,69077002,Acute basophilic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,87163000,Leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,87163000,Leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,91857003,Acute lymphoid leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,91857003,Acute lymphoid leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,91861009,"Acute myeloid leukaemia, disease",IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,91861009,"Acute myeloid leukaemia, disease",IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,92811003,Chronic leukaemia in remission,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,92811003,Chronic leukaemia in remission,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,92812005,"Chronic leukaemia, disease",IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,92812005,"Chronic leukaemia, disease",IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,92817004,Chronic myeloid leukaemia in remission,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,92817004,Chronic myeloid leukaemia in remission,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,93142004,Leukaemia in remission,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,93142004,Leukaemia in remission,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,110002002,Mast cell leukaemia (clinical),IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,110002002,Mast cell leukaemia (clinical),IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,110004001,Acute promyelocytic leukaemia (clinical),IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,110004001,Acute promyelocytic leukaemia (clinical),IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,110006004,Prolymphocytic leukaemia (clinical),IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,110006004,Prolymphocytic leukaemia (clinical),IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,128831004,Chronic myelomonocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,128831004,Chronic myelomonocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,128922003,"Plasma cell leukaemia, morphology",IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,128922003,"Plasma cell leukaemia, morphology",IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,128931003,Leukaemia - category,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,128931003,Leukaemia - category,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,128933000,Chronic leukaemia - category,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,128933000,Chronic leukaemia - category,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,128935007,Lymphoid leukaemia (category),IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,128935007,Lymphoid leukaemia (category),IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,160292002,Family history: leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,160292002,Family history: leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,161436008,History of leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,161436008,History of leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,188726003,Subacute lymphoid leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,188726003,Subacute lymphoid leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,188732008,Myeloid leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,188732008,Myeloid leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,188733003,Chronic eosinophilic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,188733003,Chronic eosinophilic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,188734009,Chronic neutrophilic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,188734009,Chronic neutrophilic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,188768003,Myelomonocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,188768003,Myelomonocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,190055003,Eosinophilic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,190055003,Eosinophilic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,277568007,Hairy cell leukaemia variant,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,277568007,Hairy cell leukaemia variant,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,277569004,Large granular lymphocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,277569004,Large granular lymphocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,277571004,Mature B-cell leukaemia Burkitt type,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,277571004,Mature B-cell leukaemia Burkitt type,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,277602003,Acute megakaryoblastic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,277602003,Acute megakaryoblastic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,315262009,Suspected leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,315262009,Suspected leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,359631009,M0 - Acute myeloblastic leukaemia - undifferentiated,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,359631009,M0 - Acute myeloblastic leukaemia - undifferentiated,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,413440007,Acute lymphoblastic leukaemia - category,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,413440007,Acute lymphoblastic leukaemia - category,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,449386007,Philadelphia chromosome negative chronic myelogenous leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,449386007,Philadelphia chromosome negative chronic myelogenous leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,634651000000103,Other specified leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,634651000000103,Other specified leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA050,leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Leukaemia (CML),TA070,leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,IMATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IMATINIB,Untreated chronic myeloid leukaemia,TA426,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,DASATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,171234009,Chronic kidney disease screening,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,431855005,Chronic kidney disease stage 1,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,431856006,Chronic kidney disease stage 2,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,431857002,Chronic kidney disease stage 4,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,433144002,Chronic kidney disease stage 3,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,433146000,Chronic kidney disease stage 5,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,472953006,H/O chronic kidney disease,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,698463001,At increased risk of chronic kidney disease,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,700378005,Chronic kidney disease stage 3A,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,700379002,Chronic kidney disease stage 3B,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,709044004,Chronic kidney disease,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,714152005,Chronic kidney disease 5d,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,248721000000108,Chronic kidney disease monitoring,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,249171000000102,Chronic kidney disease annual review,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,249311000000109,Predicted stage chronic kidney disease,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,298141000000107,Did not attend chronic kidney disease monitoring clinic,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324121000000109,CKD (chronic kidney disease stage) 1 with proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324151000000104,CKD (chronic kidney disease) stage 1 without proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324181000000105,CKD (chronic kidney disease) stage 2 with proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324211000000106,CKD (chronic kidney disease) stage 2 without proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324251000000105,CKD (chronic kidney disease) stage 3 with proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324281000000104,CKD (chronic kidney disease) stage 3 without proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324311000000101,CKD (chronic kidney disease) stage 3A with proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324341000000100,CKD (chronic kidney disease) stage 3A without proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324371000000106,CKD (chronic kidney disease) stage 3B with proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324411000000105,CKD (chronic kidney disease) stage 3B without proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324441000000106,CKD (chronic kidney disease) stage 4 with proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324471000000100,CKD (chronic kidney disease) stage 4 without proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324501000000107,CKD (chronic kidney disease) stage 5 with proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,324541000000105,CKD (chronic kidney disease) stage 5 without proteinuria,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,711421000000107,Chronic kidney disease monitoring invitation,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,713811000000100,Chronic kidney disease monitoring administration,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,716651000000106,Chronic kidney disease monitoring first letter,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,716881000000104,Excepted from chronic kidney disease quality indicators - informed dissent,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,716891000000102,Excepted from chronic kidney disease quality indicators - patient unsuitable,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,717231000000104,Chronic kidney disease monitoring verbal invite,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,717361000000100,Exception reporting - chronic kidney disease quality indicators,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,717461000000108,Chronic kidney disease monitoring third letter,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,717511000000105,Chronic kidney disease monitoring telephone invite,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,717751000000104,Chronic kidney disease monitoring second letter,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,811021000000104,Chronic kidney disease self-management plan review,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,811941000000105,Chronic kidney disease self-management plan agreed,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,857971000000104,Estimated glomerular filtration rate using Chronic Kidney Disease Epidemiology Collaboration formula,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,903261000000109,Chronic kidney disease laboratory study,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,939211000000104,Chronic kidney disease resolved,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,949401000000103,Chronic kidney disease with glomerular filtration rate category G1 and albuminuria category A1,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,949421000000107,Chronic kidney disease with glomerular filtration rate category G1 and albuminuria category A2,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,949481000000108,CKD G1A3 - chronic kidney disease with glomerular filtration rate category G1 and albuminuria category A3,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,949521000000108,CKD G2A1 - chronic kidney disease with glomerular filtration rate category G2 and albuminuria category A1,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,949561000000100,Chronic kidney disease with glomerular filtration rate category G2 and albuminuria category A2,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,949621000000109,CKD G2A3 - chronic kidney disease with glomerular filtration rate category G2 and albuminuria category A3,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,949881000000106,CKD G3aA1 - chronic kidney disease with glomerular filtration rate category G3a and albuminuria category A1,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,949901000000109,CKD G3aA2 - chronic kidney disease with glomerular filtration rate category G3a and albuminuria category A2,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,949921000000100,Chronic kidney disease with glomerular filtration rate category G3a and albuminuria category A3,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,950061000000103,Chronic kidney disease with glomerular filtration rate category G3b and albuminuria category A1,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,950081000000107,CKD G3bA2 - chronic kidney disease with glomerular filtration rate category G3b and albuminuria category A2,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,950101000000101,CKD G3bA3 - chronic kidney disease with glomerular filtration rate category G3b and albuminuria category A3,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,950181000000106,CKD G4A1 - chronic kidney disease with glomerular filtration rate category G4 and albuminuria category A1,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,950211000000107,CKD G4A2 - chronic kidney disease with glomerular filtration rate category G4 and albuminuria category A2,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,950231000000104,CKD G4A3 - chronic kidney disease with glomerular filtration rate category G4 and albuminuria category A3,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,950251000000106,CKD G5A1 - chronic kidney disease with glomerular filtration rate category G5 and albuminuria category A1,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,950291000000103,Chronic kidney disease with glomerular filtration rate category G5 and albuminuria category A2,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,950311000000102,Chronic kidney disease with glomerular filtration rate category G5 and albuminuria category A3,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,1011481000000105,Estimated glomerular filtration rate using creatinine Chronic Kidney Disease Epidemiology Collaboration equation per 1.73 square metres,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMLIFIDASE,Desensitisation treatment before kidney transplant in people with chronic kidney disease,TA809,chronic kidney disease,1011491000000107,Estimated glomerular filtration rate using cystatin C Chronic Kidney Disease Epidemiology Collaboration equation per 1.73 square metres,IMLIFIDASE,NEPHROLOGY,NEPHROLOGY
IMMEDIATE-RELEASE TACROLIMUS,Kidney transplant in adults,TA481,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
IMMEDIATE-RELEASE TACROLIMUS,Kidney transplant in adults,TA481,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
IMMEDIATE-RELEASE TACROLIMUS,Kidney transplant in adults,TA481,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
IMMEDIATE-RELEASE TACROLIMUS,Kidney transplant in adults,TA481,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
IMMEDIATE-RELEASE TACROLIMUS,Kidney transplant in adults,TA481,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
IMMEDIATE-RELEASE TACROLIMUS,Kidney transplant in adults,TA481,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
IMMEDIATE-RELEASE TACROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
IMMEDIATE-RELEASE TACROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
IMMEDIATE-RELEASE TACROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
IMMEDIATE-RELEASE TACROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
IMMEDIATE-RELEASE TACROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
IMMEDIATE-RELEASE TACROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
INDUCTION THERAPY (BASILIXIMAB),Renal transplantation (adults),TA085,renal transplantation,70536003,Renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
INDUCTION THERAPY (BASILIXIMAB),Renal transplantation (adults),TA085,renal transplantation,313030004,Donor renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
INDUCTION THERAPY (BASILIXIMAB),Renal transplantation (adults),TA085,renal transplantation,429451003,Disorder related to renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
INDUCTION THERAPY (DACLIZUMAB),Renal transplantation (adults),TA085,renal transplantation,70536003,Renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
INDUCTION THERAPY (DACLIZUMAB),Renal transplantation (adults),TA085,renal transplantation,313030004,Donor renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
INDUCTION THERAPY (DACLIZUMAB),Renal transplantation (adults),TA085,renal transplantation,429451003,Disorder related to renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
INFLIXIMAB,Active fistulising Crohn's disease (adults),TA187,crohn's disease,196578009,Oral Crohn's disease,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,Active fistulising Crohn's disease (adults),TA187,crohn's disease,196578009,Oral Crohn's disease,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,Active fistulising Crohn's disease (adults),TA187,crohn's disease,273364009,Crohn's Disease Activity Index,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,Active fistulising Crohn's disease (adults),TA187,crohn's disease,273364009,Crohn's Disease Activity Index,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,"Acute, severely active ulcerative colitis",TA163,ulcerative colitis,64766004,UC - ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,"Acute, severely active ulcerative colitis",TA163,ulcerative colitis,160383003,FH: Ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,"Acute, severely active ulcerative colitis",TA163,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,"Acute, severely active ulcerative colitis",TA163,ulcerative colitis,275129008,Family history of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,"Acute, severely active ulcerative colitis",TA163,ulcerative colitis,275549008,History of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,"Acute, severely active ulcerative colitis",TA163,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,"Acute, severely active ulcerative colitis",TA163,ulcerative colitis,445243001,Left sided ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,162930007,On examination - ankylosing spondylitis chest deformity,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
INFLIXIMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,239805001,Juvenile ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
INFLIXIMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,239810002,Ankylosing spondylitis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
INFLIXIMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,239811003,Ankylosing spondylitis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
INFLIXIMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,394990003,Family history: Ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
INFLIXIMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,429712009,Bath Ankylosing Spondylitis Disease Activity Index,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
INFLIXIMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,441562009,Bath Ankylosing Spondylitis Disease Activity Index score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
INFLIXIMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,441680005,BASFI (Bath Ankylosing Spondylitis Functional Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
INFLIXIMAB,Ankylosing spondylitis,TA383,ankylosing spondylitis,441930001,BASMI (Bath Ankylosing Spondylitis Metrology Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
INFLIXIMAB,Crohn's disease (active severe),TA040,crohn's disease,196578009,Oral Crohn's disease,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,Crohn's disease (active severe),TA040,crohn's disease,196578009,Oral Crohn's disease,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,Crohn's disease (active severe),TA040,crohn's disease,273364009,Crohn's Disease Activity Index,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,Crohn's disease (active severe),TA040,crohn's disease,273364009,Crohn's Disease Activity Index,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,Crohn's disease (fistulising),TA040,crohn's disease,196578009,Oral Crohn's disease,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,Crohn's disease (fistulising),TA040,crohn's disease,196578009,Oral Crohn's disease,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,Crohn's disease (fistulising),TA040,crohn's disease,273364009,Crohn's Disease Activity Index,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,Crohn's disease (fistulising),TA040,crohn's disease,273364009,Crohn's Disease Activity Index,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,Psoriatic arthritis,TA104,psoriatic arthritis,156370009,Psoriatic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
INFLIXIMAB,Psoriatic arthritis,TA199,psoriatic arthritis,156370009,Psoriatic arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
INFLIXIMAB,Psoriatic arthritis,TA104,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
INFLIXIMAB,Psoriatic arthritis,TA199,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
INFLIXIMAB,Psoriatic arthritis,TA104,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
INFLIXIMAB,Psoriatic arthritis,TA199,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
INFLIXIMAB,Psoriatic arthritis,TA104,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
INFLIXIMAB,Psoriatic arthritis,TA199,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
INFLIXIMAB,Psoriatic arthritis,TA104,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
INFLIXIMAB,Psoriatic arthritis,TA199,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
INFLIXIMAB,Psoriatic arthritis,TA104,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
INFLIXIMAB,Psoriatic arthritis,TA199,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
INFLIXIMAB,Severe active Crohn's disease (adults),TA187,crohn's disease,196578009,Oral Crohn's disease,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,Severe active Crohn's disease (adults),TA187,crohn's disease,196578009,Oral Crohn's disease,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,Severe active Crohn's disease (adults),TA187,crohn's disease,273364009,Crohn's Disease Activity Index,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,Severe active Crohn's disease (adults),TA187,crohn's disease,273364009,Crohn's Disease Activity Index,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,Severe active Crohn's disease (children aged 6 - 17 years),TA187,crohn's disease,196578009,Oral Crohn's disease,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,Severe active Crohn's disease (children aged 6 - 17 years),TA187,crohn's disease,196578009,Oral Crohn's disease,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,Severe active Crohn's disease (children aged 6 - 17 years),TA187,crohn's disease,273364009,Crohn's Disease Activity Index,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,Severe active Crohn's disease (children aged 6 - 17 years),TA187,crohn's disease,273364009,Crohn's Disease Activity Index,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,162930007,On examination - ankylosing spondylitis chest deformity,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
INFLIXIMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,239805001,Juvenile ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
INFLIXIMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,239810002,Ankylosing spondylitis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
INFLIXIMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,239811003,Ankylosing spondylitis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
INFLIXIMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,394990003,Family history: Ankylosing spondylitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
INFLIXIMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,429712009,Bath Ankylosing Spondylitis Disease Activity Index,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
INFLIXIMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,441562009,Bath Ankylosing Spondylitis Disease Activity Index score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
INFLIXIMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,441680005,BASFI (Bath Ankylosing Spondylitis Functional Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
INFLIXIMAB,Severe ankylosing spondylitis (adults),TA143,ankylosing spondylitis,441930001,BASMI (Bath Ankylosing Spondylitis Metrology Index) score,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY
INFLIXIMAB,"Subacute, moderately to severely active ulcerative colitis",TA140,ulcerative colitis,64766004,UC - ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,"Subacute, moderately to severely active ulcerative colitis",TA140,ulcerative colitis,160383003,FH: Ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,"Subacute, moderately to severely active ulcerative colitis",TA140,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,"Subacute, moderately to severely active ulcerative colitis",TA140,ulcerative colitis,275129008,Family history of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,"Subacute, moderately to severely active ulcerative colitis",TA140,ulcerative colitis,275549008,History of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,"Subacute, moderately to severely active ulcerative colitis",TA140,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,"Subacute, moderately to severely active ulcerative colitis",TA140,ulcerative colitis,445243001,Left sided ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,64766004,UC - ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,160383003,FH: Ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,275129008,Family history of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,275549008,History of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB,moderately to severely active ulcerative colitis after the failure of conventional therapy,TA329,ulcerative colitis,445243001,Left sided ulcerative colitis,INFLIXIMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB  IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (1ST LINE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (2ND LINE),Plaque psoriasis,TA134,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),INFLIXIMAB,DERMATOLOGY,DERMATOLOGY
INFLIXIMAB (2ND LINE),Plaque psoriasis,TA134,plaque psoriasis,402307000,Chronic large plaque psoriasis,INFLIXIMAB,DERMATOLOGY,DERMATOLOGY
INFLIXIMAB (2ND LINE),Plaque psoriasis,TA134,plaque psoriasis,402310007,Chronic stable plaque psoriasis,INFLIXIMAB,DERMATOLOGY,DERMATOLOGY
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB (AFTER DMARD FAILURE),Rheumatoid arthritis,TA130,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA036,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ETANERCEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
INFLIXIMAB WITH METHOTREXATE,Moderate rheumatoid arthritis after conventional DMARDs have failed,TA715,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,12428000,Intrinsic asthma without status asthmaticus,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,31387002,Exercise-induced asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,34015007,Flour asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,56018004,Asthmatic breathing,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,56968009,Asthma caused by wood dust,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,57607007,Industrial asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,63088003,Allergic asthma without status asthmaticus,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,71892000,Cardiac asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,93432008,Drug-induced asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,160377001,Family history of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,161105008,Asthma society member,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,161527007,History of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,162660004,Asthma resolved,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170607007,Respiratory disease monitoring (& [asthma] or [chronic]),INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170631002,Asthma disturbing sleep,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170632009,Asthma causing night waking,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170633004,Asthma disturbs sleep weekly,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170634005,Asthma disturbs sleep frequently,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170635006,Asthma not disturbing sleep,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170636007,Asthma never disturbs sleep,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170637003,Asthma limiting activities,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170638008,Asthma not limiting activities,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170642006,Asthma severity,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170647000,Asthma prophylactic medication used,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170655007,Asthma restricts exercise,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170656008,Asthma sometimes restricts exercise,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170657004,Asthma severely restricts exercise,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,170658009,Asthma never restricts exercise,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,171231001,Asthma screening,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,182724005,Further asthma - drug prevention,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,182726007,Asthma control step 0,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,182727003,Asthma control step 1,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,182728008,Asthma control step 2,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,182729000,Asthma control step 3,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,182730005,Asthma control step 4,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,182731009,Asthma control step 5,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,183099005,Asthma leaflet given,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,183478001,Emergency hospital admission for asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,185242005,Seen in asthma clinic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,185728001,Attends asthma monitoring,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,185730004,Asthma monitor offer default,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,185731000,Asthma monitoring call first letter,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,185732007,Asthma monitoring call second letter,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,185734008,Asthma monitoring call third letter,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,185735009,Asthma monitoring call verbal invite,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,185736005,Asthma monitoring call telephone invite,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,185737001,Asthma monitoring deleted,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,185940009,Patient in asthma study,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,195113008,(Left ventricular: [failure] or [impaired function]) or (cardiac asthma) or (acute pulmonary edema),INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,195949008,Chronic asthmatic bronchitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,195967001,Asthmatic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,195968006,Asthma: [extrinsic - atopic] or [allergic] or [pollen] or [childhood] or [with hay fever],INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,195973000,Late-onset asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,195977004,Mixed asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,195983001,Exercise induced asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,219036002,Adverse reaction to antiasthmatic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,225057002,Brittle asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,233678006,Childhood asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,233679003,Late-onset asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,233683003,Hay fever with asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,233691007,Eosinophilic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,266361008,Non-allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,266396008,Extrinsic asthma - atopy (& pollen),INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,266397004,Intrinsic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,266398009,Asthma attack,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,270442000,Asthma monitoring check done,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,275908000,Asthma monitoring,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,281239006,Asthma attack,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,302220000,Asthma control steps,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,304527002,Acute asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,308500005,Asthma monitoring call,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,308501009,Asthma monitoring status,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,312453004,Asthma - currently active,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,312454005,Asthma - currently dormant,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,366874008,Number of asthma exacerbations in past year,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370202007,Asthma causes daytime symptoms 1 to 2 times per month,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370203002,Asthma causes daytime symptoms 1 to 2 times per week,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370204008,Asthma causes daytime symptoms most days,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370205009,Asthma causes night symptoms 1 to 2 times per month,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370206005,Asthma limits walking on the flat,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370207001,Asthma limits walking up hills or stairs,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370208006,Asthma never causes daytime symptoms,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370218001,Mild asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370219009,Moderate asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370220003,Occasional asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370221004,Severe asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370225008,Asthma treatment compliance unsatisfactory,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,370226009,Asthma treatment compliance satisfactory,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,373899003,Asthma daytime symptoms,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,389145006,Allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,390798007,Asthma finding,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,390872009,Change in asthma management plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,390877003,Step up change in asthma management plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,390878008,Step down change in asthma management plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,390921001,Absent from work or school due to asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,390940007,Asthma monitoring due,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,394700004,Asthma annual review,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,394701000,Asthma follow-up,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,394720003,Asthma medication review,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,394967008,Suspected asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,395022009,Nocturnal asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,400987003,Asthma trigger,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,401135008,Health education - asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,401182001,Asthma monitoring by nurse,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,401183006,Asthma monitoring by doctor,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,401193004,Asthma confirmed,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,405944004,Asthmatic bronchitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,406162001,Asthma care,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,407674008,Aspirin-induced asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,409663006,Cough variant asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,415265005,Referral to asthma clinic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,423889005,Non-immunoglobulin E mediated allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,424643009,Allergic atopic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,425969006,Acute intermittent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,426656000,Severe persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,426979002,Mild persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,427295004,Moderate persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,427603009,Intermittent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,427679007,Mild intermittent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,442025000,Acute exacerbation of chronic asthmatic bronchitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,443117005,Asthma control test score,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,445427006,Seasonal asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,445531003,ACQ - Asthma control questionnaire,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,473391009,Asthma never causes night symptoms,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,698509001,Under care of asthma specialist nurse,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,699191007,Did not attend asthma review,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,702823004,Asthma clinic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,704008007,No family history of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,707445000,Acute mild persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,707446004,Acute exacerbation of moderate persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,707447008,Exacerbation of severe persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,707511009,Uncomplicated mild persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,707512002,Uncomplicated moderate persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,707513007,Uncomplicated severe persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,707979007,Acute severe exacerbation of severe persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,707980005,Acute severe exacerbation of moderate persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,707981009,Acute severe exacerbation of mild persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,708038006,Acute exacerbation of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,708090002,Acute severe exacerbation of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,708093000,Acute exacerbation of allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,708094006,Acute exacerbation of intrinsic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,708095007,Acute severe exacerbation of extrinsic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,708358003,Emergency asthma admission since last encounter,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,708373002,Emergency asthma patient visit since last encounter,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,711442001,Recent asthma management,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,715191006,Telehealth asthma monitoring,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,734346005,Use of asthma symptom diary,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,734904007,Life threatening acute exacerbation of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,734905008,Moderate acute exacerbation of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,736056000,Asthma clinical management plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,762521001,Acute allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,763077003,Asthma Control Questionnaire score,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,763221007,Asthma monitoring declined,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,763695004,Mini Asthma Quality of Life Questionnaire score,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,782520007,Exacerbation of allergic asthma due to infection,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,782559003,Asthma never causes night symptoms,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,401000119107,Asthma with irreversible airway obstruction,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,641000119106,Intermittent asthma well controlled,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,1741000119102,Intermittent asthma uncontrolled,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,72301000119103,Asthma in pregnancy,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,89581000000109,DNA (did not attend) asthma clinic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,92161000000104,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation using preferred method of communication,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,99031000119107,Acute exacerbation of asthma co-occurrent with allergic rhinitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,125011000119100,Mild persistent asthma co-occurrent with allergic rhinitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,125021000119107,Intermittent asthma co-occurrent with allergic rhinitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,135171000119106,Acute exacerbation of moderate persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,143901000000108,Registration for access to online asthma self-management application,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,143931000000102,Declined to register for access to online asthma self-management application,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,176711000000100,Does not have asthma management plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,198971000000102,Asthma outreach clinic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,201031000000108,Asthma trigger - respiratory infection,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,201041000000104,Asthma trigger - seasonal,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,201051000000101,Asthma trigger - animal,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,201191000000108,Asthma trigger - cold air,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,201201000000105,Asthma trigger - damp,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,201211000000107,Asthma trigger - emotion,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,302331000000106,RCP (Royal College of Physicians) asthma assessment,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,340891000000106,Asthma trigger - airborne dust,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,340901000000107,Asthma trigger - exercise,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,340911000000109,Asthma trigger - pollen,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,340921000000103,Asthma trigger - tobacco smoke,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,340931000000101,Asthma trigger - warm air,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,527171000000103,Patient has a written asthma personal action plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,527191000000104,Health education - asthma self management,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,527211000000100,Health education - structured asthma discussion,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,527231000000108,Health education - structured patient focused asthma discussion,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,713701000000108,Asthma monitoring administration,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,713711000000105,Asthma clinic administration,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,715801000000103,Exception reporting - asthma quality indicators,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,716491000000100,Excepted from asthma quality indicators - informed dissent,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,717291000000103,Excepted from asthma quality indicators - patient unsuitable,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,754061000000100,Asthma review using Royal College of Physicians three questions,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,771901000000100,Asthma causes night time symptoms 1 to 2 times per week,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,771941000000102,Asthma causes symptoms most nights,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,771981000000105,Asthma limits activities 1 to 2 times per month,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,772011000000107,Asthma limits activities 1 to 2 times per week,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,772051000000106,Asthma limits activities most days,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,791401000000104,Seen in school asthma clinic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,810901000000102,Asthma self-management plan review,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,811151000000105,Number of days absent from school due to asthma in past 6 months,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,811921000000103,Asthma self-management plan agreed,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,815631000000106,Asthma trigger - wind,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,818161000000104,Asthma trigger - perfume,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,866881000000101,Chronic asthma with fixed airflow obstruction,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,867171000000106,No asthma trigger identified by subject,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,892301000000100,Asthma management plan declined,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,905301000000103,Childhood Asthma Control Test score,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,928451000000107,Asthma monitoring invitation short message service text message,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,928511000000107,Asthma monitoring invitation email,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,928651000000105,Review of patient at risk of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,928691000000102,At risk of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,959401000000101,Asthma monitoring SMS (short message service) text message first invitation,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,959421000000105,Asthma monitoring SMS (short message service) text message second invitation,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,959441000000103,Asthma monitoring SMS (short message service) text message third invitation,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,959901000000107,Asthma action plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,966011000000109,At risk of severe asthma exacerbation,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,966031000000101,Severe asthma exacerbation risk assessment,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,1086701000000102,Life threatening acute exacerbation of allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,1086711000000100,Life threatening acute exacerbation of non-allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,1108701000000106,Excepted from asthma quality indicators - service unavailable,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,1110841000000103,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,10674991000119104,Intermittent allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,10675431000119106,Severe persistent allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,10675551000119104,Acute severe exacerbation of severe persistent asthma co-occurrent with allergic rhinitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,10675871000119106,Mild persistent allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,10675991000119100,Acute severe exacerbation of mild persistent allergic asthma co-occurrent with allergic rhinitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,10676031000119106,Mild persistent allergic asthma controlled,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in adults),TA138,asthma,10676111000119102,Mild persistent asthma controlled co-occurrent with allergic rhinitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,12428000,Intrinsic asthma without status asthmaticus,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,31387002,Exercise-induced asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,34015007,Flour asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,56018004,Asthmatic breathing,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,56968009,Asthma caused by wood dust,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,57607007,Industrial asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,63088003,Allergic asthma without status asthmaticus,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,71892000,Cardiac asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,93432008,Drug-induced asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,160377001,Family history of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,161105008,Asthma society member,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,161527007,History of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,162660004,Asthma resolved,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170607007,Respiratory disease monitoring (& [asthma] or [chronic]),INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170631002,Asthma disturbing sleep,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170632009,Asthma causing night waking,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170633004,Asthma disturbs sleep weekly,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170634005,Asthma disturbs sleep frequently,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170635006,Asthma not disturbing sleep,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170636007,Asthma never disturbs sleep,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170637003,Asthma limiting activities,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170638008,Asthma not limiting activities,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170642006,Asthma severity,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170647000,Asthma prophylactic medication used,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170655007,Asthma restricts exercise,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170656008,Asthma sometimes restricts exercise,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170657004,Asthma severely restricts exercise,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,170658009,Asthma never restricts exercise,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,171231001,Asthma screening,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,182724005,Further asthma - drug prevention,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,182726007,Asthma control step 0,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,182727003,Asthma control step 1,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,182728008,Asthma control step 2,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,182729000,Asthma control step 3,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,182730005,Asthma control step 4,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,182731009,Asthma control step 5,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,183099005,Asthma leaflet given,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,183478001,Emergency hospital admission for asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,185242005,Seen in asthma clinic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,185728001,Attends asthma monitoring,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,185730004,Asthma monitor offer default,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,185731000,Asthma monitoring call first letter,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,185732007,Asthma monitoring call second letter,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,185734008,Asthma monitoring call third letter,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,185735009,Asthma monitoring call verbal invite,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,185736005,Asthma monitoring call telephone invite,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,185737001,Asthma monitoring deleted,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,185940009,Patient in asthma study,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,195113008,(Left ventricular: [failure] or [impaired function]) or (cardiac asthma) or (acute pulmonary edema),INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,195949008,Chronic asthmatic bronchitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,195967001,Asthmatic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,195968006,Asthma: [extrinsic - atopic] or [allergic] or [pollen] or [childhood] or [with hay fever],INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,195973000,Late-onset asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,195977004,Mixed asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,195983001,Exercise induced asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,219036002,Adverse reaction to antiasthmatic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,225057002,Brittle asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,233678006,Childhood asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,233679003,Late-onset asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,233683003,Hay fever with asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,233691007,Eosinophilic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,266361008,Non-allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,266396008,Extrinsic asthma - atopy (& pollen),INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,266397004,Intrinsic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,266398009,Asthma attack,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,270442000,Asthma monitoring check done,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,275908000,Asthma monitoring,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,281239006,Asthma attack,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,302220000,Asthma control steps,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,304527002,Acute asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,308500005,Asthma monitoring call,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,308501009,Asthma monitoring status,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,312453004,Asthma - currently active,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,312454005,Asthma - currently dormant,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,366874008,Number of asthma exacerbations in past year,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370202007,Asthma causes daytime symptoms 1 to 2 times per month,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370203002,Asthma causes daytime symptoms 1 to 2 times per week,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370204008,Asthma causes daytime symptoms most days,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370205009,Asthma causes night symptoms 1 to 2 times per month,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370206005,Asthma limits walking on the flat,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370207001,Asthma limits walking up hills or stairs,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370208006,Asthma never causes daytime symptoms,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370218001,Mild asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370219009,Moderate asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370220003,Occasional asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370221004,Severe asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370225008,Asthma treatment compliance unsatisfactory,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,370226009,Asthma treatment compliance satisfactory,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,373899003,Asthma daytime symptoms,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,389145006,Allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,390798007,Asthma finding,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,390872009,Change in asthma management plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,390877003,Step up change in asthma management plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,390878008,Step down change in asthma management plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,390921001,Absent from work or school due to asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,390940007,Asthma monitoring due,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,394700004,Asthma annual review,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,394701000,Asthma follow-up,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,394720003,Asthma medication review,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,394967008,Suspected asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,395022009,Nocturnal asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,400987003,Asthma trigger,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,401135008,Health education - asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,401182001,Asthma monitoring by nurse,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,401183006,Asthma monitoring by doctor,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,401193004,Asthma confirmed,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,405944004,Asthmatic bronchitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,406162001,Asthma care,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,407674008,Aspirin-induced asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,409663006,Cough variant asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,415265005,Referral to asthma clinic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,423889005,Non-immunoglobulin E mediated allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,424643009,Allergic atopic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,425969006,Acute intermittent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,426656000,Severe persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,426979002,Mild persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,427295004,Moderate persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,427603009,Intermittent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,427679007,Mild intermittent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,442025000,Acute exacerbation of chronic asthmatic bronchitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,443117005,Asthma control test score,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,445427006,Seasonal asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,445531003,ACQ - Asthma control questionnaire,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,473391009,Asthma never causes night symptoms,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,698509001,Under care of asthma specialist nurse,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,699191007,Did not attend asthma review,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,702823004,Asthma clinic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,704008007,No family history of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,707445000,Acute mild persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,707446004,Acute exacerbation of moderate persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,707447008,Exacerbation of severe persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,707511009,Uncomplicated mild persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,707512002,Uncomplicated moderate persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,707513007,Uncomplicated severe persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,707979007,Acute severe exacerbation of severe persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,707980005,Acute severe exacerbation of moderate persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,707981009,Acute severe exacerbation of mild persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,708038006,Acute exacerbation of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,708090002,Acute severe exacerbation of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,708093000,Acute exacerbation of allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,708094006,Acute exacerbation of intrinsic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,708095007,Acute severe exacerbation of extrinsic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,708358003,Emergency asthma admission since last encounter,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,708373002,Emergency asthma patient visit since last encounter,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,711442001,Recent asthma management,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,715191006,Telehealth asthma monitoring,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,734346005,Use of asthma symptom diary,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,734904007,Life threatening acute exacerbation of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,734905008,Moderate acute exacerbation of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,736056000,Asthma clinical management plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,762521001,Acute allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,763077003,Asthma Control Questionnaire score,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,763221007,Asthma monitoring declined,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,763695004,Mini Asthma Quality of Life Questionnaire score,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,782520007,Exacerbation of allergic asthma due to infection,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,782559003,Asthma never causes night symptoms,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,401000119107,Asthma with irreversible airway obstruction,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,641000119106,Intermittent asthma well controlled,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,1741000119102,Intermittent asthma uncontrolled,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,72301000119103,Asthma in pregnancy,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,89581000000109,DNA (did not attend) asthma clinic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,92161000000104,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation using preferred method of communication,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,99031000119107,Acute exacerbation of asthma co-occurrent with allergic rhinitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,125011000119100,Mild persistent asthma co-occurrent with allergic rhinitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,125021000119107,Intermittent asthma co-occurrent with allergic rhinitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,135171000119106,Acute exacerbation of moderate persistent asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,143901000000108,Registration for access to online asthma self-management application,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,143931000000102,Declined to register for access to online asthma self-management application,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,176711000000100,Does not have asthma management plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,198971000000102,Asthma outreach clinic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,201031000000108,Asthma trigger - respiratory infection,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,201041000000104,Asthma trigger - seasonal,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,201051000000101,Asthma trigger - animal,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,201191000000108,Asthma trigger - cold air,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,201201000000105,Asthma trigger - damp,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,201211000000107,Asthma trigger - emotion,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,302331000000106,RCP (Royal College of Physicians) asthma assessment,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,340891000000106,Asthma trigger - airborne dust,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,340901000000107,Asthma trigger - exercise,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,340911000000109,Asthma trigger - pollen,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,340921000000103,Asthma trigger - tobacco smoke,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,340931000000101,Asthma trigger - warm air,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,527171000000103,Patient has a written asthma personal action plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,527191000000104,Health education - asthma self management,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,527211000000100,Health education - structured asthma discussion,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,527231000000108,Health education - structured patient focused asthma discussion,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,713701000000108,Asthma monitoring administration,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,713711000000105,Asthma clinic administration,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,715801000000103,Exception reporting - asthma quality indicators,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,716491000000100,Excepted from asthma quality indicators - informed dissent,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,717291000000103,Excepted from asthma quality indicators - patient unsuitable,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,754061000000100,Asthma review using Royal College of Physicians three questions,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,771901000000100,Asthma causes night time symptoms 1 to 2 times per week,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,771941000000102,Asthma causes symptoms most nights,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,771981000000105,Asthma limits activities 1 to 2 times per month,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,772011000000107,Asthma limits activities 1 to 2 times per week,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,772051000000106,Asthma limits activities most days,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,791401000000104,Seen in school asthma clinic,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,810901000000102,Asthma self-management plan review,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,811151000000105,Number of days absent from school due to asthma in past 6 months,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,811921000000103,Asthma self-management plan agreed,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,815631000000106,Asthma trigger - wind,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,818161000000104,Asthma trigger - perfume,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,866881000000101,Chronic asthma with fixed airflow obstruction,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,867171000000106,No asthma trigger identified by subject,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,892301000000100,Asthma management plan declined,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,905301000000103,Childhood Asthma Control Test score,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,928451000000107,Asthma monitoring invitation short message service text message,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,928511000000107,Asthma monitoring invitation email,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,928651000000105,Review of patient at risk of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,928691000000102,At risk of asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,959401000000101,Asthma monitoring SMS (short message service) text message first invitation,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,959421000000105,Asthma monitoring SMS (short message service) text message second invitation,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,959441000000103,Asthma monitoring SMS (short message service) text message third invitation,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,959901000000107,Asthma action plan,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,966011000000109,At risk of severe asthma exacerbation,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,966031000000101,Severe asthma exacerbation risk assessment,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,1086701000000102,Life threatening acute exacerbation of allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,1086711000000100,Life threatening acute exacerbation of non-allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,1108701000000106,Excepted from asthma quality indicators - service unavailable,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,1110841000000103,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,10674991000119104,Intermittent allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,10675431000119106,Severe persistent allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,10675551000119104,Acute severe exacerbation of severe persistent asthma co-occurrent with allergic rhinitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,10675871000119106,Mild persistent allergic asthma,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,10675991000119100,Acute severe exacerbation of mild persistent allergic asthma co-occurrent with allergic rhinitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,10676031000119106,Mild persistent allergic asthma controlled,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"INHALED CORTICOSTEROIDS (ICS) INCLUDING BECLOMETASONE, BUDESONIDE, FLUTICASONE, BUDESONIDE/FORMOTEROL COMBINATION, FLUTICASONE/SALMETEROL COMBINATION",Asthma (in children),TA131,asthma,10676111000119102,Mild persistent asthma controlled co-occurrent with allergic rhinitis,INHALED,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,2751001,Fibrocalculous pancreatic diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,4855003,Retinopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,5368009,Drug-induced diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,5969009,Diabetes mellitus associated with genetic syndrome,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,6143009,Diabetes mellitus education,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,8801005,Secondary diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,9414007,Latent diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,11530004,Brittle diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,11687002,GDM - gestational diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,15771004,Diabetes insipidus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,21584002,Maternal diabetes syndrome,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,25093002,Disorder of eye due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,25412000,Microaneurysm of retinal artery due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,26298008,Ketoacidotic coma due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,39058009,Lumbosacral radiculoplexus neuropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,43959009,Cataract of eye due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,44054006,T2DM - diabetes mellitus type 2,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,46635009,T1DM - type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,48951005,Bullous disease due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,49455004,Polyneuropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,49817004,Neonatal diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,50620007,Autonomic neuropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,51002006,Pancreatogenic type 3c diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,59276001,Proliferative retinopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,61165007,Adiuretin-resistant diabetes insipidus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,62260007,Pretibial pigmental patches due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,70694009,"DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, deafness) syndrome",INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,73211009,Diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,74627003,Complication due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,75524006,MRDM - malnutrition related diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,111552007,Diabetes mellitus without complication,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,111556005,Ketoacidosis without coma due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,126534007,Mixed sensorimotor polyneuropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,127012008,Lipodystrophic diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,127013003,Disorder of kidney due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,160274005,No family history of diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,160303001,Family history of diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,160402005,Family history: Diabetes in pregnancy,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,161445009,History of diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,161641009,At increased risk of diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,166928007,Glucose tolerance test indicates diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,170745003,Diet controlled diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,170752001,Has seen dietitian - diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,170753006,Understands diet - diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,170766006,Loss of hypoglycaemic warning due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,170774007,Diabetes: practice program,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,170775008,Diabetes: shared care program,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,171183004,Diabetes mellitus screening,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,185753003,Attends diabetes monitoring,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,185754009,Diabetes monitoring declined,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,185755005,Diabetes monitoring default,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,185756006,Diabetes monitoring first letter,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,185757002,Diabetes monitoring second letter,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,185758007,Diabetes monitoring third letter,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,185759004,Diabetes monitoring verbal invite,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,185760009,Diabetes monitoring telephone invite,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,185761008,Diabetes monitoring deleted,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190323008,Non-insulin dependent diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190349003,Diabetes mellitus with neuropathy,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190354007,Diabetes with gangrene,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190368000,Insulin-dependent diabetes mellitus with ulcer,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190372001,Insulin-dependent diabetes maturity onset,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190388001,Type 2 diabetes mellitus with multiple complications,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190389009,Type 2 diabetes mellitus with ulcer,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190406000,Ketoacidosis due to malnutrition related diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190411003,Multiple complications due to malnutrition related diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190412005,Malnutrition-related diabetes mellitus without complications,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190416008,Steroid-induced diabetes mellitus without complication,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190447002,Steroid-induced diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,190484000,Diabetes insipidus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,193141005,Mononeuritis multiplex due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,193183000,Acute painful neuropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,193184006,Chronic painful neuropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,193185007,Asymptomatic neuropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,193349004,Preproliferative retinopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,193350004,Advanced maculopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,193489006,Iritis due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,197605007,Nephrotic syndrome due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,199223000,"Diabetes mellitus during pregnancy, childbirth and the puerperium",INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,199225007,Diabetes mellitus during pregnancy - baby delivered,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,199226008,Diabetes mellitus in the puerperium - baby delivered during current episode of care,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,199227004,Diabetes mellitus during pregnancy - baby not yet delivered,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,199230006,Pre-existing type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,200687002,Cellulitis of foot due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,201250006,Ischemic ulcer of foot due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,201251005,Neuropathic ulcer of foot due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,201723002,Cheiroarthropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,201724008,Neuropathic arthropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,230572002,Neuropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,230574001,Acute painful polyneuropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,230575000,Chronic painful polyneuropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,230577008,Mononeuropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,230579006,Thoracic radiculopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,232020009,Disorder of macula due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,232021008,Proliferative retinopathy with optic disc neovascularization due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,232022001,Proliferative retinopathy with neovascularisation elsewhere than the optic disc due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,232023006,Traction detachment of retina due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,236499007,Microalbuminuric nephropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,236500003,Proteinuric nephropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,237599002,Insulin treated type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,237601000,Secondary endocrine diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,237604008,MODY2 (maturity onset diabetes of the young type 2),INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,237606005,Insulin receptor defect with insulin-resistant diabetes mellitus and acanthosis nigricans,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,237618001,Congenital insulin-dependent diabetes mellitus with fatal secretory diarrhea,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,237619009,Maternally-inherited diabetes and hearing loss,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,237620003,Abnormal metabolic state due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,237621004,Severe hyperglycemia due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,237627000,Pregnancy and type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,237632004,Hypoglycemic event due to diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,237633009,Hypoglycaemia due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,237635002,Nocturnal hypoglycemia due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,238981002,Disorder of soft tissue due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,238982009,Dermopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,238983004,Thick skin syndrome due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,267471001,Diabetes + eye manifestation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,268519009,Diabetes mellitus uncontrolled,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,270445003,Diabetes monitoring check done,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,273411009,Diabetes clinic satisfaction questionnaire,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,273412002,Diabetes treatment satisfaction questionnaire,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,273413007,Diabetes wellbeing questionnaire,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,284350006,Diabetes mellitus diet education,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,290002008,Unstable type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,303059007,Postpancreatectomy diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,304752002,Perceived control of insulin-dependent diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,308505000,Diabetes monitoring call,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,309417009,Diabetes dietitian,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,309426007,Glomerulopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,309593006,Education score - diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,309596003,Retinal abnormality - non-diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,309598002,Foot abnormality - non-diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,309635005,History of admission in last year for diabetes foot problem,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,310425007,Diabetes monitoring invitation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,310505005,Hyperosmolar non-ketotic state due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,311782002,Advanced retinal disease due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,312856000,Referral to diabetes nurse,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,312888008,Attending diabetes clinic,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,312903003,Mild nonproliferative retinopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,312904009,Moderate nonproliferative retinopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,312905005,Severe nonproliferative retinopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,312909004,Proliferative retinopathy with iris neovascularisation due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,312910009,Vitreous hemorrhage due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,312912001,Macular oedema due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,313435000,Insulin-dependent diabetes without complication,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,313436004,Type II diabetes mellitus without complication,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,314010006,Diffuse exudative maculopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,314011005,Focal exudative maculopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,314014002,Ischemic maculopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,314015001,Mixed maculopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,314537004,Optic papillopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,314771006,Insulin dependent diabetes mellitus with hypoglycemic coma,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,315051004,Diabetes resolved,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,315216001,Diabetes mellitus excluded,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,361216007,Femoral mononeuropathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,371087003,Ulcer of foot due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,385805005,Health education - diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,390834004,Nonproliferative retinopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,394725008,Diabetes medication review,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,395123002,Urine screening test for diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,398140007,Post hypoglycaemic hyperglycaemia due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,399868002,Intraretinal microvascular anomaly due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,399871005,Visually threatening retinopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,405749004,Newly diagnosed diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,407569005,Patient on maximal tolerated therapy for diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,408290003,Diabetes key contact,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,408392008,Under care of diabetes specialist nurse,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,408540003,Diabetes mellitus induced by non-steroid drugs,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,413180006,Pan retinal photocoagulation for diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,413597006,Attended diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,414229005,Family/carer attended diabetes structured education program,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,414230000,Family/carer referral to diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,415269004,Referral to diabetes preconception counselling clinic,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,415270003,Referral to diabetes structured education program,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,415744000,Transition of diabetes care options discussed,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,416554009,Seen in community diabetes specialist clinic,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,416855002,Family history of diabetes mellitus in first degree relative,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,417467000,Discharged from care of diabetes specialist nurse,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,419100001,Infection of foot due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,420422005,Ketoacidosis due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,420756003,Cataract of eye due to diabetes mellitus type 2,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,420825003,Gangrene due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,420868002,Disorder due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421631007,Gangrene due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421895002,Peripheral vascular disorder due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421920002,Cataract of eye due to diabetes mellitus type 1,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,422014003,Disorder due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,422088007,Disorder of nervous system due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,422126006,Hyperosmolar coma due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,422183001,Skin ulcer due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,422275004,Gangrene due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,426875007,Latent autoimmune diabetes mellitus in adult,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,428274007,Dietary advice for type II diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,429094000,Dietary advice for type 1 diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,430678008,Family history of diabetes mellitus type 1,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,430679000,Family history of diabetes mellitus type 2,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,439051004,Dietary advice for gestational diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,441656006,Hyperglycaemic crisis due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,443694000,Uncontrolled type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,444073006,Uncontrolled type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,444094009,History of diabetes mellitus in child of subject,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,472969004,H/O diabetes mellitus type 2,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,472970003,H/O diabetes mellitus type 1,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,472971004,Past pregnancy history of gestational diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,473127005,Suspected diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,609561005,MODY - maturity onset diabetes of young,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,609572000,HNF1B (HNF1 homeobox B) monogenic diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,698610002,Education about self management of diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,699826006,Lifestyle education regarding risk of diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,700414001,Education about diabetes and driving,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,703040004,Agreeing on diabetes care plan,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,703136005,Diabetes mellitus in remission,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,703137001,Type 1 diabetes mellitus in remission,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,703138006,Type 2 diabetes mellitus in remission,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,704408003,Invitation for diabetes screening,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,705072004,Diabetes monitoring invitation by short message service text messaging,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,714628002,Prediabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,715159005,Referral to diabetes service,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,715759002,Provision of written information about diabetes and hypertension,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,715879000,Provision of written information about diabetes and high cholesterol,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,719943000,Provision of written information about diabetes and high haemoglobin A1c level,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,720504004,Not suitable for Diabetes Education and Self Management for Ongoing and Newly Diagnosed program,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,720685006,Seen by diabetes specialist nurse,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,720724003,Has diabetes identity card,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,724136006,Mastopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,735199000,History of diabetes related lower limb amputation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,735985000,Diabetes self management plan,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,736284000,Diabetes clinical management plan,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,762291006,Syndrome of infant of mother with gestational diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,762489000,Acute complication due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,763117005,FINDRISC (Finnish Diabetes Risk Score) score,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,763782001,Provision of patient held diabetes record declined,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,765147009,Diabetes Treatment Satisfaction Questionnaire status version score,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,768794008,Cataract of bilateral eyes due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,769182000,Preproliferative retinopathy of left eye due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,769218003,Macular oedema of left eye due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,769222008,Clinically significant macular edema of left eye due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,769244003,Disorder of right macula due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,769245002,Disorder of left macula due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,770096002,Erectile dysfunction due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,816177009,Nonproliferative retinopathy of left eye due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,816178004,Nonproliferative retinopathy of right eye due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,816961009,Stable treated proliferative retinopathy of right eye due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,816962002,Stable treated proliferative retinopathy of left eye due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,860709007,No disorder of macula of left eye due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,860710002,No maculopathy of right eye due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,860712005,Disorder of macula of both eyes due to diabetes mellitus present,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,878859007,Self management of diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,890171006,KPD - ketosis-prone diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,897238003,Diabetes management using closed-loop delivery system,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1196922005,Neovascular glaucoma due to type II diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1196923000,Neovascular glaucoma due to type I diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1258872006,Family referred to diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1258873001,Caregiver referred to diabetes structured education program,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1268646002,Gestational diabetes mellitus screening,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1296758008,Diabetes insipidus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1306699009,Stable treated proliferative retinopathy due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,701000119103,Mixed hyperlipidaemia due to type II diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,24451000000107,Diabetes: shared care in pregnancy - diabetologist and obstetrician,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,40801000119106,Gestational diabetes mellitus complicating pregnancy,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,113131000000107,Informed consent for diabetes national audit,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,113141000000103,Informed dissent for diabetes national audit,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,143401000000102,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation using preferred method of communication,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,143911000000105,Registration for access to online diabetes self-management application,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,143941000000106,Declined to register for access to online diabetes self-management application,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,199481000000100,Diabetes monitoring lower risk albumin excretion,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,199491000000103,Diabetes monitoring higher risk albumin excretion,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,276651000000107,Attended DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,279291000000109,Diabetes type 1 review,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,279321000000104,Diabetes type II review,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,279521000000108,Referral to community diabetes specialist nurse,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,300641000000105,Seen by general practitioner with special interest in diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306401000000106,Attended XPERT (expert patient education versus routine treatment) diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306441000000109,Attended DAFNE (dose adjustment for normal eating) diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306471000000103,DAFNE (dose adjustment for normal eating) diabetes structured education programme completed,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306501000000105,DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme completed,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306531000000104,XPERT (expert patient education versus routine treatment) diabetes structured education programme completed,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306591000000103,Diabetes structured education programme declined,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306701000000102,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306741000000104,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) diabetes structured programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306771000000105,Referral to XPERT (expert patient education versus routine treatment) diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306861000000107,Did not attend diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306931000000106,Did not complete diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306961000000101,Did not complete DAFNE (dose adjustment for normal eating) diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,306991000000107,Did not complete DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,307021000000105,Did not complete XPERT diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,307141000000102,Did not attend DAFNE (dose adjustment for normal eating) diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,307171000000108,Did not attend DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,307201000000109,Did not attend XPERT (expert patient education versus routine treatment) diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,334711000000100,Referral to diabetes special interest general practitioner,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,335621000000101,Maternally inherited diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,344061000000104,Referral to children's diabetes nurse specialist,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,368711000119106,Mild nonproliferative retinopathy due to secondary diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,385041000000108,Diabetes mellitus with multiple complications,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,385051000000106,Pre-existing diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,494961000000102,Discharged from diabetes shared care programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,512561000000108,Unsuitable for diabetes year of care programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,512581000000104,Declined consent for diabetes year of care programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,532411000000102,"Diabetes mellitus, adult onset, with no mention of complication",INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,658011000000104,Diabetes mellitus with other specified manifestation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,658061000000102,Diabetes mellitus NOS with other specified manifestation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,713671000000109,Diabetes monitoring administration,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,713691000000108,Diabetes clinic administration,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,715111000000105,Diabetes screening administration,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,716031000000106,Excepted from diabetes quality indicators - informed dissent,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,716911000000104,Exception reporting - diabetes quality indicators,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,717421000000100,Excepted from diabetes quality indicators - patient unsuitable,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,750721000000102,Excepted from diabetes quality indicators: service unavailable,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,754461000000105,Referral to type I diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,755491000000100,Diabetes structured education programme completed,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,762811000000109,DNA (did not attend) diabetes foot screening,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,764921000000102,Gestational diabetes information leaflet given,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,771571000000102,H/O: secondary diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,781161000000107,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme declined,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,787061000000100,Diabetes care plan declined,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,810961000000103,Diabetes self-management plan review,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,811391000000104,Referral to community diabetes service,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,811981000000102,Diabetes self-management plan agreed,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,816711000000104,Gestational diabetes mellitus annual review,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,819301000000105,Diabetes monitoring injection site check declined,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,819331000000104,Diabetes monitoring injection site not checked,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,828901000000109,Endocrinology and diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,829521000000104,Provision of diabetes clinical summary,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,837491000000107,High risk of diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,838731000000104,Referral to community diabetes specialist nurse declined,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,841221000000102,Referral to community diabetes clinic,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,850581000000106,High risk of diabetes mellitus annual review,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,851501000000106,Diabetes clinical pathway,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,851991000000108,Diabetes quality of life questionnaire score,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,857921000000103,Provision of written information about diabetes and driving,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,858301000000107,Pre-diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,860981000000106,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme declined,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,863501000000102,QDiabetes risk calculator,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,863521000000106,QDiabetes risk calculator score,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,867891000000101,Erectile dysfunction due to diabetes mellitus,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,876381000000100,Conversion to insulin by diabetes specialist nurse,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,885931000000100,Diabetes structured education programme not available,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,887861000000105,Diabetes Year of Care annual review,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,909421000000102,DDS2 (Diabetes Distress Scale 2) score,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,909441000000109,DDS17 - Diabetes Distress Scale 17,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,910931000000101,DDS17 (Diabetes Distress Scale 17) score,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,923461000000103,Lifestyle education for diabetes,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,927821000000100,Discharge from secondary care diabetes service,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,956781000000107,Joint consultation with practice nurse and community diabetes specialist nurse,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,956921000000109,Joint consultation with General Practitioner and community diabetes specialist nurse,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,961931000000109,Diabetes education care plan,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,977201000000107,Recommendation to self-refer for diabetes structured education,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1019431000000105,HbA1c level (Diabetes Control and Complications Trial aligned),INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1019551000000104,HbA1 level (Diabetes Control and Complications Trial aligned),INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1024551000000109,Under care of hospital-based diabetes specialist nurse,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1024571000000100,Under care of community-based diabetes specialist nurse,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1024941000000100,NHS Diabetes Prevention Programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1025211000000108,NHS Diabetes Prevention Programme not completed,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1025251000000107,NHS Diabetes Prevention Programme completed,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1025271000000103,NHS Diabetes Prevention Programme started,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1025301000000100,Referral to NHS Diabetes Prevention Programme declined,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1025321000000109,Referral to NHS Diabetes Prevention Programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1025601000000108,Leicester Diabetes Risk Score,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1054221000000100,Seen in hospital diabetes antenatal clinic,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1065461000000102,Type II diabetes mellitus risk assessment invitation first letter,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1065491000000108,Type II diabetes mellitus risk assessment verbal invitation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1065501000000102,Type II diabetes mellitus risk assessment telephone invitation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1066911000000100,Diabetes monitoring SMS (short message service) text message first invitation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1066921000000106,Diabetes monitoring SMS (short message service) text message second invitation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1066931000000108,Diabetes monitoring SMS (short message service) text message third invitation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1083111000000108,Diabetes monitoring invitation email,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1084661000000103,Diabetes UK Diabetes Risk Score,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1087971000000105,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) score",INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1089101000000109,UKPDS (United Kingdom Prospective Diabetes Study) risk engine score,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1090701000000104,NHS Diabetes Prevention Programme invitation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1092721000000109,Signposting to Diabetes UK,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1092731000000106,Signposting to Diabetes UK Learning Zone,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1097131000000105,Remote diabetes structured education and support programme commenced,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1097141000000101,Remote diabetes structured education and support programme completed,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1098011000000102,Did not commence remote structured diabetes education and support programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1103691000000102,Diabetes structured education programme offered,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1108731000000100,Referral to online diabetes structured education programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1108741000000109,Referral to HeLP-Diabetes (Healthy Living for People with Diabetes) online self-management programme,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1110921000000100,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1362341000000103,Diabetes care plan,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INHALED INSULIN (EXUBERA),Diabetes (types 1 and 2),TA113,diabetes,12275391000119108,Diabetes screening declined,INHALED,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INOSITOL NICOTINATE,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,822611000000100,Exception reporting - peripheral arterial disease quality indicators,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
INOSITOL NICOTINATE,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,822641000000104,Excepted from peripheral arterial disease quality indicators - patient unsuitable,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
INOSITOL NICOTINATE,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,822671000000105,Excepted from peripheral arterial disease quality indicators - informed dissent,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
INOSITOL NICOTINATE,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,968121000000103,Peripheral arterial disease screening,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
INOTUZUMAB,Relapsed or refractory B-cell acute lymphoblastic leukaemia,TA541,acute lymphoblastic leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,INOTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS
INOTUZUMAB,Relapsed or refractory B-cell acute lymphoblastic leukaemia,TA541,acute lymphoblastic leukaemia,413440007,Acute lymphoblastic leukaemia - category,INOTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,46635009,T1DM - type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,290002008,Unstable type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,420825003,Gangrene due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,420868002,Disorder due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,429094000,Dietary advice for type 1 diabetes,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,444073006,Uncontrolled type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,703137001,Type 1 diabetes mellitus in remission,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 1 diabetes,TA053,type 1 diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INSULIN GLARGINE,Type 2 diabetes,TA053,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,INSULIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,62944002,Hepatitis C virus,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,62944002,Hepatitis C virus,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,72165005,Hepatitis C virus antibody,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,72165005,Hepatitis C virus antibody,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,170489004,Viral hepatitis carrier,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,170489004,Viral hepatitis carrier,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,197344005,Hepatitis caused by adenovirus,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,197344005,Hepatitis caused by adenovirus,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,235872006,Hepatitis C carrier,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,235872006,Hepatitis C carrier,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,278973007,Hepatitis C status,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,278973007,Hepatitis C status,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,278974001,Hepatitis C immune,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,278974001,Hepatitis C immune,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,278975000,Hepatitis C non-immune,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,278975000,Hepatitis C non-immune,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,314706002,Hepatitis C antibody detected,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,314706002,Hepatitis C antibody detected,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,314707006,Hepatitis C antibody test negative,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,314707006,Hepatitis C antibody test negative,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,413107006,Hepatitis C screening,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,413107006,Hepatitis C screening,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,773113008,Acute hepatitis caused by infection,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,773113008,Acute hepatitis caused by infection,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,12891000175105,Hepatitis C screening declined,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,12891000175105,Hepatitis C screening declined,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,200371000000104,Hepatitis C contact,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,200371000000104,Hepatitis C contact,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,201451000000105,Hepatitis C immunisation declined,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,201451000000105,Hepatitis C immunisation declined,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,202281000000105,Hepatitis C screening declined,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,202281000000105,Hepatitis C screening declined,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,204671000000101,Hepatitis C screening counselling,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,204671000000101,Hepatitis C screening counselling,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,304821000000107,Hepatitis C screening not offered,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,304821000000107,Hepatitis C screening not offered,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,362491000000104,Hepatitis C screening negative,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,362491000000104,Hepatitis C screening negative,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,362751000000101,Hepatitis C screening positive,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,362751000000101,Hepatitis C screening positive,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,761381000000102,Hepatitis C resolved,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,761381000000102,Hepatitis C resolved,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,824841000000105,Hepatitis C genotype 1,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,824841000000105,Hepatitis C genotype 1,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,824871000000104,Hepatitis C genotype 3,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,824871000000104,Hepatitis C genotype 3,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,829731000000106,On hepatitis C treatment plan,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,829731000000106,On hepatitis C treatment plan,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,992751000000109,Hepatitis C viral load,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,992751000000109,Hepatitis C viral load,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,992771000000100,Hepatitis C virus genotype,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,992771000000100,Hepatitis C virus genotype,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,996031000000104,Hepatitis C IgG level,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,996031000000104,Hepatitis C IgG level,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,998771000000103,Hepatitis C antibody level,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,998771000000103,Hepatitis C antibody level,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,1001331000000102,Hepatitis C antigen level,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,1001331000000102,Hepatitis C antigen level,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,1008931000000108,Hepatitis C antibody test,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,1008931000000108,Hepatitis C antibody test,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,1107671000000106,Hepatitis C screening offered,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON ALPHA,Hepatitis C,TA014,hepatitis c,1107671000000106,Hepatitis C screening offered,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,24700007,Multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,160337009,Family history of multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,192926004,Brain stem multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,192928003,Generalised multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,428700003,Primary progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,438511000,Benign multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,700409000,Suspected multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,198491000000106,Multiple sclerosis review,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,515931000000104,Multiple sclerosis review declined,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1A,Multiple sclerosis,TA527,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,24700007,Multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,160337009,Family history of multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,192926004,Brain stem multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,192928003,Generalised multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,428700003,Primary progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,438511000,Benign multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,700409000,Suspected multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,198491000000106,Multiple sclerosis review,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,515931000000104,Multiple sclerosis review declined,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (BETAFERON),Multiple sclerosis,TA527,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,24700007,Multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,160337009,Family history of multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,192926004,Brain stem multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,192928003,Generalised multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,428700003,Primary progressive multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,438511000,Benign multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,700409000,Suspected multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,198491000000106,Multiple sclerosis review,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,515931000000104,Multiple sclerosis review declined,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTERFERON BETA‑1B (EXTAVIA),Multiple sclerosis,TA527,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,INTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,134405005,Suspected breast cancer,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,160287004,FH: Breast cancer,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,268547008,Screening for breast cancer,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,429740004,Family history of breast cancer,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,431330007,Family history of breast cancer 1 gene mutation,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,431331006,Family history of breast cancer 2 gene mutation,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,706970001,TNBC - Triple-negative breast cancer,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,94361000000105,Breast cancer detected by national screening programme,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,276341000000100,Fast track referral for suspected breast cancer,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,838351000000107,Education about risk of breast cancer,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,874291000000100,QCancer breast cancer risk,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
INTRABEAM RADIOTHERAPY SYSTEM,Adjuvant treatment of early breast cancer,TA501,breast cancer,1035841000000108,Lymphoedema following breast cancer,INTRABEAM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,14651005,Drug-induced osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,18040001,Age-related osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,64859006,Osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,102447009,Postmenopausal osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,160313009,Family history of osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,203429007,Idiopathic generalised osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,203433000,Postoophorectomy osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,203435007,Localized osteoporosis - Lequesne,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,203437004,Osteoporosis in endocrine disorders,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,203438009,Osteoporosis of spine,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,240157009,Secondary generalised osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,240158004,Regional migrating osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,240159007,Transient osteoporosis of hip,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,240162005,Secondary localized osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,268028001,Localised disuse osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,276661002,Primary osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,281387004,Regional osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,300004007,Screening for osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,309745002,Osteoporosis localized to spine,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,310251007,No family history: Osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,313423004,At increased risk of osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391003008,Osteoporosis monitoring administration,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391004002,Attends osteoporosis monitoring,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391006000,Osteoporosis monitoring default,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391007009,Osteoporosis monitoring first letter,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391008004,Osteoporosis monitoring second letter,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391012005,Osteoporosis monitoring deleted,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391013000,Osteoporosis monitoring check done,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391014006,Osteoporosis risk assessment done,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391015007,Osteoporosis risk assessment declined,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391017004,Osteoporosis monitoring,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391018009,Initial osteoporosis assessment,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391019001,Follow-up osteoporosis assessment,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391020007,Osteoporosis treatment started,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391021006,Osteoporosis treatment stopped,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391022004,Osteoporosis treatment changed,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391023009,Osteoporosis - no treatment,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391024003,Osteoporosis - dietary advice,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391025002,Osteoporosis - dietary assessment,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391026001,Osteoporosis - exercise advice,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391027005,Osteoporosis - falls prevention,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391028000,Osteoporosis - treatment response,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391033001,Refer to osteoporosis specialist,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391037000,Seen in osteoporosis clinic,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,394936006,Health education - osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,412717001,Referral to osteoporosis clinic,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,473120007,History of osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,763322002,Osteoporosis monitoring refused,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,711341000000106,Osteoporosis resolved,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS BISPHOSPHONATES (IBANDRONIC ACID AND ZOLEDRONIC ACID),Osteoporosis,TA464,osteoporosis,965871000000101,Osteoporosis medication compliance review,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,162573006,Suspected lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,254637007,Non-small cell lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,275981009,Lung cancer screening,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,429011007,Family history of lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,723301009,Squamous non-small cell lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,1259727001,Primary non-small cell lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,276491000000101,Fast track referral for suspected lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,848881000000108,QCancer lung cancer risk,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,877691000000107,No FH of lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,1771781000000107,Did not attend lung cancer screening,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
INTRAVENOUS TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
INTRAVENOUS TRABECTEDIN,Advanced soft tissue sarcoma,TA185,soft tissue sarcoma,2424003,Soft tissue sarcoma,INTRAVENOUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,915007,Malignant melanoma in junctional naevus,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,1556006,Clark melanoma level 4,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,2092003,Malignant melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,2142002,Nodular melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,16974005,"Acral lentiginous melanoma, malignant",IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,21119008,Benign melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,21165006,Clark melanoma level 3,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,37138001,Epithelioid cell melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,39896009,"Malignant melanoma, regressing",IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,44474009,Lentigo maligna melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,50542000,Clark melanoma level 2,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,50813003,Spitz melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,51757004,"Desmoplastic melanoma, amelanotic",IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,55320002,Superficial spreading melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,68827007,Spindle cell melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,70594002,Amelanotic melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,77986002,Melanoma in situ,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93209006,Malignant melanoma of perianal skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93214005,Malignant melanoma of skin of back,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93217003,Malignant melanoma of skin of cheek,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93220006,Malignant melanoma of skin of ear,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93221005,Malignant melanoma of skin of elbow,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93223008,Malignant melanoma of eyebrow,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93225001,Malignant melanoma of skin of face,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93227009,Malignant melanoma of skin of foot,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93228004,Malignant melanoma of skin of forearm,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93642000,Malignant melanoma of skin of neck,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93643005,Malignant melanoma of external surface of nose,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93646002,Malignant melanoma of skin of scalp,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93647006,Malignant melanoma of skin of shoulder,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93651008,Malignant melanoma of skin of trunk,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93653006,Malignant melanoma of skin of upper limb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93654000,Malignant melanoma of skin of wrist,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,93655004,MM (malignant melanoma) of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,106243009,Breslow depth staging for melanoma of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,109266006,Melanoma in situ of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,109270003,Melanoma in situ of face,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,109272006,Melanoma in situ of lip,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,109276009,Melanoma in situ of scalp,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,109278005,Melanoma in situ of ear,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,109282007,Melanoma in situ of neck,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,109284008,Melanoma in situ of trunk,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,109290007,Melanoma in situ of upper limb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,109294003,Melanoma in situ of lower limb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,127330008,Melanoma in situ by body site (clinical),IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,161432005,History of malignant melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,177281002,Excision of melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188030005,Malignant melanoma of lip,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188033007,Malignant melanoma of auricle (ear),IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188034001,Malignant melanoma of external auditory meatus,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188038003,Malignant melanoma of chin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188040008,Malignant melanoma of forehead,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188042000,Malignant melanoma of temple,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188044004,Malignant melanoma of scalp and/or neck,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188045003,Malignant melanoma of scalp,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188046002,Malignant melanoma of neck,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188049009,Malignant melanoma of axilla,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188050009,Malignant melanoma of breast,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188051008,Malignant melanoma of buttock,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188052001,Malignant melanoma of groin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188054000,Malignant melanoma of perineum,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188055004,Malignant melanoma of umbilicus,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188060000,Malignant melanoma of shoulder,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188061001,Malignant melanoma of upper arm,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188062008,Malignant melanoma of forearm,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188063003,Malignant melanoma of hand,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188064009,Malignant melanoma of finger,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188065005,Malignant melanoma of thumb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188067002,Malignant melanoma of lower limb and hip,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188068007,Malignant melanoma of hip,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188069004,Malignant melanoma of thigh,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188070003,Malignant melanoma of knee,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188071004,Malignant melanoma of popliteal fossa area,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188072006,Malignant melanoma of lower leg,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188073001,Malignant melanoma of ankle,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188074007,Malignant melanoma of heel,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188075008,Malignant melanoma of foot,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188076009,Malignant melanoma of toe,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,188077000,Malignant melanoma of great toe,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,189758001,Melanoma in situ,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,231834005,Malignant melanoma of eyelid,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,254731001,Nodular melanoma of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,254732008,Acral lentiginous melanoma of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,254896002,Malignant melanoma of vulva,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,255004001,Malignant melanoma of conjunctiva,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,255012009,Malignant melanoma of iris,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,255015006,Malignant melanoma of ciliary body,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,255021005,Malignant melanoma of choroid,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,269578002,Malignant melanoma of head and neck,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,269579005,Malignant melanoma of trunk,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,269580008,Malignant melanoma of upper limb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,269581007,Malignant melanoma of lower limb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,274087000,MM (malignant melanoma) of eye,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,276751004,Amelanotic melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,276821000,Malignant melanoma of anus,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,276822007,Malignant melanoma of rectum,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,302837001,Lentigo maligna melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,310498001,Malignant melanoma of back,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,312941005,Melanoma associated retinopathy,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,313248004,Malignant melanoma of chest wall,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,314976006,Local recurrence of malignant melanoma of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,314987003,Metastasis from malignant melanoma of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,315036008,Melanoma in situ of back of hand,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,315230006,Melanoma in situ of back,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,372158004,"Malignant melanoma, metastatic",IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,427858005,Family history of malignant melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,443493003,Metastatic malignant melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,449636007,Malignant melanoma of skin of lower leg,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,449637003,Malignant melanoma of skin of upper arm,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,698040004,Malignant melanoma of nasal cavity,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,1197324006,Metastatic malignant melanoma to skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,351961000119109,Malignant melanoma of skin of right arm,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,352211000119108,Malignant melanoma of skin of left ear,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,546881000000105,Malignant melanoma of skin NOS,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,956331000000107,Malignant melanoma stage IA,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,956351000000100,Malignant melanoma stage IB,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,956371000000109,Malignant melanoma stage IIA,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,956391000000108,Malignant melanoma stage IIB,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,956451000000107,Malignant melanoma stage IIIB,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,956471000000103,Malignant melanoma stage IIIC,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,956511000000107,Malignant melanoma stage IV M1a,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,956551000000106,Malignant melanoma stage IV M1c,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,1080941000119109,Malignant melanoma of left choroid,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously treated advanced (unresectable or metastatic) melanoma,TA268,melanoma,1080981000119104,Malignant melanoma of right choroid,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,915007,Malignant melanoma in junctional naevus,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,1556006,Clark melanoma level 4,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,2092003,Malignant melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,2142002,Nodular melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,16974005,"Acral lentiginous melanoma, malignant",IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,21119008,Benign melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,21165006,Clark melanoma level 3,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,37138001,Epithelioid cell melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,39896009,"Malignant melanoma, regressing",IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,44474009,Lentigo maligna melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,50542000,Clark melanoma level 2,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,50813003,Spitz melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,51757004,"Desmoplastic melanoma, amelanotic",IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,55320002,Superficial spreading melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,68827007,Spindle cell melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,70594002,Amelanotic melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,77986002,Melanoma in situ,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93209006,Malignant melanoma of perianal skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93214005,Malignant melanoma of skin of back,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93217003,Malignant melanoma of skin of cheek,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93220006,Malignant melanoma of skin of ear,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93221005,Malignant melanoma of skin of elbow,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93223008,Malignant melanoma of eyebrow,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93225001,Malignant melanoma of skin of face,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93227009,Malignant melanoma of skin of foot,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93228004,Malignant melanoma of skin of forearm,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93642000,Malignant melanoma of skin of neck,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93643005,Malignant melanoma of external surface of nose,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93646002,Malignant melanoma of skin of scalp,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93647006,Malignant melanoma of skin of shoulder,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93651008,Malignant melanoma of skin of trunk,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93653006,Malignant melanoma of skin of upper limb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93654000,Malignant melanoma of skin of wrist,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,93655004,MM (malignant melanoma) of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,106243009,Breslow depth staging for melanoma of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,109266006,Melanoma in situ of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,109270003,Melanoma in situ of face,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,109272006,Melanoma in situ of lip,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,109276009,Melanoma in situ of scalp,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,109278005,Melanoma in situ of ear,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,109282007,Melanoma in situ of neck,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,109284008,Melanoma in situ of trunk,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,109290007,Melanoma in situ of upper limb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,109294003,Melanoma in situ of lower limb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,127330008,Melanoma in situ by body site (clinical),IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,161432005,History of malignant melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,177281002,Excision of melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188030005,Malignant melanoma of lip,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188033007,Malignant melanoma of auricle (ear),IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188034001,Malignant melanoma of external auditory meatus,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188038003,Malignant melanoma of chin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188040008,Malignant melanoma of forehead,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188042000,Malignant melanoma of temple,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188044004,Malignant melanoma of scalp and/or neck,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188045003,Malignant melanoma of scalp,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188046002,Malignant melanoma of neck,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188049009,Malignant melanoma of axilla,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188050009,Malignant melanoma of breast,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188051008,Malignant melanoma of buttock,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188052001,Malignant melanoma of groin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188054000,Malignant melanoma of perineum,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188055004,Malignant melanoma of umbilicus,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188060000,Malignant melanoma of shoulder,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188061001,Malignant melanoma of upper arm,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188062008,Malignant melanoma of forearm,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188063003,Malignant melanoma of hand,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188064009,Malignant melanoma of finger,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188065005,Malignant melanoma of thumb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188067002,Malignant melanoma of lower limb and hip,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188068007,Malignant melanoma of hip,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188069004,Malignant melanoma of thigh,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188070003,Malignant melanoma of knee,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188071004,Malignant melanoma of popliteal fossa area,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188072006,Malignant melanoma of lower leg,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188073001,Malignant melanoma of ankle,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188074007,Malignant melanoma of heel,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188075008,Malignant melanoma of foot,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188076009,Malignant melanoma of toe,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,188077000,Malignant melanoma of great toe,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,189758001,Melanoma in situ,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,231834005,Malignant melanoma of eyelid,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,254731001,Nodular melanoma of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,254732008,Acral lentiginous melanoma of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,254896002,Malignant melanoma of vulva,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,255004001,Malignant melanoma of conjunctiva,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,255012009,Malignant melanoma of iris,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,255015006,Malignant melanoma of ciliary body,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,255021005,Malignant melanoma of choroid,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,269578002,Malignant melanoma of head and neck,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,269579005,Malignant melanoma of trunk,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,269580008,Malignant melanoma of upper limb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,269581007,Malignant melanoma of lower limb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,274087000,MM (malignant melanoma) of eye,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,276751004,Amelanotic melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,276821000,Malignant melanoma of anus,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,276822007,Malignant melanoma of rectum,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,302837001,Lentigo maligna melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,310498001,Malignant melanoma of back,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,312941005,Melanoma associated retinopathy,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,313248004,Malignant melanoma of chest wall,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,314976006,Local recurrence of malignant melanoma of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,314987003,Metastasis from malignant melanoma of skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,315036008,Melanoma in situ of back of hand,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,315230006,Melanoma in situ of back,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,372158004,"Malignant melanoma, metastatic",IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,427858005,Family history of malignant melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,443493003,Metastatic malignant melanoma,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,449636007,Malignant melanoma of skin of lower leg,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,449637003,Malignant melanoma of skin of upper arm,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,698040004,Malignant melanoma of nasal cavity,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,1197324006,Metastatic malignant melanoma to skin,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,351961000119109,Malignant melanoma of skin of right arm,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,352211000119108,Malignant melanoma of skin of left ear,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,546881000000105,Malignant melanoma of skin NOS,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,956331000000107,Malignant melanoma stage IA,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,956351000000100,Malignant melanoma stage IB,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,956371000000109,Malignant melanoma stage IIA,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,956391000000108,Malignant melanoma stage IIB,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,956451000000107,Malignant melanoma stage IIIB,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,956471000000103,Malignant melanoma stage IIIC,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,956511000000107,Malignant melanoma stage IV M1a,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,956551000000106,Malignant melanoma stage IV M1c,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,1080941000119109,Malignant melanoma of left choroid,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IPILIMUMAB,Previously untreated advanced (unresectable or metastatic) melanoma,TA319,melanoma,1080981000119104,Malignant melanoma of right choroid,IPILIMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
IRINOTECAN,Colorectal cancer (advanced),TA093,colorectal cancer,276401000000108,Fast track referral for suspected colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
IRINOTECAN,Colorectal cancer (advanced),TA093,colorectal cancer,382651000000108,Seen in fast track suspected colorectal cancer clinic,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
IRINOTECAN,Colorectal cancer (advanced),TA093,colorectal cancer,722731000000100,Colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
IRINOTECAN,Colorectal cancer (advanced),TA093,colorectal cancer,848861000000104,QCancer colorectal cancer risk,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
IRINOTECAN,Colorectal cancer (advanced),TA093,colorectal cancer,1034401000000107,Discharge from secondary care colorectal cancer service,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID,Colorectal cancer (advanced),TA093,colorectal cancer,276401000000108,Fast track referral for suspected colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID,Colorectal cancer (advanced),TA093,colorectal cancer,382651000000108,Seen in fast track suspected colorectal cancer clinic,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID,Colorectal cancer (advanced),TA093,colorectal cancer,722731000000100,Colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID,Colorectal cancer (advanced),TA093,colorectal cancer,848861000000104,QCancer colorectal cancer risk,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID,Colorectal cancer (advanced),TA093,colorectal cancer,1034401000000107,Discharge from secondary care colorectal cancer service,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA) (1ST-LINE),Colorectal cancer (advanced),TA033,colorectal cancer,276401000000108,Fast track referral for suspected colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA) (1ST-LINE),Colorectal cancer (advanced),TA033,colorectal cancer,382651000000108,Seen in fast track suspected colorectal cancer clinic,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA) (1ST-LINE),Colorectal cancer (advanced),TA033,colorectal cancer,722731000000100,Colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA) (1ST-LINE),Colorectal cancer (advanced),TA033,colorectal cancer,848861000000104,QCancer colorectal cancer risk,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA) (1ST-LINE),Colorectal cancer (advanced),TA033,colorectal cancer,1034401000000107,Discharge from secondary care colorectal cancer service,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
IRINOTECAN MONOTHERAPY (2ND LINE),Colorectal cancer (advanced),TA033,colorectal cancer,276401000000108,Fast track referral for suspected colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
IRINOTECAN MONOTHERAPY (2ND LINE),Colorectal cancer (advanced),TA033,colorectal cancer,382651000000108,Seen in fast track suspected colorectal cancer clinic,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
IRINOTECAN MONOTHERAPY (2ND LINE),Colorectal cancer (advanced),TA033,colorectal cancer,722731000000100,Colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
IRINOTECAN MONOTHERAPY (2ND LINE),Colorectal cancer (advanced),TA033,colorectal cancer,848861000000104,QCancer colorectal cancer risk,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
IRINOTECAN MONOTHERAPY (2ND LINE),Colorectal cancer (advanced),TA033,colorectal cancer,1034401000000107,Discharge from secondary care colorectal cancer service,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
ISATUXIMAB WITH CARFILZOMIB AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA727,multiple myeloma,230586003,Neuropathy due to multiple myeloma,ISATUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
ISATUXIMAB WITH CARFILZOMIB AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA727,multiple myeloma,413587002,Smoldering multiple myeloma,ISATUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
ISATUXIMAB WITH CARFILZOMIB AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA727,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ISATUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
ISATUXIMAB WITH POMALIDOMIDE AND DEXAMETHASONE,Relapsed and refractory multiple myeloma,TA658,multiple myeloma,230586003,Neuropathy due to multiple myeloma,ISATUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
ISATUXIMAB WITH POMALIDOMIDE AND DEXAMETHASONE,Relapsed and refractory multiple myeloma,TA658,multiple myeloma,413587002,Smoldering multiple myeloma,ISATUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
ISATUXIMAB WITH POMALIDOMIDE AND DEXAMETHASONE,Relapsed and refractory multiple myeloma,TA658,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ISATUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,10335000,Chronic right-sided heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,10633002,Acute congestive heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,36315003,Malignant hypertensive heart disease without congestive heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,48447003,Chronic heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,56675007,Acute heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,77970009,Benign hypertensive heart disease without congestive heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,83105008,Malignant hypertensive heart disease with congestive heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,83291003,Right heart failure due to pulmonary hypertension,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,85232009,Left-sided heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,88805009,Chronic congestive heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,111283005,Chronic left-sided heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,128404006,Right heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,134378009,Congestive heart failure monitoring,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,134440006,Referral to heart failure clinic,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,161505003,History of heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,194779001,Hypertensive heart and renal disease with (congestive) heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,194781004,Hypertensive heart and renal disease with both (congestive) heart failure and renal failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,233924009,Heart failure as a complication of care,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,266308000,Right heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,309634009,History of heart failure in last year,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,314206003,Refractory heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,367363000,Right heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,390868005,Heart failure screen,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,390884006,Heart failure follow-up,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,390885007,Heart failure annual review,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,394887005,Suspected heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,394927007,Heart failure excluded,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,395105005,Heart failure confirmed,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,416683003,Emergency hospital admission for heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,416717003,Seen in heart failure clinic,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,417146007,Referral to heart failure nurse,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,417359009,Seen by community heart failure nurse,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,423475008,Heart failure education,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,424404003,Decompensated chronic heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,426263006,Congestive heart failure due to left ventricular systolic dysfunction,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,426611007,Congestive heart failure due to valvular disease,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,429959009,Family history of heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,441530006,Chronic diastolic heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,446221000,HFpEF - heart failure with preserved ejection fraction,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,473226007,Heart failure medication review,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,703272007,HFrEF - heart failure with reduced ejection fraction,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,703275009,Heart failure with reduced ejection fraction due to cardiomyopathy,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,704095000,Referral to heart failure exercise programme,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,704096004,Referral to heart failure exercise programme not indicated,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,704097008,Referral to heart failure exercise program declined,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,735984001,Heart failure self management plan,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,788950000,HFmEF - heart failure with mid range ejection fraction,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,1296659009,Acute on chronic heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,96311000119109,Exacerbation of congestive heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,143411000000100,QOF (Quality and Outcomes Framework) heart failure quality indicator-related care invitation using preferred method of communication,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,200171000000102,Referred by heart failure nurse specialist,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,200201000000101,Discharge from practice nurse heart failure clinic,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,200361000000106,Did not attend practice nurse heart failure clinic,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,202231000000106,Heart failure review completed,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,203791000000106,Referred to heart failure education group,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,247361000000100,Heart failure 6 month review,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,248571000000104,Did not attend heart failure clinic,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,374231000000104,High risk of heart failure screening invitation,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,521691000000100,Heart failure resolved,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,711461000000104,Heart failure monitoring invitation,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,713791000000101,Heart failure monitoring administration,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,715951000000107,Exception reporting - heart failure quality indicators,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,716621000000101,Heart failure monitoring third letter,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,716971000000109,Heart failure monitoring first letter,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,717191000000108,Heart failure monitoring second letter,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,717481000000104,Excepted from heart failure quality indicators - patient unsuitable,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,717491000000102,Excepted from heart failure quality indicators - informed dissent,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,717501000000108,Heart failure monitoring verbal invitation,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,717531000000102,Heart failure monitoring telephone invitation,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,760361000000100,Fast track heart failure referral for transthoracic two dimensional echocardiogram,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,763641000000102,Referral to heart failure education group declined,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,765661000000102,Discharge from heart failure nurse service,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,781051000000108,Has heart failure management plan,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,789621000000105,Preferred place of care for next exacerbation of heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,810971000000105,Heart failure self-management plan review,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,812001000000102,Heart failure self-management plan agreed,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,813991000000101,Education about deteriorating heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,835981000000108,Rehabilitation for heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,851071000000108,Heart failure initial assessment,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,851521000000102,Heart failure clinical pathway,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,871681000000102,Heart failure monitoring,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,872361000000105,Discussion about heart failure care plan,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,873881000000100,Referral to rapid access heart failure clinic,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,915571000000102,On optimal heart failure therapy,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,961881000000101,Provision of information about heart failure,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,1108711000000108,Excepted from heart failure quality indicators - service unavailable,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IVABRADINE,Chronic heart failure,TA267,heart failure,1110931000000103,QOF (Quality and Outcomes Framework) heart failure quality indicator-related care invitation,IVABRADINE,CARDIOLOGY,CARDIOLOGY
IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA505,multiple myeloma,230586003,Neuropathy due to multiple myeloma,IXAZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA870,multiple myeloma,230586003,Neuropathy due to multiple myeloma,IXAZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA505,multiple myeloma,413587002,Smoldering multiple myeloma,IXAZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA870,multiple myeloma,413587002,Smoldering multiple myeloma,IXAZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA505,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,IXAZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA870,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,IXAZOMIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
IXEKIZUMAB,Axial spondyloarthritis,TA718,axial spondyloarthritis,723116002,Axial spondyloarthritis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY
IXEKIZUMAB,Moderate to severe plaque psoriasis,TA442,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),IXEKIZUMAB,DERMATOLOGY,DERMATOLOGY
IXEKIZUMAB,Moderate to severe plaque psoriasis,TA442,plaque psoriasis,402307000,Chronic large plaque psoriasis,IXEKIZUMAB,DERMATOLOGY,DERMATOLOGY
IXEKIZUMAB,Moderate to severe plaque psoriasis,TA442,plaque psoriasis,402310007,Chronic stable plaque psoriasis,IXEKIZUMAB,DERMATOLOGY,DERMATOLOGY
IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,156370009,Psoriatic arthritis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,156370009,Psoriatic arthritis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,156370009,Psoriatic arthritis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
IXEKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA537,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,IXEKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (adults),TA076,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LAMOTRIGINE,Epilepsy (children),TA079,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LANSOPRAZOLE,Dyspepsia,TA007,dyspepsia,3696007,Non ulcer dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LANSOPRAZOLE,Dyspepsia,TA007,dyspepsia,191972002,Psychogenic dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LANSOPRAZOLE,Dyspepsia,TA007,dyspepsia,192434000,[X]Psychogenic dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LANSOPRAZOLE,Dyspepsia,TA007,dyspepsia,196752002,Flatulent dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LANSOPRAZOLE,Dyspepsia,TA007,dyspepsia,249511005,Flatulent dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LANSOPRAZOLE,Dyspepsia,TA007,dyspepsia,299969005,Dyspepsia caused by drug,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LANSOPRAZOLE,Dyspepsia,TA007,dyspepsia,416202003,Under care of dyspepsia specialist nurse,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LANSOPRAZOLE,Dyspepsia,TA007,dyspepsia,417691002,Discharged from care of dyspepsia specialist nurse,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LANSOPRAZOLE,Dyspepsia,TA007,dyspepsia,203661000000105,Undiagnosed dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LANSOPRAZOLE,Dyspepsia,TA007,dyspepsia,248131000000106,Referral to dyspepsia specialist nurse,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,134405005,Suspected breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,160287004,FH: Breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,268547008,Screening for breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,429740004,Family history of breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,431330007,Family history of breast cancer 1 gene mutation,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,431331006,Family history of breast cancer 2 gene mutation,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,706970001,TNBC - Triple-negative breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,94361000000105,Breast cancer detected by national screening programme,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,276341000000100,Fast track referral for suspected breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,838351000000107,Education about risk of breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,874291000000100,QCancer breast cancer risk,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LAPATINIB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,1035841000000108,Lymphoedema following breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,62944002,Hepatitis C virus,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,62944002,Hepatitis C virus,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,72165005,Hepatitis C virus antibody,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,72165005,Hepatitis C virus antibody,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,170489004,Viral hepatitis carrier,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,170489004,Viral hepatitis carrier,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,197344005,Hepatitis caused by adenovirus,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,197344005,Hepatitis caused by adenovirus,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,235872006,Hepatitis C carrier,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,235872006,Hepatitis C carrier,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,278973007,Hepatitis C status,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,278973007,Hepatitis C status,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,278974001,Hepatitis C immune,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,278974001,Hepatitis C immune,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,278975000,Hepatitis C non-immune,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,278975000,Hepatitis C non-immune,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,314706002,Hepatitis C antibody detected,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,314706002,Hepatitis C antibody detected,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,314707006,Hepatitis C antibody test negative,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,314707006,Hepatitis C antibody test negative,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,413107006,Hepatitis C screening,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,413107006,Hepatitis C screening,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,773113008,Acute hepatitis caused by infection,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,773113008,Acute hepatitis caused by infection,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,12891000175105,Hepatitis C screening declined,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,12891000175105,Hepatitis C screening declined,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,200371000000104,Hepatitis C contact,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,200371000000104,Hepatitis C contact,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,201451000000105,Hepatitis C immunisation declined,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,201451000000105,Hepatitis C immunisation declined,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,202281000000105,Hepatitis C screening declined,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,202281000000105,Hepatitis C screening declined,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,204671000000101,Hepatitis C screening counselling,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,204671000000101,Hepatitis C screening counselling,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,304821000000107,Hepatitis C screening not offered,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,304821000000107,Hepatitis C screening not offered,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,362491000000104,Hepatitis C screening negative,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,362491000000104,Hepatitis C screening negative,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,362751000000101,Hepatitis C screening positive,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,362751000000101,Hepatitis C screening positive,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,761381000000102,Hepatitis C resolved,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,761381000000102,Hepatitis C resolved,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,824841000000105,Hepatitis C genotype 1,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,824841000000105,Hepatitis C genotype 1,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,824871000000104,Hepatitis C genotype 3,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,824871000000104,Hepatitis C genotype 3,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,829731000000106,On hepatitis C treatment plan,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,829731000000106,On hepatitis C treatment plan,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,992751000000109,Hepatitis C viral load,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,992751000000109,Hepatitis C viral load,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,992771000000100,Hepatitis C virus genotype,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,992771000000100,Hepatitis C virus genotype,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,996031000000104,Hepatitis C IgG level,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,996031000000104,Hepatitis C IgG level,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,998771000000103,Hepatitis C antibody level,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,998771000000103,Hepatitis C antibody level,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,1001331000000102,Hepatitis C antigen level,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,1001331000000102,Hepatitis C antigen level,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,1008931000000108,Hepatitis C antibody test,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,1008931000000108,Hepatitis C antibody test,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,1107671000000106,Hepatitis C screening offered,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR,Chronic hepatitis C,TA363,hepatitis c,1107671000000106,Hepatitis C screening offered,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,62944002,Hepatitis C virus,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,62944002,Hepatitis C virus,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,72165005,Hepatitis C virus antibody,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,72165005,Hepatitis C virus antibody,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,170489004,Viral hepatitis carrier,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,170489004,Viral hepatitis carrier,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,197344005,Hepatitis caused by adenovirus,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,197344005,Hepatitis caused by adenovirus,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,235872006,Hepatitis C carrier,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,235872006,Hepatitis C carrier,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,278973007,Hepatitis C status,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,278973007,Hepatitis C status,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,278974001,Hepatitis C immune,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,278974001,Hepatitis C immune,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,278975000,Hepatitis C non-immune,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,278975000,Hepatitis C non-immune,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,314706002,Hepatitis C antibody detected,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,314706002,Hepatitis C antibody detected,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,314707006,Hepatitis C antibody test negative,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,314707006,Hepatitis C antibody test negative,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,413107006,Hepatitis C screening,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,413107006,Hepatitis C screening,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,773113008,Acute hepatitis caused by infection,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,773113008,Acute hepatitis caused by infection,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,12891000175105,Hepatitis C screening declined,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,12891000175105,Hepatitis C screening declined,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,200371000000104,Hepatitis C contact,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,200371000000104,Hepatitis C contact,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,201451000000105,Hepatitis C immunisation declined,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,201451000000105,Hepatitis C immunisation declined,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,202281000000105,Hepatitis C screening declined,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,202281000000105,Hepatitis C screening declined,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,204671000000101,Hepatitis C screening counselling,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,204671000000101,Hepatitis C screening counselling,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,304821000000107,Hepatitis C screening not offered,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,304821000000107,Hepatitis C screening not offered,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,362491000000104,Hepatitis C screening negative,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,362491000000104,Hepatitis C screening negative,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,362751000000101,Hepatitis C screening positive,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,362751000000101,Hepatitis C screening positive,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,761381000000102,Hepatitis C resolved,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,761381000000102,Hepatitis C resolved,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,824841000000105,Hepatitis C genotype 1,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,824841000000105,Hepatitis C genotype 1,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,824871000000104,Hepatitis C genotype 3,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,824871000000104,Hepatitis C genotype 3,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,829731000000106,On hepatitis C treatment plan,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,829731000000106,On hepatitis C treatment plan,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,992751000000109,Hepatitis C viral load,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,992751000000109,Hepatitis C viral load,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,992771000000100,Hepatitis C virus genotype,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,992771000000100,Hepatitis C virus genotype,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,996031000000104,Hepatitis C IgG level,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,996031000000104,Hepatitis C IgG level,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,998771000000103,Hepatitis C antibody level,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,998771000000103,Hepatitis C antibody level,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,1001331000000102,Hepatitis C antigen level,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,1001331000000102,Hepatitis C antigen level,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,1008931000000108,Hepatitis C antibody test,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,1008931000000108,Hepatitis C antibody test,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,1107671000000106,Hepatitis C screening offered,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LEDIPASVIR–SOFOSBUVIR PLUS RIBAVIRIN,Chronic hepatitis C,TA363,hepatitis c,1107671000000106,Hepatitis C screening offered,LEDIPASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
LENALIDOMIDE,Maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma,TA680,multiple myeloma,230586003,Neuropathy due to multiple myeloma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
LENALIDOMIDE,Maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma,TA680,multiple myeloma,413587002,Smoldering multiple myeloma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
LENALIDOMIDE,Maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma,TA680,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
LENALIDOMIDE,Myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality,TA322,myelodysplastic,109998009,MDS-RS-SLD - myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
LENALIDOMIDE,Myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality,TA322,myelodysplastic,398623004,Myelodysplastic syndrome with excess blasts,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
LENALIDOMIDE,Myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality,TA322,myelodysplastic,447596005,"Myelodysplastic/myeloproliferative neoplasm, unclassifiable",LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
LENALIDOMIDE,Relapsed or refractory mantle cell lymphoma,TA774,mantle cell lymphoma,74654000,Mantle cell lymphoma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
LENALIDOMIDE,Relapsed or refractory mantle cell lymphoma,TA774,mantle cell lymphoma,443487006,Mantle cell lymphoma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
LENALIDOMIDE WITH BORTEZOMIB AND DEXAMETHASONE,Untreated multiple myeloma,TA603,multiple myeloma,230586003,Neuropathy due to multiple myeloma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
LENALIDOMIDE WITH BORTEZOMIB AND DEXAMETHASONE,Untreated multiple myeloma,TA603,multiple myeloma,413587002,Smoldering multiple myeloma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
LENALIDOMIDE WITH BORTEZOMIB AND DEXAMETHASONE,Untreated multiple myeloma,TA603,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
LENALIDOMIDE WITH DEXAMETHASONE,Multiple myeloma in adults who have hade at least one prior therapy,TA586,multiple myeloma,230586003,Neuropathy due to multiple myeloma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
LENALIDOMIDE WITH DEXAMETHASONE,Multiple myeloma in adults who have hade at least one prior therapy,TA586,multiple myeloma,413587002,Smoldering multiple myeloma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
LENALIDOMIDE WITH DEXAMETHASONE,Multiple myeloma in adults who have hade at least one prior therapy,TA586,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
LENALIDOMIDE WITH DEXAMETHASONE,Previously untreated multiple myeloma who are not eligible for transplant,TA587,multiple myeloma,230586003,Neuropathy due to multiple myeloma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
LENALIDOMIDE WITH DEXAMETHASONE,Previously untreated multiple myeloma who are not eligible for transplant,TA587,multiple myeloma,413587002,Smoldering multiple myeloma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
LENALIDOMIDE WITH DEXAMETHASONE,Previously untreated multiple myeloma who are not eligible for transplant,TA587,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
LENALIDOMIDE WITH RITUXIMAB,Previously treated follicular lymphoma,TA627,follicular lymphoma,109962001,Nonfollicular lymphoma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
LENALIDOMIDE WITH RITUXIMAB,Previously treated follicular lymphoma,TA627,follicular lymphoma,308121000,Follicular lymphoma,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
LENALIDOMIDE WITH RITUXIMAB,Previously treated follicular lymphoma,TA627,follicular lymphoma,721555001,Follicular lymphoma of small intestine,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
LENALIDOMIDE WITH RITUXIMAB,Previously treated follicular lymphoma,TA627,follicular lymphoma,1148851002,Follicular lymphoma grade IIIa,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
LENALIDOMIDE WITH RITUXIMAB,Previously treated follicular lymphoma,TA627,follicular lymphoma,847481000000109,Follicular lymphoma grade 1,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
LENALIDOMIDE WITH RITUXIMAB,Previously treated follicular lymphoma,TA627,follicular lymphoma,847631000000107,Follicular lymphoma grade 2,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
LENALIDOMIDE WITH RITUXIMAB,Previously treated follicular lymphoma,TA627,follicular lymphoma,847651000000100,Follicular lymphoma grade 3,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
LENALIDOMIDE WITH RITUXIMAB,Previously treated follicular lymphoma,TA627,follicular lymphoma,847691000000108,Follicular lymphoma grade 3a,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
LENALIDOMIDE WITH RITUXIMAB,Previously treated follicular lymphoma,TA627,follicular lymphoma,847701000000108,Follicular lymphoma grade 3b,LENALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
LENVATINIB,Thyroid cancer,TA535,thyroid cancer,94098005,Primary malignant neoplasm of thyroid gland,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY
LENVATINIB,Thyroid cancer,TA535,thyroid cancer,363478007,Malignant tumour of thyroid gland,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY
LENVATINIB,Untreated advance hepatocellular carcinoma,TA551,hepatocellular carcinoma,15619004,"Hepatocellular carcinoma, fibrolamellar",LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
LENVATINIB,Untreated advance hepatocellular carcinoma,TA551,hepatocellular carcinoma,253018005,Fibrolamellar hepatocellular carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
LENVATINIB,Untreated advance hepatocellular carcinoma,TA551,hepatocellular carcinoma,990271000000107,Ultrasound scan surveillance of liver for hepatocellular carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,733608000,Papillary renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,733608000,Papillary renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
LENVATINIB,Untreated advanced renal cell carcinoma,TA858,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
LENVATINIB PLUS EVEROLIMUS,Previously treated advanced renal cell carcinoma,TA498,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
LENVATINIB PLUS EVEROLIMUS,Previously treated advanced renal cell carcinoma,TA498,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
LENVATINIB PLUS EVEROLIMUS,Previously treated advanced renal cell carcinoma,TA498,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
LENVATINIB PLUS EVEROLIMUS,Previously treated advanced renal cell carcinoma,TA498,renal cell carcinoma,733608000,Papillary renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
LENVATINIB PLUS EVEROLIMUS,Previously treated advanced renal cell carcinoma,TA498,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
LENVATINIB PLUS EVEROLIMUS,Previously treated advanced renal cell carcinoma,TA498,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
LENVATINIB PLUS EVEROLIMUS,Previously treated advanced renal cell carcinoma,TA498,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,9386003,Gouty neuritis,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,14763005,Gouty tophus of pinna,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,24595009,Idiopathic gout,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,27277001,Tophus of heart co-occurrent and due to gout,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,43193009,Gouty iritis,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,48440001,Gouty arthropathy,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,67148009,Arthritis of great toe due to gout,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,90560007,Gout,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,160308005,Family history: Gout,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,161451004,History of gout,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,170730005,Gout monitoring,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,170731009,Initial gout assessment,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,170732002,Follow-up gout assessment,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,170733007,Joints gout affected,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,170735000,Date gout treatment started,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,170736004,Date of last gout attack,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,170737008,Gout associated problem,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,170738003,Gout drug side effect,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,170739006,Gout treatment changed,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,170740008,Date gout treatment stopped,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,171190009,Gout screening,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,190828008,Gouty arthropathy,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,190829000,Gouty nephropathy,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,190842000,Chronic tophaceous gout of hand,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,200983001,Parapsoriasis en gouttes,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,201663006,Articular gout of shoulder region,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,201666003,Gouty arthritis of hand,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,201667007,Gouty arthritis of pelvic region and thigh,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,201669005,Gouty arthritis of ankle and/or foot,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,201670006,Articular gout of multiple joints,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,230312006,Aicardi Goutieres syndrome,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,239843003,Secondary gout,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,239844009,Gout secondary to renal impairment,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,239845005,Gout secondary to drug,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,239848007,Gouty bursitis,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,243859006,Gout monitoring status,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,268142006,Pseudogout,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,281362006,Gouty tophus of bursa,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,281363001,Tophus of tendon co-occurrent and due to gout,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,281364007,Gouty tophus of olecranon bursa,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,281365008,Gouty tophus of prepatellar bursa,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,292671009,Drug for the treatment of gout adverse reaction,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,402469004,Gouty tophus,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,428839004,Articular gout of toe,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,770924008,Gout attack,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,427211000000108,[V]Screening for gout,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,924311000000106,Acute exacerbation of gout,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LESINURAD,Chronic hyperuricaemia in people with gout,TA506,gout,1033961000000104,Gouty tophi of toe,LESINURAD,RHEUMATOLOGY,RHEUMATOLOGY
LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,28944009,Cytomegalovirus disease,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,59527008,Congenital cytomegalovirus infection,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,75469003,"Toxoplasmosis, other infections, rubella, cytomegalovirus, and herpes simplex virus antibody panel measurement",LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,120941004,Cytomegalovirus immunoglobulin,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,243579005,Human cytomegalovirus,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,252410004,Cytomegalovirus antibody screening,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,260207001,Early antigen of Cytomegalovirus,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,271500008,Intravenous injection of anticytomegalovirus immunoglobulin,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,304289003,Cytomegalovirus status,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,407444007,Genus Cytomegalovirus,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,445459004,Cytomegalovirus antibody detected in serum,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,64681000237105,CMV (cytomegalovirus) IgG antibody in serum qualitative result,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,791021000000102,Cytomegalovirus IgM antibody positive,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,791071000000103,Cytomegalovirus IgM antibody negative,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,995431000000104,CMV (cytomegalovirus) antibody level,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,998791000000104,Cytomegalovirus antigen test,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,1008531000000101,Cytomegalovirus DNA (deoxyribonucleic acid) detection assay,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,1008731000000105,CMV (cytomegalovirus) IgM antibody level,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,1008741000000101,CMV (cytomegalovirus) IgG antibody level,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,1014131000000100,Cytomegalovirus early antigen level,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,1018601000000108,Cytomegalovirus IgG avidity test,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,1030491000000105,Cytomegalovirus nucleic acid detection assay,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
LETERMOVIR,Preventing cytomegalovirus disease after a stem cell transplant,TA591,cytomegalovirus,1031441000000108,Cytomegalovirus latex test,LETERMOVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
LETROZOLE,Breast cancer (early),TA112,breast cancer,134405005,Suspected breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LETROZOLE,Breast cancer (early),TA112,breast cancer,160287004,FH: Breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LETROZOLE,Breast cancer (early),TA112,breast cancer,268547008,Screening for breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LETROZOLE,Breast cancer (early),TA112,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LETROZOLE,Breast cancer (early),TA112,breast cancer,429740004,Family history of breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LETROZOLE,Breast cancer (early),TA112,breast cancer,431330007,Family history of breast cancer 1 gene mutation,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LETROZOLE,Breast cancer (early),TA112,breast cancer,431331006,Family history of breast cancer 2 gene mutation,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LETROZOLE,Breast cancer (early),TA112,breast cancer,706970001,TNBC - Triple-negative breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LETROZOLE,Breast cancer (early),TA112,breast cancer,94361000000105,Breast cancer detected by national screening programme,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LETROZOLE,Breast cancer (early),TA112,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LETROZOLE,Breast cancer (early),TA112,breast cancer,276341000000100,Fast track referral for suspected breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LETROZOLE,Breast cancer (early),TA112,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LETROZOLE,Breast cancer (early),TA112,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LETROZOLE,Breast cancer (early),TA112,breast cancer,838351000000107,Education about risk of breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LETROZOLE,Breast cancer (early),TA112,breast cancer,874291000000100,QCancer breast cancer risk,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LETROZOLE,Breast cancer (early),TA112,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LETROZOLE,Breast cancer (early),TA112,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LETROZOLE,Breast cancer (early),TA112,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LETROZOLE,Breast cancer (early),TA112,breast cancer,1035841000000108,Lymphoedema following breast cancer,ANASTROZOLE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LEVETIRACETAM,Epilepsy (adults),TA076,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
LIPOSOMAL CYTARABINE–DAUNORUBICIN,Untreated acute myeloid leukaemia,TA552,acute myeloid leukaemia,91861009,"Acute myeloid leukaemia, disease",LIPOSOMAL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,44772007,Maternal obesity without hypertension,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,82793005,Hypothalamic obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,160311006,Family history: Obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,161453001,History of obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,162864005,Body mass index 30+ - obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,170793009,Obesity monitoring,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,170794003,Initial obesity assessment,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,170795002,Follow-up obesity assessment,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,170797005,Has seen dietician - obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,170798000,Treatment of obesity changed,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,170799008,Treatment of obesity started,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,170800007,Treatment of obesity stopped,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,170807005,Reason for obesity therapy - occupational,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,185741002,Attends obesity monitoring,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,185743004,Obesity monitoring default,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,185744005,Obesity monitoring first letter,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,185745006,Obesity monitoring second letter,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,185746007,Obesity monitoring third letter,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,185747003,Obesity monitoring verbal invite,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,185748008,Obesity monitoring telephone invite,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,185749000,Obesity monitoring deleted,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,185750000,Obesity monitoring check done,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,190965006,Drug-induced obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,190966007,Obesity hypoventilation syndrome,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,199072001,(Gestational edema &/or non-hypertension excessive weight gain) or (maternal obesity syndrome),LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,235240002,Procedure using anti-obesity gastric balloon,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,238132000,Upper body obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,238133005,Gynecoid obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,238134004,Generalized obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,238136002,Morbid obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,243862009,Obesity monitoring status,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,247824007,Fear of obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,267511009,Hyperalimentation incl.obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,268522006,Obesity monitoring,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,268551005,Obesity screening,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,270486005,Localized obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,276792008,Pulmonary hypertension with extreme obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,277831002,Anxiety about obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,284352003,Obesity diet education,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,294493008,Lifelong obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,296526005,Adult-onset obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,308504001,Obesity monitoring call,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,310428009,Obesity monitoring invitation,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,415530009,Obesity due to excess calories,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,444862003,Childhood obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,703316004,Lymphoedema associated with obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,715279006,Telehealth obesity monitoring,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,763085007,Obesity monitoring declined,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,198181000000102,Obesity resolved,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,640791000000105,Obesity and other hyperalimentation,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,713951000000106,Obesity monitoring administration,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,713971000000102,Obesity clinic administration,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,753691000000104,Exception reporting - obesity quality indicators,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,753751000000103,Excepted from obesity quality indicators - patient unsuitable,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,753771000000107,Excepted from obesity quality indicators - informed dissent,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,755881000000104,"Risk to health associated with overweight and obesity, at no increased risk",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,755901000000101,"Risk to health associated with overweight and obesity, at increased risk",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,755921000000105,"Risk to health associated with overweight and obesity, at high risk",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,755941000000103,"Risk to health associated with overweight and obesity, at very high risk",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,756001000000107,"Intervention for risk to health associated with overweight and obesity, general advice on healthy weight and lifestyle",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,756021000000103,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,756041000000105,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,756061000000106,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs, consider surgery",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,822741000000107,Anti-obesity drug therapy,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,851901000000101,Obesity and weight loss quality of life questionnaire,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,894961000000105,Referral to multidisciplinary obesity clinic,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,898011000000103,Obesity multidisciplinary case review,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,914801000000107,Anti-obesity drug therapy commenced,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,914821000000103,Obesity medication stopped,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,1269761000000101,Focal segmental glomerulosclerosis due to obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,2386191000000105,National Health Service obesity medication pathway,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,2386201000000107,Referral to National Health Service obesity medication wraparound support pathway,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,2386221000000103,Unsuitable for NHS obesity medication pathway,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,2386231000000101,NHS obesity medication pathway started,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,2386241000000105,National Health Service obesity medication pathway declined,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,2386251000000108,Review of anti-obesity drug therapy,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing obesity in people aged 12 to 17 years,TA749,obesity,2386261000000106,NHS obesity medication wraparound support pathway completed,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,44772007,Maternal obesity without hypertension,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,82793005,Hypothalamic obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,160311006,Family history: Obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,161453001,History of obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,162864005,Body mass index 30+ - obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,170793009,Obesity monitoring,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,170794003,Initial obesity assessment,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,170795002,Follow-up obesity assessment,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,170797005,Has seen dietician - obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,170798000,Treatment of obesity changed,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,170799008,Treatment of obesity started,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,170800007,Treatment of obesity stopped,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,170807005,Reason for obesity therapy - occupational,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,185741002,Attends obesity monitoring,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,185743004,Obesity monitoring default,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,185744005,Obesity monitoring first letter,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,185745006,Obesity monitoring second letter,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,185746007,Obesity monitoring third letter,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,185747003,Obesity monitoring verbal invite,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,185748008,Obesity monitoring telephone invite,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,185749000,Obesity monitoring deleted,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,185750000,Obesity monitoring check done,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,190965006,Drug-induced obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,190966007,Obesity hypoventilation syndrome,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,199072001,(Gestational edema &/or non-hypertension excessive weight gain) or (maternal obesity syndrome),LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,235240002,Procedure using anti-obesity gastric balloon,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,238132000,Upper body obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,238133005,Gynecoid obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,238134004,Generalized obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,238136002,Morbid obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,243862009,Obesity monitoring status,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,247824007,Fear of obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,267511009,Hyperalimentation incl.obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,268522006,Obesity monitoring,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,268551005,Obesity screening,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,270486005,Localized obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,276792008,Pulmonary hypertension with extreme obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,277831002,Anxiety about obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,284352003,Obesity diet education,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,294493008,Lifelong obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,296526005,Adult-onset obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,308504001,Obesity monitoring call,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,310428009,Obesity monitoring invitation,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,415530009,Obesity due to excess calories,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,444862003,Childhood obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,703316004,Lymphoedema associated with obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,715279006,Telehealth obesity monitoring,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,763085007,Obesity monitoring declined,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,198181000000102,Obesity resolved,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,640791000000105,Obesity and other hyperalimentation,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,713951000000106,Obesity monitoring administration,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,713971000000102,Obesity clinic administration,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,753691000000104,Exception reporting - obesity quality indicators,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,753751000000103,Excepted from obesity quality indicators - patient unsuitable,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,753771000000107,Excepted from obesity quality indicators - informed dissent,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,755881000000104,"Risk to health associated with overweight and obesity, at no increased risk",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,755901000000101,"Risk to health associated with overweight and obesity, at increased risk",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,755921000000105,"Risk to health associated with overweight and obesity, at high risk",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,755941000000103,"Risk to health associated with overweight and obesity, at very high risk",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,756001000000107,"Intervention for risk to health associated with overweight and obesity, general advice on healthy weight and lifestyle",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,756021000000103,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,756041000000105,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,756061000000106,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs, consider surgery",LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,822741000000107,Anti-obesity drug therapy,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,851901000000101,Obesity and weight loss quality of life questionnaire,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,894961000000105,Referral to multidisciplinary obesity clinic,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,898011000000103,Obesity multidisciplinary case review,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,914801000000107,Anti-obesity drug therapy commenced,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,914821000000103,Obesity medication stopped,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,1269761000000101,Focal segmental glomerulosclerosis due to obesity,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,2386191000000105,National Health Service obesity medication pathway,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,2386201000000107,Referral to National Health Service obesity medication wraparound support pathway,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,2386221000000103,Unsuitable for NHS obesity medication pathway,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,2386231000000101,NHS obesity medication pathway started,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,2386241000000105,National Health Service obesity medication pathway declined,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,2386251000000108,Review of anti-obesity drug therapy,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
LIRAGLUTIDE,Managing overweight and obesity,TA664,obesity,2386261000000106,NHS obesity medication wraparound support pathway completed,LIRAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG  IN TRIPLE THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN AND A SULPHONYLUREA, OR IN COMBINATION WITH METFORMIN AND A THIAZOLIDINEDIONE)",Type 2 diabetes,TA203,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
"LIRAGLUTIDE 1.2 MG IN DUAL THERAPY REGIMENS (THAT IS, IN COMBINATION WITH METFORMIN OR A SULPHONYLUREA)",Type 2 diabetes,TA203,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LIRAGLUTIDE 1.8 MG,Type 2 diabetes,TA203,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,LIRAGLUTIDE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,162573006,Suspected lung cancer,LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,254637007,Non-small cell lung cancer,LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,275981009,Lung cancer screening,LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,429011007,Family history of lung cancer,LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,877691000000107,No FH of lung cancer,LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
LORLATINIB,Previously treated ALK-positive advanced non-small-cell lung cancer,TA628,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",LORLATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,bipolar disorder,4441000,Severe bipolar disorder with psychotic features,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,4926007,Schizophrenia in remission,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,bipolar disorder,5703000,Bipolar disorder in partial remission,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,12939007,Chronic disorganized schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,bipolar disorder,13313007,Mild bipolar disorder,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,31373002,Hebephrenic schizophrenia in remission,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,31658008,Chronic paranoid schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,35252006,Disorganised schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,39610001,Undifferentiated schizophrenia in remission,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,bipolar disorder,41836007,Bipolar disorder in full remission,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,bipolar disorder,53049002,Severe bipolar disorder without psychotic features,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,58214004,Schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,63181006,"Paranoid schizophrenia, in remission",LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,64905009,Paranoid schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,bipolar disorder,79584002,Moderate bipolar disorder,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,79866005,Subchronic paranoid schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,83746006,Chronic schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,bipolar disorder,85248005,Bipolar disorder in remission,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,111482003,Subchronic schizophrenia with acute exacerbations,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,111483008,"Schizophrenia, catatonic, in remission",LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,111484002,Undifferentiated schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,160328009,Family history of schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,bipolar disorder,160331005,Family history of bipolar disorder,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,161103001,Schizophrenia association member,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,161468000,History of schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,191527001,Simple schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,191531007,Acute exacerbation of chronic schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,191548004,Chronic catatonic schizophrenia with acute exacerbation,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,191554003,Acute exacerbation of subchronic paranoid schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,191555002,Acute exacerbation of chronic paranoid schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,191559008,Latent schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,191565008,Latent schizophrenia in remission,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,191567000,Schizoaffective schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,191570001,Chronic schizoaffective schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,191572009,Acute exacerbation of chronic schizoaffective schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,191574005,"Schizophrenia, schizoaffective, in remission",LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,bipolar disorder,231444002,Organic bipolar disorder,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,247804008,Prodromal schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,274952002,Borderline schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,278853003,Acute schizophrenia-like psychotic disorder,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,444180005,History of schizophrenia in child of subject,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,712824002,Acute polymorphic psychotic disorder without symptoms of schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,712850003,Acute polymorphic psychotic disorder with symptoms of schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,bipolar disorder,767632000,"Bipolar disorder, most recent episode manic",LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,200951000000109,"Psychosis, schizophrenia and bipolar affective disorder resolved",LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,285521000000103,Schizophrenia resolved,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,417601000000102,"[X]Schizophrenia, schizotypal and delusional disorders",LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,443791000000100,[X]Pseudopsychopathic schizophrenia,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,1062101000000104,Schizophrenia TOM (Therapy Outcome Measure) activity score,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,1062121000000108,Schizophrenia TOM (Therapy Outcome Measure) impairment score,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,1062131000000105,Schizophrenia TOM (Therapy Outcome Measure) participation score,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,schizophrenia,1062141000000101,Schizophrenia TOM (Therapy Outcome Measure) wellbeing score,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LOXAPINE INHALATION,Acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder,TA286,bipolar disorder,1365951000000107,Family intervention for psychosis and bipolar disorder,LOXAPINE,MENTAL HEALTH,MENTAL HEALTH
LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,21782001,Drug-induced constipation,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,31499008,Chronic constipation with overflow,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,35298007,Colonic constipation,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,82934008,Chronic idiopathic constipation,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,129691005,At increased risk for constipation,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,191973007,Psychogenic constipation,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,197118003,Functional constipation,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,197119006,Acute constipation,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,197120000,Chronic constipation without overflow,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,235840008,Irritable bowel syndrome variant of childhood with constipation,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,236069009,Chronic constipation,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,236070005,Simple constipation,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,249517009,Constipation alternates with diarrhea,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,266524003,(Functional constipation) or (impacted feces),LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,440630006,Constipation predominant irritable bowel syndrome,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,443307007,Dietary education for constipation,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,448880001,Cleveland Clinic constipation score,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,847591000000107,Constipation in children clinical pathway,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LUBIPROSTONE,Chronic idiopathic constipation,TA318,constipation,1325741000000102,Constipation care indicated,LUBIPROSTONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,86555001,Cystic fibrosis of the lung,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,160309002,Family history of cystic fibrosis,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,171191008,Cystic fibrosis screening,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,235978006,Cystic fibrosis of pancreas,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,427022004,Liver disease due to cystic fibrosis,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,428273001,Cystic fibrosis not suspected,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,428301001,Suspected cystic fibrosis,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,428841003,Cystic fibrosis screening declined,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,441520002,Carrier of cystic fibrosis gene mutation,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,698529000,Seen in cystic fibrosis clinic,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,302651000000109,Cystic fibrosis carrier comment,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,302771000000109,Cystic fibrosis not screened for or screening incomplete,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,384341000000107,Cystic fibrosis repeat screening with further sample required,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,384401000000104,Cystic fibrosis not suspected and other disorders follow up required,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,515611000000104,Cystic fibrosis monitoring,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,515631000000107,Cystic fibrosis annual review,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,526071000000104,Arthropathy in cystic fibrosis,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,526091000000100,Cystic fibrosis with distal intestinal obstruction syndrome,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,776981000000103,Cirrhosis associated with cystic fibrosis,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,859041000000103,Exacerbation of cystic fibrosis,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947031000000109,"Cystic fibrosis screening declined, no history of being screened",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947041000000100,"Cystic fibrosis screening declined, screened in UK (as reported by parents) with no evidence of result",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947061000000104,"Cystic fibrosis screening declined, screened outside UK with evidence of result",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947081000000108,"Cystic fibrosis screening declined, screened outside UK with no evidence of result",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947101000000102,"Cystic fibrosis screening, too young for reliable screening",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947121000000106,"Cystic fibrosis screening,sample taken too soon after blood transfusion (less than 72 hours)",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947141000000104,"Cystic fibrosis screening, insufficient sample",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947161000000103,"Cystic fibrosis screening, unsuitable sample (blood quality): incorrect blood application",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947181000000107,"Cystic fibrosis screening, unsuitable sample (blood quality): compressed/damaged",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947201000000106,"Cystic fibrosis screening, unsuitable sample: day 0 and day 5 on same card",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947221000000102,"Cystic fibrosis screening, unsuitable sample: possible faecal contamination",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947241000000109,"Cystic fibrosis screening, unsuitable sample: NHS number missing/not accurately recorded",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947281000000101,"Cystic fibrosis screening, unsuitable sample: date of sample missing/not accurately recorded",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947301000000100,"Cystic fibrosis screening, unsuitable sample: date of birth not accurately matched",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947321000000109,"Cystic fibrosis screening, unsuitable sample: expired card used",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947341000000102,"Cystic fibrosis screening, unsuitable sample: more than 14 days in transit, too old for analysis",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947361000000101,"Cystic fibrosis screening, unsuitable sample: damaged in transit",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947381000000105,"Cystic fibrosis screening, inconclusive result",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947401000000105,"Cystic fibrosis not screened for or screening incomplete: more than 8 weeks, too old for screening",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947491000000103,"Cystic fibrosis not screened for or screening incomplete, moved out of area",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947511000000106,"Cystic fibrosis not screened for or screening incomplete, not contactable, reasonable efforts made",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,947551000000105,"Cystic fibrosis not screened for or screening incomplete, not required, previous valid result",LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,1015871000000108,Cystic fibrosis screening test,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUMACAFTOR–IVACAFTOR,Treating cystic fibrosis homozygous for the F508del mutation,TA398,cystic fibrosis,1028351000000108,Cystic fibrosis screening,LUMACAFTOR,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
LUSPATERCEPT,Anaemia caused by myelodysplastic syndromes,TA844,myelodysplastic,109998009,MDS-RS-SLD - myelodysplastic syndrome with ring sideroblasts and single lineage dysplasia,LUSPATERCEPT,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
LUSPATERCEPT,Anaemia caused by myelodysplastic syndromes,TA844,myelodysplastic,398623004,Myelodysplastic syndrome with excess blasts,LUSPATERCEPT,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
LUSPATERCEPT,Anaemia caused by myelodysplastic syndromes,TA844,myelodysplastic,447596005,"Myelodysplastic/myeloproliferative neoplasm, unclassifiable",LUSPATERCEPT,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
LUSUTROMBOPAG,Trombocytopenia in people with chronic liver disease needing a planned invasive procedure,TA617,chronic liver disease,197279005,Cirrhosis and chronic liver disease,LUSUTROMBOPAG,GASTROENTEROLOGY,GASTROENTEROLOGY
LUSUTROMBOPAG,Trombocytopenia in people with chronic liver disease needing a planned invasive procedure,TA617,chronic liver disease,197324004,Liver abscess and sequelae of chronic liver disease,LUSUTROMBOPAG,GASTROENTEROLOGY,GASTROENTEROLOGY
LUSUTROMBOPAG,Trombocytopenia in people with chronic liver disease needing a planned invasive procedure,TA617,chronic liver disease,328383001,Chronic liver disease,LUSUTROMBOPAG,GASTROENTEROLOGY,GASTROENTEROLOGY
LUTETIUM (177LU) OXODOTREOTIDE,Unresectable or metastatic gastrointestinal neuroendocrine tumours,TA539,neuroendocrine tumour,48554007,Enterochromaffin cell neuroendocrine tumour,LUTETIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY
LUTETIUM (177LU) OXODOTREOTIDE,Unresectable or metastatic gastrointestinal neuroendocrine tumours,TA539,neuroendocrine tumour,60346004,Non-functioning pancreatic neuroendocrine tumour,LUTETIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY
LUTETIUM (177LU) OXODOTREOTIDE,Unresectable or metastatic gastrointestinal neuroendocrine tumours,TA539,neuroendocrine tumour,707594002,Bronchial neuroendocrine tumour,LUTETIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY
LUTETIUM (177LU) OXODOTREOTIDE,Unresectable or metastatic gastrointestinal neuroendocrine tumours,TA539,neuroendocrine tumour,1287573002,Well-differentiated neuroendocrine tumour of bronchus,LUTETIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY
LUTETIUM (177LU) OXODOTREOTIDE,Unresectable or metastatic gastrointestinal neuroendocrine tumours,TA539,neuroendocrine tumour,1290068000,Well-differentiated neuroendocrine tumour of rectum,LUTETIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,86555001,Cystic fibrosis of the lung,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,160309002,Family history of cystic fibrosis,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,171191008,Cystic fibrosis screening,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,235978006,Cystic fibrosis of pancreas,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,427022004,Liver disease due to cystic fibrosis,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,428273001,Cystic fibrosis not suspected,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,428301001,Suspected cystic fibrosis,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,428841003,Cystic fibrosis screening declined,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,441520002,Carrier of cystic fibrosis gene mutation,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,698529000,Seen in cystic fibrosis clinic,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,302651000000109,Cystic fibrosis carrier comment,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,302771000000109,Cystic fibrosis not screened for or screening incomplete,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,384341000000107,Cystic fibrosis repeat screening with further sample required,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,384401000000104,Cystic fibrosis not suspected and other disorders follow up required,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,515611000000104,Cystic fibrosis monitoring,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,515631000000107,Cystic fibrosis annual review,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,526071000000104,Arthropathy in cystic fibrosis,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,526091000000100,Cystic fibrosis with distal intestinal obstruction syndrome,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,776981000000103,Cirrhosis associated with cystic fibrosis,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,859041000000103,Exacerbation of cystic fibrosis,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947031000000109,"Cystic fibrosis screening declined, no history of being screened",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947041000000100,"Cystic fibrosis screening declined, screened in UK (as reported by parents) with no evidence of result",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947061000000104,"Cystic fibrosis screening declined, screened outside UK with evidence of result",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947081000000108,"Cystic fibrosis screening declined, screened outside UK with no evidence of result",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947101000000102,"Cystic fibrosis screening, too young for reliable screening",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947121000000106,"Cystic fibrosis screening,sample taken too soon after blood transfusion (less than 72 hours)",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947141000000104,"Cystic fibrosis screening, insufficient sample",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947161000000103,"Cystic fibrosis screening, unsuitable sample (blood quality): incorrect blood application",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947181000000107,"Cystic fibrosis screening, unsuitable sample (blood quality): compressed/damaged",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947201000000106,"Cystic fibrosis screening, unsuitable sample: day 0 and day 5 on same card",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947221000000102,"Cystic fibrosis screening, unsuitable sample: possible faecal contamination",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947241000000109,"Cystic fibrosis screening, unsuitable sample: NHS number missing/not accurately recorded",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947281000000101,"Cystic fibrosis screening, unsuitable sample: date of sample missing/not accurately recorded",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947301000000100,"Cystic fibrosis screening, unsuitable sample: date of birth not accurately matched",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947321000000109,"Cystic fibrosis screening, unsuitable sample: expired card used",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947341000000102,"Cystic fibrosis screening, unsuitable sample: more than 14 days in transit, too old for analysis",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947361000000101,"Cystic fibrosis screening, unsuitable sample: damaged in transit",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947381000000105,"Cystic fibrosis screening, inconclusive result",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947401000000105,"Cystic fibrosis not screened for or screening incomplete: more than 8 weeks, too old for screening",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947491000000103,"Cystic fibrosis not screened for or screening incomplete, moved out of area",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947511000000106,"Cystic fibrosis not screened for or screening incomplete, not contactable, reasonable efforts made",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,947551000000105,"Cystic fibrosis not screened for or screening incomplete, not required, previous valid result",MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,1015871000000108,Cystic fibrosis screening test,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MANNITOL DRY POWDER FOR INHALATION,Cystic fibrosis,TA266,cystic fibrosis,1028351000000108,Cystic fibrosis screening,MANNITOL,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,28944009,Cytomegalovirus disease,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,59527008,Congenital cytomegalovirus infection,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,75469003,"Toxoplasmosis, other infections, rubella, cytomegalovirus, and herpes simplex virus antibody panel measurement",MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,120941004,Cytomegalovirus immunoglobulin,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,243579005,Human cytomegalovirus,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,252410004,Cytomegalovirus antibody screening,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,260207001,Early antigen of Cytomegalovirus,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,271500008,Intravenous injection of anticytomegalovirus immunoglobulin,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,304289003,Cytomegalovirus status,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,407444007,Genus Cytomegalovirus,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,445459004,Cytomegalovirus antibody detected in serum,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,64681000237105,CMV (cytomegalovirus) IgG antibody in serum qualitative result,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,791021000000102,Cytomegalovirus IgM antibody positive,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,791071000000103,Cytomegalovirus IgM antibody negative,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,995431000000104,CMV (cytomegalovirus) antibody level,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,998791000000104,Cytomegalovirus antigen test,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,1008531000000101,Cytomegalovirus DNA (deoxyribonucleic acid) detection assay,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,1008731000000105,CMV (cytomegalovirus) IgM antibody level,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,1008741000000101,CMV (cytomegalovirus) IgG antibody level,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,1014131000000100,Cytomegalovirus early antigen level,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,1018601000000108,Cytomegalovirus IgG avidity test,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,1030491000000105,Cytomegalovirus nucleic acid detection assay,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
MARIBAVIR,Refractory cytomegalovirus infection after transplant,TA860,cytomegalovirus,1031441000000108,Cytomegalovirus latex test,MARIBAVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|TRANSPLANTATION SURGERY
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,22193007,Osteoarthritis of joint of hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,33952002,Localised osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,37895003,Osteoarthritis of first carpometacarpal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,82300000,Osteoarthritis of ankle and/or foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,160414002,Family history: Osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,161567008,History of rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,161568003,History of osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201819000,Generalised osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201821005,(Heberdens' nodes) or (Bouchards' nodes) or (generalized osteoarthritis of the hand),CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201831003,"Localized, primary osteoarthritis of the shoulder region",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201835007,"Localized, primary osteoarthritis of the pelvic region and thigh",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201837004,"Localised, primary osteoarthritis of the ankle and foot",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201849003,"Localised, secondary osteoarthritis of the shoulder region",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201852006,"Localised, secondary osteoarthritis of the hand",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201855008,"Localized, secondary osteoarthritis of the ankle and/or foot",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201889009,"Osteoarthritis NOS, of the upper arm",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201890000,Wrist osteoarthritis NOS,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201891001,Thumb osteoarthritis NOS,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201892008,Osteoarthritis NOS: [pelvic region and/or thigh] or [hip],CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201893003,Knee osteoarthritis NOS,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201894009,"Osteoarthritis NOS, of ankle and foot",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,202655008,Osteoarthritis of spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239863005,Osteoarthritis of spinal facet joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239866002,Osteoarthritis of elbow,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239868001,Osteoarthritis of finger,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239874001,Osteoarthritis of ankle,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239877008,Osteoarthritis of first MTPJ (metatarsophalangeal joint),CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239878003,Osteoarthritis of toe joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,267889007,Generalized osteoarthritis of the hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,267890003,"Localised, secondary osteoarthritis of the pelvic region and thigh",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,267891004,"Localized osteoarthritis, unspecified, of the pelvic region and thigh",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,268054009,Osteoarthritis of multiple joints,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,313257005,"Localized, primary osteoarthritis of the wrist",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,313258000,"Localised, primary osteoarthritis of toe",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,313259008,"Localized, primary osteoarthritis of elbow",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,373623009,Osteoarthritis of glenohumeral joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,394991004,Flare of osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,443524000,Secondary osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,446165001,HOOS - hip disability and osteoarthritis outcome score,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,450521003,Osteoarthritis of patellofemoral joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,700324005,Osteoarthritis of talonavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,782845000,Knee Injury and Osteoarthritis Outcome Score,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1162304008,Oligoarticular osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343601009,OA (osteoarthritis) of spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343603007,Osteoarthritis of thoracic spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343604001,Cervical osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343605000,Osteoarthritis of lumbar spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,230771000000108,Delivery of rehabilitation for osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,323301000119109,Osteoarthritis of left knee joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,323311000119107,Osteoarthritis of right hip joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,637091000000105,"Osteoarthritis NOS, of the lower leg",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,666441000000103,"Osteoarthritis NOS, of shoulder region",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,666451000000100,"Osteoarthritis NOS, other specified site",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,805881000000109,Exception reporting - osteoarthritis quality indicators,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,805901000000107,Excepted from osteoarthritis quality indicators - patient unsuitable,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,805921000000103,Excepted from osteoarthritis quality indicators - informed dissent,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,850791000000102,Osteoarthritis of sternoclavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELOXICAM,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
MELPHALAN,Haematological diseases before allogeneic haematopoietic stem cell transplant,TA822,stem cell transplant,234336002,Haemopoietic stem cell transplant,MELPHALAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY
MELPHALAN,Haematological diseases before allogeneic haematopoietic stem cell transplant,TA822,stem cell transplant,397554006,Limbal stem cell transplantation,MELPHALAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY
MELPHALAN,Haematological diseases before allogeneic haematopoietic stem cell transplant,TA822,stem cell transplant,425843001,Allogeneic peripheral blood stem cell transplant,MELPHALAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY
MELPHALAN,Haematological diseases before allogeneic haematopoietic stem cell transplant,TA822,stem cell transplant,425983008,Autologous peripheral blood stem cell transplant,MELPHALAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY
MELPHALAN,Haematological diseases before allogeneic haematopoietic stem cell transplant,TA822,stem cell transplant,284681000000100,Syngeneic peripheral blood stem cell transplant,MELPHALAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY
MEMANTINE,Alzheimer's disease,TA111,alzheimer's disease,273269001,ADAS - Alzheimer's Disease Assessment Scale,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
MEMANTINE,Alzheimer's disease,TA111,alzheimer's disease,416780008,Dementia in Alzheimer's disease with early onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
MEMANTINE,Alzheimer's disease,TA111,alzheimer's disease,416975007,Alzheimer's disease with late onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
MEMANTINE,Alzheimer's disease,TA111,alzheimer's disease,142011000119109,Alzheimer's disease co-occurrent with delirium,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
MEMANTINE,Alzheimer's disease (moderate),TA217,alzheimer's disease,273269001,ADAS - Alzheimer's Disease Assessment Scale,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
MEMANTINE,Alzheimer's disease (moderate),TA217,alzheimer's disease,416780008,Dementia in Alzheimer's disease with early onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
MEMANTINE,Alzheimer's disease (moderate),TA217,alzheimer's disease,416975007,Alzheimer's disease with late onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
MEMANTINE,Alzheimer's disease (moderate),TA217,alzheimer's disease,142011000119109,Alzheimer's disease co-occurrent with delirium,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
MEMANTINE,Alzheimer's disease (severe),TA217,alzheimer's disease,273269001,ADAS - Alzheimer's Disease Assessment Scale,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
MEMANTINE,Alzheimer's disease (severe),TA217,alzheimer's disease,416780008,Dementia in Alzheimer's disease with early onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
MEMANTINE,Alzheimer's disease (severe),TA217,alzheimer's disease,416975007,Alzheimer's disease with late onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
MEMANTINE,Alzheimer's disease (severe),TA217,alzheimer's disease,142011000119109,Alzheimer's disease co-occurrent with delirium,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
MEPOLIZUMAB,Eosinophilic granulomatosis with polyangiitis,TA845,granulomatosis with polyangiitis,82275008,EGPA - eosinophilic granulomatosis with polyangiitis,MEPOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|THORACIC MEDICINE|NEPHROLOGY
MEPOLIZUMAB,Eosinophilic granulomatosis with polyangiitis,TA845,granulomatosis with polyangiitis,239935007,Limited granulomatosis with polyangiitis,MEPOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|THORACIC MEDICINE|NEPHROLOGY
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,12428000,Intrinsic asthma without status asthmaticus,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,31387002,Exercise-induced asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,34015007,Flour asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,56018004,Asthmatic breathing,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,56968009,Asthma caused by wood dust,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,57607007,Industrial asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,63088003,Allergic asthma without status asthmaticus,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,71892000,Cardiac asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,93432008,Drug-induced asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,160377001,Family history of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,161105008,Asthma society member,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,161527007,History of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,162660004,Asthma resolved,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170607007,Respiratory disease monitoring (& [asthma] or [chronic]),MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170631002,Asthma disturbing sleep,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170632009,Asthma causing night waking,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170633004,Asthma disturbs sleep weekly,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170634005,Asthma disturbs sleep frequently,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170635006,Asthma not disturbing sleep,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170636007,Asthma never disturbs sleep,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170637003,Asthma limiting activities,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170638008,Asthma not limiting activities,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170642006,Asthma severity,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170647000,Asthma prophylactic medication used,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170655007,Asthma restricts exercise,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170656008,Asthma sometimes restricts exercise,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170657004,Asthma severely restricts exercise,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,170658009,Asthma never restricts exercise,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,171231001,Asthma screening,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,182724005,Further asthma - drug prevention,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,182726007,Asthma control step 0,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,182727003,Asthma control step 1,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,182728008,Asthma control step 2,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,182729000,Asthma control step 3,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,182730005,Asthma control step 4,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,182731009,Asthma control step 5,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,183099005,Asthma leaflet given,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,183478001,Emergency hospital admission for asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,185242005,Seen in asthma clinic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,185728001,Attends asthma monitoring,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,185730004,Asthma monitor offer default,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,185731000,Asthma monitoring call first letter,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,185732007,Asthma monitoring call second letter,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,185734008,Asthma monitoring call third letter,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,185735009,Asthma monitoring call verbal invite,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,185736005,Asthma monitoring call telephone invite,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,185737001,Asthma monitoring deleted,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,185940009,Patient in asthma study,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,195113008,(Left ventricular: [failure] or [impaired function]) or (cardiac asthma) or (acute pulmonary edema),MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,195949008,Chronic asthmatic bronchitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,195967001,Asthmatic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,195968006,Asthma: [extrinsic - atopic] or [allergic] or [pollen] or [childhood] or [with hay fever],MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,195973000,Late-onset asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,195977004,Mixed asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,195983001,Exercise induced asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,219036002,Adverse reaction to antiasthmatic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,225057002,Brittle asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,233678006,Childhood asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,233679003,Late-onset asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,233683003,Hay fever with asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,233691007,Eosinophilic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,266361008,Non-allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,266396008,Extrinsic asthma - atopy (& pollen),MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,266397004,Intrinsic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,266398009,Asthma attack,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,270442000,Asthma monitoring check done,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,275908000,Asthma monitoring,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,281239006,Asthma attack,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,302220000,Asthma control steps,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,304527002,Acute asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,308500005,Asthma monitoring call,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,308501009,Asthma monitoring status,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,312453004,Asthma - currently active,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,312454005,Asthma - currently dormant,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,366874008,Number of asthma exacerbations in past year,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370202007,Asthma causes daytime symptoms 1 to 2 times per month,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370203002,Asthma causes daytime symptoms 1 to 2 times per week,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370204008,Asthma causes daytime symptoms most days,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370205009,Asthma causes night symptoms 1 to 2 times per month,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370206005,Asthma limits walking on the flat,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370207001,Asthma limits walking up hills or stairs,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370208006,Asthma never causes daytime symptoms,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370218001,Mild asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370219009,Moderate asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370220003,Occasional asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370221004,Severe asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370225008,Asthma treatment compliance unsatisfactory,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,370226009,Asthma treatment compliance satisfactory,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,373899003,Asthma daytime symptoms,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,389145006,Allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,390798007,Asthma finding,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,390872009,Change in asthma management plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,390877003,Step up change in asthma management plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,390878008,Step down change in asthma management plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,390921001,Absent from work or school due to asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,390940007,Asthma monitoring due,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,394700004,Asthma annual review,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,394701000,Asthma follow-up,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,394720003,Asthma medication review,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,394967008,Suspected asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,395022009,Nocturnal asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,400987003,Asthma trigger,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,401135008,Health education - asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,401182001,Asthma monitoring by nurse,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,401183006,Asthma monitoring by doctor,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,401193004,Asthma confirmed,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,405944004,Asthmatic bronchitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,406162001,Asthma care,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,407674008,Aspirin-induced asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,409663006,Cough variant asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,415265005,Referral to asthma clinic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,423889005,Non-immunoglobulin E mediated allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,424643009,Allergic atopic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,425969006,Acute intermittent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,426656000,Severe persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,426979002,Mild persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,427295004,Moderate persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,427603009,Intermittent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,427679007,Mild intermittent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,442025000,Acute exacerbation of chronic asthmatic bronchitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,443117005,Asthma control test score,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,445427006,Seasonal asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,445531003,ACQ - Asthma control questionnaire,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,473391009,Asthma never causes night symptoms,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,698509001,Under care of asthma specialist nurse,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,699191007,Did not attend asthma review,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,702823004,Asthma clinic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,704008007,No family history of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,707445000,Acute mild persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,707446004,Acute exacerbation of moderate persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,707447008,Exacerbation of severe persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,707511009,Uncomplicated mild persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,707512002,Uncomplicated moderate persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,707513007,Uncomplicated severe persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,707979007,Acute severe exacerbation of severe persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,707980005,Acute severe exacerbation of moderate persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,707981009,Acute severe exacerbation of mild persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,708038006,Acute exacerbation of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,708090002,Acute severe exacerbation of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,708093000,Acute exacerbation of allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,708094006,Acute exacerbation of intrinsic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,708095007,Acute severe exacerbation of extrinsic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,708358003,Emergency asthma admission since last encounter,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,708373002,Emergency asthma patient visit since last encounter,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,711442001,Recent asthma management,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,715191006,Telehealth asthma monitoring,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,734346005,Use of asthma symptom diary,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,734904007,Life threatening acute exacerbation of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,734905008,Moderate acute exacerbation of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,736056000,Asthma clinical management plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,762521001,Acute allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,763077003,Asthma Control Questionnaire score,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,763221007,Asthma monitoring declined,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,763695004,Mini Asthma Quality of Life Questionnaire score,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,782520007,Exacerbation of allergic asthma due to infection,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,782559003,Asthma never causes night symptoms,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,401000119107,Asthma with irreversible airway obstruction,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,641000119106,Intermittent asthma well controlled,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,1741000119102,Intermittent asthma uncontrolled,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,72301000119103,Asthma in pregnancy,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,89581000000109,DNA (did not attend) asthma clinic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,92161000000104,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation using preferred method of communication,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,99031000119107,Acute exacerbation of asthma co-occurrent with allergic rhinitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,125011000119100,Mild persistent asthma co-occurrent with allergic rhinitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,125021000119107,Intermittent asthma co-occurrent with allergic rhinitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,135171000119106,Acute exacerbation of moderate persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,143901000000108,Registration for access to online asthma self-management application,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,143931000000102,Declined to register for access to online asthma self-management application,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,176711000000100,Does not have asthma management plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,198971000000102,Asthma outreach clinic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,201031000000108,Asthma trigger - respiratory infection,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,201041000000104,Asthma trigger - seasonal,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,201051000000101,Asthma trigger - animal,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,201191000000108,Asthma trigger - cold air,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,201201000000105,Asthma trigger - damp,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,201211000000107,Asthma trigger - emotion,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,302331000000106,RCP (Royal College of Physicians) asthma assessment,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,340891000000106,Asthma trigger - airborne dust,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,340901000000107,Asthma trigger - exercise,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,340911000000109,Asthma trigger - pollen,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,340921000000103,Asthma trigger - tobacco smoke,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,340931000000101,Asthma trigger - warm air,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,527171000000103,Patient has a written asthma personal action plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,527191000000104,Health education - asthma self management,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,527211000000100,Health education - structured asthma discussion,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,527231000000108,Health education - structured patient focused asthma discussion,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,713701000000108,Asthma monitoring administration,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,713711000000105,Asthma clinic administration,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,715801000000103,Exception reporting - asthma quality indicators,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,716491000000100,Excepted from asthma quality indicators - informed dissent,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,717291000000103,Excepted from asthma quality indicators - patient unsuitable,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,754061000000100,Asthma review using Royal College of Physicians three questions,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,771901000000100,Asthma causes night time symptoms 1 to 2 times per week,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,771941000000102,Asthma causes symptoms most nights,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,771981000000105,Asthma limits activities 1 to 2 times per month,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,772011000000107,Asthma limits activities 1 to 2 times per week,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,772051000000106,Asthma limits activities most days,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,791401000000104,Seen in school asthma clinic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,810901000000102,Asthma self-management plan review,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,811151000000105,Number of days absent from school due to asthma in past 6 months,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,811921000000103,Asthma self-management plan agreed,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,815631000000106,Asthma trigger - wind,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,818161000000104,Asthma trigger - perfume,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,866881000000101,Chronic asthma with fixed airflow obstruction,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,867171000000106,No asthma trigger identified by subject,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,892301000000100,Asthma management plan declined,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,905301000000103,Childhood Asthma Control Test score,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,928451000000107,Asthma monitoring invitation short message service text message,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,928511000000107,Asthma monitoring invitation email,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,928651000000105,Review of patient at risk of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,928691000000102,At risk of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,959401000000101,Asthma monitoring SMS (short message service) text message first invitation,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,959421000000105,Asthma monitoring SMS (short message service) text message second invitation,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,959441000000103,Asthma monitoring SMS (short message service) text message third invitation,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,959901000000107,Asthma action plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,966011000000109,At risk of severe asthma exacerbation,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,966031000000101,Severe asthma exacerbation risk assessment,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,1086701000000102,Life threatening acute exacerbation of allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,1086711000000100,Life threatening acute exacerbation of non-allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,1108701000000106,Excepted from asthma quality indicators - service unavailable,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,1110841000000103,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,10674991000119104,Intermittent allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,10675431000119106,Severe persistent allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,10675551000119104,Acute severe exacerbation of severe persistent asthma co-occurrent with allergic rhinitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,10675871000119106,Mild persistent allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,10675991000119100,Acute severe exacerbation of mild persistent allergic asthma co-occurrent with allergic rhinitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,10676031000119106,Mild persistent allergic asthma controlled,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB,Severe eosinophilic asthma,TA671,asthma,10676111000119102,Mild persistent asthma controlled co-occurrent with allergic rhinitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,12428000,Intrinsic asthma without status asthmaticus,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,31387002,Exercise-induced asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,34015007,Flour asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,56018004,Asthmatic breathing,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,56968009,Asthma caused by wood dust,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,57607007,Industrial asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,63088003,Allergic asthma without status asthmaticus,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,71892000,Cardiac asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,93432008,Drug-induced asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,160377001,Family history of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,161105008,Asthma society member,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,161527007,History of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,162660004,Asthma resolved,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170607007,Respiratory disease monitoring (& [asthma] or [chronic]),MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170631002,Asthma disturbing sleep,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170632009,Asthma causing night waking,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170633004,Asthma disturbs sleep weekly,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170634005,Asthma disturbs sleep frequently,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170635006,Asthma not disturbing sleep,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170636007,Asthma never disturbs sleep,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170637003,Asthma limiting activities,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170638008,Asthma not limiting activities,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170642006,Asthma severity,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170647000,Asthma prophylactic medication used,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170655007,Asthma restricts exercise,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170656008,Asthma sometimes restricts exercise,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170657004,Asthma severely restricts exercise,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,170658009,Asthma never restricts exercise,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,171231001,Asthma screening,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,182724005,Further asthma - drug prevention,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,182726007,Asthma control step 0,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,182727003,Asthma control step 1,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,182728008,Asthma control step 2,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,182729000,Asthma control step 3,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,182730005,Asthma control step 4,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,182731009,Asthma control step 5,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,183099005,Asthma leaflet given,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,183478001,Emergency hospital admission for asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,185242005,Seen in asthma clinic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,185728001,Attends asthma monitoring,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,185730004,Asthma monitor offer default,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,185731000,Asthma monitoring call first letter,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,185732007,Asthma monitoring call second letter,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,185734008,Asthma monitoring call third letter,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,185735009,Asthma monitoring call verbal invite,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,185736005,Asthma monitoring call telephone invite,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,185737001,Asthma monitoring deleted,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,185940009,Patient in asthma study,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,195113008,(Left ventricular: [failure] or [impaired function]) or (cardiac asthma) or (acute pulmonary edema),MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,195949008,Chronic asthmatic bronchitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,195967001,Asthmatic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,195968006,Asthma: [extrinsic - atopic] or [allergic] or [pollen] or [childhood] or [with hay fever],MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,195973000,Late-onset asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,195977004,Mixed asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,195983001,Exercise induced asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,219036002,Adverse reaction to antiasthmatic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,225057002,Brittle asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,233678006,Childhood asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,233679003,Late-onset asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,233683003,Hay fever with asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,233691007,Eosinophilic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,266361008,Non-allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,266396008,Extrinsic asthma - atopy (& pollen),MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,266397004,Intrinsic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,266398009,Asthma attack,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,270442000,Asthma monitoring check done,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,275908000,Asthma monitoring,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,281239006,Asthma attack,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,302220000,Asthma control steps,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,304527002,Acute asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,308500005,Asthma monitoring call,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,308501009,Asthma monitoring status,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,312453004,Asthma - currently active,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,312454005,Asthma - currently dormant,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,366874008,Number of asthma exacerbations in past year,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370202007,Asthma causes daytime symptoms 1 to 2 times per month,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370203002,Asthma causes daytime symptoms 1 to 2 times per week,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370204008,Asthma causes daytime symptoms most days,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370205009,Asthma causes night symptoms 1 to 2 times per month,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370206005,Asthma limits walking on the flat,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370207001,Asthma limits walking up hills or stairs,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370208006,Asthma never causes daytime symptoms,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370218001,Mild asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370219009,Moderate asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370220003,Occasional asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370221004,Severe asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370225008,Asthma treatment compliance unsatisfactory,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,370226009,Asthma treatment compliance satisfactory,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,373899003,Asthma daytime symptoms,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,389145006,Allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,390798007,Asthma finding,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,390872009,Change in asthma management plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,390877003,Step up change in asthma management plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,390878008,Step down change in asthma management plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,390921001,Absent from work or school due to asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,390940007,Asthma monitoring due,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,394700004,Asthma annual review,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,394701000,Asthma follow-up,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,394720003,Asthma medication review,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,394967008,Suspected asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,395022009,Nocturnal asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,400987003,Asthma trigger,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,401135008,Health education - asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,401182001,Asthma monitoring by nurse,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,401183006,Asthma monitoring by doctor,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,401193004,Asthma confirmed,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,405944004,Asthmatic bronchitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,406162001,Asthma care,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,407674008,Aspirin-induced asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,409663006,Cough variant asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,415265005,Referral to asthma clinic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,423889005,Non-immunoglobulin E mediated allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,424643009,Allergic atopic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,425969006,Acute intermittent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,426656000,Severe persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,426979002,Mild persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,427295004,Moderate persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,427603009,Intermittent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,427679007,Mild intermittent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,442025000,Acute exacerbation of chronic asthmatic bronchitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,443117005,Asthma control test score,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,445427006,Seasonal asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,445531003,ACQ - Asthma control questionnaire,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,473391009,Asthma never causes night symptoms,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,698509001,Under care of asthma specialist nurse,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,699191007,Did not attend asthma review,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,702823004,Asthma clinic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,704008007,No family history of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,707445000,Acute mild persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,707446004,Acute exacerbation of moderate persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,707447008,Exacerbation of severe persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,707511009,Uncomplicated mild persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,707512002,Uncomplicated moderate persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,707513007,Uncomplicated severe persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,707979007,Acute severe exacerbation of severe persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,707980005,Acute severe exacerbation of moderate persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,707981009,Acute severe exacerbation of mild persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,708038006,Acute exacerbation of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,708090002,Acute severe exacerbation of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,708093000,Acute exacerbation of allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,708094006,Acute exacerbation of intrinsic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,708095007,Acute severe exacerbation of extrinsic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,708358003,Emergency asthma admission since last encounter,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,708373002,Emergency asthma patient visit since last encounter,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,711442001,Recent asthma management,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,715191006,Telehealth asthma monitoring,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,734346005,Use of asthma symptom diary,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,734904007,Life threatening acute exacerbation of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,734905008,Moderate acute exacerbation of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,736056000,Asthma clinical management plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,762521001,Acute allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,763077003,Asthma Control Questionnaire score,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,763221007,Asthma monitoring declined,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,763695004,Mini Asthma Quality of Life Questionnaire score,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,782520007,Exacerbation of allergic asthma due to infection,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,782559003,Asthma never causes night symptoms,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,401000119107,Asthma with irreversible airway obstruction,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,641000119106,Intermittent asthma well controlled,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,1741000119102,Intermittent asthma uncontrolled,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,72301000119103,Asthma in pregnancy,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,89581000000109,DNA (did not attend) asthma clinic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,92161000000104,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation using preferred method of communication,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,99031000119107,Acute exacerbation of asthma co-occurrent with allergic rhinitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,125011000119100,Mild persistent asthma co-occurrent with allergic rhinitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,125021000119107,Intermittent asthma co-occurrent with allergic rhinitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,135171000119106,Acute exacerbation of moderate persistent asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,143901000000108,Registration for access to online asthma self-management application,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,143931000000102,Declined to register for access to online asthma self-management application,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,176711000000100,Does not have asthma management plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,198971000000102,Asthma outreach clinic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,201031000000108,Asthma trigger - respiratory infection,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,201041000000104,Asthma trigger - seasonal,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,201051000000101,Asthma trigger - animal,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,201191000000108,Asthma trigger - cold air,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,201201000000105,Asthma trigger - damp,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,201211000000107,Asthma trigger - emotion,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,302331000000106,RCP (Royal College of Physicians) asthma assessment,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,340891000000106,Asthma trigger - airborne dust,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,340901000000107,Asthma trigger - exercise,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,340911000000109,Asthma trigger - pollen,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,340921000000103,Asthma trigger - tobacco smoke,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,340931000000101,Asthma trigger - warm air,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,527171000000103,Patient has a written asthma personal action plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,527191000000104,Health education - asthma self management,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,527211000000100,Health education - structured asthma discussion,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,527231000000108,Health education - structured patient focused asthma discussion,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,713701000000108,Asthma monitoring administration,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,713711000000105,Asthma clinic administration,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,715801000000103,Exception reporting - asthma quality indicators,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,716491000000100,Excepted from asthma quality indicators - informed dissent,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,717291000000103,Excepted from asthma quality indicators - patient unsuitable,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,754061000000100,Asthma review using Royal College of Physicians three questions,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,771901000000100,Asthma causes night time symptoms 1 to 2 times per week,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,771941000000102,Asthma causes symptoms most nights,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,771981000000105,Asthma limits activities 1 to 2 times per month,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,772011000000107,Asthma limits activities 1 to 2 times per week,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,772051000000106,Asthma limits activities most days,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,791401000000104,Seen in school asthma clinic,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,810901000000102,Asthma self-management plan review,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,811151000000105,Number of days absent from school due to asthma in past 6 months,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,811921000000103,Asthma self-management plan agreed,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,815631000000106,Asthma trigger - wind,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,818161000000104,Asthma trigger - perfume,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,866881000000101,Chronic asthma with fixed airflow obstruction,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,867171000000106,No asthma trigger identified by subject,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,892301000000100,Asthma management plan declined,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,905301000000103,Childhood Asthma Control Test score,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,928451000000107,Asthma monitoring invitation short message service text message,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,928511000000107,Asthma monitoring invitation email,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,928651000000105,Review of patient at risk of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,928691000000102,At risk of asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,959401000000101,Asthma monitoring SMS (short message service) text message first invitation,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,959421000000105,Asthma monitoring SMS (short message service) text message second invitation,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,959441000000103,Asthma monitoring SMS (short message service) text message third invitation,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,959901000000107,Asthma action plan,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,966011000000109,At risk of severe asthma exacerbation,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,966031000000101,Severe asthma exacerbation risk assessment,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,1086701000000102,Life threatening acute exacerbation of allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,1086711000000100,Life threatening acute exacerbation of non-allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,1108701000000106,Excepted from asthma quality indicators - service unavailable,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,1110841000000103,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,10674991000119104,Intermittent allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,10675431000119106,Severe persistent allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,10675551000119104,Acute severe exacerbation of severe persistent asthma co-occurrent with allergic rhinitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,10675871000119106,Mild persistent allergic asthma,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,10675991000119100,Acute severe exacerbation of mild persistent allergic asthma co-occurrent with allergic rhinitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,10676031000119106,Mild persistent allergic asthma controlled,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
MEPOLIZUMAB AS AN ADD-ON TO OPTIMISED STANDARD THERAPY,Severe refractory eosinophilic asthma,TA431,asthma,10676111000119102,Mild persistent asthma controlled co-occurrent with allergic rhinitis,MEPOLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,169941005,Maternal drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,228366006,Drug misuse history,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,228371004,Long-term drug misuser,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,228372006,Poly-drug misuser,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,228390007,Frequency of drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,228411009,Time since stopped drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,228413007,Age at starting drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,371435006,History of drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,439213009,Paternal drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,442080007,Drug misuse by mother,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,700187009,Seen in drug misuse clinic,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,712542001,Abstinent from drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,712543006,Abstinent from drug misuse in normal environment,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,712544000,Abstinent from drug misuse in protected environment,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,712545004,Abstinent from drug misuse on maintenance replacement,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,712546003,Abstinent from drug misuse when receiving blocking therapy,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,713070003,Drug misuser in household,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,744857009,Under care of drug misuse service,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,176811000000105,Drug misuse enhanced services administration,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,176831000000102,Drug misuse enhanced service completed,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,362451000000107,Drug misuse assessment declined,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,372511000000103,Shared care drug misuse treatment,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,372541000000102,Drug misuse treatment in primary care,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,383871000000108,Health problem secondary to drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,503771000000102,SMR25a drug misuse initial assessment form,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,503801000000104,SMR25b drug misuse follow up assessment form,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,505091000000102,Declined consent for notification of drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,507041000000101,Name of pharmacy attended due to drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,869161000000106,Drug misuse clinic administration,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHADONE (ORAL FORMULATIONS),Drug misuse,TA114,drug misuse,1364721000000101,Date stopped drug misuse,BUPRENORPHINE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,21782001,Drug-induced constipation,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,31499008,Chronic constipation with overflow,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,35298007,Colonic constipation,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,82934008,Chronic idiopathic constipation,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,129691005,At increased risk for constipation,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,191973007,Psychogenic constipation,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,197118003,Functional constipation,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,197119006,Acute constipation,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,197120000,Chronic constipation without overflow,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,235840008,Irritable bowel syndrome variant of childhood with constipation,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,236069009,Chronic constipation,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,236070005,Simple constipation,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,249517009,Constipation alternates with diarrhea,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,266524003,(Functional constipation) or (impacted feces),METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,440630006,Constipation predominant irritable bowel syndrome,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,443307007,Dietary education for constipation,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,448880001,Cleveland Clinic constipation score,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,847591000000107,Constipation in children clinical pathway,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
METHYLNALTREXONE BROMIDE,Opioid-induced constipation,TA468,constipation,1325741000000102,Constipation care indicated,METHYLNALTREXONE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,7461003,"Attention deficit hyperactivity disorder, hyperactive impulsive type",ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,31177006,"Attention deficit hyperactivity disorder, combined type",ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,702536007,Stimulant drug therapy for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,702538008,Drug therapy for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,703314001,Non-stimulant drug therapy for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,516401000000106,Attention deficit hyperactivity disorder monitoring invitation first letter,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,516891000000101,Attention deficit hyperactivity disorder monitoring invitation second letter,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,516911000000103,Attention deficit hyperactivity disorder monitoring invitation third letter,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,710071000000106,Attention deficit hyperactivity disorder annual review,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,886371000000105,On drug therapy for ADHD (attention deficit hyperactivity disorder),ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,886391000000109,On stimulant drug therapy for ADHD (attention deficit hyperactivity disorder),ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,886411000000109,On non-stimulant drug therapy for ADHD (attention deficit hyperactivity disorder),ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,1863681000000108,Attention deficit hyperactivity disorder suspected,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,1914891000000100,Diagnostic assessment for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,2427101000000103,Signposting to attention deficit hyperactivity disorder resource,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
METHYLPHENIDATE,Attention deficit hyperactivity disorder (ADHD),TA098,attention deficit hyperactivity disorder,2437121000000109,Referral for diagnostic assessment for attention deficit hyperactivity disorder,ATOMOXETINE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
METHYLPHENIDATE,Attention-Deficit Hyperactivity Disorder,TA013,attention-deficit hyperactivity disorder,769390009,World Health Organization Adult Attention-Deficit Hyperactivity Disorder Self-Report Scale,METHYLPHENIDATE,MENTAL HEALTH,MENTAL HEALTH|PAEDIATRICS
MEXILETINE,Myotonia in non-dystrophic myotonic disorders,TA748,myotonia,63135006,Amyotonia congenita,MEXILETINE,NEUROLOGY,NEUROLOGY
MIDOSTAURIN,Advanced systemic mastocytosis,TA728,systemic mastocytosis,50150000,Malignant systemic mastocytosis,MIDOSTAURIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CLINICAL IMMUNOLOGY
MIDOSTAURIN,Advanced systemic mastocytosis,TA728,systemic mastocytosis,70910003,Indolent systemic mastocytosis,MIDOSTAURIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CLINICAL IMMUNOLOGY
MIDOSTAURIN,Untreated acute myeloid leukaemia,TA523,acute myeloid leukaemia,91861009,"Acute myeloid leukaemia, disease",MIDOSTAURIN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
MIFAMURTIDE,"Treatment of high-grade resectable non-metastatic osteosarcoma in children, adolescents and young adults",TA235,osteosarcoma,12302002,Round cell osteosarcoma,MIFAMURTIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|TRAUMA & ORTHOPAEDICS|CLINICAL ONCOLOGY
MIFAMURTIDE,"Treatment of high-grade resectable non-metastatic osteosarcoma in children, adolescents and young adults",TA235,osteosarcoma,12690005,Fibroblastic osteosarcoma,MIFAMURTIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|TRAUMA & ORTHOPAEDICS|CLINICAL ONCOLOGY
MIFAMURTIDE,"Treatment of high-grade resectable non-metastatic osteosarcoma in children, adolescents and young adults",TA235,osteosarcoma,21708004,Osteosarcoma - morphology,MIFAMURTIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|TRAUMA & ORTHOPAEDICS|CLINICAL ONCOLOGY
MIFAMURTIDE,"Treatment of high-grade resectable non-metastatic osteosarcoma in children, adolescents and young adults",TA235,osteosarcoma,33681003,Osteosarcoma in Paget disease of bone,MIFAMURTIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|TRAUMA & ORTHOPAEDICS|CLINICAL ONCOLOGY
MIFAMURTIDE,"Treatment of high-grade resectable non-metastatic osteosarcoma in children, adolescents and young adults",TA235,osteosarcoma,76312009,Chondroblastic osteosarcoma,MIFAMURTIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|TRAUMA & ORTHOPAEDICS|CLINICAL ONCOLOGY
MIFAMURTIDE,"Treatment of high-grade resectable non-metastatic osteosarcoma in children, adolescents and young adults",TA235,osteosarcoma,128918008,Parosteal osteosarcoma,MIFAMURTIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|TRAUMA & ORTHOPAEDICS|CLINICAL ONCOLOGY
MIFAMURTIDE,"Treatment of high-grade resectable non-metastatic osteosarcoma in children, adolescents and young adults",TA235,osteosarcoma,307576001,Osteosarcoma of bone,MIFAMURTIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|TRAUMA & ORTHOPAEDICS|CLINICAL ONCOLOGY
MIFAMURTIDE,"Treatment of high-grade resectable non-metastatic osteosarcoma in children, adolescents and young adults",TA235,osteosarcoma,735680008,Primary osteosarcoma,MIFAMURTIDE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|TRAUMA & ORTHOPAEDICS|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,6744007,Painful urinary bladder spasm,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,13516000,Adhesions of gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,14329006,Dilation of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,19744006,Operation on gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,22421007,Congenital absence of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,31911002,Radiography of kidney-ureter-bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,36503003,Biopsy of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,39621005,Gallbladder disease,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,42111002,Urinary bladder function,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,43748006,Removal of urinary bladder catheter,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,44817001,Extracorporeal shockwave lithotripsy of bladder calculus,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,68666001,Fistula of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,76875008,Hypertrophy of gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,79184009,Trabeculation of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,89310008,Contracted bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,89837001,Bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,91992005,Benign neoplasm of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,92599005,Carcinoma in situ of gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,94754000,Neoplasm of uncertain behaviour of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,94850000,Neoplasm of uncertain behavior of gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,95586000,Telangiectasia of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,111372003,Gallbladder gangrene,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,126854002,Neoplasm of gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,126885006,Neoplasm of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,126886007,Tumor of trigone of bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,161537002,H/O: gallbladder dis.,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,163361001,On examination - bladder not palpable,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,168053004,On examination - bladder calculus,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,168854009,Contrast radiography of bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,169010007,Fluoroscopy - gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,169250003,Ultrasound scan of gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,170214001,Child examination: bladder control,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,174520006,Exploration of gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,174525001,Percutaneous drainage of gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,174526000,Percutaneous fragmentation of gallbladder stone,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,176116001,Enlargement &/or replacement of bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,176146003,Open biopsy of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,176166007,Transurethral transection of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,176167003,Balloon distension of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,176182008,Diagnostic cystoscopy and biopsy of bladder lesion using rigid instrument,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,176184009,Rigid check cystoscopy and biopsy of bladder lesion,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,176188007,Check cystoscopy and biopsy of bladder lesion using flexible instrument,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,176201006,Instillation of therapeutic substance into bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,176220008,Abdominal operations to support outlet of female bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,176234008,Open resection of female urinary bladder neck,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,176246007,Transurethral excision of female urinary bladder neck,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,176247003,Endoscopic myotomy of female bladder neck,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,181423002,Structure of outlet of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,183228000,Bladder control,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,188239000,Malignant tumour of trigone of bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,189459005,Transitional cell papilloma of bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,197859007,Stenosis of bladder neck,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,199205008,Infections of bladder in pregnancy,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,204999002,Atresia of neck of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,205022009,Congenital hernia of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,211648000,Foreign body in urinary bladder and urethra,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,213268006,Accidental bladder perforation during operation,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,235523007,Fine needle aspiration of gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,236238000,Transurethral extraction of bladder calculus without disintegration,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,236242002,Fixed suspension procedure of urinary bladder neck,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,236631000,Leukoplakia of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,236671005,Necrosis of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,237330001,Obstetric injury of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,249297006,Spasm of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,249569004,Gallbladder finding,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,249586005,Urinary bladder palpable,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,252006009,Finding of sensation of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,252010007,Functional urinary bladder capacity,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,252011006,Maximum anaesthetic urinary bladder capacity,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,252904009,Bladder neck electric conductance test,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,254339002,Tumor-node-metastasis (TNM) urinary bladder tumour staging,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,254929002,Tumour of vault of bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,258493006,Urinary bladder calculus specimen,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,262805007,Injury of gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,265566009,Enlargement or replacement of bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,266535008,Gallbladder disease,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,267590006,Cauda equina syndrome with cord bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,274037007,Transurethral excision of papilloma of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,274360007,Surgical biopsy of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,275075003,Replacement of artificial urinary bladder neck sphincter in female,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,275550008,History of gallbladder disease,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,275819003,Bladder control - child,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,279412007,Entire muscularis of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,281386008,Entire posterior wall of bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,281700003,Benign papilloma of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,285640005,Metastasis to bladder of unknown primary,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,288011009,Transurethral electroresection of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,288014001,Reconstruction of sphincter of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,300341002,Gallbladder absent,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,300344005,Gallbladder enlarged,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,300355005,Gallbladder normal,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,300455006,Large urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,300457003,Lesion of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,303088008,Incompetence of neck of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,303409005,Structure of urinary bladder and outflow,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,309248004,Urinary bladder polyp,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,309272009,Urinary bladder tissue specimen,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,309509003,Transurethral endoscopic lithotripsy of bladder calculus,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,314962005,Local recurrence of malignant neoplasm of gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,314995004,Metastasis from malignant tumour of bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,361259002,Cystoscopy and cauterization of bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,366279009,Finding of urinary bladder control,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,370984003,Removal of calculus from bladder by incision,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,371005009,Removal of calculus of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,372140005,Carcinoma of gallbladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,373721004,Urinary bladder emptying,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,384629005,Transurethral destruction of bladder lesion,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,388229009,Transurethral external sphincterotomy of male urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,398064005,Neurogenic urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,399326009,Bladder cancer,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,762619000,Screening for malignant neoplasm of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,784285002,Tenesmus of urinary bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,285081000000106,High intensity focused ultrasound of bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,500851000000105,[D]Bladder filling defect,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,571631000000102,Other gallbladder disorders NOS,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,597971000000106,Other gallbladder disorders,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,655301000000105,Bladder disorders NOS,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,661941000000101,Other disorders of bladder,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MIRABEGRON,Symptoms of overactive bladder,TA290,bladder,795311000000108,Diagnostic endoscopic examination of bladder and biopsy of lesion of prostate,MIRABEGRON,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,162573006,Suspected lung cancer,MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,254637007,Non-small cell lung cancer,MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,275981009,Lung cancer screening,MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,429011007,Family history of lung cancer,MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,877691000000107,No FH of lung cancer,MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
MOBOCERTINIB,EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy,TA855,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",MOBOCERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,62914000,Cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,72092001,Arteriosclerotic vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,123799005,Hypertension due to renovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,127014009,Diabetic peripheral vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,134379001,Peripheral vascular disease monitoring,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,160270001,No family history of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,161499004,H/O: cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,171405001,Examination for suspected cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,192813004,Cerebral degeneration due to cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,195239002,Late effects of cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,195293004,(Peripheral vascular disease (& [ischemic] or [other])) or (ischemia of legs) or (peripheral ischemia),MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,198057005,Male genital organ vascular diseases,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,230738008,Asymptomatic cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,233845001,Coronary microvascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,266320008,Peripheral vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,266894000,Family history of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,266995000,History of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,275509000,Infective vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,302909007,Diffuse cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,308064009,History of cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,308071004,History of peripheral vascular disease procedure,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,395048001,Cardiovascular disease monitoring not required,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,400047006,PVD - peripheral vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,413988000,Did not attend peripheral vascular disease clinic,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,417206009,Cardiovascular disease monitoring,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,417287002,Cardiovascular disease interim monitoring,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,417322008,Cardiovascular disease annual review,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,429284000,Cardiovascular disease risk assessment declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,429785003,Cardiovascular disease health education,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,438370008,Vascular disease risk assessment declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,440358008,Primary prevention of CVD (cardiovascular disease),MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,440401008,Vascular disease risk assessment,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,441829007,Assessment for risk of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,443929000,Small vessel cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,473109007,History of peripheral vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,166701000000106,Joint British Societies cardiovascular disease risk,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,205001000000100,Suspected cerebrovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,302881000000102,Cardiovascular disease annual review declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,375421000000101,Vascular disease risk assessment invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,375511000000106,Vascular disease risk assessment first letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,375541000000107,Vascular disease risk assessment second letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,375571000000101,Vascular disease risk assessment third letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,376591000000106,Peripheral vascular disease monitoring invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,376621000000109,Peripheral vascular disease monitoring first letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,383321000000103,Cardiovascular disease risk assessment indicated,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,492581000000108,Cardiovascular disease high risk review declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,492611000000102,Cardiovascular disease high risk review,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,646351000000103,Peripheral vascular disease NOS,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,660711000000109,Arteriosclerotic vascular disease NOS,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,752451000000100,Cardiovascular disease risk assessment by third party,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,810681000000101,Coronary microvascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,837461000000101,High risk of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,845171000000108,At risk of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,858191000000103,FH: peripheral vascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,863151000000105,Peripheral vascular disease monitoring second letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,863161000000108,Peripheral vascular disease monitoring third letter,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,863171000000101,Peripheral vascular disease monitoring verbal invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,863181000000104,Peripheral vascular disease monitoring telephone invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,865391000000100,No peripheral vascular disease symptoms,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,962871000000107,Aware of overall cardiovascular disease risk,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,990301000000105,Cardiovascular disease risk assessment done,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE (MR) DIPYRIDAMOLE,Vascular disease,TA090,vascular disease,16434071000119108,At increased risk of cardiovascular disease,MODIFIED-RELEASE,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,62914000,Cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,62914000,Cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,72092001,Arteriosclerotic vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,72092001,Arteriosclerotic vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,123799005,Hypertension due to renovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,123799005,Hypertension due to renovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,127014009,Diabetic peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,127014009,Diabetic peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,134379001,Peripheral vascular disease monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,134379001,Peripheral vascular disease monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,160270001,No family history of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,160270001,No family history of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,161499004,H/O: cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,161499004,H/O: cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,171405001,Examination for suspected cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,171405001,Examination for suspected cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,192813004,Cerebral degeneration due to cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,192813004,Cerebral degeneration due to cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,195239002,Late effects of cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,195239002,Late effects of cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,195293004,(Peripheral vascular disease (& [ischemic] or [other])) or (ischemia of legs) or (peripheral ischemia),CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,195293004,(Peripheral vascular disease (& [ischemic] or [other])) or (ischemia of legs) or (peripheral ischemia),CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,198057005,Male genital organ vascular diseases,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,198057005,Male genital organ vascular diseases,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,230738008,Asymptomatic cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,230738008,Asymptomatic cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,233845001,Coronary microvascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,233845001,Coronary microvascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,266320008,Peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,266320008,Peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,266894000,Family history of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,266894000,Family history of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,266995000,History of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,266995000,History of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,275509000,Infective vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,275509000,Infective vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,302909007,Diffuse cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,302909007,Diffuse cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,308064009,History of cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,308064009,History of cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,308071004,History of peripheral vascular disease procedure,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,308071004,History of peripheral vascular disease procedure,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,395048001,Cardiovascular disease monitoring not required,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,395048001,Cardiovascular disease monitoring not required,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,400047006,PVD - peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,400047006,PVD - peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,413988000,Did not attend peripheral vascular disease clinic,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,413988000,Did not attend peripheral vascular disease clinic,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,417206009,Cardiovascular disease monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,417206009,Cardiovascular disease monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,417287002,Cardiovascular disease interim monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,417287002,Cardiovascular disease interim monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,417322008,Cardiovascular disease annual review,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,417322008,Cardiovascular disease annual review,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,429284000,Cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,429284000,Cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,429785003,Cardiovascular disease health education,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,429785003,Cardiovascular disease health education,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,438370008,Vascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,438370008,Vascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,440358008,Primary prevention of CVD (cardiovascular disease),CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,440358008,Primary prevention of CVD (cardiovascular disease),CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,440401008,Vascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,440401008,Vascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,441829007,Assessment for risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,441829007,Assessment for risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,443929000,Small vessel cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,443929000,Small vessel cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,473109007,History of peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,473109007,History of peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,166701000000106,Joint British Societies cardiovascular disease risk,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,166701000000106,Joint British Societies cardiovascular disease risk,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,205001000000100,Suspected cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,205001000000100,Suspected cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,302881000000102,Cardiovascular disease annual review declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,302881000000102,Cardiovascular disease annual review declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375421000000101,Vascular disease risk assessment invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375421000000101,Vascular disease risk assessment invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375511000000106,Vascular disease risk assessment first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375511000000106,Vascular disease risk assessment first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375541000000107,Vascular disease risk assessment second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375541000000107,Vascular disease risk assessment second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375571000000101,Vascular disease risk assessment third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375571000000101,Vascular disease risk assessment third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,376591000000106,Peripheral vascular disease monitoring invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,376591000000106,Peripheral vascular disease monitoring invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,376621000000109,Peripheral vascular disease monitoring first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,376621000000109,Peripheral vascular disease monitoring first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,383321000000103,Cardiovascular disease risk assessment indicated,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,383321000000103,Cardiovascular disease risk assessment indicated,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,492581000000108,Cardiovascular disease high risk review declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,492581000000108,Cardiovascular disease high risk review declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,492611000000102,Cardiovascular disease high risk review,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,492611000000102,Cardiovascular disease high risk review,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,646351000000103,Peripheral vascular disease NOS,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,646351000000103,Peripheral vascular disease NOS,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,660711000000109,Arteriosclerotic vascular disease NOS,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,660711000000109,Arteriosclerotic vascular disease NOS,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,752451000000100,Cardiovascular disease risk assessment by third party,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,752451000000100,Cardiovascular disease risk assessment by third party,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,810681000000101,Coronary microvascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,810681000000101,Coronary microvascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,837461000000101,High risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,837461000000101,High risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,845171000000108,At risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,845171000000108,At risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,858191000000103,FH: peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,858191000000103,FH: peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,863151000000105,Peripheral vascular disease monitoring second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,863151000000105,Peripheral vascular disease monitoring second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,863161000000108,Peripheral vascular disease monitoring third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,863161000000108,Peripheral vascular disease monitoring third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,863171000000101,Peripheral vascular disease monitoring verbal invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,863171000000101,Peripheral vascular disease monitoring verbal invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,863181000000104,Peripheral vascular disease monitoring telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,863181000000104,Peripheral vascular disease monitoring telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,865391000000100,No peripheral vascular disease symptoms,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,865391000000100,No peripheral vascular disease symptoms,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,962871000000107,Aware of overall cardiovascular disease risk,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,962871000000107,Aware of overall cardiovascular disease risk,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,990301000000105,Cardiovascular disease risk assessment done,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,990301000000105,Cardiovascular disease risk assessment done,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,16434071000119108,At increased risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE,Vascular disease,TA210,vascular disease,16434071000119108,At increased risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,62914000,Cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,62914000,Cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,72092001,Arteriosclerotic vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,72092001,Arteriosclerotic vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,123799005,Hypertension due to renovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,123799005,Hypertension due to renovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,127014009,Diabetic peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,127014009,Diabetic peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,134379001,Peripheral vascular disease monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,134379001,Peripheral vascular disease monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,160270001,No family history of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,160270001,No family history of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,161499004,H/O: cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,161499004,H/O: cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,171405001,Examination for suspected cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,171405001,Examination for suspected cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,192813004,Cerebral degeneration due to cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,192813004,Cerebral degeneration due to cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,195239002,Late effects of cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,195239002,Late effects of cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,195293004,(Peripheral vascular disease (& [ischemic] or [other])) or (ischemia of legs) or (peripheral ischemia),CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,195293004,(Peripheral vascular disease (& [ischemic] or [other])) or (ischemia of legs) or (peripheral ischemia),CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,198057005,Male genital organ vascular diseases,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,198057005,Male genital organ vascular diseases,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,230738008,Asymptomatic cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,230738008,Asymptomatic cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,233845001,Coronary microvascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,233845001,Coronary microvascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,266320008,Peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,266320008,Peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,266894000,Family history of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,266894000,Family history of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,266995000,History of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,266995000,History of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,275509000,Infective vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,275509000,Infective vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,302909007,Diffuse cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,302909007,Diffuse cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,308064009,History of cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,308064009,History of cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,308071004,History of peripheral vascular disease procedure,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,308071004,History of peripheral vascular disease procedure,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,395048001,Cardiovascular disease monitoring not required,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,395048001,Cardiovascular disease monitoring not required,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,400047006,PVD - peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,400047006,PVD - peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,413988000,Did not attend peripheral vascular disease clinic,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,413988000,Did not attend peripheral vascular disease clinic,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,417206009,Cardiovascular disease monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,417206009,Cardiovascular disease monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,417287002,Cardiovascular disease interim monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,417287002,Cardiovascular disease interim monitoring,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,417322008,Cardiovascular disease annual review,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,417322008,Cardiovascular disease annual review,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,429284000,Cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,429284000,Cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,429785003,Cardiovascular disease health education,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,429785003,Cardiovascular disease health education,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,438370008,Vascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,438370008,Vascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,440358008,Primary prevention of CVD (cardiovascular disease),CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,440358008,Primary prevention of CVD (cardiovascular disease),CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,440401008,Vascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,440401008,Vascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,441829007,Assessment for risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,441829007,Assessment for risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,443929000,Small vessel cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,443929000,Small vessel cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,473109007,History of peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,473109007,History of peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,166701000000106,Joint British Societies cardiovascular disease risk,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,166701000000106,Joint British Societies cardiovascular disease risk,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,205001000000100,Suspected cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,205001000000100,Suspected cerebrovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,302881000000102,Cardiovascular disease annual review declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,302881000000102,Cardiovascular disease annual review declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375421000000101,Vascular disease risk assessment invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375421000000101,Vascular disease risk assessment invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375511000000106,Vascular disease risk assessment first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375511000000106,Vascular disease risk assessment first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375541000000107,Vascular disease risk assessment second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375541000000107,Vascular disease risk assessment second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375571000000101,Vascular disease risk assessment third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375571000000101,Vascular disease risk assessment third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,376591000000106,Peripheral vascular disease monitoring invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,376591000000106,Peripheral vascular disease monitoring invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,376621000000109,Peripheral vascular disease monitoring first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,376621000000109,Peripheral vascular disease monitoring first letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,383321000000103,Cardiovascular disease risk assessment indicated,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,383321000000103,Cardiovascular disease risk assessment indicated,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,492581000000108,Cardiovascular disease high risk review declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,492581000000108,Cardiovascular disease high risk review declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,492611000000102,Cardiovascular disease high risk review,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,492611000000102,Cardiovascular disease high risk review,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,646351000000103,Peripheral vascular disease NOS,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,646351000000103,Peripheral vascular disease NOS,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,660711000000109,Arteriosclerotic vascular disease NOS,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,660711000000109,Arteriosclerotic vascular disease NOS,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,752451000000100,Cardiovascular disease risk assessment by third party,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,752451000000100,Cardiovascular disease risk assessment by third party,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,810681000000101,Coronary microvascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,810681000000101,Coronary microvascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,837461000000101,High risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,837461000000101,High risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,845171000000108,At risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,845171000000108,At risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,858191000000103,FH: peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,858191000000103,FH: peripheral vascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,863151000000105,Peripheral vascular disease monitoring second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,863151000000105,Peripheral vascular disease monitoring second letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,863161000000108,Peripheral vascular disease monitoring third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,863161000000108,Peripheral vascular disease monitoring third letter,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,863171000000101,Peripheral vascular disease monitoring verbal invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,863171000000101,Peripheral vascular disease monitoring verbal invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,863181000000104,Peripheral vascular disease monitoring telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,863181000000104,Peripheral vascular disease monitoring telephone invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,865391000000100,No peripheral vascular disease symptoms,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,865391000000100,No peripheral vascular disease symptoms,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,962871000000107,Aware of overall cardiovascular disease risk,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,962871000000107,Aware of overall cardiovascular disease risk,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,990301000000105,Cardiovascular disease risk assessment done,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,990301000000105,Cardiovascular disease risk assessment done,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,16434071000119108,At increased risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MODIFIED-RELEASE DIPYRIDAMOLE IN COMBINATION WITH ASPIRIN,Vascular disease,TA210,vascular disease,16434071000119108,At increased risk of cardiovascular disease,CLOPIDOGREL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
MOMETASONE FUROATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
MOMETASONE FUROATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238543002,Discoid atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
MOMETASONE FUROATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
MOMETASONE FUROATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238545009,Follicular atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
MOMETASONE FUROATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
MOMETASONE FUROATE,Atopic dermatitis (eczema),TA081,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ALCLOMETASONE,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
MYCOPHENOLATE MOFETIL,Kidney transplant in adults,TA481,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE MOFETIL,Kidney transplant in adults,TA481,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE MOFETIL,Kidney transplant in adults,TA481,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE MOFETIL,Kidney transplant in adults,TA481,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE MOFETIL,Kidney transplant in adults,TA481,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE MOFETIL,Kidney transplant in adults,TA481,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE MOFETIL,Kidney transplant in children and young people,TA482,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE MOFETIL,Kidney transplant in children and young people,TA482,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE MOFETIL,Kidney transplant in children and young people,TA482,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE MOFETIL,Kidney transplant in children and young people,TA482,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE MOFETIL,Kidney transplant in children and young people,TA482,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE MOFETIL,Kidney transplant in children and young people,TA482,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE MOFETIL (MMF),Renal transplantation (adults),TA085,renal transplantation,70536003,Renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE MOFETIL (MMF),Renal transplantation (adults),TA085,renal transplantation,313030004,Donor renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE MOFETIL (MMF),Renal transplantation (adults),TA085,renal transplantation,429451003,Disorder related to renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE MOFETIL (MMF),Renal transplantation (children),TA099,renal transplantation,70536003,Renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE MOFETIL (MMF),Renal transplantation (children),TA099,renal transplantation,313030004,Donor renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE MOFETIL (MMF),Renal transplantation (children),TA099,renal transplantation,429451003,Disorder related to renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE SODIUM,Kidney transplant in adults,TA481,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE SODIUM,Kidney transplant in adults,TA481,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE SODIUM,Kidney transplant in adults,TA481,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE SODIUM,Kidney transplant in adults,TA481,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE SODIUM,Kidney transplant in adults,TA481,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE SODIUM,Kidney transplant in adults,TA481,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE SODIUM,Kidney transplant in children and young people,TA482,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE SODIUM,Kidney transplant in children and young people,TA482,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE SODIUM,Kidney transplant in children and young people,TA482,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE SODIUM,Kidney transplant in children and young people,TA482,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE SODIUM,Kidney transplant in children and young people,TA482,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE SODIUM,Kidney transplant in children and young people,TA482,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE SODIUM (MPS),Renal transplantation (children),TA099,renal transplantation,70536003,Renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE SODIUM (MPS),Renal transplantation (children),TA099,renal transplantation,313030004,Donor renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
MYCOPHENOLATE SODIUM (MPS),Renal transplantation (children),TA099,renal transplantation,429451003,Disorder related to renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
NAFTIDROFYRYL OXALATE,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,822611000000100,Exception reporting - peripheral arterial disease quality indicators,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
NAFTIDROFYRYL OXALATE,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,822641000000104,Excepted from peripheral arterial disease quality indicators - patient unsuitable,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
NAFTIDROFYRYL OXALATE,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,822671000000105,Excepted from peripheral arterial disease quality indicators - informed dissent,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
NAFTIDROFYRYL OXALATE,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,968121000000103,Peripheral arterial disease screening,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,21782001,Drug-induced constipation,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,31499008,Chronic constipation with overflow,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,35298007,Colonic constipation,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,82934008,Chronic idiopathic constipation,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,129691005,At increased risk for constipation,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,191973007,Psychogenic constipation,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,197118003,Functional constipation,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,197119006,Acute constipation,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,197120000,Chronic constipation without overflow,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,235840008,Irritable bowel syndrome variant of childhood with constipation,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,236069009,Chronic constipation,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,236070005,Simple constipation,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,249517009,Constipation alternates with diarrhea,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,266524003,(Functional constipation) or (impacted feces),NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,440630006,Constipation predominant irritable bowel syndrome,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,443307007,Dietary education for constipation,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,448880001,Cleveland Clinic constipation score,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,847591000000107,Constipation in children clinical pathway,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALDEMEDINE,Treating opioid-induced constipation,TA651,constipation,1325741000000102,Constipation care indicated,NALDEMEDINE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALOXEGOL,Opioid‑induced constipation,TA345,constipation,21782001,Drug-induced constipation,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALOXEGOL,Opioid‑induced constipation,TA345,constipation,31499008,Chronic constipation with overflow,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALOXEGOL,Opioid‑induced constipation,TA345,constipation,35298007,Colonic constipation,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALOXEGOL,Opioid‑induced constipation,TA345,constipation,82934008,Chronic idiopathic constipation,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALOXEGOL,Opioid‑induced constipation,TA345,constipation,129691005,At increased risk for constipation,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALOXEGOL,Opioid‑induced constipation,TA345,constipation,191973007,Psychogenic constipation,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALOXEGOL,Opioid‑induced constipation,TA345,constipation,197118003,Functional constipation,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALOXEGOL,Opioid‑induced constipation,TA345,constipation,197119006,Acute constipation,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALOXEGOL,Opioid‑induced constipation,TA345,constipation,197120000,Chronic constipation without overflow,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALOXEGOL,Opioid‑induced constipation,TA345,constipation,235840008,Irritable bowel syndrome variant of childhood with constipation,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALOXEGOL,Opioid‑induced constipation,TA345,constipation,236069009,Chronic constipation,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALOXEGOL,Opioid‑induced constipation,TA345,constipation,236070005,Simple constipation,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALOXEGOL,Opioid‑induced constipation,TA345,constipation,249517009,Constipation alternates with diarrhea,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALOXEGOL,Opioid‑induced constipation,TA345,constipation,266524003,(Functional constipation) or (impacted feces),NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALOXEGOL,Opioid‑induced constipation,TA345,constipation,440630006,Constipation predominant irritable bowel syndrome,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALOXEGOL,Opioid‑induced constipation,TA345,constipation,443307007,Dietary education for constipation,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALOXEGOL,Opioid‑induced constipation,TA345,constipation,448880001,Cleveland Clinic constipation score,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALOXEGOL,Opioid‑induced constipation,TA345,constipation,847591000000107,Constipation in children clinical pathway,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALOXEGOL,Opioid‑induced constipation,TA345,constipation,1325741000000102,Constipation care indicated,NALOXEGOL,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,169941005,Maternal drug misuse,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,228366006,Drug misuse history,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,228371004,Long-term drug misuser,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,228372006,Poly-drug misuser,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,228390007,Frequency of drug misuse,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,228411009,Time since stopped drug misuse,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,228413007,Age at starting drug misuse,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,371435006,History of drug misuse,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,439213009,Paternal drug misuse,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,442080007,Drug misuse by mother,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,700187009,Seen in drug misuse clinic,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,712542001,Abstinent from drug misuse,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,712543006,Abstinent from drug misuse in normal environment,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,712544000,Abstinent from drug misuse in protected environment,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,712545004,Abstinent from drug misuse on maintenance replacement,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,712546003,Abstinent from drug misuse when receiving blocking therapy,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,713070003,Drug misuser in household,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,744857009,Under care of drug misuse service,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,176811000000105,Drug misuse enhanced services administration,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,176831000000102,Drug misuse enhanced service completed,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,362451000000107,Drug misuse assessment declined,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,372511000000103,Shared care drug misuse treatment,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,372541000000102,Drug misuse treatment in primary care,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,383871000000108,Health problem secondary to drug misuse,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,503771000000102,SMR25a drug misuse initial assessment form,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,503801000000104,SMR25b drug misuse follow up assessment form,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,505091000000102,Declined consent for notification of drug misuse,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,507041000000101,Name of pharmacy attended due to drug misuse,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,869161000000106,Drug misuse clinic administration,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE,Drug misuse,TA115,drug misuse,1364721000000101,Date stopped drug misuse,NALTREXONE,MENTAL HEALTH,MENTAL HEALTH|ADDICTION MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,44772007,Maternal obesity without hypertension,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,82793005,Hypothalamic obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,160311006,Family history: Obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,161453001,History of obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,162864005,Body mass index 30+ - obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,170793009,Obesity monitoring,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,170794003,Initial obesity assessment,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,170795002,Follow-up obesity assessment,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,170797005,Has seen dietician - obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,170798000,Treatment of obesity changed,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,170799008,Treatment of obesity started,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,170800007,Treatment of obesity stopped,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,170807005,Reason for obesity therapy - occupational,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,185741002,Attends obesity monitoring,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,185743004,Obesity monitoring default,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,185744005,Obesity monitoring first letter,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,185745006,Obesity monitoring second letter,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,185746007,Obesity monitoring third letter,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,185747003,Obesity monitoring verbal invite,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,185748008,Obesity monitoring telephone invite,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,185749000,Obesity monitoring deleted,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,185750000,Obesity monitoring check done,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,190965006,Drug-induced obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,190966007,Obesity hypoventilation syndrome,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,199072001,(Gestational edema &/or non-hypertension excessive weight gain) or (maternal obesity syndrome),NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,235240002,Procedure using anti-obesity gastric balloon,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,238132000,Upper body obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,238133005,Gynecoid obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,238134004,Generalized obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,238136002,Morbid obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,243862009,Obesity monitoring status,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,247824007,Fear of obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,267511009,Hyperalimentation incl.obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,268522006,Obesity monitoring,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,268551005,Obesity screening,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,270486005,Localized obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,276792008,Pulmonary hypertension with extreme obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,277831002,Anxiety about obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,284352003,Obesity diet education,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,294493008,Lifelong obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,296526005,Adult-onset obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,308504001,Obesity monitoring call,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,310428009,Obesity monitoring invitation,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,415530009,Obesity due to excess calories,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,444862003,Childhood obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,703316004,Lymphoedema associated with obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,715279006,Telehealth obesity monitoring,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,763085007,Obesity monitoring declined,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,198181000000102,Obesity resolved,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,640791000000105,Obesity and other hyperalimentation,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,713951000000106,Obesity monitoring administration,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,713971000000102,Obesity clinic administration,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,753691000000104,Exception reporting - obesity quality indicators,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,753751000000103,Excepted from obesity quality indicators - patient unsuitable,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,753771000000107,Excepted from obesity quality indicators - informed dissent,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,755881000000104,"Risk to health associated with overweight and obesity, at no increased risk",NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,755901000000101,"Risk to health associated with overweight and obesity, at increased risk",NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,755921000000105,"Risk to health associated with overweight and obesity, at high risk",NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,755941000000103,"Risk to health associated with overweight and obesity, at very high risk",NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,756001000000107,"Intervention for risk to health associated with overweight and obesity, general advice on healthy weight and lifestyle",NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,756021000000103,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity",NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,756041000000105,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs",NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,756061000000106,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs, consider surgery",NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,822741000000107,Anti-obesity drug therapy,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,851901000000101,Obesity and weight loss quality of life questionnaire,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,894961000000105,Referral to multidisciplinary obesity clinic,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,898011000000103,Obesity multidisciplinary case review,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,914801000000107,Anti-obesity drug therapy commenced,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,914821000000103,Obesity medication stopped,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,1269761000000101,Focal segmental glomerulosclerosis due to obesity,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,2386191000000105,National Health Service obesity medication pathway,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,2386201000000107,Referral to National Health Service obesity medication wraparound support pathway,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,2386221000000103,Unsuitable for NHS obesity medication pathway,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,2386231000000101,NHS obesity medication pathway started,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,2386241000000105,National Health Service obesity medication pathway declined,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,2386251000000108,Review of anti-obesity drug therapy,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NALTREXONE–BUPROPION,Managing overweight and obesity,TA494,obesity,2386261000000106,NHS obesity medication wraparound support pathway completed,NALTREXONE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,24700007,Multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,160337009,Family history of multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,192926004,Brain stem multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,192928003,Generalised multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,428700003,Primary progressive multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,438511000,Benign multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,700409000,Suspected multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,198491000000106,Multiple sclerosis review,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,515931000000104,Multiple sclerosis review declined,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NATALIZUMAB,Multiple sclerosis,TA127,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,NATALIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
NBTXR-3,Advanced soft tissue sarcoma,TA745,soft tissue sarcoma,2424003,Soft tissue sarcoma,NBTXR-,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|CLINICAL ONCOLOGY
"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,162573006,Suspected lung cancer,NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,254637007,Non-small cell lung cancer,NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,275981009,Lung cancer screening,NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,429011007,Family history of lung cancer,NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,877691000000107,No FH of lung cancer,NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
"NECITUMUMAB, IN COMBINATION WITH GEMCITABINE AND CISPLATIN",Untreated advanced or metastatic squamous non-small-cell lung cancer,TA411,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",NECITUMUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,134405005,Suspected breast cancer,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,160287004,FH: Breast cancer,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,268547008,Screening for breast cancer,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,429740004,Family history of breast cancer,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,431330007,Family history of breast cancer 1 gene mutation,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,431331006,Family history of breast cancer 2 gene mutation,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,706970001,TNBC - Triple-negative breast cancer,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,94361000000105,Breast cancer detected by national screening programme,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,276341000000100,Fast track referral for suspected breast cancer,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,838351000000107,Education about risk of breast cancer,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,874291000000100,QCancer breast cancer risk,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
NERATINIB,"Extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab",TA612,breast cancer,1035841000000108,Lymphoedema following breast cancer,NERATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,390900001,Smoking cessation milestones,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,395700008,Referral to smoking cessation advisor,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,401068004,Seen by smoking cessation advisor,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,401160008,Smoking cessation programme start date,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,710081004,Smoking cessation therapy,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,713700008,Smoking cessation drug therapy,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,765001003,Monitoring of smoking cessation therapy refused,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,771155005,Brief intervention for smoking cessation,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,1290027009,Consultation for smoking cessation,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,25261000000107,Did not attend smoking cessation clinic,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,200221000000105,Smoking cessation advice provided by community pharmacist,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,201931000000109,Attends practice smoking cessation clinic,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,201941000000100,Attends smoking cessation clinic not at practice,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,374361000000100,Smoking cessation enhanced services administration,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,374391000000106,Smoking cessation enhanced services administration monitoring template completed,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,506491000000102,Brief intervention for smoking cessation,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,527151000000107,Smoking cessation advice declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,712971000000108,Practice based smoking cessation programme start date,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,720401000000103,Smoking cessation,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,750821000000109,Consent given for follow-up evaluation after smoking cessation intervention,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,750851000000104,Consent given for smoking cessation data sharing,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,751101000000101,Declined consent for follow-up evaluation after smoking cessation intervention,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,751661000000106,Declined consent for smoking cessation data sharing,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,755721000000107,Consent given for follow-up by smoking cessation team,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,755741000000100,Declined consent for follow-up by smoking cessation team,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,767641000000109,Referral for smoking cessation service offered,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,768971000000109,Lost to smoking cessation follow-up,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,822591000000108,Smoking cessation drug therapy declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,850331000000104,Smoking cessation 12 week follow-up,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,871641000000105,Referral to smoking cessation service declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,871661000000106,Referral to smoking cessation service,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,966971000000103,Varenicline smoking cessation therapy declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,966991000000104,Varenicline smoking cessation therapy offered,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,1084381000000100,Signposting to smoking cessation service,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,1087441000000106,Smoking cessation programme declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT),Smoking cessation,TA039,smoking cessation,2140191000000108,Referral to Community Pharmacy Smoking Cessation Service,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,390900001,Smoking cessation milestones,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,395700008,Referral to smoking cessation advisor,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,401068004,Seen by smoking cessation advisor,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,401160008,Smoking cessation programme start date,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,710081004,Smoking cessation therapy,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,713700008,Smoking cessation drug therapy,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,765001003,Monitoring of smoking cessation therapy refused,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,771155005,Brief intervention for smoking cessation,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,1290027009,Consultation for smoking cessation,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,25261000000107,Did not attend smoking cessation clinic,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,200221000000105,Smoking cessation advice provided by community pharmacist,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,201931000000109,Attends practice smoking cessation clinic,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,201941000000100,Attends smoking cessation clinic not at practice,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,374361000000100,Smoking cessation enhanced services administration,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,374391000000106,Smoking cessation enhanced services administration monitoring template completed,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,506491000000102,Brief intervention for smoking cessation,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,527151000000107,Smoking cessation advice declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,712971000000108,Practice based smoking cessation programme start date,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,720401000000103,Smoking cessation,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,750821000000109,Consent given for follow-up evaluation after smoking cessation intervention,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,750851000000104,Consent given for smoking cessation data sharing,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,751101000000101,Declined consent for follow-up evaluation after smoking cessation intervention,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,751661000000106,Declined consent for smoking cessation data sharing,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,755721000000107,Consent given for follow-up by smoking cessation team,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,755741000000100,Declined consent for follow-up by smoking cessation team,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,767641000000109,Referral for smoking cessation service offered,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,768971000000109,Lost to smoking cessation follow-up,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,822591000000108,Smoking cessation drug therapy declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,850331000000104,Smoking cessation 12 week follow-up,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,871641000000105,Referral to smoking cessation service declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,871661000000106,Referral to smoking cessation service,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,966971000000103,Varenicline smoking cessation therapy declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,966991000000104,Varenicline smoking cessation therapy offered,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,1084381000000100,Signposting to smoking cessation service,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,1087441000000106,Smoking cessation programme declined,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NICOTINE REPLACEMENT THERAPY (NRT) AND BUPROPION IN COMBINATION,Smoking cessation,TA039,smoking cessation,2140191000000108,Referral to Community Pharmacy Smoking Cessation Service,NICOTINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
NILOTINIB,Treating imatinib-resistant or intolerant chronic myeloid leukaemia,TA425,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,DASITINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
NILOTINIB,Treatment of chronic or accelerated phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults whose CML is resistant to treatment with standard-dose imatinib or who have imatinib intolerance,TA241,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,NILOTINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
NILOTINIB,Treatment of chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia,TA251,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,STANDARD-DOSE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
NILOTINIB,Untreated chronic myeloid leukaemia,TA426,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,DASATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
NINTEDANIB,Idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted,TA864,pulmonary fibrosis,90610005,Interstitial pulmonary fibrosis of prematurity,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE
NINTEDANIB,Idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted,TA864,pulmonary fibrosis,196028003,Chronic pulmonary fibrosis caused by chemical fumes,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE
NINTEDANIB,Idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted,TA864,pulmonary fibrosis,196125002,Diffuse interstitial pulmonary fibrosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE
NINTEDANIB,Idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted,TA864,pulmonary fibrosis,233724002,Chemical-induced diffuse interstitial pulmonary fibrosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE
NINTEDANIB,Idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted,TA864,pulmonary fibrosis,233725001,Drug-induced diffuse interstitial pulmonary fibrosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE
NINTEDANIB,Idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted,TA864,pulmonary fibrosis,233726000,Localised pulmonary fibrosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE
NINTEDANIB,Idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted,TA864,pulmonary fibrosis,233770009,Pulmonary fibrosis due to sarcoidosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE
NINTEDANIB,Idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted,TA864,pulmonary fibrosis,266368002,Post-inflammatory pulmonary fibrosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE
NINTEDANIB,Idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted,TA864,pulmonary fibrosis,700250006,IPF - idiopathic pulmonary fibrosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE
NINTEDANIB,Treating idiopathic pulmonary fibrosis,TA379,pulmonary fibrosis,90610005,Interstitial pulmonary fibrosis of prematurity,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE
NINTEDANIB,Treating idiopathic pulmonary fibrosis,TA379,pulmonary fibrosis,196028003,Chronic pulmonary fibrosis caused by chemical fumes,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE
NINTEDANIB,Treating idiopathic pulmonary fibrosis,TA379,pulmonary fibrosis,196125002,Diffuse interstitial pulmonary fibrosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE
NINTEDANIB,Treating idiopathic pulmonary fibrosis,TA379,pulmonary fibrosis,233724002,Chemical-induced diffuse interstitial pulmonary fibrosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE
NINTEDANIB,Treating idiopathic pulmonary fibrosis,TA379,pulmonary fibrosis,233725001,Drug-induced diffuse interstitial pulmonary fibrosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE
NINTEDANIB,Treating idiopathic pulmonary fibrosis,TA379,pulmonary fibrosis,233726000,Localised pulmonary fibrosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE
NINTEDANIB,Treating idiopathic pulmonary fibrosis,TA379,pulmonary fibrosis,233770009,Pulmonary fibrosis due to sarcoidosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE
NINTEDANIB,Treating idiopathic pulmonary fibrosis,TA379,pulmonary fibrosis,266368002,Post-inflammatory pulmonary fibrosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE
NINTEDANIB,Treating idiopathic pulmonary fibrosis,TA379,pulmonary fibrosis,700250006,IPF - idiopathic pulmonary fibrosis,NINTEDANIB,THORACIC MEDICINE,THORACIC MEDICINE
NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,162573006,Suspected lung cancer,NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,254637007,Non-small cell lung cancer,NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,275981009,Lung cancer screening,NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,429011007,Family history of lung cancer,NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,723301009,Squamous non-small cell lung cancer,NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,1259727001,Primary non-small cell lung cancer,NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,276491000000101,Fast track referral for suspected lung cancer,NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,848881000000108,QCancer lung cancer risk,NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,877691000000107,No FH of lung cancer,NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,1771781000000107,Did not attend lung cancer screening,NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NINTEDANIB IN COMBINATION WITH DOCETAXEL,"Locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer",TA347,lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",NINTEDANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,8100009,Structure of infundibulum of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,9361007,Downward displacement of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,22611009,Endometriosis of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,25344002,Fimbriectomy of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,25811000,Excision of entire bilateral fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,29827000,Excision of both fallopian tubes and ovaries,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,32587001,Rupture of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,32987009,Both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,38043007,Implantation of prosthesis into fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,41393008,Excision of cyst of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,42618007,Atresia of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,44793005,Excision of lesion of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,46536000,Inflammation of ovary and fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,46946009,Torsion of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,49558004,Fallopian tube tuberculosis,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,56900004,Infarction of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,64233004,Congenital cyst of fimbria of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,78328007,Aspiration of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,78517009,Dilation of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,79586000,Fallopian tube pregnancy,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,85029000,Congenital anomaly of fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,88157006,Inflammation of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,92100009,Benign neoplasm of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,92591008,Carcinoma in situ of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,118869008,Procedure on fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,120062000,Fallopian tube reconstruction,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,128134005,Fallopian tube disorder,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176936004,Open occlusion of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176937008,Open ligation of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176938003,Open bilateral clipping of fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176942000,Open ligation of remaining solitary fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176948001,Open ligation of right fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176949009,Open ligation of left fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176965005,Drainage of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176975008,Exploration of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176978005,Endoscopic bilateral cauterisation of fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176979002,Endoscopic bilateral clipping of fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176980004,Ligation of fallopian tubes with Fallope ring by endoscopy,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176984008,Endoscopic occlusion of remaining solitary fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176985009,Endoscopic occlusion of right fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,176986005,Endoscopic occlusion of left fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,177002003,Laparoscopy of fallopian tube: [diagnostic NOS] or [NEC],NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,189120005,Benign neoplasm of fallopian tubes and uterine ligaments,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,193331004,Laparoscopy with occlusion of fallopian tube by device,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,198299001,Acquired ovarian and fallopian tube atrophy,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,198305004,Prolapse of ovary and fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,198308002,"Torsion of the ovary, ovarian pedicle or fallopian tube",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,198311001,"Other ovary, fallopian tube and broad ligament disorders",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,198313003,"Ovarian, fallopian tube and broad ligament disorder NOS",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,204826004,Fallopian tube and broad ligament anomalies,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,236927008,Removal of clip from fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,236938008,Laparoscopy of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,237050007,Fimbrial phimosis of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,245482004,Entire left cornu of Fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,262931005,Transection of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,265071006,Open clipping of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,265076001,Open clipping of left fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,266591002,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,266592009,Acquired absence of ovary or fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,271414005,Fallopian tube prosthesis operation,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,271415006,Removal of products of conception from fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,274975009,Open ringing of bilateral fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,274977001,Unilateral occlusion of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,280504001,Fallopian tube stenosis,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,281258002,LAP DYE - laparoscopic dye test of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,283958000,Hematoma of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,287664005,Ligation of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,287931008,Fallopian tube cornual resection,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,287943009,Insufflation of fallopian tube using saline,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,287944003,Insufflation of fallopian tube using gas,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,288032001,Transection of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,288033006,Unilateral ligation of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,288034000,Unilateral fallopian tube division,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,289832005,Fallopian tube present,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,289833000,Fallopian tube absent,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,292002002,Open unilateral occlusion of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,300020002,Diathermy of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,302954008,Congenital cyst of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,307264000,Remaining fallopian tube removed,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,309290005,Fallopian tube biopsy specimen,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,309500004,Excised uterus and single fallopian tube and ovary sample,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,310808000,Fallopian tube clip,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,369514009,Metastatic malignant neoplasm of left fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,387615001,Removal of gestational sac from fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,387617009,Aspiration of gestational sac from fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,391993002,Reestablishment of continuity of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,392250009,Operation on fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,398319002,Abscess of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,427543006,Recanalisation of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,609321005,Endoscopic bilateral occlusion of fallopian tubes using intrafallopian implants,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,719447009,Ectopic fallopian tube tissue,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,560681000000101,Reanastomosis of fallopian tube NEC,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,561491000000108,Fallopian tube operations NOS,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy",TA673,fallopian tube,647361000000102,"Ovarian, fallopian tube and broad ligament disorder NOS",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,8100009,Structure of infundibulum of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,9361007,Downward displacement of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,22611009,Endometriosis of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,25344002,Fimbriectomy of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,25811000,Excision of entire bilateral fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,29827000,Excision of both fallopian tubes and ovaries,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,32587001,Rupture of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,32987009,Both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,38043007,Implantation of prosthesis into fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,41393008,Excision of cyst of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,42618007,Atresia of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,44793005,Excision of lesion of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,46536000,Inflammation of ovary and fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,46946009,Torsion of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,49558004,Fallopian tube tuberculosis,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,56900004,Infarction of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,64233004,Congenital cyst of fimbria of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,78328007,Aspiration of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,78517009,Dilation of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,79586000,Fallopian tube pregnancy,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,85029000,Congenital anomaly of fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,88157006,Inflammation of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,92100009,Benign neoplasm of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,92591008,Carcinoma in situ of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,118869008,Procedure on fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,120062000,Fallopian tube reconstruction,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,128134005,Fallopian tube disorder,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176936004,Open occlusion of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176937008,Open ligation of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176938003,Open bilateral clipping of fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176942000,Open ligation of remaining solitary fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176948001,Open ligation of right fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176949009,Open ligation of left fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176965005,Drainage of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176975008,Exploration of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176978005,Endoscopic bilateral cauterisation of fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176979002,Endoscopic bilateral clipping of fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176980004,Ligation of fallopian tubes with Fallope ring by endoscopy,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176984008,Endoscopic occlusion of remaining solitary fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176985009,Endoscopic occlusion of right fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,176986005,Endoscopic occlusion of left fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,177002003,Laparoscopy of fallopian tube: [diagnostic NOS] or [NEC],NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,189120005,Benign neoplasm of fallopian tubes and uterine ligaments,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,193331004,Laparoscopy with occlusion of fallopian tube by device,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,198299001,Acquired ovarian and fallopian tube atrophy,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,198305004,Prolapse of ovary and fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,198308002,"Torsion of the ovary, ovarian pedicle or fallopian tube",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,198311001,"Other ovary, fallopian tube and broad ligament disorders",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,198313003,"Ovarian, fallopian tube and broad ligament disorder NOS",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,204826004,Fallopian tube and broad ligament anomalies,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,236927008,Removal of clip from fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,236938008,Laparoscopy of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,237050007,Fimbrial phimosis of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,245482004,Entire left cornu of Fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,262931005,Transection of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,265071006,Open clipping of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,265076001,Open clipping of left fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,266591002,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,266592009,Acquired absence of ovary or fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,271414005,Fallopian tube prosthesis operation,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,271415006,Removal of products of conception from fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,274975009,Open ringing of bilateral fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,274977001,Unilateral occlusion of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,280504001,Fallopian tube stenosis,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,281258002,LAP DYE - laparoscopic dye test of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,283958000,Hematoma of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,287664005,Ligation of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,287931008,Fallopian tube cornual resection,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,287943009,Insufflation of fallopian tube using saline,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,287944003,Insufflation of fallopian tube using gas,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,288032001,Transection of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,288033006,Unilateral ligation of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,288034000,Unilateral fallopian tube division,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,289832005,Fallopian tube present,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,289833000,Fallopian tube absent,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,292002002,Open unilateral occlusion of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,300020002,Diathermy of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,302954008,Congenital cyst of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,307264000,Remaining fallopian tube removed,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,309290005,Fallopian tube biopsy specimen,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,309500004,Excised uterus and single fallopian tube and ovary sample,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,310808000,Fallopian tube clip,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,369514009,Metastatic malignant neoplasm of left fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,387615001,Removal of gestational sac from fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,387617009,Aspiration of gestational sac from fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,391993002,Reestablishment of continuity of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,392250009,Operation on fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,398319002,Abscess of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,427543006,Recanalisation of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,609321005,Endoscopic bilateral occlusion of fallopian tubes using intrafallopian implants,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,719447009,Ectopic fallopian tube tissue,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,560681000000101,Reanastomosis of fallopian tube NEC,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,561491000000108,Fallopian tube operations NOS,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA784,fallopian tube,647361000000102,"Ovarian, fallopian tube and broad ligament disorder NOS",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,8100009,Structure of infundibulum of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,9361007,Downward displacement of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,22611009,Endometriosis of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,25344002,Fimbriectomy of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,25811000,Excision of entire bilateral fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,29827000,Excision of both fallopian tubes and ovaries,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,32587001,Rupture of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,32987009,Both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,38043007,Implantation of prosthesis into fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,41393008,Excision of cyst of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,42618007,Atresia of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,44793005,Excision of lesion of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,46536000,Inflammation of ovary and fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,46946009,Torsion of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,49558004,Fallopian tube tuberculosis,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,56900004,Infarction of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,64233004,Congenital cyst of fimbria of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,78328007,Aspiration of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,78517009,Dilation of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,79586000,Fallopian tube pregnancy,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,85029000,Congenital anomaly of fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,88157006,Inflammation of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,92100009,Benign neoplasm of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,92591008,Carcinoma in situ of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,118869008,Procedure on fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,120062000,Fallopian tube reconstruction,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,128134005,Fallopian tube disorder,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176936004,Open occlusion of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176937008,Open ligation of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176938003,Open bilateral clipping of fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176942000,Open ligation of remaining solitary fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176948001,Open ligation of right fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176949009,Open ligation of left fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176965005,Drainage of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176975008,Exploration of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176978005,Endoscopic bilateral cauterisation of fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176979002,Endoscopic bilateral clipping of fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176980004,Ligation of fallopian tubes with Fallope ring by endoscopy,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176984008,Endoscopic occlusion of remaining solitary fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176985009,Endoscopic occlusion of right fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,176986005,Endoscopic occlusion of left fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,177002003,Laparoscopy of fallopian tube: [diagnostic NOS] or [NEC],NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,189120005,Benign neoplasm of fallopian tubes and uterine ligaments,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,193331004,Laparoscopy with occlusion of fallopian tube by device,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,198299001,Acquired ovarian and fallopian tube atrophy,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,198305004,Prolapse of ovary and fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,198308002,"Torsion of the ovary, ovarian pedicle or fallopian tube",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,198311001,"Other ovary, fallopian tube and broad ligament disorders",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,198313003,"Ovarian, fallopian tube and broad ligament disorder NOS",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,204826004,Fallopian tube and broad ligament anomalies,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,236927008,Removal of clip from fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,236938008,Laparoscopy of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,237050007,Fimbrial phimosis of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,245482004,Entire left cornu of Fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,262931005,Transection of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,265071006,Open clipping of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,265076001,Open clipping of left fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,266591002,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,266592009,Acquired absence of ovary or fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,271414005,Fallopian tube prosthesis operation,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,271415006,Removal of products of conception from fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,274975009,Open ringing of bilateral fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,274977001,Unilateral occlusion of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,280504001,Fallopian tube stenosis,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,281258002,LAP DYE - laparoscopic dye test of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,283958000,Hematoma of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,287664005,Ligation of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,287931008,Fallopian tube cornual resection,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,287943009,Insufflation of fallopian tube using saline,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,287944003,Insufflation of fallopian tube using gas,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,288032001,Transection of both fallopian tubes,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,288033006,Unilateral ligation of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,288034000,Unilateral fallopian tube division,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,289832005,Fallopian tube present,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,289833000,Fallopian tube absent,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,292002002,Open unilateral occlusion of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,300020002,Diathermy of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,302954008,Congenital cyst of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,307264000,Remaining fallopian tube removed,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,309290005,Fallopian tube biopsy specimen,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,309500004,Excised uterus and single fallopian tube and ovary sample,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,310808000,Fallopian tube clip,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,369514009,Metastatic malignant neoplasm of left fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,387615001,Removal of gestational sac from fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,387617009,Aspiration of gestational sac from fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,391993002,Reestablishment of continuity of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,392250009,Operation on fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,398319002,Abscess of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,427543006,Recanalisation of fallopian tube,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,609321005,Endoscopic bilateral occlusion of fallopian tubes using intrafallopian implants,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,719447009,Ectopic fallopian tube tissue,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,560681000000101,Reanastomosis of fallopian tube NEC,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,561491000000108,Fallopian tube operations NOS,NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRAPARIB,"Relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer",TA528,fallopian tube,647361000000102,"Ovarian, fallopian tube and broad ligament disorder NOS",NIRAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,840544004,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,840544004,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,840544004,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,840544004,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,840544004,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,840544004,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,840544004,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,840544004,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870589006,Acute kidney injury due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870589006,Acute kidney injury due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870589006,Acute kidney injury due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870589006,Acute kidney injury due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870589006,Acute kidney injury due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870589006,Acute kidney injury due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870589006,Acute kidney injury due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870589006,Acute kidney injury due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870591003,Rhabdomyolysis due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870591003,Rhabdomyolysis due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870591003,Rhabdomyolysis due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870591003,Rhabdomyolysis due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870591003,Rhabdomyolysis due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870591003,Rhabdomyolysis due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870591003,Rhabdomyolysis due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,870591003,Rhabdomyolysis due to COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,895448002,PIMS-TS - paediatric inflammatory multisystem syndrome temporally associated with COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,895448002,PIMS-TS - paediatric inflammatory multisystem syndrome temporally associated with COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,895448002,PIMS-TS - paediatric inflammatory multisystem syndrome temporally associated with COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,895448002,PIMS-TS - paediatric inflammatory multisystem syndrome temporally associated with COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,895448002,PIMS-TS - paediatric inflammatory multisystem syndrome temporally associated with COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,895448002,PIMS-TS - paediatric inflammatory multisystem syndrome temporally associated with COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,895448002,PIMS-TS - paediatric inflammatory multisystem syndrome temporally associated with COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,895448002,PIMS-TS - paediatric inflammatory multisystem syndrome temporally associated with COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119303003,Post-acute COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119303003,Post-acute COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119303003,Post-acute COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119303003,Post-acute COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119303003,Post-acute COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119303003,Post-acute COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119303003,Post-acute COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119303003,Post-acute COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119304009,Post COVID-19 condition,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119304009,Post COVID-19 condition,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119304009,Post COVID-19 condition,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119304009,Post COVID-19 condition,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119304009,Post COVID-19 condition,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119304009,Post COVID-19 condition,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119304009,Post COVID-19 condition,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1119304009,Post COVID-19 condition,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1142180003,Adverse reaction to COVID-19 vaccine,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1142180003,Adverse reaction to COVID-19 vaccine,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1142180003,Adverse reaction to COVID-19 vaccine,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1142180003,Adverse reaction to COVID-19 vaccine,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1142180003,Adverse reaction to COVID-19 vaccine,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1142180003,Adverse reaction to COVID-19 vaccine,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1142180003,Adverse reaction to COVID-19 vaccine,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1142180003,Adverse reaction to COVID-19 vaccine,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,28531000087107,COVID-19 vaccine,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,28531000087107,COVID-19 vaccine,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,28531000087107,COVID-19 vaccine,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,28531000087107,COVID-19 vaccine,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240751000000100,COVID-19 caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240751000000100,COVID-19 caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240751000000100,COVID-19 caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240751000000100,COVID-19 caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240751000000100,COVID-19 caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240751000000100,COVID-19 caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240751000000100,COVID-19 caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240751000000100,COVID-19 caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240761000000102,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240761000000102,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240761000000102,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240761000000102,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240761000000102,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240761000000102,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240761000000102,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1240761000000102,Possible COVID-19,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300561000000107,High risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300561000000107,High risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300561000000107,High risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300561000000107,High risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300561000000107,High risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300561000000107,High risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300561000000107,High risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300561000000107,High risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300571000000100,Moderate risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300571000000100,Moderate risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300571000000100,Moderate risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300571000000100,Moderate risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300571000000100,Moderate risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300571000000100,Moderate risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300571000000100,Moderate risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300571000000100,Moderate risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300591000000101,Low risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300591000000101,Low risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300591000000101,Low risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300591000000101,Low risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300591000000101,Low risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300591000000101,Low risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300591000000101,Low risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300591000000101,Low risk category for developing complication from COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300631000000101,COVID-19 severity score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300631000000101,COVID-19 severity score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300631000000101,COVID-19 severity score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300631000000101,COVID-19 severity score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300631000000101,COVID-19 severity score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300631000000101,COVID-19 severity score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300631000000101,COVID-19 severity score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300631000000101,COVID-19 severity score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300671000000104,COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300671000000104,COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300671000000104,COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300671000000104,COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300671000000104,COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300671000000104,COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300671000000104,COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300671000000104,COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300681000000102,Assessment using COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300681000000102,Assessment using COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300681000000102,Assessment using COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300681000000102,Assessment using COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300681000000102,Assessment using COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300681000000102,Assessment using COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300681000000102,Assessment using COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300681000000102,Assessment using COVID-19 severity scale,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300721000000109,COVID-19 confirmed by laboratory test,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300721000000109,COVID-19 confirmed by laboratory test,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300721000000109,COVID-19 confirmed by laboratory test,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300721000000109,COVID-19 confirmed by laboratory test,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300731000000106,COVID-19 confirmed clinically,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300731000000106,COVID-19 confirmed clinically,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300731000000106,COVID-19 confirmed clinically,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300731000000106,COVID-19 confirmed clinically,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300731000000106,COVID-19 confirmed clinically,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300731000000106,COVID-19 confirmed clinically,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300731000000106,COVID-19 confirmed clinically,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1300731000000106,COVID-19 confirmed clinically,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321101000000103,COVID-19 excluded,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321101000000103,COVID-19 excluded,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321101000000103,COVID-19 excluded,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321101000000103,COVID-19 excluded,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321101000000103,COVID-19 excluded,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321101000000103,COVID-19 excluded,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321101000000103,COVID-19 excluded,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321101000000103,COVID-19 excluded,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321111000000101,COVID-19 excluded by laboratory test,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321111000000101,COVID-19 excluded by laboratory test,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321111000000101,COVID-19 excluded by laboratory test,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321111000000101,COVID-19 excluded by laboratory test,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321111000000101,COVID-19 excluded by laboratory test,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321111000000101,COVID-19 excluded by laboratory test,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321111000000101,COVID-19 excluded by laboratory test,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321111000000101,COVID-19 excluded by laboratory test,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321121000000107,COVID-19 excluded using clinical diagnostic criteria,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321121000000107,COVID-19 excluded using clinical diagnostic criteria,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321121000000107,COVID-19 excluded using clinical diagnostic criteria,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321121000000107,COVID-19 excluded using clinical diagnostic criteria,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321121000000107,COVID-19 excluded using clinical diagnostic criteria,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321121000000107,COVID-19 excluded using clinical diagnostic criteria,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321121000000107,COVID-19 excluded using clinical diagnostic criteria,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321121000000107,COVID-19 excluded using clinical diagnostic criteria,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321171000000106,"Provision of advice, assessment or treatment limited due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321171000000106,"Provision of advice, assessment or treatment limited due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321171000000106,"Provision of advice, assessment or treatment limited due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321171000000106,"Provision of advice, assessment or treatment limited due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321171000000106,"Provision of advice, assessment or treatment limited due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321171000000106,"Provision of advice, assessment or treatment limited due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321171000000106,"Provision of advice, assessment or treatment limited due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321171000000106,"Provision of advice, assessment or treatment limited due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321231000000101,Signposting to CHMS (COVID-19 Home Management Service),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321231000000101,Signposting to CHMS (COVID-19 Home Management Service),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321231000000101,Signposting to CHMS (COVID-19 Home Management Service),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321231000000101,Signposting to CHMS (COVID-19 Home Management Service),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321231000000101,Signposting to CHMS (COVID-19 Home Management Service),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321231000000101,Signposting to CHMS (COVID-19 Home Management Service),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321231000000101,Signposting to CHMS (COVID-19 Home Management Service),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321231000000101,Signposting to CHMS (COVID-19 Home Management Service),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321851000000109,"Provision of advice, assessment or treatment delayed due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321851000000109,"Provision of advice, assessment or treatment delayed due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321851000000109,"Provision of advice, assessment or treatment delayed due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321851000000109,"Provision of advice, assessment or treatment delayed due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321851000000109,"Provision of advice, assessment or treatment delayed due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321851000000109,"Provision of advice, assessment or treatment delayed due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321851000000109,"Provision of advice, assessment or treatment delayed due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1321851000000109,"Provision of advice, assessment or treatment delayed due to COVID-19 pandemic",NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325031000000108,Referral to long term effects of COVID-19 assessment clinic,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325031000000108,Referral to long term effects of COVID-19 assessment clinic,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325031000000108,Referral to long term effects of COVID-19 assessment clinic,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325031000000108,Referral to long term effects of COVID-19 assessment clinic,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325071000000105,COVID-19 Yorkshire Rehabilitation Screening tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325071000000105,COVID-19 Yorkshire Rehabilitation Screening tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325071000000105,COVID-19 Yorkshire Rehabilitation Screening tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325071000000105,COVID-19 Yorkshire Rehabilitation Screening tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325071000000105,COVID-19 Yorkshire Rehabilitation Screening tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325071000000105,COVID-19 Yorkshire Rehabilitation Screening tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325071000000105,COVID-19 Yorkshire Rehabilitation Screening tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325071000000105,COVID-19 Yorkshire Rehabilitation Screening tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325081000000107,Assessment using C19-YRS (COVID-19 Yorkshire Rehabilitation Screening) tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325081000000107,Assessment using C19-YRS (COVID-19 Yorkshire Rehabilitation Screening) tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325081000000107,Assessment using C19-YRS (COVID-19 Yorkshire Rehabilitation Screening) tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325081000000107,Assessment using C19-YRS (COVID-19 Yorkshire Rehabilitation Screening) tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325081000000107,Assessment using C19-YRS (COVID-19 Yorkshire Rehabilitation Screening) tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325081000000107,Assessment using C19-YRS (COVID-19 Yorkshire Rehabilitation Screening) tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325081000000107,Assessment using C19-YRS (COVID-19 Yorkshire Rehabilitation Screening) tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325081000000107,Assessment using C19-YRS (COVID-19 Yorkshire Rehabilitation Screening) tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325101000000101,Assessment using Post-COVID-19 Functional Status Scale patient self-report,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325101000000101,Assessment using Post-COVID-19 Functional Status Scale patient self-report,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325101000000101,Assessment using Post-COVID-19 Functional Status Scale patient self-report,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325101000000101,Assessment using Post-COVID-19 Functional Status Scale patient self-report,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325101000000101,Assessment using Post-COVID-19 Functional Status Scale patient self-report,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325101000000101,Assessment using Post-COVID-19 Functional Status Scale patient self-report,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325101000000101,Assessment using Post-COVID-19 Functional Status Scale patient self-report,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325101000000101,Assessment using Post-COVID-19 Functional Status Scale patient self-report,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325121000000105,Post-COVID-19 Functional Status Scale patient self-report final scale grade,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325121000000105,Post-COVID-19 Functional Status Scale patient self-report final scale grade,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325121000000105,Post-COVID-19 Functional Status Scale patient self-report final scale grade,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325121000000105,Post-COVID-19 Functional Status Scale patient self-report final scale grade,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325121000000105,Post-COVID-19 Functional Status Scale patient self-report final scale grade,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325121000000105,Post-COVID-19 Functional Status Scale patient self-report final scale grade,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325121000000105,Post-COVID-19 Functional Status Scale patient self-report final scale grade,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325121000000105,Post-COVID-19 Functional Status Scale patient self-report final scale grade,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325141000000103,Assessment using PCFS (Post-COVID-19 Functional Status) Scale structured interview,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325141000000103,Assessment using PCFS (Post-COVID-19 Functional Status) Scale structured interview,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325141000000103,Assessment using PCFS (Post-COVID-19 Functional Status) Scale structured interview,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325141000000103,Assessment using PCFS (Post-COVID-19 Functional Status) Scale structured interview,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325141000000103,Assessment using PCFS (Post-COVID-19 Functional Status) Scale structured interview,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325141000000103,Assessment using PCFS (Post-COVID-19 Functional Status) Scale structured interview,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325141000000103,Assessment using PCFS (Post-COVID-19 Functional Status) Scale structured interview,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325141000000103,Assessment using PCFS (Post-COVID-19 Functional Status) Scale structured interview,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325151000000100,PCFS (Post-COVID-19 Functional Status) Scale structured interview,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325151000000100,PCFS (Post-COVID-19 Functional Status) Scale structured interview,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325151000000100,PCFS (Post-COVID-19 Functional Status) Scale structured interview,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325151000000100,PCFS (Post-COVID-19 Functional Status) Scale structured interview,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325161000000102,Post-COVID-19 syndrome,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325161000000102,Post-COVID-19 syndrome,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325161000000102,Post-COVID-19 syndrome,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325161000000102,Post-COVID-19 syndrome,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325161000000102,Post-COVID-19 syndrome,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325161000000102,Post-COVID-19 syndrome,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325161000000102,Post-COVID-19 syndrome,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325161000000102,Post-COVID-19 syndrome,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325171000000109,Acute COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325171000000109,Acute COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325171000000109,Acute COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325171000000109,Acute COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325171000000109,Acute COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325171000000109,Acute COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325171000000109,Acute COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325171000000109,Acute COVID-19 infection,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325831000000100,Post-COVID-19 syndrome service,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325831000000100,Post-COVID-19 syndrome service,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325831000000100,Post-COVID-19 syndrome service,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325831000000100,Post-COVID-19 syndrome service,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325831000000100,Post-COVID-19 syndrome service,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325831000000100,Post-COVID-19 syndrome service,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325831000000100,Post-COVID-19 syndrome service,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325831000000100,Post-COVID-19 syndrome service,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325951000000102,Assessment using NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325951000000102,Assessment using NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325951000000102,Assessment using NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325951000000102,Assessment using NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325951000000102,Assessment using NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325951000000102,Assessment using NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325951000000102,Assessment using NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325951000000102,Assessment using NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325961000000104,NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325961000000104,NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325961000000104,NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325961000000104,NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325961000000104,NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325961000000104,NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325961000000104,NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325961000000104,NHS Digital COVID-19 Clinical Risk Assessment Tool,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325981000000108,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and dying from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325981000000108,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and dying from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325981000000108,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and dying from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325981000000108,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and dying from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325981000000108,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and dying from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325981000000108,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and dying from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325981000000108,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and dying from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325981000000108,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and dying from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325991000000105,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325991000000105,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325991000000105,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325991000000105,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325991000000105,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325991000000105,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325991000000105,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1325991000000105,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 relative risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326001000000109,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 absolute risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326001000000109,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 absolute risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326001000000109,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 absolute risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326001000000109,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 absolute risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326001000000109,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 absolute risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326001000000109,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 absolute risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326001000000109,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 absolute risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326001000000109,NHS Digital COVID-19 Clinical Risk Assessment Tool combined risk of catching and hospitalisation from COVID-19 absolute risk score,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326351000000108,Post-COVID-19 syndrome resolved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326351000000108,Post-COVID-19 syndrome resolved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326351000000108,Post-COVID-19 syndrome resolved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326351000000108,Post-COVID-19 syndrome resolved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326351000000108,Post-COVID-19 syndrome resolved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326351000000108,Post-COVID-19 syndrome resolved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326351000000108,Post-COVID-19 syndrome resolved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1326351000000108,Post-COVID-19 syndrome resolved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1365751000000105,Application for medical exemption from COVID-19 vaccination approved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1365751000000105,Application for medical exemption from COVID-19 vaccination approved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1365751000000105,Application for medical exemption from COVID-19 vaccination approved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1365751000000105,Application for medical exemption from COVID-19 vaccination approved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1365751000000105,Application for medical exemption from COVID-19 vaccination approved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1365751000000105,Application for medical exemption from COVID-19 vaccination approved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1365751000000105,Application for medical exemption from COVID-19 vaccination approved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,1365751000000105,Application for medical exemption from COVID-19 vaccination approved,NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,39230211000001104,COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]) 0.5ml dose suspension for injection multidose vials (Janssen-Cilag Ltd),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,39230211000001104,COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]) 0.5ml dose suspension for injection multidose vials (Janssen-Cilag Ltd),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,39230211000001104,COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]) 0.5ml dose suspension for injection multidose vials (Janssen-Cilag Ltd),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,39230211000001104,COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]) 0.5ml dose suspension for injection multidose vials (Janssen-Cilag Ltd),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,39230211000001104,COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]) 0.5ml dose suspension for injection multidose vials (Janssen-Cilag Ltd),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,39230211000001104,COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]) 0.5ml dose suspension for injection multidose vials (Janssen-Cilag Ltd),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,39230211000001104,COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]) 0.5ml dose suspension for injection multidose vials (Janssen-Cilag Ltd),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,39230211000001104,COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]) 0.5ml dose suspension for injection multidose vials (Janssen-Cilag Ltd),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,40872011000001104,COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials (Sanofi),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,40872011000001104,COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials (Sanofi),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,40872011000001104,COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials (Sanofi),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,40872011000001104,COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials (Sanofi),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,40872011000001104,COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials (Sanofi),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,40872011000001104,COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials (Sanofi),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,40872011000001104,COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials (Sanofi),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,40872011000001104,COVID-19 Vaccine VidPrevtyn Beta (CoV2 preS dTM monovalent B.1.351 [recombinant adjuvanted]) 5micrograms/0.5ml dose solution and emulsion for emulsion for injection multidose vials (Sanofi),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,42985911000001104,Spikevax JN.1 COVID-19 mRNA Vaccine 0.1mg/ml dispersion for injection multidose vials (Moderna Biotech Distributor UK Ltd),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,42985911000001104,Spikevax JN.1 COVID-19 mRNA Vaccine 0.1mg/ml dispersion for injection multidose vials (Moderna Biotech Distributor UK Ltd),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,42985911000001104,Spikevax JN.1 COVID-19 mRNA Vaccine 0.1mg/ml dispersion for injection multidose vials (Moderna Biotech Distributor UK Ltd),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIRMATRELVIR PLUS RITONAVIR,Treating COVID-19,TA878,covid-19,42985911000001104,Spikevax JN.1 COVID-19 mRNA Vaccine 0.1mg/ml dispersion for injection multidose vials (Moderna Biotech Distributor UK Ltd),NIRMATRELVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|THORACIC MEDICINE
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,915007,Malignant melanoma in junctional naevus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,1556006,Clark melanoma level 4,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,2092003,Malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,2142002,Nodular melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,16974005,"Acral lentiginous melanoma, malignant",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,21119008,Benign melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,21165006,Clark melanoma level 3,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,37138001,Epithelioid cell melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,39896009,"Malignant melanoma, regressing",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,44474009,Lentigo maligna melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,50542000,Clark melanoma level 2,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,50813003,Spitz melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,51757004,"Desmoplastic melanoma, amelanotic",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,55320002,Superficial spreading melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,68827007,Spindle cell melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,70594002,Amelanotic melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,77986002,Melanoma in situ,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93209006,Malignant melanoma of perianal skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93214005,Malignant melanoma of skin of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93217003,Malignant melanoma of skin of cheek,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93220006,Malignant melanoma of skin of ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93221005,Malignant melanoma of skin of elbow,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93223008,Malignant melanoma of eyebrow,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93225001,Malignant melanoma of skin of face,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93227009,Malignant melanoma of skin of foot,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93228004,Malignant melanoma of skin of forearm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93642000,Malignant melanoma of skin of neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93643005,Malignant melanoma of external surface of nose,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93646002,Malignant melanoma of skin of scalp,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93647006,Malignant melanoma of skin of shoulder,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93651008,Malignant melanoma of skin of trunk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93653006,Malignant melanoma of skin of upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93654000,Malignant melanoma of skin of wrist,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,93655004,MM (malignant melanoma) of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,106243009,Breslow depth staging for melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,109266006,Melanoma in situ of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,109270003,Melanoma in situ of face,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,109272006,Melanoma in situ of lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,109276009,Melanoma in situ of scalp,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,109278005,Melanoma in situ of ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,109282007,Melanoma in situ of neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,109284008,Melanoma in situ of trunk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,109290007,Melanoma in situ of upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,109294003,Melanoma in situ of lower limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,127330008,Melanoma in situ by body site (clinical),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,161432005,History of malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,177281002,Excision of melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188030005,Malignant melanoma of lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188033007,Malignant melanoma of auricle (ear),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188034001,Malignant melanoma of external auditory meatus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188038003,Malignant melanoma of chin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188040008,Malignant melanoma of forehead,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188042000,Malignant melanoma of temple,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188044004,Malignant melanoma of scalp and/or neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188045003,Malignant melanoma of scalp,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188046002,Malignant melanoma of neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188049009,Malignant melanoma of axilla,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188050009,Malignant melanoma of breast,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188051008,Malignant melanoma of buttock,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188052001,Malignant melanoma of groin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188054000,Malignant melanoma of perineum,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188055004,Malignant melanoma of umbilicus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188060000,Malignant melanoma of shoulder,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188061001,Malignant melanoma of upper arm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188062008,Malignant melanoma of forearm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188063003,Malignant melanoma of hand,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188064009,Malignant melanoma of finger,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188065005,Malignant melanoma of thumb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188067002,Malignant melanoma of lower limb and hip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188068007,Malignant melanoma of hip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188069004,Malignant melanoma of thigh,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188070003,Malignant melanoma of knee,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188071004,Malignant melanoma of popliteal fossa area,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188072006,Malignant melanoma of lower leg,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188073001,Malignant melanoma of ankle,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188074007,Malignant melanoma of heel,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188075008,Malignant melanoma of foot,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188076009,Malignant melanoma of toe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,188077000,Malignant melanoma of great toe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,189758001,Melanoma in situ,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,231834005,Malignant melanoma of eyelid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,254731001,Nodular melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,254732008,Acral lentiginous melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,254896002,Malignant melanoma of vulva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,255004001,Malignant melanoma of conjunctiva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,255012009,Malignant melanoma of iris,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,255015006,Malignant melanoma of ciliary body,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,255021005,Malignant melanoma of choroid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,269578002,Malignant melanoma of head and neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,269579005,Malignant melanoma of trunk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,269580008,Malignant melanoma of upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,269581007,Malignant melanoma of lower limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,274087000,MM (malignant melanoma) of eye,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,276751004,Amelanotic melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,276821000,Malignant melanoma of anus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,276822007,Malignant melanoma of rectum,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,302837001,Lentigo maligna melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,310498001,Malignant melanoma of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,312941005,Melanoma associated retinopathy,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,313248004,Malignant melanoma of chest wall,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,314976006,Local recurrence of malignant melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,314987003,Metastasis from malignant melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,315036008,Melanoma in situ of back of hand,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,315230006,Melanoma in situ of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,372158004,"Malignant melanoma, metastatic",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,427858005,Family history of malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,443493003,Metastatic malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,449636007,Malignant melanoma of skin of lower leg,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,449637003,Malignant melanoma of skin of upper arm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,698040004,Malignant melanoma of nasal cavity,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,1197324006,Metastatic malignant melanoma to skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,351961000119109,Malignant melanoma of skin of right arm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,352211000119108,Malignant melanoma of skin of left ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,546881000000105,Malignant melanoma of skin NOS,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,956331000000107,Malignant melanoma stage IA,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,956351000000100,Malignant melanoma stage IB,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,956371000000109,Malignant melanoma stage IIA,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,956391000000108,Malignant melanoma stage IIB,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,956451000000107,Malignant melanoma stage IIIB,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,956471000000103,Malignant melanoma stage IIIC,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,956511000000107,Malignant melanoma stage IV M1a,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,956551000000106,Malignant melanoma stage IV M1c,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,1080941000119109,Malignant melanoma of left choroid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease,TA684,melanoma,1080981000119104,Malignant melanoma of right choroid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,915007,Malignant melanoma in junctional naevus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,1556006,Clark melanoma level 4,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,2092003,Malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,2142002,Nodular melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,16974005,"Acral lentiginous melanoma, malignant",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,21119008,Benign melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,21165006,Clark melanoma level 3,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,37138001,Epithelioid cell melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,39896009,"Malignant melanoma, regressing",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,44474009,Lentigo maligna melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,50542000,Clark melanoma level 2,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,50813003,Spitz melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,51757004,"Desmoplastic melanoma, amelanotic",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,55320002,Superficial spreading melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,68827007,Spindle cell melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,70594002,Amelanotic melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,77986002,Melanoma in situ,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93209006,Malignant melanoma of perianal skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93214005,Malignant melanoma of skin of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93217003,Malignant melanoma of skin of cheek,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93220006,Malignant melanoma of skin of ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93221005,Malignant melanoma of skin of elbow,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93223008,Malignant melanoma of eyebrow,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93225001,Malignant melanoma of skin of face,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93227009,Malignant melanoma of skin of foot,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93228004,Malignant melanoma of skin of forearm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93642000,Malignant melanoma of skin of neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93643005,Malignant melanoma of external surface of nose,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93646002,Malignant melanoma of skin of scalp,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93647006,Malignant melanoma of skin of shoulder,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93651008,Malignant melanoma of skin of trunk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93653006,Malignant melanoma of skin of upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93654000,Malignant melanoma of skin of wrist,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,93655004,MM (malignant melanoma) of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,106243009,Breslow depth staging for melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,109266006,Melanoma in situ of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,109270003,Melanoma in situ of face,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,109272006,Melanoma in situ of lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,109276009,Melanoma in situ of scalp,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,109278005,Melanoma in situ of ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,109282007,Melanoma in situ of neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,109284008,Melanoma in situ of trunk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,109290007,Melanoma in situ of upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,109294003,Melanoma in situ of lower limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,127330008,Melanoma in situ by body site (clinical),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,161432005,History of malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,177281002,Excision of melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188030005,Malignant melanoma of lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188033007,Malignant melanoma of auricle (ear),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188034001,Malignant melanoma of external auditory meatus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188038003,Malignant melanoma of chin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188040008,Malignant melanoma of forehead,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188042000,Malignant melanoma of temple,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188044004,Malignant melanoma of scalp and/or neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188045003,Malignant melanoma of scalp,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188046002,Malignant melanoma of neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188049009,Malignant melanoma of axilla,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188050009,Malignant melanoma of breast,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188051008,Malignant melanoma of buttock,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188052001,Malignant melanoma of groin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188054000,Malignant melanoma of perineum,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188055004,Malignant melanoma of umbilicus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188060000,Malignant melanoma of shoulder,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188061001,Malignant melanoma of upper arm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188062008,Malignant melanoma of forearm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188063003,Malignant melanoma of hand,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188064009,Malignant melanoma of finger,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188065005,Malignant melanoma of thumb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188067002,Malignant melanoma of lower limb and hip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188068007,Malignant melanoma of hip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188069004,Malignant melanoma of thigh,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188070003,Malignant melanoma of knee,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188071004,Malignant melanoma of popliteal fossa area,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188072006,Malignant melanoma of lower leg,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188073001,Malignant melanoma of ankle,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188074007,Malignant melanoma of heel,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188075008,Malignant melanoma of foot,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188076009,Malignant melanoma of toe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,188077000,Malignant melanoma of great toe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,189758001,Melanoma in situ,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,231834005,Malignant melanoma of eyelid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,254731001,Nodular melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,254732008,Acral lentiginous melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,254896002,Malignant melanoma of vulva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,255004001,Malignant melanoma of conjunctiva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,255012009,Malignant melanoma of iris,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,255015006,Malignant melanoma of ciliary body,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,255021005,Malignant melanoma of choroid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,269578002,Malignant melanoma of head and neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,269579005,Malignant melanoma of trunk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,269580008,Malignant melanoma of upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,269581007,Malignant melanoma of lower limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,274087000,MM (malignant melanoma) of eye,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,276751004,Amelanotic melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,276821000,Malignant melanoma of anus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,276822007,Malignant melanoma of rectum,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,302837001,Lentigo maligna melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,310498001,Malignant melanoma of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,312941005,Melanoma associated retinopathy,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,313248004,Malignant melanoma of chest wall,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,314976006,Local recurrence of malignant melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,314987003,Metastasis from malignant melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,315036008,Melanoma in situ of back of hand,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,315230006,Melanoma in situ of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,372158004,"Malignant melanoma, metastatic",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,427858005,Family history of malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,443493003,Metastatic malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,449636007,Malignant melanoma of skin of lower leg,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,449637003,Malignant melanoma of skin of upper arm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,698040004,Malignant melanoma of nasal cavity,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,1197324006,Metastatic malignant melanoma to skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,351961000119109,Malignant melanoma of skin of right arm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,352211000119108,Malignant melanoma of skin of left ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,546881000000105,Malignant melanoma of skin NOS,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,956331000000107,Malignant melanoma stage IA,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,956351000000100,Malignant melanoma stage IB,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,956371000000109,Malignant melanoma stage IIA,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,956391000000108,Malignant melanoma stage IIB,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,956451000000107,Malignant melanoma stage IIIB,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,956471000000103,Malignant melanoma stage IIIC,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,956511000000107,Malignant melanoma stage IV M1a,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,956551000000106,Malignant melanoma stage IV M1c,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,1080941000119109,Malignant melanoma of left choroid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced (unresectable or metastatic) melanoma,TA384,melanoma,1080981000119104,Malignant melanoma of right choroid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,162573006,Suspected lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,254637007,Non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,275981009,Lung cancer screening,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,429011007,Family history of lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,877691000000107,No FH of lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced non-squamous non-small-cell lung cancer after chemotherapy,TA713,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,162573006,Suspected lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,254637007,Non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,275981009,Lung cancer screening,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,429011007,Family history of lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,877691000000107,No FH of lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Advanced squamous non-small-cell lung cancer after chemotherapy,TA655,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,915007,Malignant melanoma in junctional naevus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,1556006,Clark melanoma level 4,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,2092003,Malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,2142002,Nodular melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,16974005,"Acral lentiginous melanoma, malignant",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,21119008,Benign melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,21165006,Clark melanoma level 3,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,37138001,Epithelioid cell melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,39896009,"Malignant melanoma, regressing",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,44474009,Lentigo maligna melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,50542000,Clark melanoma level 2,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,50813003,Spitz melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,51757004,"Desmoplastic melanoma, amelanotic",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,55320002,Superficial spreading melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,68827007,Spindle cell melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,70594002,Amelanotic melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,77986002,Melanoma in situ,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93209006,Malignant melanoma of perianal skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93214005,Malignant melanoma of skin of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93217003,Malignant melanoma of skin of cheek,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93220006,Malignant melanoma of skin of ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93221005,Malignant melanoma of skin of elbow,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93223008,Malignant melanoma of eyebrow,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93225001,Malignant melanoma of skin of face,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93227009,Malignant melanoma of skin of foot,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93228004,Malignant melanoma of skin of forearm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93642000,Malignant melanoma of skin of neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93643005,Malignant melanoma of external surface of nose,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93646002,Malignant melanoma of skin of scalp,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93647006,Malignant melanoma of skin of shoulder,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93651008,Malignant melanoma of skin of trunk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93653006,Malignant melanoma of skin of upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93654000,Malignant melanoma of skin of wrist,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,93655004,MM (malignant melanoma) of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,106243009,Breslow depth staging for melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,109266006,Melanoma in situ of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,109270003,Melanoma in situ of face,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,109272006,Melanoma in situ of lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,109276009,Melanoma in situ of scalp,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,109278005,Melanoma in situ of ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,109282007,Melanoma in situ of neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,109284008,Melanoma in situ of trunk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,109290007,Melanoma in situ of upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,109294003,Melanoma in situ of lower limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,127330008,Melanoma in situ by body site (clinical),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,161432005,History of malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,177281002,Excision of melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188030005,Malignant melanoma of lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188033007,Malignant melanoma of auricle (ear),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188034001,Malignant melanoma of external auditory meatus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188038003,Malignant melanoma of chin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188040008,Malignant melanoma of forehead,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188042000,Malignant melanoma of temple,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188044004,Malignant melanoma of scalp and/or neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188045003,Malignant melanoma of scalp,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188046002,Malignant melanoma of neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188049009,Malignant melanoma of axilla,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188050009,Malignant melanoma of breast,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188051008,Malignant melanoma of buttock,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188052001,Malignant melanoma of groin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188054000,Malignant melanoma of perineum,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188055004,Malignant melanoma of umbilicus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188060000,Malignant melanoma of shoulder,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188061001,Malignant melanoma of upper arm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188062008,Malignant melanoma of forearm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188063003,Malignant melanoma of hand,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188064009,Malignant melanoma of finger,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188065005,Malignant melanoma of thumb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188067002,Malignant melanoma of lower limb and hip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188068007,Malignant melanoma of hip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188069004,Malignant melanoma of thigh,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188070003,Malignant melanoma of knee,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188071004,Malignant melanoma of popliteal fossa area,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188072006,Malignant melanoma of lower leg,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188073001,Malignant melanoma of ankle,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188074007,Malignant melanoma of heel,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188075008,Malignant melanoma of foot,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188076009,Malignant melanoma of toe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,188077000,Malignant melanoma of great toe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,189758001,Melanoma in situ,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,231834005,Malignant melanoma of eyelid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,254731001,Nodular melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,254732008,Acral lentiginous melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,254896002,Malignant melanoma of vulva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,255004001,Malignant melanoma of conjunctiva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,255012009,Malignant melanoma of iris,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,255015006,Malignant melanoma of ciliary body,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,255021005,Malignant melanoma of choroid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,269578002,Malignant melanoma of head and neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,269579005,Malignant melanoma of trunk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,269580008,Malignant melanoma of upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,269581007,Malignant melanoma of lower limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,274087000,MM (malignant melanoma) of eye,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,276751004,Amelanotic melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,276821000,Malignant melanoma of anus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,276822007,Malignant melanoma of rectum,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,302837001,Lentigo maligna melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,310498001,Malignant melanoma of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,312941005,Melanoma associated retinopathy,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,313248004,Malignant melanoma of chest wall,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,314976006,Local recurrence of malignant melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,314987003,Metastasis from malignant melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,315036008,Melanoma in situ of back of hand,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,315230006,Melanoma in situ of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,372158004,"Malignant melanoma, metastatic",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,427858005,Family history of malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,443493003,Metastatic malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,449636007,Malignant melanoma of skin of lower leg,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,449637003,Malignant melanoma of skin of upper arm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,698040004,Malignant melanoma of nasal cavity,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,1197324006,Metastatic malignant melanoma to skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,351961000119109,Malignant melanoma of skin of right arm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,352211000119108,Malignant melanoma of skin of left ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,546881000000105,Malignant melanoma of skin NOS,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,956331000000107,Malignant melanoma stage IA,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,956351000000100,Malignant melanoma stage IB,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,956371000000109,Malignant melanoma stage IIA,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,956391000000108,Malignant melanoma stage IIB,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,956451000000107,Malignant melanoma stage IIIB,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,956471000000103,Malignant melanoma stage IIIC,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,956511000000107,Malignant melanoma stage IV M1a,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,956551000000106,Malignant melanoma stage IV M1c,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,1080941000119109,Malignant melanoma of left choroid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Completely resected melanoma with lymph node involvement or metastatic disease,TA558,melanoma,1080981000119104,Malignant melanoma of right choroid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated advanced renal cell carcinoma,TA417,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated advanced renal cell carcinoma,TA417,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated advanced renal cell carcinoma,TA417,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated advanced renal cell carcinoma,TA417,renal cell carcinoma,733608000,Papillary renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated advanced renal cell carcinoma,TA417,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated advanced renal cell carcinoma,TA417,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated advanced renal cell carcinoma,TA417,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,162573006,Suspected lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,254637007,Non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,275981009,Lung cancer screening,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,429011007,Family history of lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,877691000000107,No FH of lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated non-squamous non-small-cell lung cancer,TA484,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,162573006,Suspected lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,254637007,Non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,275981009,Lung cancer screening,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,429011007,Family history of lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,877691000000107,No FH of lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated squamous non-small-cell lung cancer,TA483,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB,Previously treated unresectable advanced or recurrent oesophageal cancer,TA707,oesophageal cancer,848871000000106,QCancer gastro-oesophageal cancer risk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,10288008,Squamous cell carcinoma - spindle cell,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,12478003,Microinvasive squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,18048008,"Squamous cell carcinoma, keratinising",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,35718007,"Squamous cell carcinoma, small cell, nonkeratinizing",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,37304002,Mixed basal-squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,39056008,Papillary squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,59529006,Squamous cell carcinoma in situ,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,64204000,Metastatic squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,65692009,Polypoid squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,85956000,Pseudoglandular squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,89906000,Verrucous SCC (squamous cell carcinoma),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,231830001,Squamous cell carcinoma in situ of eyelid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,231831002,Squamous cell carcinoma of eyelid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,254620000,Squamous cell carcinoma of trachea,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,254634000,Squamous cell carcinoma of lung,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,254652000,Clear cell squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,254654004,Acantholytic squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,254886006,Squamous cell carcinoma of cervix,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,255003007,Squamous cell carcinoma of conjunctiva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,255071008,Squamous cell carcinoma of lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,255111004,Squamous cell carcinoma of urinary bladder,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,276804009,Squamous cell carcinoma of esophagus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,276860003,Squamous cell carcinoma of scrotum,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,276952000,Squamous cell carcinoma of tongue,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,276953005,Squamous cell carcinoma of gingiva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,276954004,Squamous cell carcinoma of floor of mouth,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,276962007,Squamous cell carcinoma of palate,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,285307007,Squamous cell carcinoma of skin of upper lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,285308002,Squamous cell carcinoma of skin of lower lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,285309005,Squamous cell carcinoma of skin of cheek,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,300987004,Disseminated squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,307502000,Squamous cell carcinoma of mouth,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,313353007,Squamous cell carcinoma of bronchus in left lower lobe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,313354001,Squamous cell carcinoma of bronchus in left upper lobe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,313355000,Squamous cell carcinoma of bronchus in right lower lobe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,313356004,Squamous cell carcinoma of bronchus of middle lobe of right lung,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,313357008,Squamous cell carcinoma of bronchus in right upper lobe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,400066006,Intraepithelial squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,400155002,Squamous cell carcinoma - category,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,402815007,Squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,402816008,Squamous cell carcinoma of anogenital area,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,403901001,Acantholytic squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,403904009,Verrucous squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,403906006,Metastatic squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,408649007,Squamous cell carcinoma of pharynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,422599000,Squamous cell carcinoma of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,423700001,Squamous cell carcinoma of auricle,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,698011002,Keratinizing squamous cell carcinoma of nasopharynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,700193001,Family history of squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,707388009,Primary squamous cell carcinoma of trachea,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,707429002,Overlapping squamous cell carcinoma of larynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,707576008,Primary squamous cell carcinoma of subglottis,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,707581004,Primary papillary squamous cell carcinoma of oropharynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,707662004,Primary basaloid squamous cell carcinoma of larynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,716659002,Squamous cell carcinoma of head and neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,719052006,Recurrent SCC (squamous cell carcinoma),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,721618006,Primary squamous cell carcinoma of upper third of esophagus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,722530005,Primary squamous cell carcinoma of adenoid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,722542000,Primary squamous cell carcinoma of anal canal,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,722672002,Primary squamous cell carcinoma of root of tongue,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,722673007,Primary squamous cell carcinoma of lingual tonsil,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,722674001,Primary squamous cell carcinoma of parotid gland,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,723182009,Primary squamous cell carcinoma of nasal cavity,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,723265000,Primary squamous cell carcinoma of anus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,733343005,Primary squamous cell carcinoma of oral cavity,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,1254755004,Metastatic basosquamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,1255632004,Spindle cell squamous cell carcinoma of larynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,18121000119104,Primary squamous cell carcinoma of palatine tonsil,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,78461000119105,Metastatic squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,91271000119101,Metastatic squamous cell carcinoma of bone,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,105041000119109,Metastatic squamous cell carcinoma to lung,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,688851000119108,Primary squamous cell carcinoma of glans penis,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,689361000119108,Primary squamous cell carcinoma of tonsillar fossa,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,878441000000101,No FH of squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,1014611000000103,Squamous cell carcinoma antigen level,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,1082071000119102,Primary squamous cell carcinoma of left ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA736,squamous cell carcinoma,12240991000119102,Squamous cell carcinoma of right lung,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA462,hodgkin lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",NIVOLUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
NIVOLUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA462,hodgkin lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",NIVOLUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
NIVOLUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA462,hodgkin lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",NIVOLUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
NIVOLUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA462,hodgkin lymphoma,118601006,Non-Hodgkin lymphoma,NIVOLUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
NIVOLUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA462,hodgkin lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,NIVOLUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
NIVOLUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA462,hodgkin lymphoma,128929007,Non-Hodgkin lymphoma - category,NIVOLUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
NIVOLUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA462,hodgkin lymphoma,128930002,Hodgkin lymphoma - category,NIVOLUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
NIVOLUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA462,hodgkin lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),NIVOLUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
NIVOLUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA462,hodgkin lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,NIVOLUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
NIVOLUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA462,hodgkin lymphoma,433450000,Family history of non-Hodgkin lymphoma,NIVOLUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
NIVOLUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA462,hodgkin lymphoma,448709005,Non-Hodgkin lymphoma of stomach,NIVOLUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
NIVOLUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA462,hodgkin lymphoma,762690000,Classical Hodgkin lymphoma,NIVOLUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
NIVOLUMAB,Resected oesophageal or gastro-oesophageal junction cancer,TA746,gastro-oesophageal junction,427421001,Fibreoptic endoscopic endoluminal plication of gastro-oesophageal junction,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,10288008,Squamous cell carcinoma - spindle cell,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,12478003,Microinvasive squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,18048008,"Squamous cell carcinoma, keratinising",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,35718007,"Squamous cell carcinoma, small cell, nonkeratinizing",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,37304002,Mixed basal-squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,39056008,Papillary squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,59529006,Squamous cell carcinoma in situ,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,64204000,Metastatic squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,65692009,Polypoid squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,85956000,Pseudoglandular squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,89906000,Verrucous SCC (squamous cell carcinoma),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,231830001,Squamous cell carcinoma in situ of eyelid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,231831002,Squamous cell carcinoma of eyelid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,254620000,Squamous cell carcinoma of trachea,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,254634000,Squamous cell carcinoma of lung,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,254652000,Clear cell squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,254654004,Acantholytic squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,254886006,Squamous cell carcinoma of cervix,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,255003007,Squamous cell carcinoma of conjunctiva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,255071008,Squamous cell carcinoma of lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,255111004,Squamous cell carcinoma of urinary bladder,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,276804009,Squamous cell carcinoma of esophagus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,276860003,Squamous cell carcinoma of scrotum,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,276952000,Squamous cell carcinoma of tongue,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,276953005,Squamous cell carcinoma of gingiva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,276954004,Squamous cell carcinoma of floor of mouth,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,276962007,Squamous cell carcinoma of palate,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,285307007,Squamous cell carcinoma of skin of upper lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,285308002,Squamous cell carcinoma of skin of lower lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,285309005,Squamous cell carcinoma of skin of cheek,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,300987004,Disseminated squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,307502000,Squamous cell carcinoma of mouth,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,313353007,Squamous cell carcinoma of bronchus in left lower lobe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,313354001,Squamous cell carcinoma of bronchus in left upper lobe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,313355000,Squamous cell carcinoma of bronchus in right lower lobe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,313356004,Squamous cell carcinoma of bronchus of middle lobe of right lung,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,313357008,Squamous cell carcinoma of bronchus in right upper lobe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,400066006,Intraepithelial squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,400155002,Squamous cell carcinoma - category,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,402815007,Squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,402816008,Squamous cell carcinoma of anogenital area,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,403901001,Acantholytic squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,403904009,Verrucous squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,403906006,Metastatic squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,408649007,Squamous cell carcinoma of pharynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,422599000,Squamous cell carcinoma of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,423700001,Squamous cell carcinoma of auricle,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,698011002,Keratinizing squamous cell carcinoma of nasopharynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,700193001,Family history of squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,707388009,Primary squamous cell carcinoma of trachea,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,707429002,Overlapping squamous cell carcinoma of larynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,707576008,Primary squamous cell carcinoma of subglottis,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,707581004,Primary papillary squamous cell carcinoma of oropharynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,707662004,Primary basaloid squamous cell carcinoma of larynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,716659002,Squamous cell carcinoma of head and neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,719052006,Recurrent SCC (squamous cell carcinoma),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,721618006,Primary squamous cell carcinoma of upper third of esophagus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,722530005,Primary squamous cell carcinoma of adenoid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,722542000,Primary squamous cell carcinoma of anal canal,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,722672002,Primary squamous cell carcinoma of root of tongue,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,722673007,Primary squamous cell carcinoma of lingual tonsil,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,722674001,Primary squamous cell carcinoma of parotid gland,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,723182009,Primary squamous cell carcinoma of nasal cavity,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,723265000,Primary squamous cell carcinoma of anus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,733343005,Primary squamous cell carcinoma of oral cavity,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,1254755004,Metastatic basosquamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,1255632004,Spindle cell squamous cell carcinoma of larynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,18121000119104,Primary squamous cell carcinoma of palatine tonsil,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,78461000119105,Metastatic squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,91271000119101,Metastatic squamous cell carcinoma of bone,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,105041000119109,Metastatic squamous cell carcinoma to lung,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,688851000119108,Primary squamous cell carcinoma of glans penis,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,689361000119108,Primary squamous cell carcinoma of tonsillar fossa,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,878441000000101,No FH of squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,1014611000000103,Squamous cell carcinoma antigen level,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,1082071000119102,Primary squamous cell carcinoma of left ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB,Squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA490,squamous cell carcinoma,12240991000119102,Squamous cell carcinoma of right lung,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,915007,Malignant melanoma in junctional naevus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,1556006,Clark melanoma level 4,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,2092003,Malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,2142002,Nodular melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,16974005,"Acral lentiginous melanoma, malignant",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,21119008,Benign melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,21165006,Clark melanoma level 3,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,37138001,Epithelioid cell melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,39896009,"Malignant melanoma, regressing",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,44474009,Lentigo maligna melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,50542000,Clark melanoma level 2,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,50813003,Spitz melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,51757004,"Desmoplastic melanoma, amelanotic",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,55320002,Superficial spreading melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,68827007,Spindle cell melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,70594002,Amelanotic melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,77986002,Melanoma in situ,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93209006,Malignant melanoma of perianal skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93214005,Malignant melanoma of skin of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93217003,Malignant melanoma of skin of cheek,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93220006,Malignant melanoma of skin of ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93221005,Malignant melanoma of skin of elbow,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93223008,Malignant melanoma of eyebrow,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93225001,Malignant melanoma of skin of face,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93227009,Malignant melanoma of skin of foot,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93228004,Malignant melanoma of skin of forearm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93642000,Malignant melanoma of skin of neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93643005,Malignant melanoma of external surface of nose,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93646002,Malignant melanoma of skin of scalp,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93647006,Malignant melanoma of skin of shoulder,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93651008,Malignant melanoma of skin of trunk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93653006,Malignant melanoma of skin of upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93654000,Malignant melanoma of skin of wrist,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,93655004,MM (malignant melanoma) of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,106243009,Breslow depth staging for melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,109266006,Melanoma in situ of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,109270003,Melanoma in situ of face,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,109272006,Melanoma in situ of lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,109276009,Melanoma in situ of scalp,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,109278005,Melanoma in situ of ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,109282007,Melanoma in situ of neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,109284008,Melanoma in situ of trunk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,109290007,Melanoma in situ of upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,109294003,Melanoma in situ of lower limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,127330008,Melanoma in situ by body site (clinical),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,161432005,History of malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,177281002,Excision of melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188030005,Malignant melanoma of lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188033007,Malignant melanoma of auricle (ear),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188034001,Malignant melanoma of external auditory meatus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188038003,Malignant melanoma of chin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188040008,Malignant melanoma of forehead,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188042000,Malignant melanoma of temple,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188044004,Malignant melanoma of scalp and/or neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188045003,Malignant melanoma of scalp,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188046002,Malignant melanoma of neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188049009,Malignant melanoma of axilla,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188050009,Malignant melanoma of breast,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188051008,Malignant melanoma of buttock,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188052001,Malignant melanoma of groin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188054000,Malignant melanoma of perineum,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188055004,Malignant melanoma of umbilicus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188060000,Malignant melanoma of shoulder,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188061001,Malignant melanoma of upper arm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188062008,Malignant melanoma of forearm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188063003,Malignant melanoma of hand,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188064009,Malignant melanoma of finger,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188065005,Malignant melanoma of thumb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188067002,Malignant melanoma of lower limb and hip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188068007,Malignant melanoma of hip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188069004,Malignant melanoma of thigh,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188070003,Malignant melanoma of knee,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188071004,Malignant melanoma of popliteal fossa area,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188072006,Malignant melanoma of lower leg,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188073001,Malignant melanoma of ankle,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188074007,Malignant melanoma of heel,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188075008,Malignant melanoma of foot,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188076009,Malignant melanoma of toe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,188077000,Malignant melanoma of great toe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,189758001,Melanoma in situ,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,231834005,Malignant melanoma of eyelid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,254731001,Nodular melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,254732008,Acral lentiginous melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,254896002,Malignant melanoma of vulva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,255004001,Malignant melanoma of conjunctiva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,255012009,Malignant melanoma of iris,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,255015006,Malignant melanoma of ciliary body,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,255021005,Malignant melanoma of choroid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,269578002,Malignant melanoma of head and neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,269579005,Malignant melanoma of trunk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,269580008,Malignant melanoma of upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,269581007,Malignant melanoma of lower limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,274087000,MM (malignant melanoma) of eye,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,276751004,Amelanotic melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,276821000,Malignant melanoma of anus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,276822007,Malignant melanoma of rectum,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,302837001,Lentigo maligna melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,310498001,Malignant melanoma of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,312941005,Melanoma associated retinopathy,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,313248004,Malignant melanoma of chest wall,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,314976006,Local recurrence of malignant melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,314987003,Metastasis from malignant melanoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,315036008,Melanoma in situ of back of hand,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,315230006,Melanoma in situ of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,372158004,"Malignant melanoma, metastatic",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,427858005,Family history of malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,443493003,Metastatic malignant melanoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,449636007,Malignant melanoma of skin of lower leg,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,449637003,Malignant melanoma of skin of upper arm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,698040004,Malignant melanoma of nasal cavity,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,1197324006,Metastatic malignant melanoma to skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,351961000119109,Malignant melanoma of skin of right arm,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,352211000119108,Malignant melanoma of skin of left ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,546881000000105,Malignant melanoma of skin NOS,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,956331000000107,Malignant melanoma stage IA,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,956351000000100,Malignant melanoma stage IB,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,956371000000109,Malignant melanoma stage IIA,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,956391000000108,Malignant melanoma stage IIB,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,956451000000107,Malignant melanoma stage IIIB,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,956471000000103,Malignant melanoma stage IIIC,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,956511000000107,Malignant melanoma stage IV M1a,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,956551000000106,Malignant melanoma stage IV M1c,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,1080941000119109,Malignant melanoma of left choroid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB IN COMBINATION WITH IPILIMUMAB,Treating advanced melanoma,TA400,melanoma,1080981000119104,Malignant melanoma of right choroid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
NIVOLUMAB WITH CABOZANTINIB,Untreated advanced renal cell carcinoma,TA785,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB WITH CABOZANTINIB,Untreated advanced renal cell carcinoma,TA785,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB WITH CABOZANTINIB,Untreated advanced renal cell carcinoma,TA785,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB WITH CABOZANTINIB,Untreated advanced renal cell carcinoma,TA785,renal cell carcinoma,733608000,Papillary renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB WITH CABOZANTINIB,Untreated advanced renal cell carcinoma,TA785,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB WITH CABOZANTINIB,Untreated advanced renal cell carcinoma,TA785,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB WITH CABOZANTINIB,Untreated advanced renal cell carcinoma,TA785,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,162573006,Suspected lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,254637007,Non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,275981009,Lung cancer screening,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,429011007,Family history of lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,877691000000107,No FH of lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH CHEMOTHERAPY,Neoadjuvant treatment of resectable non-small-cell lung cancer,TA876,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,10288008,Squamous cell carcinoma - spindle cell,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,12478003,Microinvasive squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,18048008,"Squamous cell carcinoma, keratinising",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,35718007,"Squamous cell carcinoma, small cell, nonkeratinizing",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,37304002,Mixed basal-squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,39056008,Papillary squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,59529006,Squamous cell carcinoma in situ,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,64204000,Metastatic squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,65692009,Polypoid squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,85956000,Pseudoglandular squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,89906000,Verrucous SCC (squamous cell carcinoma),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,231830001,Squamous cell carcinoma in situ of eyelid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,231831002,Squamous cell carcinoma of eyelid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,254620000,Squamous cell carcinoma of trachea,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,254634000,Squamous cell carcinoma of lung,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,254652000,Clear cell squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,254654004,Acantholytic squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,254886006,Squamous cell carcinoma of cervix,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,255003007,Squamous cell carcinoma of conjunctiva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,255071008,Squamous cell carcinoma of lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,255111004,Squamous cell carcinoma of urinary bladder,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,276804009,Squamous cell carcinoma of esophagus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,276860003,Squamous cell carcinoma of scrotum,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,276952000,Squamous cell carcinoma of tongue,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,276953005,Squamous cell carcinoma of gingiva,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,276954004,Squamous cell carcinoma of floor of mouth,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,276962007,Squamous cell carcinoma of palate,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,285307007,Squamous cell carcinoma of skin of upper lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,285308002,Squamous cell carcinoma of skin of lower lip,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,285309005,Squamous cell carcinoma of skin of cheek,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,300987004,Disseminated squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,307502000,Squamous cell carcinoma of mouth,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,313353007,Squamous cell carcinoma of bronchus in left lower lobe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,313354001,Squamous cell carcinoma of bronchus in left upper lobe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,313355000,Squamous cell carcinoma of bronchus in right lower lobe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,313356004,Squamous cell carcinoma of bronchus of middle lobe of right lung,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,313357008,Squamous cell carcinoma of bronchus in right upper lobe,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,400066006,Intraepithelial squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,400155002,Squamous cell carcinoma - category,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,402815007,Squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,402816008,Squamous cell carcinoma of anogenital area,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,403901001,Acantholytic squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,403904009,Verrucous squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,403906006,Metastatic squamous cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,408649007,Squamous cell carcinoma of pharynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,422599000,Squamous cell carcinoma of back,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,423700001,Squamous cell carcinoma of auricle,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,698011002,Keratinizing squamous cell carcinoma of nasopharynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,700193001,Family history of squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,707388009,Primary squamous cell carcinoma of trachea,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,707429002,Overlapping squamous cell carcinoma of larynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,707576008,Primary squamous cell carcinoma of subglottis,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,707581004,Primary papillary squamous cell carcinoma of oropharynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,707662004,Primary basaloid squamous cell carcinoma of larynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,716659002,Squamous cell carcinoma of head and neck,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,719052006,Recurrent SCC (squamous cell carcinoma),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,721618006,Primary squamous cell carcinoma of upper third of esophagus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,722530005,Primary squamous cell carcinoma of adenoid,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,722542000,Primary squamous cell carcinoma of anal canal,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,722672002,Primary squamous cell carcinoma of root of tongue,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,722673007,Primary squamous cell carcinoma of lingual tonsil,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,722674001,Primary squamous cell carcinoma of parotid gland,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,723182009,Primary squamous cell carcinoma of nasal cavity,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,723265000,Primary squamous cell carcinoma of anus,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,733343005,Primary squamous cell carcinoma of oral cavity,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,1254755004,Metastatic basosquamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,1255632004,Spindle cell squamous cell carcinoma of larynx,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,18121000119104,Primary squamous cell carcinoma of palatine tonsil,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,78461000119105,Metastatic squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,91271000119101,Metastatic squamous cell carcinoma of bone,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,105041000119109,Metastatic squamous cell carcinoma to lung,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,688851000119108,Primary squamous cell carcinoma of glans penis,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,689361000119108,Primary squamous cell carcinoma of tonsillar fossa,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,878441000000101,No FH of squamous cell carcinoma of skin,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,1014611000000103,Squamous cell carcinoma antigen level,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,1082071000119102,Primary squamous cell carcinoma of left ear,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH FLUOROPYRIMIDINE- AND PLATINUM-BASED CHEMOTHERAPY,"Untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma",TA865,squamous cell carcinoma,12240991000119102,Squamous cell carcinoma of right lung,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA581,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA780,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA581,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA780,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA581,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA780,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA581,renal cell carcinoma,733608000,Papillary renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA780,renal cell carcinoma,733608000,Papillary renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA581,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA780,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA581,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA780,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA581,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB,Untreated advanced renal cell carcinoma,TA780,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB,Untreated unresectable malignant pleural mesothelioma,TA818,malignant pleural mesothelioma,254645002,Malignant pleural mesothelioma,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,162573006,Suspected lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,254637007,Non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,275981009,Lung cancer screening,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,429011007,Family history of lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,877691000000107,No FH of lung cancer,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH IPILIMUMAB AND CHEMOTHERAPY,Untreated metastatic non-small-cell lung cancer,TA724,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
NIVOLUMAB WITH PLATINUM- AND FLUOROPYRIMIDINE-BASED CHEMOTHERAPY,"Untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma",TA857,gastro-oesophageal junction,427421001,Fibreoptic endoscopic endoluminal plication of gastro-oesophageal junction,NIVOLUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
NUSINERSEN,Spinal muscular atrophy,TA588,spinal muscular atrophy,5262007,Progressive spinal muscular atrophy,NUSINERSEN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
NUSINERSEN,Spinal muscular atrophy,TA588,spinal muscular atrophy,54280009,Familial spinal muscular atrophy,NUSINERSEN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
NUSINERSEN,Spinal muscular atrophy,TA588,spinal muscular atrophy,64383006,Infantile spinal muscular atrophy,NUSINERSEN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
NUSINERSEN,Spinal muscular atrophy,TA588,spinal muscular atrophy,85505000,Generalized spinal muscular atrophy of late onset,NUSINERSEN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
NUSINERSEN,Spinal muscular atrophy,TA588,spinal muscular atrophy,128212001,Late infantile spinal muscular atrophy,NUSINERSEN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
NUSINERSEN,Spinal muscular atrophy,TA588,spinal muscular atrophy,230247001,Distal spinal muscular atrophy,NUSINERSEN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
NUSINERSEN,Spinal muscular atrophy,TA588,spinal muscular atrophy,230252006,Oculopharyngeal spinal muscular atrophy,NUSINERSEN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OBETICHOLIC ACID,Primary biliary cholangitis,TA443,primary biliary cholangitis,31712002,Primary biliary cholangitis,OBETICHOLIC,GASTROENTEROLOGY,GASTROENTEROLOGY
OBINUTUZUMAB,Untreated advanced follicular lymphoma,TA513,follicular lymphoma,109962001,Nonfollicular lymphoma,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB,Untreated advanced follicular lymphoma,TA513,follicular lymphoma,308121000,Follicular lymphoma,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB,Untreated advanced follicular lymphoma,TA513,follicular lymphoma,721555001,Follicular lymphoma of small intestine,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB,Untreated advanced follicular lymphoma,TA513,follicular lymphoma,1148851002,Follicular lymphoma grade IIIa,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB,Untreated advanced follicular lymphoma,TA513,follicular lymphoma,847481000000109,Follicular lymphoma grade 1,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB,Untreated advanced follicular lymphoma,TA513,follicular lymphoma,847631000000107,Follicular lymphoma grade 2,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB,Untreated advanced follicular lymphoma,TA513,follicular lymphoma,847651000000100,Follicular lymphoma grade 3,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB,Untreated advanced follicular lymphoma,TA513,follicular lymphoma,847691000000108,Follicular lymphoma grade 3a,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB,Untreated advanced follicular lymphoma,TA513,follicular lymphoma,847701000000108,Follicular lymphoma grade 3b,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB IN COMBINATION WITH CHLORAMBUCIL,Untreated chronic lymphocytic leukaemia,TA343,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
OBINUTUZUMAB IN COMBINATION WITH CHLORAMBUCIL,Untreated chronic lymphocytic leukaemia,TA343,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
OBINUTUZUMAB IN COMBINATION WITH CHLORAMBUCIL,Untreated chronic lymphocytic leukaemia,TA343,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
OBINUTUZUMAB IN COMBINATION WITH CHLORAMBUCIL,Untreated chronic lymphocytic leukaemia,TA343,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma after rituximab,TA629,follicular lymphoma,109962001,Nonfollicular lymphoma,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma after rituximab,TA629,follicular lymphoma,308121000,Follicular lymphoma,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma after rituximab,TA629,follicular lymphoma,721555001,Follicular lymphoma of small intestine,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma after rituximab,TA629,follicular lymphoma,1148851002,Follicular lymphoma grade IIIa,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma after rituximab,TA629,follicular lymphoma,847481000000109,Follicular lymphoma grade 1,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma after rituximab,TA629,follicular lymphoma,847631000000107,Follicular lymphoma grade 2,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma after rituximab,TA629,follicular lymphoma,847651000000100,Follicular lymphoma grade 3,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma after rituximab,TA629,follicular lymphoma,847691000000108,Follicular lymphoma grade 3a,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma after rituximab,TA629,follicular lymphoma,847701000000108,Follicular lymphoma grade 3b,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma refractory to rituximab,TA472,follicular lymphoma,109962001,Nonfollicular lymphoma,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma refractory to rituximab,TA472,follicular lymphoma,308121000,Follicular lymphoma,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma refractory to rituximab,TA472,follicular lymphoma,721555001,Follicular lymphoma of small intestine,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma refractory to rituximab,TA472,follicular lymphoma,1148851002,Follicular lymphoma grade IIIa,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma refractory to rituximab,TA472,follicular lymphoma,847481000000109,Follicular lymphoma grade 1,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma refractory to rituximab,TA472,follicular lymphoma,847631000000107,Follicular lymphoma grade 2,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma refractory to rituximab,TA472,follicular lymphoma,847651000000100,Follicular lymphoma grade 3,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma refractory to rituximab,TA472,follicular lymphoma,847691000000108,Follicular lymphoma grade 3a,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OBINUTUZUMAB WITH BENDAMUSTINE,Follicular lymphoma refractory to rituximab,TA472,follicular lymphoma,847701000000108,Follicular lymphoma grade 3b,OBINUTUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,24700007,Multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,160337009,Family history of multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,192926004,Brain stem multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,192928003,Generalised multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,428700003,Primary progressive multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,438511000,Benign multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,700409000,Suspected multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,198491000000106,Multiple sclerosis review,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,515931000000104,Multiple sclerosis review declined,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Early primary progressive multiple sclerosis,TA585,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,24700007,Multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,160337009,Family history of multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,192926004,Brain stem multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,192928003,Generalised multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,428700003,Primary progressive multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,438511000,Benign multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,700409000,Suspected multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,198491000000106,Multiple sclerosis review,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,515931000000104,Multiple sclerosis review declined,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OCRELIZUMAB,Relapsing–remitting multiple sclerosis,TA533,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,OCRELIZUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OFATUMUMAB,Chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab,TA202,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,OFATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
OFATUMUMAB,Chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab,TA202,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,OFATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
OFATUMUMAB,Chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab,TA202,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,OFATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
OFATUMUMAB,Chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab,TA202,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,OFATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
OFATUMUMAB FOR TREATING RELAPSING MULTIPLE SCLEROSIS,Relapsing multiple sclerosis,TA699,relapsing multiple sclerosis,230372003,Acute relapsing multiple sclerosis,OFATUMUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OFATUMUMAB FOR TREATING RELAPSING MULTIPLE SCLEROSIS,Relapsing multiple sclerosis,TA699,relapsing multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,OFATUMUMAB,NEUROLOGY,NEUROLOGY|REHABILITATION
OFATUMUMAB IN COMBINATION WITH CHLORAMBUCIL,Untreated chronic lymphocytic leukaemia,TA344,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,OFATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
OFATUMUMAB IN COMBINATION WITH CHLORAMBUCIL,Untreated chronic lymphocytic leukaemia,TA344,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,OFATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
OFATUMUMAB IN COMBINATION WITH CHLORAMBUCIL,Untreated chronic lymphocytic leukaemia,TA344,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,OFATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
OFATUMUMAB IN COMBINATION WITH CHLORAMBUCIL,Untreated chronic lymphocytic leukaemia,TA344,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,OFATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
OFATUMUMAB WITH CHEMOTHERAPY,Chronic lymphocytic leukaemia,TA470,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,OFATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
OFATUMUMAB WITH CHEMOTHERAPY,Chronic lymphocytic leukaemia,TA470,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,OFATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
OFATUMUMAB WITH CHEMOTHERAPY,Chronic lymphocytic leukaemia,TA470,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,OFATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
OFATUMUMAB WITH CHEMOTHERAPY,Chronic lymphocytic leukaemia,TA470,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,OFATUMUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
OLANZAPINE,Bipolar disorder,TA066,bipolar disorder,4441000,Severe bipolar disorder with psychotic features,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Bipolar disorder,TA066,bipolar disorder,5703000,Bipolar disorder in partial remission,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Bipolar disorder,TA066,bipolar disorder,13313007,Mild bipolar disorder,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Bipolar disorder,TA066,bipolar disorder,41836007,Bipolar disorder in full remission,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Bipolar disorder,TA066,bipolar disorder,53049002,Severe bipolar disorder without psychotic features,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Bipolar disorder,TA066,bipolar disorder,79584002,Moderate bipolar disorder,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Bipolar disorder,TA066,bipolar disorder,85248005,Bipolar disorder in remission,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Bipolar disorder,TA066,bipolar disorder,160331005,Family history of bipolar disorder,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Bipolar disorder,TA066,bipolar disorder,231444002,Organic bipolar disorder,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Bipolar disorder,TA066,bipolar disorder,767632000,"Bipolar disorder, most recent episode manic",OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Bipolar disorder,TA066,bipolar disorder,1365951000000107,Family intervention for psychosis and bipolar disorder,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,4926007,Schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,12939007,Chronic disorganized schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,31373002,Hebephrenic schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,31658008,Chronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,35252006,Disorganised schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,39610001,Undifferentiated schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,58214004,Schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,63181006,"Paranoid schizophrenia, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,64905009,Paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,79866005,Subchronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,83746006,Chronic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,111482003,Subchronic schizophrenia with acute exacerbations,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,111483008,"Schizophrenia, catatonic, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,111484002,Undifferentiated schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,160328009,Family history of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,161103001,Schizophrenia association member,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,161468000,History of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,191527001,Simple schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,191531007,Acute exacerbation of chronic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,191548004,Chronic catatonic schizophrenia with acute exacerbation,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,191554003,Acute exacerbation of subchronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,191555002,Acute exacerbation of chronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,191559008,Latent schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,191565008,Latent schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,191567000,Schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,191570001,Chronic schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,191572009,Acute exacerbation of chronic schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,191574005,"Schizophrenia, schizoaffective, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,247804008,Prodromal schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,274952002,Borderline schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,278853003,Acute schizophrenia-like psychotic disorder,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,444180005,History of schizophrenia in child of subject,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,712824002,Acute polymorphic psychotic disorder without symptoms of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,712850003,Acute polymorphic psychotic disorder with symptoms of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,200951000000109,"Psychosis, schizophrenia and bipolar affective disorder resolved",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,285521000000103,Schizophrenia resolved,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,417601000000102,"[X]Schizophrenia, schizotypal and delusional disorders",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,443791000000100,[X]Pseudopsychopathic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,1062101000000104,Schizophrenia TOM (Therapy Outcome Measure) activity score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,1062121000000108,Schizophrenia TOM (Therapy Outcome Measure) impairment score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,1062131000000105,Schizophrenia TOM (Therapy Outcome Measure) participation score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLANZAPINE,Schizophrenia,TA043,schizophrenia,1062141000000101,Schizophrenia TOM (Therapy Outcome Measure) wellbeing score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,8100009,Structure of infundibulum of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,9361007,Downward displacement of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,22611009,Endometriosis of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,25344002,Fimbriectomy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,25811000,Excision of entire bilateral fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,29827000,Excision of both fallopian tubes and ovaries,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,32587001,Rupture of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,32987009,Both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,38043007,Implantation of prosthesis into fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,41393008,Excision of cyst of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,42618007,Atresia of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,44793005,Excision of lesion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,46536000,Inflammation of ovary and fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,46946009,Torsion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,49558004,Fallopian tube tuberculosis,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,56900004,Infarction of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,64233004,Congenital cyst of fimbria of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,78328007,Aspiration of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,78517009,Dilation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,79586000,Fallopian tube pregnancy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,85029000,Congenital anomaly of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,88157006,Inflammation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,92100009,Benign neoplasm of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,92591008,Carcinoma in situ of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,118869008,Procedure on fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,120062000,Fallopian tube reconstruction,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,128134005,Fallopian tube disorder,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176936004,Open occlusion of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176937008,Open ligation of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176938003,Open bilateral clipping of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176942000,Open ligation of remaining solitary fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176948001,Open ligation of right fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176949009,Open ligation of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176965005,Drainage of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176975008,Exploration of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176978005,Endoscopic bilateral cauterisation of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176979002,Endoscopic bilateral clipping of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176980004,Ligation of fallopian tubes with Fallope ring by endoscopy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176984008,Endoscopic occlusion of remaining solitary fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176985009,Endoscopic occlusion of right fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,176986005,Endoscopic occlusion of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,177002003,Laparoscopy of fallopian tube: [diagnostic NOS] or [NEC],OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,189120005,Benign neoplasm of fallopian tubes and uterine ligaments,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,193331004,Laparoscopy with occlusion of fallopian tube by device,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,198299001,Acquired ovarian and fallopian tube atrophy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,198305004,Prolapse of ovary and fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,198308002,"Torsion of the ovary, ovarian pedicle or fallopian tube",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,198311001,"Other ovary, fallopian tube and broad ligament disorders",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,198313003,"Ovarian, fallopian tube and broad ligament disorder NOS",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,204826004,Fallopian tube and broad ligament anomalies,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,236927008,Removal of clip from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,236938008,Laparoscopy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,237050007,Fimbrial phimosis of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,245482004,Entire left cornu of Fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,262931005,Transection of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,265071006,Open clipping of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,265076001,Open clipping of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,266591002,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,266592009,Acquired absence of ovary or fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,271414005,Fallopian tube prosthesis operation,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,271415006,Removal of products of conception from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,274975009,Open ringing of bilateral fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,274977001,Unilateral occlusion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,280504001,Fallopian tube stenosis,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,281258002,LAP DYE - laparoscopic dye test of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,283958000,Hematoma of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,287664005,Ligation of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,287931008,Fallopian tube cornual resection,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,287943009,Insufflation of fallopian tube using saline,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,287944003,Insufflation of fallopian tube using gas,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,288032001,Transection of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,288033006,Unilateral ligation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,288034000,Unilateral fallopian tube division,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,289832005,Fallopian tube present,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,289833000,Fallopian tube absent,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,292002002,Open unilateral occlusion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,300020002,Diathermy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,302954008,Congenital cyst of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,307264000,Remaining fallopian tube removed,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,309290005,Fallopian tube biopsy specimen,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,309500004,Excised uterus and single fallopian tube and ovary sample,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,310808000,Fallopian tube clip,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,369514009,Metastatic malignant neoplasm of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,387615001,Removal of gestational sac from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,387617009,Aspiration of gestational sac from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,391993002,Reestablishment of continuity of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,392250009,Operation on fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,398319002,Abscess of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,427543006,Recanalisation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,609321005,Endoscopic bilateral occlusion of fallopian tubes using intrafallopian implants,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,719447009,Ectopic fallopian tube tissue,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,560681000000101,Reanastomosis of fallopian tube NEC,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,561491000000108,Fallopian tube operations NOS,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Advanced ovarian, fallopian tube or peritoneal cancer",TA598,fallopian tube,647361000000102,"Ovarian, fallopian tube and broad ligament disorder NOS",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,134405005,Suspected breast cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,160287004,FH: Breast cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,268547008,Screening for breast cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,brca,412734009,BRCA1 gene mutation detected,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|BREAST SURGERY
OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,brca,412736006,BRCA1 gene mutation not detected,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|BREAST SURGERY
OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,brca,412738007,BRCA2 gene mutation detected,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|BREAST SURGERY
OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,brca,412739004,BRCA2 gene mutation not detected,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|BREAST SURGERY
OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,429740004,Family history of breast cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,431330007,Family history of breast cancer 1 gene mutation,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,431331006,Family history of breast cancer 2 gene mutation,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,706970001,TNBC - Triple-negative breast cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,brca,31881000119108,Family history of BRCA gene mutation,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|BREAST SURGERY
OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,94361000000105,Breast cancer detected by national screening programme,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,276341000000100,Fast track referral for suspected breast cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,838351000000107,Education about risk of breast cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,874291000000100,QCancer breast cancer risk,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
OLAPARIB,BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy,TA762,breast cancer,1035841000000108,Lymphoedema following breast cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
OLAPARIB,Maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy,TA750,pancreatic cancer,429000004,Family history of pancreatic cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
OLAPARIB,Maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy,TA750,pancreatic cancer,247591000000101,Suspected pancreatic cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
OLAPARIB,Maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy,TA750,pancreatic cancer,848901000000106,QCancer pancreatic cancer risk,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,8100009,Structure of infundibulum of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,8100009,Structure of infundibulum of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,9361007,Downward displacement of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,9361007,Downward displacement of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,22611009,Endometriosis of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,22611009,Endometriosis of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,25344002,Fimbriectomy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,25344002,Fimbriectomy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,25811000,Excision of entire bilateral fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,25811000,Excision of entire bilateral fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,29827000,Excision of both fallopian tubes and ovaries,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,29827000,Excision of both fallopian tubes and ovaries,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,32587001,Rupture of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,32587001,Rupture of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,32987009,Both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,32987009,Both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,38043007,Implantation of prosthesis into fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,38043007,Implantation of prosthesis into fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,41393008,Excision of cyst of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,41393008,Excision of cyst of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,42618007,Atresia of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,42618007,Atresia of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,44793005,Excision of lesion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,44793005,Excision of lesion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,46536000,Inflammation of ovary and fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,46536000,Inflammation of ovary and fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,46946009,Torsion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,46946009,Torsion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,49558004,Fallopian tube tuberculosis,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,49558004,Fallopian tube tuberculosis,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,56900004,Infarction of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,56900004,Infarction of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,64233004,Congenital cyst of fimbria of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,64233004,Congenital cyst of fimbria of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,78328007,Aspiration of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,78328007,Aspiration of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,78517009,Dilation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,78517009,Dilation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,79586000,Fallopian tube pregnancy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,79586000,Fallopian tube pregnancy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,85029000,Congenital anomaly of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,85029000,Congenital anomaly of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,88157006,Inflammation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,88157006,Inflammation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,92100009,Benign neoplasm of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,92100009,Benign neoplasm of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,92591008,Carcinoma in situ of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,92591008,Carcinoma in situ of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,118869008,Procedure on fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,118869008,Procedure on fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,120062000,Fallopian tube reconstruction,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,120062000,Fallopian tube reconstruction,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,128134005,Fallopian tube disorder,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,128134005,Fallopian tube disorder,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176936004,Open occlusion of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176936004,Open occlusion of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176937008,Open ligation of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176937008,Open ligation of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176938003,Open bilateral clipping of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176938003,Open bilateral clipping of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176942000,Open ligation of remaining solitary fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176942000,Open ligation of remaining solitary fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176948001,Open ligation of right fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176948001,Open ligation of right fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176949009,Open ligation of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176949009,Open ligation of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176965005,Drainage of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176965005,Drainage of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176975008,Exploration of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176975008,Exploration of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176978005,Endoscopic bilateral cauterisation of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176978005,Endoscopic bilateral cauterisation of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176979002,Endoscopic bilateral clipping of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176979002,Endoscopic bilateral clipping of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176980004,Ligation of fallopian tubes with Fallope ring by endoscopy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176980004,Ligation of fallopian tubes with Fallope ring by endoscopy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176984008,Endoscopic occlusion of remaining solitary fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176984008,Endoscopic occlusion of remaining solitary fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176985009,Endoscopic occlusion of right fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176985009,Endoscopic occlusion of right fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176986005,Endoscopic occlusion of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,176986005,Endoscopic occlusion of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,177002003,Laparoscopy of fallopian tube: [diagnostic NOS] or [NEC],OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,177002003,Laparoscopy of fallopian tube: [diagnostic NOS] or [NEC],OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,189120005,Benign neoplasm of fallopian tubes and uterine ligaments,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,189120005,Benign neoplasm of fallopian tubes and uterine ligaments,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,193331004,Laparoscopy with occlusion of fallopian tube by device,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,193331004,Laparoscopy with occlusion of fallopian tube by device,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,198299001,Acquired ovarian and fallopian tube atrophy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,198299001,Acquired ovarian and fallopian tube atrophy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,198305004,Prolapse of ovary and fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,198305004,Prolapse of ovary and fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,198308002,"Torsion of the ovary, ovarian pedicle or fallopian tube",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,198308002,"Torsion of the ovary, ovarian pedicle or fallopian tube",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,198311001,"Other ovary, fallopian tube and broad ligament disorders",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,198311001,"Other ovary, fallopian tube and broad ligament disorders",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,198313003,"Ovarian, fallopian tube and broad ligament disorder NOS",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,198313003,"Ovarian, fallopian tube and broad ligament disorder NOS",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,204826004,Fallopian tube and broad ligament anomalies,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,204826004,Fallopian tube and broad ligament anomalies,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,236927008,Removal of clip from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,236927008,Removal of clip from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,236938008,Laparoscopy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,236938008,Laparoscopy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,237050007,Fimbrial phimosis of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,237050007,Fimbrial phimosis of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,245482004,Entire left cornu of Fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,245482004,Entire left cornu of Fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,262931005,Transection of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,262931005,Transection of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,265071006,Open clipping of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,265071006,Open clipping of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,265076001,Open clipping of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,265076001,Open clipping of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,266591002,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,266591002,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,266592009,Acquired absence of ovary or fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,266592009,Acquired absence of ovary or fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,271414005,Fallopian tube prosthesis operation,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,271414005,Fallopian tube prosthesis operation,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,271415006,Removal of products of conception from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,271415006,Removal of products of conception from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,274975009,Open ringing of bilateral fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,274975009,Open ringing of bilateral fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,274977001,Unilateral occlusion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,274977001,Unilateral occlusion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,280504001,Fallopian tube stenosis,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,280504001,Fallopian tube stenosis,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,281258002,LAP DYE - laparoscopic dye test of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,281258002,LAP DYE - laparoscopic dye test of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,283958000,Hematoma of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,283958000,Hematoma of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,287664005,Ligation of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,287664005,Ligation of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,287931008,Fallopian tube cornual resection,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,287931008,Fallopian tube cornual resection,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,287943009,Insufflation of fallopian tube using saline,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,287943009,Insufflation of fallopian tube using saline,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,287944003,Insufflation of fallopian tube using gas,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,287944003,Insufflation of fallopian tube using gas,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,288032001,Transection of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,288032001,Transection of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,288033006,Unilateral ligation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,288033006,Unilateral ligation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,288034000,Unilateral fallopian tube division,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,288034000,Unilateral fallopian tube division,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,289832005,Fallopian tube present,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,289832005,Fallopian tube present,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,289833000,Fallopian tube absent,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,289833000,Fallopian tube absent,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,292002002,Open unilateral occlusion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,292002002,Open unilateral occlusion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,300020002,Diathermy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,300020002,Diathermy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,302954008,Congenital cyst of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,302954008,Congenital cyst of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,307264000,Remaining fallopian tube removed,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,307264000,Remaining fallopian tube removed,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,309290005,Fallopian tube biopsy specimen,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,309290005,Fallopian tube biopsy specimen,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,309500004,Excised uterus and single fallopian tube and ovary sample,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,309500004,Excised uterus and single fallopian tube and ovary sample,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,310808000,Fallopian tube clip,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,310808000,Fallopian tube clip,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,369514009,Metastatic malignant neoplasm of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,369514009,Metastatic malignant neoplasm of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,387615001,Removal of gestational sac from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,387615001,Removal of gestational sac from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,387617009,Aspiration of gestational sac from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,387617009,Aspiration of gestational sac from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,391993002,Reestablishment of continuity of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,391993002,Reestablishment of continuity of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,392250009,Operation on fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,392250009,Operation on fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,398319002,Abscess of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,398319002,Abscess of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,427543006,Recanalisation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,427543006,Recanalisation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,609321005,Endoscopic bilateral occlusion of fallopian tubes using intrafallopian implants,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,609321005,Endoscopic bilateral occlusion of fallopian tubes using intrafallopian implants,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,719447009,Ectopic fallopian tube tissue,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,719447009,Ectopic fallopian tube tissue,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,560681000000101,Reanastomosis of fallopian tube NEC,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,560681000000101,Reanastomosis of fallopian tube NEC,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,561491000000108,Fallopian tube operations NOS,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,561491000000108,Fallopian tube operations NOS,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,647361000000102,"Ovarian, fallopian tube and broad ligament disorder NOS",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA620,fallopian tube,647361000000102,"Ovarian, fallopian tube and broad ligament disorder NOS",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,Previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer,TA831,prostate cancer,315268008,Suspected prostate cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
OLAPARIB,Previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer,TA831,prostate cancer,428262008,H/O: prostate cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
OLAPARIB,Previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer,TA831,prostate cancer,698470001,Advice given about prostate cancer screening,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
OLAPARIB,Previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer,TA831,prostate cancer,712837004,Active surveillance of prostate cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
OLAPARIB,Previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer,TA831,prostate cancer,720007002,Prostate cancer care review,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
OLAPARIB,Previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer,TA831,prostate cancer,31011000119107,Prostate cancer screening declined,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
OLAPARIB,Previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer,TA831,prostate cancer,874211000000109,QCancer prostate cancer risk,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
OLAPARIB,Previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer,TA831,prostate cancer,878401000000104,No FH of prostate cancer,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
OLAPARIB,Previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer,TA831,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
OLAPARIB,Previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer,TA831,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,8100009,Structure of infundibulum of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,9361007,Downward displacement of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,22611009,Endometriosis of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,25344002,Fimbriectomy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,25811000,Excision of entire bilateral fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,29827000,Excision of both fallopian tubes and ovaries,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,32587001,Rupture of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,32987009,Both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,38043007,Implantation of prosthesis into fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,41393008,Excision of cyst of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,42618007,Atresia of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,44793005,Excision of lesion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,46536000,Inflammation of ovary and fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,46946009,Torsion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,49558004,Fallopian tube tuberculosis,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,56900004,Infarction of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,64233004,Congenital cyst of fimbria of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,78328007,Aspiration of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,78517009,Dilation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,79586000,Fallopian tube pregnancy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,85029000,Congenital anomaly of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,88157006,Inflammation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,92100009,Benign neoplasm of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,92591008,Carcinoma in situ of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,118869008,Procedure on fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,120062000,Fallopian tube reconstruction,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,128134005,Fallopian tube disorder,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176936004,Open occlusion of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176937008,Open ligation of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176938003,Open bilateral clipping of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176942000,Open ligation of remaining solitary fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176948001,Open ligation of right fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176949009,Open ligation of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176965005,Drainage of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176975008,Exploration of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176978005,Endoscopic bilateral cauterisation of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176979002,Endoscopic bilateral clipping of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176980004,Ligation of fallopian tubes with Fallope ring by endoscopy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176984008,Endoscopic occlusion of remaining solitary fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176985009,Endoscopic occlusion of right fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,176986005,Endoscopic occlusion of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,177002003,Laparoscopy of fallopian tube: [diagnostic NOS] or [NEC],OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,189120005,Benign neoplasm of fallopian tubes and uterine ligaments,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,193331004,Laparoscopy with occlusion of fallopian tube by device,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,198299001,Acquired ovarian and fallopian tube atrophy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,198305004,Prolapse of ovary and fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,198308002,"Torsion of the ovary, ovarian pedicle or fallopian tube",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,198311001,"Other ovary, fallopian tube and broad ligament disorders",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,198313003,"Ovarian, fallopian tube and broad ligament disorder NOS",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,204826004,Fallopian tube and broad ligament anomalies,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,236927008,Removal of clip from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,236938008,Laparoscopy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,237050007,Fimbrial phimosis of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,245482004,Entire left cornu of Fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,262931005,Transection of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,265071006,Open clipping of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,265076001,Open clipping of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,266591002,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,266592009,Acquired absence of ovary or fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,271414005,Fallopian tube prosthesis operation,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,271415006,Removal of products of conception from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,274975009,Open ringing of bilateral fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,274977001,Unilateral occlusion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,280504001,Fallopian tube stenosis,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,281258002,LAP DYE - laparoscopic dye test of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,283958000,Hematoma of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,287664005,Ligation of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,287931008,Fallopian tube cornual resection,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,287943009,Insufflation of fallopian tube using saline,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,287944003,Insufflation of fallopian tube using gas,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,288032001,Transection of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,288033006,Unilateral ligation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,288034000,Unilateral fallopian tube division,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,289832005,Fallopian tube present,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,289833000,Fallopian tube absent,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,292002002,Open unilateral occlusion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,300020002,Diathermy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,302954008,Congenital cyst of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,307264000,Remaining fallopian tube removed,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,309290005,Fallopian tube biopsy specimen,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,309500004,Excised uterus and single fallopian tube and ovary sample,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,310808000,Fallopian tube clip,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,369514009,Metastatic malignant neoplasm of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,387615001,Removal of gestational sac from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,387617009,Aspiration of gestational sac from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,391993002,Reestablishment of continuity of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,392250009,Operation on fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,398319002,Abscess of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,427543006,Recanalisation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,609321005,Endoscopic bilateral occlusion of fallopian tubes using intrafallopian implants,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,719447009,Ectopic fallopian tube tissue,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,560681000000101,Reanastomosis of fallopian tube NEC,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,561491000000108,Fallopian tube operations NOS,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB,"Treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy",TA381,fallopian tube,647361000000102,"Ovarian, fallopian tube and broad ligament disorder NOS",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,8100009,Structure of infundibulum of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,9361007,Downward displacement of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,22611009,Endometriosis of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,25344002,Fimbriectomy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,25811000,Excision of entire bilateral fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,29827000,Excision of both fallopian tubes and ovaries,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,32587001,Rupture of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,32987009,Both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,38043007,Implantation of prosthesis into fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,41393008,Excision of cyst of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,42618007,Atresia of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,44793005,Excision of lesion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,46536000,Inflammation of ovary and fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,46946009,Torsion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,49558004,Fallopian tube tuberculosis,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,56900004,Infarction of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,64233004,Congenital cyst of fimbria of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,78328007,Aspiration of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,78517009,Dilation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,79586000,Fallopian tube pregnancy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,85029000,Congenital anomaly of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,88157006,Inflammation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,92100009,Benign neoplasm of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,92591008,Carcinoma in situ of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,118869008,Procedure on fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,120062000,Fallopian tube reconstruction,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,128134005,Fallopian tube disorder,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176936004,Open occlusion of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176937008,Open ligation of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176938003,Open bilateral clipping of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176942000,Open ligation of remaining solitary fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176948001,Open ligation of right fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176949009,Open ligation of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176965005,Drainage of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176975008,Exploration of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176978005,Endoscopic bilateral cauterisation of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176979002,Endoscopic bilateral clipping of fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176980004,Ligation of fallopian tubes with Fallope ring by endoscopy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176984008,Endoscopic occlusion of remaining solitary fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176985009,Endoscopic occlusion of right fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,176986005,Endoscopic occlusion of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,177002003,Laparoscopy of fallopian tube: [diagnostic NOS] or [NEC],OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,189120005,Benign neoplasm of fallopian tubes and uterine ligaments,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,193331004,Laparoscopy with occlusion of fallopian tube by device,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,198299001,Acquired ovarian and fallopian tube atrophy,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,198305004,Prolapse of ovary and fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,198308002,"Torsion of the ovary, ovarian pedicle or fallopian tube",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,198311001,"Other ovary, fallopian tube and broad ligament disorders",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,198313003,"Ovarian, fallopian tube and broad ligament disorder NOS",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,204826004,Fallopian tube and broad ligament anomalies,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,236927008,Removal of clip from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,236938008,Laparoscopy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,237050007,Fimbrial phimosis of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,245482004,Entire left cornu of Fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,262931005,Transection of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,265071006,Open clipping of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,265076001,Open clipping of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,266591002,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,266592009,Acquired absence of ovary or fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,271414005,Fallopian tube prosthesis operation,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,271415006,Removal of products of conception from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,274975009,Open ringing of bilateral fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,274977001,Unilateral occlusion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,280504001,Fallopian tube stenosis,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,281258002,LAP DYE - laparoscopic dye test of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,283958000,Hematoma of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,287664005,Ligation of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,287931008,Fallopian tube cornual resection,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,287943009,Insufflation of fallopian tube using saline,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,287944003,Insufflation of fallopian tube using gas,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,288032001,Transection of both fallopian tubes,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,288033006,Unilateral ligation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,288034000,Unilateral fallopian tube division,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,289832005,Fallopian tube present,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,289833000,Fallopian tube absent,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,292002002,Open unilateral occlusion of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,300020002,Diathermy of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,302954008,Congenital cyst of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,307264000,Remaining fallopian tube removed,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,309290005,Fallopian tube biopsy specimen,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,309500004,Excised uterus and single fallopian tube and ovary sample,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,310808000,Fallopian tube clip,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,369514009,Metastatic malignant neoplasm of left fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,387615001,Removal of gestational sac from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,387617009,Aspiration of gestational sac from fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,391993002,Reestablishment of continuity of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,392250009,Operation on fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,398319002,Abscess of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,427543006,Recanalisation of fallopian tube,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,609321005,Endoscopic bilateral occlusion of fallopian tubes using intrafallopian implants,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,719447009,Ectopic fallopian tube tissue,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,560681000000101,Reanastomosis of fallopian tube NEC,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,561491000000108,Fallopian tube operations NOS,OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLAPARIB PLUS BEVACIZUMAB,"Maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer",TA693,fallopian tube,647361000000102,"Ovarian, fallopian tube and broad ligament disorder NOS",OLAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
OLARATUMAB IN COMBINATION WITH DOXORUBICIN,Advanced soft tissue sarcoma,TA465,soft tissue sarcoma,2424003,Soft tissue sarcoma,OLARATUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|CLINICAL ONCOLOGY
OMALIZUMAB,Add-on treatment for severe persistent allergic asthma,TA278,severe persistent allergic asthma,10675431000119106,Severe persistent allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,4244005,Urticaria neonatorum,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,10347006,Sunlight-induced angio-oedema-urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,14907004,Urticaria bullosa,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,40178009,Allergic urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,42265009,Idiopathic urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,51247001,Vibratory urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,62211002,Urticaria caused by heat,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,64305001,Urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,73098005,Cholinergic urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,74774004,Cold-induced angio-oedema-urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,89322006,Allergic urticaria due to drug,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,89870006,Aquagenic urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,123584008,Urticaria perstans,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,126485001,Urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,201260002,Drug induced urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,201261003,Urticaria caused by cold and heat,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,201268009,Urticaria geographica,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,201269001,Menstrual urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,213325008,Urticaria caused by serum,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,238688005,Cold reflex urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,238690006,Persisting cholinergic urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,238693008,Reflex urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,238697009,Immune complex urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,241956005,Venom-induced angio-oedema-urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,241957001,Food-induced angioedema-urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,241958006,Drug-aggravated angio-oedema-urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,241959003,Non-steroid anti-inflammatory drug-induced angioedema-urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,241960008,Aspirin-induced angioedema-urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,241962000,Chemical-aggravated angio-oedema-urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,241963005,Azo-dye-induced angioedema-urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,241964004,Sodium benzoate-induced angio-oedema-urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,241965003,Latex-induced angioedema-urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,252507009,Physical urticaria test,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,269433002,(Angioneurotic edema) or (urticaria),OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,277785006,Penicillin-induced angio-oedema-urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,302161006,Acute idiopathic urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,302162004,Chronic spontaneous urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,302163009,Idiopathic micropapular urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,302165002,Idiopathic cold urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,302167005,Cold urticaria with cryoglobulins,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,302972002,Urticarial transfusion reaction,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,361200005,Familial febrile urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,373907006,Minimal urticarial dose,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,387788000,Delayed pressure urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,402305008,Non-immunological contact urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,402394004,Urticaria caused by salicylate,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,402408009,Acute urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,402413008,Arthus type urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,402601007,Physical urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,230191000000108,Reverse passive transfer test for solar urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,230201000000105,Autologous serum skin test for urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,230211000000107,Physical challenge tests for urticaria,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Previously treated chronic spontaneous urticaria,TA339,urticaria,462821000000106,[X]Urticaria and erythema,OMALIZUMAB,DERMATOLOGY,DERMATOLOGY|CLINICAL IMMUNOLOGY
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,12428000,Intrinsic asthma without status asthmaticus,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,31387002,Exercise-induced asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,34015007,Flour asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,56018004,Asthmatic breathing,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,56968009,Asthma caused by wood dust,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,57607007,Industrial asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,63088003,Allergic asthma without status asthmaticus,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,71892000,Cardiac asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,93432008,Drug-induced asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,160377001,Family history of asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,161105008,Asthma society member,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,161527007,History of asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,162660004,Asthma resolved,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170607007,Respiratory disease monitoring (& [asthma] or [chronic]),OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170631002,Asthma disturbing sleep,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170632009,Asthma causing night waking,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170633004,Asthma disturbs sleep weekly,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170634005,Asthma disturbs sleep frequently,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170635006,Asthma not disturbing sleep,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170636007,Asthma never disturbs sleep,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170637003,Asthma limiting activities,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170638008,Asthma not limiting activities,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170642006,Asthma severity,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170647000,Asthma prophylactic medication used,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170655007,Asthma restricts exercise,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170656008,Asthma sometimes restricts exercise,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170657004,Asthma severely restricts exercise,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,170658009,Asthma never restricts exercise,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,171231001,Asthma screening,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,182724005,Further asthma - drug prevention,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,182726007,Asthma control step 0,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,182727003,Asthma control step 1,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,182728008,Asthma control step 2,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,182729000,Asthma control step 3,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,182730005,Asthma control step 4,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,182731009,Asthma control step 5,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,183099005,Asthma leaflet given,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,183478001,Emergency hospital admission for asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,185242005,Seen in asthma clinic,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,185728001,Attends asthma monitoring,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,185730004,Asthma monitor offer default,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,185731000,Asthma monitoring call first letter,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,185732007,Asthma monitoring call second letter,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,185734008,Asthma monitoring call third letter,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,185735009,Asthma monitoring call verbal invite,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,185736005,Asthma monitoring call telephone invite,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,185737001,Asthma monitoring deleted,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,185940009,Patient in asthma study,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,195113008,(Left ventricular: [failure] or [impaired function]) or (cardiac asthma) or (acute pulmonary edema),OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,195949008,Chronic asthmatic bronchitis,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,195967001,Asthmatic,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,195968006,Asthma: [extrinsic - atopic] or [allergic] or [pollen] or [childhood] or [with hay fever],OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,195973000,Late-onset asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,195977004,Mixed asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,195983001,Exercise induced asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,219036002,Adverse reaction to antiasthmatic,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,225057002,Brittle asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,233678006,Childhood asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,233679003,Late-onset asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,233683003,Hay fever with asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,233691007,Eosinophilic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,266361008,Non-allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,266396008,Extrinsic asthma - atopy (& pollen),OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,266397004,Intrinsic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,266398009,Asthma attack,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,270442000,Asthma monitoring check done,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,275908000,Asthma monitoring,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,281239006,Asthma attack,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,302220000,Asthma control steps,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,304527002,Acute asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,308500005,Asthma monitoring call,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,308501009,Asthma monitoring status,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,312453004,Asthma - currently active,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,312454005,Asthma - currently dormant,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,366874008,Number of asthma exacerbations in past year,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370202007,Asthma causes daytime symptoms 1 to 2 times per month,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370203002,Asthma causes daytime symptoms 1 to 2 times per week,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370204008,Asthma causes daytime symptoms most days,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370205009,Asthma causes night symptoms 1 to 2 times per month,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370206005,Asthma limits walking on the flat,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370207001,Asthma limits walking up hills or stairs,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370208006,Asthma never causes daytime symptoms,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370218001,Mild asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370219009,Moderate asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370220003,Occasional asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370221004,Severe asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370225008,Asthma treatment compliance unsatisfactory,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,370226009,Asthma treatment compliance satisfactory,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,373899003,Asthma daytime symptoms,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,389145006,Allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,390798007,Asthma finding,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,390872009,Change in asthma management plan,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,390877003,Step up change in asthma management plan,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,390878008,Step down change in asthma management plan,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,390921001,Absent from work or school due to asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,390940007,Asthma monitoring due,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,394700004,Asthma annual review,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,394701000,Asthma follow-up,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,394720003,Asthma medication review,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,394967008,Suspected asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,395022009,Nocturnal asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,400987003,Asthma trigger,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,401135008,Health education - asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,401182001,Asthma monitoring by nurse,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,401183006,Asthma monitoring by doctor,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,401193004,Asthma confirmed,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,405944004,Asthmatic bronchitis,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,406162001,Asthma care,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,407674008,Aspirin-induced asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,409663006,Cough variant asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,415265005,Referral to asthma clinic,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,423889005,Non-immunoglobulin E mediated allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,424643009,Allergic atopic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,425969006,Acute intermittent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,426656000,Severe persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,426979002,Mild persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,427295004,Moderate persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,427603009,Intermittent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,427679007,Mild intermittent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,442025000,Acute exacerbation of chronic asthmatic bronchitis,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,443117005,Asthma control test score,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,445427006,Seasonal asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,445531003,ACQ - Asthma control questionnaire,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,473391009,Asthma never causes night symptoms,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,698509001,Under care of asthma specialist nurse,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,699191007,Did not attend asthma review,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,702823004,Asthma clinic,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,704008007,No family history of asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,707445000,Acute mild persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,707446004,Acute exacerbation of moderate persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,707447008,Exacerbation of severe persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,707511009,Uncomplicated mild persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,707512002,Uncomplicated moderate persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,707513007,Uncomplicated severe persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,707979007,Acute severe exacerbation of severe persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,707980005,Acute severe exacerbation of moderate persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,707981009,Acute severe exacerbation of mild persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,708038006,Acute exacerbation of asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,708090002,Acute severe exacerbation of asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,708093000,Acute exacerbation of allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,708094006,Acute exacerbation of intrinsic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,708095007,Acute severe exacerbation of extrinsic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,708358003,Emergency asthma admission since last encounter,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,708373002,Emergency asthma patient visit since last encounter,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,711442001,Recent asthma management,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,715191006,Telehealth asthma monitoring,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,734346005,Use of asthma symptom diary,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,734904007,Life threatening acute exacerbation of asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,734905008,Moderate acute exacerbation of asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,736056000,Asthma clinical management plan,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,762521001,Acute allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,763077003,Asthma Control Questionnaire score,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,763221007,Asthma monitoring declined,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,763695004,Mini Asthma Quality of Life Questionnaire score,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,782520007,Exacerbation of allergic asthma due to infection,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,782559003,Asthma never causes night symptoms,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,401000119107,Asthma with irreversible airway obstruction,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,641000119106,Intermittent asthma well controlled,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,1741000119102,Intermittent asthma uncontrolled,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,72301000119103,Asthma in pregnancy,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,89581000000109,DNA (did not attend) asthma clinic,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,92161000000104,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation using preferred method of communication,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,99031000119107,Acute exacerbation of asthma co-occurrent with allergic rhinitis,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,125011000119100,Mild persistent asthma co-occurrent with allergic rhinitis,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,125021000119107,Intermittent asthma co-occurrent with allergic rhinitis,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,135171000119106,Acute exacerbation of moderate persistent asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,143901000000108,Registration for access to online asthma self-management application,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,143931000000102,Declined to register for access to online asthma self-management application,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,176711000000100,Does not have asthma management plan,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,198971000000102,Asthma outreach clinic,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,201031000000108,Asthma trigger - respiratory infection,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,201041000000104,Asthma trigger - seasonal,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,201051000000101,Asthma trigger - animal,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,201191000000108,Asthma trigger - cold air,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,201201000000105,Asthma trigger - damp,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,201211000000107,Asthma trigger - emotion,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,302331000000106,RCP (Royal College of Physicians) asthma assessment,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,340891000000106,Asthma trigger - airborne dust,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,340901000000107,Asthma trigger - exercise,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,340911000000109,Asthma trigger - pollen,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,340921000000103,Asthma trigger - tobacco smoke,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,340931000000101,Asthma trigger - warm air,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,527171000000103,Patient has a written asthma personal action plan,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,527191000000104,Health education - asthma self management,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,527211000000100,Health education - structured asthma discussion,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,527231000000108,Health education - structured patient focused asthma discussion,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,713701000000108,Asthma monitoring administration,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,713711000000105,Asthma clinic administration,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,715801000000103,Exception reporting - asthma quality indicators,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,716491000000100,Excepted from asthma quality indicators - informed dissent,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,717291000000103,Excepted from asthma quality indicators - patient unsuitable,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,754061000000100,Asthma review using Royal College of Physicians three questions,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,771901000000100,Asthma causes night time symptoms 1 to 2 times per week,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,771941000000102,Asthma causes symptoms most nights,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,771981000000105,Asthma limits activities 1 to 2 times per month,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,772011000000107,Asthma limits activities 1 to 2 times per week,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,772051000000106,Asthma limits activities most days,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,791401000000104,Seen in school asthma clinic,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,810901000000102,Asthma self-management plan review,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,811151000000105,Number of days absent from school due to asthma in past 6 months,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,811921000000103,Asthma self-management plan agreed,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,815631000000106,Asthma trigger - wind,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,818161000000104,Asthma trigger - perfume,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,866881000000101,Chronic asthma with fixed airflow obstruction,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,867171000000106,No asthma trigger identified by subject,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,892301000000100,Asthma management plan declined,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,905301000000103,Childhood Asthma Control Test score,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,928451000000107,Asthma monitoring invitation short message service text message,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,928511000000107,Asthma monitoring invitation email,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,928651000000105,Review of patient at risk of asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,928691000000102,At risk of asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,959401000000101,Asthma monitoring SMS (short message service) text message first invitation,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,959421000000105,Asthma monitoring SMS (short message service) text message second invitation,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,959441000000103,Asthma monitoring SMS (short message service) text message third invitation,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,959901000000107,Asthma action plan,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,966011000000109,At risk of severe asthma exacerbation,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,966031000000101,Severe asthma exacerbation risk assessment,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,1086701000000102,Life threatening acute exacerbation of allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,1086711000000100,Life threatening acute exacerbation of non-allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,1108701000000106,Excepted from asthma quality indicators - service unavailable,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,1110841000000103,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,10674991000119104,Intermittent allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,10675431000119106,Severe persistent allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,10675551000119104,Acute severe exacerbation of severe persistent asthma co-occurrent with allergic rhinitis,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,10675871000119106,Mild persistent allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,10675991000119100,Acute severe exacerbation of mild persistent allergic asthma co-occurrent with allergic rhinitis,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,10676031000119106,Mild persistent allergic asthma controlled,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,Severe persistent allergic (IgE mediated) asthma,TA133,asthma,10676111000119102,Mild persistent asthma controlled co-occurrent with allergic rhinitis,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
OMALIZUMAB,"Treatment of severe
persistent allergic asthma in
children aged 6 to 11 years",TA201,allergic asthma,63088003,Allergic asthma without status asthmaticus,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY
OMALIZUMAB,"Treatment of severe
persistent allergic asthma in
children aged 6 to 11 years",TA201,allergic asthma,266361008,Non-allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY
OMALIZUMAB,"Treatment of severe
persistent allergic asthma in
children aged 6 to 11 years",TA201,allergic asthma,389145006,Allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY
OMALIZUMAB,"Treatment of severe
persistent allergic asthma in
children aged 6 to 11 years",TA201,allergic asthma,423889005,Non-immunoglobulin E mediated allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY
OMALIZUMAB,"Treatment of severe
persistent allergic asthma in
children aged 6 to 11 years",TA201,allergic asthma,708093000,Acute exacerbation of allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY
OMALIZUMAB,"Treatment of severe
persistent allergic asthma in
children aged 6 to 11 years",TA201,allergic asthma,762521001,Acute allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY
OMALIZUMAB,"Treatment of severe
persistent allergic asthma in
children aged 6 to 11 years",TA201,allergic asthma,782520007,Exacerbation of allergic asthma due to infection,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY
OMALIZUMAB,"Treatment of severe
persistent allergic asthma in
children aged 6 to 11 years",TA201,allergic asthma,1086701000000102,Life threatening acute exacerbation of allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY
OMALIZUMAB,"Treatment of severe
persistent allergic asthma in
children aged 6 to 11 years",TA201,allergic asthma,1086711000000100,Life threatening acute exacerbation of non-allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY
OMALIZUMAB,"Treatment of severe
persistent allergic asthma in
children aged 6 to 11 years",TA201,allergic asthma,10674991000119104,Intermittent allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY
OMALIZUMAB,"Treatment of severe
persistent allergic asthma in
children aged 6 to 11 years",TA201,allergic asthma,10675431000119106,Severe persistent allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY
OMALIZUMAB,"Treatment of severe
persistent allergic asthma in
children aged 6 to 11 years",TA201,allergic asthma,10675871000119106,Mild persistent allergic asthma,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY
OMALIZUMAB,"Treatment of severe
persistent allergic asthma in
children aged 6 to 11 years",TA201,allergic asthma,10675991000119100,Acute severe exacerbation of mild persistent allergic asthma co-occurrent with allergic rhinitis,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY
OMALIZUMAB,"Treatment of severe
persistent allergic asthma in
children aged 6 to 11 years",TA201,allergic asthma,10676031000119106,Mild persistent allergic asthma controlled,OMALIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|CLINICAL IMMUNOLOGY
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,62944002,Hepatitis C virus,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,62944002,Hepatitis C virus,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,72165005,Hepatitis C virus antibody,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,72165005,Hepatitis C virus antibody,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,170489004,Viral hepatitis carrier,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,170489004,Viral hepatitis carrier,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,197344005,Hepatitis caused by adenovirus,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,197344005,Hepatitis caused by adenovirus,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,235872006,Hepatitis C carrier,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,235872006,Hepatitis C carrier,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,278973007,Hepatitis C status,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,278973007,Hepatitis C status,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,278974001,Hepatitis C immune,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,278974001,Hepatitis C immune,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,278975000,Hepatitis C non-immune,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,278975000,Hepatitis C non-immune,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,314706002,Hepatitis C antibody detected,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,314706002,Hepatitis C antibody detected,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,314707006,Hepatitis C antibody test negative,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,314707006,Hepatitis C antibody test negative,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,413107006,Hepatitis C screening,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,413107006,Hepatitis C screening,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,773113008,Acute hepatitis caused by infection,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,773113008,Acute hepatitis caused by infection,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,12891000175105,Hepatitis C screening declined,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,12891000175105,Hepatitis C screening declined,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,200371000000104,Hepatitis C contact,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,200371000000104,Hepatitis C contact,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,201451000000105,Hepatitis C immunisation declined,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,201451000000105,Hepatitis C immunisation declined,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,202281000000105,Hepatitis C screening declined,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,202281000000105,Hepatitis C screening declined,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,204671000000101,Hepatitis C screening counselling,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,204671000000101,Hepatitis C screening counselling,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,304821000000107,Hepatitis C screening not offered,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,304821000000107,Hepatitis C screening not offered,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,362491000000104,Hepatitis C screening negative,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,362491000000104,Hepatitis C screening negative,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,362751000000101,Hepatitis C screening positive,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,362751000000101,Hepatitis C screening positive,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,761381000000102,Hepatitis C resolved,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,761381000000102,Hepatitis C resolved,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,824841000000105,Hepatitis C genotype 1,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,824841000000105,Hepatitis C genotype 1,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,824871000000104,Hepatitis C genotype 3,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,824871000000104,Hepatitis C genotype 3,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,829731000000106,On hepatitis C treatment plan,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,829731000000106,On hepatitis C treatment plan,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,992751000000109,Hepatitis C viral load,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,992751000000109,Hepatitis C viral load,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,992771000000100,Hepatitis C virus genotype,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,992771000000100,Hepatitis C virus genotype,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,996031000000104,Hepatitis C IgG level,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,996031000000104,Hepatitis C IgG level,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,998771000000103,Hepatitis C antibody level,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,998771000000103,Hepatitis C antibody level,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1001331000000102,Hepatitis C antigen level,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1001331000000102,Hepatitis C antigen level,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1008931000000108,Hepatitis C antibody test,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1008931000000108,Hepatitis C antibody test,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1107671000000106,Hepatitis C screening offered,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH DASABUVIR AND RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1107671000000106,Hepatitis C screening offered,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,62944002,Hepatitis C virus,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,62944002,Hepatitis C virus,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,72165005,Hepatitis C virus antibody,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,72165005,Hepatitis C virus antibody,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,170489004,Viral hepatitis carrier,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,170489004,Viral hepatitis carrier,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,197344005,Hepatitis caused by adenovirus,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,197344005,Hepatitis caused by adenovirus,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,235872006,Hepatitis C carrier,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,235872006,Hepatitis C carrier,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,278973007,Hepatitis C status,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,278973007,Hepatitis C status,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,278974001,Hepatitis C immune,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,278974001,Hepatitis C immune,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,278975000,Hepatitis C non-immune,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,278975000,Hepatitis C non-immune,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,314706002,Hepatitis C antibody detected,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,314706002,Hepatitis C antibody detected,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,314707006,Hepatitis C antibody test negative,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,314707006,Hepatitis C antibody test negative,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,413107006,Hepatitis C screening,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,413107006,Hepatitis C screening,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,773113008,Acute hepatitis caused by infection,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,773113008,Acute hepatitis caused by infection,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,12891000175105,Hepatitis C screening declined,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,12891000175105,Hepatitis C screening declined,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,200371000000104,Hepatitis C contact,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,200371000000104,Hepatitis C contact,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,201451000000105,Hepatitis C immunisation declined,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,201451000000105,Hepatitis C immunisation declined,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,202281000000105,Hepatitis C screening declined,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,202281000000105,Hepatitis C screening declined,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,204671000000101,Hepatitis C screening counselling,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,204671000000101,Hepatitis C screening counselling,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,304821000000107,Hepatitis C screening not offered,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,304821000000107,Hepatitis C screening not offered,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,362491000000104,Hepatitis C screening negative,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,362491000000104,Hepatitis C screening negative,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,362751000000101,Hepatitis C screening positive,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,362751000000101,Hepatitis C screening positive,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,761381000000102,Hepatitis C resolved,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,761381000000102,Hepatitis C resolved,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,824841000000105,Hepatitis C genotype 1,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,824841000000105,Hepatitis C genotype 1,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,824871000000104,Hepatitis C genotype 3,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,824871000000104,Hepatitis C genotype 3,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,829731000000106,On hepatitis C treatment plan,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,829731000000106,On hepatitis C treatment plan,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,992751000000109,Hepatitis C viral load,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,992751000000109,Hepatitis C viral load,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,992771000000100,Hepatitis C virus genotype,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,992771000000100,Hepatitis C virus genotype,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,996031000000104,Hepatitis C IgG level,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,996031000000104,Hepatitis C IgG level,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,998771000000103,Hepatitis C antibody level,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,998771000000103,Hepatitis C antibody level,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1001331000000102,Hepatitis C antigen level,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1001331000000102,Hepatitis C antigen level,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1008931000000108,Hepatitis C antibody test,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1008931000000108,Hepatitis C antibody test,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1107671000000106,Hepatitis C screening offered,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMBITASVIR–PARITAPREVIR–RITONAVIR WITH RIBAVIRIN,Chronic hepatitis C,TA365,hepatitis c,1107671000000106,Hepatitis C screening offered,OMBITASVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
OMEPRAZOLE,Dyspepsia,TA007,dyspepsia,3696007,Non ulcer dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
OMEPRAZOLE,Dyspepsia,TA007,dyspepsia,191972002,Psychogenic dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
OMEPRAZOLE,Dyspepsia,TA007,dyspepsia,192434000,[X]Psychogenic dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
OMEPRAZOLE,Dyspepsia,TA007,dyspepsia,196752002,Flatulent dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
OMEPRAZOLE,Dyspepsia,TA007,dyspepsia,249511005,Flatulent dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
OMEPRAZOLE,Dyspepsia,TA007,dyspepsia,299969005,Dyspepsia caused by drug,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
OMEPRAZOLE,Dyspepsia,TA007,dyspepsia,416202003,Under care of dyspepsia specialist nurse,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
OMEPRAZOLE,Dyspepsia,TA007,dyspepsia,417691002,Discharged from care of dyspepsia specialist nurse,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
OMEPRAZOLE,Dyspepsia,TA007,dyspepsia,203661000000105,Undiagnosed dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
OMEPRAZOLE,Dyspepsia,TA007,dyspepsia,248131000000106,Referral to dyspepsia specialist nurse,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
ORAL AZACITIDINE,Maintenance treatment of acute myeloid leukaemia after induction therapy,TA827,acute myeloid leukaemia,91861009,"Acute myeloid leukaemia, disease",ORAL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,14651005,Drug-induced osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,18040001,Age-related osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,64859006,Osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,102447009,Postmenopausal osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,160313009,Family history of osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,203429007,Idiopathic generalised osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,203433000,Postoophorectomy osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,203435007,Localized osteoporosis - Lequesne,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,203437004,Osteoporosis in endocrine disorders,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,203438009,Osteoporosis of spine,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,240157009,Secondary generalised osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,240158004,Regional migrating osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,240159007,Transient osteoporosis of hip,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,240162005,Secondary localized osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,268028001,Localised disuse osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,276661002,Primary osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,281387004,Regional osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,300004007,Screening for osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,309745002,Osteoporosis localized to spine,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,310251007,No family history: Osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,313423004,At increased risk of osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391003008,Osteoporosis monitoring administration,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391004002,Attends osteoporosis monitoring,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391006000,Osteoporosis monitoring default,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391007009,Osteoporosis monitoring first letter,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391008004,Osteoporosis monitoring second letter,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391012005,Osteoporosis monitoring deleted,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391013000,Osteoporosis monitoring check done,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391014006,Osteoporosis risk assessment done,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391015007,Osteoporosis risk assessment declined,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391017004,Osteoporosis monitoring,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391018009,Initial osteoporosis assessment,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391019001,Follow-up osteoporosis assessment,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391020007,Osteoporosis treatment started,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391021006,Osteoporosis treatment stopped,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391022004,Osteoporosis treatment changed,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391023009,Osteoporosis - no treatment,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391024003,Osteoporosis - dietary advice,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391025002,Osteoporosis - dietary assessment,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391026001,Osteoporosis - exercise advice,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391027005,Osteoporosis - falls prevention,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391028000,Osteoporosis - treatment response,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391033001,Refer to osteoporosis specialist,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391037000,Seen in osteoporosis clinic,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,394936006,Health education - osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,412717001,Referral to osteoporosis clinic,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,473120007,History of osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,763322002,Osteoporosis monitoring refused,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,711341000000106,Osteoporosis resolved,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
"ORAL BISPHOSPHONATES (ALENDRONIC ACID, IBANDRONIC ACID AND RISEDRONATE SODIUM)",Osteoporosis,TA464,osteoporosis,965871000000101,Osteoporosis medication compliance review,ORAL,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,162573006,Suspected lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,254637007,Non-small cell lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,275981009,Lung cancer screening,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,429011007,Family history of lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,723301009,Squamous non-small cell lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,1259727001,Primary non-small cell lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,276491000000101,Fast track referral for suspected lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,848881000000108,QCancer lung cancer risk,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,877691000000107,No FH of lung cancer,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,1771781000000107,Did not attend lung cancer screening,ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ORAL TOPOTECAN,Relapsed small-cell lung cancer,TA184,lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",ORAL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
ORLISTAT,Obesity,TA022,obesity,44772007,Maternal obesity without hypertension,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,82793005,Hypothalamic obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,160311006,Family history: Obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,161453001,History of obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,162864005,Body mass index 30+ - obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,170793009,Obesity monitoring,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,170794003,Initial obesity assessment,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,170795002,Follow-up obesity assessment,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,170797005,Has seen dietician - obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,170798000,Treatment of obesity changed,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,170799008,Treatment of obesity started,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,170800007,Treatment of obesity stopped,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,170807005,Reason for obesity therapy - occupational,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,185741002,Attends obesity monitoring,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,185743004,Obesity monitoring default,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,185744005,Obesity monitoring first letter,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,185745006,Obesity monitoring second letter,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,185746007,Obesity monitoring third letter,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,185747003,Obesity monitoring verbal invite,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,185748008,Obesity monitoring telephone invite,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,185749000,Obesity monitoring deleted,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,185750000,Obesity monitoring check done,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,190965006,Drug-induced obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,190966007,Obesity hypoventilation syndrome,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,199072001,(Gestational edema &/or non-hypertension excessive weight gain) or (maternal obesity syndrome),ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,235240002,Procedure using anti-obesity gastric balloon,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,238132000,Upper body obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,238133005,Gynecoid obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,238134004,Generalized obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,238136002,Morbid obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,243862009,Obesity monitoring status,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,247824007,Fear of obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,267511009,Hyperalimentation incl.obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,268522006,Obesity monitoring,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,268551005,Obesity screening,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,270486005,Localized obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,276792008,Pulmonary hypertension with extreme obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,277831002,Anxiety about obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,284352003,Obesity diet education,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,294493008,Lifelong obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,296526005,Adult-onset obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,308504001,Obesity monitoring call,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,310428009,Obesity monitoring invitation,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,415530009,Obesity due to excess calories,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,444862003,Childhood obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,703316004,Lymphoedema associated with obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,715279006,Telehealth obesity monitoring,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,763085007,Obesity monitoring declined,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,198181000000102,Obesity resolved,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,640791000000105,Obesity and other hyperalimentation,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,713951000000106,Obesity monitoring administration,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,713971000000102,Obesity clinic administration,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,753691000000104,Exception reporting - obesity quality indicators,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,753751000000103,Excepted from obesity quality indicators - patient unsuitable,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,753771000000107,Excepted from obesity quality indicators - informed dissent,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,755881000000104,"Risk to health associated with overweight and obesity, at no increased risk",ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,755901000000101,"Risk to health associated with overweight and obesity, at increased risk",ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,755921000000105,"Risk to health associated with overweight and obesity, at high risk",ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,755941000000103,"Risk to health associated with overweight and obesity, at very high risk",ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,756001000000107,"Intervention for risk to health associated with overweight and obesity, general advice on healthy weight and lifestyle",ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,756021000000103,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity",ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,756041000000105,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs",ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,756061000000106,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs, consider surgery",ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,822741000000107,Anti-obesity drug therapy,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,851901000000101,Obesity and weight loss quality of life questionnaire,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,894961000000105,Referral to multidisciplinary obesity clinic,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,898011000000103,Obesity multidisciplinary case review,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,914801000000107,Anti-obesity drug therapy commenced,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,914821000000103,Obesity medication stopped,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,1269761000000101,Focal segmental glomerulosclerosis due to obesity,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,2386191000000105,National Health Service obesity medication pathway,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,2386201000000107,Referral to National Health Service obesity medication wraparound support pathway,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,2386221000000103,Unsuitable for NHS obesity medication pathway,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,2386231000000101,NHS obesity medication pathway started,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,2386241000000105,National Health Service obesity medication pathway declined,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,2386251000000108,Review of anti-obesity drug therapy,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
ORLISTAT,Obesity,TA022,obesity,2386261000000106,NHS obesity medication wraparound support pathway completed,ORLISTAT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,6142004,Influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,24662006,Influenza caused by Influenza B virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,41269000,Influenzal bronchopneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,44470000,Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,46233009,Influenza virus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,51593004,Haemophilus parainfluenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,64917006,Pneumonia due to parainfluenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,70036007,Haemophilus influenzae pneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,74644004,Influenza with encephalopathy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,89117003,Parainfluenza virus type 4,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,91428005,Haemophilus influenzae infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,95891005,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,120753009,Influenza A virus antibody,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,120843002,Influenza B virus Ab,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,120975003,Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,127787002,Haemophilus influenzae type b immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170343007,First Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170345000,Third Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,171272004,No consent - influenza immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,171282003,Influenza immunization advised at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,171290003,Influenza vaccination consent given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,171291004,No consent for Haemophilus influenzae type b immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,185900003,Has influenza vaccination at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,185901004,Has influenza vaccination at surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,185902006,Has influenza vaccination at hospital,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,185903001,Needs influenza immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,192721000,Post influenza vaccination encephalitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,194946005,Acute myocarditis - influenzal,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195726000,Acute parainfluenza virus bronchitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195878008,Pneumonia and influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195923003,Influenza with laryngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195924009,Influenza with pharyngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195929004,Influenza with gastrointestinal tract involvement,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195931008,Influenza like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,266393000,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,268561003,Influenza immunization advised in surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,275983007,Influenza immunisation advised,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,291749008,Influenza vaccine poisoning,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,293112000,Influenza split virion vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,293113005,Influenza surface antigen vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,294647003,Allergy to influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,294648008,Allergy to influenza split virion vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,294649000,Allergy to influenza surface antigen vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,294664000,Haemophilus influenzae type b vaccine allergy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,308532005,Influenza vaccination status,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,309789002,Encephalitis caused by Influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,315640000,Influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,315641001,Influenza vaccination invitation letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,390796006,Influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,396425006,FLU - Influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407479009,Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407480007,Influenza B virus(B/Lee/40),AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407489008,Human parainfluenza virus 1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407491000,Parainfluenza virus type 2,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407493002,Human parainfluenza virus 3,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407498006,Human parainfluenza viruses,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407573008,Influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,414496007,Influenza vaccination telephone invite,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,416928007,Has influenza vaccination at work,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,441043003,Influenza A virus subtype H1 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,441049004,Influenza A virus subtype H3 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,441343005,Influenza A virus subtype H5 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,441344004,Human parainfluenza virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,441345003,Influenza B virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,442438000,Influenza caused by Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,442696006,Influenza A (H1N1) swine flu,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,444426005,Swine influenza contact,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,473169009,History of influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,698353005,Requires influenza virus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,709410003,Hib (Haemophilus influenzae type b) infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,711330007,Influenza A virus subtype H1N1 detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,711334003,Influenza A virus H1N1 subtype not detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,736818002,Influenza vaccination requested,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,737041000,Influenza immunisation telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,787016008,Administration of influenza vaccine via nasal route,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,73701000119109,Vaccination for influenza given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,135221000119101,Influenza A H1N1 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,199331000000106,Did not attend influenza vaccination appointment,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,200481000000107,Influenza vaccination invitation first letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,200491000000109,Influenza vaccination invitation second letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,200501000000103,Influenza vaccination invitation third letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,201391000000106,Booster influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,202301000000106,First pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,202311000000108,Second pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,380271000000101,Consent given for pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,380381000000108,Pandemic influenza vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,380631000000100,Pandemic influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,380801000000105,Pandemic influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,506751000000104,Possible influenza A virus H1N1 subtype,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,516101000000103,No response to influenza vaccination invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,540151000000108,Pneumonia or influenza NOS,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,761311000000109,Influenza vaccination verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,777791000000102,Influenza vaccination invitation first text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,822851000000102,Seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,822931000000100,Seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,822951000000107,Seasonal influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,822971000000103,Seasonal influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,822991000000104,Consent given for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,844941000000103,Influenza vaccination invitation email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,844961000000102,Influenza vaccination invitation first email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,844981000000106,Influenza vaccination invitation second email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,845001000000101,Influenza vaccination invitation third email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,860151000000103,Influenza vaccination first verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,860171000000107,Influenza vaccination second verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,860211000000105,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,860291000000101,Influenza vaccination third verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,868241000000109,Administration of intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,868491000000103,No consent for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,871521000000104,First intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,871541000000106,Second intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,871751000000104,Administration of first intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,871781000000105,Administration of second intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,873681000000101,Provision of information about seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,913961000000102,Education about influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,932221000000103,At risk of influenza related complication,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,935351000000106,Long term indication for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955641000000103,Influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,996211000000100,Influenza (A and B) serology,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,996761000000106,Haemophilus influenzae B IgG level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1001341000000106,Influenza A antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1001351000000109,Influenza B antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1005101000000108,Parainfluenza virus antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1005111000000105,Parainfluenza type 3 antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1008771000000107,Haemophilus influenzae B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1014261000000103,Influenza A antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1014271000000105,Influenza B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1020381000000100,Parainfluenza virus antigen assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1033051000000101,Influenza due to zoonotic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1033071000000105,Influenza due to pandemic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1033091000000109,Influenza due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1095821000000105,Influenza vaccination first telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1095831000000107,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1095841000000103,Influenza vaccination third telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1239861000000100,Seasonal influenza vaccination given in school,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,6142004,Influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,24662006,Influenza caused by Influenza B virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,41269000,Influenzal bronchopneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,44470000,Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,46233009,Influenza virus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,51593004,Haemophilus parainfluenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,64917006,Pneumonia due to parainfluenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,70036007,Haemophilus influenzae pneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,74644004,Influenza with encephalopathy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,89117003,Parainfluenza virus type 4,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,91428005,Haemophilus influenzae infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,95891005,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,120753009,Influenza A virus antibody,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,120843002,Influenza B virus Ab,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,120975003,Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,127787002,Haemophilus influenzae type b immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,170343007,First Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,170345000,Third Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,171272004,No consent - influenza immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,171282003,Influenza immunization advised at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,171290003,Influenza vaccination consent given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,171291004,No consent for Haemophilus influenzae type b immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,185900003,Has influenza vaccination at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,185901004,Has influenza vaccination at surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,185902006,Has influenza vaccination at hospital,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,185903001,Needs influenza immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,192721000,Post influenza vaccination encephalitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,194946005,Acute myocarditis - influenzal,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,195726000,Acute parainfluenza virus bronchitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,195878008,Pneumonia and influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,195923003,Influenza with laryngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,195924009,Influenza with pharyngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,195929004,Influenza with gastrointestinal tract involvement,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,195931008,Influenza like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,266393000,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,268561003,Influenza immunization advised in surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,275983007,Influenza immunisation advised,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,291749008,Influenza vaccine poisoning,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,293112000,Influenza split virion vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,293113005,Influenza surface antigen vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,294647003,Allergy to influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,294648008,Allergy to influenza split virion vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,294649000,Allergy to influenza surface antigen vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,294664000,Haemophilus influenzae type b vaccine allergy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,308532005,Influenza vaccination status,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,309789002,Encephalitis caused by Influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,315640000,Influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,315641001,Influenza vaccination invitation letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,390796006,Influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,396425006,FLU - Influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,407479009,Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,407480007,Influenza B virus(B/Lee/40),AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,407489008,Human parainfluenza virus 1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,407491000,Parainfluenza virus type 2,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,407493002,Human parainfluenza virus 3,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,407498006,Human parainfluenza viruses,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,407573008,Influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,414496007,Influenza vaccination telephone invite,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,416928007,Has influenza vaccination at work,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,441043003,Influenza A virus subtype H1 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,441049004,Influenza A virus subtype H3 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,441343005,Influenza A virus subtype H5 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,441344004,Human parainfluenza virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,441345003,Influenza B virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,442438000,Influenza caused by Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,442696006,Influenza A (H1N1) swine flu,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,444426005,Swine influenza contact,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,473169009,History of influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,698353005,Requires influenza virus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,709410003,Hib (Haemophilus influenzae type b) infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,711330007,Influenza A virus subtype H1N1 detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,711334003,Influenza A virus H1N1 subtype not detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,736818002,Influenza vaccination requested,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,737041000,Influenza immunisation telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,787016008,Administration of influenza vaccine via nasal route,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,73701000119109,Vaccination for influenza given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,135221000119101,Influenza A H1N1 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,199331000000106,Did not attend influenza vaccination appointment,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,200481000000107,Influenza vaccination invitation first letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,200491000000109,Influenza vaccination invitation second letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,200501000000103,Influenza vaccination invitation third letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,201391000000106,Booster influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,202301000000106,First pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,202311000000108,Second pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,380271000000101,Consent given for pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,380381000000108,Pandemic influenza vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,380631000000100,Pandemic influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,380801000000105,Pandemic influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,506751000000104,Possible influenza A virus H1N1 subtype,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,516101000000103,No response to influenza vaccination invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,540151000000108,Pneumonia or influenza NOS,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,761311000000109,Influenza vaccination verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,777791000000102,Influenza vaccination invitation first text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,822851000000102,Seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,822931000000100,Seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,822951000000107,Seasonal influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,822971000000103,Seasonal influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,822991000000104,Consent given for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,844941000000103,Influenza vaccination invitation email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,844961000000102,Influenza vaccination invitation first email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,844981000000106,Influenza vaccination invitation second email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,845001000000101,Influenza vaccination invitation third email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,860151000000103,Influenza vaccination first verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,860171000000107,Influenza vaccination second verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,860211000000105,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,860291000000101,Influenza vaccination third verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,868241000000109,Administration of intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,868491000000103,No consent for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,871521000000104,First intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,871541000000106,Second intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,871751000000104,Administration of first intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,871781000000105,Administration of second intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,873681000000101,Provision of information about seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,913961000000102,Education about influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,932221000000103,At risk of influenza related complication,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,935351000000106,Long term indication for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,955641000000103,Influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,996211000000100,Influenza (A and B) serology,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,996761000000106,Haemophilus influenzae B IgG level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1001341000000106,Influenza A antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1001351000000109,Influenza B antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1005101000000108,Parainfluenza virus antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1005111000000105,Parainfluenza type 3 antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1008771000000107,Haemophilus influenzae B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1014261000000103,Influenza A antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1014271000000105,Influenza B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1020381000000100,Parainfluenza virus antigen assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1033051000000101,Influenza due to zoonotic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1033071000000105,Influenza due to pandemic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1033091000000109,Influenza due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1095821000000105,Influenza vaccination first telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1095831000000107,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1095841000000103,Influenza vaccination third telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1239861000000100,Seasonal influenza vaccination given in school,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (prevention),TA067,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,6142004,Influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,6142004,Influenza,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,24662006,Influenza caused by Influenza B virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,24662006,Influenza caused by Influenza B virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,41269000,Influenzal bronchopneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,41269000,Influenzal bronchopneumonia,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,44470000,Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,44470000,Haemophilus influenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,46233009,Influenza virus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,46233009,Influenza virus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,51593004,Haemophilus parainfluenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,51593004,Haemophilus parainfluenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,64917006,Pneumonia due to parainfluenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,64917006,Pneumonia due to parainfluenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,70036007,Haemophilus influenzae pneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,70036007,Haemophilus influenzae pneumonia,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,74644004,Influenza with encephalopathy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,74644004,Influenza with encephalopathy,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,89117003,Parainfluenza virus type 4,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,89117003,Parainfluenza virus type 4,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,91428005,Haemophilus influenzae infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,91428005,Haemophilus influenzae infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,95891005,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,95891005,Influenza-like illness,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,120753009,Influenza A virus antibody,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,120753009,Influenza A virus antibody,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,120843002,Influenza B virus Ab,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,120843002,Influenza B virus Ab,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,120975003,Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,120975003,Haemophilus influenzae type b antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,127787002,Haemophilus influenzae type b immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,127787002,Haemophilus influenzae type b immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,170343007,First Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,170343007,First Haemophilus influenzae type b vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,170345000,Third Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,170345000,Third Haemophilus influenzae type b vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,171272004,No consent - influenza immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,171272004,No consent - influenza immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,171282003,Influenza immunization advised at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,171282003,Influenza immunization advised at home,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,171290003,Influenza vaccination consent given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,171290003,Influenza vaccination consent given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,171291004,No consent for Haemophilus influenzae type b immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,171291004,No consent for Haemophilus influenzae type b immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,185900003,Has influenza vaccination at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,185900003,Has influenza vaccination at home,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,185901004,Has influenza vaccination at surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,185901004,Has influenza vaccination at surgery,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,185902006,Has influenza vaccination at hospital,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,185902006,Has influenza vaccination at hospital,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,185903001,Needs influenza immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,185903001,Needs influenza immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,192721000,Post influenza vaccination encephalitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,192721000,Post influenza vaccination encephalitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,194946005,Acute myocarditis - influenzal,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,194946005,Acute myocarditis - influenzal,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,195726000,Acute parainfluenza virus bronchitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,195726000,Acute parainfluenza virus bronchitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,195878008,Pneumonia and influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,195878008,Pneumonia and influenza,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,195923003,Influenza with laryngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,195923003,Influenza with laryngitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,195924009,Influenza with pharyngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,195924009,Influenza with pharyngitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,195929004,Influenza with gastrointestinal tract involvement,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,195929004,Influenza with gastrointestinal tract involvement,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,195931008,Influenza like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,195931008,Influenza like illness,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,266393000,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,266393000,Influenza-like illness,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,268561003,Influenza immunization advised in surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,268561003,Influenza immunization advised in surgery,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,275983007,Influenza immunisation advised,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,275983007,Influenza immunisation advised,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,291749008,Influenza vaccine poisoning,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,291749008,Influenza vaccine poisoning,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,293112000,Influenza split virion vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,293112000,Influenza split virion vaccine adverse reaction,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,293113005,Influenza surface antigen vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,293113005,Influenza surface antigen vaccine adverse reaction,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,294647003,Allergy to influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,294647003,Allergy to influenza vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,294648008,Allergy to influenza split virion vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,294648008,Allergy to influenza split virion vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,294649000,Allergy to influenza surface antigen vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,294649000,Allergy to influenza surface antigen vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,294664000,Haemophilus influenzae type b vaccine allergy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,294664000,Haemophilus influenzae type b vaccine allergy,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,308532005,Influenza vaccination status,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,308532005,Influenza vaccination status,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,309789002,Encephalitis caused by Influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,309789002,Encephalitis caused by Influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,315640000,Influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,315640000,Influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,315641001,Influenza vaccination invitation letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,315641001,Influenza vaccination invitation letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,390796006,Influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,390796006,Influenza vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,396425006,FLU - Influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,396425006,FLU - Influenza vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,407479009,Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,407479009,Influenza A virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,407480007,Influenza B virus(B/Lee/40),AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,407480007,Influenza B virus(B/Lee/40),ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,407489008,Human parainfluenza virus 1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,407489008,Human parainfluenza virus 1,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,407491000,Parainfluenza virus type 2,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,407491000,Parainfluenza virus type 2,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,407493002,Human parainfluenza virus 3,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,407493002,Human parainfluenza virus 3,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,407498006,Human parainfluenza viruses,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,407498006,Human parainfluenza viruses,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,407573008,Influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,407573008,Influenza vaccination not indicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,414496007,Influenza vaccination telephone invite,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,414496007,Influenza vaccination telephone invite,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,416928007,Has influenza vaccination at work,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,416928007,Has influenza vaccination at work,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,441043003,Influenza A virus subtype H1 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,441043003,Influenza A virus subtype H1 present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,441049004,Influenza A virus subtype H3 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,441049004,Influenza A virus subtype H3 present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,441343005,Influenza A virus subtype H5 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,441343005,Influenza A virus subtype H5 present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,441344004,Human parainfluenza virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,441344004,Human parainfluenza virus present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,441345003,Influenza B virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,441345003,Influenza B virus present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,442438000,Influenza caused by Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,442438000,Influenza caused by Influenza A virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,442696006,Influenza A (H1N1) swine flu,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,442696006,Influenza A (H1N1) swine flu,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,444426005,Swine influenza contact,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,444426005,Swine influenza contact,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,473169009,History of influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,473169009,History of influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,698353005,Requires influenza virus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,698353005,Requires influenza virus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,709410003,Hib (Haemophilus influenzae type b) infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,709410003,Hib (Haemophilus influenzae type b) infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,711330007,Influenza A virus subtype H1N1 detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,711330007,Influenza A virus subtype H1N1 detected,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,711334003,Influenza A virus H1N1 subtype not detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,711334003,Influenza A virus H1N1 subtype not detected,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,736818002,Influenza vaccination requested,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,736818002,Influenza vaccination requested,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,737041000,Influenza immunisation telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,737041000,Influenza immunisation telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,787016008,Administration of influenza vaccine via nasal route,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,787016008,Administration of influenza vaccine via nasal route,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,73701000119109,Vaccination for influenza given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,73701000119109,Vaccination for influenza given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,135221000119101,Influenza A H1N1 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,135221000119101,Influenza A H1N1 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,199331000000106,Did not attend influenza vaccination appointment,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,199331000000106,Did not attend influenza vaccination appointment,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,200481000000107,Influenza vaccination invitation first letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,200481000000107,Influenza vaccination invitation first letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,200491000000109,Influenza vaccination invitation second letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,200491000000109,Influenza vaccination invitation second letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,200501000000103,Influenza vaccination invitation third letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,200501000000103,Influenza vaccination invitation third letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,201391000000106,Booster influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,201391000000106,Booster influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,202301000000106,First pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,202301000000106,First pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,202311000000108,Second pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,202311000000108,Second pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,380271000000101,Consent given for pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,380271000000101,Consent given for pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,380381000000108,Pandemic influenza vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,380381000000108,Pandemic influenza vaccination refused,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,380631000000100,Pandemic influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,380631000000100,Pandemic influenza vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,380801000000105,Pandemic influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,380801000000105,Pandemic influenza vaccination not indicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,506751000000104,Possible influenza A virus H1N1 subtype,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,506751000000104,Possible influenza A virus H1N1 subtype,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,516101000000103,No response to influenza vaccination invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,516101000000103,No response to influenza vaccination invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,540151000000108,Pneumonia or influenza NOS,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,540151000000108,Pneumonia or influenza NOS,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,761311000000109,Influenza vaccination verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,761311000000109,Influenza vaccination verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,777791000000102,Influenza vaccination invitation first text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,777791000000102,Influenza vaccination invitation first text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,822851000000102,Seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,822851000000102,Seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,822931000000100,Seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,822931000000100,Seasonal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,822951000000107,Seasonal influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,822951000000107,Seasonal influenza vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,822971000000103,Seasonal influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,822971000000103,Seasonal influenza vaccination not indicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,822991000000104,Consent given for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,822991000000104,Consent given for seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,844941000000103,Influenza vaccination invitation email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,844941000000103,Influenza vaccination invitation email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,844961000000102,Influenza vaccination invitation first email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,844961000000102,Influenza vaccination invitation first email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,844981000000106,Influenza vaccination invitation second email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,844981000000106,Influenza vaccination invitation second email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,845001000000101,Influenza vaccination invitation third email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,845001000000101,Influenza vaccination invitation third email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,860151000000103,Influenza vaccination first verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,860151000000103,Influenza vaccination first verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,860171000000107,Influenza vaccination second verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,860171000000107,Influenza vaccination second verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,860211000000105,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,860211000000105,Influenza vaccination second telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,860291000000101,Influenza vaccination third verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,860291000000101,Influenza vaccination third verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,868241000000109,Administration of intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,868241000000109,Administration of intranasal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,868491000000103,No consent for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,868491000000103,No consent for seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,871521000000104,First intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,871521000000104,First intranasal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,871541000000106,Second intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,871541000000106,Second intranasal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,871751000000104,Administration of first intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,871751000000104,Administration of first intranasal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,871781000000105,Administration of second intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,871781000000105,Administration of second intranasal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,873681000000101,Provision of information about seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,873681000000101,Provision of information about seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,913961000000102,Education about influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,913961000000102,Education about influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,932221000000103,At risk of influenza related complication,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,932221000000103,At risk of influenza related complication,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,935351000000106,Long term indication for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,935351000000106,Long term indication for seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,955641000000103,Influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,955641000000103,Influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,996211000000100,Influenza (A and B) serology,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,996211000000100,Influenza (A and B) serology,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,996761000000106,Haemophilus influenzae B IgG level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,996761000000106,Haemophilus influenzae B IgG level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1001341000000106,Influenza A antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1001341000000106,Influenza A antigen level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1001351000000109,Influenza B antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1001351000000109,Influenza B antigen level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1005101000000108,Parainfluenza virus antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1005101000000108,Parainfluenza virus antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1005111000000105,Parainfluenza type 3 antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1005111000000105,Parainfluenza type 3 antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1008771000000107,Haemophilus influenzae B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1008771000000107,Haemophilus influenzae B antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1014261000000103,Influenza A antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1014261000000103,Influenza A antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1014271000000105,Influenza B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1014271000000105,Influenza B antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1020381000000100,Parainfluenza virus antigen assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1020381000000100,Parainfluenza virus antigen assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1033051000000101,Influenza due to zoonotic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1033051000000101,Influenza due to zoonotic influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1033071000000105,Influenza due to pandemic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1033071000000105,Influenza due to pandemic influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1033091000000109,Influenza due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1033091000000109,Influenza due to seasonal influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1095821000000105,Influenza vaccination first telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1095821000000105,Influenza vaccination first telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1095831000000107,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1095831000000107,Influenza vaccination second telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1095841000000103,Influenza vaccination third telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1095841000000103,Influenza vaccination third telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1239861000000100,Seasonal influenza vaccination given in school,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1239861000000100,Seasonal influenza vaccination given in school,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA058,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSELTAMIVIR,Influenza (treatment),TA168,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,162573006,Suspected lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,254637007,Non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,275981009,Lung cancer screening,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,429011007,Family history of lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,877691000000107,No FH of lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection,TA761,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,162573006,Suspected lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,254637007,Non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,275981009,Lung cancer screening,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,429011007,Family history of lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,877691000000107,No FH of lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,EGFR T790M mutation-positive advanced non-small-cell lung cancer,TA653,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,162573006,Suspected lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,254637007,Non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,275981009,Lung cancer screening,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,429011007,Family history of lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,877691000000107,No FH of lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer,TA416,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,162573006,Suspected lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,162573006,Suspected lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,254637007,Non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,254637007,Non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,275981009,Lung cancer screening,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,275981009,Lung cancer screening,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,429011007,Family history of lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,429011007,Family history of lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,877691000000107,No FH of lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,877691000000107,No FH of lung cancer,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA621,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OSIMERTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA654,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",OSIMERTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
OXALIPLATIN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA),Colorectal cancer (advanced),TA093,colorectal cancer,276401000000108,Fast track referral for suspected colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
OXALIPLATIN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA),Colorectal cancer (advanced),TA093,colorectal cancer,382651000000108,Seen in fast track suspected colorectal cancer clinic,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
OXALIPLATIN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA),Colorectal cancer (advanced),TA093,colorectal cancer,722731000000100,Colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
OXALIPLATIN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA),Colorectal cancer (advanced),TA093,colorectal cancer,848861000000104,QCancer colorectal cancer risk,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
OXALIPLATIN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA),Colorectal cancer (advanced),TA093,colorectal cancer,1034401000000107,Discharge from secondary care colorectal cancer service,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
OXALIPLATIN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA) (1ST-LINE),Colorectal cancer (advanced),TA033,colorectal cancer,276401000000108,Fast track referral for suspected colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
OXALIPLATIN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA) (1ST-LINE),Colorectal cancer (advanced),TA033,colorectal cancer,382651000000108,Seen in fast track suspected colorectal cancer clinic,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
OXALIPLATIN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA) (1ST-LINE),Colorectal cancer (advanced),TA033,colorectal cancer,722731000000100,Colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
OXALIPLATIN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA) (1ST-LINE),Colorectal cancer (advanced),TA033,colorectal cancer,848861000000104,QCancer colorectal cancer risk,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
OXALIPLATIN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA) (1ST-LINE),Colorectal cancer (advanced),TA033,colorectal cancer,1034401000000107,Discharge from secondary care colorectal cancer service,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
OXALIPLATIN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA) (ADJUVANT),Colon cancer,TA100,colon cancer,275978004,Screening for colon cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
OXALIPLATIN IN COMBINATION WITH 5-FLUOROURACIL AND FOLINIC ACID (5FU/FA) (ADJUVANT),Colon cancer,TA100,colon cancer,315058005,Hereditary nonpolyposis colon cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (adults),TA076,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OXCARBAZEPINE,Epilepsy (children),TA079,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
OZANIMOD,Moderately to severely active ulcerative colitis,TA828,ulcerative colitis,64766004,UC - ulcerative colitis,OZANIMOD,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
OZANIMOD,Moderately to severely active ulcerative colitis,TA828,ulcerative colitis,160383003,FH: Ulcerative colitis,OZANIMOD,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
OZANIMOD,Moderately to severely active ulcerative colitis,TA828,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,OZANIMOD,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
OZANIMOD,Moderately to severely active ulcerative colitis,TA828,ulcerative colitis,275129008,Family history of ulcerative colitis,OZANIMOD,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
OZANIMOD,Moderately to severely active ulcerative colitis,TA828,ulcerative colitis,275549008,History of ulcerative colitis,OZANIMOD,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
OZANIMOD,Moderately to severely active ulcerative colitis,TA828,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,OZANIMOD,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
OZANIMOD,Moderately to severely active ulcerative colitis,TA828,ulcerative colitis,445243001,Left sided ulcerative colitis,OZANIMOD,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,24700007,Multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,160337009,Family history of multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,192926004,Brain stem multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,192928003,Generalised multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,428700003,Primary progressive multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,438511000,Benign multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,700409000,Suspected multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,198491000000106,Multiple sclerosis review,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,515931000000104,Multiple sclerosis review declined,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
OZANIMOD,Relapsing–remitting multiple sclerosis,TA706,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,OZANIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PACLITAXEL,Advanced breast cancer,TA006,breast cancer,134405005,Suspected breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Advanced breast cancer,TA006,breast cancer,160287004,FH: Breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Advanced breast cancer,TA006,breast cancer,268547008,Screening for breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Advanced breast cancer,TA006,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Advanced breast cancer,TA006,breast cancer,429740004,Family history of breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Advanced breast cancer,TA006,breast cancer,431330007,Family history of breast cancer 1 gene mutation,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Advanced breast cancer,TA006,breast cancer,431331006,Family history of breast cancer 2 gene mutation,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Advanced breast cancer,TA006,breast cancer,706970001,TNBC - Triple-negative breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Advanced breast cancer,TA006,breast cancer,94361000000105,Breast cancer detected by national screening programme,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Advanced breast cancer,TA006,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Advanced breast cancer,TA006,breast cancer,276341000000100,Fast track referral for suspected breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Advanced breast cancer,TA006,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Advanced breast cancer,TA006,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Advanced breast cancer,TA006,breast cancer,838351000000107,Education about risk of breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Advanced breast cancer,TA006,breast cancer,874291000000100,QCancer breast cancer risk,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Advanced breast cancer,TA006,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Advanced breast cancer,TA006,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Advanced breast cancer,TA006,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Advanced breast cancer,TA006,breast cancer,1035841000000108,Lymphoedema following breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Breast cancer (early),TA108,breast cancer,134405005,Suspected breast cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Breast cancer (early),TA108,breast cancer,160287004,FH: Breast cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Breast cancer (early),TA108,breast cancer,268547008,Screening for breast cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Breast cancer (early),TA108,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Breast cancer (early),TA108,breast cancer,429740004,Family history of breast cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Breast cancer (early),TA108,breast cancer,431330007,Family history of breast cancer 1 gene mutation,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Breast cancer (early),TA108,breast cancer,431331006,Family history of breast cancer 2 gene mutation,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Breast cancer (early),TA108,breast cancer,706970001,TNBC - Triple-negative breast cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Breast cancer (early),TA108,breast cancer,94361000000105,Breast cancer detected by national screening programme,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Breast cancer (early),TA108,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Breast cancer (early),TA108,breast cancer,276341000000100,Fast track referral for suspected breast cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Breast cancer (early),TA108,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Breast cancer (early),TA108,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Breast cancer (early),TA108,breast cancer,838351000000107,Education about risk of breast cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Breast cancer (early),TA108,breast cancer,874291000000100,QCancer breast cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Breast cancer (early),TA108,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Breast cancer (early),TA108,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Breast cancer (early),TA108,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Breast cancer (early),TA108,breast cancer,1035841000000108,Lymphoedema following breast cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL,Ovarian cancer,TA003,ovarian cancer,423274005,Ovarian cancer stage 4,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PACLITAXEL,Ovarian cancer,TA003,ovarian cancer,762997004,Suspected ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PACLITAXEL,Ovarian cancer,TA003,ovarian cancer,758821000000106,No family history of ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PACLITAXEL,Ovarian cancer,TA003,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PACLITAXEL,Ovarian cancer (advanced),TA091,ovarian cancer,423274005,Ovarian cancer stage 4,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PACLITAXEL,Ovarian cancer (advanced),TA091,ovarian cancer,762997004,Suspected ovarian cancer,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PACLITAXEL,Ovarian cancer (advanced),TA091,ovarian cancer,758821000000106,No family history of ovarian cancer,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PACLITAXEL,Ovarian cancer (advanced),TA091,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PACLITAXEL (1ST LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,254637007,Non-small cell lung cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PACLITAXEL (1ST LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,723301009,Squamous non-small cell lung cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PACLITAXEL (1ST LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,1259727001,Primary non-small cell lung cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PACLITAXEL (1ST LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PACLITAXEL (1ST LINE),Ovarian cancer,TA055,ovarian cancer,423274005,Ovarian cancer stage 4,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PACLITAXEL (1ST LINE),Ovarian cancer,TA055,ovarian cancer,762997004,Suspected ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PACLITAXEL (1ST LINE),Ovarian cancer,TA055,ovarian cancer,758821000000106,No family history of ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PACLITAXEL (1ST LINE),Ovarian cancer,TA055,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,134405005,Suspected breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,160287004,FH: Breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,268547008,Screening for breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,429740004,Family history of breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,431330007,Family history of breast cancer 1 gene mutation,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,431331006,Family history of breast cancer 2 gene mutation,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,706970001,TNBC - Triple-negative breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,94361000000105,Breast cancer detected by national screening programme,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,276341000000100,Fast track referral for suspected breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,838351000000107,Education about risk of breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,874291000000100,QCancer breast cancer risk,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL (2ND LINE),Advanced breast cancer,TA030,breast cancer,1035841000000108,Lymphoedema following breast cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PACLITAXEL (2ND LINE),Ovarian cancer,TA055,ovarian cancer,423274005,Ovarian cancer stage 4,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PACLITAXEL (2ND LINE),Ovarian cancer,TA055,ovarian cancer,762997004,Suspected ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PACLITAXEL (2ND LINE),Ovarian cancer,TA055,ovarian cancer,758821000000106,No family history of ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PACLITAXEL (2ND LINE),Ovarian cancer,TA055,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES (NAB‑PACLITAXEL) WITH GEMCITABINE,Untreated metastatic pancreatic cancer,TA476,pancreatic cancer,429000004,Family history of pancreatic cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES (NAB‑PACLITAXEL) WITH GEMCITABINE,Untreated metastatic pancreatic cancer,TA476,pancreatic cancer,247591000000101,Suspected pancreatic cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES (NAB‑PACLITAXEL) WITH GEMCITABINE,Untreated metastatic pancreatic cancer,TA476,pancreatic cancer,848901000000106,QCancer pancreatic cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,162573006,Suspected lung cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,275981009,Lung cancer screening,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,429011007,Family history of lung cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PACLITAXEL AS ALBUMIN-BOUND NANOPARTICLES WITH CARBOPLATIN,Untreated non-small-cell lung cancer,TA362,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PACLITAXEL AS ALBUMIN‑BOUND NANOPARTICLES IN COMBINATION WITH GEMCITABINE,Previously untreated metastatic pancreatic cancer,TA360,pancreatic cancer,429000004,Family history of pancreatic cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
PACLITAXEL AS ALBUMIN‑BOUND NANOPARTICLES IN COMBINATION WITH GEMCITABINE,Previously untreated metastatic pancreatic cancer,TA360,pancreatic cancer,247591000000101,Suspected pancreatic cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
PACLITAXEL AS ALBUMIN‑BOUND NANOPARTICLES IN COMBINATION WITH GEMCITABINE,Previously untreated metastatic pancreatic cancer,TA360,pancreatic cancer,848901000000106,QCancer pancreatic cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
PACLITAXEL IN COMBINATION WITH A PLATINUM-BASED COMPOUND,Ovarian cancer (advanced),TA091,ovarian cancer,423274005,Ovarian cancer stage 4,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PACLITAXEL IN COMBINATION WITH A PLATINUM-BASED COMPOUND,Ovarian cancer (advanced),TA091,ovarian cancer,762997004,Suspected ovarian cancer,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PACLITAXEL IN COMBINATION WITH A PLATINUM-BASED COMPOUND,Ovarian cancer (advanced),TA091,ovarian cancer,758821000000106,No family history of ovarian cancer,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PACLITAXEL IN COMBINATION WITH A PLATINUM-BASED COMPOUND,Ovarian cancer (advanced),TA091,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PACLITAXEL IN COMBINATION WITH PLATINUM OR AS MONOTHERAPY,Treating recurrent ovarian cancer,TA389,ovarian cancer,423274005,Ovarian cancer stage 4,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PACLITAXEL IN COMBINATION WITH PLATINUM OR AS MONOTHERAPY,Treating recurrent ovarian cancer,TA389,ovarian cancer,762997004,Suspected ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PACLITAXEL IN COMBINATION WITH PLATINUM OR AS MONOTHERAPY,Treating recurrent ovarian cancer,TA389,ovarian cancer,758821000000106,No family history of ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PACLITAXEL IN COMBINATION WITH PLATINUM OR AS MONOTHERAPY,Treating recurrent ovarian cancer,TA389,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PADELIPORFIN,"Adults with previously untreated, unilateral, low-risk prostate cancer in adults",TA546,prostate cancer,315268008,Suspected prostate cancer,PADELIPORFIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PADELIPORFIN,"Adults with previously untreated, unilateral, low-risk prostate cancer in adults",TA546,prostate cancer,428262008,H/O: prostate cancer,PADELIPORFIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PADELIPORFIN,"Adults with previously untreated, unilateral, low-risk prostate cancer in adults",TA546,prostate cancer,698470001,Advice given about prostate cancer screening,PADELIPORFIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PADELIPORFIN,"Adults with previously untreated, unilateral, low-risk prostate cancer in adults",TA546,prostate cancer,712837004,Active surveillance of prostate cancer,PADELIPORFIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PADELIPORFIN,"Adults with previously untreated, unilateral, low-risk prostate cancer in adults",TA546,prostate cancer,720007002,Prostate cancer care review,PADELIPORFIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PADELIPORFIN,"Adults with previously untreated, unilateral, low-risk prostate cancer in adults",TA546,prostate cancer,31011000119107,Prostate cancer screening declined,PADELIPORFIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PADELIPORFIN,"Adults with previously untreated, unilateral, low-risk prostate cancer in adults",TA546,prostate cancer,874211000000109,QCancer prostate cancer risk,PADELIPORFIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PADELIPORFIN,"Adults with previously untreated, unilateral, low-risk prostate cancer in adults",TA546,prostate cancer,878401000000104,No FH of prostate cancer,PADELIPORFIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PADELIPORFIN,"Adults with previously untreated, unilateral, low-risk prostate cancer in adults",TA546,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,PADELIPORFIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PADELIPORFIN,"Adults with previously untreated, unilateral, low-risk prostate cancer in adults",TA546,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,PADELIPORFIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,134405005,Suspected breast cancer,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,160287004,FH: Breast cancer,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,268547008,Screening for breast cancer,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,429740004,Family history of breast cancer,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,431330007,Family history of breast cancer 1 gene mutation,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,431331006,Family history of breast cancer 2 gene mutation,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,706970001,TNBC - Triple-negative breast cancer,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,94361000000105,Breast cancer detected by national screening programme,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,276341000000100,Fast track referral for suspected breast cancer,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,838351000000107,Education about risk of breast cancer,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,874291000000100,QCancer breast cancer risk,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
"PALBOCICLI, WITH AN AROMATASE INHIBITOR","Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA495,breast cancer,1035841000000108,Lymphoedema following breast cancer,PALBOCICLI,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,134405005,Suspected breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,160287004,FH: Breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,268547008,Screening for breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,429740004,Family history of breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,431330007,Family history of breast cancer 1 gene mutation,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,431331006,Family history of breast cancer 2 gene mutation,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,706970001,TNBC - Triple-negative breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,94361000000105,Breast cancer detected by national screening programme,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,276341000000100,Fast track referral for suspected breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,838351000000107,Education about risk of breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,874291000000100,QCancer breast cancer risk,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA836,breast cancer,1035841000000108,Lymphoedema following breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,134405005,Suspected breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,160287004,FH: Breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,268547008,Screening for breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,429740004,Family history of breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,431330007,Family history of breast cancer 1 gene mutation,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,431331006,Family history of breast cancer 2 gene mutation,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,706970001,TNBC - Triple-negative breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,94361000000105,Breast cancer detected by national screening programme,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,276341000000100,Fast track referral for suspected breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,838351000000107,Education about risk of breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,874291000000100,QCancer breast cancer risk,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PALBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA619,breast cancer,1035841000000108,Lymphoedema following breast cancer,PALBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PANOBINOSTAT IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE,Treating multiple myeloma after at least 2 previous treatments,TA380,multiple myeloma,230586003,Neuropathy due to multiple myeloma,PANOBINOSTAT,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PANOBINOSTAT IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE,Treating multiple myeloma after at least 2 previous treatments,TA380,multiple myeloma,413587002,Smoldering multiple myeloma,PANOBINOSTAT,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PANOBINOSTAT IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE,Treating multiple myeloma after at least 2 previous treatments,TA380,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,PANOBINOSTAT,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PANTOPRAZOLE,Dyspepsia,TA007,dyspepsia,3696007,Non ulcer dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PANTOPRAZOLE,Dyspepsia,TA007,dyspepsia,191972002,Psychogenic dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PANTOPRAZOLE,Dyspepsia,TA007,dyspepsia,192434000,[X]Psychogenic dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PANTOPRAZOLE,Dyspepsia,TA007,dyspepsia,196752002,Flatulent dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PANTOPRAZOLE,Dyspepsia,TA007,dyspepsia,249511005,Flatulent dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PANTOPRAZOLE,Dyspepsia,TA007,dyspepsia,299969005,Dyspepsia caused by drug,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PANTOPRAZOLE,Dyspepsia,TA007,dyspepsia,416202003,Under care of dyspepsia specialist nurse,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PANTOPRAZOLE,Dyspepsia,TA007,dyspepsia,417691002,Discharged from care of dyspepsia specialist nurse,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PANTOPRAZOLE,Dyspepsia,TA007,dyspepsia,203661000000105,Undiagnosed dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PANTOPRAZOLE,Dyspepsia,TA007,dyspepsia,248131000000106,Referral to dyspepsia specialist nurse,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PAZOPANIB (1ST LINE),Metastatic renal cell carcinoma,TA215,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,PAZOPANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PAZOPANIB (1ST LINE),Metastatic renal cell carcinoma,TA215,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,PAZOPANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PAZOPANIB (1ST LINE),Metastatic renal cell carcinoma,TA215,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,PAZOPANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PAZOPANIB (1ST LINE),Metastatic renal cell carcinoma,TA215,renal cell carcinoma,733608000,Papillary renal cell carcinoma,PAZOPANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PAZOPANIB (1ST LINE),Metastatic renal cell carcinoma,TA215,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,PAZOPANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PAZOPANIB (1ST LINE),Metastatic renal cell carcinoma,TA215,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,PAZOPANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PAZOPANIB (1ST LINE),Metastatic renal cell carcinoma,TA215,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,PAZOPANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PEGAPTANIB,Wet age-related macular degeneration,TA155,macular degeneration,70099003,Familial juvenile macular degeneration syndrome,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
PEGAPTANIB,Wet age-related macular degeneration,TA155,macular degeneration,193384000,Senile macular degeneration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
PEGAPTANIB,Wet age-related macular degeneration,TA155,macular degeneration,267718000,Age-related macular degeneration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
PEGAPTANIB,Wet age-related macular degeneration,TA155,macular degeneration,312898002,Myopic macular degeneration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
PEGAPTANIB,Wet age-related macular degeneration,TA155,macular degeneration,314427006,Drusen plus pigment change stage macular degeneration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
PEGAPTANIB,Wet age-related macular degeneration,TA155,macular degeneration,1296526000,Disciform macular degeneration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
"PEGASPARGASE, AS PART OF ANTINEOPLASTIC COMBINATION THERAPY",Treating acute lymphoblastic leukaemia,TA408,acute lymphoblastic leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,PEGASPARGASE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS
"PEGASPARGASE, AS PART OF ANTINEOPLASTIC COMBINATION THERAPY",Treating acute lymphoblastic leukaemia,TA408,acute lymphoblastic leukaemia,413440007,Acute lymphoblastic leukaemia - category,PEGASPARGASE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS
PEGCETACOPLAN,Paroxysmal nocturnal haemoglobinuria,TA778,paroxysmal nocturnal haemoglobinuria,1006421000000103,PNH (paroxysmal nocturnal haemoglobinuria) screening test,PEGCETACOPLAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
PEGCETACOPLAN,Paroxysmal nocturnal haemoglobinuria,TA778,paroxysmal nocturnal haemoglobinuria,1013561000000103,Paroxysmal nocturnal haemoglobinuria cell marker analysis,PEGCETACOPLAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,62944002,Hepatitis C virus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,62944002,Hepatitis C virus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,72165005,Hepatitis C virus antibody,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,72165005,Hepatitis C virus antibody,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,170489004,Viral hepatitis carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,170489004,Viral hepatitis carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,235872006,Hepatitis C carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,235872006,Hepatitis C carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,278973007,Hepatitis C status,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,278973007,Hepatitis C status,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,278974001,Hepatitis C immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,278974001,Hepatitis C immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,278975000,Hepatitis C non-immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,278975000,Hepatitis C non-immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,314706002,Hepatitis C antibody detected,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,314706002,Hepatitis C antibody detected,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,314707006,Hepatitis C antibody test negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,314707006,Hepatitis C antibody test negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,413107006,Hepatitis C screening,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,413107006,Hepatitis C screening,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,773113008,Acute hepatitis caused by infection,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,773113008,Acute hepatitis caused by infection,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,12891000175105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,12891000175105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,200371000000104,Hepatitis C contact,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,200371000000104,Hepatitis C contact,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,202281000000105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,202281000000105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,362491000000104,Hepatitis C screening negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,362491000000104,Hepatitis C screening negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,362751000000101,Hepatitis C screening positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,362751000000101,Hepatitis C screening positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,761381000000102,Hepatitis C resolved,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,761381000000102,Hepatitis C resolved,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,992751000000109,Hepatitis C viral load,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,992751000000109,Hepatitis C viral load,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,996031000000104,Hepatitis C IgG level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,996031000000104,Hepatitis C IgG level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,998771000000103,Hepatitis C antibody level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,998771000000103,Hepatitis C antibody level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA AND RIBAVIRIN – COMBINATION THERAPY,Hepatitis C,TA075,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,62944002,Hepatitis C virus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,62944002,Hepatitis C virus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,72165005,Hepatitis C virus antibody,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,72165005,Hepatitis C virus antibody,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,170489004,Viral hepatitis carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,170489004,Viral hepatitis carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,235872006,Hepatitis C carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,235872006,Hepatitis C carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,278973007,Hepatitis C status,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,278973007,Hepatitis C status,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,278974001,Hepatitis C immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,278974001,Hepatitis C immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,278975000,Hepatitis C non-immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,278975000,Hepatitis C non-immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,314706002,Hepatitis C antibody detected,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,314706002,Hepatitis C antibody detected,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,314707006,Hepatitis C antibody test negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,314707006,Hepatitis C antibody test negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,413107006,Hepatitis C screening,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,413107006,Hepatitis C screening,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,773113008,Acute hepatitis caused by infection,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,773113008,Acute hepatitis caused by infection,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,12891000175105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,12891000175105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,200371000000104,Hepatitis C contact,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,200371000000104,Hepatitis C contact,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,202281000000105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,202281000000105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,362491000000104,Hepatitis C screening negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,362491000000104,Hepatitis C screening negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,362751000000101,Hepatitis C screening positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,362751000000101,Hepatitis C screening positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,761381000000102,Hepatitis C resolved,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,761381000000102,Hepatitis C resolved,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,992751000000109,Hepatitis C viral load,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,992751000000109,Hepatitis C viral load,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,996031000000104,Hepatitis C IgG level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,996031000000104,Hepatitis C IgG level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,998771000000103,Hepatitis C antibody level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,998771000000103,Hepatitis C antibody level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C in children and young people,TA300,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,62944002,Hepatitis C virus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,62944002,Hepatitis C virus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,72165005,Hepatitis C virus antibody,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,72165005,Hepatitis C virus antibody,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,170489004,Viral hepatitis carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,170489004,Viral hepatitis carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,235872006,Hepatitis C carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,235872006,Hepatitis C carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,278973007,Hepatitis C status,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,278973007,Hepatitis C status,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,278974001,Hepatitis C immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,278974001,Hepatitis C immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,278975000,Hepatitis C non-immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,278975000,Hepatitis C non-immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,314706002,Hepatitis C antibody detected,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,314706002,Hepatitis C antibody detected,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,314707006,Hepatitis C antibody test negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,314707006,Hepatitis C antibody test negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,413107006,Hepatitis C screening,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,413107006,Hepatitis C screening,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,773113008,Acute hepatitis caused by infection,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,773113008,Acute hepatitis caused by infection,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,12891000175105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,12891000175105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,200371000000104,Hepatitis C contact,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,200371000000104,Hepatitis C contact,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,202281000000105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,202281000000105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,362491000000104,Hepatitis C screening negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,362491000000104,Hepatitis C screening negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,362751000000101,Hepatitis C screening positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,362751000000101,Hepatitis C screening positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,761381000000102,Hepatitis C resolved,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,761381000000102,Hepatitis C resolved,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,992751000000109,Hepatitis C viral load,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,992751000000109,Hepatitis C viral load,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,996031000000104,Hepatitis C IgG level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,996031000000104,Hepatitis C IgG level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,998771000000103,Hepatitis C antibody level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,998771000000103,Hepatitis C antibody level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA MONOTHERAPY,Hepatitis C,TA075,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,16584000,Administration of vaccine product containing only Hepatitis B virus antigen,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,17627009,Hepatitis B e antigen Ab,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,22290004,Hepatitis B virus surface antigen,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,47758006,Hepatitis B surface antigen level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,61977001,Chronic viral hepatitis B,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,76795007,Acute hepatitis B,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,81665004,Hepatitis B virus,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,82409003,Hepatitis B core antigen Ab,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,82645009,Hepatitis B virus surface antigen Ab,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,116800003,Hepatitis B Virus immune globulin administration,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,122450004,Hepatitis B virus antibody,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,161638000,Hepatitis B Occupational risk,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,165806002,Hepatitis B surface antigen positive,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,165807006,Hepatitis Be antigen present,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,165808001,Hepatitis B non-immune,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,170370000,First hepatitis B immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,170371001,Administration of second dose of hepatitis B vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,170372008,Third hepatitis B immunisation,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,170373003,Hepatitis B booster vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,170374009,Fourth hepatitis B immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,170375005,Administration of fifth dose of hepatitis B vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,170436000,Administration of third dose of vaccine product containing only Hepatitis A and Hepatitis B virus antigens,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,170542003,Requires course of hepatitis B vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,171122006,Hepatitis B screening,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,171123001,Hepatitis B screening required,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,186626002,Acute hepatitis B with delta-agent (coinfection) without hepatic coma,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,192723002,Post hepatitis B vaccination encephalitis,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,235871004,Hepatitis B carrier,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,268504008,Anti-hepatitis B immunoglobulin given,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,271511000,Hepatitis B immune,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,278969009,Hepatitis B status,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,293110008,Adverse reaction to component of vaccine product containing Hepatitis B virus antigen,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,294637001,Hepatitis B immunoglobulin allergy,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,294646007,Hepatitis B vaccine allergy,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,303233001,Antigen of Hepatitis B virus,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,313234004,Hepatitis B antibody present,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,406010001,Hepatitis B surface antigen not detected,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,408778004,Hepatitis B vaccination declined,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,416923003,Sixth hepatitis B immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,425569004,Hepatitis B immunization recommended,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,426519003,History of two doses hepatitis B vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,426980004,History of one dose of hepatitis B vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,427390007,History of hepatitis B vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,429203008,History of three hepatitis B vaccinations,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,429721005,History of hepatitis B,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,698604002,Hepatitis B outbreak education,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,699037006,Hepatitis B vaccination contraindicated,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,707287001,Hepatitis B vaccination not indicated,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,736687002,Hepatitis B core antibody detected,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,736693005,Hepatitis B core antibody negative,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,736699009,Requires hepatitis B booster,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,198041000000109,Hepatitis B vaccination refused,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,201591000000101,Advice on hepatitis B vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,202271000000108,Hepatitis B screening declined,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,204681000000104,Hepatitis B screening counselling,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,221021000000103,Hepatitis B treatment drugs Band 1,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,356121000000100,Hepatitis B screening positive,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,362851000000109,Hepatitis B screening negative,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,835791000000107,Hepatitis B vaccination invitation,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,835811000000108,Hepatitis B vaccination invitation first letter,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,835831000000100,Hepatitis B vaccination invitation second letter,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,835851000000107,Hepatitis B vaccination invitation third letter,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,835871000000103,Hepatitis B vaccination verbal invitation,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,839711000000101,Hepatitis B vaccination not offered,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,846421000000105,Hepatitis B screening not offered,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,865061000000108,First hepatitis B junior vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,865081000000104,Second hepatitis B junior vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,865101000000105,Third hepatitis B junior vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,865121000000101,Fourth hepatitis B junior vaccination,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,991971000000109,Hepatitis B immunity test,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,991981000000106,Hepatitis B core antigen test,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,991991000000108,Hepatitis B e antigen test,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,995941000000101,Anti HBc (hepatitis B core) IgG level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1008441000000106,Hepatitis B deoxyribonucleic acid detection assay,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1008791000000106,HBsAg (hepatitis B surface antigen) antibody level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1009271000000109,Hepatitis B screening test,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1014201000000102,Hepatitis B surface antibody level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1014211000000100,Hepatitis B surface antigen level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1014231000000108,Hepatitis B core antibody level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1014241000000104,Hepatitis B e antibody level,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1028341000000105,Hepatitis B antigen screening,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1037211000000101,First hepatitis B vaccination given by other healthcare provider,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1037231000000109,Second hepatitis B vaccination given by other healthcare provider,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1060591000000103,Hepatitis B resolved,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1091701000000105,At risk of hepatitis B infection,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,1107691000000105,Hepatitis B screening offered,ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A,Hepatitis B (chronic),TA096,hepatitis b,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ADEFOVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,62944002,Hepatitis C virus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,62944002,Hepatitis C virus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,72165005,Hepatitis C virus antibody,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,72165005,Hepatitis C virus antibody,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,170489004,Viral hepatitis carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,170489004,Viral hepatitis carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,235872006,Hepatitis C carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,235872006,Hepatitis C carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,278973007,Hepatitis C status,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,278973007,Hepatitis C status,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,278974001,Hepatitis C immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,278974001,Hepatitis C immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,278975000,Hepatitis C non-immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,278975000,Hepatitis C non-immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,314706002,Hepatitis C antibody detected,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,314706002,Hepatitis C antibody detected,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,314707006,Hepatitis C antibody test negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,314707006,Hepatitis C antibody test negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,413107006,Hepatitis C screening,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,413107006,Hepatitis C screening,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,773113008,Acute hepatitis caused by infection,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,773113008,Acute hepatitis caused by infection,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,12891000175105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,12891000175105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,200371000000104,Hepatitis C contact,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,200371000000104,Hepatitis C contact,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,202281000000105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,202281000000105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,362491000000104,Hepatitis C screening negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,362491000000104,Hepatitis C screening negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,362751000000101,Hepatitis C screening positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,362751000000101,Hepatitis C screening positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,761381000000102,Hepatitis C resolved,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,761381000000102,Hepatitis C resolved,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,992751000000109,Hepatitis C viral load,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,992751000000109,Hepatitis C viral load,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,996031000000104,Hepatitis C IgG level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,996031000000104,Hepatitis C IgG level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,998771000000103,Hepatitis C antibody level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,998771000000103,Hepatitis C antibody level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A AND RIBAVIRIN OR PEGINTERFERON ALFA-2B AND RIBAVIRIN COMBINATION THERAPY,Hepatitis C,TA106,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,62944002,Hepatitis C virus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,62944002,Hepatitis C virus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,72165005,Hepatitis C virus antibody,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,72165005,Hepatitis C virus antibody,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,170489004,Viral hepatitis carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,170489004,Viral hepatitis carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,235872006,Hepatitis C carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,235872006,Hepatitis C carrier,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,278973007,Hepatitis C status,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,278973007,Hepatitis C status,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,278974001,Hepatitis C immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,278974001,Hepatitis C immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,278975000,Hepatitis C non-immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,278975000,Hepatitis C non-immune,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,314706002,Hepatitis C antibody detected,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,314706002,Hepatitis C antibody detected,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,314707006,Hepatitis C antibody test negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,314707006,Hepatitis C antibody test negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,413107006,Hepatitis C screening,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,413107006,Hepatitis C screening,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,773113008,Acute hepatitis caused by infection,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,773113008,Acute hepatitis caused by infection,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,12891000175105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,12891000175105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,200371000000104,Hepatitis C contact,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,200371000000104,Hepatitis C contact,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,202281000000105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,202281000000105,Hepatitis C screening declined,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,362491000000104,Hepatitis C screening negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,362491000000104,Hepatitis C screening negative,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,362751000000101,Hepatitis C screening positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,362751000000101,Hepatitis C screening positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,761381000000102,Hepatitis C resolved,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,761381000000102,Hepatitis C resolved,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,992751000000109,Hepatitis C viral load,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,992751000000109,Hepatitis C viral load,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,996031000000104,Hepatitis C IgG level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,996031000000104,Hepatitis C IgG level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,998771000000103,Hepatitis C antibody level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,998771000000103,Hepatitis C antibody level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B,Hepatitis C,TA106,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGINTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,24700007,Multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,160337009,Family history of multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,192926004,Brain stem multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,192928003,Generalised multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,428700003,Primary progressive multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,438511000,Benign multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,700409000,Suspected multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,198491000000106,Multiple sclerosis review,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,515931000000104,Multiple sclerosis review declined,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGINTERFERON BETA-1A,Relapsing–remitting multiple sclerosis,TA624,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,PEGINTERFERON,NEUROLOGY,NEUROLOGY|REHABILITATION
PEGLOTICASE,Severe debilitating chronic tophaceous gout,TA291,tophaceous gout,190842000,Chronic tophaceous gout of hand,PEGLOTICASE,RHEUMATOLOGY,RHEUMATOLOGY
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,62944002,Hepatitis C virus,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,62944002,Hepatitis C virus,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,72165005,Hepatitis C virus antibody,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,72165005,Hepatitis C virus antibody,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,170489004,Viral hepatitis carrier,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,170489004,Viral hepatitis carrier,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,235872006,Hepatitis C carrier,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,235872006,Hepatitis C carrier,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,278973007,Hepatitis C status,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,278973007,Hepatitis C status,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,278974001,Hepatitis C immune,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,278974001,Hepatitis C immune,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,278975000,Hepatitis C non-immune,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,278975000,Hepatitis C non-immune,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,314706002,Hepatitis C antibody detected,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,314706002,Hepatitis C antibody detected,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,314707006,Hepatitis C antibody test negative,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,314707006,Hepatitis C antibody test negative,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,413107006,Hepatitis C screening,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,413107006,Hepatitis C screening,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,773113008,Acute hepatitis caused by infection,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,773113008,Acute hepatitis caused by infection,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,12891000175105,Hepatitis C screening declined,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,12891000175105,Hepatitis C screening declined,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,200371000000104,Hepatitis C contact,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,200371000000104,Hepatitis C contact,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,202281000000105,Hepatitis C screening declined,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,202281000000105,Hepatitis C screening declined,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,362491000000104,Hepatitis C screening negative,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,362491000000104,Hepatitis C screening negative,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,362751000000101,Hepatitis C screening positive,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,362751000000101,Hepatitis C screening positive,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,761381000000102,Hepatitis C resolved,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,761381000000102,Hepatitis C resolved,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,992751000000109,Hepatitis C viral load,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,992751000000109,Hepatitis C viral load,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,996031000000104,Hepatitis C IgG level,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,996031000000104,Hepatitis C IgG level,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,998771000000103,Hepatitis C antibody level,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,998771000000103,Hepatitis C antibody level,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN,Chronic hepatitis C,TA200,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,62944002,Hepatitis C virus,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,62944002,Hepatitis C virus,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,72165005,Hepatitis C virus antibody,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,72165005,Hepatitis C virus antibody,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,170489004,Viral hepatitis carrier,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,170489004,Viral hepatitis carrier,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,197344005,Hepatitis caused by adenovirus,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,235872006,Hepatitis C carrier,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,235872006,Hepatitis C carrier,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,278973007,Hepatitis C status,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,278973007,Hepatitis C status,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,278974001,Hepatitis C immune,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,278974001,Hepatitis C immune,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,278975000,Hepatitis C non-immune,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,278975000,Hepatitis C non-immune,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,314706002,Hepatitis C antibody detected,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,314706002,Hepatitis C antibody detected,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,314707006,Hepatitis C antibody test negative,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,314707006,Hepatitis C antibody test negative,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,413107006,Hepatitis C screening,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,413107006,Hepatitis C screening,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,773113008,Acute hepatitis caused by infection,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,773113008,Acute hepatitis caused by infection,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,12891000175105,Hepatitis C screening declined,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,12891000175105,Hepatitis C screening declined,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,200371000000104,Hepatitis C contact,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,200371000000104,Hepatitis C contact,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,201451000000105,Hepatitis C immunisation declined,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,202281000000105,Hepatitis C screening declined,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,202281000000105,Hepatitis C screening declined,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,204671000000101,Hepatitis C screening counselling,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,304821000000107,Hepatitis C screening not offered,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,362491000000104,Hepatitis C screening negative,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,362491000000104,Hepatitis C screening negative,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,362751000000101,Hepatitis C screening positive,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,362751000000101,Hepatitis C screening positive,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,761381000000102,Hepatitis C resolved,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,761381000000102,Hepatitis C resolved,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,824841000000105,Hepatitis C genotype 1,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,824871000000104,Hepatitis C genotype 3,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,829731000000106,On hepatitis C treatment plan,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,992751000000109,Hepatitis C viral load,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,992751000000109,Hepatitis C viral load,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,992771000000100,Hepatitis C virus genotype,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,996031000000104,Hepatitis C IgG level,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,996031000000104,Hepatitis C IgG level,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,998771000000103,Hepatitis C antibody level,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,998771000000103,Hepatitis C antibody level,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,1001331000000102,Hepatitis C antigen level,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,1008931000000108,Hepatitis C antibody test,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED INTERFERON (2A AND 2B) IN COMBINATION WITH RIBAVIRIN – SHORTENED TREATMENT COURSE,Chronic hepatitis C,TA200,hepatitis c,1107671000000106,Hepatitis C screening offered,PEGYLATED,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE (PLDH),Ovarian cancer (advanced),TA045,ovarian cancer,423274005,Ovarian cancer stage 4,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE (PLDH),Ovarian cancer (advanced),TA091,ovarian cancer,423274005,Ovarian cancer stage 4,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE (PLDH),Ovarian cancer (advanced),TA045,ovarian cancer,762997004,Suspected ovarian cancer,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE (PLDH),Ovarian cancer (advanced),TA091,ovarian cancer,762997004,Suspected ovarian cancer,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE (PLDH),Ovarian cancer (advanced),TA045,ovarian cancer,758821000000106,No family history of ovarian cancer,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE (PLDH),Ovarian cancer (advanced),TA091,ovarian cancer,758821000000106,No family history of ovarian cancer,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE (PLDH),Ovarian cancer (advanced),TA045,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE (PLDH),Ovarian cancer (advanced),TA091,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE (PLDH) MONOTHERAPY,Treating recurrent ovarian cancer,TA389,ovarian cancer,423274005,Ovarian cancer stage 4,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE (PLDH) MONOTHERAPY,Treating recurrent ovarian cancer,TA389,ovarian cancer,762997004,Suspected ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE (PLDH) MONOTHERAPY,Treating recurrent ovarian cancer,TA389,ovarian cancer,758821000000106,No family history of ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE (PLDH) MONOTHERAPY,Treating recurrent ovarian cancer,TA389,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PEGYLATED LIPOSOMAL IRINOTECAN IN COMBINATION WITH 5‑FLUOROURACIL AND LEUCOVORIN,Pancreatic cancer after gemcitabine,TA440,pancreatic cancer,429000004,Family history of pancreatic cancer,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
PEGYLATED LIPOSOMAL IRINOTECAN IN COMBINATION WITH 5‑FLUOROURACIL AND LEUCOVORIN,Pancreatic cancer after gemcitabine,TA440,pancreatic cancer,247591000000101,Suspected pancreatic cancer,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
PEGYLATED LIPOSOMAL IRINOTECAN IN COMBINATION WITH 5‑FLUOROURACIL AND LEUCOVORIN,Pancreatic cancer after gemcitabine,TA440,pancreatic cancer,848901000000106,QCancer pancreatic cancer risk,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,915007,Malignant melanoma in junctional naevus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,1556006,Clark melanoma level 4,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,2092003,Malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,2142002,Nodular melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,16974005,"Acral lentiginous melanoma, malignant",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,21119008,Benign melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,21165006,Clark melanoma level 3,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,37138001,Epithelioid cell melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,39896009,"Malignant melanoma, regressing",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,44474009,Lentigo maligna melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,50542000,Clark melanoma level 2,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,50813003,Spitz melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,51757004,"Desmoplastic melanoma, amelanotic",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,55320002,Superficial spreading melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,68827007,Spindle cell melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,70594002,Amelanotic melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,77986002,Melanoma in situ,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93209006,Malignant melanoma of perianal skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93214005,Malignant melanoma of skin of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93217003,Malignant melanoma of skin of cheek,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93220006,Malignant melanoma of skin of ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93221005,Malignant melanoma of skin of elbow,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93223008,Malignant melanoma of eyebrow,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93225001,Malignant melanoma of skin of face,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93227009,Malignant melanoma of skin of foot,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93228004,Malignant melanoma of skin of forearm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93642000,Malignant melanoma of skin of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93643005,Malignant melanoma of external surface of nose,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93646002,Malignant melanoma of skin of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93647006,Malignant melanoma of skin of shoulder,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93651008,Malignant melanoma of skin of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93653006,Malignant melanoma of skin of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93654000,Malignant melanoma of skin of wrist,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,93655004,MM (malignant melanoma) of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,106243009,Breslow depth staging for melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,109266006,Melanoma in situ of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,109270003,Melanoma in situ of face,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,109272006,Melanoma in situ of lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,109276009,Melanoma in situ of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,109278005,Melanoma in situ of ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,109282007,Melanoma in situ of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,109284008,Melanoma in situ of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,109290007,Melanoma in situ of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,109294003,Melanoma in situ of lower limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,127330008,Melanoma in situ by body site (clinical),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,161432005,History of malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,177281002,Excision of melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188030005,Malignant melanoma of lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188033007,Malignant melanoma of auricle (ear),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188034001,Malignant melanoma of external auditory meatus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188038003,Malignant melanoma of chin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188040008,Malignant melanoma of forehead,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188042000,Malignant melanoma of temple,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188044004,Malignant melanoma of scalp and/or neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188045003,Malignant melanoma of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188046002,Malignant melanoma of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188049009,Malignant melanoma of axilla,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188050009,Malignant melanoma of breast,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188051008,Malignant melanoma of buttock,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188052001,Malignant melanoma of groin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188054000,Malignant melanoma of perineum,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188055004,Malignant melanoma of umbilicus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188060000,Malignant melanoma of shoulder,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188061001,Malignant melanoma of upper arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188062008,Malignant melanoma of forearm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188063003,Malignant melanoma of hand,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188064009,Malignant melanoma of finger,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188065005,Malignant melanoma of thumb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188067002,Malignant melanoma of lower limb and hip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188068007,Malignant melanoma of hip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188069004,Malignant melanoma of thigh,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188070003,Malignant melanoma of knee,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188071004,Malignant melanoma of popliteal fossa area,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188072006,Malignant melanoma of lower leg,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188073001,Malignant melanoma of ankle,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188074007,Malignant melanoma of heel,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188075008,Malignant melanoma of foot,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188076009,Malignant melanoma of toe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,188077000,Malignant melanoma of great toe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,189758001,Melanoma in situ,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,231834005,Malignant melanoma of eyelid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,254731001,Nodular melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,254732008,Acral lentiginous melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,254896002,Malignant melanoma of vulva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,255004001,Malignant melanoma of conjunctiva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,255012009,Malignant melanoma of iris,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,255015006,Malignant melanoma of ciliary body,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,255021005,Malignant melanoma of choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,269578002,Malignant melanoma of head and neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,269579005,Malignant melanoma of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,269580008,Malignant melanoma of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,269581007,Malignant melanoma of lower limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,274087000,MM (malignant melanoma) of eye,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,276751004,Amelanotic melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,276821000,Malignant melanoma of anus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,276822007,Malignant melanoma of rectum,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,302837001,Lentigo maligna melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,310498001,Malignant melanoma of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,312941005,Melanoma associated retinopathy,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,313248004,Malignant melanoma of chest wall,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,314976006,Local recurrence of malignant melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,314987003,Metastasis from malignant melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,315036008,Melanoma in situ of back of hand,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,315230006,Melanoma in situ of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,372158004,"Malignant melanoma, metastatic",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,427858005,Family history of malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,443493003,Metastatic malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,449636007,Malignant melanoma of skin of lower leg,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,449637003,Malignant melanoma of skin of upper arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,698040004,Malignant melanoma of nasal cavity,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,1197324006,Metastatic malignant melanoma to skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,351961000119109,Malignant melanoma of skin of right arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,352211000119108,Malignant melanoma of skin of left ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,546881000000105,Malignant melanoma of skin NOS,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,956331000000107,Malignant melanoma stage IA,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,956351000000100,Malignant melanoma stage IB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,956371000000109,Malignant melanoma stage IIA,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,956391000000108,Malignant melanoma stage IIB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,956451000000107,Malignant melanoma stage IIIB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,956471000000103,Malignant melanoma stage IIIC,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,956511000000107,Malignant melanoma stage IV M1a,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,956551000000106,Malignant melanoma stage IV M1c,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,1080941000119109,Malignant melanoma of left choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of completely resected stage 3 melanoma,TA766,melanoma,1080981000119104,Malignant melanoma of right choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of renal cell carcinoma,TA830,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of renal cell carcinoma,TA830,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of renal cell carcinoma,TA830,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of renal cell carcinoma,TA830,renal cell carcinoma,733608000,Papillary renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of renal cell carcinoma,TA830,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of renal cell carcinoma,TA830,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of renal cell carcinoma,TA830,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,915007,Malignant melanoma in junctional naevus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,1556006,Clark melanoma level 4,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,2092003,Malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,2142002,Nodular melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,16974005,"Acral lentiginous melanoma, malignant",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,21119008,Benign melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,21165006,Clark melanoma level 3,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,37138001,Epithelioid cell melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,39896009,"Malignant melanoma, regressing",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,44474009,Lentigo maligna melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,50542000,Clark melanoma level 2,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,50813003,Spitz melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,51757004,"Desmoplastic melanoma, amelanotic",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,55320002,Superficial spreading melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,68827007,Spindle cell melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,70594002,Amelanotic melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,77986002,Melanoma in situ,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93209006,Malignant melanoma of perianal skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93214005,Malignant melanoma of skin of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93217003,Malignant melanoma of skin of cheek,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93220006,Malignant melanoma of skin of ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93221005,Malignant melanoma of skin of elbow,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93223008,Malignant melanoma of eyebrow,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93225001,Malignant melanoma of skin of face,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93227009,Malignant melanoma of skin of foot,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93228004,Malignant melanoma of skin of forearm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93642000,Malignant melanoma of skin of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93643005,Malignant melanoma of external surface of nose,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93646002,Malignant melanoma of skin of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93647006,Malignant melanoma of skin of shoulder,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93651008,Malignant melanoma of skin of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93653006,Malignant melanoma of skin of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93654000,Malignant melanoma of skin of wrist,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,93655004,MM (malignant melanoma) of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,106243009,Breslow depth staging for melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,109266006,Melanoma in situ of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,109270003,Melanoma in situ of face,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,109272006,Melanoma in situ of lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,109276009,Melanoma in situ of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,109278005,Melanoma in situ of ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,109282007,Melanoma in situ of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,109284008,Melanoma in situ of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,109290007,Melanoma in situ of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,109294003,Melanoma in situ of lower limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,127330008,Melanoma in situ by body site (clinical),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,161432005,History of malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,177281002,Excision of melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188030005,Malignant melanoma of lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188033007,Malignant melanoma of auricle (ear),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188034001,Malignant melanoma of external auditory meatus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188038003,Malignant melanoma of chin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188040008,Malignant melanoma of forehead,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188042000,Malignant melanoma of temple,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188044004,Malignant melanoma of scalp and/or neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188045003,Malignant melanoma of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188046002,Malignant melanoma of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188049009,Malignant melanoma of axilla,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188050009,Malignant melanoma of breast,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188051008,Malignant melanoma of buttock,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188052001,Malignant melanoma of groin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188054000,Malignant melanoma of perineum,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188055004,Malignant melanoma of umbilicus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188060000,Malignant melanoma of shoulder,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188061001,Malignant melanoma of upper arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188062008,Malignant melanoma of forearm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188063003,Malignant melanoma of hand,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188064009,Malignant melanoma of finger,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188065005,Malignant melanoma of thumb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188067002,Malignant melanoma of lower limb and hip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188068007,Malignant melanoma of hip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188069004,Malignant melanoma of thigh,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188070003,Malignant melanoma of knee,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188071004,Malignant melanoma of popliteal fossa area,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188072006,Malignant melanoma of lower leg,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188073001,Malignant melanoma of ankle,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188074007,Malignant melanoma of heel,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188075008,Malignant melanoma of foot,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188076009,Malignant melanoma of toe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,188077000,Malignant melanoma of great toe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,189758001,Melanoma in situ,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,231834005,Malignant melanoma of eyelid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,254731001,Nodular melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,254732008,Acral lentiginous melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,254896002,Malignant melanoma of vulva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,255004001,Malignant melanoma of conjunctiva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,255012009,Malignant melanoma of iris,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,255015006,Malignant melanoma of ciliary body,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,255021005,Malignant melanoma of choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,269578002,Malignant melanoma of head and neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,269579005,Malignant melanoma of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,269580008,Malignant melanoma of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,269581007,Malignant melanoma of lower limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,274087000,MM (malignant melanoma) of eye,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,276751004,Amelanotic melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,276821000,Malignant melanoma of anus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,276822007,Malignant melanoma of rectum,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,302837001,Lentigo maligna melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,310498001,Malignant melanoma of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,312941005,Melanoma associated retinopathy,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,313248004,Malignant melanoma of chest wall,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,314976006,Local recurrence of malignant melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,314987003,Metastasis from malignant melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,315036008,Melanoma in situ of back of hand,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,315230006,Melanoma in situ of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,372158004,"Malignant melanoma, metastatic",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,427858005,Family history of malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,443493003,Metastatic malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,449636007,Malignant melanoma of skin of lower leg,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,449637003,Malignant melanoma of skin of upper arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,698040004,Malignant melanoma of nasal cavity,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,1197324006,Metastatic malignant melanoma to skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,351961000119109,Malignant melanoma of skin of right arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,352211000119108,Malignant melanoma of skin of left ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,546881000000105,Malignant melanoma of skin NOS,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,956331000000107,Malignant melanoma stage IA,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,956351000000100,Malignant melanoma stage IB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,956371000000109,Malignant melanoma stage IIA,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,956391000000108,Malignant melanoma stage IIB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,956451000000107,Malignant melanoma stage IIIB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,956471000000103,Malignant melanoma stage IIIC,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,956511000000107,Malignant melanoma stage IV M1a,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,956551000000106,Malignant melanoma stage IV M1c,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,1080941000119109,Malignant melanoma of left choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Adjuvant treatment of resected stage 2B or 2C melanoma,TA837,melanoma,1080981000119104,Malignant melanoma of right choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,915007,Malignant melanoma in junctional naevus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,1556006,Clark melanoma level 4,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,2092003,Malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,2142002,Nodular melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,16974005,"Acral lentiginous melanoma, malignant",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,21119008,Benign melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,21165006,Clark melanoma level 3,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,37138001,Epithelioid cell melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,39896009,"Malignant melanoma, regressing",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,44474009,Lentigo maligna melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,50542000,Clark melanoma level 2,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,50813003,Spitz melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,51757004,"Desmoplastic melanoma, amelanotic",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,55320002,Superficial spreading melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,68827007,Spindle cell melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,70594002,Amelanotic melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,77986002,Melanoma in situ,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93209006,Malignant melanoma of perianal skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93214005,Malignant melanoma of skin of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93217003,Malignant melanoma of skin of cheek,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93220006,Malignant melanoma of skin of ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93221005,Malignant melanoma of skin of elbow,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93223008,Malignant melanoma of eyebrow,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93225001,Malignant melanoma of skin of face,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93227009,Malignant melanoma of skin of foot,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93228004,Malignant melanoma of skin of forearm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93642000,Malignant melanoma of skin of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93643005,Malignant melanoma of external surface of nose,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93646002,Malignant melanoma of skin of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93647006,Malignant melanoma of skin of shoulder,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93651008,Malignant melanoma of skin of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93653006,Malignant melanoma of skin of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93654000,Malignant melanoma of skin of wrist,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,93655004,MM (malignant melanoma) of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,106243009,Breslow depth staging for melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,109266006,Melanoma in situ of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,109270003,Melanoma in situ of face,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,109272006,Melanoma in situ of lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,109276009,Melanoma in situ of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,109278005,Melanoma in situ of ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,109282007,Melanoma in situ of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,109284008,Melanoma in situ of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,109290007,Melanoma in situ of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,109294003,Melanoma in situ of lower limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,127330008,Melanoma in situ by body site (clinical),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,161432005,History of malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,177281002,Excision of melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188030005,Malignant melanoma of lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188033007,Malignant melanoma of auricle (ear),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188034001,Malignant melanoma of external auditory meatus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188038003,Malignant melanoma of chin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188040008,Malignant melanoma of forehead,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188042000,Malignant melanoma of temple,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188044004,Malignant melanoma of scalp and/or neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188045003,Malignant melanoma of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188046002,Malignant melanoma of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188049009,Malignant melanoma of axilla,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188050009,Malignant melanoma of breast,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188051008,Malignant melanoma of buttock,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188052001,Malignant melanoma of groin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188054000,Malignant melanoma of perineum,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188055004,Malignant melanoma of umbilicus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188060000,Malignant melanoma of shoulder,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188061001,Malignant melanoma of upper arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188062008,Malignant melanoma of forearm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188063003,Malignant melanoma of hand,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188064009,Malignant melanoma of finger,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188065005,Malignant melanoma of thumb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188067002,Malignant melanoma of lower limb and hip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188068007,Malignant melanoma of hip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188069004,Malignant melanoma of thigh,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188070003,Malignant melanoma of knee,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188071004,Malignant melanoma of popliteal fossa area,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188072006,Malignant melanoma of lower leg,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188073001,Malignant melanoma of ankle,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188074007,Malignant melanoma of heel,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188075008,Malignant melanoma of foot,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188076009,Malignant melanoma of toe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,188077000,Malignant melanoma of great toe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,189758001,Melanoma in situ,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,231834005,Malignant melanoma of eyelid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,254731001,Nodular melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,254732008,Acral lentiginous melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,254896002,Malignant melanoma of vulva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,255004001,Malignant melanoma of conjunctiva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,255012009,Malignant melanoma of iris,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,255015006,Malignant melanoma of ciliary body,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,255021005,Malignant melanoma of choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,269578002,Malignant melanoma of head and neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,269579005,Malignant melanoma of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,269580008,Malignant melanoma of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,269581007,Malignant melanoma of lower limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,274087000,MM (malignant melanoma) of eye,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,276751004,Amelanotic melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,276821000,Malignant melanoma of anus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,276822007,Malignant melanoma of rectum,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,302837001,Lentigo maligna melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,310498001,Malignant melanoma of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,312941005,Melanoma associated retinopathy,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,313248004,Malignant melanoma of chest wall,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,314976006,Local recurrence of malignant melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,314987003,Metastasis from malignant melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,315036008,Melanoma in situ of back of hand,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,315230006,Melanoma in situ of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,372158004,"Malignant melanoma, metastatic",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,427858005,Family history of malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,443493003,Metastatic malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,449636007,Malignant melanoma of skin of lower leg,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,449637003,Malignant melanoma of skin of upper arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,698040004,Malignant melanoma of nasal cavity,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,1197324006,Metastatic malignant melanoma to skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,351961000119109,Malignant melanoma of skin of right arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,352211000119108,Malignant melanoma of skin of left ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,546881000000105,Malignant melanoma of skin NOS,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,956331000000107,Malignant melanoma stage IA,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,956351000000100,Malignant melanoma stage IB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,956371000000109,Malignant melanoma stage IIA,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,956391000000108,Malignant melanoma stage IIB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,956451000000107,Malignant melanoma stage IIIB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,956471000000103,Malignant melanoma stage IIIC,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,956511000000107,Malignant melanoma stage IV M1a,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,956551000000106,Malignant melanoma stage IV M1c,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,1080941000119109,Malignant melanoma of left choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Advanced melanoma not previously treated with ipilimumab,TA366,melanoma,1080981000119104,Malignant melanoma of right choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,TA519,urothelial carcinoma,12400006,Papillary urothelial carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,TA692,urothelial carcinoma,12400006,Papillary urothelial carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,TA519,urothelial carcinoma,27090000,Urothelial carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,TA692,urothelial carcinoma,27090000,Urothelial carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,TA519,urothelial carcinoma,1259709004,Primary micropapillary urothelial carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy,TA692,urothelial carcinoma,1259709004,Primary micropapillary urothelial carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,915007,Malignant melanoma in junctional naevus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,1556006,Clark melanoma level 4,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,2092003,Malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,2142002,Nodular melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,16974005,"Acral lentiginous melanoma, malignant",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,21119008,Benign melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,21165006,Clark melanoma level 3,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,37138001,Epithelioid cell melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,39896009,"Malignant melanoma, regressing",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,44474009,Lentigo maligna melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,50542000,Clark melanoma level 2,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,50813003,Spitz melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,51757004,"Desmoplastic melanoma, amelanotic",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,55320002,Superficial spreading melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,68827007,Spindle cell melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,70594002,Amelanotic melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,77986002,Melanoma in situ,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93209006,Malignant melanoma of perianal skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93214005,Malignant melanoma of skin of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93217003,Malignant melanoma of skin of cheek,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93220006,Malignant melanoma of skin of ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93221005,Malignant melanoma of skin of elbow,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93223008,Malignant melanoma of eyebrow,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93225001,Malignant melanoma of skin of face,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93227009,Malignant melanoma of skin of foot,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93228004,Malignant melanoma of skin of forearm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93642000,Malignant melanoma of skin of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93643005,Malignant melanoma of external surface of nose,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93646002,Malignant melanoma of skin of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93647006,Malignant melanoma of skin of shoulder,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93651008,Malignant melanoma of skin of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93653006,Malignant melanoma of skin of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93654000,Malignant melanoma of skin of wrist,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,93655004,MM (malignant melanoma) of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,106243009,Breslow depth staging for melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,109266006,Melanoma in situ of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,109270003,Melanoma in situ of face,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,109272006,Melanoma in situ of lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,109276009,Melanoma in situ of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,109278005,Melanoma in situ of ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,109282007,Melanoma in situ of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,109284008,Melanoma in situ of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,109290007,Melanoma in situ of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,109294003,Melanoma in situ of lower limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,127330008,Melanoma in situ by body site (clinical),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,161432005,History of malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,177281002,Excision of melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188030005,Malignant melanoma of lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188033007,Malignant melanoma of auricle (ear),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188034001,Malignant melanoma of external auditory meatus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188038003,Malignant melanoma of chin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188040008,Malignant melanoma of forehead,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188042000,Malignant melanoma of temple,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188044004,Malignant melanoma of scalp and/or neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188045003,Malignant melanoma of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188046002,Malignant melanoma of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188049009,Malignant melanoma of axilla,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188050009,Malignant melanoma of breast,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188051008,Malignant melanoma of buttock,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188052001,Malignant melanoma of groin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188054000,Malignant melanoma of perineum,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188055004,Malignant melanoma of umbilicus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188060000,Malignant melanoma of shoulder,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188061001,Malignant melanoma of upper arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188062008,Malignant melanoma of forearm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188063003,Malignant melanoma of hand,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188064009,Malignant melanoma of finger,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188065005,Malignant melanoma of thumb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188067002,Malignant melanoma of lower limb and hip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188068007,Malignant melanoma of hip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188069004,Malignant melanoma of thigh,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188070003,Malignant melanoma of knee,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188071004,Malignant melanoma of popliteal fossa area,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188072006,Malignant melanoma of lower leg,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188073001,Malignant melanoma of ankle,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188074007,Malignant melanoma of heel,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188075008,Malignant melanoma of foot,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188076009,Malignant melanoma of toe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,188077000,Malignant melanoma of great toe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,189758001,Melanoma in situ,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,231834005,Malignant melanoma of eyelid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,254731001,Nodular melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,254732008,Acral lentiginous melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,254896002,Malignant melanoma of vulva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,255004001,Malignant melanoma of conjunctiva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,255012009,Malignant melanoma of iris,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,255015006,Malignant melanoma of ciliary body,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,255021005,Malignant melanoma of choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,269578002,Malignant melanoma of head and neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,269579005,Malignant melanoma of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,269580008,Malignant melanoma of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,269581007,Malignant melanoma of lower limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,274087000,MM (malignant melanoma) of eye,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,276751004,Amelanotic melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,276821000,Malignant melanoma of anus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,276822007,Malignant melanoma of rectum,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,302837001,Lentigo maligna melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,310498001,Malignant melanoma of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,312941005,Melanoma associated retinopathy,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,313248004,Malignant melanoma of chest wall,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,314976006,Local recurrence of malignant melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,314987003,Metastasis from malignant melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,315036008,Melanoma in situ of back of hand,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,315230006,Melanoma in situ of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,372158004,"Malignant melanoma, metastatic",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,427858005,Family history of malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,443493003,Metastatic malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,449636007,Malignant melanoma of skin of lower leg,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,449637003,Malignant melanoma of skin of upper arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,698040004,Malignant melanoma of nasal cavity,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,1197324006,Metastatic malignant melanoma to skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,351961000119109,Malignant melanoma of skin of right arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,352211000119108,Malignant melanoma of skin of left ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,546881000000105,Malignant melanoma of skin NOS,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,956331000000107,Malignant melanoma stage IA,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,956351000000100,Malignant melanoma stage IB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,956371000000109,Malignant melanoma stage IIA,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,956391000000108,Malignant melanoma stage IIB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,956451000000107,Malignant melanoma stage IIIB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,956471000000103,Malignant melanoma stage IIIC,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,956511000000107,Malignant melanoma stage IV M1a,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,956551000000106,Malignant melanoma stage IV M1c,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,1080941000119109,Malignant melanoma of left choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Melanoma with high risk of recurrence,TA553,melanoma,1080981000119104,Malignant melanoma of right choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,134405005,Suspected breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,160287004,FH: Breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,268547008,Screening for breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,429740004,Family history of breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,431330007,Family history of breast cancer 1 gene mutation,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,431331006,Family history of breast cancer 2 gene mutation,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,706970001,TNBC - Triple-negative breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,94361000000105,Breast cancer detected by national screening programme,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,276341000000100,Fast track referral for suspected breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,838351000000107,Education about risk of breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,874291000000100,QCancer breast cancer risk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer,TA851,breast cancer,1035841000000108,Lymphoedema following breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,162573006,Suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,275981009,Lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,429011007,Family history of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,PD-L1-positive non-small-cell lung cancer after chemotherapy,TA428,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,10288008,Squamous cell carcinoma - spindle cell,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,12478003,Microinvasive squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,18048008,"Squamous cell carcinoma, keratinising",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,35718007,"Squamous cell carcinoma, small cell, nonkeratinizing",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,37304002,Mixed basal-squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,39056008,Papillary squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,59529006,Squamous cell carcinoma in situ,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,64204000,Metastatic squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,65692009,Polypoid squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,85956000,Pseudoglandular squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,89906000,Verrucous SCC (squamous cell carcinoma),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,231830001,Squamous cell carcinoma in situ of eyelid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,231831002,Squamous cell carcinoma of eyelid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,254620000,Squamous cell carcinoma of trachea,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,254634000,Squamous cell carcinoma of lung,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,254652000,Clear cell squamous cell carcinoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,254654004,Acantholytic squamous cell carcinoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,254886006,Squamous cell carcinoma of cervix,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,255003007,Squamous cell carcinoma of conjunctiva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,255071008,Squamous cell carcinoma of lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,255111004,Squamous cell carcinoma of urinary bladder,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,276804009,Squamous cell carcinoma of esophagus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,276860003,Squamous cell carcinoma of scrotum,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,276952000,Squamous cell carcinoma of tongue,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,276953005,Squamous cell carcinoma of gingiva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,276954004,Squamous cell carcinoma of floor of mouth,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,276962007,Squamous cell carcinoma of palate,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,285307007,Squamous cell carcinoma of skin of upper lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,285308002,Squamous cell carcinoma of skin of lower lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,285309005,Squamous cell carcinoma of skin of cheek,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,300987004,Disseminated squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,307502000,Squamous cell carcinoma of mouth,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,313353007,Squamous cell carcinoma of bronchus in left lower lobe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,313354001,Squamous cell carcinoma of bronchus in left upper lobe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,313355000,Squamous cell carcinoma of bronchus in right lower lobe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,313356004,Squamous cell carcinoma of bronchus of middle lobe of right lung,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,313357008,Squamous cell carcinoma of bronchus in right upper lobe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,400066006,Intraepithelial squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,400155002,Squamous cell carcinoma - category,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,402815007,Squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,402816008,Squamous cell carcinoma of anogenital area,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,403901001,Acantholytic squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,403904009,Verrucous squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,403906006,Metastatic squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,408649007,Squamous cell carcinoma of pharynx,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,422599000,Squamous cell carcinoma of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,423700001,Squamous cell carcinoma of auricle,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,698011002,Keratinizing squamous cell carcinoma of nasopharynx,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,700193001,Family history of squamous cell carcinoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,707388009,Primary squamous cell carcinoma of trachea,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,707429002,Overlapping squamous cell carcinoma of larynx,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,707576008,Primary squamous cell carcinoma of subglottis,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,707581004,Primary papillary squamous cell carcinoma of oropharynx,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,707662004,Primary basaloid squamous cell carcinoma of larynx,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,716659002,Squamous cell carcinoma of head and neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,719052006,Recurrent SCC (squamous cell carcinoma),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,721618006,Primary squamous cell carcinoma of upper third of esophagus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,722530005,Primary squamous cell carcinoma of adenoid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,722542000,Primary squamous cell carcinoma of anal canal,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,722672002,Primary squamous cell carcinoma of root of tongue,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,722673007,Primary squamous cell carcinoma of lingual tonsil,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,722674001,Primary squamous cell carcinoma of parotid gland,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,723182009,Primary squamous cell carcinoma of nasal cavity,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,723265000,Primary squamous cell carcinoma of anus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,733343005,Primary squamous cell carcinoma of oral cavity,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,1254755004,Metastatic basosquamous cell carcinoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,1255632004,Spindle cell squamous cell carcinoma of larynx,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,18121000119104,Primary squamous cell carcinoma of palatine tonsil,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,78461000119105,Metastatic squamous cell carcinoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,91271000119101,Metastatic squamous cell carcinoma of bone,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,105041000119109,Metastatic squamous cell carcinoma to lung,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,688851000119108,Primary squamous cell carcinoma of glans penis,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,689361000119108,Primary squamous cell carcinoma of tonsillar fossa,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,878441000000101,No FH of squamous cell carcinoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,1014611000000103,Squamous cell carcinoma antigen level,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,1082071000119102,Primary squamous cell carcinoma of left ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy,TA570,squamous cell carcinoma,12240991000119102,Squamous cell carcinoma of right lung,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA540,hodgkin lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA540,hodgkin lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA540,hodgkin lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA540,hodgkin lymphoma,118601006,Non-Hodgkin lymphoma,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA540,hodgkin lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA540,hodgkin lymphoma,128929007,Non-Hodgkin lymphoma - category,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA540,hodgkin lymphoma,128930002,Hodgkin lymphoma - category,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA540,hodgkin lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA540,hodgkin lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA540,hodgkin lymphoma,433450000,Family history of non-Hodgkin lymphoma,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA540,hodgkin lymphoma,448709005,Non-Hodgkin lymphoma of stomach,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma,TA540,hodgkin lymphoma,762690000,Classical Hodgkin lymphoma,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,TA772,hodgkin lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,TA772,hodgkin lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,TA772,hodgkin lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,TA772,hodgkin lymphoma,118601006,Non-Hodgkin lymphoma,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,TA772,hodgkin lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,TA772,hodgkin lymphoma,128929007,Non-Hodgkin lymphoma - category,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,TA772,hodgkin lymphoma,128930002,Hodgkin lymphoma - category,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,TA772,hodgkin lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,TA772,hodgkin lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,TA772,hodgkin lymphoma,433450000,Family history of non-Hodgkin lymphoma,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,TA772,hodgkin lymphoma,448709005,Non-Hodgkin lymphoma of stomach,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PEMBROLIZUMAB,Relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies,TA772,hodgkin lymphoma,762690000,Classical Hodgkin lymphoma,PEMBROLIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,915007,Malignant melanoma in junctional naevus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,1556006,Clark melanoma level 4,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,2092003,Malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,2142002,Nodular melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,16974005,"Acral lentiginous melanoma, malignant",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,21119008,Benign melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,21165006,Clark melanoma level 3,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,37138001,Epithelioid cell melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,39896009,"Malignant melanoma, regressing",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,44474009,Lentigo maligna melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,50542000,Clark melanoma level 2,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,50813003,Spitz melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,51757004,"Desmoplastic melanoma, amelanotic",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,55320002,Superficial spreading melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,68827007,Spindle cell melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,70594002,Amelanotic melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,77986002,Melanoma in situ,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93209006,Malignant melanoma of perianal skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93214005,Malignant melanoma of skin of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93217003,Malignant melanoma of skin of cheek,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93220006,Malignant melanoma of skin of ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93221005,Malignant melanoma of skin of elbow,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93223008,Malignant melanoma of eyebrow,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93225001,Malignant melanoma of skin of face,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93227009,Malignant melanoma of skin of foot,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93228004,Malignant melanoma of skin of forearm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93642000,Malignant melanoma of skin of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93643005,Malignant melanoma of external surface of nose,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93646002,Malignant melanoma of skin of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93647006,Malignant melanoma of skin of shoulder,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93651008,Malignant melanoma of skin of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93653006,Malignant melanoma of skin of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93654000,Malignant melanoma of skin of wrist,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,93655004,MM (malignant melanoma) of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,106243009,Breslow depth staging for melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,109266006,Melanoma in situ of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,109270003,Melanoma in situ of face,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,109272006,Melanoma in situ of lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,109276009,Melanoma in situ of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,109278005,Melanoma in situ of ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,109282007,Melanoma in situ of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,109284008,Melanoma in situ of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,109290007,Melanoma in situ of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,109294003,Melanoma in situ of lower limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,127330008,Melanoma in situ by body site (clinical),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,161432005,History of malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,177281002,Excision of melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188030005,Malignant melanoma of lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188033007,Malignant melanoma of auricle (ear),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188034001,Malignant melanoma of external auditory meatus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188038003,Malignant melanoma of chin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188040008,Malignant melanoma of forehead,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188042000,Malignant melanoma of temple,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188044004,Malignant melanoma of scalp and/or neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188045003,Malignant melanoma of scalp,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188046002,Malignant melanoma of neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188049009,Malignant melanoma of axilla,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188050009,Malignant melanoma of breast,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188051008,Malignant melanoma of buttock,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188052001,Malignant melanoma of groin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188054000,Malignant melanoma of perineum,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188055004,Malignant melanoma of umbilicus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188060000,Malignant melanoma of shoulder,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188061001,Malignant melanoma of upper arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188062008,Malignant melanoma of forearm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188063003,Malignant melanoma of hand,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188064009,Malignant melanoma of finger,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188065005,Malignant melanoma of thumb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188067002,Malignant melanoma of lower limb and hip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188068007,Malignant melanoma of hip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188069004,Malignant melanoma of thigh,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188070003,Malignant melanoma of knee,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188071004,Malignant melanoma of popliteal fossa area,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188072006,Malignant melanoma of lower leg,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188073001,Malignant melanoma of ankle,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188074007,Malignant melanoma of heel,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188075008,Malignant melanoma of foot,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188076009,Malignant melanoma of toe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,188077000,Malignant melanoma of great toe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,189758001,Melanoma in situ,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,231834005,Malignant melanoma of eyelid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,254731001,Nodular melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,254732008,Acral lentiginous melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,254896002,Malignant melanoma of vulva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,255004001,Malignant melanoma of conjunctiva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,255012009,Malignant melanoma of iris,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,255015006,Malignant melanoma of ciliary body,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,255021005,Malignant melanoma of choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,269578002,Malignant melanoma of head and neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,269579005,Malignant melanoma of trunk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,269580008,Malignant melanoma of upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,269581007,Malignant melanoma of lower limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,274087000,MM (malignant melanoma) of eye,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,276751004,Amelanotic melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,276821000,Malignant melanoma of anus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,276822007,Malignant melanoma of rectum,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,302837001,Lentigo maligna melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,310498001,Malignant melanoma of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,312941005,Melanoma associated retinopathy,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,313248004,Malignant melanoma of chest wall,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,314976006,Local recurrence of malignant melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,314987003,Metastasis from malignant melanoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,315036008,Melanoma in situ of back of hand,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,315230006,Melanoma in situ of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,372158004,"Malignant melanoma, metastatic",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,427858005,Family history of malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,443493003,Metastatic malignant melanoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,449636007,Malignant melanoma of skin of lower leg,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,449637003,Malignant melanoma of skin of upper arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,698040004,Malignant melanoma of nasal cavity,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,1197324006,Metastatic malignant melanoma to skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,351961000119109,Malignant melanoma of skin of right arm,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,352211000119108,Malignant melanoma of skin of left ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,546881000000105,Malignant melanoma of skin NOS,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,956331000000107,Malignant melanoma stage IA,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,956351000000100,Malignant melanoma stage IB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,956371000000109,Malignant melanoma stage IIA,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,956391000000108,Malignant melanoma stage IIB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,956451000000107,Malignant melanoma stage IIIB,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,956471000000103,Malignant melanoma stage IIIC,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,956511000000107,Malignant melanoma stage IV M1a,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,956551000000106,Malignant melanoma stage IV M1c,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,1080941000119109,Malignant melanoma of left choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Treating advanced melanoma after disease progression with ipilimumab,TA357,melanoma,1080981000119104,Malignant melanoma of right choroid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,162573006,Suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,162573006,Suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,275981009,Lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,275981009,Lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,429011007,Family history of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,429011007,Family history of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA447,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated PD-L1-positive metastatic non-small-cell lung cancer,TA531,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,10288008,Squamous cell carcinoma - spindle cell,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,12478003,Microinvasive squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,18048008,"Squamous cell carcinoma, keratinising",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,35718007,"Squamous cell carcinoma, small cell, nonkeratinizing",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,37304002,Mixed basal-squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,39056008,Papillary squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,59529006,Squamous cell carcinoma in situ,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,64204000,Metastatic squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,65692009,Polypoid squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,85956000,Pseudoglandular squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,89906000,Verrucous SCC (squamous cell carcinoma),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,231830001,Squamous cell carcinoma in situ of eyelid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,231831002,Squamous cell carcinoma of eyelid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,254620000,Squamous cell carcinoma of trachea,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,254634000,Squamous cell carcinoma of lung,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,254652000,Clear cell squamous cell carcinoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,254654004,Acantholytic squamous cell carcinoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,254886006,Squamous cell carcinoma of cervix,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,255003007,Squamous cell carcinoma of conjunctiva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,255071008,Squamous cell carcinoma of lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,255111004,Squamous cell carcinoma of urinary bladder,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,276804009,Squamous cell carcinoma of esophagus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,276860003,Squamous cell carcinoma of scrotum,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,276952000,Squamous cell carcinoma of tongue,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,276953005,Squamous cell carcinoma of gingiva,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,276954004,Squamous cell carcinoma of floor of mouth,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,276962007,Squamous cell carcinoma of palate,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,285307007,Squamous cell carcinoma of skin of upper lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,285308002,Squamous cell carcinoma of skin of lower lip,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,285309005,Squamous cell carcinoma of skin of cheek,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,300987004,Disseminated squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,307502000,Squamous cell carcinoma of mouth,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,313353007,Squamous cell carcinoma of bronchus in left lower lobe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,313354001,Squamous cell carcinoma of bronchus in left upper lobe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,313355000,Squamous cell carcinoma of bronchus in right lower lobe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,313356004,Squamous cell carcinoma of bronchus of middle lobe of right lung,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,313357008,Squamous cell carcinoma of bronchus in right upper lobe,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,400066006,Intraepithelial squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,400155002,Squamous cell carcinoma - category,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,402815007,Squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,402816008,Squamous cell carcinoma of anogenital area,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,403901001,Acantholytic squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,403904009,Verrucous squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,403906006,Metastatic squamous cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,408649007,Squamous cell carcinoma of pharynx,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,422599000,Squamous cell carcinoma of back,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,423700001,Squamous cell carcinoma of auricle,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,698011002,Keratinizing squamous cell carcinoma of nasopharynx,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,700193001,Family history of squamous cell carcinoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,707388009,Primary squamous cell carcinoma of trachea,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,707429002,Overlapping squamous cell carcinoma of larynx,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,707576008,Primary squamous cell carcinoma of subglottis,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,707581004,Primary papillary squamous cell carcinoma of oropharynx,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,707662004,Primary basaloid squamous cell carcinoma of larynx,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,716659002,Squamous cell carcinoma of head and neck,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,719052006,Recurrent SCC (squamous cell carcinoma),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,721618006,Primary squamous cell carcinoma of upper third of esophagus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,722530005,Primary squamous cell carcinoma of adenoid,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,722542000,Primary squamous cell carcinoma of anal canal,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,722672002,Primary squamous cell carcinoma of root of tongue,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,722673007,Primary squamous cell carcinoma of lingual tonsil,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,722674001,Primary squamous cell carcinoma of parotid gland,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,723182009,Primary squamous cell carcinoma of nasal cavity,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,723265000,Primary squamous cell carcinoma of anus,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,733343005,Primary squamous cell carcinoma of oral cavity,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,1254755004,Metastatic basosquamous cell carcinoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,1255632004,Spindle cell squamous cell carcinoma of larynx,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,18121000119104,Primary squamous cell carcinoma of palatine tonsil,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,78461000119105,Metastatic squamous cell carcinoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,91271000119101,Metastatic squamous cell carcinoma of bone,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,105041000119109,Metastatic squamous cell carcinoma to lung,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,688851000119108,Primary squamous cell carcinoma of glans penis,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,689361000119108,Primary squamous cell carcinoma of tonsillar fossa,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,878441000000101,No FH of squamous cell carcinoma of skin,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,1014611000000103,Squamous cell carcinoma antigen level,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,1082071000119102,Primary squamous cell carcinoma of left ear,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,Untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma,TA661,squamous cell carcinoma,12240991000119102,Squamous cell carcinoma of right lung,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|ENT|CLINICAL ONCOLOGY
PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,162573006,Suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,275981009,Lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,429011007,Family history of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA557,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,134405005,Suspected breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,160287004,FH: Breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,268547008,Screening for breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,429740004,Family history of breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,431330007,Family history of breast cancer 1 gene mutation,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,431331006,Family history of breast cancer 2 gene mutation,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,706970001,TNBC - Triple-negative breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,94361000000105,Breast cancer detected by national screening programme,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,276341000000100,Fast track referral for suspected breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,838351000000107,Education about risk of breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,874291000000100,QCancer breast cancer risk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB PLUS CHEMOTHERAPY,"Untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer",TA801,breast cancer,1035841000000108,Lymphoedema following breast cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH AXITINIB,Untreated advanced renal cell carcinoma,TA650,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH AXITINIB,Untreated advanced renal cell carcinoma,TA650,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH AXITINIB,Untreated advanced renal cell carcinoma,TA650,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH AXITINIB,Untreated advanced renal cell carcinoma,TA650,renal cell carcinoma,733608000,Papillary renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH AXITINIB,Untreated advanced renal cell carcinoma,TA650,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH AXITINIB,Untreated advanced renal cell carcinoma,TA650,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH AXITINIB,Untreated advanced renal cell carcinoma,TA650,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,162573006,Suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,162573006,Suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,275981009,Lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,275981009,Lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,429011007,Family history of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,429011007,Family history of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA600,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH CARBOPLATIN AND PACLITAXEL,Untreated metastatic squamous non-small-cell lung cancer,TA770,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,162573006,Suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,275981009,Lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,429011007,Family history of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH PEMETREXED AND PLATINUM CHEMOTHERAPY,"Untreated, metastatic, non-squamous non-small-cell lung cancer",TA683,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMBROLIZUMAB WITH PLATINUM- AND FLUOROPYRIMIDINE-BASED CHEMOTHERAPY,Untreated advanced oesophageal and gastro-oesophageal junction cancer,TA737,gastro-oesophageal junction,427421001,Fibreoptic endoscopic endoluminal plication of gastro-oesophageal junction,PEMBROLIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,162573006,Suspected lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,275981009,Lung cancer screening,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,429011007,Family history of lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer,TA309,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,162573006,Suspected lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,275981009,Lung cancer screening,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,429011007,Family history of lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED,Non-squamous non-small-cell lung cancer after pemetrexed and cisplatin,TA402,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED (2ND LINE),Non-small cell lung cancer,TA124,non-small cell lung cancer,254637007,Non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED (2ND LINE),Non-small cell lung cancer,TA124,non-small cell lung cancer,723301009,Squamous non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED (2ND LINE),Non-small cell lung cancer,TA124,non-small cell lung cancer,1259727001,Primary non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED (2ND LINE),Non-small cell lung cancer,TA124,non-small cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,162573006,Suspected lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,275981009,Lung cancer screening,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,429011007,Family history of lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED (MAINTENANCE TREATMENT),Non-small-cell lung cancer,TA190,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED DISODIUM,Malignant pleural mesothelioma,TA135,malignant pleural mesothelioma,254645002,Malignant pleural mesothelioma,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,162573006,Suspected lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,275981009,Lung cancer screening,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,429011007,Family history of lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMETREXED IN COMBINATION WITH CISPLATIN (1ST LINE),Locally advanced or metastatic non-small-cell lung cancer,TA181,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PEMETREXED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PEMIGATINIB,Relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement,TA722,cholangiocarcinoma,52178006,Hepatocholangiocarcinoma,PEMIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
PEMIGATINIB,Relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement,TA722,cholangiocarcinoma,253017000,Hilar cholangiocarcinoma,PEMIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
PEMIGATINIB,Relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement,TA722,cholangiocarcinoma,274902006,Hepatocholangiocarcinoma,PEMIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
PEMIGATINIB,Relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement,TA722,cholangiocarcinoma,312104005,Cholangiocarcinoma,PEMIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
PEMIGATINIB,Relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement,TA722,cholangiocarcinoma,721716004,Primary intrahepatic cholangiocarcinoma,PEMIGATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
PENTOXIFYLLINE,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,822611000000100,Exception reporting - peripheral arterial disease quality indicators,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
PENTOXIFYLLINE,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,822641000000104,Excepted from peripheral arterial disease quality indicators - patient unsuitable,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
PENTOXIFYLLINE,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,822671000000105,Excepted from peripheral arterial disease quality indicators - informed dissent,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
PENTOXIFYLLINE,Intermittent claudication in people with peripheral arterial disease,TA223,peripheral arterial disease,968121000000103,Peripheral arterial disease screening,NAFTIDROFYRYL,VASCULAR SURGERY,VASCULAR SURGERY|CARDIOLOGY
PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,134405005,Suspected breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,160287004,FH: Breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,268547008,Screening for breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,429740004,Family history of breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,431330007,Family history of breast cancer 1 gene mutation,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,431331006,Family history of breast cancer 2 gene mutation,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,706970001,TNBC - Triple-negative breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,94361000000105,Breast cancer detected by national screening programme,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,276341000000100,Fast track referral for suspected breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,838351000000107,Education about risk of breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,874291000000100,QCancer breast cancer risk,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB,Adjuvant treatment of HER2-positive early stage breast cancer,TA569,breast cancer,1035841000000108,Lymphoedema following breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,134405005,Suspected breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,160287004,FH: Breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,268547008,Screening for breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,429740004,Family history of breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,431330007,Family history of breast cancer 1 gene mutation,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,431331006,Family history of breast cancer 2 gene mutation,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,706970001,TNBC - Triple-negative breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,94361000000105,Breast cancer detected by national screening programme,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,276341000000100,Fast track referral for suspected breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,838351000000107,Education about risk of breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,874291000000100,QCancer breast cancer risk,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND CHEMOTHERAPY,Neoadjuvant treatment of HER2-positive breast cancer,TA424,breast cancer,1035841000000108,Lymphoedema following breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,134405005,Suspected breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,160287004,FH: Breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,268547008,Screening for breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,429740004,Family history of breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,431330007,Family history of breast cancer 1 gene mutation,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,431331006,Family history of breast cancer 2 gene mutation,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,706970001,TNBC - Triple-negative breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,94361000000105,Breast cancer detected by national screening programme,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,276341000000100,Fast track referral for suspected breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,838351000000107,Education about risk of breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,874291000000100,QCancer breast cancer risk,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PERTUZUMAB IN COMBINATION WITH TRASTUZUMAB AND DOCETAXEL,HER2-positive breast cancer,TA509,breast cancer,1035841000000108,Lymphoedema following breast cancer,PERTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
PIMECROLIMUS,Atopic dermatitis (eczema),TA082,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,PIMECROLIMUS,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
PIMECROLIMUS,Atopic dermatitis (eczema),TA082,atopic dermatitis,238543002,Discoid atopic dermatitis,PIMECROLIMUS,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
PIMECROLIMUS,Atopic dermatitis (eczema),TA082,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,PIMECROLIMUS,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
PIMECROLIMUS,Atopic dermatitis (eczema),TA082,atopic dermatitis,238545009,Follicular atopic dermatitis,PIMECROLIMUS,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
PIMECROLIMUS,Atopic dermatitis (eczema),TA082,atopic dermatitis,238546005,Pruriginous atopic dermatitis,PIMECROLIMUS,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
PIMECROLIMUS,Atopic dermatitis (eczema),TA082,atopic dermatitis,584621000000108,Atopic dermatitis NOS,PIMECROLIMUS,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE,Type 2 Diabetes,TA021,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIOGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
PIRFENIDONE,Idiopathic pulmonary fibrosis,TA282,pulmonary fibrosis,90610005,Interstitial pulmonary fibrosis of prematurity,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE
PIRFENIDONE,Idiopathic pulmonary fibrosis,TA504,pulmonary fibrosis,90610005,Interstitial pulmonary fibrosis of prematurity,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE
PIRFENIDONE,Idiopathic pulmonary fibrosis,TA282,pulmonary fibrosis,196028003,Chronic pulmonary fibrosis caused by chemical fumes,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE
PIRFENIDONE,Idiopathic pulmonary fibrosis,TA504,pulmonary fibrosis,196028003,Chronic pulmonary fibrosis caused by chemical fumes,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE
PIRFENIDONE,Idiopathic pulmonary fibrosis,TA282,pulmonary fibrosis,196125002,Diffuse interstitial pulmonary fibrosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE
PIRFENIDONE,Idiopathic pulmonary fibrosis,TA504,pulmonary fibrosis,196125002,Diffuse interstitial pulmonary fibrosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE
PIRFENIDONE,Idiopathic pulmonary fibrosis,TA282,pulmonary fibrosis,233724002,Chemical-induced diffuse interstitial pulmonary fibrosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE
PIRFENIDONE,Idiopathic pulmonary fibrosis,TA504,pulmonary fibrosis,233724002,Chemical-induced diffuse interstitial pulmonary fibrosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE
PIRFENIDONE,Idiopathic pulmonary fibrosis,TA282,pulmonary fibrosis,233725001,Drug-induced diffuse interstitial pulmonary fibrosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE
PIRFENIDONE,Idiopathic pulmonary fibrosis,TA504,pulmonary fibrosis,233725001,Drug-induced diffuse interstitial pulmonary fibrosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE
PIRFENIDONE,Idiopathic pulmonary fibrosis,TA282,pulmonary fibrosis,233726000,Localised pulmonary fibrosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE
PIRFENIDONE,Idiopathic pulmonary fibrosis,TA504,pulmonary fibrosis,233726000,Localised pulmonary fibrosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE
PIRFENIDONE,Idiopathic pulmonary fibrosis,TA282,pulmonary fibrosis,233770009,Pulmonary fibrosis due to sarcoidosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE
PIRFENIDONE,Idiopathic pulmonary fibrosis,TA504,pulmonary fibrosis,233770009,Pulmonary fibrosis due to sarcoidosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE
PIRFENIDONE,Idiopathic pulmonary fibrosis,TA282,pulmonary fibrosis,266368002,Post-inflammatory pulmonary fibrosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE
PIRFENIDONE,Idiopathic pulmonary fibrosis,TA504,pulmonary fibrosis,266368002,Post-inflammatory pulmonary fibrosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE
PIRFENIDONE,Idiopathic pulmonary fibrosis,TA282,pulmonary fibrosis,700250006,IPF - idiopathic pulmonary fibrosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE
PIRFENIDONE,Idiopathic pulmonary fibrosis,TA504,pulmonary fibrosis,700250006,IPF - idiopathic pulmonary fibrosis,PIRFENIDONE,THORACIC MEDICINE,THORACIC MEDICINE
PITOLISANT HYDROCHLORIDE,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA776,sleep apnoea,79280005,Hypersomnia with sleep apnoea,PITOLISANT,THORACIC MEDICINE,THORACIC MEDICINE|ENT
PITOLISANT HYDROCHLORIDE,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA776,sleep apnoea,206750008,Sleep apnoea syndrome,PITOLISANT,THORACIC MEDICINE,THORACIC MEDICINE|ENT
PITOLISANT HYDROCHLORIDE,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA776,sleep apnoea,230493001,Complex sleep apnoea,PITOLISANT,THORACIC MEDICINE,THORACIC MEDICINE|ENT
PITOLISANT HYDROCHLORIDE,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA776,sleep apnoea,230494007,Alveolar sleep apnoea,PITOLISANT,THORACIC MEDICINE,THORACIC MEDICINE|ENT
PITOLISANT HYDROCHLORIDE,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA776,sleep apnoea,232531007,Pharyngeal operation for obstructive sleep apnoea and snoring,PITOLISANT,THORACIC MEDICINE,THORACIC MEDICINE|ENT
PITOLISANT HYDROCHLORIDE,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA776,sleep apnoea,361208003,Primary sleep apnoea of newborn,PITOLISANT,THORACIC MEDICINE,THORACIC MEDICINE|ENT
PITOLISANT HYDROCHLORIDE,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA776,sleep apnoea,774068004,"AHDC1-related intellectual disability, obstructive sleep apnoea, mild dysmorphism syndrome",PITOLISANT,THORACIC MEDICINE,THORACIC MEDICINE|ENT
PITOLISANT HYDROCHLORIDE,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA776,sleep apnoea,502901000000102,[D]Sleep apnoea syndrome,PITOLISANT,THORACIC MEDICINE,THORACIC MEDICINE|ENT
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,835009,Angioimmunoblastic lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,1929004,"Malignant lymphoma, diffuse",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,19340000,Plasmacytic lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,20776008,Adenolymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,21964009,Lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,21983002,Struma lymphomatosa,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,28054005,Cutaneous lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,28175004,Gastric pseudolymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,30440004,Lymphoma stage I,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,31047003,Lymphomatoid papulosis,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,40411000,"Malignant lymphoma, histiocytic, nodular",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,41529000,"Classical Hodgkin lymphoma, mixed cellularity",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,46732000,"Malignant lymphoma, large cell, cleaved, diffuse",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,51092000,Malignant lymphoma lymphocytic well differentiated diffuse,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,52248008,"Classical Hodgkin lymphoma, nodular sclerosis",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,55020008,"Malignant lymphoma, mixed cell type, follicular",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,55150002,"Malignant lymphoma, nodular",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,56944001,Lymphoma stage III,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,64575004,"Malignant lymphoma, small lymphocytic, diffuse",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,66445009,Lymphoma stage IV,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,70600005,"Hodgkin lymphoma, nodular lymphocyte predominance",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,74654000,Mantle cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,76422004,Lymphoma stage II,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,92814006,B-cell CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma),PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,93191005,Malignant lymphoma of intra-abdominal lymph nodes,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,93192003,Malignant lymphoma of intrapelvic lymph nodes,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,93194002,Malignant lymphoma of lymph nodes of axilla AND/OR upper limb,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,93195001,"Malignant lymphoma of lymph nodes of head, face AND/OR neck",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,93197009,Malignant lymphoma of lymph nodes of multiple sites,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,93198004,Malignant lymphoma of spleen,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,95186006,Nodular lymphoma of intra-abdominal lymph nodes,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,95192000,Nodular lymphoma of lymph nodes of multiple sites,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,95193005,Nodular lymphoma of spleen,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,106252000,Staging classification for lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,109962001,Nonfollicular lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,109966003,"Lymphoma, immunoblastic, high grade",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,109969005,Diffuse large B-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,109975001,T-zone lymphoma (clinical),PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,109976000,Lymphoepithelioid lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,109977009,Peripheral T-cell lymphoma pleomorphic medium and large cell,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,109978004,T-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,109979007,B-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,109988003,True histiocytic lymphoma (clinical),PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,115244002,Malignant lymphoma - category,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,115245001,"Malignant lymphoma, follicular AND/OR nodular",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,118599009,"Lymphoma, Hodgkins",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,118600007,Malignant lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,118601006,Non-Hodgkin lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,118605002,"Hodgkin lymphoma, nodular lymphocyte predominance",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,118609008,Hodgkin mixed cellularity lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,118617000,Burkitt lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,128799007,"Hodgkin lymphoma, lymphocyte-rich",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,128803008,Marginal zone lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,128805001,Angiocentric natural killer cell and T-cell malignant lymphoma nasal type,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,128875000,Primary cutaneous CD30 antigen positive large T-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,128929007,Non-Hodgkin lymphoma - category,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,128930002,Hodgkin lymphoma - category,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,188609000,"Nodular lymphoma of lymph nodes of head, face and neck",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,188612002,Nodular lymphoma of lymph nodes of axilla and upper limb,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,188613007,Nodular lymphoma of lymph nodes of inguinal region and lower limb,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,188674006,Diffuse malignant lymphoma - small non-cleaved cell,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,188675007,"Malignant lymphoma, lymphocytic - poorly differentiated",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,188676008,Malignant lymphoma - mixed lymphocytic-histiocytic,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,189958005,"Lymphomatous tumour, benign",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,189962004,"Malignant lymphoma, stem cell type",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,232075002,Lymphoma of retina,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,236513009,Lymphoma of kidney,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,238994000,Drug-induced pseudolymphomatous eruption,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,239297008,Lymphomatoid granulomatosis of lung,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,239940004,Lymphomatoid granulomatosis,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,240794006,Splenic schistosomal giant cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,254372002,Ann Arbor lymphoma staging system,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,255102004,Intravascular lymphomatosis,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,258279002,Lymphoma staging symptom status values,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,269476000,Nodular lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,274905008,Mantle zone lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,276811008,Gastric lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,276815004,Lymphoma of intestine,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,276836002,Primary cerebral lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277024002,Working formulation of non-Hodgkin lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277551008,Splenic lymphoma with villous lymphocytes,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277570003,Lymphoma with spill,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277613000,Cutaneous peripheral T-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277615007,Low grade B-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277616008,Diffuse low grade B-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277617004,High grade B-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277618009,Nodular malignant lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277623009,Monocytoid B-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277624003,Follicular malignant lymphoma - mixed cell type,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277625002,Follicular malignant lymphoma - small cleaved cell,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277626001,Diffuse high grade B-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277627005,Nodular high grade B-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277637000,Large cell anaplastic lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277641001,Follicular malignant lymphoma - large cell,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277642008,Low grade T-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277643003,High grade T-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277651000,Peripheral T-cell lymphoma - pleomorphic small cell,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277654008,Enteropathy-type T-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,277664004,Malignant lymphoma of testis,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,278051002,Malignant lymphoma of thyroid gland,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,278052009,Malignant lymphoma of breast,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,302841002,Malignant lymphoma - small cell,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,303055001,"Malignant lymphoma, follicular centre cell",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,307623001,Malignant lymphoma - lymphoplasmacytic,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,308121000,Follicular lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,314922006,B-cell lymphoma morphology,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,314923001,Low grade B-cell lymphoma morphology,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,314924007,Follicular low grade B-cell lymphoma morphology,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,314925008,High grade B-cell lymphoma morphology,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,314926009,T-cell lymphoma morphology,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,314929002,Diffuse low grade B-cell lymphoma morphology,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,314934003,Diffuse high grade B-cell lymphoma morphology,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,315264005,Suspected lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,400001003,Primary cutaneous lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,400122007,CTCL - Cutaneous T-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,404111002,Lymphomatoid papulosis-associated mycosis fungoides,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,404140004,SALT type B-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,413537009,Angioimmunoblastic T-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,414166008,Natural Killer cell and T-cell malignant lymphoma nasal type,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,414780005,Mucosa-associated lymphoid tissue lymphoma of orbit,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,420788006,Vitreoretinal lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,426071002,Hodgkin lymphoma in remission,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,427141003,Malignant lymphoma in remission,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,428046009,History of non-Hodgkins lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,433450000,Family history of non-Hodgkin lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,443487006,Mantle cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,444597005,Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of stomach,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,444910004,Primary mediastinal (thymic) large B-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,445269007,Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,445406001,Hepatosplenic T-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,447100004,Marginal zone lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,448211002,Adenolymphoma of parotid gland,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,448212009,Anaplastic lymphoma kinase negative anaplastic large cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,448709005,Non-Hodgkin lymphoma of stomach,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,449074003,Lymphoma of small intestine,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,449220000,Diffuse follicle center lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,450958009,"Malignant lymphoma, diffuse large B-cell, immunoblastic",PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,721555001,Follicular lymphoma of small intestine,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,724648008,Plasmablastic lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,738770003,Anaplastic lymphoma kinase positive anaplastic large cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,762690000,Classical Hodgkin lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,763666008,Splenic marginal zone B-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,830057003,Relapsing classical Hodgkin lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,1148845007,Follicular non-Hodgkin lymphoma grade 3b,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,1148851002,Follicular lymphoma grade IIIa,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,143291000119104,Non-Hodgkin's lymphoma in remission,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,847481000000109,Follicular lymphoma grade 1,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,847631000000107,Follicular lymphoma grade 2,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,847651000000100,Follicular lymphoma grade 3,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,847691000000108,Follicular lymphoma grade 3a,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,847701000000108,Follicular lymphoma grade 3b,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,847741000000106,Diffuse large B-cell lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,878461000000100,No FH of non-Hodgkin lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,1090241000000107,Angioimmunoblastic T-cell lymphoma with dysproteinaemia,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,1091861000000100,Cutaneous follicle centre lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,1091891000000106,B-cell Hodgkin's lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PIXANTRONE MONOTHERAPY,Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma,TA306,lymphoma,1091921000000103,B-cell non-Hodgkin's lymphoma,PIXANTRONE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PLDH IN COMBINATION WITH PLATINUM,Treating recurrent ovarian cancer,TA389,ovarian cancer,423274005,Ovarian cancer stage 4,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PLDH IN COMBINATION WITH PLATINUM,Treating recurrent ovarian cancer,TA389,ovarian cancer,762997004,Suspected ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PLDH IN COMBINATION WITH PLATINUM,Treating recurrent ovarian cancer,TA389,ovarian cancer,758821000000106,No family history of ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
PLDH IN COMBINATION WITH PLATINUM,Treating recurrent ovarian cancer,TA389,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
POLATUZUMAB VEDOTIN IN COMBINATION,Untreated diffuse large B-cell lymphoma,TA874,diffuse large b-cell lymphoma,109969005,Diffuse large B-cell lymphoma,POLATUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
POLATUZUMAB VEDOTIN IN COMBINATION,Untreated diffuse large B-cell lymphoma,TA874,diffuse large b-cell lymphoma,847741000000106,Diffuse large B-cell lymphoma,POLATUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
POLATUZUMAB VEDOTIN WITH RITUXIMAB AND BENDAMUSTINE,Relapsed or refractory diffuse large B-cell lymphoma,TA649,diffuse large b-cell lymphoma,109969005,Diffuse large B-cell lymphoma,POLATUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
POLATUZUMAB VEDOTIN WITH RITUXIMAB AND BENDAMUSTINE,Relapsed or refractory diffuse large B-cell lymphoma,TA649,diffuse large b-cell lymphoma,847741000000106,Diffuse large B-cell lymphoma,POLATUZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
POMALIDOMIDE IN COMBINATION WITH DEXAMETHASONE,Relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib,TA338,multiple myeloma,230586003,Neuropathy due to multiple myeloma,POMALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
POMALIDOMIDE IN COMBINATION WITH DEXAMETHASONE,Relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib,TA338,multiple myeloma,413587002,Smoldering multiple myeloma,POMALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
POMALIDOMIDE IN COMBINATION WITH DEXAMETHASONE,Relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib,TA338,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,POMALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
POMALIDOMIDE WITH BORTEZOMIB AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA602,multiple myeloma,230586003,Neuropathy due to multiple myeloma,POMALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
POMALIDOMIDE WITH BORTEZOMIB AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA602,multiple myeloma,413587002,Smoldering multiple myeloma,POMALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
POMALIDOMIDE WITH BORTEZOMIB AND DEXAMETHASONE,Relapsed or refractory multiple myeloma,TA602,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,POMALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
"POMALIDOMIDE, IN COMBINATION WITH LOW‑DOSE DEXAMETHASONE",Multiple myeloma previously treated with lenalidomide and bortezomib,TA427,multiple myeloma,230586003,Neuropathy due to multiple myeloma,POMALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
"POMALIDOMIDE, IN COMBINATION WITH LOW‑DOSE DEXAMETHASONE",Multiple myeloma previously treated with lenalidomide and bortezomib,TA427,multiple myeloma,413587002,Smoldering multiple myeloma,POMALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
"POMALIDOMIDE, IN COMBINATION WITH LOW‑DOSE DEXAMETHASONE",Multiple myeloma previously treated with lenalidomide and bortezomib,TA427,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,POMALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
PONATINIB,Chronic myeloid leukaemia and acute lymphoblastic leukaemia,TA451,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,PONATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
PONATINIB,Chronic myeloid leukaemia and acute lymphoblastic leukaemia,TA451,acute lymphoblastic leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,PONATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS
PONATINIB,Chronic myeloid leukaemia and acute lymphoblastic leukaemia,TA451,acute lymphoblastic leukaemia,413440007,Acute lymphoblastic leukaemia - category,PONATINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,24700007,Multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,160337009,Family history of multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,192926004,Brain stem multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,192928003,Generalised multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,428700003,Primary progressive multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,438511000,Benign multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,700409000,Suspected multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,198491000000106,Multiple sclerosis review,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,515931000000104,Multiple sclerosis review declined,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PONESIMOD,Relapsing–remitting multiple sclerosis,TA767,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,PONESIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,162573006,Suspected lung cancer,PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,254637007,Non-small cell lung cancer,PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,275981009,Lung cancer screening,PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,429011007,Family history of lung cancer,PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,877691000000107,No FH of lung cancer,PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PRALSETINIB,RET fusion-positive advanced non-small-cell lung cancer,TA812,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",PRALSETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
PRASUGREL IN COMBINATION WITH ASPIRIN,Acute coronary syndromes,TA317,acute coronary syndrome,837091000000100,H/O acute coronary syndrome,PRASUGREL,CARDIOLOGY,CARDIOLOGY
PRASUGREL IN COMBINATION WITH ASPIRIN,Atherothrombotic events in people with acute coronary syndromes (prevention),TA182,acute coronary syndrome,837091000000100,H/O acute coronary syndrome,PRASUGREL,CARDIOLOGY,CARDIOLOGY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,160270001,No family history of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,161499004,H/O: cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,171405001,Examination for suspected cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,266894000,Family history of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,266995000,History of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,395048001,Cardiovascular disease monitoring not required,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417206009,Cardiovascular disease monitoring,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417287002,Cardiovascular disease interim monitoring,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417322008,Cardiovascular disease annual review,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,429284000,Cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,429785003,Cardiovascular disease health education,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,440358008,Primary prevention of CVD (cardiovascular disease),ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,441829007,Assessment for risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166701000000106,Joint British Societies cardiovascular disease risk,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,302881000000102,Cardiovascular disease annual review declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,383321000000103,Cardiovascular disease risk assessment indicated,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,492581000000108,Cardiovascular disease high risk review declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,492611000000102,Cardiovascular disease high risk review,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,752451000000100,Cardiovascular disease risk assessment by third party,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,837461000000101,High risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,845171000000108,At risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,962871000000107,Aware of overall cardiovascular disease risk,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,990301000000105,Cardiovascular disease risk assessment done,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PRAVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,16434071000119108,At increased risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
PROLONGED-RELEASE TACROLIMUS,Kidney transplant in adults,TA481,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
PROLONGED-RELEASE TACROLIMUS,Kidney transplant in adults,TA481,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
PROLONGED-RELEASE TACROLIMUS,Kidney transplant in adults,TA481,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
PROLONGED-RELEASE TACROLIMUS,Kidney transplant in adults,TA481,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
PROLONGED-RELEASE TACROLIMUS,Kidney transplant in adults,TA481,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
PROLONGED-RELEASE TACROLIMUS,Kidney transplant in adults,TA481,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
PROLONGED-RELEASE TACROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
PROLONGED-RELEASE TACROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
PROLONGED-RELEASE TACROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
PROLONGED-RELEASE TACROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
PROLONGED-RELEASE TACROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
PROLONGED-RELEASE TACROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,21782001,Drug-induced constipation,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,31499008,Chronic constipation with overflow,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,35298007,Colonic constipation,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,82934008,Chronic idiopathic constipation,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,129691005,At increased risk for constipation,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,191973007,Psychogenic constipation,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,197118003,Functional constipation,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,197119006,Acute constipation,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,197120000,Chronic constipation without overflow,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,235840008,Irritable bowel syndrome variant of childhood with constipation,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,236069009,Chronic constipation,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,236070005,Simple constipation,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,249517009,Constipation alternates with diarrhea,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,266524003,(Functional constipation) or (impacted feces),PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,440630006,Constipation predominant irritable bowel syndrome,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,443307007,Dietary education for constipation,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,448880001,Cleveland Clinic constipation score,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,847591000000107,Constipation in children clinical pathway,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
PRUCALOPRIDE,Chronic constipation (in women),TA211,constipation,1325741000000102,Constipation care indicated,PRUCALOPRIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
QUETIAPINE,Schizophrenia,TA043,schizophrenia,4926007,Schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,12939007,Chronic disorganized schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,31373002,Hebephrenic schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,31658008,Chronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,35252006,Disorganised schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,39610001,Undifferentiated schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,58214004,Schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,63181006,"Paranoid schizophrenia, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,64905009,Paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,79866005,Subchronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,83746006,Chronic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,111482003,Subchronic schizophrenia with acute exacerbations,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,111483008,"Schizophrenia, catatonic, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,111484002,Undifferentiated schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,160328009,Family history of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,161103001,Schizophrenia association member,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,161468000,History of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,191527001,Simple schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,191531007,Acute exacerbation of chronic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,191548004,Chronic catatonic schizophrenia with acute exacerbation,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,191554003,Acute exacerbation of subchronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,191555002,Acute exacerbation of chronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,191559008,Latent schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,191565008,Latent schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,191567000,Schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,191570001,Chronic schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,191572009,Acute exacerbation of chronic schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,191574005,"Schizophrenia, schizoaffective, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,247804008,Prodromal schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,274952002,Borderline schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,278853003,Acute schizophrenia-like psychotic disorder,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,444180005,History of schizophrenia in child of subject,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,712824002,Acute polymorphic psychotic disorder without symptoms of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,712850003,Acute polymorphic psychotic disorder with symptoms of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,200951000000109,"Psychosis, schizophrenia and bipolar affective disorder resolved",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,285521000000103,Schizophrenia resolved,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,417601000000102,"[X]Schizophrenia, schizotypal and delusional disorders",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,443791000000100,[X]Pseudopsychopathic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,1062101000000104,Schizophrenia TOM (Therapy Outcome Measure) activity score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,1062121000000108,Schizophrenia TOM (Therapy Outcome Measure) impairment score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,1062131000000105,Schizophrenia TOM (Therapy Outcome Measure) participation score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
QUETIAPINE,Schizophrenia,TA043,schizophrenia,1062141000000101,Schizophrenia TOM (Therapy Outcome Measure) wellbeing score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN,Kidney transplant in adults,TA481,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN,Kidney transplant in adults,TA481,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN,Kidney transplant in adults,TA481,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN,Kidney transplant in adults,TA481,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN,Kidney transplant in adults,TA481,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN,Kidney transplant in adults,TA481,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN,Kidney transplant in children and young people,TA482,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN,Kidney transplant in children and young people,TA482,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN,Kidney transplant in children and young people,TA482,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN,Kidney transplant in children and young people,TA482,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN,Kidney transplant in children and young people,TA482,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN,Kidney transplant in children and young people,TA482,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
RABEPRAZOLE,Dyspepsia,TA007,dyspepsia,3696007,Non ulcer dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
RABEPRAZOLE,Dyspepsia,TA007,dyspepsia,191972002,Psychogenic dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
RABEPRAZOLE,Dyspepsia,TA007,dyspepsia,192434000,[X]Psychogenic dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
RABEPRAZOLE,Dyspepsia,TA007,dyspepsia,196752002,Flatulent dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
RABEPRAZOLE,Dyspepsia,TA007,dyspepsia,249511005,Flatulent dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
RABEPRAZOLE,Dyspepsia,TA007,dyspepsia,299969005,Dyspepsia caused by drug,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
RABEPRAZOLE,Dyspepsia,TA007,dyspepsia,416202003,Under care of dyspepsia specialist nurse,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
RABEPRAZOLE,Dyspepsia,TA007,dyspepsia,417691002,Discharged from care of dyspepsia specialist nurse,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
RABEPRAZOLE,Dyspepsia,TA007,dyspepsia,203661000000105,Undiagnosed dyspepsia,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
RABEPRAZOLE,Dyspepsia,TA007,dyspepsia,248131000000106,Referral to dyspepsia specialist nurse,LANSOPRAZOLE,GASTROENTEROLOGY,GASTROENTEROLOGY|GENERAL MEDICINE
RADIUM-223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA376,prostate cancer,315268008,Suspected prostate cancer,RADIUM-,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
RADIUM-223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA376,prostate cancer,428262008,H/O: prostate cancer,RADIUM-,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
RADIUM-223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA376,prostate cancer,698470001,Advice given about prostate cancer screening,RADIUM-,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
RADIUM-223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA376,prostate cancer,712837004,Active surveillance of prostate cancer,RADIUM-,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
RADIUM-223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA376,prostate cancer,720007002,Prostate cancer care review,RADIUM-,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
RADIUM-223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA376,prostate cancer,31011000119107,Prostate cancer screening declined,RADIUM-,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
RADIUM-223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA376,prostate cancer,874211000000109,QCancer prostate cancer risk,RADIUM-,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
RADIUM-223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA376,prostate cancer,878401000000104,No FH of prostate cancer,RADIUM-,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
RADIUM-223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA376,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,RADIUM-,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
RADIUM-223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA376,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,RADIUM-,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
RADIUM‑223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA412,prostate cancer,315268008,Suspected prostate cancer,RADIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
RADIUM‑223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA412,prostate cancer,428262008,H/O: prostate cancer,RADIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
RADIUM‑223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA412,prostate cancer,698470001,Advice given about prostate cancer screening,RADIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
RADIUM‑223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA412,prostate cancer,712837004,Active surveillance of prostate cancer,RADIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
RADIUM‑223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA412,prostate cancer,720007002,Prostate cancer care review,RADIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
RADIUM‑223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA412,prostate cancer,31011000119107,Prostate cancer screening declined,RADIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
RADIUM‑223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA412,prostate cancer,874211000000109,QCancer prostate cancer risk,RADIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
RADIUM‑223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA412,prostate cancer,878401000000104,No FH of prostate cancer,RADIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
RADIUM‑223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA412,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,RADIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
RADIUM‑223 DICHLORIDE,Treating hormone-relapsed prostate cancer with bone metastases,TA412,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,RADIUM,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Osteoporosis - secondary prevention,TA087,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALOXIFENE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RALTITREXED,Colorectal cancer (advanced),TA033,colorectal cancer,276401000000108,Fast track referral for suspected colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
RALTITREXED,Colorectal cancer (advanced),TA093,colorectal cancer,276401000000108,Fast track referral for suspected colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
RALTITREXED,Colorectal cancer (advanced),TA033,colorectal cancer,382651000000108,Seen in fast track suspected colorectal cancer clinic,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
RALTITREXED,Colorectal cancer (advanced),TA093,colorectal cancer,382651000000108,Seen in fast track suspected colorectal cancer clinic,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
RALTITREXED,Colorectal cancer (advanced),TA033,colorectal cancer,722731000000100,Colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
RALTITREXED,Colorectal cancer (advanced),TA093,colorectal cancer,722731000000100,Colorectal cancer,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
RALTITREXED,Colorectal cancer (advanced),TA033,colorectal cancer,848861000000104,QCancer colorectal cancer risk,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
RALTITREXED,Colorectal cancer (advanced),TA093,colorectal cancer,848861000000104,QCancer colorectal cancer risk,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
RALTITREXED,Colorectal cancer (advanced),TA033,colorectal cancer,1034401000000107,Discharge from secondary care colorectal cancer service,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
RALTITREXED,Colorectal cancer (advanced),TA093,colorectal cancer,1034401000000107,Discharge from secondary care colorectal cancer service,IRINOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
RAMUCIRUMAB,Unresectable hepatocellular carcinoma after sorafenib,TA609,hepatocellular carcinoma,15619004,"Hepatocellular carcinoma, fibrolamellar",RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
RAMUCIRUMAB,Unresectable hepatocellular carcinoma after sorafenib,TA609,hepatocellular carcinoma,253018005,Fibrolamellar hepatocellular carcinoma,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
RAMUCIRUMAB,Unresectable hepatocellular carcinoma after sorafenib,TA609,hepatocellular carcinoma,990271000000107,Ultrasound scan surveillance of liver for hepatocellular carcinoma,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
RAMUCIRUMAB ALONE OR WITH PACLITAXEL,Treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy,TA378,gastric cancer,276809004,Early gastric cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
RAMUCIRUMAB ALONE OR WITH PACLITAXEL,Treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy,TA378,gastric cancer,276810009,Late gastric cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,162573006,Suspected lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,254637007,Non-small cell lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,275981009,Lung cancer screening,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,429011007,Family history of lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,877691000000107,No FH of lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB IN COMBINATION WITH DOCETAXEL,Previously treated locally advanced or metastatic non-small-cell lung cancer,TA403,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,162573006,Suspected lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,254637007,Non-small cell lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,275981009,Lung cancer screening,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,429011007,Family history of lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,877691000000107,No FH of lung cancer,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RAMUCIRUMAB WITH ERLOTINIB,Untreated EGFR mutation-positive non-small-cell lung cancer,TA635,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",RAMUCIRUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
RANIBIZUMAB,Choroidal neovascularisation associated with pathological myopia,TA298,choroidal neovascularisation,733124000,Myopic choroidal neovascularisation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Choroidal neovascularisation associated with pathological myopia,TA298,choroidal neovascularisation,380621000000102,Subfoveal choroidal neovascularisation drugs Band 1,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,macular oedema,37231002,Macular oedema,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,retinal vein occlusion,232038007,Central retinal vein occlusion with neovascularization,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,macular oedema,232039004,Central retinal vein occlusion with macular oedema,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,retinal vein occlusion,232042005,Macular edema due to juvenile central retinal vein occlusion,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,macular oedema,232045007,Macular oedema due to hemispheric retinal vein occlusion,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,retinal vein occlusion,232045007,Macular oedema due to hemispheric retinal vein occlusion,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,macular oedema,312911008,CSME - clinically significant macular oedema,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,macular oedema,312912001,Macular oedema due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,macular oedema,312920004,Postoperative cystoid macular oedema,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,macular oedema,312921000,Autosomal dominant cystoid macular oedema,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,macular oedema,312922007,Uveitis related cystoid macular oedema,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,macular oedema,769218003,Macular oedema of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,macular oedema,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to branch retinal vein occlusion,TA283,macular oedema,895021000000102,Macular oedema drugs Band 1,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,macular oedema,37231002,Macular oedema,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,retinal vein occlusion,232038007,Central retinal vein occlusion with neovascularization,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,macular oedema,232039004,Central retinal vein occlusion with macular oedema,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,retinal vein occlusion,232042005,Macular edema due to juvenile central retinal vein occlusion,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,macular oedema,232045007,Macular oedema due to hemispheric retinal vein occlusion,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,retinal vein occlusion,232045007,Macular oedema due to hemispheric retinal vein occlusion,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,macular oedema,312911008,CSME - clinically significant macular oedema,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,macular oedema,312912001,Macular oedema due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,macular oedema,312920004,Postoperative cystoid macular oedema,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,macular oedema,312921000,Autosomal dominant cystoid macular oedema,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,macular oedema,312922007,Uveitis related cystoid macular oedema,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,macular oedema,769218003,Macular oedema of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,macular oedema,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Visual impairment caused by macular oedema secondary to central retinal vein occlusion,TA283,macular oedema,895021000000102,Macular oedema drugs Band 1,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Wet age-related macular degeneration,TA155,macular degeneration,70099003,Familial juvenile macular degeneration syndrome,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Wet age-related macular degeneration,TA155,macular degeneration,193384000,Senile macular degeneration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Wet age-related macular degeneration,TA155,macular degeneration,267718000,Age-related macular degeneration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Wet age-related macular degeneration,TA155,macular degeneration,312898002,Myopic macular degeneration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Wet age-related macular degeneration,TA155,macular degeneration,314427006,Drusen plus pigment change stage macular degeneration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBIZUMAB,Wet age-related macular degeneration,TA155,macular degeneration,1296526000,Disciform macular degeneration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,134395001,Diabetic retinopathy screening,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,312906006,Early PDR (proliferative diabetic retinopathy),RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,312907002,High risk PDR (proliferative diabetic retinopathy),RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,312908007,Inactive PDR (proliferative diabetic retinopathy),RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,390850007,On examination - no right diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,390853009,On examination - no left diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,408384004,Diabetic retinopathy 12 month review,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,408385003,Diabetic retinopathy 6 month review,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,408396006,Diabetic retinopathy screening not indicated,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,408409007,On examination - right eye background diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,408410002,On examination - left eye background diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,408411003,On examination - right eye preproliferative diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,408412005,On examination - left eye preproliferative diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,408413000,On examination - right eye proliferative diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,408414006,On examination - left eye proliferative diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,413122001,Diabetic retinopathy screening declined,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,414894003,On examination - left eye stable treated proliferative diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,414910007,On examination - right eye stable treated proliferative diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,417677008,On examination - sight threatening diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,702850009,Diabetic retinopathy clinic,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,769181007,Preproliferative diabetic retinopathy of right eye,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,199301000000100,Did not attend diabetic retinopathy clinic,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,201141000000103,No diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,248161000000101,Referral for diabetic retinopathy screening,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,305401000000104,Information sharing consent status for national screening programme for diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,371781000000108,Eligible for diabetic retinopathy screening,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,371811000000106,Ineligible for diabetic retinopathy screening,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,371841000000107,Eligibility temporarily inactive for diabetic retinopathy screening,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,371871000000101,Eligibility permanently inactive for diabetic retinopathy screening,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,373031000000105,Diabetic retinopathy screening administrative status,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,373041000000101,Impaired vision due to diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,374601000000107,Excluded from diabetic retinopathy screening as moved away,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,374631000000101,Excluded from diabetic retinopathy screening as deceased,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,374661000000106,Excluded from diabetic retinopathy screening as under care of ophthalmologist,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,374691000000100,Excluded from diabetic retinopathy screening as blind,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,374721000000109,Excluded from diabetic retinopathy screening as no longer diabetic,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,374781000000105,Excluded from diabetic retinopathy screening as no current contact details,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,374811000000108,Excluded from diabetic retinopathy screening as terminal illness,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,374841000000109,Excluded from diabetic retinopathy screening as learning disability,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,374871000000103,Excluded from diabetic retinopathy screening as physical disorder,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,374901000000103,Excluded from diabetic retinopathy screening,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,775841000000109,Diabetic retinopathy detected by national screening programme,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,839811000000106,Diabetic retinopathy screening declined,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,846721000000101,Education about diabetic retinopathy,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RANIBUZIMAB,Diabetic retinopathy,TA637,diabetic retinopathy,1103701000000102,Diabetic retinopathy screening offered,RANIBUZIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY|MEDICAL OPHTHALMOLOGY|DIABETIC MEDICINE
RAVULIZUMAB,Paroxysmal nocturnal haemoglobinuria,TA698,paroxysmal nocturnal haemoglobinuria,1006421000000103,PNH (paroxysmal nocturnal haemoglobinuria) screening test,RAVULIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
RAVULIZUMAB,Paroxysmal nocturnal haemoglobinuria,TA698,paroxysmal nocturnal haemoglobinuria,1013561000000103,Paroxysmal nocturnal haemoglobinuria cell marker analysis,RAVULIZUMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
REGORAFENIB,Previously treated advanced hepatocellular carcinoma,TA514,hepatocellular carcinoma,15619004,"Hepatocellular carcinoma, fibrolamellar",REGORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
REGORAFENIB,Previously treated advanced hepatocellular carcinoma,TA555,hepatocellular carcinoma,15619004,"Hepatocellular carcinoma, fibrolamellar",REGORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
REGORAFENIB,Previously treated advanced hepatocellular carcinoma,TA514,hepatocellular carcinoma,253018005,Fibrolamellar hepatocellular carcinoma,REGORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
REGORAFENIB,Previously treated advanced hepatocellular carcinoma,TA555,hepatocellular carcinoma,253018005,Fibrolamellar hepatocellular carcinoma,REGORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
REGORAFENIB,Previously treated advanced hepatocellular carcinoma,TA514,hepatocellular carcinoma,990271000000107,Ultrasound scan surveillance of liver for hepatocellular carcinoma,REGORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
REGORAFENIB,Previously treated advanced hepatocellular carcinoma,TA555,hepatocellular carcinoma,990271000000107,Ultrasound scan surveillance of liver for hepatocellular carcinoma,REGORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
RELUGOLIX–ESTRADIOL–NORETHISTERONE ACETATE,Moderate to severe symptoms of uterine fibroids,TA832,uterine fibroids,237217000,"Uterine fibroids in pregnancy, childbirth and the puerperium",RELUGOLIX,GYNAECOLOGY,GYNAECOLOGY
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,12428000,Intrinsic asthma without status asthmaticus,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,31387002,Exercise-induced asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,34015007,Flour asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,56018004,Asthmatic breathing,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,56968009,Asthma caused by wood dust,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,57607007,Industrial asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,63088003,Allergic asthma without status asthmaticus,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,71892000,Cardiac asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,93432008,Drug-induced asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,160377001,Family history of asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,161105008,Asthma society member,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,161527007,History of asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,162660004,Asthma resolved,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170607007,Respiratory disease monitoring (& [asthma] or [chronic]),RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170631002,Asthma disturbing sleep,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170632009,Asthma causing night waking,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170633004,Asthma disturbs sleep weekly,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170634005,Asthma disturbs sleep frequently,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170635006,Asthma not disturbing sleep,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170636007,Asthma never disturbs sleep,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170637003,Asthma limiting activities,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170638008,Asthma not limiting activities,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170642006,Asthma severity,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170647000,Asthma prophylactic medication used,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170655007,Asthma restricts exercise,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170656008,Asthma sometimes restricts exercise,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170657004,Asthma severely restricts exercise,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,170658009,Asthma never restricts exercise,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,171231001,Asthma screening,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,182724005,Further asthma - drug prevention,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,182726007,Asthma control step 0,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,182727003,Asthma control step 1,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,182728008,Asthma control step 2,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,182729000,Asthma control step 3,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,182730005,Asthma control step 4,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,182731009,Asthma control step 5,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,183099005,Asthma leaflet given,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,183478001,Emergency hospital admission for asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,185242005,Seen in asthma clinic,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,185728001,Attends asthma monitoring,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,185730004,Asthma monitor offer default,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,185731000,Asthma monitoring call first letter,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,185732007,Asthma monitoring call second letter,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,185734008,Asthma monitoring call third letter,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,185735009,Asthma monitoring call verbal invite,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,185736005,Asthma monitoring call telephone invite,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,185737001,Asthma monitoring deleted,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,185940009,Patient in asthma study,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,195113008,(Left ventricular: [failure] or [impaired function]) or (cardiac asthma) or (acute pulmonary edema),RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,195949008,Chronic asthmatic bronchitis,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,195967001,Asthmatic,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,195968006,Asthma: [extrinsic - atopic] or [allergic] or [pollen] or [childhood] or [with hay fever],RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,195973000,Late-onset asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,195977004,Mixed asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,195983001,Exercise induced asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,219036002,Adverse reaction to antiasthmatic,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,225057002,Brittle asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,233678006,Childhood asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,233679003,Late-onset asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,233683003,Hay fever with asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,233691007,Eosinophilic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,266361008,Non-allergic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,266396008,Extrinsic asthma - atopy (& pollen),RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,266397004,Intrinsic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,266398009,Asthma attack,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,270442000,Asthma monitoring check done,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,275908000,Asthma monitoring,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,281239006,Asthma attack,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,302220000,Asthma control steps,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,304527002,Acute asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,308500005,Asthma monitoring call,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,308501009,Asthma monitoring status,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,312453004,Asthma - currently active,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,312454005,Asthma - currently dormant,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,366874008,Number of asthma exacerbations in past year,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370202007,Asthma causes daytime symptoms 1 to 2 times per month,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370203002,Asthma causes daytime symptoms 1 to 2 times per week,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370204008,Asthma causes daytime symptoms most days,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370205009,Asthma causes night symptoms 1 to 2 times per month,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370206005,Asthma limits walking on the flat,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370207001,Asthma limits walking up hills or stairs,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370208006,Asthma never causes daytime symptoms,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370218001,Mild asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370219009,Moderate asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370220003,Occasional asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370221004,Severe asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370225008,Asthma treatment compliance unsatisfactory,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,370226009,Asthma treatment compliance satisfactory,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,373899003,Asthma daytime symptoms,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,389145006,Allergic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,390798007,Asthma finding,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,390872009,Change in asthma management plan,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,390877003,Step up change in asthma management plan,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,390878008,Step down change in asthma management plan,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,390921001,Absent from work or school due to asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,390940007,Asthma monitoring due,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,394700004,Asthma annual review,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,394701000,Asthma follow-up,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,394720003,Asthma medication review,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,394967008,Suspected asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,395022009,Nocturnal asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,400987003,Asthma trigger,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,401135008,Health education - asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,401182001,Asthma monitoring by nurse,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,401183006,Asthma monitoring by doctor,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,401193004,Asthma confirmed,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,405944004,Asthmatic bronchitis,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,406162001,Asthma care,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,407674008,Aspirin-induced asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,409663006,Cough variant asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,415265005,Referral to asthma clinic,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,423889005,Non-immunoglobulin E mediated allergic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,424643009,Allergic atopic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,425969006,Acute intermittent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,426656000,Severe persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,426979002,Mild persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,427295004,Moderate persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,427603009,Intermittent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,427679007,Mild intermittent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,442025000,Acute exacerbation of chronic asthmatic bronchitis,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,443117005,Asthma control test score,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,445427006,Seasonal asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,445531003,ACQ - Asthma control questionnaire,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,473391009,Asthma never causes night symptoms,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,698509001,Under care of asthma specialist nurse,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,699191007,Did not attend asthma review,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,702823004,Asthma clinic,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,704008007,No family history of asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,707445000,Acute mild persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,707446004,Acute exacerbation of moderate persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,707447008,Exacerbation of severe persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,707511009,Uncomplicated mild persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,707512002,Uncomplicated moderate persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,707513007,Uncomplicated severe persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,707979007,Acute severe exacerbation of severe persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,707980005,Acute severe exacerbation of moderate persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,707981009,Acute severe exacerbation of mild persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,708038006,Acute exacerbation of asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,708090002,Acute severe exacerbation of asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,708093000,Acute exacerbation of allergic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,708094006,Acute exacerbation of intrinsic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,708095007,Acute severe exacerbation of extrinsic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,708358003,Emergency asthma admission since last encounter,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,708373002,Emergency asthma patient visit since last encounter,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,711442001,Recent asthma management,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,715191006,Telehealth asthma monitoring,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,734346005,Use of asthma symptom diary,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,734904007,Life threatening acute exacerbation of asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,734905008,Moderate acute exacerbation of asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,736056000,Asthma clinical management plan,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,762521001,Acute allergic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,763077003,Asthma Control Questionnaire score,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,763221007,Asthma monitoring declined,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,763695004,Mini Asthma Quality of Life Questionnaire score,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,782520007,Exacerbation of allergic asthma due to infection,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,782559003,Asthma never causes night symptoms,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,401000119107,Asthma with irreversible airway obstruction,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,641000119106,Intermittent asthma well controlled,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,1741000119102,Intermittent asthma uncontrolled,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,72301000119103,Asthma in pregnancy,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,89581000000109,DNA (did not attend) asthma clinic,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,92161000000104,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation using preferred method of communication,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,99031000119107,Acute exacerbation of asthma co-occurrent with allergic rhinitis,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,125011000119100,Mild persistent asthma co-occurrent with allergic rhinitis,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,125021000119107,Intermittent asthma co-occurrent with allergic rhinitis,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,135171000119106,Acute exacerbation of moderate persistent asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,143901000000108,Registration for access to online asthma self-management application,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,143931000000102,Declined to register for access to online asthma self-management application,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,176711000000100,Does not have asthma management plan,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,198971000000102,Asthma outreach clinic,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,201031000000108,Asthma trigger - respiratory infection,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,201041000000104,Asthma trigger - seasonal,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,201051000000101,Asthma trigger - animal,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,201191000000108,Asthma trigger - cold air,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,201201000000105,Asthma trigger - damp,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,201211000000107,Asthma trigger - emotion,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,302331000000106,RCP (Royal College of Physicians) asthma assessment,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,340891000000106,Asthma trigger - airborne dust,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,340901000000107,Asthma trigger - exercise,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,340911000000109,Asthma trigger - pollen,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,340921000000103,Asthma trigger - tobacco smoke,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,340931000000101,Asthma trigger - warm air,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,527171000000103,Patient has a written asthma personal action plan,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,527191000000104,Health education - asthma self management,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,527211000000100,Health education - structured asthma discussion,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,527231000000108,Health education - structured patient focused asthma discussion,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,713701000000108,Asthma monitoring administration,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,713711000000105,Asthma clinic administration,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,715801000000103,Exception reporting - asthma quality indicators,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,716491000000100,Excepted from asthma quality indicators - informed dissent,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,717291000000103,Excepted from asthma quality indicators - patient unsuitable,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,754061000000100,Asthma review using Royal College of Physicians three questions,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,771901000000100,Asthma causes night time symptoms 1 to 2 times per week,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,771941000000102,Asthma causes symptoms most nights,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,771981000000105,Asthma limits activities 1 to 2 times per month,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,772011000000107,Asthma limits activities 1 to 2 times per week,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,772051000000106,Asthma limits activities most days,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,791401000000104,Seen in school asthma clinic,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,810901000000102,Asthma self-management plan review,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,811151000000105,Number of days absent from school due to asthma in past 6 months,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,811921000000103,Asthma self-management plan agreed,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,815631000000106,Asthma trigger - wind,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,818161000000104,Asthma trigger - perfume,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,866881000000101,Chronic asthma with fixed airflow obstruction,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,867171000000106,No asthma trigger identified by subject,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,892301000000100,Asthma management plan declined,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,905301000000103,Childhood Asthma Control Test score,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,928451000000107,Asthma monitoring invitation short message service text message,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,928511000000107,Asthma monitoring invitation email,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,928651000000105,Review of patient at risk of asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,928691000000102,At risk of asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,959401000000101,Asthma monitoring SMS (short message service) text message first invitation,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,959421000000105,Asthma monitoring SMS (short message service) text message second invitation,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,959441000000103,Asthma monitoring SMS (short message service) text message third invitation,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,959901000000107,Asthma action plan,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,966011000000109,At risk of severe asthma exacerbation,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,966031000000101,Severe asthma exacerbation risk assessment,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,1086701000000102,Life threatening acute exacerbation of allergic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,1086711000000100,Life threatening acute exacerbation of non-allergic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,1108701000000106,Excepted from asthma quality indicators - service unavailable,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,1110841000000103,QOF (Quality and Outcomes Framework) asthma quality indicator-related care invitation,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,10674991000119104,Intermittent allergic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,10675431000119106,Severe persistent allergic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,10675551000119104,Acute severe exacerbation of severe persistent asthma co-occurrent with allergic rhinitis,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,10675871000119106,Mild persistent allergic asthma,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,10675991000119100,Acute severe exacerbation of mild persistent allergic asthma co-occurrent with allergic rhinitis,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,10676031000119106,Mild persistent allergic asthma controlled,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
"RESLIZUMAB, AS AN ADD-ON THERAPY",Severe eosinophilic asthma,TA479,asthma,10676111000119102,Mild persistent asthma controlled co-occurrent with allergic rhinitis,RESLIZUMAB,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,1755008,Healed myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,15990001,Acute myocardial infarction of posterolateral wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,22298006,MI - myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,41380003,Radioisotope scan for myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,52035003,Acute anteroapical myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,54329005,Acute anterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,57054005,Acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,58612006,Acute myocardial infarction of lateral wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,62695002,Acute anteroseptal myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,65547006,Acute inferolateral myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,66189004,Postmyocardial infarction syndrome,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,70211005,Acute anterolateral myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,73795002,Acute myocardial infarction of diaphragmatic wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,76593002,Acute myocardial infarction of inferoposterior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,79009004,Acute myocardial infarction of septum,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,129574000,Postoperative myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,160361002,FH: ischemic heart disease (& [myocardial infarction] or [coronary thrombosis]),ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,164866006,Electrocardiogram: no myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,164867002,Electrocardiographic old myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,194809007,Acute myocardial infarction of atrium,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,194821006,Aborted myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,194856005,Subsequent myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,194857001,Subsequent myocardial infarction of anterior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,194858006,Subsequent myocardial infarction of inferior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,194862000,Hemopericardium due to and following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,194863005,Atrial septal defect due to and following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,194865003,Rupture of cardiac wall without haemopericardium as current complication following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,194868001,"Thrombosis of atrium, auricular appendage, and ventricle due to and following acute myocardial infarction",ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,233838001,Acute posterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,233839009,Old anterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,233840006,Old inferior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,233841005,Old lateral myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,233842003,Old posterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,233843008,Silent myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,233847009,Cardiac rupture due to and following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,233885007,Pericarditis following myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,266288001,Myocardial infarction (& [acute]) or coronary thrombosis,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,266897007,Family history of myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,275122004,Family history: Myocardial infarction at less than 60,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,275123009,Family history: Myocardial infarction at greater than 60,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,304914007,Acute Q wave myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,308065005,History of myocardial infarction in last year,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,311793000,Postoperative transmural myocardial infarction of inferior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,311796008,Postoperative subendocardial myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,314207007,Non-Q wave myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,315619001,"Family history of myocardial infarction in male relative of first degree, age known",ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,315620007,"Family history of myocardial infarction in male relative of first degree, age unknown",ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,315621006,"Family history of myocardial infarction in female relative of first degree, age known",ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,315622004,"Family history of myocardial infarction in female relative of first degree, age unknown",ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,394710008,First myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,399211009,Previous myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,401303003,STEMI - ST elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,401314000,Acute non-ST segment elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,698593009,History of non-ST segment elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,703164000,Acute anterior ST segment elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,703213009,Acute STEMI (ST elevation myocardial infarction) of inferior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,827164008,Delayed postmyocardial infarction syndrome,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,879955009,MINOCA - myocardial infarction with non-obstructive coronary artery,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,515711000000105,Family history of myocardial infarction in second degree relative less than 50 years,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,515741000000106,Family history of myocardial infarction in first degree relative less than 60 years,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,715971000000103,Excepted from myocardial infarction quality indicators - informed dissent,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,715981000000101,Excepted from myocardial infarction quality indicators - patient unsuitable,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,717541000000106,Exception reporting - myocardial infarction quality indicators,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,883961000000109,Thrombolysis In Myocardial Infarction risk score for unstable angina or non-ST-segment-elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,12238111000119106,Acute ST segment elevation myocardial infarction of inferolateral wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETEPLASE,Myocardial infarction,TA052,myocardial infarction,16837681000119104,Myocardial infarction due to demand ischaemia,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,6204001,Juvenile myoclonic epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,16873003,Musicogenic epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,19598007,Generalized epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,36803009,IGE - idiopathic generalized epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,38281008,Self-limited neonatal epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,50866000,CAE - childhood absence epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,65120008,Generalised convulsive epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,71831005,Secondary generalised epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,79745005,Sensory-induced epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,84757009,Epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,95208000,Photic epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,160341008,Family history of epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,161480008,History of epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,162658001,Epilepsy resolved,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,170702005,Epilepsy monitoring,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,170703000,Initial epilepsy assessment,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,170704006,Follow-up epilepsy assessment,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,170706008,Epilepsy associated problems,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,170709001,Epilepsy drug side effect,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,170710006,Epilepsy treatment changed,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,170711005,Epilepsy treatment started,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,170712003,Epilepsy treatment stopped,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,192979009,Generalized non-convulsive epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,192990004,Myoclonic epilepsy in infancy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,192999003,Partial epilepsy with impairment of consciousness,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,193000002,Temporal lobe epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,193002005,Psychosensory epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,193007004,Focal epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,193008009,Somatosensory epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,193009001,Partial epilepsy with autonomic symptoms,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,193011005,Unilateral epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,193021002,Running epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230381009,Localization-related epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230382002,Benign frontal epilepsy of childhood,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230384001,Benign atypical partial epilepsy in childhood,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230386004,Benign occipital epilepsy of childhood,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230388003,Late onset occipital epilepsy of childhood,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230390002,Localisation-related symptomatic epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230393000,Lateral temporal lobe epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230394006,Frontal lobe epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230403005,Parietal lobe epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230404004,Occipital lobe epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230408001,Localisation-related cryptogenic epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230412007,Myoclonic epilepsy of early childhood,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230413002,JAE - juvenile absence epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230415009,Cryptogenic generalised epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230422001,Epilepsy with myoclonic absence,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230428002,Idiopathic myoclonic epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230430000,Symptomatic myoclonic epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230438007,Aphasia co-occurrent with epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230440002,Secondary reading epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230441003,Drug-induced epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230444006,Catamenial epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230450001,Eating epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230452009,Toothbrushing epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,230454005,Bathing epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,243857008,Epilepsy monitoring status,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,267581004,Progressive myoclonic epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,278510009,Localisation-related idiopathic epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,307356008,Motor epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,314827004,Epilepsy control good,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,314828009,Epilepsy control poor,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,352818000,Grand mal epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,361123003,Psychomotor epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,361268000,Alcohol-induced epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,401062003,Epilepsy medication review,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,401178003,Epilepsy care arrangement,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,407616001,Epilepsy severity,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,407623000,Emergency epilepsy treatment since last appointment,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,407625007,Suspected epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,407627004,Epilepsy confirmed,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,413101007,Stress-induced epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,414113005,Epilepsy leaflet given,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,414860000,No epilepsy drug side effects,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,416090009,Epilepsy monitoring verbal invite,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,417568007,Epilepsy monitoring call,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,429279006,Seen in epilepsy clinic,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,719425009,Sudden unexpected death in epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,1260117009,Combined focal and generalized epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,1260407007,Genetic generalised epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,88491000000102,Epilepsy limits activities,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,93141000000105,Epilepsy restricts employment,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,93151000000108,Epilepsy prevents employment,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,93211000000101,Epilepsy does not limit activities,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,108211000000104,Epilepsy impairs education,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,109121000000109,Epilepsy society member,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,116401000119105,Recurrent complex partial epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,202061000000107,Epilepsy monitoring call first letter,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,202071000000100,Epilepsy monitoring call second letter,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,202081000000103,Epilepsy monitoring call third letter,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,509341000000107,Petit-mal epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,711501000000104,Epilepsy screening invitation,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,715091000000100,Epilepsy screening administration,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,715791000000102,Epilepsy screening second invitation,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,716011000000103,Epilepsy screening first invitation,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,716811000000106,Epilepsy screening third invitation,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,809381000000103,Referral for epilepsy review,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,809551000000103,Referral to epilepsy clinic,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,810161000000101,Epilepsy monitoring in secondary care,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,811411000000104,Under care of epilepsy specialist nurse,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,840261000000103,Epilepsy management plan given,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,850201000000104,Epilepsy annual review,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,865371000000104,No history of epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,876461000000101,No FH of epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,892181000000107,Referral to epilepsy service,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RETIGABINE (ADJUVANT),Partial onset seizures in epilepsy,TA232,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,RETIGABINE,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,62944002,Hepatitis C virus,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,62944002,Hepatitis C virus,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,72165005,Hepatitis C virus antibody,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,72165005,Hepatitis C virus antibody,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,170489004,Viral hepatitis carrier,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,170489004,Viral hepatitis carrier,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,197344005,Hepatitis caused by adenovirus,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,197344005,Hepatitis caused by adenovirus,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,235872006,Hepatitis C carrier,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,235872006,Hepatitis C carrier,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,278973007,Hepatitis C status,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,278973007,Hepatitis C status,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,278974001,Hepatitis C immune,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,278974001,Hepatitis C immune,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,278975000,Hepatitis C non-immune,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,278975000,Hepatitis C non-immune,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,314706002,Hepatitis C antibody detected,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,314706002,Hepatitis C antibody detected,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,314707006,Hepatitis C antibody test negative,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,314707006,Hepatitis C antibody test negative,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,413107006,Hepatitis C screening,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,413107006,Hepatitis C screening,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,773113008,Acute hepatitis caused by infection,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,773113008,Acute hepatitis caused by infection,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,12891000175105,Hepatitis C screening declined,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,12891000175105,Hepatitis C screening declined,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,200371000000104,Hepatitis C contact,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,200371000000104,Hepatitis C contact,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,201451000000105,Hepatitis C immunisation declined,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,201451000000105,Hepatitis C immunisation declined,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,202281000000105,Hepatitis C screening declined,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,202281000000105,Hepatitis C screening declined,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,204671000000101,Hepatitis C screening counselling,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,204671000000101,Hepatitis C screening counselling,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,304821000000107,Hepatitis C screening not offered,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,304821000000107,Hepatitis C screening not offered,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,362491000000104,Hepatitis C screening negative,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,362491000000104,Hepatitis C screening negative,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,362751000000101,Hepatitis C screening positive,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,362751000000101,Hepatitis C screening positive,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,761381000000102,Hepatitis C resolved,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,761381000000102,Hepatitis C resolved,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,824841000000105,Hepatitis C genotype 1,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,824841000000105,Hepatitis C genotype 1,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,824871000000104,Hepatitis C genotype 3,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,824871000000104,Hepatitis C genotype 3,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,829731000000106,On hepatitis C treatment plan,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,829731000000106,On hepatitis C treatment plan,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,992751000000109,Hepatitis C viral load,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,992751000000109,Hepatitis C viral load,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,992771000000100,Hepatitis C virus genotype,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,992771000000100,Hepatitis C virus genotype,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,996031000000104,Hepatitis C IgG level,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,996031000000104,Hepatitis C IgG level,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,998771000000103,Hepatitis C antibody level,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,998771000000103,Hepatitis C antibody level,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,1001331000000102,Hepatitis C antigen level,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,1001331000000102,Hepatitis C antigen level,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,1008931000000108,Hepatitis C antibody test,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,1008931000000108,Hepatitis C antibody test,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,1107671000000106,Hepatitis C screening offered,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBAVIRIN AND INTERFERON ALPHA COMBINATION THERAPY,Hepatitis C,TA014,hepatitis c,1107671000000106,Hepatitis C screening offered,INTERFERON,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,134405005,Suspected breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,160287004,FH: Breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,268547008,Screening for breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,429740004,Family history of breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,431330007,Family history of breast cancer 1 gene mutation,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,431331006,Family history of breast cancer 2 gene mutation,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,706970001,TNBC - Triple-negative breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,94361000000105,Breast cancer detected by national screening programme,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,276341000000100,Fast track referral for suspected breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,838351000000107,Education about risk of breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,874291000000100,QCancer breast cancer risk,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH AN AROMATASE INHIBITOR,"Untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer",TA496,breast cancer,1035841000000108,Lymphoedema following breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,134405005,Suspected breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,160287004,FH: Breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,268547008,Screening for breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,429740004,Family history of breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,431330007,Family history of breast cancer 1 gene mutation,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,431331006,Family history of breast cancer 2 gene mutation,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,706970001,TNBC - Triple-negative breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,94361000000105,Breast cancer detected by national screening programme,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,276341000000100,Fast track referral for suspected breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,838351000000107,Education about risk of breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,874291000000100,QCancer breast cancer risk,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy",TA687,breast cancer,1035841000000108,Lymphoedema following breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,134405005,Suspected breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,160287004,FH: Breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,268547008,Screening for breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,429740004,Family history of breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,431330007,Family history of breast cancer 1 gene mutation,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,431331006,Family history of breast cancer 2 gene mutation,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,706970001,TNBC - Triple-negative breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,94361000000105,Breast cancer detected by national screening programme,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,276341000000100,Fast track referral for suspected breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,838351000000107,Education about risk of breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,874291000000100,QCancer breast cancer risk,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RIBOCICLIB WITH FULVESTRANT,"Hormone receptor-positive, HER2-negative, advanced breast cancer",TA593,breast cancer,1035841000000108,Lymphoedema following breast cancer,RIBOCICLIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
RILUZOLE,Motor neurone disease,TA020,motor neurone disease,160344000,Family history of motor neurone disease,RILUZOLE,NEUROLOGY,NEUROLOGY|REHABILITATION|PALLIATIVE CARE
RILUZOLE,Motor neurone disease,TA020,motor neurone disease,230257000,Paraneoplastic motor neurone disease,RILUZOLE,NEUROLOGY,NEUROLOGY|REHABILITATION|PALLIATIVE CARE
RILUZOLE,Motor neurone disease,TA020,motor neurone disease,230274000,Frontal lobe degeneration with motor neurone disease,RILUZOLE,NEUROLOGY,NEUROLOGY|REHABILITATION|PALLIATIVE CARE
RIMONABANT,Overweight and obese adults,TA144,overweight,755881000000104,"Risk to health associated with overweight and obesity, at no increased risk",RIMONABANT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE
RIMONABANT,Overweight and obese adults,TA144,overweight,755921000000105,"Risk to health associated with overweight and obesity, at high risk",RIMONABANT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE
RIMONABANT,Overweight and obese adults,TA144,overweight,756041000000105,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs",RIMONABANT,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE
RISANKIZUMAB,Moderate to severe plaque psoriasis,TA596,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),RISANKIZUMAB,DERMATOLOGY,DERMATOLOGY
RISANKIZUMAB,Moderate to severe plaque psoriasis,TA596,plaque psoriasis,402307000,Chronic large plaque psoriasis,RISANKIZUMAB,DERMATOLOGY,DERMATOLOGY
RISANKIZUMAB,Moderate to severe plaque psoriasis,TA596,plaque psoriasis,402310007,Chronic stable plaque psoriasis,RISANKIZUMAB,DERMATOLOGY,DERMATOLOGY
RISANKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA803,psoriatic arthritis,156370009,Psoriatic arthritis,RISANKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
RISANKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA803,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,RISANKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
RISANKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA803,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,RISANKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
RISANKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA803,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,RISANKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
RISANKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA803,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,RISANKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
RISANKIZUMAB,Psoriatic arthritis after inadequate response to DMARDs,TA803,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,RISANKIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
RISDIPLAM,Spinal muscular atrophy,TA755,spinal muscular atrophy,5262007,Progressive spinal muscular atrophy,RISDIPLAM,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RISDIPLAM,Spinal muscular atrophy,TA755,spinal muscular atrophy,54280009,Familial spinal muscular atrophy,RISDIPLAM,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RISDIPLAM,Spinal muscular atrophy,TA755,spinal muscular atrophy,64383006,Infantile spinal muscular atrophy,RISDIPLAM,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RISDIPLAM,Spinal muscular atrophy,TA755,spinal muscular atrophy,85505000,Generalized spinal muscular atrophy of late onset,RISDIPLAM,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RISDIPLAM,Spinal muscular atrophy,TA755,spinal muscular atrophy,128212001,Late infantile spinal muscular atrophy,RISDIPLAM,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RISDIPLAM,Spinal muscular atrophy,TA755,spinal muscular atrophy,230247001,Distal spinal muscular atrophy,RISDIPLAM,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RISDIPLAM,Spinal muscular atrophy,TA755,spinal muscular atrophy,230252006,Oculopharyngeal spinal muscular atrophy,RISDIPLAM,NEUROLOGY,NEUROLOGY|PAEDIATRICS
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Osteoporosis - secondary prevention,TA087,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISEDRONATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
RISPERIDONE,Schizophrenia,TA043,schizophrenia,4926007,Schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,12939007,Chronic disorganized schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,31373002,Hebephrenic schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,31658008,Chronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,35252006,Disorganised schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,39610001,Undifferentiated schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,58214004,Schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,63181006,"Paranoid schizophrenia, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,64905009,Paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,79866005,Subchronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,83746006,Chronic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,111482003,Subchronic schizophrenia with acute exacerbations,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,111483008,"Schizophrenia, catatonic, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,111484002,Undifferentiated schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,160328009,Family history of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,161103001,Schizophrenia association member,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,161468000,History of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,191527001,Simple schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,191531007,Acute exacerbation of chronic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,191548004,Chronic catatonic schizophrenia with acute exacerbation,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,191554003,Acute exacerbation of subchronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,191555002,Acute exacerbation of chronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,191559008,Latent schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,191565008,Latent schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,191567000,Schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,191570001,Chronic schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,191572009,Acute exacerbation of chronic schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,191574005,"Schizophrenia, schizoaffective, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,247804008,Prodromal schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,274952002,Borderline schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,278853003,Acute schizophrenia-like psychotic disorder,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,444180005,History of schizophrenia in child of subject,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,712824002,Acute polymorphic psychotic disorder without symptoms of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,712850003,Acute polymorphic psychotic disorder with symptoms of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,200951000000109,"Psychosis, schizophrenia and bipolar affective disorder resolved",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,285521000000103,Schizophrenia resolved,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,417601000000102,"[X]Schizophrenia, schizotypal and delusional disorders",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,443791000000100,[X]Pseudopsychopathic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,1062101000000104,Schizophrenia TOM (Therapy Outcome Measure) activity score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,1062121000000108,Schizophrenia TOM (Therapy Outcome Measure) impairment score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,1062131000000105,Schizophrenia TOM (Therapy Outcome Measure) participation score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RISPERIDONE,Schizophrenia,TA043,schizophrenia,1062141000000101,Schizophrenia TOM (Therapy Outcome Measure) wellbeing score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
RITUXIMAB,Follicular lymphoma,TA110,follicular lymphoma,109962001,Nonfollicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Follicular lymphoma,TA110,follicular lymphoma,308121000,Follicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Follicular lymphoma,TA110,follicular lymphoma,721555001,Follicular lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Follicular lymphoma,TA110,follicular lymphoma,1148851002,Follicular lymphoma grade IIIa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Follicular lymphoma,TA110,follicular lymphoma,847481000000109,Follicular lymphoma grade 1,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Follicular lymphoma,TA110,follicular lymphoma,847631000000107,Follicular lymphoma grade 2,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Follicular lymphoma,TA110,follicular lymphoma,847651000000100,Follicular lymphoma grade 3,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Follicular lymphoma,TA110,follicular lymphoma,847691000000108,Follicular lymphoma grade 3a,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Follicular lymphoma,TA110,follicular lymphoma,847701000000108,Follicular lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,835009,Angioimmunoblastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,1929004,"Malignant lymphoma, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,19340000,Plasmacytic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,20776008,Adenolymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,21964009,Lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,21983002,Struma lymphomatosa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,28054005,Cutaneous lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,28175004,Gastric pseudolymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,30440004,Lymphoma stage I,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,31047003,Lymphomatoid papulosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,40411000,"Malignant lymphoma, histiocytic, nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,41529000,"Classical Hodgkin lymphoma, mixed cellularity",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,46732000,"Malignant lymphoma, large cell, cleaved, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,51092000,Malignant lymphoma lymphocytic well differentiated diffuse,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,52248008,"Classical Hodgkin lymphoma, nodular sclerosis",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,55020008,"Malignant lymphoma, mixed cell type, follicular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,55150002,"Malignant lymphoma, nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,56944001,Lymphoma stage III,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,64575004,"Malignant lymphoma, small lymphocytic, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,66445009,Lymphoma stage IV,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,70600005,"Hodgkin lymphoma, nodular lymphocyte predominance",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,74654000,Mantle cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,76422004,Lymphoma stage II,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,92814006,B-cell CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,93191005,Malignant lymphoma of intra-abdominal lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,93192003,Malignant lymphoma of intrapelvic lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,93194002,Malignant lymphoma of lymph nodes of axilla AND/OR upper limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,93195001,"Malignant lymphoma of lymph nodes of head, face AND/OR neck",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,93197009,Malignant lymphoma of lymph nodes of multiple sites,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,93198004,Malignant lymphoma of spleen,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,95186006,Nodular lymphoma of intra-abdominal lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,95192000,Nodular lymphoma of lymph nodes of multiple sites,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,95193005,Nodular lymphoma of spleen,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,106252000,Staging classification for lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,109962001,Nonfollicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,109966003,"Lymphoma, immunoblastic, high grade",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,109969005,Diffuse large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,109975001,T-zone lymphoma (clinical),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,109976000,Lymphoepithelioid lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,109977009,Peripheral T-cell lymphoma pleomorphic medium and large cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,109978004,T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,109979007,B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,109988003,True histiocytic lymphoma (clinical),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,115244002,Malignant lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,115245001,"Malignant lymphoma, follicular AND/OR nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,118599009,"Lymphoma, Hodgkins",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,118600007,Malignant lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,118601006,Non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,118605002,"Hodgkin lymphoma, nodular lymphocyte predominance",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,118609008,Hodgkin mixed cellularity lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,118617000,Burkitt lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,128799007,"Hodgkin lymphoma, lymphocyte-rich",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,128803008,Marginal zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,128805001,Angiocentric natural killer cell and T-cell malignant lymphoma nasal type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,128875000,Primary cutaneous CD30 antigen positive large T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,128929007,Non-Hodgkin lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,128930002,Hodgkin lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,188609000,"Nodular lymphoma of lymph nodes of head, face and neck",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,188612002,Nodular lymphoma of lymph nodes of axilla and upper limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,188613007,Nodular lymphoma of lymph nodes of inguinal region and lower limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,188674006,Diffuse malignant lymphoma - small non-cleaved cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,188675007,"Malignant lymphoma, lymphocytic - poorly differentiated",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,188676008,Malignant lymphoma - mixed lymphocytic-histiocytic,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,189958005,"Lymphomatous tumour, benign",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,189962004,"Malignant lymphoma, stem cell type",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,232075002,Lymphoma of retina,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,236513009,Lymphoma of kidney,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,238994000,Drug-induced pseudolymphomatous eruption,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,239297008,Lymphomatoid granulomatosis of lung,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,239940004,Lymphomatoid granulomatosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,240794006,Splenic schistosomal giant cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,254372002,Ann Arbor lymphoma staging system,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,255102004,Intravascular lymphomatosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,258279002,Lymphoma staging symptom status values,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,269476000,Nodular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,274905008,Mantle zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,276811008,Gastric lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,276815004,Lymphoma of intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,276836002,Primary cerebral lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277024002,Working formulation of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277551008,Splenic lymphoma with villous lymphocytes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277570003,Lymphoma with spill,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277613000,Cutaneous peripheral T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277615007,Low grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277616008,Diffuse low grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277617004,High grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277618009,Nodular malignant lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277623009,Monocytoid B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277624003,Follicular malignant lymphoma - mixed cell type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277625002,Follicular malignant lymphoma - small cleaved cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277626001,Diffuse high grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277627005,Nodular high grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277637000,Large cell anaplastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277641001,Follicular malignant lymphoma - large cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277642008,Low grade T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277643003,High grade T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277651000,Peripheral T-cell lymphoma - pleomorphic small cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277654008,Enteropathy-type T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,277664004,Malignant lymphoma of testis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,278051002,Malignant lymphoma of thyroid gland,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,278052009,Malignant lymphoma of breast,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,302841002,Malignant lymphoma - small cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,303055001,"Malignant lymphoma, follicular centre cell",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,307623001,Malignant lymphoma - lymphoplasmacytic,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,308121000,Follicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,314922006,B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,314923001,Low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,314924007,Follicular low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,314925008,High grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,314926009,T-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,314929002,Diffuse low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,314934003,Diffuse high grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,315264005,Suspected lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,400001003,Primary cutaneous lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,400122007,CTCL - Cutaneous T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,404111002,Lymphomatoid papulosis-associated mycosis fungoides,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,404140004,SALT type B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,413537009,Angioimmunoblastic T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,414166008,Natural Killer cell and T-cell malignant lymphoma nasal type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,414780005,Mucosa-associated lymphoid tissue lymphoma of orbit,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,420788006,Vitreoretinal lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,426071002,Hodgkin lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,427141003,Malignant lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,428046009,History of non-Hodgkins lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,433450000,Family history of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,443487006,Mantle cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,444597005,Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of stomach,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,444910004,Primary mediastinal (thymic) large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,445269007,Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,445406001,Hepatosplenic T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,447100004,Marginal zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,448211002,Adenolymphoma of parotid gland,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,448212009,Anaplastic lymphoma kinase negative anaplastic large cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,448709005,Non-Hodgkin lymphoma of stomach,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,449074003,Lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,449220000,Diffuse follicle center lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,450958009,"Malignant lymphoma, diffuse large B-cell, immunoblastic",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,721555001,Follicular lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,724648008,Plasmablastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,738770003,Anaplastic lymphoma kinase positive anaplastic large cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,762690000,Classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,763666008,Splenic marginal zone B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,830057003,Relapsing classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,1148845007,Follicular non-Hodgkin lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,1148851002,Follicular lymphoma grade IIIa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,143291000119104,Non-Hodgkin's lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,847481000000109,Follicular lymphoma grade 1,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,847631000000107,Follicular lymphoma grade 2,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,847651000000100,Follicular lymphoma grade 3,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,847691000000108,Follicular lymphoma grade 3a,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,847701000000108,Follicular lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,847741000000106,Diffuse large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,878461000000100,No FH of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,1090241000000107,Angioimmunoblastic T-cell lymphoma with dysproteinaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,1091861000000100,Cutaneous follicle centre lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,1091891000000106,B-cell Hodgkin's lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage I,TA065,lymphoma,1091921000000103,B-cell non-Hodgkin's lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,835009,Angioimmunoblastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,1929004,"Malignant lymphoma, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,19340000,Plasmacytic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,20776008,Adenolymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,21964009,Lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,21983002,Struma lymphomatosa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,28054005,Cutaneous lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,28175004,Gastric pseudolymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,30440004,Lymphoma stage I,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,31047003,Lymphomatoid papulosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,40411000,"Malignant lymphoma, histiocytic, nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,41529000,"Classical Hodgkin lymphoma, mixed cellularity",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,46732000,"Malignant lymphoma, large cell, cleaved, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,51092000,Malignant lymphoma lymphocytic well differentiated diffuse,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,52248008,"Classical Hodgkin lymphoma, nodular sclerosis",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,55020008,"Malignant lymphoma, mixed cell type, follicular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,55150002,"Malignant lymphoma, nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,56944001,Lymphoma stage III,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,64575004,"Malignant lymphoma, small lymphocytic, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,66445009,Lymphoma stage IV,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,70600005,"Hodgkin lymphoma, nodular lymphocyte predominance",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,74654000,Mantle cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,76422004,Lymphoma stage II,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,92814006,B-cell CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,93191005,Malignant lymphoma of intra-abdominal lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,93192003,Malignant lymphoma of intrapelvic lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,93194002,Malignant lymphoma of lymph nodes of axilla AND/OR upper limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,93195001,"Malignant lymphoma of lymph nodes of head, face AND/OR neck",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,93197009,Malignant lymphoma of lymph nodes of multiple sites,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,93198004,Malignant lymphoma of spleen,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,95186006,Nodular lymphoma of intra-abdominal lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,95192000,Nodular lymphoma of lymph nodes of multiple sites,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,95193005,Nodular lymphoma of spleen,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,106252000,Staging classification for lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,109962001,Nonfollicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,109966003,"Lymphoma, immunoblastic, high grade",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,109969005,Diffuse large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,109975001,T-zone lymphoma (clinical),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,109976000,Lymphoepithelioid lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,109977009,Peripheral T-cell lymphoma pleomorphic medium and large cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,109978004,T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,109979007,B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,109988003,True histiocytic lymphoma (clinical),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,115244002,Malignant lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,115245001,"Malignant lymphoma, follicular AND/OR nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,118599009,"Lymphoma, Hodgkins",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,118600007,Malignant lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,118601006,Non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,118605002,"Hodgkin lymphoma, nodular lymphocyte predominance",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,118609008,Hodgkin mixed cellularity lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,118617000,Burkitt lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,128799007,"Hodgkin lymphoma, lymphocyte-rich",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,128803008,Marginal zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,128805001,Angiocentric natural killer cell and T-cell malignant lymphoma nasal type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,128875000,Primary cutaneous CD30 antigen positive large T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,128929007,Non-Hodgkin lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,128930002,Hodgkin lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,188609000,"Nodular lymphoma of lymph nodes of head, face and neck",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,188612002,Nodular lymphoma of lymph nodes of axilla and upper limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,188613007,Nodular lymphoma of lymph nodes of inguinal region and lower limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,188674006,Diffuse malignant lymphoma - small non-cleaved cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,188675007,"Malignant lymphoma, lymphocytic - poorly differentiated",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,188676008,Malignant lymphoma - mixed lymphocytic-histiocytic,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,189958005,"Lymphomatous tumour, benign",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,189962004,"Malignant lymphoma, stem cell type",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,232075002,Lymphoma of retina,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,236513009,Lymphoma of kidney,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,238994000,Drug-induced pseudolymphomatous eruption,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,239297008,Lymphomatoid granulomatosis of lung,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,239940004,Lymphomatoid granulomatosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,240794006,Splenic schistosomal giant cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,254372002,Ann Arbor lymphoma staging system,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,255102004,Intravascular lymphomatosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,258279002,Lymphoma staging symptom status values,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,269476000,Nodular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,274905008,Mantle zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,276811008,Gastric lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,276815004,Lymphoma of intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,276836002,Primary cerebral lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277024002,Working formulation of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277551008,Splenic lymphoma with villous lymphocytes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277570003,Lymphoma with spill,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277613000,Cutaneous peripheral T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277615007,Low grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277616008,Diffuse low grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277617004,High grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277618009,Nodular malignant lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277623009,Monocytoid B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277624003,Follicular malignant lymphoma - mixed cell type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277625002,Follicular malignant lymphoma - small cleaved cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277626001,Diffuse high grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277627005,Nodular high grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277637000,Large cell anaplastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277641001,Follicular malignant lymphoma - large cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277642008,Low grade T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277643003,High grade T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277651000,Peripheral T-cell lymphoma - pleomorphic small cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277654008,Enteropathy-type T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,277664004,Malignant lymphoma of testis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,278051002,Malignant lymphoma of thyroid gland,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,278052009,Malignant lymphoma of breast,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,302841002,Malignant lymphoma - small cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,303055001,"Malignant lymphoma, follicular centre cell",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,307623001,Malignant lymphoma - lymphoplasmacytic,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,308121000,Follicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,314922006,B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,314923001,Low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,314924007,Follicular low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,314925008,High grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,314926009,T-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,314929002,Diffuse low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,314934003,Diffuse high grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,315264005,Suspected lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,400001003,Primary cutaneous lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,400122007,CTCL - Cutaneous T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,404111002,Lymphomatoid papulosis-associated mycosis fungoides,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,404140004,SALT type B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,413537009,Angioimmunoblastic T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,414166008,Natural Killer cell and T-cell malignant lymphoma nasal type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,414780005,Mucosa-associated lymphoid tissue lymphoma of orbit,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,420788006,Vitreoretinal lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,426071002,Hodgkin lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,427141003,Malignant lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,428046009,History of non-Hodgkins lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,433450000,Family history of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,443487006,Mantle cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,444597005,Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of stomach,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,444910004,Primary mediastinal (thymic) large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,445269007,Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,445406001,Hepatosplenic T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,447100004,Marginal zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,448211002,Adenolymphoma of parotid gland,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,448212009,Anaplastic lymphoma kinase negative anaplastic large cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,448709005,Non-Hodgkin lymphoma of stomach,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,449074003,Lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,449220000,Diffuse follicle center lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,450958009,"Malignant lymphoma, diffuse large B-cell, immunoblastic",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,721555001,Follicular lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,724648008,Plasmablastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,738770003,Anaplastic lymphoma kinase positive anaplastic large cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,762690000,Classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,763666008,Splenic marginal zone B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,830057003,Relapsing classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,1148845007,Follicular non-Hodgkin lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,1148851002,Follicular lymphoma grade IIIa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,143291000119104,Non-Hodgkin's lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,847481000000109,Follicular lymphoma grade 1,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,847631000000107,Follicular lymphoma grade 2,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,847651000000100,Follicular lymphoma grade 3,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,847691000000108,Follicular lymphoma grade 3a,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,847701000000108,Follicular lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,847741000000106,Diffuse large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,878461000000100,No FH of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,1090241000000107,Angioimmunoblastic T-cell lymphoma with dysproteinaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,1091861000000100,Cutaneous follicle centre lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,1091891000000106,B-cell Hodgkin's lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Non-Hodgkin's lymphoma - stage II - IV,TA065,lymphoma,1091921000000103,B-cell non-Hodgkin's lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,161567008,History of rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB,Rheumatoid arthritis (refractory),TA126,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,835009,Angioimmunoblastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,1929004,"Malignant lymphoma, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,19340000,Plasmacytic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,20776008,Adenolymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,21964009,Lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,21983002,Struma lymphomatosa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,28054005,Cutaneous lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,28175004,Gastric pseudolymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,30440004,Lymphoma stage I,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,31047003,Lymphomatoid papulosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,40411000,"Malignant lymphoma, histiocytic, nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,41529000,"Classical Hodgkin lymphoma, mixed cellularity",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,46732000,"Malignant lymphoma, large cell, cleaved, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,51092000,Malignant lymphoma lymphocytic well differentiated diffuse,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,52248008,"Classical Hodgkin lymphoma, nodular sclerosis",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,55020008,"Malignant lymphoma, mixed cell type, follicular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,55150002,"Malignant lymphoma, nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,56944001,Lymphoma stage III,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,64575004,"Malignant lymphoma, small lymphocytic, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,66445009,Lymphoma stage IV,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,70600005,"Hodgkin lymphoma, nodular lymphocyte predominance",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,74654000,Mantle cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,76422004,Lymphoma stage II,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,92814006,B-cell CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,93191005,Malignant lymphoma of intra-abdominal lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,93192003,Malignant lymphoma of intrapelvic lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,93194002,Malignant lymphoma of lymph nodes of axilla AND/OR upper limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,93195001,"Malignant lymphoma of lymph nodes of head, face AND/OR neck",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,93197009,Malignant lymphoma of lymph nodes of multiple sites,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,93198004,Malignant lymphoma of spleen,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,95186006,Nodular lymphoma of intra-abdominal lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,95192000,Nodular lymphoma of lymph nodes of multiple sites,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,95193005,Nodular lymphoma of spleen,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,106252000,Staging classification for lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,109962001,Nonfollicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,109966003,"Lymphoma, immunoblastic, high grade",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,109969005,Diffuse large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,109975001,T-zone lymphoma (clinical),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,109976000,Lymphoepithelioid lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,109977009,Peripheral T-cell lymphoma pleomorphic medium and large cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,109978004,T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,109979007,B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,109988003,True histiocytic lymphoma (clinical),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,115244002,Malignant lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,115245001,"Malignant lymphoma, follicular AND/OR nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,118599009,"Lymphoma, Hodgkins",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,118600007,Malignant lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,118601006,Non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,118605002,"Hodgkin lymphoma, nodular lymphocyte predominance",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,118609008,Hodgkin mixed cellularity lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,118617000,Burkitt lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,128799007,"Hodgkin lymphoma, lymphocyte-rich",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,128803008,Marginal zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,128805001,Angiocentric natural killer cell and T-cell malignant lymphoma nasal type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,128875000,Primary cutaneous CD30 antigen positive large T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,128929007,Non-Hodgkin lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,128930002,Hodgkin lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,188609000,"Nodular lymphoma of lymph nodes of head, face and neck",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,188612002,Nodular lymphoma of lymph nodes of axilla and upper limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,188613007,Nodular lymphoma of lymph nodes of inguinal region and lower limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,188674006,Diffuse malignant lymphoma - small non-cleaved cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,188675007,"Malignant lymphoma, lymphocytic - poorly differentiated",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,188676008,Malignant lymphoma - mixed lymphocytic-histiocytic,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,189958005,"Lymphomatous tumour, benign",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,189962004,"Malignant lymphoma, stem cell type",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,232075002,Lymphoma of retina,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,236513009,Lymphoma of kidney,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,238994000,Drug-induced pseudolymphomatous eruption,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,239297008,Lymphomatoid granulomatosis of lung,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,239940004,Lymphomatoid granulomatosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,240794006,Splenic schistosomal giant cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,254372002,Ann Arbor lymphoma staging system,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,255102004,Intravascular lymphomatosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,258279002,Lymphoma staging symptom status values,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,269476000,Nodular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,274905008,Mantle zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,276811008,Gastric lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,276815004,Lymphoma of intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,276836002,Primary cerebral lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277024002,Working formulation of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277551008,Splenic lymphoma with villous lymphocytes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277570003,Lymphoma with spill,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277613000,Cutaneous peripheral T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277615007,Low grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277616008,Diffuse low grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277617004,High grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277618009,Nodular malignant lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277623009,Monocytoid B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277624003,Follicular malignant lymphoma - mixed cell type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277625002,Follicular malignant lymphoma - small cleaved cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277626001,Diffuse high grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277627005,Nodular high grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277637000,Large cell anaplastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277641001,Follicular malignant lymphoma - large cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277642008,Low grade T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277643003,High grade T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277651000,Peripheral T-cell lymphoma - pleomorphic small cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277654008,Enteropathy-type T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,277664004,Malignant lymphoma of testis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,278051002,Malignant lymphoma of thyroid gland,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,278052009,Malignant lymphoma of breast,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,302841002,Malignant lymphoma - small cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,303055001,"Malignant lymphoma, follicular centre cell",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,307623001,Malignant lymphoma - lymphoplasmacytic,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,308121000,Follicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,314922006,B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,314923001,Low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,314924007,Follicular low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,314925008,High grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,314926009,T-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,314929002,Diffuse low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,314934003,Diffuse high grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,315264005,Suspected lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,400001003,Primary cutaneous lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,400122007,CTCL - Cutaneous T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,404111002,Lymphomatoid papulosis-associated mycosis fungoides,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,404140004,SALT type B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,413537009,Angioimmunoblastic T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,414166008,Natural Killer cell and T-cell malignant lymphoma nasal type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,414780005,Mucosa-associated lymphoid tissue lymphoma of orbit,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,420788006,Vitreoretinal lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,426071002,Hodgkin lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,427141003,Malignant lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,428046009,History of non-Hodgkins lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,433450000,Family history of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,443487006,Mantle cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,444597005,Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of stomach,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,444910004,Primary mediastinal (thymic) large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,445269007,Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,445406001,Hepatosplenic T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,447100004,Marginal zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,448211002,Adenolymphoma of parotid gland,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,448212009,Anaplastic lymphoma kinase negative anaplastic large cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,448709005,Non-Hodgkin lymphoma of stomach,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,449074003,Lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,449220000,Diffuse follicle center lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,450958009,"Malignant lymphoma, diffuse large B-cell, immunoblastic",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,721555001,Follicular lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,724648008,Plasmablastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,738770003,Anaplastic lymphoma kinase positive anaplastic large cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,762690000,Classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,763666008,Splenic marginal zone B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,830057003,Relapsing classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,1148845007,Follicular non-Hodgkin lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,1148851002,Follicular lymphoma grade IIIa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,143291000119104,Non-Hodgkin's lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,847481000000109,Follicular lymphoma grade 1,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,847631000000107,Follicular lymphoma grade 2,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,847651000000100,Follicular lymphoma grade 3,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,847691000000108,Follicular lymphoma grade 3a,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,847701000000108,Follicular lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,847741000000106,Diffuse large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,878461000000100,No FH of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,1090241000000107,Angioimmunoblastic T-cell lymphoma with dysproteinaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,1091861000000100,Cutaneous follicle centre lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,1091891000000106,B-cell Hodgkin's lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (1ST LINE MAINTENANCE TREATMENT),Follicular non-Hodgkin’s lymphoma that has responded to first-line induction therapy with rituximab plus chemotherapy.,TA226,lymphoma,1091921000000103,B-cell non-Hodgkin's lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,835009,Angioimmunoblastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1929004,"Malignant lymphoma, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,19340000,Plasmacytic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,20776008,Adenolymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,21964009,Lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,21983002,Struma lymphomatosa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,28054005,Cutaneous lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,28175004,Gastric pseudolymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,30440004,Lymphoma stage I,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,31047003,Lymphomatoid papulosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,40411000,"Malignant lymphoma, histiocytic, nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,41529000,"Classical Hodgkin lymphoma, mixed cellularity",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,46732000,"Malignant lymphoma, large cell, cleaved, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,51092000,Malignant lymphoma lymphocytic well differentiated diffuse,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,52248008,"Classical Hodgkin lymphoma, nodular sclerosis",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,55020008,"Malignant lymphoma, mixed cell type, follicular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,55150002,"Malignant lymphoma, nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,56944001,Lymphoma stage III,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,64575004,"Malignant lymphoma, small lymphocytic, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,66445009,Lymphoma stage IV,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,70600005,"Hodgkin lymphoma, nodular lymphocyte predominance",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,74654000,Mantle cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,76422004,Lymphoma stage II,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,92814006,B-cell CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,93191005,Malignant lymphoma of intra-abdominal lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,93192003,Malignant lymphoma of intrapelvic lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,93194002,Malignant lymphoma of lymph nodes of axilla AND/OR upper limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,93195001,"Malignant lymphoma of lymph nodes of head, face AND/OR neck",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,93197009,Malignant lymphoma of lymph nodes of multiple sites,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,93198004,Malignant lymphoma of spleen,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,95186006,Nodular lymphoma of intra-abdominal lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,95192000,Nodular lymphoma of lymph nodes of multiple sites,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,95193005,Nodular lymphoma of spleen,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,106252000,Staging classification for lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109962001,Nonfollicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109966003,"Lymphoma, immunoblastic, high grade",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109969005,Diffuse large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109975001,T-zone lymphoma (clinical),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109976000,Lymphoepithelioid lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109977009,Peripheral T-cell lymphoma pleomorphic medium and large cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109978004,T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109979007,B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109988003,True histiocytic lymphoma (clinical),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,115244002,Malignant lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,115245001,"Malignant lymphoma, follicular AND/OR nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118599009,"Lymphoma, Hodgkins",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118600007,Malignant lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118601006,Non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118605002,"Hodgkin lymphoma, nodular lymphocyte predominance",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118609008,Hodgkin mixed cellularity lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118617000,Burkitt lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,128799007,"Hodgkin lymphoma, lymphocyte-rich",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,128803008,Marginal zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,128805001,Angiocentric natural killer cell and T-cell malignant lymphoma nasal type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,128875000,Primary cutaneous CD30 antigen positive large T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,128929007,Non-Hodgkin lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,128930002,Hodgkin lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188609000,"Nodular lymphoma of lymph nodes of head, face and neck",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188612002,Nodular lymphoma of lymph nodes of axilla and upper limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188613007,Nodular lymphoma of lymph nodes of inguinal region and lower limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188674006,Diffuse malignant lymphoma - small non-cleaved cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188675007,"Malignant lymphoma, lymphocytic - poorly differentiated",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188676008,Malignant lymphoma - mixed lymphocytic-histiocytic,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,189958005,"Lymphomatous tumour, benign",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,189962004,"Malignant lymphoma, stem cell type",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,232075002,Lymphoma of retina,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,236513009,Lymphoma of kidney,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,238994000,Drug-induced pseudolymphomatous eruption,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,239297008,Lymphomatoid granulomatosis of lung,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,239940004,Lymphomatoid granulomatosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,240794006,Splenic schistosomal giant cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,254372002,Ann Arbor lymphoma staging system,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,255102004,Intravascular lymphomatosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,258279002,Lymphoma staging symptom status values,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,269476000,Nodular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,274905008,Mantle zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,276811008,Gastric lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,276815004,Lymphoma of intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,276836002,Primary cerebral lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277024002,Working formulation of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277551008,Splenic lymphoma with villous lymphocytes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277570003,Lymphoma with spill,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277613000,Cutaneous peripheral T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277615007,Low grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277616008,Diffuse low grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277617004,High grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277618009,Nodular malignant lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277623009,Monocytoid B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277624003,Follicular malignant lymphoma - mixed cell type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277625002,Follicular malignant lymphoma - small cleaved cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277626001,Diffuse high grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277627005,Nodular high grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277637000,Large cell anaplastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277641001,Follicular malignant lymphoma - large cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277642008,Low grade T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277643003,High grade T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277651000,Peripheral T-cell lymphoma - pleomorphic small cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277654008,Enteropathy-type T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277664004,Malignant lymphoma of testis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,278051002,Malignant lymphoma of thyroid gland,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,278052009,Malignant lymphoma of breast,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,302841002,Malignant lymphoma - small cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,303055001,"Malignant lymphoma, follicular centre cell",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,307623001,Malignant lymphoma - lymphoplasmacytic,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,308121000,Follicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314922006,B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314923001,Low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314924007,Follicular low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314925008,High grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314926009,T-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314929002,Diffuse low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314934003,Diffuse high grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,315264005,Suspected lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,400001003,Primary cutaneous lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,400122007,CTCL - Cutaneous T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,404111002,Lymphomatoid papulosis-associated mycosis fungoides,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,404140004,SALT type B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,413537009,Angioimmunoblastic T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,414166008,Natural Killer cell and T-cell malignant lymphoma nasal type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,414780005,Mucosa-associated lymphoid tissue lymphoma of orbit,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,420788006,Vitreoretinal lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,426071002,Hodgkin lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,427141003,Malignant lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,428046009,History of non-Hodgkins lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,433450000,Family history of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,443487006,Mantle cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,444597005,Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of stomach,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,444910004,Primary mediastinal (thymic) large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,445269007,Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,445406001,Hepatosplenic T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,447100004,Marginal zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,448211002,Adenolymphoma of parotid gland,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,448212009,Anaplastic lymphoma kinase negative anaplastic large cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,448709005,Non-Hodgkin lymphoma of stomach,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,449074003,Lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,449220000,Diffuse follicle center lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,450958009,"Malignant lymphoma, diffuse large B-cell, immunoblastic",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,721555001,Follicular lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,724648008,Plasmablastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,738770003,Anaplastic lymphoma kinase positive anaplastic large cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,762690000,Classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,763666008,Splenic marginal zone B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,830057003,Relapsing classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1148845007,Follicular non-Hodgkin lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1148851002,Follicular lymphoma grade IIIa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,143291000119104,Non-Hodgkin's lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,847481000000109,Follicular lymphoma grade 1,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,847631000000107,Follicular lymphoma grade 2,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,847651000000100,Follicular lymphoma grade 3,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,847691000000108,Follicular lymphoma grade 3a,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,847701000000108,Follicular lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,847741000000106,Diffuse large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,878461000000100,No FH of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1090241000000107,Angioimmunoblastic T-cell lymphoma with dysproteinaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1091861000000100,Cutaneous follicle centre lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1091891000000106,B-cell Hodgkin's lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD AND SUBSEQUENT LINES OF TREATMENT),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1091921000000103,B-cell non-Hodgkin's lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,835009,Angioimmunoblastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,1929004,"Malignant lymphoma, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,19340000,Plasmacytic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,20776008,Adenolymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,21964009,Lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,21983002,Struma lymphomatosa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,28054005,Cutaneous lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,28175004,Gastric pseudolymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,30440004,Lymphoma stage I,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,31047003,Lymphomatoid papulosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,40411000,"Malignant lymphoma, histiocytic, nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,41529000,"Classical Hodgkin lymphoma, mixed cellularity",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,46732000,"Malignant lymphoma, large cell, cleaved, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,51092000,Malignant lymphoma lymphocytic well differentiated diffuse,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,52248008,"Classical Hodgkin lymphoma, nodular sclerosis",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,55020008,"Malignant lymphoma, mixed cell type, follicular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,55150002,"Malignant lymphoma, nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,56944001,Lymphoma stage III,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,64575004,"Malignant lymphoma, small lymphocytic, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,66445009,Lymphoma stage IV,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,70600005,"Hodgkin lymphoma, nodular lymphocyte predominance",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,74654000,Mantle cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,76422004,Lymphoma stage II,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,92814006,B-cell CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,93191005,Malignant lymphoma of intra-abdominal lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,93192003,Malignant lymphoma of intrapelvic lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,93194002,Malignant lymphoma of lymph nodes of axilla AND/OR upper limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,93195001,"Malignant lymphoma of lymph nodes of head, face AND/OR neck",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,93197009,Malignant lymphoma of lymph nodes of multiple sites,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,93198004,Malignant lymphoma of spleen,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,95186006,Nodular lymphoma of intra-abdominal lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,95192000,Nodular lymphoma of lymph nodes of multiple sites,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,95193005,Nodular lymphoma of spleen,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,106252000,Staging classification for lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,109962001,Nonfollicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,109966003,"Lymphoma, immunoblastic, high grade",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,109969005,Diffuse large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,109975001,T-zone lymphoma (clinical),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,109976000,Lymphoepithelioid lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,109977009,Peripheral T-cell lymphoma pleomorphic medium and large cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,109978004,T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,109979007,B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,109988003,True histiocytic lymphoma (clinical),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,115244002,Malignant lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,115245001,"Malignant lymphoma, follicular AND/OR nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,118599009,"Lymphoma, Hodgkins",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,118600007,Malignant lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,118601006,Non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,118605002,"Hodgkin lymphoma, nodular lymphocyte predominance",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,118609008,Hodgkin mixed cellularity lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,118617000,Burkitt lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,128799007,"Hodgkin lymphoma, lymphocyte-rich",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,128803008,Marginal zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,128805001,Angiocentric natural killer cell and T-cell malignant lymphoma nasal type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,128875000,Primary cutaneous CD30 antigen positive large T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,128929007,Non-Hodgkin lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,128930002,Hodgkin lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,188609000,"Nodular lymphoma of lymph nodes of head, face and neck",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,188612002,Nodular lymphoma of lymph nodes of axilla and upper limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,188613007,Nodular lymphoma of lymph nodes of inguinal region and lower limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,188674006,Diffuse malignant lymphoma - small non-cleaved cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,188675007,"Malignant lymphoma, lymphocytic - poorly differentiated",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,188676008,Malignant lymphoma - mixed lymphocytic-histiocytic,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,189958005,"Lymphomatous tumour, benign",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,189962004,"Malignant lymphoma, stem cell type",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,232075002,Lymphoma of retina,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,236513009,Lymphoma of kidney,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,238994000,Drug-induced pseudolymphomatous eruption,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,239297008,Lymphomatoid granulomatosis of lung,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,239940004,Lymphomatoid granulomatosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,240794006,Splenic schistosomal giant cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,254372002,Ann Arbor lymphoma staging system,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,255102004,Intravascular lymphomatosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,258279002,Lymphoma staging symptom status values,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,269476000,Nodular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,274905008,Mantle zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,276811008,Gastric lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,276815004,Lymphoma of intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,276836002,Primary cerebral lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277024002,Working formulation of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277551008,Splenic lymphoma with villous lymphocytes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277570003,Lymphoma with spill,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277613000,Cutaneous peripheral T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277615007,Low grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277616008,Diffuse low grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277617004,High grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277618009,Nodular malignant lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277623009,Monocytoid B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277624003,Follicular malignant lymphoma - mixed cell type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277625002,Follicular malignant lymphoma - small cleaved cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277626001,Diffuse high grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277627005,Nodular high grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277637000,Large cell anaplastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277641001,Follicular malignant lymphoma - large cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277642008,Low grade T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277643003,High grade T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277651000,Peripheral T-cell lymphoma - pleomorphic small cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277654008,Enteropathy-type T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,277664004,Malignant lymphoma of testis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,278051002,Malignant lymphoma of thyroid gland,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,278052009,Malignant lymphoma of breast,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,302841002,Malignant lymphoma - small cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,303055001,"Malignant lymphoma, follicular centre cell",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,307623001,Malignant lymphoma - lymphoplasmacytic,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,308121000,Follicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,314922006,B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,314923001,Low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,314924007,Follicular low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,314925008,High grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,314926009,T-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,314929002,Diffuse low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,314934003,Diffuse high grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,315264005,Suspected lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,400001003,Primary cutaneous lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,400122007,CTCL - Cutaneous T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,404111002,Lymphomatoid papulosis-associated mycosis fungoides,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,404140004,SALT type B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,413537009,Angioimmunoblastic T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,414166008,Natural Killer cell and T-cell malignant lymphoma nasal type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,414780005,Mucosa-associated lymphoid tissue lymphoma of orbit,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,420788006,Vitreoretinal lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,426071002,Hodgkin lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,427141003,Malignant lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,428046009,History of non-Hodgkins lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,433450000,Family history of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,443487006,Mantle cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,444597005,Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of stomach,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,444910004,Primary mediastinal (thymic) large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,445269007,Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,445406001,Hepatosplenic T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,447100004,Marginal zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,448211002,Adenolymphoma of parotid gland,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,448212009,Anaplastic lymphoma kinase negative anaplastic large cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,448709005,Non-Hodgkin lymphoma of stomach,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,449074003,Lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,449220000,Diffuse follicle center lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,450958009,"Malignant lymphoma, diffuse large B-cell, immunoblastic",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,721555001,Follicular lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,724648008,Plasmablastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,738770003,Anaplastic lymphoma kinase positive anaplastic large cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,762690000,Classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,763666008,Splenic marginal zone B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,830057003,Relapsing classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,1148845007,Follicular non-Hodgkin lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,1148851002,Follicular lymphoma grade IIIa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,143291000119104,Non-Hodgkin's lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,847481000000109,Follicular lymphoma grade 1,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,847631000000107,Follicular lymphoma grade 2,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,847651000000100,Follicular lymphoma grade 3,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,847691000000108,Follicular lymphoma grade 3a,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,847701000000108,Follicular lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,847741000000106,Diffuse large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,878461000000100,No FH of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,1090241000000107,Angioimmunoblastic T-cell lymphoma with dysproteinaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,1091861000000100,Cutaneous follicle centre lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,1091891000000106,B-cell Hodgkin's lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (3RD LINE),Relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma,TA137,lymphoma,1091921000000103,B-cell non-Hodgkin's lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,835009,Angioimmunoblastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1929004,"Malignant lymphoma, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,14537002,"Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,16893006,"Hodgkin lymphoma, lymphocyte depletion, diffuse fibrosis",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,19340000,Plasmacytic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,20776008,Adenolymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,21964009,Lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,21983002,Struma lymphomatosa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,28054005,Cutaneous lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,28175004,Gastric pseudolymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,30440004,Lymphoma stage I,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,31047003,Lymphomatoid papulosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,40411000,"Malignant lymphoma, histiocytic, nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,41529000,"Classical Hodgkin lymphoma, mixed cellularity",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,46732000,"Malignant lymphoma, large cell, cleaved, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,51092000,Malignant lymphoma lymphocytic well differentiated diffuse,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,52248008,"Classical Hodgkin lymphoma, nodular sclerosis",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,55020008,"Malignant lymphoma, mixed cell type, follicular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,55150002,"Malignant lymphoma, nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,56944001,Lymphoma stage III,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,64575004,"Malignant lymphoma, small lymphocytic, diffuse",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,66445009,Lymphoma stage IV,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,70600005,"Hodgkin lymphoma, nodular lymphocyte predominance",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,74654000,Mantle cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,76422004,Lymphoma stage II,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,77430005,Adult T-cell lymphoma/leukaemia (HTLV-1 +),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,92814006,B-cell CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,93191005,Malignant lymphoma of intra-abdominal lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,93192003,Malignant lymphoma of intrapelvic lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,93194002,Malignant lymphoma of lymph nodes of axilla AND/OR upper limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,93195001,"Malignant lymphoma of lymph nodes of head, face AND/OR neck",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,93197009,Malignant lymphoma of lymph nodes of multiple sites,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,93198004,Malignant lymphoma of spleen,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,95186006,Nodular lymphoma of intra-abdominal lymph nodes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,95192000,Nodular lymphoma of lymph nodes of multiple sites,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,95193005,Nodular lymphoma of spleen,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,106252000,Staging classification for lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109962001,Nonfollicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109966003,"Lymphoma, immunoblastic, high grade",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109969005,Diffuse large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109975001,T-zone lymphoma (clinical),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109976000,Lymphoepithelioid lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109977009,Peripheral T-cell lymphoma pleomorphic medium and large cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109978004,T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109979007,B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,109988003,True histiocytic lymphoma (clinical),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,112687003,"Hodgkin lymphoma, lymphocyte depletion",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,115244002,Malignant lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,115245001,"Malignant lymphoma, follicular AND/OR nodular",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118599009,"Lymphoma, Hodgkins",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118600007,Malignant lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118601006,Non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118605002,"Hodgkin lymphoma, nodular lymphocyte predominance",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118607005,Lymphocyte-rich classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118609008,Hodgkin mixed cellularity lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,118617000,Burkitt lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,128799007,"Hodgkin lymphoma, lymphocyte-rich",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,128803008,Marginal zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,128805001,Angiocentric natural killer cell and T-cell malignant lymphoma nasal type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,128875000,Primary cutaneous CD30 antigen positive large T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,128929007,Non-Hodgkin lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,128930002,Hodgkin lymphoma - category,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188609000,"Nodular lymphoma of lymph nodes of head, face and neck",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188612002,Nodular lymphoma of lymph nodes of axilla and upper limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188613007,Nodular lymphoma of lymph nodes of inguinal region and lower limb,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188674006,Diffuse malignant lymphoma - small non-cleaved cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188675007,"Malignant lymphoma, lymphocytic - poorly differentiated",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188676008,Malignant lymphoma - mixed lymphocytic-histiocytic,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,188679001,Diffuse non-Hodgkin lymphoma undifferentiated (diffuse),RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,189958005,"Lymphomatous tumour, benign",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,189962004,"Malignant lymphoma, stem cell type",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,232075002,Lymphoma of retina,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,236513009,Lymphoma of kidney,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,238994000,Drug-induced pseudolymphomatous eruption,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,239297008,Lymphomatoid granulomatosis of lung,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,239940004,Lymphomatoid granulomatosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,240794006,Splenic schistosomal giant cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,254355009,Tumor-node-metastasis (TNM) non-Hodgkin lymphoma staging,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,254372002,Ann Arbor lymphoma staging system,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,255102004,Intravascular lymphomatosis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,258279002,Lymphoma staging symptom status values,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,269476000,Nodular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,274905008,Mantle zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,276811008,Gastric lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,276815004,Lymphoma of intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,276836002,Primary cerebral lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277024002,Working formulation of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277551008,Splenic lymphoma with villous lymphocytes,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277570003,Lymphoma with spill,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277613000,Cutaneous peripheral T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277615007,Low grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277616008,Diffuse low grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277617004,High grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277618009,Nodular malignant lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277623009,Monocytoid B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277624003,Follicular malignant lymphoma - mixed cell type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277625002,Follicular malignant lymphoma - small cleaved cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277626001,Diffuse high grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277627005,Nodular high grade B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277637000,Large cell anaplastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277641001,Follicular malignant lymphoma - large cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277642008,Low grade T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277643003,High grade T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277651000,Peripheral T-cell lymphoma - pleomorphic small cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277654008,Enteropathy-type T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,277664004,Malignant lymphoma of testis,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,278051002,Malignant lymphoma of thyroid gland,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,278052009,Malignant lymphoma of breast,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,302841002,Malignant lymphoma - small cell,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,303055001,"Malignant lymphoma, follicular centre cell",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,307623001,Malignant lymphoma - lymphoplasmacytic,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,308121000,Follicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314922006,B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314923001,Low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314924007,Follicular low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314925008,High grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314926009,T-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314929002,Diffuse low grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,314934003,Diffuse high grade B-cell lymphoma morphology,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,315264005,Suspected lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,400001003,Primary cutaneous lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,400122007,CTCL - Cutaneous T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,404111002,Lymphomatoid papulosis-associated mycosis fungoides,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,404140004,SALT type B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,413537009,Angioimmunoblastic T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,414166008,Natural Killer cell and T-cell malignant lymphoma nasal type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,414780005,Mucosa-associated lymphoid tissue lymphoma of orbit,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,420788006,Vitreoretinal lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,426071002,Hodgkin lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,427141003,Malignant lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,428046009,History of non-Hodgkins lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,433450000,Family history of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,443487006,Mantle cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,444597005,Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue of stomach,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,444910004,Primary mediastinal (thymic) large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,445269007,Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,445406001,Hepatosplenic T-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,447100004,Marginal zone lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,448211002,Adenolymphoma of parotid gland,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,448212009,Anaplastic lymphoma kinase negative anaplastic large cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,448709005,Non-Hodgkin lymphoma of stomach,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,449074003,Lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,449220000,Diffuse follicle center lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,450958009,"Malignant lymphoma, diffuse large B-cell, immunoblastic",RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,721555001,Follicular lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,724648008,Plasmablastic lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,738770003,Anaplastic lymphoma kinase positive anaplastic large cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,762690000,Classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,763666008,Splenic marginal zone B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,830057003,Relapsing classical Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1148845007,Follicular non-Hodgkin lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1148851002,Follicular lymphoma grade IIIa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,143291000119104,Non-Hodgkin's lymphoma in remission,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,847481000000109,Follicular lymphoma grade 1,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,847631000000107,Follicular lymphoma grade 2,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,847651000000100,Follicular lymphoma grade 3,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,847691000000108,Follicular lymphoma grade 3a,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,847701000000108,Follicular lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,847741000000106,Diffuse large B-cell lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,878461000000100,No FH of non-Hodgkin lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1090241000000107,Angioimmunoblastic T-cell lymphoma with dysproteinaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1091861000000100,Cutaneous follicle centre lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1091891000000106,B-cell Hodgkin's lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB (LAST LINE),Lymphoma (follicular non-Hodgkin's),TA037,lymphoma,1091921000000103,B-cell non-Hodgkin's lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY,First-line treatment of stage III-IV follicular lymphoma,TA243,follicular lymphoma,109962001,Nonfollicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY,First-line treatment of stage III-IV follicular lymphoma,TA243,follicular lymphoma,308121000,Follicular lymphoma,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY,First-line treatment of stage III-IV follicular lymphoma,TA243,follicular lymphoma,721555001,Follicular lymphoma of small intestine,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY,First-line treatment of stage III-IV follicular lymphoma,TA243,follicular lymphoma,1148851002,Follicular lymphoma grade IIIa,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY,First-line treatment of stage III-IV follicular lymphoma,TA243,follicular lymphoma,847481000000109,Follicular lymphoma grade 1,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY,First-line treatment of stage III-IV follicular lymphoma,TA243,follicular lymphoma,847631000000107,Follicular lymphoma grade 2,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY,First-line treatment of stage III-IV follicular lymphoma,TA243,follicular lymphoma,847651000000100,Follicular lymphoma grade 3,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY,First-line treatment of stage III-IV follicular lymphoma,TA243,follicular lymphoma,847691000000108,Follicular lymphoma grade 3a,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY,First-line treatment of stage III-IV follicular lymphoma,TA243,follicular lymphoma,847701000000108,Follicular lymphoma grade 3b,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY (OTHER THAN FLUDARABINE AND CYCLOPHOSPHAMIDE),Relapsed or refractory chronic lymphocytic leukaemia,TA193,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY (OTHER THAN FLUDARABINE AND CYCLOPHOSPHAMIDE),Relapsed or refractory chronic lymphocytic leukaemia,TA193,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY (OTHER THAN FLUDARABINE AND CYCLOPHOSPHAMIDE),Relapsed or refractory chronic lymphocytic leukaemia,TA193,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
RITUXIMAB IN COMBINATION WITH CHEMOTHERAPY (OTHER THAN FLUDARABINE AND CYCLOPHOSPHAMIDE),Relapsed or refractory chronic lymphocytic leukaemia,TA193,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
RITUXIMAB IN COMBINATION WITH FLUDARABINE AND CYCLOPHOSPHAMIDE,Relapsed or refractory chronic lymphocytic leukaemia,TA193,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
RITUXIMAB IN COMBINATION WITH FLUDARABINE AND CYCLOPHOSPHAMIDE,Relapsed or refractory chronic lymphocytic leukaemia,TA193,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
RITUXIMAB IN COMBINATION WITH FLUDARABINE AND CYCLOPHOSPHAMIDE,Relapsed or refractory chronic lymphocytic leukaemia,TA193,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
RITUXIMAB IN COMBINATION WITH FLUDARABINE AND CYCLOPHOSPHAMIDE,Relapsed or refractory chronic lymphocytic leukaemia,TA193,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
RITUXIMAB IN COMBINATION WITH FLUDARABINE AND CYCLOPHOSPHAMIDE,Relapsed or refractory chronic lymphocytic leukaemia,TA193,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
RITUXIMAB IN COMBINATION WITH FLUDARABINE AND CYCLOPHOSPHAMIDE,Relapsed or refractory chronic lymphocytic leukaemia,TA193,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
RITUXIMAB IN COMBINATION WITH FLUDARABINE AND CYCLOPHOSPHAMIDE,Relapsed or refractory chronic lymphocytic leukaemia,TA193,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
RITUXIMAB IN COMBINATION WITH FLUDARABINE AND CYCLOPHOSPHAMIDE,Relapsed or refractory chronic lymphocytic leukaemia,TA193,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
RITUXIMAB IN COMBINATION WITH FLUDARABINE AND CYCLOPHOSPHAMIDE (1ST LINE),Chronic lymphocytic leukaemia,TA174,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
RITUXIMAB IN COMBINATION WITH FLUDARABINE AND CYCLOPHOSPHAMIDE (1ST LINE),Chronic lymphocytic leukaemia,TA174,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
RITUXIMAB IN COMBINATION WITH FLUDARABINE AND CYCLOPHOSPHAMIDE (1ST LINE),Chronic lymphocytic leukaemia,TA174,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
RITUXIMAB IN COMBINATION WITH FLUDARABINE AND CYCLOPHOSPHAMIDE (1ST LINE),Chronic lymphocytic leukaemia,TA174,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,RITUXIMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,228007,Lepromatous cutaneous vasculitis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY
RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,77628002,Retinal vasculitis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY
RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,235992000,Peritoneal vasculitis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY
RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,238787009,Secondary cutaneous vasculitis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY
RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,239924002,Primary necrotising systemic vasculitis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY
RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,239933000,Primary necrotising vasculitis with granulomata,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY
RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,239944008,Vasculitis due to lupus erythematosus,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY
RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,239945009,Anti-C1q vasculitis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY
RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,239947001,Essential cryoglobulinemic vasculitis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY
RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,400054000,Rheumatoid arthritis with vasculitis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY
RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,407530004,Primary systemic vasculitis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY
RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,472974007,H/O vasculitis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY
RITUXIMAB IN COMBINATION WITH GLUCOCORTICOIDS,Anti-neutrophil cytoplasmic antibody-associated vasculitis,TA308,vasculitis,724599009,Small vessel vasculitis,RITUXIMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RITUXIMAB IN COMBINATION WITH METHOTREXATE (AFTER TNF FAILURE),Rheumatoid arthritis,TA195,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ABATACEPT,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,2517002,Stroke rehabilitation,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,25133001,Completed stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,28690004,Stroke test,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,39925003,"MELAS - mitochondrial encephalopathy, lactic acidosis and stroke-like episodes",RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,44922000,Bounding pulse with rapid upstroke and descent,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,49436004,Atrial fibrillation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,90096001,Stroke volume,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,134377004,Atrial fibrillation monitoring,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,135875009,Stroke prevention,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,135877001,Stroke risk,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,160252004,No family history of cardiovascular accident or stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,160271002,No family history of stroke and/or transient ischaemic attack,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,170600009,Stroke monitoring,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,195080001,Atrial fibrillation and flutter,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,195163003,Stroke due to intracerebral haemorrhage,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,195212005,Brainstem stroke syndrome,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,195213000,Cerebellar stroke syndrome,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,212937007,Heat stroke and sunstroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,230690007,Stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,230694003,Total anterior cerebral circulation stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,230695002,Partial anterior cerebral circulation stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,230696001,Posterior cerebral circulation stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,230700009,Pure sensory stroke due to and following lacunar infarction,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,230713003,Stroke of uncertain pathology,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,230714009,Anterior circulation stroke of uncertain pathology,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,230715005,Posterior circulation stroke of uncertain pathology,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,230739000,Spinal cord stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,233911009,Non-rheumatic atrial fibrillation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,275434003,Stroke in the puerperium,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,276898003,Left ventricular stroke work index,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,277286006,Chronic central post-stroke pain,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,277381004,Stroke index,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,282825002,Intermittent atrial fibrillation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,297250002,No family history of stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,299403002,Stroke test positive,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,299404008,Stroke test negative,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,300996004,Controlled atrial fibrillation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,306802002,Referral to stroke service,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,306803007,Admission to stroke unit,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,306808003,Discharge from stroke service,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,306810001,Seen by stroke service,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,308067002,History of stroke in last year,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,309966001,Stroke unit,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,310137004,Stroke service,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,312442005,History of atrial fibrillation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,371040005,Thrombotic stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,371041009,Embolic stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,412773009,Referral to stroke clinic,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,413119003,Stroke group member,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,413124000,Stroke/transient ischaemic attack referral,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,415628004,Stroke/transient ischaemic attack monitoring first letter,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,415629007,Stroke/transient ischemic attack monitoring second letter,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,415630002,Stroke/transient ischaemic attack monitoring status,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,415631003,Stroke/transient ischemic attack monitoring third letter,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,417059002,Stroke/transient ischemic attack monitoring verbal invitation,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,417506008,Hemorrhagic stroke monitoring,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,417540008,Stroke/transient ischaemic attack monitoring invitation,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,422504002,Ischaemic stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,440028005,Permanent atrial fibrillation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,440059007,Persistent atrial fibrillation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,449863006,Insertion of pacemaker for control of atrial fibrillation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,450743008,NIHSS (National Institutes of Health stroke scale) score,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,699833006,Provision of written information about atrial fibrillation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,704154001,"HAS-BLED (hypertension, abnormal renal and/or liver function, stroke, bleeding history or predisposition, labile INR (international normalised ratio), elderly over 65, and drugs and/or alcohol concomitantly) score",RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,704180000,"HAS-BLED (hypertension, abnormal renal and/or liver function, stroke, bleeding history or predisposition, labile international normalised ratio, elderly over 65, and drugs and/or alcohol concomitantly) bleeding risk score",RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,706923002,Longstanding persistent atrial fibrillation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,707514001,Stroke impact scale version 3.0 score,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,719008003,At increased risk of atrial fibrillation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,722929005,Perinatal arterial ischemic stroke of fetus and/or neonate,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,724424009,Cerebral ischemic stroke due to small artery occlusion,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,736712009,PASS (Postural Assessment Scale for Stroke Patients) score,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,788880006,Cerebral ischaemic stroke due to dissection of artery,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,788884002,Cerebral ischemic stroke due to subarachnoid hemorrhage,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,1010405004,Paroxysmal AF (atrial fibrillation) with RVR (rapid ventricular response),RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,88601000000107,DNA (did not attend) stroke clinic,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,112901000000108,Referral to multidisciplinary stroke function improvement service,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,120041000119109,Atrial fibrillation with rapid ventricular response,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,133111000000106,QOF (Quality and Outcomes Framework) atrial fibrillation quality indicator-related care invitation using preferred method of communication,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,140921000119102,Ischemic stroke without coma,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,143471000000105,QOF (Quality and Outcomes Framework) stroke and transient ischaemic attack quality indicator-related care invitation using preferred method of communication,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,196371000000102,Atrial fibrillation resolved,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,201501000000108,Seen in stroke clinic,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,231231000000107,Delivery of rehabilitation for stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,248411000000105,Atrial fibrillation annual review,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,519751000000106,Stroke 6 month review,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,521411000000106,Did not attend stroke review,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,685631000000102,Stroke and cerebrovascular accident unspecified,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,711411000000101,Atrial fibrillation monitoring invitation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,713771000000100,Stroke/transient ischaemic attack monitoring administration,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,713801000000102,Atrial fibrillation monitoring administration,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,715941000000109,Excepted from atrial fibrillation quality indicators - patient unsuitable,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,716021000000109,Excepted from stroke quality indicators - informed dissent,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,716181000000109,Atrial fibrillation monitoring third letter,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,716331000000108,Exception reporting - stroke quality indicators,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,716581000000101,Excepted from stroke quality indicators - patient unsuitable,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,716721000000107,Atrial fibrillation monitoring telephone invitation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,716871000000101,Exception reporting - atrial fibrillation quality indicators,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,716981000000106,Atrial fibrillation monitoring second letter,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,717011000000100,Atrial fibrillation monitoring verbal invite,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,717221000000101,Atrial fibrillation monitoring first letter,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,717241000000108,Stroke/transient ischaemic attack monitoring telephone invitation,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,717381000000109,Excepted from atrial fibrillation quality indicators - informed dissent,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,769211000000103,Suspected stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,810991000000109,Stroke self-management plan review,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,812041000000104,Stroke self-management plan agreed,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,816401000000105,Atrial fibrillation excluded,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,816561000000108,Stroke initial post discharge review,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,842441000000104,Provision of written information about stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,847611000000104,Atrial fibrillation care pathway,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,870631000000105,QStroke 10 year risk of stroke calculator,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,1025021000000107,High risk of atrial fibrillation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,1062151000000103,Stroke TOM (Therapy Outcome Measure) activity score,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,1062171000000107,Stroke TOM (Therapy Outcome Measure) impairment score,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,1062181000000109,Stroke TOM (Therapy Outcome Measure) participation score,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,1062191000000106,Stroke TOM (Therapy Outcome Measure) wellbeing score,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,1066831000000104,Atrial fibrillation detected,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,1067061000000104,Atrial fibrillation not detected,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,1078001000000105,Haemorrhagic stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,1085311000000106,QStroke risk calculator score,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,atrial fibrillation,1110851000000100,QOF (Quality and Outcomes Framework) atrial fibrillation quality indicator-related care invitation,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,1110981000000104,QOF (Quality and Outcomes Framework) stroke and transient ischaemic attack quality indicator-related care invitation,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Prevention of stroke and systemic embolism in atrial fibrillation,TA256,stroke,16371781000119100,Cerebellar stroke,RIVAROXABAN,STROKE MEDICINE,STROKE MEDICINE|NEUROLOGY
RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,pulmonary embolism,59282003,Pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,pulmonary embolism,200284000,Obstetric pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,pulmonary embolism,200286003,Obstetric air pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,pulmonary embolism,200303005,Obstetric blood-clot pulmonary embolism with antenatal complication,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,pulmonary embolism,233217004,Operation for pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,pulmonary embolism,233936003,Acute massive pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,pulmonary embolism,233937007,Subacute massive pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,pulmonary embolism,417113001,Suspected PE (pulmonary embolism),RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,pulmonary embolism,430801003,Family history of pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,pulmonary embolism,438773007,Recurrent pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,venous thromboembolism,443749004,Venous thromboembolism risk assessment,RIVAROXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY
RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,venous thromboembolism,699035003,At low risk of venous thromboembolism,RIVAROXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY
RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,venous thromboembolism,711293008,At moderate risk of venous thromboembolism,RIVAROXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY
RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,venous thromboembolism,711328005,At high risk of venous thromboembolism,RIVAROXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY
RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,venous thromboembolism,787331000000107,Venous thromboembolism prevention management,RIVAROXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY
RIVAROXABAN,Treating pulmonary embolism and preventing recurrent venous thromboembolism,TA287,venous thromboembolism,844041000000102,Education about risk of venous thromboembolism,RIVAROXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,14534009,Deep vein thrombosis of splenic vein,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,49956009,Antenatal DVT (deep vein thrombosis),RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,56272000,Puerperal DVT (deep vein thrombosis),RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,pulmonary embolism,59282003,Pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,128053003,Deep vein thrombosis,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,134399007,Deep vein thrombosis of leg related to air travel,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,161508001,History of DVT (deep vein thrombosis),RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,200232006,Antenatal deep vein thrombosis - delivered,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,200233001,Antenatal deep vein thrombosis with antenatal complication,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,200238005,Postnatal deep vein thrombosis with postnatal complication,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,pulmonary embolism,200284000,Obstetric pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,pulmonary embolism,200286003,Obstetric air pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,pulmonary embolism,200303005,Obstetric blood-clot pulmonary embolism with antenatal complication,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,213220000,Postoperative deep vein thrombosis,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,225999004,At increased risk of DVT (deep vein thrombosis),RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,pulmonary embolism,233217004,Operation for pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,pulmonary embolism,233936003,Acute massive pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,pulmonary embolism,233937007,Subacute massive pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,234044007,Ileofemoral deep vein thrombosis,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,401186003,Deep vein thrombosis screening,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,413459009,Advised risk of deep vein thrombosis in air travel,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,413956008,Deep vein thrombosis of leg related to intravenous drug use,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,pulmonary embolism,417113001,Suspected PE (pulmonary embolism),RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,429053008,Wells deep vein thrombosis clinical probability score,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,pulmonary embolism,430801003,Family history of pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,432805000,Suspected deep vein thrombosis,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,pulmonary embolism,438773007,Recurrent pulmonary embolism,RIVAROXABAN,THORACIC MEDICINE,THORACIC MEDICINE|CARDIOLOGY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,443210003,Deep vein thrombosis of peroneal vein,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,710167004,Recurrent DVT (deep vein thrombosis),RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,198301000000109,FH: deep vein thrombosis,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,323631000000102,DVT (deep vein thrombosis) prevention,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,492161000000109,Deep vein thrombosis enhanced services administration,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,503421000000105,Deep vein thrombosis enhanced services administration stage 1 service level,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,503451000000100,Deep vein thrombosis enhanced services administration stage 2 service level,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,503481000000106,Deep vein thrombosis enhanced services administration stage 3 service level,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,513251000000101,Low probability of deep vein thrombosis,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,513271000000105,Moderate probability of deep vein thrombosis,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,513291000000109,High probability of deep vein thrombosis,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,869611000000104,On deep vein thrombosis care pathway,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,872221000000109,No history of deep vein thrombosis,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,978421000000101,Unprovoked deep vein thrombosis,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism,TA261,deep vein thrombosis,978441000000108,Provoked deep vein thrombosis,RIVAROXABAN,VASCULAR SURGERY,VASCULAR SURGERY|CLINICAL HAEMATOLOGY
RIVAROXABAN,Venous thromboembolism in adults having elective total hip replacement surgery or elective total knee replacement surgery (prevention),TA170,venous thromboembolism,443749004,Venous thromboembolism risk assessment,RIVAROXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY
RIVAROXABAN,Venous thromboembolism in adults having elective total hip replacement surgery or elective total knee replacement surgery (prevention),TA170,venous thromboembolism,699035003,At low risk of venous thromboembolism,RIVAROXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY
RIVAROXABAN,Venous thromboembolism in adults having elective total hip replacement surgery or elective total knee replacement surgery (prevention),TA170,venous thromboembolism,711293008,At moderate risk of venous thromboembolism,RIVAROXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY
RIVAROXABAN,Venous thromboembolism in adults having elective total hip replacement surgery or elective total knee replacement surgery (prevention),TA170,venous thromboembolism,711328005,At high risk of venous thromboembolism,RIVAROXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY
RIVAROXABAN,Venous thromboembolism in adults having elective total hip replacement surgery or elective total knee replacement surgery (prevention),TA170,venous thromboembolism,787331000000107,Venous thromboembolism prevention management,RIVAROXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY
RIVAROXABAN,Venous thromboembolism in adults having elective total hip replacement surgery or elective total knee replacement surgery (prevention),TA170,venous thromboembolism,844041000000102,Education about risk of venous thromboembolism,RIVAROXABAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|VASCULAR SURGERY
RIVAROXABAN IN COMBINATION WITH ASPIRIN PLUS CLOPIDOGREL OR ASPIRIN ALONE,Preventing adverse outcomes after acute management of acute coronary syndrome,TA335,acute coronary syndrome,837091000000100,H/O acute coronary syndrome,RIVAROXABAN,CARDIOLOGY,CARDIOLOGY
RIVASTIGMINE,Alzheimer's disease,TA019,alzheimer's disease,273269001,ADAS - Alzheimer's Disease Assessment Scale,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
RIVASTIGMINE,Alzheimer's disease,TA111,alzheimer's disease,273269001,ADAS - Alzheimer's Disease Assessment Scale,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
RIVASTIGMINE,Alzheimer's disease,TA019,alzheimer's disease,416780008,Dementia in Alzheimer's disease with early onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
RIVASTIGMINE,Alzheimer's disease,TA111,alzheimer's disease,416780008,Dementia in Alzheimer's disease with early onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
RIVASTIGMINE,Alzheimer's disease,TA019,alzheimer's disease,416975007,Alzheimer's disease with late onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
RIVASTIGMINE,Alzheimer's disease,TA111,alzheimer's disease,416975007,Alzheimer's disease with late onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
RIVASTIGMINE,Alzheimer's disease,TA019,alzheimer's disease,142011000119109,Alzheimer's disease co-occurrent with delirium,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
RIVASTIGMINE,Alzheimer's disease,TA111,alzheimer's disease,142011000119109,Alzheimer's disease co-occurrent with delirium,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
RIVASTIGMINE,Alzheimer's disease (mild to moderate),TA217,alzheimer's disease,273269001,ADAS - Alzheimer's Disease Assessment Scale,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
RIVASTIGMINE,Alzheimer's disease (mild to moderate),TA217,alzheimer's disease,416780008,Dementia in Alzheimer's disease with early onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
RIVASTIGMINE,Alzheimer's disease (mild to moderate),TA217,alzheimer's disease,416975007,Alzheimer's disease with late onset,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
RIVASTIGMINE,Alzheimer's disease (mild to moderate),TA217,alzheimer's disease,142011000119109,Alzheimer's disease co-occurrent with delirium,DONEPEZIL,NEUROLOGY,NEUROLOGY|GERIATRIC MEDICINE|MENTAL HEALTH
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,22193007,Osteoarthritis of joint of hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,33952002,Localised osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,37895003,Osteoarthritis of first carpometacarpal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,82300000,Osteoarthritis of ankle and/or foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,160414002,Family history: Osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,161567008,History of rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,161568003,History of osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201819000,Generalised osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201821005,(Heberdens' nodes) or (Bouchards' nodes) or (generalized osteoarthritis of the hand),CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201831003,"Localized, primary osteoarthritis of the shoulder region",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201835007,"Localized, primary osteoarthritis of the pelvic region and thigh",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201837004,"Localised, primary osteoarthritis of the ankle and foot",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201849003,"Localised, secondary osteoarthritis of the shoulder region",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201852006,"Localised, secondary osteoarthritis of the hand",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201855008,"Localized, secondary osteoarthritis of the ankle and/or foot",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201889009,"Osteoarthritis NOS, of the upper arm",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201890000,Wrist osteoarthritis NOS,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201891001,Thumb osteoarthritis NOS,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201892008,Osteoarthritis NOS: [pelvic region and/or thigh] or [hip],CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201893003,Knee osteoarthritis NOS,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,201894009,"Osteoarthritis NOS, of ankle and foot",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,202655008,Osteoarthritis of spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239863005,Osteoarthritis of spinal facet joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239866002,Osteoarthritis of elbow,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239868001,Osteoarthritis of finger,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239874001,Osteoarthritis of ankle,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239877008,Osteoarthritis of first MTPJ (metatarsophalangeal joint),CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,239878003,Osteoarthritis of toe joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,267889007,Generalized osteoarthritis of the hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,267890003,"Localised, secondary osteoarthritis of the pelvic region and thigh",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,267891004,"Localized osteoarthritis, unspecified, of the pelvic region and thigh",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,268054009,Osteoarthritis of multiple joints,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,313257005,"Localized, primary osteoarthritis of the wrist",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,313258000,"Localised, primary osteoarthritis of toe",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,313259008,"Localized, primary osteoarthritis of elbow",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,373623009,Osteoarthritis of glenohumeral joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,394991004,Flare of osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,443524000,Secondary osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,446165001,HOOS - hip disability and osteoarthritis outcome score,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,450521003,Osteoarthritis of patellofemoral joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,700324005,Osteoarthritis of talonavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,782845000,Knee Injury and Osteoarthritis Outcome Score,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1162304008,Oligoarticular osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343601009,OA (osteoarthritis) of spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343603007,Osteoarthritis of thoracic spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343604001,Cervical osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,1343605000,Osteoarthritis of lumbar spine,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,230771000000108,Delivery of rehabilitation for osteoarthritis,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,323301000119109,Osteoarthritis of left knee joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,323311000119107,Osteoarthritis of right hip joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,637091000000105,"Osteoarthritis NOS, of the lower leg",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,666441000000103,"Osteoarthritis NOS, of shoulder region",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,666451000000100,"Osteoarthritis NOS, other specified site",CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,805881000000109,Exception reporting - osteoarthritis quality indicators,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,805901000000107,Excepted from osteoarthritis quality indicators - patient unsuitable,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,805921000000103,Excepted from osteoarthritis quality indicators - informed dissent,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,osteoarthritis,850791000000102,Osteoarthritis of sternoclavicular joint,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|TRAUMA & ORTHOPAEDICS|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFECOXIB,Osteoarthritis and rheumatoid arthritis,TA027,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,CELECOXIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,135836000,End stage chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,171230000,Chronic obstructive pulmonary disease screening,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,195951007,Acute exacerbation of COPD (chronic obstructive pulmonary disease),ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,196001008,COPD (chronic obstructive pulmonary disease) with acute lower respiratory infection,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,270473001,History of chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,285381006,Acute infective exacerbation of chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,297241004,Family history of chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,313296004,Mild chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,313297008,Moderate chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,313299006,Severe chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,390891009,Chronic obstructive pulmonary disease monitoring,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,390941006,Chronic obstructive pulmonary disease monitoring due,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,394702007,Chronic obstructive pulmonary disease follow-up,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,394703002,Chronic obstructive pulmonary disease annual review,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,395159008,Chronic obstructive pulmonary disease leaflet given,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,401184000,Chronic obstructive pulmonary disease monitoring by nurse,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,401185004,Chronic obstructive pulmonary disease monitoring by doctor,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,401200002,At increased risk of chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,408501008,Emergency hospital admission for chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,408552005,No family history of chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,413845009,Chronic obstructive pulmonary disease accident and emergency attendance since last visit,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,414087000,Emergency chronic obstructive pulmonary disease admission since last appointment,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,445192002,Clinical COPD (chronic obstructive pulmonary disease) questionnaire total score,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,445312005,CCQ - Clinical COPD (chronic obstructive pulmonary disease) questionnaire,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,446660005,CAT - COPD (chronic obstructive pulmonary disease) assessment test score,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,473202005,Optimization of medication for chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,704121003,Step up change in chronic obstructive pulmonary disease management plan,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,704123000,Step down change in chronic obstructive pulmonary disease management plan,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,716358000,Telehealth chronic obstructive pulmonary disease monitoring,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,723245007,Number of chronic obstructive pulmonary disease exacerbations in past year,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,736283006,Chronic obstructive pulmonary disease clinical management plan,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,741056003,COPD (chronic obstructive pulmonary disease) education,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,57671000052108,CAT - COPD (chronic obstructive pulmonary disease) assessment test,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,110011000000107,DNA - Did not attend chronic obstructive pulmonary disease clinic,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,143371000000104,QOF (Quality and Outcomes Framework) chronic obstructive pulmonary disease quality indicator-related care invitation using preferred method of communication,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,198401000000104,COPD (chronic obstructive pulmonary disease) disturbs sleep,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,198411000000102,COPD (chronic obstructive pulmonary disease) does not disturb sleep,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,198901000000105,Multiple chronic obstructive pulmonary disease emergency hospital admissions,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,201341000000101,Chronic obstructive pulmonary disease monitoring status,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,204991000000107,Suspected chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,293991000000106,Very severe chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,371611000000107,Chronic obstructive pulmonary disease patient unsuitable for pulmonary rehabilitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,374591000000101,Chronic obstructive pulmonary disease enhanced services administration,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,375851000000108,Referred for chronic obstructive pulmonary disease structured smoking assessment,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,375911000000102,Chronic obstructive pulmonary disease structured smoking assessment declined,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,383611000000102,At risk of COPD (chronic obstructive pulmonary disease) exacerbation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,527361000000107,CAT - COPD (chronic obstructive pulmonary disease) assessment test,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,711431000000109,Chronic obstructive pulmonary disease monitoring invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,713731000000102,Chronic obstructive pulmonary disease monitoring administration,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,716241000000106,Chronic obstructive pulmonary disease monitoring first letter,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,716281000000103,Chronic obstructive pulmonary disease monitoring verbal invite,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,716901000000101,Chronic obstructive pulmonary disease monitoring telephone invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,717021000000106,Chronic obstructive pulmonary disease monitoring second letter,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,717521000000104,Chronic obstructive pulmonary disease monitoring third letter,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,718241000000107,Provision of chronic obstructive pulmonary disease rescue pack,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,753941000000104,Discussion about chronic obstructive pulmonary disease exacerbation plan,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,760601000000107,Chronic obstructive pulmonary disease 3 monthly review,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,760621000000103,Chronic obstructive pulmonary disease 6 monthly review,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,783631000000109,General practitioner out of hours service notified of chronic obstructive pulmonary disease care plan,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,789661000000102,Preferred place of care for next exacerbation of COPD (chronic obstructive pulmonary disease),ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,790301000000101,Referral to chronic obstructive pulmonary disease community nursing team,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,810951000000101,COPD (chronic obstructive pulmonary disease) self-management plan review,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,811961000000106,Chronic obstructive pulmonary disease self-management plan agreed,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,820341000000109,COPD (chronic obstructive pulmonary disease) rescue pack not indicated,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,826111000000109,On chronic obstructive pulmonary disease supportive care pathway,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,827571000000106,Has chronic obstructive pulmonary disease care plan,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,847091000000104,Acute non-infective exacerbation of chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,848431000000106,COPD (chronic obstructive pulmonary disease) care pathway,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,857661000000104,Seen in chronic obstructive pulmonary disease clinic,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,857791000000103,Chronic obstructive pulmonary disease rescue pack declined,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,857811000000102,Chronic obstructive pulmonary disease written self management plan declined,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,857821000000108,Chronic obstructive pulmonary disease self management plan not appropriate,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,892321000000109,Chronic obstructive pulmonary disease management plan declined,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,897311000000101,Shared care COPD (chronic obstructive pulmonary disease) monitoring,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,941201000000103,Chronic obstructive pulmonary disease resolved,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,1065151000000105,Number of hospital admissions due to COPD (chronic obstructive pulmonary disease) in past year,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,1066231000000103,Chronic obstructive pulmonary disease monitoring email invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,1066281000000104,COPD (chronic obstructive pulmonary disease) monitoring SMS (short message service) text message invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,1066821000000101,COPD (chronic obstructive pulmonary disease) monitoring SMS (short message service) text message first invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,1066841000000108,COPD (chronic obstructive pulmonary disease) monitoring SMS (short message service) text message second invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,1066851000000106,COPD (chronic obstructive pulmonary disease) monitoring SMS (short message service) text message third invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,1108721000000102,Excepted from COPD (chronic obstructive pulmonary disease) quality indicators - service unavailable,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST,Management of severe chronic obstructive pulmonary disease,TA244,chronic obstructive pulmonary disease,1110861000000102,QOF (Quality and Outcomes Framework) chronic obstructive pulmonary disease quality indicator-related care invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,135836000,End stage chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,171230000,Chronic obstructive pulmonary disease screening,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,195951007,Acute exacerbation of COPD (chronic obstructive pulmonary disease),ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,196001008,COPD (chronic obstructive pulmonary disease) with acute lower respiratory infection,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,270473001,History of chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,285381006,Acute infective exacerbation of chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,297241004,Family history of chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,313296004,Mild chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,313297008,Moderate chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,313299006,Severe chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,390891009,Chronic obstructive pulmonary disease monitoring,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,390941006,Chronic obstructive pulmonary disease monitoring due,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,394702007,Chronic obstructive pulmonary disease follow-up,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,394703002,Chronic obstructive pulmonary disease annual review,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,395159008,Chronic obstructive pulmonary disease leaflet given,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,401184000,Chronic obstructive pulmonary disease monitoring by nurse,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,401185004,Chronic obstructive pulmonary disease monitoring by doctor,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,401200002,At increased risk of chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,408501008,Emergency hospital admission for chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,408552005,No family history of chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,413845009,Chronic obstructive pulmonary disease accident and emergency attendance since last visit,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,414087000,Emergency chronic obstructive pulmonary disease admission since last appointment,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,445192002,Clinical COPD (chronic obstructive pulmonary disease) questionnaire total score,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,445312005,CCQ - Clinical COPD (chronic obstructive pulmonary disease) questionnaire,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,446660005,CAT - COPD (chronic obstructive pulmonary disease) assessment test score,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,473202005,Optimization of medication for chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,704121003,Step up change in chronic obstructive pulmonary disease management plan,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,704123000,Step down change in chronic obstructive pulmonary disease management plan,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,716358000,Telehealth chronic obstructive pulmonary disease monitoring,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,723245007,Number of chronic obstructive pulmonary disease exacerbations in past year,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,736283006,Chronic obstructive pulmonary disease clinical management plan,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,741056003,COPD (chronic obstructive pulmonary disease) education,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,57671000052108,CAT - COPD (chronic obstructive pulmonary disease) assessment test,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,110011000000107,DNA - Did not attend chronic obstructive pulmonary disease clinic,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,143371000000104,QOF (Quality and Outcomes Framework) chronic obstructive pulmonary disease quality indicator-related care invitation using preferred method of communication,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,198401000000104,COPD (chronic obstructive pulmonary disease) disturbs sleep,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,198411000000102,COPD (chronic obstructive pulmonary disease) does not disturb sleep,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,198901000000105,Multiple chronic obstructive pulmonary disease emergency hospital admissions,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,201341000000101,Chronic obstructive pulmonary disease monitoring status,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,204991000000107,Suspected chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,293991000000106,Very severe chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,371611000000107,Chronic obstructive pulmonary disease patient unsuitable for pulmonary rehabilitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,374591000000101,Chronic obstructive pulmonary disease enhanced services administration,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,375851000000108,Referred for chronic obstructive pulmonary disease structured smoking assessment,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,375911000000102,Chronic obstructive pulmonary disease structured smoking assessment declined,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,383611000000102,At risk of COPD (chronic obstructive pulmonary disease) exacerbation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,527361000000107,CAT - COPD (chronic obstructive pulmonary disease) assessment test,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,711431000000109,Chronic obstructive pulmonary disease monitoring invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,713731000000102,Chronic obstructive pulmonary disease monitoring administration,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,716241000000106,Chronic obstructive pulmonary disease monitoring first letter,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,716281000000103,Chronic obstructive pulmonary disease monitoring verbal invite,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,716901000000101,Chronic obstructive pulmonary disease monitoring telephone invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,717021000000106,Chronic obstructive pulmonary disease monitoring second letter,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,717521000000104,Chronic obstructive pulmonary disease monitoring third letter,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,718241000000107,Provision of chronic obstructive pulmonary disease rescue pack,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,753941000000104,Discussion about chronic obstructive pulmonary disease exacerbation plan,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,760601000000107,Chronic obstructive pulmonary disease 3 monthly review,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,760621000000103,Chronic obstructive pulmonary disease 6 monthly review,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,783631000000109,General practitioner out of hours service notified of chronic obstructive pulmonary disease care plan,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,789661000000102,Preferred place of care for next exacerbation of COPD (chronic obstructive pulmonary disease),ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,790301000000101,Referral to chronic obstructive pulmonary disease community nursing team,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,810951000000101,COPD (chronic obstructive pulmonary disease) self-management plan review,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,811961000000106,Chronic obstructive pulmonary disease self-management plan agreed,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,820341000000109,COPD (chronic obstructive pulmonary disease) rescue pack not indicated,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,826111000000109,On chronic obstructive pulmonary disease supportive care pathway,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,827571000000106,Has chronic obstructive pulmonary disease care plan,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,847091000000104,Acute non-infective exacerbation of chronic obstructive pulmonary disease,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,848431000000106,COPD (chronic obstructive pulmonary disease) care pathway,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,857661000000104,Seen in chronic obstructive pulmonary disease clinic,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,857791000000103,Chronic obstructive pulmonary disease rescue pack declined,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,857811000000102,Chronic obstructive pulmonary disease written self management plan declined,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,857821000000108,Chronic obstructive pulmonary disease self management plan not appropriate,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,892321000000109,Chronic obstructive pulmonary disease management plan declined,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,897311000000101,Shared care COPD (chronic obstructive pulmonary disease) monitoring,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,941201000000103,Chronic obstructive pulmonary disease resolved,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,1065151000000105,Number of hospital admissions due to COPD (chronic obstructive pulmonary disease) in past year,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,1066231000000103,Chronic obstructive pulmonary disease monitoring email invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,1066281000000104,COPD (chronic obstructive pulmonary disease) monitoring SMS (short message service) text message invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,1066821000000101,COPD (chronic obstructive pulmonary disease) monitoring SMS (short message service) text message first invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,1066841000000108,COPD (chronic obstructive pulmonary disease) monitoring SMS (short message service) text message second invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,1066851000000106,COPD (chronic obstructive pulmonary disease) monitoring SMS (short message service) text message third invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,1108721000000102,Excepted from COPD (chronic obstructive pulmonary disease) quality indicators - service unavailable,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROFLUMILAST AS AN ADD-ON TO BRONCHODILATOR THERAPY,Chronic obstructive pulmonary disease,TA461,chronic obstructive pulmonary disease,1110861000000102,QOF (Quality and Outcomes Framework) chronic obstructive pulmonary disease quality indicator-related care invitation,ROFLUMILAST,THORACIC MEDICINE,THORACIC MEDICINE
ROMIPLOSTIM,Chronic immune (idiopathic) thrombocytopenic purpura,TA221,thrombocytopenic purpura,78129009,TTP - thrombotic thrombocytopenic purpura,ROMIPLOSTIM,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
ROMIPLOSTIM,Chronic immune (idiopathic) thrombocytopenic purpura,TA221,thrombocytopenic purpura,234493006,Non-thrombocytopenic purpura,ROMIPLOSTIM,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
ROMIPLOSTIM,Chronic immune (idiopathic) thrombocytopenic purpura,TA221,thrombocytopenic purpura,234494000,Primary non-thrombocytopenic purpura,ROMIPLOSTIM,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
ROMIPLOSTIM,Chronic immune (idiopathic) thrombocytopenic purpura,TA221,thrombocytopenic purpura,302873008,Thrombocytopenic purpura,ROMIPLOSTIM,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,14651005,Drug-induced osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,18040001,Age-related osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,64859006,Osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,102447009,Postmenopausal osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,160313009,Family history of osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,203429007,Idiopathic generalised osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,203433000,Postoophorectomy osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,203435007,Localized osteoporosis - Lequesne,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,203437004,Osteoporosis in endocrine disorders,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,203438009,Osteoporosis of spine,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,240157009,Secondary generalised osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,240158004,Regional migrating osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,240159007,Transient osteoporosis of hip,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,240162005,Secondary localized osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,268028001,Localised disuse osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,276661002,Primary osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,281387004,Regional osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,300004007,Screening for osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,309745002,Osteoporosis localized to spine,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,310251007,No family history: Osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,313423004,At increased risk of osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391003008,Osteoporosis monitoring administration,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391004002,Attends osteoporosis monitoring,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391006000,Osteoporosis monitoring default,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391007009,Osteoporosis monitoring first letter,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391008004,Osteoporosis monitoring second letter,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391012005,Osteoporosis monitoring deleted,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391013000,Osteoporosis monitoring check done,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391014006,Osteoporosis risk assessment done,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391015007,Osteoporosis risk assessment declined,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391017004,Osteoporosis monitoring,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391018009,Initial osteoporosis assessment,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391019001,Follow-up osteoporosis assessment,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391020007,Osteoporosis treatment started,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391021006,Osteoporosis treatment stopped,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391022004,Osteoporosis treatment changed,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391023009,Osteoporosis - no treatment,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391024003,Osteoporosis - dietary advice,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391025002,Osteoporosis - dietary assessment,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391026001,Osteoporosis - exercise advice,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391027005,Osteoporosis - falls prevention,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391028000,Osteoporosis - treatment response,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391033001,Refer to osteoporosis specialist,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391037000,Seen in osteoporosis clinic,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,394936006,Health education - osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,412717001,Referral to osteoporosis clinic,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,473120007,History of osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,763322002,Osteoporosis monitoring refused,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,711341000000106,Osteoporosis resolved,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROMOSOZUMAB,Treating severe osteoporosis,TA791,osteoporosis,965871000000101,Osteoporosis medication compliance review,ROMOSOZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE,Type 2 diabetes,TA009,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,ROSIGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH A SULPHONYLUREA,Type 2 diabetes,TA063,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,190388001,Type 2 diabetes mellitus with multiple complications,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,190389009,Type 2 diabetes mellitus with ulcer,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,199230006,Pre-existing type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,237599002,Insulin treated type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,237627000,Pregnancy and type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,421631007,Gangrene due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,422014003,Disorder due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,443694000,Uncontrolled type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,703138006,Type 2 diabetes mellitus in remission,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSIGLITAZONE IN COMBINATION WITH METFORMIN,Type 2 diabetes,TA063,type 2 diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,PIOGLITAZONE,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,160270001,No family history of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,161499004,H/O: cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,171405001,Examination for suspected cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,266894000,Family history of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,266995000,History of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,395048001,Cardiovascular disease monitoring not required,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417206009,Cardiovascular disease monitoring,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417287002,Cardiovascular disease interim monitoring,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417322008,Cardiovascular disease annual review,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,429284000,Cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,429785003,Cardiovascular disease health education,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,440358008,Primary prevention of CVD (cardiovascular disease),ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,441829007,Assessment for risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166701000000106,Joint British Societies cardiovascular disease risk,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,302881000000102,Cardiovascular disease annual review declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,383321000000103,Cardiovascular disease risk assessment indicated,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,492581000000108,Cardiovascular disease high risk review declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,492611000000102,Cardiovascular disease high risk review,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,752451000000100,Cardiovascular disease risk assessment by third party,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,837461000000101,High risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,845171000000108,At risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,962871000000107,Aware of overall cardiovascular disease risk,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,990301000000105,Cardiovascular disease risk assessment done,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROSUVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,16434071000119108,At increased risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,8619003,Cannot achieve a pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,9899009,Ovarian pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,15230009,Liver disorder in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,15394000,Toxemia of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,16356006,Multiple pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,16756008,Albuminuria in pregnancy without hypertension,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,17433009,Ruptured ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,17787002,Peripheral neuritis in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,18302006,Incision of uterus for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,20956009,Phlebitis complicating pregnancy AND/OR puerperium,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,31563000,Asymptomatic bacteriuria in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,31601007,Combined pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,34500003,Legal termination of pregnancy without complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,34801009,Ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,38720006,Septuplet pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,40609001,"Infections of pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,43990006,Sextuplet pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,44782008,Molar pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,44795003,Rhesus isoimmunisation in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,45828008,"Anaemia in mother complicating pregnancy, childbirth AND/OR puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,46764007,Severe proteinuric hypertension of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,47200007,HRP - high risk pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,48194001,Pregnancy-induced hypertension,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,57630001,First trimester pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,57797005,Termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,58532003,Unwanted pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,59466002,Second trimester pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,60810003,Quadruplet pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,64254006,Triplet pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,65147003,Twin pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,65727000,Intrauterine pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,67313008,Fetal death due to termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,69532007,Mural pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,72892002,Normal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,74036000,Pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,77386006,Pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,79290002,Cervical pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,79586000,Fallopian tube pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,82661006,Abdominal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,83074005,Accidental pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,84939004,"Rubella in mother complicating pregnancy, childbirth AND/OR puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,87605005,Cornual pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,88697005,Papular dermatitis of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,88895004,Fatigue during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,90325002,Vomiting of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,90968009,Post-term pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,95212006,Gingival disease due to pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,102955006,Pregnancy with contraceptive device,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,111208003,Mask of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,118185001,Pregnancy observations,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,127365008,Second pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,127366009,Third pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,127367000,Fourth pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,127368005,Fifth pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,127369002,Sixth pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,127370001,Seventh pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,127371002,Eighth pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,127372009,Ninth pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,127373004,Tenth pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,135881001,Review of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,146799005,Possible pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,160401003,Family history: Raised blood pressure in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,160402005,Family history: Diabetes in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161009004,Pregnancy benefits (& maternity allowances),ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161742008,Past pregnancy outcome,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161743003,Past pregnancy history of stillbirth,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161744009,Past pregnancy history of miscarriage,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161755009,No history of induced termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161763005,Past pregnancy history of ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161765003,Past pregnancy history of premature delivery,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161804005,Past pregnancy history of antepartum hemorrhage,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161805006,Past pregnancy history of caesarean section,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161806007,Past pregnancy history of eclampsia,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161807003,Past pregnancy history of severe pre-eclampsia,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161809000,Past pregnancy history of postpartum hemorrhage,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161810005,Past pregnancy history of prolonged labor,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,161813007,Past pregnancy history of previous forceps delivery,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,166434005,Serum pregnancy test (B-human chorionic gonadotropin),ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,166435006,Serum pregnancy test negative,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,166436007,Serum pregnancy test equivocal,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,166437003,Serum pregnancy test positive,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,167252002,Urine pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,167253007,Urine pregnancy test requested,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,167254001,Urine pregnancy test negative,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,167255000,Urine pregnancy test equivocal,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,167256004,Urine pregnancy test positive,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169488004,Pregnancy on intrauterine contraceptive device,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169566002,Pregnancy unplanned but wanted,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169567006,Pregnancy unplanned and unwanted,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169568001,Unplanned pregnancy unknown if child is wanted,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169569009,Questionable if pregnancy was planned,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169574001,Antenatal care of second pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169575000,Antenatal care of 3rd pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169587007,Antenatal care: precious pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169602005,Antenatal care: 10 years plus since last pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169611005,No antenatal care: subject unaware of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169676009,Rhesus screening - 1st pregnancy sample,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169677000,Rhesus screening - Second pregnancy sample,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169678005,Rhesus screening - third pregnancy sample,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169681000,"Rhesus - random, non-pregnancy sample",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,169826009,Single live birth from singleton pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,171054004,Diet in pregnancy advice,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,171055003,Pregnancy smoking education,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,171056002,Pregnancy exercise education,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,171057006,Pregnancy alcohol education,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,171058001,Drugs in pregnancy advice,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,171059009,Pregnancy dental advice,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,171063002,Pregnancy prescription exemption education,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,173300003,Disorder of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,176928008,Excision of ectopic ovarian pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,176929000,Excision of ruptured ectopic tubal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,176964009,Fimbrial extraction of tubal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,182936009,Pregnancy prophylactic therapy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,182947002,Administration of prophylactic iron during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,182948007,Vitamin supplement in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,183606009,Referral for counselling for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,184005004,Requests pregnancy termination,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,191733007,Fear of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198609003,"Complication of pregnancy, childbirth and/or puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198617006,Delivery of viable foetus in abdominal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198620003,Ruptured tubal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198690009,Termination of pregnancy (& [named variants]),ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198820000,Endometritis following abortive pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198824009,Salpingo-oophoritis following abortive pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198830009,Intravascular hemolysis following abortive pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198841006,Renal failure following abortive pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198849008,Shock following abortive pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198863002,"Readmission for retained products of conception, illegal termination of pregnancy",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198941007,"Hypertension complicating pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198942000,"Benign essential hypertension complicating pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198944004,"Benign essential hypertension complicating pregnancy, childbirth and the puerperium - delivered",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198945003,"Benign essential hypertension complicating pregnancy, childbirth and the puerperium - delivered with postnatal complication",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198946002,"Benign essential hypertension complicating pregnancy, childbirth and the puerperium - not delivered",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198947006,"Benign essential hypertension complicating pregnancy, childbirth and the puerperium with postnatal complication",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198949009,"Renal hypertension complicating pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198953006,"Renal hypertension complicating pregnancy, childbirth and the puerperium - not delivered",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198965005,Transient hypertension of pregnancy - delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198966006,Transient hypertension of pregnancy - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198967002,Transient hypertension of pregnancy - not delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198968007,Transient hypertension of pregnancy with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,198992004,Eclampsia in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199008003,"Pre-existing secondary hypertension complicating pregnancy, childbirth and puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199015006,"Unspecified hypertension complicating pregnancy, childbirth and the puerperium - delivered with postnatal complication",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199018008,"Unspecified hypertension complicating pregnancy, childbirth and the puerperium with postnatal complication",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199063009,Post-term pregnancy - delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199101006,Asymptomatic bacteriuria in pregnancy - not delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199104003,Genitourinary tract infections in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199106001,Genitourinary tract infection in pregnancy - delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199107005,Genitourinary tract infection in pregnancy - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199108000,Genitourinary tract infection in pregnancy - not delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199110003,Infections of kidney in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199112006,Infections of the genital tract in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199122000,Fatigue during pregnancy - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199123005,Fatigue during pregnancy - not delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199132007,Glycosuria during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199135009,Glycosuria during pregnancy - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199136005,Glycosuria during pregnancy - not delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199175001,"Maternal tuberculosis during pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199187008,Maternal malaria during pregnancy - baby not yet delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199190002,"Maternal rubella in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199192005,Maternal rubella during pregnancy - baby delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199194006,Maternal rubella during pregnancy - baby not yet delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199205008,Infections of bladder in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199223000,"Diabetes mellitus during pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199225007,Diabetes mellitus during pregnancy - baby delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199227004,Diabetes mellitus during pregnancy - baby not yet delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199235001,"Thyroid dysfunction during pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199244000,Anaemia during pregnancy - baby delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199246003,"Maternal anemia in pregnancy, before birth",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199248002,Iron deficiency anemia of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199257008,"Mental disorders during pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199261002,Mental disorder during pregnancy - baby not yet delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199268008,Congenital cardiovascular disorder during pregnancy - baby not yet delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199293005,"Disease of the respiratory system complicating pregnancy, childbirth and/or the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199295003,"Disease of skin and subcutaneous tissue complicating pregnancy, childbirth and/or puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199296002,"Endocrine, nutritional and metabolic disease complicating pregnancy, childbirth and puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199297006,"Disease of nervous system complicating pregnancy, childbirth and puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199307003,Continuing pregnancy after intrauterine death of one or more foetuses,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199308008,"Subluxation of symphysis pubis in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199312002,Finding related to risk factor in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199317008,Twin pregnancy - delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199318003,Twin pregnancy with antenatal problem,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199321001,Triplet pregnancy - delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199325005,Quadruplet pregnancy - delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199378009,Multiple pregnancy with malpresentation,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199446000,"Pelvic soft tissue abnormality in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199447009,"Congenital abnormality of uterus in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199461004,"Uterine scar from previous surgery in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199610002,Small-for-dates fetus in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199741009,Malnutrition in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,199742002,Retained intrauterine contraceptive device in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200147006,Caesarean section - pregnancy at term,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200204002,Varicose veins of legs in pregnancy and the puerperium,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200207009,Varicose veins of legs in pregnancy and the puerperium - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200208004,Varicose veins of legs in pregnancy and the puerperium with antenatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200217004,Varicose veins of perineum and vulva in pregnancy and the puerperium with antenatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200219001,Vaginal varices in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200222004,Superficial thrombophlebitis in pregnancy and the puerperium,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200224003,Superficial thrombophlebitis in pregnancy and the puerperium - delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200226001,Superficial thrombophlebitis in pregnancy and the puerperium with antenatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200227005,Superficial thrombophlebitis in pregnancy and the puerperium with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200249004,Pregnancy and postpartum piles,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200251000,Haemorrhoids in pregnancy and the puerperium - delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200254008,Haemorrhoids in pregnancy and the puerperium with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200259003,Cerebral venous thrombosis in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200402001,"Retraction of nipple in pregnancy, the puerperium or lactation",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200411001,"Cracked nipple in pregnancy, the puerperium or lactation - delivered",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200412008,"Cracked nipple in pregnancy, the puerperium or lactation - delivered with postnatal complication",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200413003,"Cracked nipple in pregnancy, the puerperium or lactation with antenatal complication",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200414009,"Cracked nipple in pregnancy, the puerperium or lactation with postnatal complication",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200416006,"Breast engorgement in pregnancy, the puerperium or lactation",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200418007,"Breast engorgement in pregnancy, the puerperium or lactation - delivered",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200444007,Galactorrhoea in pregnancy and the puerperium,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200446009,Galactorrhea in pregnancy and the puerperium - delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200447000,Galactorrhoea in pregnancy and the puerperium - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200448005,Galactorrhea in pregnancy and the puerperium with antenatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200449002,Galactorrhoea in pregnancy and the puerperium with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,201134009,Alopecia of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,206001006,Foetal or neonatal effect of maternal problem unrelated to pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,206035009,Fetal or neonatal effect of maternal complication of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,206044005,Fetal or neonatal effect of tubal ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,206046007,Foetal or neonatal effect of multiple pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,206048008,Fetal or neonatal effect of twin pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,225327004,Counseling prior to the termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,234058009,Varicose veins of genitalia in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,235003004,Gingival pregnancy tumour,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,235888006,RICP - recurrent intrahepatic cholestasis of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,236931002,Methotrexate injection into tubal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237036002,"Recurrent pregnancy loss, not pregnant",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237155000,"Disorder of vulva in pregnancy, childbirth, and/or puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237170004,"Vaginal abnormality in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237179003,"Septate vagina in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237186006,"Stenosis of cervix in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237191007,"Polyp of cervix in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237196002,"Rectocele in pregnancy, childbirth or the puerperium NOS",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237197006,"Cystocele in pregnancy, childbirth or the puerperium NOS",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237208000,"Rectocele in pregnancy, childbirth and puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237209008,"Pendulous abdomen in pregnancy, childbirth and/or the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237210003,"Cystocele in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237217000,"Uterine fibroids in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237225003,"Double uterus in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237228001,Pregnancy and drug dependence,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237233002,Concealed pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237234008,Undiagnosed pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237237001,Undiagnosed twin pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237238006,Pregnancy with uncertain dates,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237239003,Low risk pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237240001,Teenage pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237241002,Viable pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237242009,Non-viable pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237243004,Biochemical pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237244005,Single pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237253003,Viable foetus in abdominal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237254009,Unruptured tubal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237279007,Transient hypertension of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237284001,Symptomatic disorders in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237285000,Pregnancy induced oedema,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237286004,Varicose veins of vulva in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237300009,Pregnancy with isoimmunization,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237625008,Hyperglycemic disorder in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237627000,Pregnancy and type 2 diabetes mellitus,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,237628005,Impaired glucose tolerance in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,238820002,Erythema multiforme of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,239101008,Pregnancy dermatosis,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,239102001,Pruritus of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,239103006,Prurigo of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,239104000,Pruritic folliculitis of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,240160002,Transient osteoporosis of hip in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,240284002,Multifetal pregnancy reduction,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,246435002,Number of babies current pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,248982007,"Pregnancy, childbirth and puerperium finding",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,248985009,Reported conception - pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,248987001,Date symptom of pregnancy first noted,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,248990007,Duration of pregnancy at time of previous miscarriage,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,249122000,Postmature pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,250421003,Pregnancy test finding,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,250423000,Pregnancy test positive,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,250424006,Pregnancy test weakly positive,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,250425007,Pregnancy test negative,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,250426008,Pregnancy test indeterminate,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,252113007,Number of miscarriages or induced terminations of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,252114001,Number of induced terminations of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,252160004,Standard pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,252161000,Sensitive pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,259636000,Pregnancy associated plasma protein A,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,266906006,Family history: Multiple pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267013003,Past pregnancy outcome,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267015005,Past pregnancy history of full term delivery,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267193004,Incomplete legal termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267194005,Complete legal termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267204006,Genitourinary tract infection in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267206008,"Drug dependence during pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267207004,"Congenital cardiovascular disorders during pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267212003,"Congenital abnormality of uterus in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267219007,"Tumor of uterine body in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267238003,"Congenital or acquired abnormality of vagina in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267280004,Venous complication of pregnancy and/or puerperium,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267282007,Varicose veins of perineum and vulva in pregnancy and the puerperium,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267283002,Superficial thrombophlebitis in pregnancy and the puerperium - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267291006,"Cracked nipple in pregnancy, the puerperium or lactation",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267306006,Toxemia of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267308007,Pregnancy vomiting,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267320004,Pregnancy with mental disorders,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,267322007,Pregnancy with orthopaedic problem,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,271903000,History of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,272058002,Past pregnancy history of delivery procedure,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,274116002,Herpes in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,274117006,Pregnancy and infectious disease,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,274119009,Rubella in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,274120003,Thyroid disease in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,274973002,Dilation and curettage for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,275133001,Family history: Twin pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,275412000,Cystitis of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,275425008,Retained products of conception following spontaneous termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,275568006,Past pregnancy history of normal delivery,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,275569003,Past pregnancy history of delivery with no details,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,275922000,Administration of prophylactic vitamin and iron in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,276367008,Wanted pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,276881003,Secondary abdominal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,281307002,Uncertain viability of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,284075002,Spotting per vagina in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,288043009,Hysterectomy in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,288045002,Injection of substance into amniotic cavity for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,289203002,Finding of pattern of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,289205009,Finding of measures of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,289208006,Observation of viability of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,289209003,Pregnancy problem,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,289908002,Pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,301801008,Finding of position of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,302253005,Delivered by cesarean section - pregnancy at term,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,302375005,Operative termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,305875008,Seen by pregnancy termination service,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,307534009,UTI (urinary tract infection) in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,307632004,Non-proteinuric hypertension of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,308133005,Varicose veins of legs in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,308136002,Superficial thrombophlebitis in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,308140006,Hemorrhoids in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,309737007,Abdominal pain in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,310062002,Pregnancy termination service,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,310506006,Reason for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,310592002,Pregnancy prolonged - 41 weeks,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,310594001,Pregnancy prolonged - 42 weeks,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,312891008,Pregnancy-related examination,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,313107007,Pre-pregnancy folic acid education,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,314041007,Abdominal pain in early pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,314204000,Early stage of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,363681007,Pregnancy with abortive outcome,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,370381000,Antenatal scan unable to confirm pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,370382007,Antenatal ultrasound confirms ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,370383002,Antenatal ultrasound confirms intrauterine pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,372046001,"Abnormal glucose tolerance test during pregnancy, childbirth and puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,372048000,Pregnancy with abnormal glucose tolerance test,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,372054004,Glucose tolerance test during pregnancy - baby not yet delivered outside reference range,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,372055003,Glucose tolerance test during pregnancy - baby delivered outside reference range,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,373901007,Legal termination of pregnancy complicated by genital-pelvic infection,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,386394001,Pregnancy termination care,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,386639001,Termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,391897002,STOP - suction termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,394684000,Diabetic pre-pregnancy education,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,398254007,Toxaemia of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,412758008,Past pregnancy history of medical termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,413179008,Patient advised to have pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,415262008,Referral for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,417044008,Molar pregnancy with hydatid mole,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,417577000,Refer to early pregnancy unit,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,424040008,Delusion of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,426997005,Traumatic injury during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,428566005,Pregnancy with gestation less than 20 weeks,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,439163006,Referral for medical termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,439310005,Referral for surgical termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,439733009,Education about toxoplasmosis precautions during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,444517009,Exposure to rubella in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,449345000,Smoker before confirmation of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,449368009,Stopped smoking during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,449369001,Stopped smoking before pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,459168005,Monochorionic diamniotic twin pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,472971004,Past pregnancy history of gestational diabetes mellitus,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,473180009,Discussion about diabetic ketoacidosis in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609443003,Retained products of conception following induced termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609446006,Induced termination of pregnancy with complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609448007,Termination of pregnancy complicated by delayed and/or excessive hemorrhage,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609449004,Termination of pregnancy complicated by embolism,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609450004,Termination of pregnancy complicated by genital-pelvic infection,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609452007,Termination of pregnancy complicated by renal failure,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609458006,Induced termination of pregnancy complicated by amniotic fluid embolism,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609459003,Termination of pregnancy complicated by blood-clot embolism,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609472002,Induced termination of pregnancy complicated by acute renal failure with oliguria,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609480009,Induced termination of pregnancy complicated by pulmonary embolism,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609483006,Termination of pregnancy complicated by salpingitis,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609485004,Induced termination of pregnancy complicated by sepsis,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609486003,Induced termination of pregnancy complicated by septic embolism,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609491002,Induced termination of pregnancy complicated by urinary tract infection,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609496007,Complication occurring during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609506003,Induced termination of pregnancy complicated by cardiac arrest,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609510000,Induced termination of pregnancy complicated by infectious disease,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,609525000,Miscarriage of tubal ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,699950009,Anti-D isoimmunisation affecting pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,700145007,No history of ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,702738006,Supervision of high risk pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,702742009,Supervision of high risk pregnancy for social problem,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,702744005,Supervision of high risk pregnancy for primigravida age 15 years or younger,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,707998009,Assessment for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,709881001,Past pregnancy history of gestational hypertension,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,710973002,Prevention of unwanted pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,713575004,Binovular twin pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,713651007,Past pregnancy history of pregnancy with abortive outcome,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,716379000,Nonalcoholic fatty liver during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,725944002,Past pregnancy history of episiotomy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,726565008,Past pregnancy history of small for gestational age baby,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,733899004,Past pregnancy history of fetal growth restriction,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,735260000,Seen in early pregnancy assessment unit,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,769087009,Vomiting during third trimester of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1156031002,Varicosities in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1290209002,Past pregnancy history of recurrent miscarriage,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1290210007,Past pregnancy history of multiple miscarriages,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,4121000000101,Pregnancy test result received,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,10231000132102,In-vitro fertilization pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,24451000000107,Diabetes: shared care in pregnancy - diabetologist and obstetrician,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,40801000119106,Gestational diabetes mellitus complicating pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,72301000119103,Asthma in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,105651000119100,Past pregnancy history of pre-eclampsia,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,151901000119101,Psychosocial problems related to unwanted pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,200851000000104,Pregnancy test kit given,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,228881000000102,Ultrasound monitoring of early pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,299451000000108,Checking possibility of pregnancy prior to radiation,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,339361000000101,Pregnancy counselling,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,410801000000102,[V]Illegitimate pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,426871000000102,"[V]Pregnancy examination or test, pregnancy unconfirmed",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,516071000000107,Health in Pregnancy grant claim form issued,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,526961000000105,Pregnancy advice for patients with epilepsy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,527131000000100,Pregnancy advice for patients with epilepsy declined,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,579531000000104,Unspecified pregnancy vomiting,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,590851000000108,Risk factors in pregnancy NOS,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,695711000000100,Transient hypertension of pregnancy NOS,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,769411000000104,Self referral to termination of pregnancy service,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,775821000000102,Referral to teenage pregnancy and parenting support service,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,813791000000104,Discussion about ectopic pregnancy risk,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,816051000000102,Plasma PAPP-A MoM (pregnancy associated plasma protein A multiple of median) measurement,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,837291000000106,At risk of unwanted pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,858901000000108,Pregnancy of unknown location,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,865901000000108,Pertussis vaccination in pregnancy invitation,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,866141000000103,Pertussis vaccination in pregnancy invitation first letter,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,866191000000108,Pertussis vaccination in pregnancy invitation second letter,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,866251000000106,Pertussis vaccination in pregnancy invitation third letter,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,866351000000103,Did not attend pertussis vaccination in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,866641000000105,Whooping cough vaccination in pregnancy refused,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,889881000000105,Advice on risks of harm to mother from maternal medication during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,889901000000108,Advice on risks of harm to fetus from maternal medication during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,926811000000109,Education about thyroid disease in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,956951000000104,Pertussis vaccination in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,956971000000108,Pertussis vaccination in pregnancy given by other healthcare provider,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,957291000000102,Pertussis vaccination in pregnancy contraindicated,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,980681000000106,Readmission (NHS codes): [abortive pregnancy] or [RPOC],ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,996401000000103,Serum pregnancy associated plasma protein-A mean of median,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,997141000000107,Serum B-HCG (beta human chorionic gonadotrophin) pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,998051000000105,Pregnancy associated plasma protein A level,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1003161000000106,Urine pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1003171000000104,High sensitivity urine pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1097321000000106,Signposting to pregnancy counselling service,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1129761000000105,Pregnancy prevention programme,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1129771000000103,Pregnancy prevention programme started,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1129791000000104,Pregnancy prevention programme not needed,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1129801000000100,Pregnancy prevention programme declined,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1129811000000103,Pregnancy prevention programme declined caregiver,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1129821000000109,Pregnancy prevention programme declined by parent,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1129831000000106,Did not attend pregnancy prevention programme,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1129841000000102,Pregnancy prevention programme discontinued,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1188251000000101,Signposting to teenage pregnancy and parenting support service,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1382571000000100,Pregnancy status unknown,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1874001000000104,Concern related to pregnancy less than 20 weeks of gestation,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,1874011000000102,Concern related to pregnancy at or greater than 20 weeks of gestation,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,2181271000000102,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form completed,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS,Pregnancy (rhesus negative women),TA156,pregnancy,16216731000119106,Past pregnancy history of intrauterine foetal death,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,8619003,Cannot achieve a pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,9899009,Ovarian pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,15230009,Liver disorder in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,15394000,Toxemia of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,16356006,Multiple pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,16756008,Albuminuria in pregnancy without hypertension,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,17433009,Ruptured ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,17787002,Peripheral neuritis in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,18302006,Incision of uterus for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,20956009,Phlebitis complicating pregnancy AND/OR puerperium,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,31563000,Asymptomatic bacteriuria in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,31601007,Combined pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,34500003,Legal termination of pregnancy without complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,34801009,Ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,38720006,Septuplet pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,40609001,"Infections of pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,43990006,Sextuplet pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,44782008,Molar pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,44795003,Rhesus isoimmunisation in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,45828008,"Anaemia in mother complicating pregnancy, childbirth AND/OR puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,46764007,Severe proteinuric hypertension of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,47200007,HRP - high risk pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,48194001,Pregnancy-induced hypertension,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,57630001,First trimester pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,57797005,Termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,58532003,Unwanted pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,59466002,Second trimester pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,60810003,Quadruplet pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,64254006,Triplet pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,65147003,Twin pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,65727000,Intrauterine pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,67313008,Fetal death due to termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,69532007,Mural pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,72892002,Normal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,74036000,Pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,77386006,Pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,79290002,Cervical pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,79586000,Fallopian tube pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,82661006,Abdominal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,83074005,Accidental pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,84939004,"Rubella in mother complicating pregnancy, childbirth AND/OR puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,87605005,Cornual pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,88697005,Papular dermatitis of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,88895004,Fatigue during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,90325002,Vomiting of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,90968009,Post-term pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,95212006,Gingival disease due to pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,102955006,Pregnancy with contraceptive device,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,111208003,Mask of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,118185001,Pregnancy observations,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,127365008,Second pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,127366009,Third pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,127367000,Fourth pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,127368005,Fifth pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,127369002,Sixth pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,127370001,Seventh pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,127371002,Eighth pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,127372009,Ninth pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,127373004,Tenth pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,135881001,Review of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,146799005,Possible pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,160401003,Family history: Raised blood pressure in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,160402005,Family history: Diabetes in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161009004,Pregnancy benefits (& maternity allowances),ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161742008,Past pregnancy outcome,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161743003,Past pregnancy history of stillbirth,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161744009,Past pregnancy history of miscarriage,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161755009,No history of induced termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161763005,Past pregnancy history of ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161765003,Past pregnancy history of premature delivery,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161804005,Past pregnancy history of antepartum hemorrhage,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161805006,Past pregnancy history of caesarean section,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161806007,Past pregnancy history of eclampsia,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161807003,Past pregnancy history of severe pre-eclampsia,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161809000,Past pregnancy history of postpartum hemorrhage,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161810005,Past pregnancy history of prolonged labor,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,161813007,Past pregnancy history of previous forceps delivery,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,166434005,Serum pregnancy test (B-human chorionic gonadotropin),ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,166435006,Serum pregnancy test negative,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,166436007,Serum pregnancy test equivocal,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,166437003,Serum pregnancy test positive,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,167252002,Urine pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,167253007,Urine pregnancy test requested,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,167254001,Urine pregnancy test negative,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,167255000,Urine pregnancy test equivocal,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,167256004,Urine pregnancy test positive,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169488004,Pregnancy on intrauterine contraceptive device,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169566002,Pregnancy unplanned but wanted,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169567006,Pregnancy unplanned and unwanted,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169568001,Unplanned pregnancy unknown if child is wanted,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169569009,Questionable if pregnancy was planned,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169574001,Antenatal care of second pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169575000,Antenatal care of 3rd pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169587007,Antenatal care: precious pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169602005,Antenatal care: 10 years plus since last pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169611005,No antenatal care: subject unaware of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169676009,Rhesus screening - 1st pregnancy sample,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169677000,Rhesus screening - Second pregnancy sample,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169678005,Rhesus screening - third pregnancy sample,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169681000,"Rhesus - random, non-pregnancy sample",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,169826009,Single live birth from singleton pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,171054004,Diet in pregnancy advice,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,171055003,Pregnancy smoking education,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,171056002,Pregnancy exercise education,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,171057006,Pregnancy alcohol education,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,171058001,Drugs in pregnancy advice,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,171059009,Pregnancy dental advice,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,171063002,Pregnancy prescription exemption education,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,173300003,Disorder of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,176928008,Excision of ectopic ovarian pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,176929000,Excision of ruptured ectopic tubal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,176964009,Fimbrial extraction of tubal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,182936009,Pregnancy prophylactic therapy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,182947002,Administration of prophylactic iron during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,182948007,Vitamin supplement in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,183606009,Referral for counselling for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,184005004,Requests pregnancy termination,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,191733007,Fear of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198609003,"Complication of pregnancy, childbirth and/or puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198617006,Delivery of viable foetus in abdominal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198620003,Ruptured tubal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198690009,Termination of pregnancy (& [named variants]),ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198820000,Endometritis following abortive pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198824009,Salpingo-oophoritis following abortive pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198830009,Intravascular hemolysis following abortive pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198841006,Renal failure following abortive pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198849008,Shock following abortive pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198863002,"Readmission for retained products of conception, illegal termination of pregnancy",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198941007,"Hypertension complicating pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198942000,"Benign essential hypertension complicating pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198944004,"Benign essential hypertension complicating pregnancy, childbirth and the puerperium - delivered",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198945003,"Benign essential hypertension complicating pregnancy, childbirth and the puerperium - delivered with postnatal complication",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198946002,"Benign essential hypertension complicating pregnancy, childbirth and the puerperium - not delivered",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198947006,"Benign essential hypertension complicating pregnancy, childbirth and the puerperium with postnatal complication",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198949009,"Renal hypertension complicating pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198953006,"Renal hypertension complicating pregnancy, childbirth and the puerperium - not delivered",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198965005,Transient hypertension of pregnancy - delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198966006,Transient hypertension of pregnancy - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198967002,Transient hypertension of pregnancy - not delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198968007,Transient hypertension of pregnancy with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,198992004,Eclampsia in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199008003,"Pre-existing secondary hypertension complicating pregnancy, childbirth and puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199015006,"Unspecified hypertension complicating pregnancy, childbirth and the puerperium - delivered with postnatal complication",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199018008,"Unspecified hypertension complicating pregnancy, childbirth and the puerperium with postnatal complication",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199063009,Post-term pregnancy - delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199101006,Asymptomatic bacteriuria in pregnancy - not delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199104003,Genitourinary tract infections in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199106001,Genitourinary tract infection in pregnancy - delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199107005,Genitourinary tract infection in pregnancy - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199108000,Genitourinary tract infection in pregnancy - not delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199110003,Infections of kidney in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199112006,Infections of the genital tract in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199122000,Fatigue during pregnancy - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199123005,Fatigue during pregnancy - not delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199132007,Glycosuria during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199135009,Glycosuria during pregnancy - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199136005,Glycosuria during pregnancy - not delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199175001,"Maternal tuberculosis during pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199187008,Maternal malaria during pregnancy - baby not yet delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199190002,"Maternal rubella in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199192005,Maternal rubella during pregnancy - baby delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199194006,Maternal rubella during pregnancy - baby not yet delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199205008,Infections of bladder in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199223000,"Diabetes mellitus during pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199225007,Diabetes mellitus during pregnancy - baby delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199227004,Diabetes mellitus during pregnancy - baby not yet delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199235001,"Thyroid dysfunction during pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199244000,Anaemia during pregnancy - baby delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199246003,"Maternal anemia in pregnancy, before birth",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199248002,Iron deficiency anemia of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199257008,"Mental disorders during pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199261002,Mental disorder during pregnancy - baby not yet delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199268008,Congenital cardiovascular disorder during pregnancy - baby not yet delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199293005,"Disease of the respiratory system complicating pregnancy, childbirth and/or the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199295003,"Disease of skin and subcutaneous tissue complicating pregnancy, childbirth and/or puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199296002,"Endocrine, nutritional and metabolic disease complicating pregnancy, childbirth and puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199297006,"Disease of nervous system complicating pregnancy, childbirth and puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199307003,Continuing pregnancy after intrauterine death of one or more foetuses,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199308008,"Subluxation of symphysis pubis in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199312002,Finding related to risk factor in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199317008,Twin pregnancy - delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199318003,Twin pregnancy with antenatal problem,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199321001,Triplet pregnancy - delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199325005,Quadruplet pregnancy - delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199378009,Multiple pregnancy with malpresentation,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199446000,"Pelvic soft tissue abnormality in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199447009,"Congenital abnormality of uterus in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199461004,"Uterine scar from previous surgery in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199610002,Small-for-dates fetus in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199741009,Malnutrition in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,199742002,Retained intrauterine contraceptive device in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200147006,Caesarean section - pregnancy at term,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200204002,Varicose veins of legs in pregnancy and the puerperium,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200207009,Varicose veins of legs in pregnancy and the puerperium - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200208004,Varicose veins of legs in pregnancy and the puerperium with antenatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200217004,Varicose veins of perineum and vulva in pregnancy and the puerperium with antenatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200219001,Vaginal varices in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200222004,Superficial thrombophlebitis in pregnancy and the puerperium,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200224003,Superficial thrombophlebitis in pregnancy and the puerperium - delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200226001,Superficial thrombophlebitis in pregnancy and the puerperium with antenatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200227005,Superficial thrombophlebitis in pregnancy and the puerperium with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200249004,Pregnancy and postpartum piles,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200251000,Haemorrhoids in pregnancy and the puerperium - delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200254008,Haemorrhoids in pregnancy and the puerperium with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200259003,Cerebral venous thrombosis in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200402001,"Retraction of nipple in pregnancy, the puerperium or lactation",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200411001,"Cracked nipple in pregnancy, the puerperium or lactation - delivered",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200412008,"Cracked nipple in pregnancy, the puerperium or lactation - delivered with postnatal complication",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200413003,"Cracked nipple in pregnancy, the puerperium or lactation with antenatal complication",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200414009,"Cracked nipple in pregnancy, the puerperium or lactation with postnatal complication",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200416006,"Breast engorgement in pregnancy, the puerperium or lactation",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200418007,"Breast engorgement in pregnancy, the puerperium or lactation - delivered",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200444007,Galactorrhoea in pregnancy and the puerperium,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200446009,Galactorrhea in pregnancy and the puerperium - delivered,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200447000,Galactorrhoea in pregnancy and the puerperium - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200448005,Galactorrhea in pregnancy and the puerperium with antenatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200449002,Galactorrhoea in pregnancy and the puerperium with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,201134009,Alopecia of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,206001006,Foetal or neonatal effect of maternal problem unrelated to pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,206035009,Fetal or neonatal effect of maternal complication of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,206044005,Fetal or neonatal effect of tubal ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,206046007,Foetal or neonatal effect of multiple pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,206048008,Fetal or neonatal effect of twin pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,225327004,Counseling prior to the termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,234058009,Varicose veins of genitalia in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,235003004,Gingival pregnancy tumour,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,235888006,RICP - recurrent intrahepatic cholestasis of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,236931002,Methotrexate injection into tubal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237036002,"Recurrent pregnancy loss, not pregnant",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237155000,"Disorder of vulva in pregnancy, childbirth, and/or puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237170004,"Vaginal abnormality in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237179003,"Septate vagina in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237186006,"Stenosis of cervix in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237191007,"Polyp of cervix in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237196002,"Rectocele in pregnancy, childbirth or the puerperium NOS",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237197006,"Cystocele in pregnancy, childbirth or the puerperium NOS",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237208000,"Rectocele in pregnancy, childbirth and puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237209008,"Pendulous abdomen in pregnancy, childbirth and/or the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237210003,"Cystocele in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237217000,"Uterine fibroids in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237225003,"Double uterus in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237228001,Pregnancy and drug dependence,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237233002,Concealed pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237234008,Undiagnosed pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237237001,Undiagnosed twin pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237238006,Pregnancy with uncertain dates,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237239003,Low risk pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237240001,Teenage pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237241002,Viable pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237242009,Non-viable pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237243004,Biochemical pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237244005,Single pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237253003,Viable foetus in abdominal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237254009,Unruptured tubal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237279007,Transient hypertension of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237284001,Symptomatic disorders in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237285000,Pregnancy induced oedema,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237286004,Varicose veins of vulva in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237300009,Pregnancy with isoimmunization,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237625008,Hyperglycemic disorder in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237627000,Pregnancy and type 2 diabetes mellitus,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,237628005,Impaired glucose tolerance in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,238820002,Erythema multiforme of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,239101008,Pregnancy dermatosis,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,239102001,Pruritus of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,239103006,Prurigo of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,239104000,Pruritic folliculitis of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,240160002,Transient osteoporosis of hip in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,240284002,Multifetal pregnancy reduction,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,246435002,Number of babies current pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,248982007,"Pregnancy, childbirth and puerperium finding",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,248985009,Reported conception - pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,248987001,Date symptom of pregnancy first noted,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,248990007,Duration of pregnancy at time of previous miscarriage,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,249122000,Postmature pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,250421003,Pregnancy test finding,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,250423000,Pregnancy test positive,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,250424006,Pregnancy test weakly positive,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,250425007,Pregnancy test negative,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,250426008,Pregnancy test indeterminate,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,252113007,Number of miscarriages or induced terminations of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,252114001,Number of induced terminations of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,252160004,Standard pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,252161000,Sensitive pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,259636000,Pregnancy associated plasma protein A,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,266906006,Family history: Multiple pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267013003,Past pregnancy outcome,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267015005,Past pregnancy history of full term delivery,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267193004,Incomplete legal termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267194005,Complete legal termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267204006,Genitourinary tract infection in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267206008,"Drug dependence during pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267207004,"Congenital cardiovascular disorders during pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267212003,"Congenital abnormality of uterus in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267219007,"Tumor of uterine body in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267238003,"Congenital or acquired abnormality of vagina in pregnancy, childbirth and the puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267280004,Venous complication of pregnancy and/or puerperium,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267282007,Varicose veins of perineum and vulva in pregnancy and the puerperium,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267283002,Superficial thrombophlebitis in pregnancy and the puerperium - delivered with postnatal complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267291006,"Cracked nipple in pregnancy, the puerperium or lactation",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267306006,Toxemia of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267308007,Pregnancy vomiting,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267320004,Pregnancy with mental disorders,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,267322007,Pregnancy with orthopaedic problem,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,271903000,History of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,272058002,Past pregnancy history of delivery procedure,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,274116002,Herpes in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,274117006,Pregnancy and infectious disease,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,274119009,Rubella in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,274120003,Thyroid disease in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,274973002,Dilation and curettage for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,275133001,Family history: Twin pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,275412000,Cystitis of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,275425008,Retained products of conception following spontaneous termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,275568006,Past pregnancy history of normal delivery,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,275569003,Past pregnancy history of delivery with no details,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,275922000,Administration of prophylactic vitamin and iron in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,276367008,Wanted pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,276881003,Secondary abdominal pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,281307002,Uncertain viability of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,284075002,Spotting per vagina in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,288043009,Hysterectomy in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,288045002,Injection of substance into amniotic cavity for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,289203002,Finding of pattern of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,289205009,Finding of measures of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,289208006,Observation of viability of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,289209003,Pregnancy problem,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,289908002,Pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,301801008,Finding of position of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,302253005,Delivered by cesarean section - pregnancy at term,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,302375005,Operative termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,305875008,Seen by pregnancy termination service,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,307534009,UTI (urinary tract infection) in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,307632004,Non-proteinuric hypertension of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,308133005,Varicose veins of legs in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,308136002,Superficial thrombophlebitis in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,308140006,Hemorrhoids in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,309737007,Abdominal pain in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,310062002,Pregnancy termination service,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,310506006,Reason for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,310592002,Pregnancy prolonged - 41 weeks,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,310594001,Pregnancy prolonged - 42 weeks,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,312891008,Pregnancy-related examination,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,313107007,Pre-pregnancy folic acid education,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,314041007,Abdominal pain in early pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,314204000,Early stage of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,363681007,Pregnancy with abortive outcome,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,370381000,Antenatal scan unable to confirm pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,370382007,Antenatal ultrasound confirms ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,370383002,Antenatal ultrasound confirms intrauterine pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,372046001,"Abnormal glucose tolerance test during pregnancy, childbirth and puerperium",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,372048000,Pregnancy with abnormal glucose tolerance test,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,372054004,Glucose tolerance test during pregnancy - baby not yet delivered outside reference range,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,372055003,Glucose tolerance test during pregnancy - baby delivered outside reference range,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,373901007,Legal termination of pregnancy complicated by genital-pelvic infection,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,386394001,Pregnancy termination care,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,386639001,Termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,391897002,STOP - suction termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,394684000,Diabetic pre-pregnancy education,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,398254007,Toxaemia of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,412758008,Past pregnancy history of medical termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,413179008,Patient advised to have pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,415262008,Referral for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,417044008,Molar pregnancy with hydatid mole,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,417577000,Refer to early pregnancy unit,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,424040008,Delusion of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,426997005,Traumatic injury during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,428566005,Pregnancy with gestation less than 20 weeks,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,439163006,Referral for medical termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,439310005,Referral for surgical termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,439733009,Education about toxoplasmosis precautions during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,444517009,Exposure to rubella in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,449345000,Smoker before confirmation of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,449368009,Stopped smoking during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,449369001,Stopped smoking before pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,459168005,Monochorionic diamniotic twin pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,472971004,Past pregnancy history of gestational diabetes mellitus,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,473180009,Discussion about diabetic ketoacidosis in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609443003,Retained products of conception following induced termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609446006,Induced termination of pregnancy with complication,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609448007,Termination of pregnancy complicated by delayed and/or excessive hemorrhage,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609449004,Termination of pregnancy complicated by embolism,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609450004,Termination of pregnancy complicated by genital-pelvic infection,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609452007,Termination of pregnancy complicated by renal failure,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609458006,Induced termination of pregnancy complicated by amniotic fluid embolism,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609459003,Termination of pregnancy complicated by blood-clot embolism,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609472002,Induced termination of pregnancy complicated by acute renal failure with oliguria,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609480009,Induced termination of pregnancy complicated by pulmonary embolism,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609483006,Termination of pregnancy complicated by salpingitis,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609485004,Induced termination of pregnancy complicated by sepsis,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609486003,Induced termination of pregnancy complicated by septic embolism,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609491002,Induced termination of pregnancy complicated by urinary tract infection,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609496007,Complication occurring during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609506003,Induced termination of pregnancy complicated by cardiac arrest,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609510000,Induced termination of pregnancy complicated by infectious disease,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,609525000,Miscarriage of tubal ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,699950009,Anti-D isoimmunisation affecting pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,700145007,No history of ectopic pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,702738006,Supervision of high risk pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,702742009,Supervision of high risk pregnancy for social problem,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,702744005,Supervision of high risk pregnancy for primigravida age 15 years or younger,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,707998009,Assessment for termination of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,709881001,Past pregnancy history of gestational hypertension,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,710973002,Prevention of unwanted pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,713575004,Binovular twin pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,713651007,Past pregnancy history of pregnancy with abortive outcome,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,716379000,Nonalcoholic fatty liver during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,725944002,Past pregnancy history of episiotomy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,726565008,Past pregnancy history of small for gestational age baby,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,733899004,Past pregnancy history of fetal growth restriction,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,735260000,Seen in early pregnancy assessment unit,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,769087009,Vomiting during third trimester of pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1156031002,Varicosities in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1290209002,Past pregnancy history of recurrent miscarriage,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1290210007,Past pregnancy history of multiple miscarriages,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,4121000000101,Pregnancy test result received,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,10231000132102,In-vitro fertilization pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,24451000000107,Diabetes: shared care in pregnancy - diabetologist and obstetrician,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,40801000119106,Gestational diabetes mellitus complicating pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,72301000119103,Asthma in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,105651000119100,Past pregnancy history of pre-eclampsia,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,151901000119101,Psychosocial problems related to unwanted pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,200851000000104,Pregnancy test kit given,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,228881000000102,Ultrasound monitoring of early pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,299451000000108,Checking possibility of pregnancy prior to radiation,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,339361000000101,Pregnancy counselling,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,410801000000102,[V]Illegitimate pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,426871000000102,"[V]Pregnancy examination or test, pregnancy unconfirmed",ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,516071000000107,Health in Pregnancy grant claim form issued,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,526961000000105,Pregnancy advice for patients with epilepsy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,527131000000100,Pregnancy advice for patients with epilepsy declined,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,579531000000104,Unspecified pregnancy vomiting,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,590851000000108,Risk factors in pregnancy NOS,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,695711000000100,Transient hypertension of pregnancy NOS,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,769411000000104,Self referral to termination of pregnancy service,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,775821000000102,Referral to teenage pregnancy and parenting support service,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,813791000000104,Discussion about ectopic pregnancy risk,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,816051000000102,Plasma PAPP-A MoM (pregnancy associated plasma protein A multiple of median) measurement,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,837291000000106,At risk of unwanted pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,858901000000108,Pregnancy of unknown location,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,865901000000108,Pertussis vaccination in pregnancy invitation,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,866141000000103,Pertussis vaccination in pregnancy invitation first letter,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,866191000000108,Pertussis vaccination in pregnancy invitation second letter,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,866251000000106,Pertussis vaccination in pregnancy invitation third letter,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,866351000000103,Did not attend pertussis vaccination in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,866641000000105,Whooping cough vaccination in pregnancy refused,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,889881000000105,Advice on risks of harm to mother from maternal medication during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,889901000000108,Advice on risks of harm to fetus from maternal medication during pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,926811000000109,Education about thyroid disease in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,956951000000104,Pertussis vaccination in pregnancy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,956971000000108,Pertussis vaccination in pregnancy given by other healthcare provider,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,957291000000102,Pertussis vaccination in pregnancy contraindicated,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,980681000000106,Readmission (NHS codes): [abortive pregnancy] or [RPOC],ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,996401000000103,Serum pregnancy associated plasma protein-A mean of median,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,997141000000107,Serum B-HCG (beta human chorionic gonadotrophin) pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,998051000000105,Pregnancy associated plasma protein A level,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1003161000000106,Urine pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1003171000000104,High sensitivity urine pregnancy test,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1097321000000106,Signposting to pregnancy counselling service,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1129761000000105,Pregnancy prevention programme,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1129771000000103,Pregnancy prevention programme started,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1129791000000104,Pregnancy prevention programme not needed,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1129801000000100,Pregnancy prevention programme declined,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1129811000000103,Pregnancy prevention programme declined caregiver,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1129821000000109,Pregnancy prevention programme declined by parent,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1129831000000106,Did not attend pregnancy prevention programme,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1129841000000102,Pregnancy prevention programme discontinued,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1188251000000101,Signposting to teenage pregnancy and parenting support service,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1382571000000100,Pregnancy status unknown,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1874001000000104,Concern related to pregnancy less than 20 weeks of gestation,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,1874011000000102,Concern related to pregnancy at or greater than 20 weeks of gestation,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,2181271000000102,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form completed,ROUTINE,OBSTETRICS,OBSTETRICS
ROUTINE ANTENATAL ANTI-D PROPHYLAXIS (RAADP),Pregnancy,TA041,pregnancy,16216731000119106,Past pregnancy history of intrauterine foetal death,ROUTINE,OBSTETRICS,OBSTETRICS
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,171234009,Chronic kidney disease screening,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,431855005,Chronic kidney disease stage 1,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,431856006,Chronic kidney disease stage 2,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,431857002,Chronic kidney disease stage 4,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,433144002,Chronic kidney disease stage 3,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,433146000,Chronic kidney disease stage 5,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,472953006,H/O chronic kidney disease,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,698463001,At increased risk of chronic kidney disease,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,700378005,Chronic kidney disease stage 3A,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,700379002,Chronic kidney disease stage 3B,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,709044004,Chronic kidney disease,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,714152005,Chronic kidney disease 5d,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,248721000000108,Chronic kidney disease monitoring,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,249171000000102,Chronic kidney disease annual review,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,249311000000109,Predicted stage chronic kidney disease,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,298141000000107,Did not attend chronic kidney disease monitoring clinic,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324121000000109,CKD (chronic kidney disease stage) 1 with proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324151000000104,CKD (chronic kidney disease) stage 1 without proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324181000000105,CKD (chronic kidney disease) stage 2 with proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324211000000106,CKD (chronic kidney disease) stage 2 without proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324251000000105,CKD (chronic kidney disease) stage 3 with proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324281000000104,CKD (chronic kidney disease) stage 3 without proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324311000000101,CKD (chronic kidney disease) stage 3A with proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324341000000100,CKD (chronic kidney disease) stage 3A without proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324371000000106,CKD (chronic kidney disease) stage 3B with proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324411000000105,CKD (chronic kidney disease) stage 3B without proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324441000000106,CKD (chronic kidney disease) stage 4 with proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324471000000100,CKD (chronic kidney disease) stage 4 without proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324501000000107,CKD (chronic kidney disease) stage 5 with proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,324541000000105,CKD (chronic kidney disease) stage 5 without proteinuria,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,711421000000107,Chronic kidney disease monitoring invitation,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,713811000000100,Chronic kidney disease monitoring administration,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,716651000000106,Chronic kidney disease monitoring first letter,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,716881000000104,Excepted from chronic kidney disease quality indicators - informed dissent,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,716891000000102,Excepted from chronic kidney disease quality indicators - patient unsuitable,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,717231000000104,Chronic kidney disease monitoring verbal invite,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,717361000000100,Exception reporting - chronic kidney disease quality indicators,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,717461000000108,Chronic kidney disease monitoring third letter,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,717511000000105,Chronic kidney disease monitoring telephone invite,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,717751000000104,Chronic kidney disease monitoring second letter,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,811021000000104,Chronic kidney disease self-management plan review,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,811941000000105,Chronic kidney disease self-management plan agreed,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,857971000000104,Estimated glomerular filtration rate using Chronic Kidney Disease Epidemiology Collaboration formula,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,903261000000109,Chronic kidney disease laboratory study,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,939211000000104,Chronic kidney disease resolved,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,949401000000103,Chronic kidney disease with glomerular filtration rate category G1 and albuminuria category A1,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,949421000000107,Chronic kidney disease with glomerular filtration rate category G1 and albuminuria category A2,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,949481000000108,CKD G1A3 - chronic kidney disease with glomerular filtration rate category G1 and albuminuria category A3,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,949521000000108,CKD G2A1 - chronic kidney disease with glomerular filtration rate category G2 and albuminuria category A1,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,949561000000100,Chronic kidney disease with glomerular filtration rate category G2 and albuminuria category A2,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,949621000000109,CKD G2A3 - chronic kidney disease with glomerular filtration rate category G2 and albuminuria category A3,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,949881000000106,CKD G3aA1 - chronic kidney disease with glomerular filtration rate category G3a and albuminuria category A1,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,949901000000109,CKD G3aA2 - chronic kidney disease with glomerular filtration rate category G3a and albuminuria category A2,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,949921000000100,Chronic kidney disease with glomerular filtration rate category G3a and albuminuria category A3,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,950061000000103,Chronic kidney disease with glomerular filtration rate category G3b and albuminuria category A1,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,950081000000107,CKD G3bA2 - chronic kidney disease with glomerular filtration rate category G3b and albuminuria category A2,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,950101000000101,CKD G3bA3 - chronic kidney disease with glomerular filtration rate category G3b and albuminuria category A3,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,950181000000106,CKD G4A1 - chronic kidney disease with glomerular filtration rate category G4 and albuminuria category A1,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,950211000000107,CKD G4A2 - chronic kidney disease with glomerular filtration rate category G4 and albuminuria category A2,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,950231000000104,CKD G4A3 - chronic kidney disease with glomerular filtration rate category G4 and albuminuria category A3,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,950251000000106,CKD G5A1 - chronic kidney disease with glomerular filtration rate category G5 and albuminuria category A1,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,950291000000103,Chronic kidney disease with glomerular filtration rate category G5 and albuminuria category A2,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,950311000000102,Chronic kidney disease with glomerular filtration rate category G5 and albuminuria category A3,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,1011481000000105,Estimated glomerular filtration rate using creatinine Chronic Kidney Disease Epidemiology Collaboration equation per 1.73 square metres,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
ROXADUSTAT,Symptomatic anaemia in chronic kidney disease,TA807,chronic kidney disease,1011491000000107,Estimated glomerular filtration rate using cystatin C Chronic Kidney Disease Epidemiology Collaboration equation per 1.73 square metres,ROXADUSTAT,NEPHROLOGY,NEPHROLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,8100009,Structure of infundibulum of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,9361007,Downward displacement of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,22611009,Endometriosis of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,25344002,Fimbriectomy of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,25811000,Excision of entire bilateral fallopian tubes,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,29827000,Excision of both fallopian tubes and ovaries,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,32587001,Rupture of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,32987009,Both fallopian tubes,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,38043007,Implantation of prosthesis into fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,41393008,Excision of cyst of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,42618007,Atresia of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,44793005,Excision of lesion of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,46536000,Inflammation of ovary and fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,46946009,Torsion of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,49558004,Fallopian tube tuberculosis,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,56900004,Infarction of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,64233004,Congenital cyst of fimbria of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,78328007,Aspiration of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,78517009,Dilation of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,79586000,Fallopian tube pregnancy,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,85029000,Congenital anomaly of fallopian tubes,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,88157006,Inflammation of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,92100009,Benign neoplasm of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,92591008,Carcinoma in situ of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,118869008,Procedure on fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,120062000,Fallopian tube reconstruction,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,128134005,Fallopian tube disorder,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176936004,Open occlusion of both fallopian tubes,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176937008,Open ligation of both fallopian tubes,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176938003,Open bilateral clipping of fallopian tubes,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176942000,Open ligation of remaining solitary fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176948001,Open ligation of right fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176949009,Open ligation of left fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176965005,Drainage of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176975008,Exploration of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176978005,Endoscopic bilateral cauterisation of fallopian tubes,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176979002,Endoscopic bilateral clipping of fallopian tubes,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176980004,Ligation of fallopian tubes with Fallope ring by endoscopy,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176984008,Endoscopic occlusion of remaining solitary fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176985009,Endoscopic occlusion of right fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,176986005,Endoscopic occlusion of left fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,177002003,Laparoscopy of fallopian tube: [diagnostic NOS] or [NEC],RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,189120005,Benign neoplasm of fallopian tubes and uterine ligaments,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,193331004,Laparoscopy with occlusion of fallopian tube by device,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,198299001,Acquired ovarian and fallopian tube atrophy,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,198305004,Prolapse of ovary and fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,198308002,"Torsion of the ovary, ovarian pedicle or fallopian tube",RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,198311001,"Other ovary, fallopian tube and broad ligament disorders",RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,198313003,"Ovarian, fallopian tube and broad ligament disorder NOS",RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,204826004,Fallopian tube and broad ligament anomalies,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,236927008,Removal of clip from fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,236938008,Laparoscopy of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,237050007,Fimbrial phimosis of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,245482004,Entire left cornu of Fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,262931005,Transection of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,265071006,Open clipping of both fallopian tubes,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,265076001,Open clipping of left fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,266591002,"Noninflammatory disorders of the ovary, fallopian tube and broad ligament",RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,266592009,Acquired absence of ovary or fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,271414005,Fallopian tube prosthesis operation,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,271415006,Removal of products of conception from fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,274975009,Open ringing of bilateral fallopian tubes,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,274977001,Unilateral occlusion of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,280504001,Fallopian tube stenosis,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,281258002,LAP DYE - laparoscopic dye test of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,283958000,Hematoma of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,287664005,Ligation of both fallopian tubes,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,287931008,Fallopian tube cornual resection,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,287943009,Insufflation of fallopian tube using saline,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,287944003,Insufflation of fallopian tube using gas,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,288032001,Transection of both fallopian tubes,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,288033006,Unilateral ligation of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,288034000,Unilateral fallopian tube division,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,289832005,Fallopian tube present,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,289833000,Fallopian tube absent,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,292002002,Open unilateral occlusion of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,300020002,Diathermy of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,302954008,Congenital cyst of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,307264000,Remaining fallopian tube removed,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,309290005,Fallopian tube biopsy specimen,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,309500004,Excised uterus and single fallopian tube and ovary sample,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,310808000,Fallopian tube clip,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,369514009,Metastatic malignant neoplasm of left fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,387615001,Removal of gestational sac from fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,387617009,Aspiration of gestational sac from fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,391993002,Reestablishment of continuity of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,392250009,Operation on fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,398319002,Abscess of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,427543006,Recanalisation of fallopian tube,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,609321005,Endoscopic bilateral occlusion of fallopian tubes using intrafallopian implants,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,719447009,Ectopic fallopian tube tissue,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,560681000000101,Reanastomosis of fallopian tube NEC,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,561491000000108,Fallopian tube operations NOS,RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUCAPARIB,"Relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer",TA611,fallopian tube,647361000000102,"Ovarian, fallopian tube and broad ligament disorder NOS",RUCAPARIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
RUXOLITINIB,Acute graft versus host disease refractory to corticosteroids,TA839,graft versus host disease,234646005,Graft versus host disease,RUXOLITINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY
RUXOLITINIB,Acute graft versus host disease refractory to corticosteroids,TA839,graft versus host disease,402356004,Chronic graft versus host disease,RUXOLITINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY
RUXOLITINIB,Chronic graft versus host disease refractory to corticosteroids,TA840,graft versus host disease,234646005,Graft versus host disease,RUXOLITINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY
RUXOLITINIB,Chronic graft versus host disease refractory to corticosteroids,TA840,graft versus host disease,402356004,Chronic graft versus host disease,RUXOLITINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY
RUXOLITINIB,Disease-related splenomegaly or symptoms in adults with myelofibrosis,TA289,myelofibrosis,80570006,Acute panmyelosis with myelofibrosis,RUXOLITINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
RUXOLITINIB,Treating disease-related splenomegaly or symptoms in adults with myelofibrosis,TA386,myelofibrosis,80570006,Acute panmyelosis with myelofibrosis,RUXOLITINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
RUXOLITINIB,Treating polycythaemia vera,TA356,polycythaemia vera,1659461000000103,JAK2-positive PV (polycythaemia vera),RUXOLITINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
RUXOLITINIB,Treating polycythaemia vera,TA356,polycythaemia vera,1659471000000105,Janus kinase 2 negative polycythaemia vera,RUXOLITINIB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,134405005,Suspected breast cancer,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,160287004,FH: Breast cancer,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,268547008,Screening for breast cancer,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,429740004,Family history of breast cancer,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,431330007,Family history of breast cancer 1 gene mutation,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,431331006,Family history of breast cancer 2 gene mutation,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,706970001,TNBC - Triple-negative breast cancer,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,94361000000105,Breast cancer detected by national screening programme,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,276341000000100,Fast track referral for suspected breast cancer,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,838351000000107,Education about risk of breast cancer,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,874291000000100,QCancer breast cancer risk,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
SACITUZUMAB GOVITECAN,Unresectable triple-negative advanced breast cancer after 2 or more therapies,TA819,breast cancer,1035841000000108,Lymphoedema following breast cancer,SACITUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,10335000,Chronic right-sided heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,10633002,Acute congestive heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,36315003,Malignant hypertensive heart disease without congestive heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,48447003,Chronic heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,56675007,Acute heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,77970009,Benign hypertensive heart disease without congestive heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,83105008,Malignant hypertensive heart disease with congestive heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,83291003,Right heart failure due to pulmonary hypertension,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,85232009,Left-sided heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,88805009,Chronic congestive heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,111283005,Chronic left-sided heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,128404006,Right heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,134378009,Congestive heart failure monitoring,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,134440006,Referral to heart failure clinic,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,161505003,History of heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,194779001,Hypertensive heart and renal disease with (congestive) heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,194781004,Hypertensive heart and renal disease with both (congestive) heart failure and renal failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,233924009,Heart failure as a complication of care,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,266308000,Right heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,309634009,History of heart failure in last year,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,314206003,Refractory heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,367363000,Right heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,390868005,Heart failure screen,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,390884006,Heart failure follow-up,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,390885007,Heart failure annual review,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,394887005,Suspected heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,394927007,Heart failure excluded,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,395105005,Heart failure confirmed,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,416683003,Emergency hospital admission for heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,416717003,Seen in heart failure clinic,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,417146007,Referral to heart failure nurse,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,417359009,Seen by community heart failure nurse,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,423475008,Heart failure education,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,424404003,Decompensated chronic heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,426263006,Congestive heart failure due to left ventricular systolic dysfunction,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,426611007,Congestive heart failure due to valvular disease,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,429959009,Family history of heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,441530006,Chronic diastolic heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,446221000,HFpEF - heart failure with preserved ejection fraction,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,473226007,Heart failure medication review,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,703272007,HFrEF - heart failure with reduced ejection fraction,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,703275009,Heart failure with reduced ejection fraction due to cardiomyopathy,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,704095000,Referral to heart failure exercise programme,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,704096004,Referral to heart failure exercise programme not indicated,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,704097008,Referral to heart failure exercise program declined,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,735984001,Heart failure self management plan,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,788950000,HFmEF - heart failure with mid range ejection fraction,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,1296659009,Acute on chronic heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,96311000119109,Exacerbation of congestive heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,143411000000100,QOF (Quality and Outcomes Framework) heart failure quality indicator-related care invitation using preferred method of communication,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,200171000000102,Referred by heart failure nurse specialist,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,200201000000101,Discharge from practice nurse heart failure clinic,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,200361000000106,Did not attend practice nurse heart failure clinic,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,202231000000106,Heart failure review completed,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,203791000000106,Referred to heart failure education group,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,247361000000100,Heart failure 6 month review,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,248571000000104,Did not attend heart failure clinic,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,374231000000104,High risk of heart failure screening invitation,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,521691000000100,Heart failure resolved,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,711461000000104,Heart failure monitoring invitation,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,713791000000101,Heart failure monitoring administration,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,715951000000107,Exception reporting - heart failure quality indicators,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,716621000000101,Heart failure monitoring third letter,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,716971000000109,Heart failure monitoring first letter,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,717191000000108,Heart failure monitoring second letter,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,717481000000104,Excepted from heart failure quality indicators - patient unsuitable,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,717491000000102,Excepted from heart failure quality indicators - informed dissent,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,717501000000108,Heart failure monitoring verbal invitation,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,717531000000102,Heart failure monitoring telephone invitation,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,760361000000100,Fast track heart failure referral for transthoracic two dimensional echocardiogram,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,763641000000102,Referral to heart failure education group declined,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,765661000000102,Discharge from heart failure nurse service,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,781051000000108,Has heart failure management plan,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,789621000000105,Preferred place of care for next exacerbation of heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,810971000000105,Heart failure self-management plan review,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,812001000000102,Heart failure self-management plan agreed,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,813991000000101,Education about deteriorating heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,835981000000108,Rehabilitation for heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,851071000000108,Heart failure initial assessment,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,851521000000102,Heart failure clinical pathway,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,871681000000102,Heart failure monitoring,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,872361000000105,Discussion about heart failure care plan,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,873881000000100,Referral to rapid access heart failure clinic,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,915571000000102,On optimal heart failure therapy,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,961881000000101,Provision of information about heart failure,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,1108711000000108,Excepted from heart failure quality indicators - service unavailable,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SACUBITRIL VALSARTAN,Treating symptomatic chronic heart failure with reduced ejection fraction,TA388,heart failure,1110931000000103,QOF (Quality and Outcomes Framework) heart failure quality indicator-related care invitation,SACUBITRIL,CARDIOLOGY,CARDIOLOGY
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,161567008,History of rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,161567008,History of rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,161567008,History of rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,161567008,History of rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SARILUMAB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA485,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,SARILUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
SECUKINUMAB,Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors,TA407,ankylosing spondylitis,162930007,On examination - ankylosing spondylitis chest deformity,SECUKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
SECUKINUMAB,Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors,TA407,ankylosing spondylitis,239805001,Juvenile ankylosing spondylitis,SECUKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
SECUKINUMAB,Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors,TA407,ankylosing spondylitis,239810002,Ankylosing spondylitis with organ / system involvement,SECUKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
SECUKINUMAB,Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors,TA407,ankylosing spondylitis,239811003,Ankylosing spondylitis with multisystem involvement,SECUKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
SECUKINUMAB,Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors,TA407,ankylosing spondylitis,394990003,Family history: Ankylosing spondylitis,SECUKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
SECUKINUMAB,Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors,TA407,ankylosing spondylitis,429712009,Bath Ankylosing Spondylitis Disease Activity Index,SECUKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
SECUKINUMAB,Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors,TA407,ankylosing spondylitis,441562009,Bath Ankylosing Spondylitis Disease Activity Index score,SECUKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
SECUKINUMAB,Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors,TA407,ankylosing spondylitis,441680005,BASFI (Bath Ankylosing Spondylitis Functional Index) score,SECUKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
SECUKINUMAB,Active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors,TA407,ankylosing spondylitis,441930001,BASMI (Bath Ankylosing Spondylitis Metrology Index) score,SECUKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
SECUKINUMAB,Moderate to severe plaque psoriasis,TA350,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),SECUKINUMAB,DERMATOLOGY,DERMATOLOGY
SECUKINUMAB,Moderate to severe plaque psoriasis,TA350,plaque psoriasis,402307000,Chronic large plaque psoriasis,SECUKINUMAB,DERMATOLOGY,DERMATOLOGY
SECUKINUMAB,Moderate to severe plaque psoriasis,TA350,plaque psoriasis,402310007,Chronic stable plaque psoriasis,SECUKINUMAB,DERMATOLOGY,DERMATOLOGY
SECUKINUMAB,Moderate to severe plaque psoriasis in children and young people,TA734,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),SECUKINUMAB,DERMATOLOGY,DERMATOLOGY
SECUKINUMAB,Moderate to severe plaque psoriasis in children and young people,TA734,plaque psoriasis,402307000,Chronic large plaque psoriasis,SECUKINUMAB,DERMATOLOGY,DERMATOLOGY
SECUKINUMAB,Moderate to severe plaque psoriasis in children and young people,TA734,plaque psoriasis,402310007,Chronic stable plaque psoriasis,SECUKINUMAB,DERMATOLOGY,DERMATOLOGY
SECUKINUMAB,Non-radiographic axial spondyloarthritis,TA719,axial spondyloarthritis,723116002,Axial spondyloarthritis,SECUKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY
"SECUKINUMAB ALONE, OR IN COMBINATION WITH METHOTREXATE",Psoriatic arthritis after inadequate response to DMARDs,TA445,psoriatic arthritis,156370009,Psoriatic arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
"SECUKINUMAB ALONE, OR IN COMBINATION WITH METHOTREXATE",Psoriatic arthritis after inadequate response to DMARDs,TA445,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
"SECUKINUMAB ALONE, OR IN COMBINATION WITH METHOTREXATE",Psoriatic arthritis after inadequate response to DMARDs,TA445,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
"SECUKINUMAB ALONE, OR IN COMBINATION WITH METHOTREXATE",Psoriatic arthritis after inadequate response to DMARDs,TA445,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
"SECUKINUMAB ALONE, OR IN COMBINATION WITH METHOTREXATE",Psoriatic arthritis after inadequate response to DMARDs,TA445,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
"SECUKINUMAB ALONE, OR IN COMBINATION WITH METHOTREXATE",Psoriatic arthritis after inadequate response to DMARDs,TA445,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,CERTOLIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
SELECTIVE INTERNAL RADIATION THERAPY QUIREMSPHERES,Hepatocellular carcinoma,TA688,hepatocellular carcinoma,15619004,"Hepatocellular carcinoma, fibrolamellar",SELECTIVE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
SELECTIVE INTERNAL RADIATION THERAPY QUIREMSPHERES,Hepatocellular carcinoma,TA688,hepatocellular carcinoma,253018005,Fibrolamellar hepatocellular carcinoma,SELECTIVE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
SELECTIVE INTERNAL RADIATION THERAPY QUIREMSPHERES,Hepatocellular carcinoma,TA688,hepatocellular carcinoma,990271000000107,Ultrasound scan surveillance of liver for hepatocellular carcinoma,SELECTIVE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
SELECTIVE INTERNAL RADIATION THERAPY SIR-SPHERES,Hepatocellular carcinoma,TA688,hepatocellular carcinoma,15619004,"Hepatocellular carcinoma, fibrolamellar",SELECTIVE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
SELECTIVE INTERNAL RADIATION THERAPY SIR-SPHERES,Hepatocellular carcinoma,TA688,hepatocellular carcinoma,253018005,Fibrolamellar hepatocellular carcinoma,SELECTIVE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
SELECTIVE INTERNAL RADIATION THERAPY SIR-SPHERES,Hepatocellular carcinoma,TA688,hepatocellular carcinoma,990271000000107,Ultrasound scan surveillance of liver for hepatocellular carcinoma,SELECTIVE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
SELECTIVE INTERNAL RADIATION THERAPY THERASPHERE,Hepatocellular carcinoma,TA688,hepatocellular carcinoma,15619004,"Hepatocellular carcinoma, fibrolamellar",SELECTIVE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
SELECTIVE INTERNAL RADIATION THERAPY THERASPHERE,Hepatocellular carcinoma,TA688,hepatocellular carcinoma,253018005,Fibrolamellar hepatocellular carcinoma,SELECTIVE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
SELECTIVE INTERNAL RADIATION THERAPY THERASPHERE,Hepatocellular carcinoma,TA688,hepatocellular carcinoma,990271000000107,Ultrasound scan surveillance of liver for hepatocellular carcinoma,SELECTIVE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
SELINEXOR WITH LOW-DOSE DEXAMETHASONE FOR TREATING REFRACTORY MULTIPLE MYELOMA,Refractory multiple myeloma,TA700,multiple myeloma,230586003,Neuropathy due to multiple myeloma,SELINEXOR,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
SELINEXOR WITH LOW-DOSE DEXAMETHASONE FOR TREATING REFRACTORY MULTIPLE MYELOMA,Refractory multiple myeloma,TA700,multiple myeloma,413587002,Smoldering multiple myeloma,SELINEXOR,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
SELINEXOR WITH LOW-DOSE DEXAMETHASONE FOR TREATING REFRACTORY MULTIPLE MYELOMA,Refractory multiple myeloma,TA700,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,SELINEXOR,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
SELPERCATINIB,Advanced thyroid cancer with RET alterations,TA742,thyroid cancer,94098005,Primary malignant neoplasm of thyroid gland,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY
SELPERCATINIB,Advanced thyroid cancer with RET alterations,TA742,thyroid cancer,363478007,Malignant tumour of thyroid gland,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY
SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,162573006,Suspected lung cancer,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,254637007,Non-small cell lung cancer,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,275981009,Lung cancer screening,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,429011007,Family history of lung cancer,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,877691000000107,No FH of lung cancer,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SELPERCATINIB,Previously treated RET fusion-positive advanced non-small-cell lung cancer,TA760,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",SELPERCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,44772007,Maternal obesity without hypertension,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,82793005,Hypothalamic obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,160311006,Family history: Obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,161453001,History of obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,162864005,Body mass index 30+ - obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,170793009,Obesity monitoring,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,170794003,Initial obesity assessment,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,170795002,Follow-up obesity assessment,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,170797005,Has seen dietician - obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,170798000,Treatment of obesity changed,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,170799008,Treatment of obesity started,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,170800007,Treatment of obesity stopped,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,170807005,Reason for obesity therapy - occupational,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,185741002,Attends obesity monitoring,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,185743004,Obesity monitoring default,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,185744005,Obesity monitoring first letter,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,185745006,Obesity monitoring second letter,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,185746007,Obesity monitoring third letter,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,185747003,Obesity monitoring verbal invite,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,185748008,Obesity monitoring telephone invite,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,185749000,Obesity monitoring deleted,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,185750000,Obesity monitoring check done,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,190965006,Drug-induced obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,190966007,Obesity hypoventilation syndrome,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,199072001,(Gestational edema &/or non-hypertension excessive weight gain) or (maternal obesity syndrome),SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,235240002,Procedure using anti-obesity gastric balloon,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,238132000,Upper body obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,238133005,Gynecoid obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,238134004,Generalized obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,238136002,Morbid obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,243862009,Obesity monitoring status,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,247824007,Fear of obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,267511009,Hyperalimentation incl.obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,268522006,Obesity monitoring,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,268551005,Obesity screening,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,270486005,Localized obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,276792008,Pulmonary hypertension with extreme obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,277831002,Anxiety about obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,284352003,Obesity diet education,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,294493008,Lifelong obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,296526005,Adult-onset obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,308504001,Obesity monitoring call,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,310428009,Obesity monitoring invitation,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,415530009,Obesity due to excess calories,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,444862003,Childhood obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,703316004,Lymphoedema associated with obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,715279006,Telehealth obesity monitoring,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,763085007,Obesity monitoring declined,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,198181000000102,Obesity resolved,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,640791000000105,Obesity and other hyperalimentation,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,713951000000106,Obesity monitoring administration,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,713971000000102,Obesity clinic administration,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,753691000000104,Exception reporting - obesity quality indicators,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,753751000000103,Excepted from obesity quality indicators - patient unsuitable,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,753771000000107,Excepted from obesity quality indicators - informed dissent,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,755881000000104,"Risk to health associated with overweight and obesity, at no increased risk",SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,755901000000101,"Risk to health associated with overweight and obesity, at increased risk",SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,755921000000105,"Risk to health associated with overweight and obesity, at high risk",SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,755941000000103,"Risk to health associated with overweight and obesity, at very high risk",SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,756001000000107,"Intervention for risk to health associated with overweight and obesity, general advice on healthy weight and lifestyle",SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,756021000000103,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity",SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,756041000000105,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs",SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,756061000000106,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs, consider surgery",SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,822741000000107,Anti-obesity drug therapy,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,851901000000101,Obesity and weight loss quality of life questionnaire,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,894961000000105,Referral to multidisciplinary obesity clinic,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,898011000000103,Obesity multidisciplinary case review,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,914801000000107,Anti-obesity drug therapy commenced,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,914821000000103,Obesity medication stopped,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,1269761000000101,Focal segmental glomerulosclerosis due to obesity,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,2386191000000105,National Health Service obesity medication pathway,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,2386201000000107,Referral to National Health Service obesity medication wraparound support pathway,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,2386221000000103,Unsuitable for NHS obesity medication pathway,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,2386231000000101,NHS obesity medication pathway started,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,2386241000000105,National Health Service obesity medication pathway declined,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,2386251000000108,Review of anti-obesity drug therapy,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SEMAGLUTIDE,Managing overweight and obesity,TA875,obesity,2386261000000106,NHS obesity medication wraparound support pathway completed,SEMAGLUTIDE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SERTINDOLE,Schizophrenia,TA043,schizophrenia,4926007,Schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,12939007,Chronic disorganized schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,31373002,Hebephrenic schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,31658008,Chronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,35252006,Disorganised schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,39610001,Undifferentiated schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,58214004,Schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,63181006,"Paranoid schizophrenia, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,64905009,Paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,79866005,Subchronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,83746006,Chronic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,111482003,Subchronic schizophrenia with acute exacerbations,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,111483008,"Schizophrenia, catatonic, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,111484002,Undifferentiated schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,160328009,Family history of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,161103001,Schizophrenia association member,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,161468000,History of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,191527001,Simple schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,191531007,Acute exacerbation of chronic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,191548004,Chronic catatonic schizophrenia with acute exacerbation,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,191554003,Acute exacerbation of subchronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,191555002,Acute exacerbation of chronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,191559008,Latent schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,191565008,Latent schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,191567000,Schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,191570001,Chronic schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,191572009,Acute exacerbation of chronic schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,191574005,"Schizophrenia, schizoaffective, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,247804008,Prodromal schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,274952002,Borderline schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,278853003,Acute schizophrenia-like psychotic disorder,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,444180005,History of schizophrenia in child of subject,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,712824002,Acute polymorphic psychotic disorder without symptoms of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,712850003,Acute polymorphic psychotic disorder with symptoms of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,200951000000109,"Psychosis, schizophrenia and bipolar affective disorder resolved",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,285521000000103,Schizophrenia resolved,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,417601000000102,"[X]Schizophrenia, schizotypal and delusional disorders",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,443791000000100,[X]Pseudopsychopathic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,1062101000000104,Schizophrenia TOM (Therapy Outcome Measure) activity score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,1062121000000108,Schizophrenia TOM (Therapy Outcome Measure) impairment score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,1062131000000105,Schizophrenia TOM (Therapy Outcome Measure) participation score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SERTINDOLE,Schizophrenia,TA043,schizophrenia,1062141000000101,Schizophrenia TOM (Therapy Outcome Measure) wellbeing score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
SIBUTRAMINE,Obesity,TA031,obesity,44772007,Maternal obesity without hypertension,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,82793005,Hypothalamic obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,160311006,Family history: Obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,161453001,History of obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,162864005,Body mass index 30+ - obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,170793009,Obesity monitoring,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,170794003,Initial obesity assessment,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,170795002,Follow-up obesity assessment,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,170797005,Has seen dietician - obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,170798000,Treatment of obesity changed,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,170799008,Treatment of obesity started,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,170800007,Treatment of obesity stopped,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,170807005,Reason for obesity therapy - occupational,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,185741002,Attends obesity monitoring,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,185743004,Obesity monitoring default,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,185744005,Obesity monitoring first letter,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,185745006,Obesity monitoring second letter,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,185746007,Obesity monitoring third letter,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,185747003,Obesity monitoring verbal invite,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,185748008,Obesity monitoring telephone invite,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,185749000,Obesity monitoring deleted,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,185750000,Obesity monitoring check done,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,190965006,Drug-induced obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,190966007,Obesity hypoventilation syndrome,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,199072001,(Gestational edema &/or non-hypertension excessive weight gain) or (maternal obesity syndrome),SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,235240002,Procedure using anti-obesity gastric balloon,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,238132000,Upper body obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,238133005,Gynecoid obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,238134004,Generalized obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,238136002,Morbid obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,243862009,Obesity monitoring status,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,247824007,Fear of obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,267511009,Hyperalimentation incl.obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,268522006,Obesity monitoring,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,268551005,Obesity screening,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,270486005,Localized obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,276792008,Pulmonary hypertension with extreme obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,277831002,Anxiety about obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,284352003,Obesity diet education,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,294493008,Lifelong obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,296526005,Adult-onset obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,308504001,Obesity monitoring call,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,310428009,Obesity monitoring invitation,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,415530009,Obesity due to excess calories,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,444862003,Childhood obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,703316004,Lymphoedema associated with obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,715279006,Telehealth obesity monitoring,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,763085007,Obesity monitoring declined,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,198181000000102,Obesity resolved,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,640791000000105,Obesity and other hyperalimentation,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,713951000000106,Obesity monitoring administration,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,713971000000102,Obesity clinic administration,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,753691000000104,Exception reporting - obesity quality indicators,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,753751000000103,Excepted from obesity quality indicators - patient unsuitable,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,753771000000107,Excepted from obesity quality indicators - informed dissent,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,755881000000104,"Risk to health associated with overweight and obesity, at no increased risk",SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,755901000000101,"Risk to health associated with overweight and obesity, at increased risk",SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,755921000000105,"Risk to health associated with overweight and obesity, at high risk",SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,755941000000103,"Risk to health associated with overweight and obesity, at very high risk",SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,756001000000107,"Intervention for risk to health associated with overweight and obesity, general advice on healthy weight and lifestyle",SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,756021000000103,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity",SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,756041000000105,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs",SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,756061000000106,"Intervention for risk to health associated with overweight and obesity, advice about diet and physical activity, consider drugs, consider surgery",SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,822741000000107,Anti-obesity drug therapy,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,851901000000101,Obesity and weight loss quality of life questionnaire,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,894961000000105,Referral to multidisciplinary obesity clinic,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,898011000000103,Obesity multidisciplinary case review,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,914801000000107,Anti-obesity drug therapy commenced,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,914821000000103,Obesity medication stopped,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,1269761000000101,Focal segmental glomerulosclerosis due to obesity,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,2386191000000105,National Health Service obesity medication pathway,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,2386201000000107,Referral to National Health Service obesity medication wraparound support pathway,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,2386221000000103,Unsuitable for NHS obesity medication pathway,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,2386231000000101,NHS obesity medication pathway started,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,2386241000000105,National Health Service obesity medication pathway declined,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,2386251000000108,Review of anti-obesity drug therapy,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIBUTRAMINE,Obesity,TA031,obesity,2386261000000106,NHS obesity medication wraparound support pathway completed,SIBUTRAMINE,ENDOCRINOLOGY,ENDOCRINOLOGY|DIABETIC MEDICINE|GENERAL MEDICINE
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,62944002,Hepatitis C virus,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,62944002,Hepatitis C virus,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,72165005,Hepatitis C virus antibody,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,72165005,Hepatitis C virus antibody,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,170489004,Viral hepatitis carrier,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,170489004,Viral hepatitis carrier,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,197344005,Hepatitis caused by adenovirus,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,197344005,Hepatitis caused by adenovirus,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,235872006,Hepatitis C carrier,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,235872006,Hepatitis C carrier,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,278973007,Hepatitis C status,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,278973007,Hepatitis C status,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,278974001,Hepatitis C immune,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,278974001,Hepatitis C immune,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,278975000,Hepatitis C non-immune,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,278975000,Hepatitis C non-immune,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,314706002,Hepatitis C antibody detected,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,314706002,Hepatitis C antibody detected,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,314707006,Hepatitis C antibody test negative,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,314707006,Hepatitis C antibody test negative,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,413107006,Hepatitis C screening,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,413107006,Hepatitis C screening,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,773113008,Acute hepatitis caused by infection,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,773113008,Acute hepatitis caused by infection,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,12891000175105,Hepatitis C screening declined,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,12891000175105,Hepatitis C screening declined,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,200371000000104,Hepatitis C contact,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,200371000000104,Hepatitis C contact,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,201451000000105,Hepatitis C immunisation declined,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,201451000000105,Hepatitis C immunisation declined,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,202281000000105,Hepatitis C screening declined,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,202281000000105,Hepatitis C screening declined,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,204671000000101,Hepatitis C screening counselling,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,204671000000101,Hepatitis C screening counselling,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,304821000000107,Hepatitis C screening not offered,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,304821000000107,Hepatitis C screening not offered,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,362491000000104,Hepatitis C screening negative,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,362491000000104,Hepatitis C screening negative,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,362751000000101,Hepatitis C screening positive,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,362751000000101,Hepatitis C screening positive,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,761381000000102,Hepatitis C resolved,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,761381000000102,Hepatitis C resolved,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,824841000000105,Hepatitis C genotype 1,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,824841000000105,Hepatitis C genotype 1,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,824871000000104,Hepatitis C genotype 3,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,824871000000104,Hepatitis C genotype 3,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,829731000000106,On hepatitis C treatment plan,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,829731000000106,On hepatitis C treatment plan,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,992751000000109,Hepatitis C viral load,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,992751000000109,Hepatitis C viral load,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,992771000000100,Hepatitis C virus genotype,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,992771000000100,Hepatitis C virus genotype,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,996031000000104,Hepatitis C IgG level,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,996031000000104,Hepatitis C IgG level,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,998771000000103,Hepatitis C antibody level,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,998771000000103,Hepatitis C antibody level,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,1001331000000102,Hepatitis C antigen level,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,1001331000000102,Hepatitis C antigen level,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,1008931000000108,Hepatitis C antibody test,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,1008931000000108,Hepatitis C antibody test,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,1107671000000106,Hepatitis C screening offered,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treating genotypes 1 and 4 chronic hepatitis C,TA331,hepatitis c,1107671000000106,Hepatitis C screening offered,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,62944002,Hepatitis C virus,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,62944002,Hepatitis C virus,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,72165005,Hepatitis C virus antibody,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,72165005,Hepatitis C virus antibody,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,170489004,Viral hepatitis carrier,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,170489004,Viral hepatitis carrier,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,197344005,Hepatitis caused by adenovirus,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,197344005,Hepatitis caused by adenovirus,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,235872006,Hepatitis C carrier,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,235872006,Hepatitis C carrier,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,278973007,Hepatitis C status,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,278973007,Hepatitis C status,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,278974001,Hepatitis C immune,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,278974001,Hepatitis C immune,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,278975000,Hepatitis C non-immune,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,278975000,Hepatitis C non-immune,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,314706002,Hepatitis C antibody detected,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,314706002,Hepatitis C antibody detected,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,314707006,Hepatitis C antibody test negative,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,314707006,Hepatitis C antibody test negative,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,413107006,Hepatitis C screening,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,413107006,Hepatitis C screening,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,773113008,Acute hepatitis caused by infection,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,773113008,Acute hepatitis caused by infection,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,12891000175105,Hepatitis C screening declined,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,12891000175105,Hepatitis C screening declined,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,200371000000104,Hepatitis C contact,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,200371000000104,Hepatitis C contact,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,201451000000105,Hepatitis C immunisation declined,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,201451000000105,Hepatitis C immunisation declined,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,202281000000105,Hepatitis C screening declined,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,202281000000105,Hepatitis C screening declined,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,204671000000101,Hepatitis C screening counselling,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,204671000000101,Hepatitis C screening counselling,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,304821000000107,Hepatitis C screening not offered,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,304821000000107,Hepatitis C screening not offered,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,362491000000104,Hepatitis C screening negative,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,362491000000104,Hepatitis C screening negative,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,362751000000101,Hepatitis C screening positive,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,362751000000101,Hepatitis C screening positive,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,761381000000102,Hepatitis C resolved,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,761381000000102,Hepatitis C resolved,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,824841000000105,Hepatitis C genotype 1,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,824841000000105,Hepatitis C genotype 1,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,824871000000104,Hepatitis C genotype 3,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,824871000000104,Hepatitis C genotype 3,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,829731000000106,On hepatitis C treatment plan,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,829731000000106,On hepatitis C treatment plan,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,992751000000109,Hepatitis C viral load,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,992751000000109,Hepatitis C viral load,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,992771000000100,Hepatitis C virus genotype,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,992771000000100,Hepatitis C virus genotype,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,996031000000104,Hepatitis C IgG level,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,996031000000104,Hepatitis C IgG level,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,998771000000103,Hepatitis C antibody level,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,998771000000103,Hepatitis C antibody level,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,1001331000000102,Hepatitis C antigen level,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,1001331000000102,Hepatitis C antigen level,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,1008931000000108,Hepatitis C antibody test,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,1008931000000108,Hepatitis C antibody test,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,1107671000000106,Hepatitis C screening offered,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMEPREVIR IN COMBINATION WITH SOFOSBUVIR,Treating genotype 1 or 4 chronic hepatitis C,TA361,hepatitis c,1107671000000106,Hepatitis C screening offered,SIMEPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,160270001,No family history of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,161499004,H/O: cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,171405001,Examination for suspected cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,266894000,Family history of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,266995000,History of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,395048001,Cardiovascular disease monitoring not required,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417206009,Cardiovascular disease monitoring,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417287002,Cardiovascular disease interim monitoring,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,417322008,Cardiovascular disease annual review,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,429284000,Cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,429785003,Cardiovascular disease health education,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,438825005,Family history of cardiovascular disease (CVD) in first degree female relative less than 65 years of age,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,439724007,Family history of cardiovascular disease (CVD) in first degree male relative less than 55 years of age,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,440358008,Primary prevention of CVD (cardiovascular disease),ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,441829007,Assessment for risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,718087004,QRISK2 cardiovascular disease 10 year risk score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763243004,Assessment using QRISK cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763244005,QRISK cardiovascular disease 10 year risk calculator score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,763245006,QRISK2 cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,143361000000106,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation using preferred method of communication,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166701000000106,Joint British Societies cardiovascular disease risk,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166711000000108,Joint British Societies cardiovascular disease risk less than ten percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166721000000102,Joint British Societies cardiovascular disease risk ten percent to twenty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166731000000100,Joint British Societies cardiovascular disease risk greater than twenty percent up to thirty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,166741000000109,Joint British Societies cardiovascular disease risk greater than thirty percent over next ten years,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,302881000000102,Cardiovascular disease annual review declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,303951000000105,Cardiovascular disease high risk monitoring telephone invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,303981000000104,Cardiovascular disease high risk monitoring invitation letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375451000000106,Cardiovascular disease risk assessment telephone invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375481000000100,Cardiovascular disease risk assessment verbal invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375601000000108,Did not attend cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375631000000102,Failed to respond to cardiovascular disease risk assessment invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375721000000105,Cardiovascular disease high risk monitoring invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375731000000107,Cardiovascular disease high risk monitoring invitation first letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375761000000102,Cardiovascular disease high risk monitoring invitation second letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,375791000000108,Cardiovascular disease high risk monitoring invitation third letter,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,382201000000105,DNA (did not attend) cardiovascular disease primary prevention programme,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,383321000000103,Cardiovascular disease risk assessment indicated,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,412491000000105,[V]Screening for other/unspecified cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,492581000000108,Cardiovascular disease high risk review declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,492611000000102,Cardiovascular disease high risk review,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,713851000000101,At high risk of cardiovascular disease monitoring administration,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716191000000106,Exception reporting - cardiovascular disease quality indicators,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716201000000108,Excepted from cardiovascular disease quality indicators - patient unsuitable,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,716211000000105,Excepted from cardiovascular disease quality indicators - informed dissent,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,752451000000100,Cardiovascular disease risk assessment by third party,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,775201000000105,Cardiovascular disease risk assessment invitation SMS (short message service) text message sent,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,809311000000105,Joint British Societies cardiovascular disease risk score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,822541000000103,QRISK cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,837461000000101,High risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,845171000000108,At risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,847201000000103,Unsuitable for QRISK2 cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,847241000000100,QRISK2 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,888731000000105,ASSIGN2 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,962871000000107,Aware of overall cardiovascular disease risk,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,990301000000105,Cardiovascular disease risk assessment done,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085771000000100,QRISK3 cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085871000000105,QRISK3 cardiovascular disease 10 year risk calculator score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085891000000109,QRISK3 cardiovascular disease risk assessment declined,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085911000000107,Unsuitable for QRISK3 cardiovascular disease risk assessment,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1085971000000102,Assessment using QRISK cardiovascular disease 10 year risk calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1086271000000104,Framingham Cardiovascular Disease 10 year risk score calculator,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1090061000000102,Framingham Coronary Heart Disease or Cardiovascular Disease 10 year risk adjusted to JBS2 (Joint British Societies 2) guidelines score,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,1110891000000108,QOF (Quality and Outcomes Framework) cardiovascular disease primary prevention quality indicator-related care invitation,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIMVASTATIN,Cardiovascular disease,TA094,cardiovascular disease,16434071000119108,At increased risk of cardiovascular disease,ATORVASTATIN,CARDIOLOGY,CARDIOLOGY|VASCULAR SURGERY
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,24700007,Multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,160337009,Family history of multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,192926004,Brain stem multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,192928003,Generalised multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,428700003,Primary progressive multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,438511000,Benign multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,700409000,Suspected multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,198491000000106,Multiple sclerosis review,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,515931000000104,Multiple sclerosis review declined,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPONIMOD,Secondary progressive multiple sclerosis,TA656,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,SIPONIMOD,NEUROLOGY,NEUROLOGY|REHABILITATION
SIPULEUCEL-T,Treating asymptomatic or minimally symptomatic metastatic hormone-replased prostate cancer,TA332,prostate cancer,315268008,Suspected prostate cancer,SIPULEUCEL-T,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SIPULEUCEL-T,Treating asymptomatic or minimally symptomatic metastatic hormone-replased prostate cancer,TA332,prostate cancer,428262008,H/O: prostate cancer,SIPULEUCEL-T,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SIPULEUCEL-T,Treating asymptomatic or minimally symptomatic metastatic hormone-replased prostate cancer,TA332,prostate cancer,698470001,Advice given about prostate cancer screening,SIPULEUCEL-T,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SIPULEUCEL-T,Treating asymptomatic or minimally symptomatic metastatic hormone-replased prostate cancer,TA332,prostate cancer,712837004,Active surveillance of prostate cancer,SIPULEUCEL-T,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SIPULEUCEL-T,Treating asymptomatic or minimally symptomatic metastatic hormone-replased prostate cancer,TA332,prostate cancer,720007002,Prostate cancer care review,SIPULEUCEL-T,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SIPULEUCEL-T,Treating asymptomatic or minimally symptomatic metastatic hormone-replased prostate cancer,TA332,prostate cancer,31011000119107,Prostate cancer screening declined,SIPULEUCEL-T,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SIPULEUCEL-T,Treating asymptomatic or minimally symptomatic metastatic hormone-replased prostate cancer,TA332,prostate cancer,874211000000109,QCancer prostate cancer risk,SIPULEUCEL-T,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SIPULEUCEL-T,Treating asymptomatic or minimally symptomatic metastatic hormone-replased prostate cancer,TA332,prostate cancer,878401000000104,No FH of prostate cancer,SIPULEUCEL-T,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SIPULEUCEL-T,Treating asymptomatic or minimally symptomatic metastatic hormone-replased prostate cancer,TA332,prostate cancer,1000561000000108,Urine PCA3 (prostate cancer antigen 3) targeted genetic test,SIPULEUCEL-T,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SIPULEUCEL-T,Treating asymptomatic or minimally symptomatic metastatic hormone-replased prostate cancer,TA332,prostate cancer,1034421000000103,Discharge from secondary care prostate cancer service,SIPULEUCEL-T,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SIROLIMUS,Kidney transplant in adults,TA481,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
SIROLIMUS,Kidney transplant in adults,TA481,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
SIROLIMUS,Kidney transplant in adults,TA481,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
SIROLIMUS,Kidney transplant in adults,TA481,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
SIROLIMUS,Kidney transplant in adults,TA481,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
SIROLIMUS,Kidney transplant in adults,TA481,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
SIROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,175948009,Exploration of kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
SIROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,213150003,Kidney transplant failure and rejection,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
SIROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,236138007,Xenogenous kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
SIROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,429496005,Examination of live donor after kidney transplant,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
SIROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,365061000000106,Active on kidney transplant waiting list,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
SIROLIMUS,Kidney transplant in children and young people,TA482,kidney transplant,858421000000106,Discussion about kidney transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
SIROLIMUS,Renal transplantation (adults),TA085,renal transplantation,70536003,Renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
SIROLIMUS,Renal transplantation (adults),TA085,renal transplantation,313030004,Donor renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
SIROLIMUS,Renal transplantation (adults),TA085,renal transplantation,429451003,Disorder related to renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
SIROLIMUS,Renal transplantation (children),TA099,renal transplantation,70536003,Renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
SIROLIMUS,Renal transplantation (children),TA099,renal transplantation,313030004,Donor renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
SIROLIMUS,Renal transplantation (children),TA099,renal transplantation,429451003,Disorder related to renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,62944002,Hepatitis C virus,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,62944002,Hepatitis C virus,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,72165005,Hepatitis C virus antibody,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,72165005,Hepatitis C virus antibody,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,170489004,Viral hepatitis carrier,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,170489004,Viral hepatitis carrier,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,197344005,Hepatitis caused by adenovirus,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,197344005,Hepatitis caused by adenovirus,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,235872006,Hepatitis C carrier,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,235872006,Hepatitis C carrier,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,278973007,Hepatitis C status,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,278973007,Hepatitis C status,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,278974001,Hepatitis C immune,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,278974001,Hepatitis C immune,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,278975000,Hepatitis C non-immune,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,278975000,Hepatitis C non-immune,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,314706002,Hepatitis C antibody detected,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,314706002,Hepatitis C antibody detected,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,314707006,Hepatitis C antibody test negative,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,314707006,Hepatitis C antibody test negative,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,413107006,Hepatitis C screening,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,413107006,Hepatitis C screening,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,773113008,Acute hepatitis caused by infection,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,773113008,Acute hepatitis caused by infection,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,12891000175105,Hepatitis C screening declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,12891000175105,Hepatitis C screening declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,200371000000104,Hepatitis C contact,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,200371000000104,Hepatitis C contact,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,201451000000105,Hepatitis C immunisation declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,201451000000105,Hepatitis C immunisation declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,202281000000105,Hepatitis C screening declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,202281000000105,Hepatitis C screening declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,204671000000101,Hepatitis C screening counselling,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,204671000000101,Hepatitis C screening counselling,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,304821000000107,Hepatitis C screening not offered,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,304821000000107,Hepatitis C screening not offered,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,362491000000104,Hepatitis C screening negative,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,362491000000104,Hepatitis C screening negative,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,362751000000101,Hepatitis C screening positive,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,362751000000101,Hepatitis C screening positive,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,761381000000102,Hepatitis C resolved,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,761381000000102,Hepatitis C resolved,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,824841000000105,Hepatitis C genotype 1,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,824841000000105,Hepatitis C genotype 1,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,824871000000104,Hepatitis C genotype 3,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,824871000000104,Hepatitis C genotype 3,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,829731000000106,On hepatitis C treatment plan,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,829731000000106,On hepatitis C treatment plan,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,992751000000109,Hepatitis C viral load,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,992751000000109,Hepatitis C viral load,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,992771000000100,Hepatitis C virus genotype,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,992771000000100,Hepatitis C virus genotype,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,996031000000104,Hepatitis C IgG level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,996031000000104,Hepatitis C IgG level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,998771000000103,Hepatitis C antibody level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,998771000000103,Hepatitis C antibody level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,1001331000000102,Hepatitis C antigen level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,1001331000000102,Hepatitis C antigen level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,1008931000000108,Hepatitis C antibody test,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,1008931000000108,Hepatitis C antibody test,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,1107671000000106,Hepatitis C screening offered,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR,Chronic hepatitis C,TA330,hepatitis c,1107671000000106,Hepatitis C screening offered,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,62944002,Hepatitis C virus,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,62944002,Hepatitis C virus,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,72165005,Hepatitis C virus antibody,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,72165005,Hepatitis C virus antibody,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,170489004,Viral hepatitis carrier,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,170489004,Viral hepatitis carrier,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,197344005,Hepatitis caused by adenovirus,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,197344005,Hepatitis caused by adenovirus,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,235872006,Hepatitis C carrier,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,235872006,Hepatitis C carrier,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,278973007,Hepatitis C status,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,278973007,Hepatitis C status,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,278974001,Hepatitis C immune,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,278974001,Hepatitis C immune,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,278975000,Hepatitis C non-immune,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,278975000,Hepatitis C non-immune,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,314706002,Hepatitis C antibody detected,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,314706002,Hepatitis C antibody detected,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,314707006,Hepatitis C antibody test negative,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,314707006,Hepatitis C antibody test negative,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,413107006,Hepatitis C screening,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,413107006,Hepatitis C screening,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,773113008,Acute hepatitis caused by infection,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,773113008,Acute hepatitis caused by infection,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,12891000175105,Hepatitis C screening declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,12891000175105,Hepatitis C screening declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,200371000000104,Hepatitis C contact,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,200371000000104,Hepatitis C contact,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,201451000000105,Hepatitis C immunisation declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,201451000000105,Hepatitis C immunisation declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,202281000000105,Hepatitis C screening declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,202281000000105,Hepatitis C screening declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,204671000000101,Hepatitis C screening counselling,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,204671000000101,Hepatitis C screening counselling,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,304821000000107,Hepatitis C screening not offered,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,304821000000107,Hepatitis C screening not offered,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,362491000000104,Hepatitis C screening negative,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,362491000000104,Hepatitis C screening negative,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,362751000000101,Hepatitis C screening positive,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,362751000000101,Hepatitis C screening positive,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,761381000000102,Hepatitis C resolved,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,761381000000102,Hepatitis C resolved,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,824841000000105,Hepatitis C genotype 1,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,824841000000105,Hepatitis C genotype 1,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,824871000000104,Hepatitis C genotype 3,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,824871000000104,Hepatitis C genotype 3,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,829731000000106,On hepatitis C treatment plan,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,829731000000106,On hepatitis C treatment plan,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,992751000000109,Hepatitis C viral load,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,992751000000109,Hepatitis C viral load,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,992771000000100,Hepatitis C virus genotype,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,992771000000100,Hepatitis C virus genotype,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,996031000000104,Hepatitis C IgG level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,996031000000104,Hepatitis C IgG level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,998771000000103,Hepatitis C antibody level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,998771000000103,Hepatitis C antibody level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,1001331000000102,Hepatitis C antigen level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,1001331000000102,Hepatitis C antigen level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,1008931000000108,Hepatitis C antibody test,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,1008931000000108,Hepatitis C antibody test,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,1107671000000106,Hepatitis C screening offered,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR,Chronic hepatitis C,TA430,hepatitis c,1107671000000106,Hepatitis C screening offered,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,62944002,Hepatitis C virus,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,62944002,Hepatitis C virus,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,72165005,Hepatitis C virus antibody,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,72165005,Hepatitis C virus antibody,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,170489004,Viral hepatitis carrier,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,170489004,Viral hepatitis carrier,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,197344005,Hepatitis caused by adenovirus,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,197344005,Hepatitis caused by adenovirus,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,235872006,Hepatitis C carrier,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,235872006,Hepatitis C carrier,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,278973007,Hepatitis C status,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,278973007,Hepatitis C status,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,278974001,Hepatitis C immune,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,278974001,Hepatitis C immune,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,278975000,Hepatitis C non-immune,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,278975000,Hepatitis C non-immune,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,314706002,Hepatitis C antibody detected,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,314706002,Hepatitis C antibody detected,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,314707006,Hepatitis C antibody test negative,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,314707006,Hepatitis C antibody test negative,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,413107006,Hepatitis C screening,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,413107006,Hepatitis C screening,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,773113008,Acute hepatitis caused by infection,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,773113008,Acute hepatitis caused by infection,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,12891000175105,Hepatitis C screening declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,12891000175105,Hepatitis C screening declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,200371000000104,Hepatitis C contact,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,200371000000104,Hepatitis C contact,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,201451000000105,Hepatitis C immunisation declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,201451000000105,Hepatitis C immunisation declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,202281000000105,Hepatitis C screening declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,202281000000105,Hepatitis C screening declined,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,204671000000101,Hepatitis C screening counselling,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,204671000000101,Hepatitis C screening counselling,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,304821000000107,Hepatitis C screening not offered,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,304821000000107,Hepatitis C screening not offered,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,362491000000104,Hepatitis C screening negative,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,362491000000104,Hepatitis C screening negative,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,362751000000101,Hepatitis C screening positive,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,362751000000101,Hepatitis C screening positive,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,761381000000102,Hepatitis C resolved,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,761381000000102,Hepatitis C resolved,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,824841000000105,Hepatitis C genotype 1,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,824841000000105,Hepatitis C genotype 1,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,824871000000104,Hepatitis C genotype 3,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,824871000000104,Hepatitis C genotype 3,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,829731000000106,On hepatitis C treatment plan,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,829731000000106,On hepatitis C treatment plan,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,992751000000109,Hepatitis C viral load,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,992751000000109,Hepatitis C viral load,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,992771000000100,Hepatitis C virus genotype,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,992771000000100,Hepatitis C virus genotype,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,996031000000104,Hepatitis C IgG level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,996031000000104,Hepatitis C IgG level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,998771000000103,Hepatitis C antibody level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,998771000000103,Hepatitis C antibody level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,1001331000000102,Hepatitis C antigen level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,1001331000000102,Hepatitis C antigen level,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,1008931000000108,Hepatitis C antibody test,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,1008931000000108,Hepatitis C antibody test,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,1107671000000106,Hepatitis C screening offered,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOFOSBUVIR–VELPATASVIR–VOXILAPREVIR,Chronic hepatitis C,TA507,hepatitis c,1107671000000106,Hepatitis C screening offered,SOFOSBUVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
SOLRIAMFETOL,Excessive daytime sleepiness caused by narcolepsy,TA758,narcolepsy,193042000,Cataplexy and narcolepsy,SOLRIAMFETOL,NEUROLOGY,NEUROLOGY
SOLRIAMFETOL,Excessive daytime sleepiness caused by narcolepsy,TA758,narcolepsy,735676003,Narcolepsy type 1,SOLRIAMFETOL,NEUROLOGY,NEUROLOGY
SOLRIAMFETOL,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA777,sleep apnoea,79280005,Hypersomnia with sleep apnoea,SOLRIAMFETOL,THORACIC MEDICINE,THORACIC MEDICINE|ENT
SOLRIAMFETOL,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA777,sleep apnoea,206750008,Sleep apnoea syndrome,SOLRIAMFETOL,THORACIC MEDICINE,THORACIC MEDICINE|ENT
SOLRIAMFETOL,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA777,sleep apnoea,230493001,Complex sleep apnoea,SOLRIAMFETOL,THORACIC MEDICINE,THORACIC MEDICINE|ENT
SOLRIAMFETOL,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA777,sleep apnoea,230494007,Alveolar sleep apnoea,SOLRIAMFETOL,THORACIC MEDICINE,THORACIC MEDICINE|ENT
SOLRIAMFETOL,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA777,sleep apnoea,232531007,Pharyngeal operation for obstructive sleep apnoea and snoring,SOLRIAMFETOL,THORACIC MEDICINE,THORACIC MEDICINE|ENT
SOLRIAMFETOL,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA777,sleep apnoea,361208003,Primary sleep apnoea of newborn,SOLRIAMFETOL,THORACIC MEDICINE,THORACIC MEDICINE|ENT
SOLRIAMFETOL,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA777,sleep apnoea,774068004,"AHDC1-related intellectual disability, obstructive sleep apnoea, mild dysmorphism syndrome",SOLRIAMFETOL,THORACIC MEDICINE,THORACIC MEDICINE|ENT
SOLRIAMFETOL,Excessive daytime sleepiness caused by obstructive sleep apnoea,TA777,sleep apnoea,502901000000102,[D]Sleep apnoea syndrome,SOLRIAMFETOL,THORACIC MEDICINE,THORACIC MEDICINE|ENT
SOMATROPIN,Growth hormone deficiency (adults),TA064,growth hormone deficiency,2109003,Isolated growth hormone deficiency,SOMATROPIN,ENDOCRINOLOGY,ENDOCRINOLOGY|PAEDIATRICS
SOMATROPIN,Growth hormone deficiency (adults),TA064,growth hormone deficiency,234533006,Short stature due to isolated growth hormone deficiency with X-linked hypogammaglobulinaemia,SOMATROPIN,ENDOCRINOLOGY,ENDOCRINOLOGY|PAEDIATRICS
SOMATROPIN,Growth hormone deficiency (children),TA042,growth hormone deficiency,2109003,Isolated growth hormone deficiency,SOMATROPIN,ENDOCRINOLOGY,ENDOCRINOLOGY|PAEDIATRICS
SOMATROPIN,Growth hormone deficiency (children),TA042,growth hormone deficiency,234533006,Short stature due to isolated growth hormone deficiency with X-linked hypogammaglobulinaemia,SOMATROPIN,ENDOCRINOLOGY,ENDOCRINOLOGY|PAEDIATRICS
SORAFENIB,Advanced hepatocellular carcinoma,TA474,hepatocellular carcinoma,15619004,"Hepatocellular carcinoma, fibrolamellar",SORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
SORAFENIB,Advanced hepatocellular carcinoma,TA474,hepatocellular carcinoma,253018005,Fibrolamellar hepatocellular carcinoma,SORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
SORAFENIB,Advanced hepatocellular carcinoma,TA474,hepatocellular carcinoma,990271000000107,Ultrasound scan surveillance of liver for hepatocellular carcinoma,SORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
SORAFENIB,Thyroid cancer,TA535,thyroid cancer,94098005,Primary malignant neoplasm of thyroid gland,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY
SORAFENIB,Thyroid cancer,TA535,thyroid cancer,363478007,Malignant tumour of thyroid gland,LENVATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY
SORAFENIB (1ST LINE),Advanced and metastatic hepatocellular carcinoma,TA189,hepatocellular carcinoma,15619004,"Hepatocellular carcinoma, fibrolamellar",SORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
SORAFENIB (1ST LINE),Advanced and metastatic hepatocellular carcinoma,TA189,hepatocellular carcinoma,253018005,Fibrolamellar hepatocellular carcinoma,SORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
SORAFENIB (1ST LINE),Advanced and metastatic hepatocellular carcinoma,TA189,hepatocellular carcinoma,990271000000107,Ultrasound scan surveillance of liver for hepatocellular carcinoma,SORAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GASTROENTEROLOGY|CLINICAL ONCOLOGY
SORAFENIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SORAFENIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SORAFENIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SORAFENIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,733608000,Papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SORAFENIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SORAFENIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SORAFENIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SORAFENIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SORAFENIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SORAFENIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SORAFENIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,733608000,Papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SORAFENIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SORAFENIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SORAFENIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,46635009,T1DM - type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,290002008,Unstable type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,420825003,Gangrene due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,420868002,Disorder due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,429094000,Dietary advice for type 1 diabetes,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,444073006,Uncontrolled type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,703137001,Type 1 diabetes mellitus in remission,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTAGLIFLOZIN WITH INSULIN,Type 1 diabetes,TA622,type 1 diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,SOTAGLIFLOZIN,DIABETIC MEDICINE,DIABETIC MEDICINE|ENDOCRINOLOGY|PAEDIATRICS
SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,162573006,Suspected lung cancer,SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,254637007,Non-small cell lung cancer,SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,275981009,Lung cancer screening,SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,429011007,Family history of lung cancer,SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,877691000000107,No FH of lung cancer,SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SOTORASIB,Previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer,TA781,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",SOTORASIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
SQ HDM SLIT,Allergic rhinitis and allergic asthma caused by house dust mites,TA834,allergic rhinitis,61582004,Allergic rhinitis due to allergen,SQ,ENT,ENT|CLINICAL IMMUNOLOGY
SQ HDM SLIT,Allergic rhinitis and allergic asthma caused by house dust mites,TA834,allergic rhinitis,93447004,Eosinophilic nonallergic rhinitis,SQ,ENT,ENT|CLINICAL IMMUNOLOGY
SQ HDM SLIT,Allergic rhinitis and allergic asthma caused by house dust mites,TA834,allergic rhinitis,232345000,Non-infective non-allergic rhinitis,SQ,ENT,ENT|CLINICAL IMMUNOLOGY
SQ HDM SLIT,Allergic rhinitis and allergic asthma caused by house dust mites,TA834,allergic rhinitis,232353008,Perennial allergic rhinitis with seasonal variation,SQ,ENT,ENT|CLINICAL IMMUNOLOGY
SQ HDM SLIT,Allergic rhinitis and allergic asthma caused by house dust mites,TA834,allergic rhinitis,266386004,Perennial allergic rhinitis,SQ,ENT,ENT|CLINICAL IMMUNOLOGY
SQ HDM SLIT,Allergic rhinitis and allergic asthma caused by house dust mites,TA834,allergic rhinitis,446096008,Nonseasonal allergic rhinitis,SQ,ENT,ENT|CLINICAL IMMUNOLOGY
SQ HDM SLIT,Allergic rhinitis and allergic asthma caused by house dust mites,TA834,allergic rhinitis,99031000119107,Acute exacerbation of asthma co-occurrent with allergic rhinitis,SQ,ENT,ENT|CLINICAL IMMUNOLOGY
SQ HDM SLIT,Allergic rhinitis and allergic asthma caused by house dust mites,TA834,allergic rhinitis,125011000119100,Mild persistent asthma co-occurrent with allergic rhinitis,SQ,ENT,ENT|CLINICAL IMMUNOLOGY
SQ HDM SLIT,Allergic rhinitis and allergic asthma caused by house dust mites,TA834,allergic rhinitis,125021000119107,Intermittent asthma co-occurrent with allergic rhinitis,SQ,ENT,ENT|CLINICAL IMMUNOLOGY
SQ HDM SLIT,Allergic rhinitis and allergic asthma caused by house dust mites,TA834,allergic rhinitis,10675551000119104,Acute severe exacerbation of severe persistent asthma co-occurrent with allergic rhinitis,SQ,ENT,ENT|CLINICAL IMMUNOLOGY
SQ HDM SLIT,Allergic rhinitis and allergic asthma caused by house dust mites,TA834,allergic rhinitis,10675991000119100,Acute severe exacerbation of mild persistent allergic asthma co-occurrent with allergic rhinitis,SQ,ENT,ENT|CLINICAL IMMUNOLOGY
SQ HDM SLIT,Allergic rhinitis and allergic asthma caused by house dust mites,TA834,allergic rhinitis,10676111000119102,Mild persistent asthma controlled co-occurrent with allergic rhinitis,SQ,ENT,ENT|CLINICAL IMMUNOLOGY
STANDARD-DOSE IMATINIB (400MG/DAY),Treatment of chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia,TA251,chronic myeloid leukaemia,92817004,Chronic myeloid leukaemia in remission,STANDARD-DOSE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,1755008,Healed myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,15990001,Acute myocardial infarction of posterolateral wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,22298006,MI - myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,41380003,Radioisotope scan for myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,52035003,Acute anteroapical myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,54329005,Acute anterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,57054005,Acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,58612006,Acute myocardial infarction of lateral wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,62695002,Acute anteroseptal myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,65547006,Acute inferolateral myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,66189004,Postmyocardial infarction syndrome,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,70211005,Acute anterolateral myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,73795002,Acute myocardial infarction of diaphragmatic wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,76593002,Acute myocardial infarction of inferoposterior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,79009004,Acute myocardial infarction of septum,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,129574000,Postoperative myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,160361002,FH: ischemic heart disease (& [myocardial infarction] or [coronary thrombosis]),ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,164866006,Electrocardiogram: no myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,164867002,Electrocardiographic old myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,194809007,Acute myocardial infarction of atrium,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,194821006,Aborted myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,194856005,Subsequent myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,194857001,Subsequent myocardial infarction of anterior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,194858006,Subsequent myocardial infarction of inferior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,194862000,Hemopericardium due to and following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,194863005,Atrial septal defect due to and following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,194865003,Rupture of cardiac wall without haemopericardium as current complication following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,194868001,"Thrombosis of atrium, auricular appendage, and ventricle due to and following acute myocardial infarction",ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,233838001,Acute posterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,233839009,Old anterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,233840006,Old inferior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,233841005,Old lateral myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,233842003,Old posterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,233843008,Silent myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,233847009,Cardiac rupture due to and following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,233885007,Pericarditis following myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,266288001,Myocardial infarction (& [acute]) or coronary thrombosis,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,266897007,Family history of myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,275122004,Family history: Myocardial infarction at less than 60,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,275123009,Family history: Myocardial infarction at greater than 60,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,304914007,Acute Q wave myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,308065005,History of myocardial infarction in last year,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,311793000,Postoperative transmural myocardial infarction of inferior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,311796008,Postoperative subendocardial myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,314207007,Non-Q wave myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,315619001,"Family history of myocardial infarction in male relative of first degree, age known",ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,315620007,"Family history of myocardial infarction in male relative of first degree, age unknown",ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,315621006,"Family history of myocardial infarction in female relative of first degree, age known",ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,315622004,"Family history of myocardial infarction in female relative of first degree, age unknown",ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,394710008,First myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,399211009,Previous myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,401303003,STEMI - ST elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,401314000,Acute non-ST segment elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,698593009,History of non-ST segment elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,703164000,Acute anterior ST segment elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,703213009,Acute STEMI (ST elevation myocardial infarction) of inferior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,827164008,Delayed postmyocardial infarction syndrome,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,879955009,MINOCA - myocardial infarction with non-obstructive coronary artery,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,515711000000105,Family history of myocardial infarction in second degree relative less than 50 years,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,515741000000106,Family history of myocardial infarction in first degree relative less than 60 years,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,715971000000103,Excepted from myocardial infarction quality indicators - informed dissent,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,715981000000101,Excepted from myocardial infarction quality indicators - patient unsuitable,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,717541000000106,Exception reporting - myocardial infarction quality indicators,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,883961000000109,Thrombolysis In Myocardial Infarction risk score for unstable angina or non-ST-segment-elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,12238111000119106,Acute ST segment elevation myocardial infarction of inferolateral wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STREPTOKINASE,Myocardial infarction,TA052,myocardial infarction,16837681000119104,Myocardial infarction due to demand ischaemia,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
STRONTIUM RANELATE,Primary prevention of fragility fractures in postmenopausal women with osteoporosis,TA160,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
SUNITINIB,Unresectable or metastatic neuroendocrine tumours in people with progressive disease,TA449,neuroendocrine tumour,48554007,Enterochromaffin cell neuroendocrine tumour,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY
SUNITINIB,Unresectable or metastatic neuroendocrine tumours in people with progressive disease,TA449,neuroendocrine tumour,60346004,Non-functioning pancreatic neuroendocrine tumour,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY
SUNITINIB,Unresectable or metastatic neuroendocrine tumours in people with progressive disease,TA449,neuroendocrine tumour,707594002,Bronchial neuroendocrine tumour,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY
SUNITINIB,Unresectable or metastatic neuroendocrine tumours in people with progressive disease,TA449,neuroendocrine tumour,1287573002,Well-differentiated neuroendocrine tumour of bronchus,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY
SUNITINIB,Unresectable or metastatic neuroendocrine tumours in people with progressive disease,TA449,neuroendocrine tumour,1290068000,Well-differentiated neuroendocrine tumour of rectum,EVEROLIMUS,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY
SUNITINIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA169,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,SUNITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SUNITINIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA169,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,SUNITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SUNITINIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA169,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,SUNITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SUNITINIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA169,renal cell carcinoma,733608000,Papillary renal cell carcinoma,SUNITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SUNITINIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA169,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,SUNITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SUNITINIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA169,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,SUNITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SUNITINIB (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA169,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,SUNITINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SUNITINIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SUNITINIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SUNITINIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SUNITINIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,733608000,Papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SUNITINIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SUNITINIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
SUNITINIB (2ND LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
TACROLIMUS,Atopic dermatitis (eczema),TA082,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,PIMECROLIMUS,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
TACROLIMUS,Atopic dermatitis (eczema),TA082,atopic dermatitis,238543002,Discoid atopic dermatitis,PIMECROLIMUS,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
TACROLIMUS,Atopic dermatitis (eczema),TA082,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,PIMECROLIMUS,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
TACROLIMUS,Atopic dermatitis (eczema),TA082,atopic dermatitis,238545009,Follicular atopic dermatitis,PIMECROLIMUS,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
TACROLIMUS,Atopic dermatitis (eczema),TA082,atopic dermatitis,238546005,Pruriginous atopic dermatitis,PIMECROLIMUS,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
TACROLIMUS,Atopic dermatitis (eczema),TA082,atopic dermatitis,584621000000108,Atopic dermatitis NOS,PIMECROLIMUS,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
TACROLIMUS,Renal transplantation (adults),TA085,renal transplantation,70536003,Renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
TACROLIMUS,Renal transplantation (adults),TA085,renal transplantation,313030004,Donor renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
TACROLIMUS,Renal transplantation (adults),TA085,renal transplantation,429451003,Disorder related to renal transplantation,INDUCTION,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
TACROLIMUS,Renal transplantation (children),TA099,renal transplantation,70536003,Renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
TACROLIMUS,Renal transplantation (children),TA099,renal transplantation,313030004,Donor renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
TACROLIMUS,Renal transplantation (children),TA099,renal transplantation,429451003,Disorder related to renal transplantation,BASILIXIMAB,NEPHROLOGY,NEPHROLOGY|TRANSPLANTATION SURGERY
TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,35728003,Primary familial cardiomyopathy,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY
TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,62377009,Peripartum cardiomyopathy in puerperium,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY
TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,72972005,Dilated cardiomyopathy secondary to drug,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY
TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,83521008,Dilated cardiomyopathy caused by alcohol,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY
TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,195030007,Cardiomyopathy in Friedreich ataxia,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY
TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,195031006,Cardiomyopathy in myotonic dystrophy,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY
TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,195032004,Dystrophic cardiomyopathy,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY
TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,233873004,Hypertrophic cardiomyopathy,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY
TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,233875006,Post-myocarditic cardiomyopathy,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY
TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,281170005,Arrhythmogenic right ventricular cardiomyopathy,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY
TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,398754006,Restrictive cardiomyopathy with endomyocardial fibrosis,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY
TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,426300009,Tachycardiomyopathy,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY
TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,426856002,Dilated cardiomyopathy of ischemic origin,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY
TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,441541008,Stress cardiomyopathy,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY
TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,1234750000,Dilated cardiomyopathy caused by alcohol,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY
TAFAMIDIS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS WITH CARDIOMYOPATHY,Transthyretin amyloidosis with cardiomyopathy,TA696,cardiomyopathy,847041000000109,Amyloid cardiomyopathy,TAFAMIDIS,CARDIOLOGY,CARDIOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,915007,Malignant melanoma in junctional naevus,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,1556006,Clark melanoma level 4,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,2092003,Malignant melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,2142002,Nodular melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,16974005,"Acral lentiginous melanoma, malignant",TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,21119008,Benign melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,21165006,Clark melanoma level 3,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,37138001,Epithelioid cell melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,39896009,"Malignant melanoma, regressing",TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,44474009,Lentigo maligna melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,50542000,Clark melanoma level 2,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,50813003,Spitz melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,51757004,"Desmoplastic melanoma, amelanotic",TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,55320002,Superficial spreading melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,68827007,Spindle cell melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,70594002,Amelanotic melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,77986002,Melanoma in situ,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93209006,Malignant melanoma of perianal skin,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93214005,Malignant melanoma of skin of back,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93217003,Malignant melanoma of skin of cheek,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93220006,Malignant melanoma of skin of ear,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93221005,Malignant melanoma of skin of elbow,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93223008,Malignant melanoma of eyebrow,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93225001,Malignant melanoma of skin of face,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93227009,Malignant melanoma of skin of foot,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93228004,Malignant melanoma of skin of forearm,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93642000,Malignant melanoma of skin of neck,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93643005,Malignant melanoma of external surface of nose,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93646002,Malignant melanoma of skin of scalp,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93647006,Malignant melanoma of skin of shoulder,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93651008,Malignant melanoma of skin of trunk,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93653006,Malignant melanoma of skin of upper limb,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93654000,Malignant melanoma of skin of wrist,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,93655004,MM (malignant melanoma) of skin,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,106243009,Breslow depth staging for melanoma of skin,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,109266006,Melanoma in situ of skin,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,109270003,Melanoma in situ of face,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,109272006,Melanoma in situ of lip,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,109276009,Melanoma in situ of scalp,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,109278005,Melanoma in situ of ear,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,109282007,Melanoma in situ of neck,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,109284008,Melanoma in situ of trunk,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,109290007,Melanoma in situ of upper limb,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,109294003,Melanoma in situ of lower limb,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,127330008,Melanoma in situ by body site (clinical),TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,161432005,History of malignant melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,177281002,Excision of melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188030005,Malignant melanoma of lip,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188033007,Malignant melanoma of auricle (ear),TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188034001,Malignant melanoma of external auditory meatus,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188038003,Malignant melanoma of chin,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188040008,Malignant melanoma of forehead,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188042000,Malignant melanoma of temple,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188044004,Malignant melanoma of scalp and/or neck,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188045003,Malignant melanoma of scalp,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188046002,Malignant melanoma of neck,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188049009,Malignant melanoma of axilla,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188050009,Malignant melanoma of breast,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188051008,Malignant melanoma of buttock,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188052001,Malignant melanoma of groin,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188054000,Malignant melanoma of perineum,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188055004,Malignant melanoma of umbilicus,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188060000,Malignant melanoma of shoulder,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188061001,Malignant melanoma of upper arm,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188062008,Malignant melanoma of forearm,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188063003,Malignant melanoma of hand,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188064009,Malignant melanoma of finger,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188065005,Malignant melanoma of thumb,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188067002,Malignant melanoma of lower limb and hip,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188068007,Malignant melanoma of hip,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188069004,Malignant melanoma of thigh,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188070003,Malignant melanoma of knee,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188071004,Malignant melanoma of popliteal fossa area,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188072006,Malignant melanoma of lower leg,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188073001,Malignant melanoma of ankle,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188074007,Malignant melanoma of heel,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188075008,Malignant melanoma of foot,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188076009,Malignant melanoma of toe,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,188077000,Malignant melanoma of great toe,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,189758001,Melanoma in situ,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,231834005,Malignant melanoma of eyelid,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,254731001,Nodular melanoma of skin,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,254732008,Acral lentiginous melanoma of skin,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,254896002,Malignant melanoma of vulva,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,255004001,Malignant melanoma of conjunctiva,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,255012009,Malignant melanoma of iris,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,255015006,Malignant melanoma of ciliary body,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,255021005,Malignant melanoma of choroid,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,269578002,Malignant melanoma of head and neck,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,269579005,Malignant melanoma of trunk,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,269580008,Malignant melanoma of upper limb,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,269581007,Malignant melanoma of lower limb,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,274087000,MM (malignant melanoma) of eye,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,276751004,Amelanotic melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,276821000,Malignant melanoma of anus,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,276822007,Malignant melanoma of rectum,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,302837001,Lentigo maligna melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,310498001,Malignant melanoma of back,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,312941005,Melanoma associated retinopathy,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,313248004,Malignant melanoma of chest wall,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,314976006,Local recurrence of malignant melanoma of skin,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,314987003,Metastasis from malignant melanoma of skin,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,315036008,Melanoma in situ of back of hand,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,315230006,Melanoma in situ of back,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,372158004,"Malignant melanoma, metastatic",TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,427858005,Family history of malignant melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,443493003,Metastatic malignant melanoma,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,449636007,Malignant melanoma of skin of lower leg,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,449637003,Malignant melanoma of skin of upper arm,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,698040004,Malignant melanoma of nasal cavity,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,1197324006,Metastatic malignant melanoma to skin,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,351961000119109,Malignant melanoma of skin of right arm,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,352211000119108,Malignant melanoma of skin of left ear,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,546881000000105,Malignant melanoma of skin NOS,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,956331000000107,Malignant melanoma stage IA,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,956351000000100,Malignant melanoma stage IB,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,956371000000109,Malignant melanoma stage IIA,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,956391000000108,Malignant melanoma stage IIB,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,956451000000107,Malignant melanoma stage IIIB,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,956471000000103,Malignant melanoma stage IIIC,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,956511000000107,Malignant melanoma stage IV M1a,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,956551000000106,Malignant melanoma stage IV M1c,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,1080941000119109,Malignant melanoma of left choroid,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TALIMOGENE LAHERPAREPVEC,Treating unresectable metastatic melanoma,TA410,melanoma,1080981000119104,Malignant melanoma of right choroid,TALIMOGENE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TECLISTAMAB,Relapsed or refractory multiple myeloma after 3 or more therapies,TA869,multiple myeloma,230586003,Neuropathy due to multiple myeloma,TECLISTAMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
TECLISTAMAB,Relapsed or refractory multiple myeloma after 3 or more therapies,TA869,multiple myeloma,413587002,Smoldering multiple myeloma,TECLISTAMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
TECLISTAMAB,Relapsed or refractory multiple myeloma after 3 or more therapies,TA869,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,TECLISTAMAB,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
TEDUGLUTIDE,Short bowel syndrome,TA690,short bowel syndrome,235724004,Post-resection short bowel syndrome,TEDUGLUTIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
TEDUGLUTIDE,Short bowel syndrome,TA804,short bowel syndrome,235724004,Post-resection short bowel syndrome,TEDUGLUTIDE,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
TEGAFUR WITH URACIL,Colorectal cancer,TA061,colorectal cancer,276401000000108,Fast track referral for suspected colorectal cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
TEGAFUR WITH URACIL,Colorectal cancer,TA061,colorectal cancer,382651000000108,Seen in fast track suspected colorectal cancer clinic,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
TEGAFUR WITH URACIL,Colorectal cancer,TA061,colorectal cancer,722731000000100,Colorectal cancer,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
TEGAFUR WITH URACIL,Colorectal cancer,TA061,colorectal cancer,848861000000104,QCancer colorectal cancer risk,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
TEGAFUR WITH URACIL,Colorectal cancer,TA061,colorectal cancer,1034401000000107,Discharge from secondary care colorectal cancer service,CAPECITABINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|COLORECTAL SURGERY|CLINICAL ONCOLOGY
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,62944002,Hepatitis C virus,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,62944002,Hepatitis C virus,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,72165005,Hepatitis C virus antibody,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,72165005,Hepatitis C virus antibody,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,170489004,Viral hepatitis carrier,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,170489004,Viral hepatitis carrier,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,197344005,Hepatitis caused by adenovirus,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,197344005,Hepatitis caused by adenovirus,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,235872006,Hepatitis C carrier,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,235872006,Hepatitis C carrier,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,278973007,Hepatitis C status,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,278973007,Hepatitis C status,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,278974001,Hepatitis C immune,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,278974001,Hepatitis C immune,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,278975000,Hepatitis C non-immune,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,278975000,Hepatitis C non-immune,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,314706002,Hepatitis C antibody detected,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,314706002,Hepatitis C antibody detected,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,314707006,Hepatitis C antibody test negative,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,314707006,Hepatitis C antibody test negative,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,413107006,Hepatitis C screening,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,413107006,Hepatitis C screening,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,440420005,Hepatitis C viral ribonucleic acid not detected by polymerase chain reaction,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,773113008,Acute hepatitis caused by infection,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,773113008,Acute hepatitis caused by infection,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,12891000175105,Hepatitis C screening declined,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,12891000175105,Hepatitis C screening declined,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,200371000000104,Hepatitis C contact,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,200371000000104,Hepatitis C contact,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,201451000000105,Hepatitis C immunisation declined,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,201451000000105,Hepatitis C immunisation declined,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,202281000000105,Hepatitis C screening declined,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,202281000000105,Hepatitis C screening declined,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,204671000000101,Hepatitis C screening counselling,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,204671000000101,Hepatitis C screening counselling,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,221061000000106,Respiratory syncytial virus treatment and Hepatitis C treatment drugs Band 1,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,304821000000107,Hepatitis C screening not offered,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,304821000000107,Hepatitis C screening not offered,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,362491000000104,Hepatitis C screening negative,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,362491000000104,Hepatitis C screening negative,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,362751000000101,Hepatitis C screening positive,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,362751000000101,Hepatitis C screening positive,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,760421000000100,Hepatitis C viral ribonucleic acid polymerase chain reaction positive,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,761381000000102,Hepatitis C resolved,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,761381000000102,Hepatitis C resolved,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,824841000000105,Hepatitis C genotype 1,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,824841000000105,Hepatitis C genotype 1,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,824871000000104,Hepatitis C genotype 3,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,824871000000104,Hepatitis C genotype 3,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,829691000000100,H/O hepatitis C antiviral drug therapy,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,829731000000106,On hepatitis C treatment plan,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,829731000000106,On hepatitis C treatment plan,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,868191000000109,Hepatitis C antiviral treatment completed,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,992751000000109,Hepatitis C viral load,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,992751000000109,Hepatitis C viral load,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,992771000000100,Hepatitis C virus genotype,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,992771000000100,Hepatitis C virus genotype,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,996031000000104,Hepatitis C IgG level,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,996031000000104,Hepatitis C IgG level,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,998771000000103,Hepatitis C antibody level,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,998771000000103,Hepatitis C antibody level,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,1001331000000102,Hepatitis C antigen level,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,1001331000000102,Hepatitis C antigen level,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,1008931000000108,Hepatitis C antibody test,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,1008931000000108,Hepatitis C antibody test,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,1012941000000104,Hepatitis C virus RNA (ribonucleic acid) assay,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,1030511000000102,Hepatitis C nucleic acid detection assay,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,1030531000000105,Hepatitis C PCR (polymerase chain reaction),TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,1107671000000106,Hepatitis C screening offered,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN,Treatment of genotype 1 chronic hepatitis C,TA252,hepatitis c,1107671000000106,Hepatitis C screening offered,TELAPREVIR,GASTROENTEROLOGY,GASTROENTEROLOGY|INFECTIOUS DISEASES
TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,803009,Paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,3102004,"Oligodendroglioma, anaplastic",CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,9903002,"Paraganglioma, malignant",CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,26138003,Gliomatosis cerebri,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,31794002,Sympathetic paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,32037004,Jugular paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,72787006,Gangliocytic paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,73348003,Oligodendroglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,74532006,"Glioma, malignant",CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,89880005,Ganglioglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,107694002,"Paraganglioma, benign",CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,115222007,Paraganglioma AND/OR glomus tumor,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,115240006,Glioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,253029009,Gangliocytic paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,253031000,Tympanic paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,254940005,Oligodendroglioma of brain,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,254947008,Glioma of spinal cord,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,254976006,Optic nerve glioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,276826005,Malignant glioma of brain,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,276827001,Malignant glioma of spinal cord,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,302833002,Paraganglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,307649006,Microglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,307829004,Excision of nasal glioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,443565000,Oligodendroglioma - category,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
TEMOZOLOMIDE,Glioma (newly diagnosed),TA121,glioma,443936004,Oligodendroglioma,CARMUSTINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|NEUROSURGERY|CLINICAL ONCOLOGY
TEMSIROLIMUS,Mantle cell lymphoma (relapsed),TA207,mantle cell lymphoma,74654000,Mantle cell lymphoma,TEMSIROLIMUS,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
TEMSIROLIMUS,Mantle cell lymphoma (relapsed),TA207,mantle cell lymphoma,443487006,Mantle cell lymphoma,TEMSIROLIMUS,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
TEMSIROLIMUS (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
TEMSIROLIMUS (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
TEMSIROLIMUS (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
TEMSIROLIMUS (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,733608000,Papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
TEMSIROLIMUS (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
TEMSIROLIMUS (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
TEMSIROLIMUS (1ST LINE),Advanced and/or metastatic renal cell carcinoma,TA178,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,BEVACIZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,1755008,Healed myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,15990001,Acute myocardial infarction of posterolateral wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,22298006,MI - myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,41380003,Radioisotope scan for myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,52035003,Acute anteroapical myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,54329005,Acute anterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,57054005,Acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,58612006,Acute myocardial infarction of lateral wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,62695002,Acute anteroseptal myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,65547006,Acute inferolateral myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,66189004,Postmyocardial infarction syndrome,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,70211005,Acute anterolateral myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,73795002,Acute myocardial infarction of diaphragmatic wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,76593002,Acute myocardial infarction of inferoposterior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,79009004,Acute myocardial infarction of septum,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,129574000,Postoperative myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,160361002,FH: ischemic heart disease (& [myocardial infarction] or [coronary thrombosis]),ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,164866006,Electrocardiogram: no myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,164867002,Electrocardiographic old myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,194809007,Acute myocardial infarction of atrium,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,194821006,Aborted myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,194856005,Subsequent myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,194857001,Subsequent myocardial infarction of anterior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,194858006,Subsequent myocardial infarction of inferior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,194862000,Hemopericardium due to and following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,194863005,Atrial septal defect due to and following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,194865003,Rupture of cardiac wall without haemopericardium as current complication following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,194868001,"Thrombosis of atrium, auricular appendage, and ventricle due to and following acute myocardial infarction",ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,233838001,Acute posterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,233839009,Old anterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,233840006,Old inferior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,233841005,Old lateral myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,233842003,Old posterior myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,233843008,Silent myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,233847009,Cardiac rupture due to and following acute myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,233885007,Pericarditis following myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,266288001,Myocardial infarction (& [acute]) or coronary thrombosis,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,266897007,Family history of myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,275122004,Family history: Myocardial infarction at less than 60,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,275123009,Family history: Myocardial infarction at greater than 60,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,304914007,Acute Q wave myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,308065005,History of myocardial infarction in last year,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,311793000,Postoperative transmural myocardial infarction of inferior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,311796008,Postoperative subendocardial myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,314207007,Non-Q wave myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,315619001,"Family history of myocardial infarction in male relative of first degree, age known",ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,315620007,"Family history of myocardial infarction in male relative of first degree, age unknown",ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,315621006,"Family history of myocardial infarction in female relative of first degree, age known",ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,315622004,"Family history of myocardial infarction in female relative of first degree, age unknown",ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,394710008,First myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,399211009,Previous myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,401303003,STEMI - ST elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,401314000,Acute non-ST segment elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,698593009,History of non-ST segment elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,703164000,Acute anterior ST segment elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,703213009,Acute STEMI (ST elevation myocardial infarction) of inferior wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,827164008,Delayed postmyocardial infarction syndrome,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,879955009,MINOCA - myocardial infarction with non-obstructive coronary artery,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,515711000000105,Family history of myocardial infarction in second degree relative less than 50 years,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,515741000000106,Family history of myocardial infarction in first degree relative less than 60 years,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,715971000000103,Excepted from myocardial infarction quality indicators - informed dissent,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,715981000000101,Excepted from myocardial infarction quality indicators - patient unsuitable,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,717541000000106,Exception reporting - myocardial infarction quality indicators,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,883961000000109,Thrombolysis In Myocardial Infarction risk score for unstable angina or non-ST-segment-elevation myocardial infarction,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,12238111000119106,Acute ST segment elevation myocardial infarction of inferolateral wall,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TENECTEPLASE,Myocardial infarction,TA052,myocardial infarction,16837681000119104,Myocardial infarction due to demand ischaemia,ALTEPLASE,CARDIOLOGY,CARDIOLOGY
TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,162573006,Suspected lung cancer,TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,254637007,Non-small cell lung cancer,TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,275981009,Lung cancer screening,TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,429011007,Family history of lung cancer,TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,723301009,Squamous non-small cell lung cancer,TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,1259727001,Primary non-small cell lung cancer,TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,276491000000101,Fast track referral for suspected lung cancer,TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,382681000000102,Seen in fast track suspected lung cancer clinic,TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,848881000000108,QCancer lung cancer risk,TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,877691000000107,No FH of lung cancer,TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,1771781000000107,Did not attend lung cancer screening,TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,1792021000000109,"PLCOm2012 (Prostate, Lung, Colorectal, and Ovarian modified 2012) 6-year lung cancer risk calculator for smokers",TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,1792031000000106,"Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers score",TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
TEPOTINIB,Advanced non-small-cell lung cancer with MET gene alterations,TA789,non-small-cell lung cancer,1792041000000102,"Assessment using Prostate, Lung, Colorectal, and Ovarian modified 2012 6-year lung cancer risk calculator for smokers",TEPOTINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,24700007,Multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,160337009,Family history of multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,192926004,Brain stem multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,192927008,Multiple sclerosis of the spinal cord,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,192928003,Generalised multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,192929006,Exacerbation of multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,230372003,Acute relapsing multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,230373008,Chronic progressive multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,230374002,Remittent-progressive multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,425500002,Secondary progressive multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,426373005,Relapsing remitting multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,428700003,Primary progressive multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,438511000,Benign multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,698626001,Dementia associated with multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,700409000,Suspected multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,724778008,Progressive relapsing multiple sclerosis,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,166411000000100,Specialised services for patients with multiple sclerosis enhanced services administration,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,198491000000106,Multiple sclerosis review,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,205631000000104,Multiple sclerosis multidisciplinary review,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,367591000000101,Management of multiple sclerosis in early disease phase,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,367621000000103,Management of multiple sclerosis in stable disability phase,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,367651000000108,Management of multiple sclerosis in progressive disability phase,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,515931000000104,Multiple sclerosis review declined,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,758981000000100,Multiple sclerosis monitoring administration,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,759091000000105,Multiple sclerosis monitoring second letter,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,759131000000108,Multiple sclerosis monitoring telephone invitation,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,785851000000104,Referral to community multiple sclerosis team,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIFLUNOMIDE,Relapsing-remitting multiple sclerosis,TA303,multiple sclerosis,811881000000109,Multiple sclerosis care plan agreed,TERIFLUNOMIDE,NEUROLOGY,NEUROLOGY|REHABILITATION
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Fragility fractures in postmenopausal women with osteoporosis (secondary prevention),TA161,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,14651005,Drug-induced osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,18040001,Age-related osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,64859006,Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,102447009,Postmenopausal osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,160313009,Family history of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,203429007,Idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,203433000,Postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,203435007,Localized osteoporosis - Lequesne,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,203437004,Osteoporosis in endocrine disorders,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,203438009,Osteoporosis of spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,203444008,Osteoporotic fracture due to postoophorectomy osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,203445009,Osteoporosis of disuse with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,203447001,Drug-induced osteoporosis with osteoporotic fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,203448006,Idiopathic osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,203453001,Postmenopausal osteoporosis with pathological fracture,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,240155001,Adult idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,240156000,Juvenile idiopathic generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,240157009,Secondary generalised osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,240158004,Regional migrating osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,240159007,Transient osteoporosis of hip,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,240160002,Transient osteoporosis of hip in pregnancy,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,240162005,Secondary localized osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,268028001,Localised disuse osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,276661002,Primary osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,281387004,Regional osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,300004007,Screening for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,309745002,Osteoporosis localized to spine,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,310251007,No family history: Osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,313423004,At increased risk of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,390833005,Osteoporosis caused by corticosteroid,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391003008,Osteoporosis monitoring administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391004002,Attends osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391006000,Osteoporosis monitoring default,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391007009,Osteoporosis monitoring first letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391008004,Osteoporosis monitoring second letter,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391011003,Osteoporosis monitoring telephone invitation,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391012005,Osteoporosis monitoring deleted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391013000,Osteoporosis monitoring check done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391014006,Osteoporosis risk assessment done,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391015007,Osteoporosis risk assessment declined,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391016008,Osteoporosis risk assessment defaulted,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391017004,Osteoporosis monitoring,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391018009,Initial osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391019001,Follow-up osteoporosis assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391020007,Osteoporosis treatment started,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391021006,Osteoporosis treatment stopped,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391022004,Osteoporosis treatment changed,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391023009,Osteoporosis - no treatment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391024003,Osteoporosis - dietary advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391025002,Osteoporosis - dietary assessment,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391026001,Osteoporosis - exercise advice,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391027005,Osteoporosis - falls prevention,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391028000,Osteoporosis - treatment response,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391033001,Refer to osteoporosis specialist,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391037000,Seen in osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391060008,Dual energy X-ray absorptiometry of bone of forearm result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391065003,Dual energy X-ray absorptiometry of calcaneum result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391070005,Dual energy X-ray absorptiometry of bone of hip joint region result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,391075000,Dual energy X-ray absorptiometry of bone of lumbar vertebra result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,394936006,Health education - osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,412717001,Referral to osteoporosis clinic,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,440100002,Dual energy X-ray absorptiometry of neck of femur result osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,473120007,History of osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,739301006,Osteoporosis co-occurrent and due to multiple myeloma,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,763322002,Osteoporosis monitoring refused,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,278781000000105,Osteoporosis treatment not indicated,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,505141000000108,Osteoporosis enhanced services administration,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,505171000000102,Bone sparing drug treatment offered for osteoporosis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,711141000000109,Osteoporosis medication prophylaxis,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,711341000000106,Osteoporosis resolved,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,753711000000102,Exception reporting - osteoporosis quality indicators,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,753791000000106,Excepted from osteoporosis quality indicators - patient unsuitable,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,753831000000104,Excepted from osteoporosis quality indicators - informed dissent,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
TERIPARATIDE,Osteoporosis - secondary prevention,TA087,osteoporosis,965871000000101,Osteoporosis medication compliance review,ALENDRONATE,RHEUMATOLOGY,RHEUMATOLOGY|ENDOCRINOLOGY|GERIATRIC MEDICINE
THALIDOMIDE IN COMBINATION WITH AN ALKYLATING AGENT AND A CORTICOSTEROID,Multiple myeloma,TA228,multiple myeloma,230586003,Neuropathy due to multiple myeloma,THALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
THALIDOMIDE IN COMBINATION WITH AN ALKYLATING AGENT AND A CORTICOSTEROID,Multiple myeloma,TA228,multiple myeloma,413587002,Smoldering multiple myeloma,THALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
THALIDOMIDE IN COMBINATION WITH AN ALKYLATING AGENT AND A CORTICOSTEROID,Multiple myeloma,TA228,multiple myeloma,739301006,Osteoporosis co-occurrent and due to multiple myeloma,THALIDOMIDE,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
TIAGABINE,Epilepsy (adults),TA076,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (adults),TA076,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TIAGABINE,Epilepsy (children),TA079,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,1755008,Healed myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,15990001,Acute myocardial infarction of posterolateral wall,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,22298006,MI - myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,41380003,Radioisotope scan for myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,52035003,Acute anteroapical myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,54329005,Acute anterior myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,57054005,Acute myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,58612006,Acute myocardial infarction of lateral wall,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,62695002,Acute anteroseptal myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,65547006,Acute inferolateral myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,66189004,Postmyocardial infarction syndrome,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,70211005,Acute anterolateral myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,73795002,Acute myocardial infarction of diaphragmatic wall,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,76593002,Acute myocardial infarction of inferoposterior wall,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,79009004,Acute myocardial infarction of septum,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,129574000,Postoperative myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,160361002,FH: ischemic heart disease (& [myocardial infarction] or [coronary thrombosis]),TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,164866006,Electrocardiogram: no myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,164867002,Electrocardiographic old myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,194809007,Acute myocardial infarction of atrium,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,194821006,Aborted myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,194856005,Subsequent myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,194857001,Subsequent myocardial infarction of anterior wall,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,194858006,Subsequent myocardial infarction of inferior wall,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,194862000,Hemopericardium due to and following acute myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,194863005,Atrial septal defect due to and following acute myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,194865003,Rupture of cardiac wall without haemopericardium as current complication following acute myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,194868001,"Thrombosis of atrium, auricular appendage, and ventricle due to and following acute myocardial infarction",TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,233838001,Acute posterior myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,233839009,Old anterior myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,233840006,Old inferior myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,233841005,Old lateral myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,233842003,Old posterior myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,233843008,Silent myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,233847009,Cardiac rupture due to and following acute myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,233885007,Pericarditis following myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,266288001,Myocardial infarction (& [acute]) or coronary thrombosis,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,266897007,Family history of myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,275122004,Family history: Myocardial infarction at less than 60,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,275123009,Family history: Myocardial infarction at greater than 60,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,304914007,Acute Q wave myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,308065005,History of myocardial infarction in last year,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,311793000,Postoperative transmural myocardial infarction of inferior wall,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,311796008,Postoperative subendocardial myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,314207007,Non-Q wave myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,315619001,"Family history of myocardial infarction in male relative of first degree, age known",TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,315620007,"Family history of myocardial infarction in male relative of first degree, age unknown",TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,315621006,"Family history of myocardial infarction in female relative of first degree, age known",TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,315622004,"Family history of myocardial infarction in female relative of first degree, age unknown",TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,394710008,First myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,399211009,Previous myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,401303003,STEMI - ST elevation myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,401314000,Acute non-ST segment elevation myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,698593009,History of non-ST segment elevation myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,703164000,Acute anterior ST segment elevation myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,703213009,Acute STEMI (ST elevation myocardial infarction) of inferior wall,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,827164008,Delayed postmyocardial infarction syndrome,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,879955009,MINOCA - myocardial infarction with non-obstructive coronary artery,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,515711000000105,Family history of myocardial infarction in second degree relative less than 50 years,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,515741000000106,Family history of myocardial infarction in first degree relative less than 60 years,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,715971000000103,Excepted from myocardial infarction quality indicators - informed dissent,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,715981000000101,Excepted from myocardial infarction quality indicators - patient unsuitable,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,717541000000106,Exception reporting - myocardial infarction quality indicators,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,883961000000109,Thrombolysis In Myocardial Infarction risk score for unstable angina or non-ST-segment-elevation myocardial infarction,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,12238111000119106,Acute ST segment elevation myocardial infarction of inferolateral wall,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH ASPIRIN,Preventing atherothrombotic events after myocardial infarction,TA420,myocardial infarction,16837681000119104,Myocardial infarction due to demand ischaemia,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TICAGRELOR IN COMBINATION WITH LOW-DOSE ASPIRIN,Treatment of acute coronary syndromes,TA236,acute coronary syndrome,837091000000100,H/O acute coronary syndrome,TICAGRELOR,CARDIOLOGY,CARDIOLOGY
TILDRAKIZUAMB,Moderate to severe plaque psoriasis,TA575,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),TILDRAKIZUAMB,DERMATOLOGY,DERMATOLOGY
TILDRAKIZUAMB,Moderate to severe plaque psoriasis,TA575,plaque psoriasis,402307000,Chronic large plaque psoriasis,TILDRAKIZUAMB,DERMATOLOGY,DERMATOLOGY
TILDRAKIZUAMB,Moderate to severe plaque psoriasis,TA575,plaque psoriasis,402310007,Chronic stable plaque psoriasis,TILDRAKIZUAMB,DERMATOLOGY,DERMATOLOGY
TIROFIBAN,Acute coronary syndromes,TA047,acute coronary syndrome,837091000000100,H/O acute coronary syndrome,ABCIXIMAB,CARDIOLOGY,CARDIOLOGY
TIROFIBAN (INTRAVENOUS),Acute coronary syndromes,TA012,acute coronary syndrome,837091000000100,H/O acute coronary syndrome,ABCIXIMAB,CARDIOLOGY,CARDIOLOGY
TISAGENLECLEUCEL,Follicular lymphoma after 2 or more therapies,TA842,follicular lymphoma,109962001,Nonfollicular lymphoma,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
TISAGENLECLEUCEL,Follicular lymphoma after 2 or more therapies,TA842,follicular lymphoma,308121000,Follicular lymphoma,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
TISAGENLECLEUCEL,Follicular lymphoma after 2 or more therapies,TA842,follicular lymphoma,721555001,Follicular lymphoma of small intestine,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
TISAGENLECLEUCEL,Follicular lymphoma after 2 or more therapies,TA842,follicular lymphoma,1148851002,Follicular lymphoma grade IIIa,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
TISAGENLECLEUCEL,Follicular lymphoma after 2 or more therapies,TA842,follicular lymphoma,847481000000109,Follicular lymphoma grade 1,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
TISAGENLECLEUCEL,Follicular lymphoma after 2 or more therapies,TA842,follicular lymphoma,847631000000107,Follicular lymphoma grade 2,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
TISAGENLECLEUCEL,Follicular lymphoma after 2 or more therapies,TA842,follicular lymphoma,847651000000100,Follicular lymphoma grade 3,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
TISAGENLECLEUCEL,Follicular lymphoma after 2 or more therapies,TA842,follicular lymphoma,847691000000108,Follicular lymphoma grade 3a,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
TISAGENLECLEUCEL,Follicular lymphoma after 2 or more therapies,TA842,follicular lymphoma,847701000000108,Follicular lymphoma grade 3b,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
TISAGENLECLEUCEL,Relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years,TA554,acute lymphoblastic leukaemia,277572006,Precursor B-cell acute lymphoblastic leukaemia,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS
TISAGENLECLEUCEL,Relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years,TA554,acute lymphoblastic leukaemia,413440007,Acute lymphoblastic leukaemia - category,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|PAEDIATRICS
TISAGENLECLEUCEL,Relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies,TA567,diffuse large b-cell lymphoma,109969005,Diffuse large B-cell lymphoma,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
TISAGENLECLEUCEL,Relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies,TA567,diffuse large b-cell lymphoma,847741000000106,Diffuse large B-cell lymphoma,TISAGENLECLEUCEL,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
TIVOZANIB,Advanced renal cell carcinoma,TA512,renal cell carcinoma,254915003,Clear cell renal cell carcinoma,TIVOZANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
TIVOZANIB,Advanced renal cell carcinoma,TA512,renal cell carcinoma,702392008,Metastatic renal cell carcinoma,TIVOZANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
TIVOZANIB,Advanced renal cell carcinoma,TA512,renal cell carcinoma,733471003,Chromophobe renal cell carcinoma,TIVOZANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
TIVOZANIB,Advanced renal cell carcinoma,TA512,renal cell carcinoma,733608000,Papillary renal cell carcinoma,TIVOZANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
TIVOZANIB,Advanced renal cell carcinoma,TA512,renal cell carcinoma,734015000,Clear cell papillary renal cell carcinoma,TIVOZANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
TIVOZANIB,Advanced renal cell carcinoma,TA512,renal cell carcinoma,1187285005,Metastatic clear cell renal cell carcinoma,TIVOZANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
TIVOZANIB,Advanced renal cell carcinoma,TA512,renal cell carcinoma,1268503008,Primary papillary renal cell carcinoma,TIVOZANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,86555001,Cystic fibrosis of the lung,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,160309002,Family history of cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,171191008,Cystic fibrosis screening,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,235978006,Cystic fibrosis of pancreas,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,427022004,Liver disease due to cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,428273001,Cystic fibrosis not suspected,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,428301001,Suspected cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,428841003,Cystic fibrosis screening declined,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,441520002,Carrier of cystic fibrosis gene mutation,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,698529000,Seen in cystic fibrosis clinic,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,302651000000109,Cystic fibrosis carrier comment,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,302771000000109,Cystic fibrosis not screened for or screening incomplete,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,384341000000107,Cystic fibrosis repeat screening with further sample required,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,384401000000104,Cystic fibrosis not suspected and other disorders follow up required,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,515611000000104,Cystic fibrosis monitoring,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,515631000000107,Cystic fibrosis annual review,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,526071000000104,Arthropathy in cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,526091000000100,Cystic fibrosis with distal intestinal obstruction syndrome,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,776981000000103,Cirrhosis associated with cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,859041000000103,Exacerbation of cystic fibrosis,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947031000000109,"Cystic fibrosis screening declined, no history of being screened",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947041000000100,"Cystic fibrosis screening declined, screened in UK (as reported by parents) with no evidence of result",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947061000000104,"Cystic fibrosis screening declined, screened outside UK with evidence of result",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947081000000108,"Cystic fibrosis screening declined, screened outside UK with no evidence of result",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947101000000102,"Cystic fibrosis screening, too young for reliable screening",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947121000000106,"Cystic fibrosis screening,sample taken too soon after blood transfusion (less than 72 hours)",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947141000000104,"Cystic fibrosis screening, insufficient sample",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947161000000103,"Cystic fibrosis screening, unsuitable sample (blood quality): incorrect blood application",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947181000000107,"Cystic fibrosis screening, unsuitable sample (blood quality): compressed/damaged",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947201000000106,"Cystic fibrosis screening, unsuitable sample: day 0 and day 5 on same card",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947221000000102,"Cystic fibrosis screening, unsuitable sample: possible faecal contamination",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947241000000109,"Cystic fibrosis screening, unsuitable sample: NHS number missing/not accurately recorded",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947281000000101,"Cystic fibrosis screening, unsuitable sample: date of sample missing/not accurately recorded",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947301000000100,"Cystic fibrosis screening, unsuitable sample: date of birth not accurately matched",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947321000000109,"Cystic fibrosis screening, unsuitable sample: expired card used",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947341000000102,"Cystic fibrosis screening, unsuitable sample: more than 14 days in transit, too old for analysis",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947361000000101,"Cystic fibrosis screening, unsuitable sample: damaged in transit",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947381000000105,"Cystic fibrosis screening, inconclusive result",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947401000000105,"Cystic fibrosis not screened for or screening incomplete: more than 8 weeks, too old for screening",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947491000000103,"Cystic fibrosis not screened for or screening incomplete, moved out of area",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947511000000106,"Cystic fibrosis not screened for or screening incomplete, not contactable, reasonable efforts made",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,947551000000105,"Cystic fibrosis not screened for or screening incomplete, not required, previous valid result",COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,1015871000000108,Cystic fibrosis screening test,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOBRAMYCIN,Pseudomonas lung infection in cystic fibrosis,TA276,cystic fibrosis,1028351000000108,Cystic fibrosis screening,COLISTIMETHATE,THORACIC MEDICINE,THORACIC MEDICINE|PAEDIATRICS|GASTROENTEROLOGY
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,161567008,History of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed,TA375,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,ADALIMUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB,Treating juvenile idiopathic arthritis,TA373,juvenile idiopathic arthritis,410798004,Oligoarticular juvenile idiopathic arthritis,ABATECEPT,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS
TOCILIZUMAB,Treating juvenile idiopathic arthritis,TA373,juvenile idiopathic arthritis,16044751000119106,"Juvenile idiopathic arthritis, polyarthritis",ABATECEPT,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS
TOCILIZUMAB,Treatment of systemic juvenile idiopathic arthritis in children and young people aged 2 years and older whose disease continues to respond to methotrexate or who have not been previously treated with methotrexate,TA238,juvenile idiopathic arthritis,410798004,Oligoarticular juvenile idiopathic arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS
TOCILIZUMAB,Treatment of systemic juvenile idiopathic arthritis in children and young people aged 2 years and older whose disease continues to respond to methotrexate or who have not been previously treated with methotrexate,TA238,juvenile idiopathic arthritis,16044751000119106,"Juvenile idiopathic arthritis, polyarthritis",TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS
TOCILIZUMAB,"Treatment of systemic juvenile idiopathic arthritis in children and young people aged 2 years and older whose disease has responded inadequately to non-steroidal anti-inflammatory drugs (NSAIDs), systemic corticosteroids and methotrexate",TA238,juvenile idiopathic arthritis,410798004,Oligoarticular juvenile idiopathic arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS
TOCILIZUMAB,"Treatment of systemic juvenile idiopathic arthritis in children and young people aged 2 years and older whose disease has responded inadequately to non-steroidal anti-inflammatory drugs (NSAIDs), systemic corticosteroids and methotrexate",TA238,juvenile idiopathic arthritis,16044751000119106,"Juvenile idiopathic arthritis, polyarthritis",TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,161567008,History of rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Rheumatoid arthritis,TA198,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,161567008,History of rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB IN COMBINATION WITH METHOTREXATE,Treatment of rheumatoid arthritis,TA247,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOCILIZUMAB WHEN USED WITH A TAPERING COURSE OF GLUCOCORTICOIDS (AND WHEN USED ALONE AFTER GLUCOCORTICOIDS),Giant cell arteritis,TA518,giant cell arteritis,400130008,Temporal giant cell arteritis,TOCILIZUMAB,RHEUMATOLOGY,RHEUMATOLOGY
TOFACITINIB,Juvenile idiopathic arthritis,TA735,juvenile idiopathic arthritis,410798004,Oligoarticular juvenile idiopathic arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS
TOFACITINIB,Juvenile idiopathic arthritis,TA735,juvenile idiopathic arthritis,16044751000119106,"Juvenile idiopathic arthritis, polyarthritis",TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|PAEDIATRICS
TOFACITINIB,Moderately to severely active ulcerative colitis with inadequate response or  intolerant to conventional therapy or a biologic agent,TA547,ulcerative colitis,64766004,UC - ulcerative colitis,TOFACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
TOFACITINIB,Moderately to severely active ulcerative colitis with inadequate response or  intolerant to conventional therapy or a biologic agent,TA547,ulcerative colitis,160383003,FH: Ulcerative colitis,TOFACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
TOFACITINIB,Moderately to severely active ulcerative colitis with inadequate response or  intolerant to conventional therapy or a biologic agent,TA547,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,TOFACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
TOFACITINIB,Moderately to severely active ulcerative colitis with inadequate response or  intolerant to conventional therapy or a biologic agent,TA547,ulcerative colitis,275129008,Family history of ulcerative colitis,TOFACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
TOFACITINIB,Moderately to severely active ulcerative colitis with inadequate response or  intolerant to conventional therapy or a biologic agent,TA547,ulcerative colitis,275549008,History of ulcerative colitis,TOFACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
TOFACITINIB,Moderately to severely active ulcerative colitis with inadequate response or  intolerant to conventional therapy or a biologic agent,TA547,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,TOFACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
TOFACITINIB,Moderately to severely active ulcerative colitis with inadequate response or  intolerant to conventional therapy or a biologic agent,TA547,ulcerative colitis,445243001,Left sided ulcerative colitis,TOFACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
TOFACITINIB,Psoriatic arthritis after inadequate response to DMARDs,TA543,psoriatic arthritis,156370009,Psoriatic arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
TOFACITINIB,Psoriatic arthritis after inadequate response to DMARDs,TA543,psoriatic arthritis,156370009,Psoriatic arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
TOFACITINIB,Psoriatic arthritis after inadequate response to DMARDs,TA543,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
TOFACITINIB,Psoriatic arthritis after inadequate response to DMARDs,TA543,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
TOFACITINIB,Psoriatic arthritis after inadequate response to DMARDs,TA543,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
TOFACITINIB,Psoriatic arthritis after inadequate response to DMARDs,TA543,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
TOFACITINIB,Psoriatic arthritis after inadequate response to DMARDs,TA543,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
TOFACITINIB,Psoriatic arthritis after inadequate response to DMARDs,TA543,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
TOFACITINIB,Psoriatic arthritis after inadequate response to DMARDs,TA543,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
TOFACITINIB,Psoriatic arthritis after inadequate response to DMARDs,TA543,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
TOFACITINIB,Psoriatic arthritis after inadequate response to DMARDs,TA543,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
TOFACITINIB,Psoriatic arthritis after inadequate response to DMARDs,TA543,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,161567008,History of rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB MONOTHERAPY,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,161567008,History of rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,161567008,History of rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOFACITINIB WITH METHOTREXATE,Moderate to severe rheumatoid arthritis,TA480,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,TOFACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
TOLVAPTAN,Treating autosomal dominant polycystic kidney disease,TA358,polycystic kidney disease,28770003,Infantile polycystic kidney disease,TOLVAPTAN,NEPHROLOGY,NEPHROLOGY
TOLVAPTAN,Treating autosomal dominant polycystic kidney disease,TA358,polycystic kidney disease,253878003,Autosomal dominant polycystic kidney disease type 1,TOLVAPTAN,NEPHROLOGY,NEPHROLOGY
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (adults),TA076,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPIRAMATE,Epilepsy (children),TA079,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
TOPOTECAN,Ovarian cancer (advanced),TA091,ovarian cancer,423274005,Ovarian cancer stage 4,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TOPOTECAN,Ovarian cancer (advanced),TA091,ovarian cancer,762997004,Suspected ovarian cancer,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TOPOTECAN,Ovarian cancer (advanced),TA091,ovarian cancer,758821000000106,No family history of ovarian cancer,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TOPOTECAN,Ovarian cancer (advanced),TA091,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PEGYLATED,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TOPOTECAN,Treating recurrent ovarian cancer,TA389,ovarian cancer,423274005,Ovarian cancer stage 4,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TOPOTECAN,Treating recurrent ovarian cancer,TA389,ovarian cancer,762997004,Suspected ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TOPOTECAN,Treating recurrent ovarian cancer,TA389,ovarian cancer,758821000000106,No family history of ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TOPOTECAN,Treating recurrent ovarian cancer,TA389,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TOPOTECAN (2ND AND SUBSEQUENT LINES OF TREATMENT),Advanced ovarian cancer,TA028,ovarian cancer,423274005,Ovarian cancer stage 4,TOPOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TOPOTECAN (2ND AND SUBSEQUENT LINES OF TREATMENT),Advanced ovarian cancer,TA028,ovarian cancer,762997004,Suspected ovarian cancer,TOPOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TOPOTECAN (2ND AND SUBSEQUENT LINES OF TREATMENT),Advanced ovarian cancer,TA028,ovarian cancer,758821000000106,No family history of ovarian cancer,TOPOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TOPOTECAN (2ND AND SUBSEQUENT LINES OF TREATMENT),Advanced ovarian cancer,TA028,ovarian cancer,848891000000105,QCancer ovarian cancer risk,TOPOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TOPOTECAN IN COMBINATION WITH CISPLATIN,Recurrent or stage IV cervical cancer,TA183,cervical cancer,315266007,Suspected cervical cancer,TOPOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TOPOTECAN IN COMBINATION WITH CISPLATIN,Recurrent or stage IV cervical cancer,TA183,cervical cancer,736595007,Cervical cancer screening refused,TOPOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TOPOTECAN IN COMBINATION WITH CISPLATIN,Recurrent or stage IV cervical cancer,TA183,cervical cancer,112241000119107,Cervical cancer Papanicolaou smear screening declined,TOPOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TOPOTECAN IN COMBINATION WITH CISPLATIN,Recurrent or stage IV cervical cancer,TA183,cervical cancer,874251000000108,QCancer cervical cancer risk,TOPOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TOPOTECAN IN COMBINATION WITH CISPLATIN,Recurrent or stage IV cervical cancer,TA183,cervical cancer,1104621000000103,Cervical cancer screening offered,TOPOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TOPOTECAN IN COMBINATION WITH CISPLATIN,Recurrent or stage IV cervical cancer,TA183,cervical cancer,1104671000000104,Cervical cancer screening not offered,TOPOTECAN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TRABECTEDIN IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE,Relapsed platinum-sensitive ovarian cancer in women,TA222,ovarian cancer,423274005,Ovarian cancer stage 4,TRABECTEDIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TRABECTEDIN IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE,Relapsed platinum-sensitive ovarian cancer in women,TA222,ovarian cancer,762997004,Suspected ovarian cancer,TRABECTEDIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TRABECTEDIN IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE,Relapsed platinum-sensitive ovarian cancer in women,TA222,ovarian cancer,758821000000106,No family history of ovarian cancer,TRABECTEDIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TRABECTEDIN IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN HYDROCHLORIDE,Relapsed platinum-sensitive ovarian cancer in women,TA222,ovarian cancer,848891000000105,QCancer ovarian cancer risk,TRABECTEDIN,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TRABECTEDIN IN COMBINATION WITH PLDH,Treating recurrent ovarian cancer,TA389,ovarian cancer,423274005,Ovarian cancer stage 4,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TRABECTEDIN IN COMBINATION WITH PLDH,Treating recurrent ovarian cancer,TA389,ovarian cancer,762997004,Suspected ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TRABECTEDIN IN COMBINATION WITH PLDH,Treating recurrent ovarian cancer,TA389,ovarian cancer,758821000000106,No family history of ovarian cancer,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TRABECTEDIN IN COMBINATION WITH PLDH,Treating recurrent ovarian cancer,TA389,ovarian cancer,848891000000105,QCancer ovarian cancer risk,PACLITAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|GYNAECOLOGICAL ONCOLOGY|CLINICAL ONCOLOGY
TRALOKINUMAB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
TRALOKINUMAB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238543002,Discoid atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
TRALOKINUMAB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
TRALOKINUMAB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238545009,Follicular atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
TRALOKINUMAB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
TRALOKINUMAB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,915007,Malignant melanoma in junctional naevus,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,1556006,Clark melanoma level 4,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,2092003,Malignant melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,2142002,Nodular melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,16974005,"Acral lentiginous melanoma, malignant",TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,21119008,Benign melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,21165006,Clark melanoma level 3,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,37138001,Epithelioid cell melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,39896009,"Malignant melanoma, regressing",TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,44474009,Lentigo maligna melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,50542000,Clark melanoma level 2,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,50813003,Spitz melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,51757004,"Desmoplastic melanoma, amelanotic",TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,55320002,Superficial spreading melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,68827007,Spindle cell melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,70594002,Amelanotic melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,77986002,Melanoma in situ,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93209006,Malignant melanoma of perianal skin,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93214005,Malignant melanoma of skin of back,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93217003,Malignant melanoma of skin of cheek,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93220006,Malignant melanoma of skin of ear,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93221005,Malignant melanoma of skin of elbow,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93223008,Malignant melanoma of eyebrow,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93225001,Malignant melanoma of skin of face,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93227009,Malignant melanoma of skin of foot,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93228004,Malignant melanoma of skin of forearm,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93642000,Malignant melanoma of skin of neck,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93643005,Malignant melanoma of external surface of nose,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93646002,Malignant melanoma of skin of scalp,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93647006,Malignant melanoma of skin of shoulder,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93651008,Malignant melanoma of skin of trunk,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93653006,Malignant melanoma of skin of upper limb,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93654000,Malignant melanoma of skin of wrist,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,93655004,MM (malignant melanoma) of skin,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,106243009,Breslow depth staging for melanoma of skin,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,109266006,Melanoma in situ of skin,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,109270003,Melanoma in situ of face,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,109272006,Melanoma in situ of lip,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,109274007,"Melanoma in situ of eyelid, including canthus",TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,109276009,Melanoma in situ of scalp,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,109278005,Melanoma in situ of ear,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,109282007,Melanoma in situ of neck,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,109284008,Melanoma in situ of trunk,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,109290007,Melanoma in situ of upper limb,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,109294003,Melanoma in situ of lower limb,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,127330008,Melanoma in situ by body site (clinical),TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,161432005,History of malignant melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,177281002,Excision of melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188030005,Malignant melanoma of lip,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188032002,Malignant melanoma of ear and/or external auditory canal,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188033007,Malignant melanoma of auricle (ear),TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188034001,Malignant melanoma of external auditory meatus,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188038003,Malignant melanoma of chin,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188040008,Malignant melanoma of forehead,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188042000,Malignant melanoma of temple,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188044004,Malignant melanoma of scalp and/or neck,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188045003,Malignant melanoma of scalp,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188046002,Malignant melanoma of neck,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188049009,Malignant melanoma of axilla,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188050009,Malignant melanoma of breast,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188051008,Malignant melanoma of buttock,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188052001,Malignant melanoma of groin,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188054000,Malignant melanoma of perineum,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188055004,Malignant melanoma of umbilicus,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188060000,Malignant melanoma of shoulder,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188061001,Malignant melanoma of upper arm,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188062008,Malignant melanoma of forearm,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188063003,Malignant melanoma of hand,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188064009,Malignant melanoma of finger,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188065005,Malignant melanoma of thumb,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188067002,Malignant melanoma of lower limb and hip,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188068007,Malignant melanoma of hip,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188069004,Malignant melanoma of thigh,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188070003,Malignant melanoma of knee,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188071004,Malignant melanoma of popliteal fossa area,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188072006,Malignant melanoma of lower leg,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188073001,Malignant melanoma of ankle,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188074007,Malignant melanoma of heel,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188075008,Malignant melanoma of foot,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188076009,Malignant melanoma of toe,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,188077000,Malignant melanoma of great toe,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,189324006,Melanoma in situ of skin structure of scalp and/or neck,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,189758001,Melanoma in situ,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,231834005,Malignant melanoma of eyelid,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,254325002,Tumor-node-metastasis (TNM) malignant melanoma of skin staging,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,254730000,SMMM (superficial spreading malignant melanoma) of skin,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,254731001,Nodular melanoma of skin,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,254732008,Acral lentiginous melanoma of skin,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,254896002,Malignant melanoma of vulva,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,255004001,Malignant melanoma of conjunctiva,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,255012009,Malignant melanoma of iris,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,255015006,Malignant melanoma of ciliary body,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,255021005,Malignant melanoma of choroid,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,269578002,Malignant melanoma of head and neck,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,269579005,Malignant melanoma of trunk,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,269580008,Malignant melanoma of upper limb,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,269581007,Malignant melanoma of lower limb,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,274087000,MM (malignant melanoma) of eye,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,276751004,Amelanotic melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,276821000,Malignant melanoma of anus,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,276822007,Malignant melanoma of rectum,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,302837001,Lentigo maligna melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,310498001,Malignant melanoma of back,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,312941005,Melanoma associated retinopathy,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,313248004,Malignant melanoma of chest wall,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,314976006,Local recurrence of malignant melanoma of skin,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,314987003,Metastasis from malignant melanoma of skin,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,315036008,Melanoma in situ of back of hand,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,315230006,Melanoma in situ of back,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,372158004,"Malignant melanoma, metastatic",TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,427858005,Family history of malignant melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,443493003,Metastatic malignant melanoma,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,449636007,Malignant melanoma of skin of lower leg,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,449637003,Malignant melanoma of skin of upper arm,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,698040004,Malignant melanoma of nasal cavity,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,1197324006,Metastatic malignant melanoma to skin,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,351961000119109,Malignant melanoma of skin of right arm,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,352201000119105,Malignant melanoma of skin of left upper limb,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,352211000119108,Malignant melanoma of skin of left ear,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,546881000000105,Malignant melanoma of skin NOS,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,956331000000107,Malignant melanoma stage IA,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,956351000000100,Malignant melanoma stage IB,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,956371000000109,Malignant melanoma stage IIA,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,956391000000108,Malignant melanoma stage IIB,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,956451000000107,Malignant melanoma stage IIIB,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,956471000000103,Malignant melanoma stage IIIC,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,956511000000107,Malignant melanoma stage IV M1a,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,956551000000106,Malignant melanoma stage IV M1c,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,1080941000119109,Malignant melanoma of left choroid,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRAMETINIB IN COMBINATION WITH DABRAFENIB,Treating unresectable or metastatic melanoma,TA396,melanoma,1080981000119104,Malignant melanoma of right choroid,TRAMETINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,134405005,Suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,160287004,FH: Breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,268547008,Screening for breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,429740004,Family history of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,431330007,Family history of breast cancer 1 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,431331006,Family history of breast cancer 2 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,706970001,TNBC - Triple-negative breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,94361000000105,Breast cancer detected by national screening programme,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,276341000000100,Fast track referral for suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,838351000000107,Education about risk of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,874291000000100,QCancer breast cancer risk,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB,Breast cancer (early),TA107,breast cancer,1035841000000108,Lymphoedema following breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,134405005,Suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,160287004,FH: Breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,268547008,Screening for breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,429740004,Family history of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,431330007,Family history of breast cancer 1 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,431331006,Family history of breast cancer 2 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,706970001,TNBC - Triple-negative breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,94361000000105,Breast cancer detected by national screening programme,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,276341000000100,Fast track referral for suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,838351000000107,Education about risk of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,874291000000100,QCancer breast cancer risk,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments,TA862,breast cancer,1035841000000108,Lymphoedema following breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,134405005,Suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,160287004,FH: Breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,268547008,Screening for breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,429740004,Family history of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,431330007,Family history of breast cancer 1 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,431331006,Family history of breast cancer 2 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,706970001,TNBC - Triple-negative breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,94361000000105,Breast cancer detected by national screening programme,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,276341000000100,Fast track referral for suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,838351000000107,Education about risk of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,874291000000100,QCancer breast cancer risk,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB DERUXTECAN,HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies,TA704,breast cancer,1035841000000108,Lymphoedema following breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,134405005,Suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,160287004,FH: Breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,268547008,Screening for breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,429740004,Family history of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,431330007,Family history of breast cancer 1 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,431331006,Family history of breast cancer 2 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,706970001,TNBC - Triple-negative breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,94361000000105,Breast cancer detected by national screening programme,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,276341000000100,Fast track referral for suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,838351000000107,Education about risk of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,874291000000100,QCancer breast cancer risk,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,HER2-positive advanced breast cancer after trastuzumab and a taxane,TA458,breast cancer,1035841000000108,Lymphoedema following breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,134405005,Suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,160287004,FH: Breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,268547008,Screening for breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,429740004,Family history of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,431330007,Family history of breast cancer 1 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,431331006,Family history of breast cancer 2 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,706970001,TNBC - Triple-negative breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,94361000000105,Breast cancer detected by national screening programme,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,276341000000100,Fast track referral for suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,838351000000107,Education about risk of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,874291000000100,QCancer breast cancer risk,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"Treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane",TA371,breast cancer,1035841000000108,Lymphoedema following breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,134405005,Suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,160287004,FH: Breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,268547008,Screening for breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,429740004,Family history of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,431330007,Family history of breast cancer 1 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,431331006,Family history of breast cancer 2 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,706970001,TNBC - Triple-negative breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,94361000000105,Breast cancer detected by national screening programme,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,276341000000100,Fast track referral for suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,838351000000107,Education about risk of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,874291000000100,QCancer breast cancer risk,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB EMTANSINE,"adjuvant treatment of adult patients with HER2‑positive early breast cancer who have residual invasive disease, in the breast and/or lymph nodes, after neoadjuvant taxane-based and HER2‑targeted therapy",TA632,breast cancer,1035841000000108,Lymphoedema following breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,134405005,Suspected breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,160287004,FH: Breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,268547008,Screening for breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,429740004,Family history of breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,431330007,Family history of breast cancer 1 gene mutation,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,431331006,Family history of breast cancer 2 gene mutation,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,706970001,TNBC - Triple-negative breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,94361000000105,Breast cancer detected by national screening programme,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,276341000000100,Fast track referral for suspected breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,838351000000107,Education about risk of breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,874291000000100,QCancer breast cancer risk,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH AN AROMATASE INHIBITOR (1ST LINE),Treatment of postmenopausal women with metastatic hormone receptor-positive breast cancer that overexpresses HER2.,TA257,breast cancer,1035841000000108,Lymphoedema following breast cancer,LAPATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH CISPLATIN AND CAPECITABINE OR 5-FLUOROURACIL,"Gastric cancer (HER2-positive, metastatic)",TA208,gastric cancer,276809004,Early gastric cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH CISPLATIN AND CAPECITABINE OR 5-FLUOROURACIL,"Gastric cancer (HER2-positive, metastatic)",TA208,gastric cancer,276810009,Late gastric cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,134405005,Suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,160287004,FH: Breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,268547008,Screening for breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,429740004,Family history of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,431330007,Family history of breast cancer 1 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,431331006,Family history of breast cancer 2 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,706970001,TNBC - Triple-negative breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,94361000000105,Breast cancer detected by national screening programme,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,276341000000100,Fast track referral for suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,838351000000107,Education about risk of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,874291000000100,QCancer breast cancer risk,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB IN COMBINATION WITH PACLITAXEL,Breast cancer,TA034,breast cancer,1035841000000108,Lymphoedema following breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,134405005,Suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,160287004,FH: Breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,268547008,Screening for breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,429740004,Family history of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,431330007,Family history of breast cancer 1 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,431331006,Family history of breast cancer 2 gene mutation,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,706970001,TNBC - Triple-negative breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,94361000000105,Breast cancer detected by national screening programme,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,276341000000100,Fast track referral for suspected breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,838351000000107,Education about risk of breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,874291000000100,QCancer breast cancer risk,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TRASTUZUMAB MONOTHERAPY,Breast cancer,TA034,breast cancer,1035841000000108,Lymphoedema following breast cancer,TRASTUZUMAB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TREOSULFAN WITH FLUDARABINE,Malignant disease before allogeneic stem cell transplant,TA640,stem cell transplant,234336002,Haemopoietic stem cell transplant,TREOSULFAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY
TREOSULFAN WITH FLUDARABINE,Malignant disease before allogeneic stem cell transplant,TA640,stem cell transplant,397554006,Limbal stem cell transplantation,TREOSULFAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY
TREOSULFAN WITH FLUDARABINE,Malignant disease before allogeneic stem cell transplant,TA640,stem cell transplant,425843001,Allogeneic peripheral blood stem cell transplant,TREOSULFAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY
TREOSULFAN WITH FLUDARABINE,Malignant disease before allogeneic stem cell transplant,TA640,stem cell transplant,425983008,Autologous peripheral blood stem cell transplant,TREOSULFAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY
TREOSULFAN WITH FLUDARABINE,Malignant disease before allogeneic stem cell transplant,TA640,stem cell transplant,284681000000100,Syngeneic peripheral blood stem cell transplant,TREOSULFAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|TRANSPLANTATION SURGERY
TRIFLURIDINE–TIPIRACIL,Metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies,TA669,gastric cancer,276809004,Early gastric cancer,TRIFLURIDINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
TRIFLURIDINE–TIPIRACIL,Metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies,TA669,gastric cancer,276810009,Late gastric cancer,TRIFLURIDINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
TRIFLURIDINE–TIPIRACIL,Metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments,TA852,gastric cancer,276809004,Early gastric cancer,TRIFLURIDINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
TRIFLURIDINE–TIPIRACIL,Metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments,TA852,gastric cancer,276810009,Late gastric cancer,TRIFLURIDINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UPPER GASTROINTESTINAL SURGERY|CLINICAL ONCOLOGY
TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,134405005,Suspected breast cancer,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,160287004,FH: Breast cancer,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,268547008,Screening for breast cancer,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,429740004,Family history of breast cancer,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,431330007,Family history of breast cancer 1 gene mutation,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,431331006,Family history of breast cancer 2 gene mutation,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,706970001,TNBC - Triple-negative breast cancer,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,94361000000105,Breast cancer detected by national screening programme,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,276341000000100,Fast track referral for suspected breast cancer,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,838351000000107,Education about risk of breast cancer,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,874291000000100,QCancer breast cancer risk,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
TUCATINIB WITH TRASTUZUMAB AND CAPECITABINE,HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies,TA786,breast cancer,1035841000000108,Lymphoedema following breast cancer,TUCATINIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
UPADACITINIB,Active ankylosing spondylitis,TA829,ankylosing spondylitis,162930007,On examination - ankylosing spondylitis chest deformity,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY
UPADACITINIB,Active ankylosing spondylitis,TA829,ankylosing spondylitis,239805001,Juvenile ankylosing spondylitis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY
UPADACITINIB,Active ankylosing spondylitis,TA829,ankylosing spondylitis,239810002,Ankylosing spondylitis with organ / system involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY
UPADACITINIB,Active ankylosing spondylitis,TA829,ankylosing spondylitis,239811003,Ankylosing spondylitis with multisystem involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY
UPADACITINIB,Active ankylosing spondylitis,TA829,ankylosing spondylitis,394990003,Family history: Ankylosing spondylitis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY
UPADACITINIB,Active ankylosing spondylitis,TA829,ankylosing spondylitis,429712009,Bath Ankylosing Spondylitis Disease Activity Index,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY
UPADACITINIB,Active ankylosing spondylitis,TA829,ankylosing spondylitis,441562009,Bath Ankylosing Spondylitis Disease Activity Index score,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY
UPADACITINIB,Active ankylosing spondylitis,TA829,ankylosing spondylitis,441680005,BASFI (Bath Ankylosing Spondylitis Functional Index) score,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY
UPADACITINIB,Active ankylosing spondylitis,TA829,ankylosing spondylitis,441930001,BASMI (Bath Ankylosing Spondylitis Metrology Index) score,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY
UPADACITINIB,Active non-radiographic axial spondyloarthritis,TA861,axial spondyloarthritis,723116002,Axial spondyloarthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY
UPADACITINIB,Active psoriatic arthritis after inadequate response to DMARDs,TA768,psoriatic arthritis,156370009,Psoriatic arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
UPADACITINIB,Active psoriatic arthritis after inadequate response to DMARDs,TA768,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
UPADACITINIB,Active psoriatic arthritis after inadequate response to DMARDs,TA768,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
UPADACITINIB,Active psoriatic arthritis after inadequate response to DMARDs,TA768,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
UPADACITINIB,Active psoriatic arthritis after inadequate response to DMARDs,TA768,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
UPADACITINIB,Active psoriatic arthritis after inadequate response to DMARDs,TA768,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
UPADACITINIB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238542007,Inverse pattern atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
UPADACITINIB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238543002,Discoid atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
UPADACITINIB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238544008,Erythrodermic atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
UPADACITINIB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238545009,Follicular atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
UPADACITINIB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,238546005,Pruriginous atopic dermatitis,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
UPADACITINIB,Moderate to severe atopic dermatitis,TA814,atopic dermatitis,584621000000108,Atopic dermatitis NOS,ABROCITINIB,DERMATOLOGY,DERMATOLOGY|PAEDIATRICS|CLINICAL IMMUNOLOGY
UPADACITINIB,Moderately to severely active ulcerative colitis,TA856,ulcerative colitis,64766004,UC - ulcerative colitis,UPADACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
UPADACITINIB,Moderately to severely active ulcerative colitis,TA856,ulcerative colitis,160383003,FH: Ulcerative colitis,UPADACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
UPADACITINIB,Moderately to severely active ulcerative colitis,TA856,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,UPADACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
UPADACITINIB,Moderately to severely active ulcerative colitis,TA856,ulcerative colitis,275129008,Family history of ulcerative colitis,UPADACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
UPADACITINIB,Moderately to severely active ulcerative colitis,TA856,ulcerative colitis,275549008,History of ulcerative colitis,UPADACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
UPADACITINIB,Moderately to severely active ulcerative colitis,TA856,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,UPADACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
UPADACITINIB,Moderately to severely active ulcerative colitis,TA856,ulcerative colitis,445243001,Left sided ulcerative colitis,UPADACITINIB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,161567008,History of rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,161567008,History of rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB MONOTHERAPY,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,161567008,History of rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Moderate rheumatoid arthritis,TA744,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1961000,Chronic polyarticular juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,28880005,Rheumatoid arthritis with carditis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,75822003,Acute juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,160413008,Family history: Rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,161567008,History of rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,161567008,History of rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,161567008,History of rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,193180002,Polyneuropathy in rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,193250002,Myopathy due to rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201764007,Rheumatoid arthritis of cervical spine,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201766009,Rheumatoid arthritis of shoulder,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201767000,Rheumatoid arthritis of sternoclavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201768005,Rheumatoid arthritis of acromioclavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201769002,Rheumatoid arthritis of elbow,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201771002,Rheumatoid arthritis of wrist,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201772009,Rheumatoid arthritis of metacarpophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201773004,Rheumatoid arthritis of proximal interphalangeal joint of finger,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201774005,Rheumatoid arthritis of distal interphalangeal joint of finger,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201775006,Rheumatoid arthritis of hip,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201776007,Rheumatoid arthritis of sacroiliac joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201777003,Rheumatoid arthritis of knee,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201778008,Rheumatoid arthritis of tibiofibular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201779000,Rheumatoid arthritis of ankle,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201780002,Rheumatoid arthritis of subtalar joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201781003,Rheumatoid arthritis of talonavicular joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201783000,Rheumatoid arthritis of 1st metatarsophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201784006,Rheumatoid arthritis of lesser metatarsophalangeal joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201785007,Rheumatoid arthritis of interphalangeal joint of toe,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201791009,Flare of rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201796004,Systemic onset juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,201799006,Monoarticular juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239791005,Seropositive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239792003,Seronegative rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239793008,Rheumatoid arthritis with organ / system involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,239795001,Rheumatoid arthritis with multisystem involvement,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,275902004,Rheumatoid arthritis monitoring,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,287006005,Rheumatoid arthritis of multiple joints,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,287007001,Rheumatoid arthritis of hand,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,287008006,Rheumatoid arthritis of ankle and/or foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,308143008,Seropositive erosive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,398640008,Rheumatoid arthritis with pneumoconiosis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,399923009,Rheumatoid arthritis with arteritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,400054000,Rheumatoid arthritis with vasculitis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,410502007,Juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,410795001,Juvenile rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,429192004,Rheumatoid arthritis of foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,443728000,Disease activity score 28 joint in rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,735599007,Rheumatoid arthritis with erosion of joint,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1162303002,Seronegative erosive rheumatoid arthritis,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,143441000000104,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation using preferred method of communication,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,143441000119108,Rheumatoid arthritis in remission,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,805941000000105,Exception reporting - rheumatoid arthritis quality indicators,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,805961000000106,Excepted from rheumatoid arthritis quality indicators - patient unsuitable,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,805981000000102,Excepted from rheumatoid arthritis quality indicators - informed dissent,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,847261000000104,Rheumatoid arthritis annual review,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882321000000105,Rheumatoid arthritis monitoring invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882401000000106,Rheumatoid arthritis monitoring invitation first letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882421000000102,Rheumatoid arthritis monitoring invitation second letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882441000000109,Rheumatoid arthritis monitoring invitation third letter,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882461000000105,Rheumatoid arthritis monitoring verbal invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,882481000000101,Rheumatoid arthritis monitoring telephone invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1010071000000108,Rheumatoid arthritis particle agglutination test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1016811000000108,Rheumatoid arthritis screening test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1029271000000101,Rheumatoid arthritis latex test,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1066991000000109,Rheumatoid arthritis monitoring invitation by SMS (short message service) text messaging,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1067001000000103,Rheumatoid arthritis monitoring SMS (short message service) text message first invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1067011000000101,Rheumatoid arthritis monitoring SMS (short message service) text message second invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1067021000000107,Rheumatoid arthritis monitoring SMS (short message service) text message third invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1073781000119104,Rheumatoid arthritis of right foot,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1073791000119101,Rheumatoid arthritis of right hand,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1083081000000100,Rheumatoid arthritis monitoring invitation email,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
UPADACITINIB WITH METHOTREXATE,Severe rheumatoid arthritis,TA665,rheumatoid arthritis,1110961000000108,QOF (Quality and Outcomes Framework) rheumatoid arthritis quality indicator-related care invitation,UPADACITINIB,RHEUMATOLOGY,RHEUMATOLOGY|CLINICAL IMMUNOLOGY|GERIATRIC MEDICINE
USTEKINUMAB,Plaque psoriasis,TA180,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),USTEKINUMAB,DERMATOLOGY,DERMATOLOGY
USTEKINUMAB,Plaque psoriasis,TA180,plaque psoriasis,402307000,Chronic large plaque psoriasis,USTEKINUMAB,DERMATOLOGY,DERMATOLOGY
USTEKINUMAB,Plaque psoriasis,TA180,plaque psoriasis,402310007,Chronic stable plaque psoriasis,USTEKINUMAB,DERMATOLOGY,DERMATOLOGY
USTEKINUMAB,Plaque psoriasis in children and young people,TA455,plaque psoriasis,200975007,Psoriasis vulgaris & (Chronic large plaque psoriasis),ADALIMUMAB,DERMATOLOGY,DERMATOLOGY
USTEKINUMAB,Plaque psoriasis in children and young people,TA455,plaque psoriasis,402307000,Chronic large plaque psoriasis,ADALIMUMAB,DERMATOLOGY,DERMATOLOGY
USTEKINUMAB,Plaque psoriasis in children and young people,TA455,plaque psoriasis,402310007,Chronic stable plaque psoriasis,ADALIMUMAB,DERMATOLOGY,DERMATOLOGY
USTEKINUMAB,"Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies'",TA633,ulcerative colitis,64766004,UC - ulcerative colitis,USTEKINUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
USTEKINUMAB,"Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies'",TA633,ulcerative colitis,160383003,FH: Ulcerative colitis,USTEKINUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
USTEKINUMAB,"Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies'",TA633,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,USTEKINUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
USTEKINUMAB,"Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies'",TA633,ulcerative colitis,275129008,Family history of ulcerative colitis,USTEKINUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
USTEKINUMAB,"Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies'",TA633,ulcerative colitis,275549008,History of ulcerative colitis,USTEKINUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
USTEKINUMAB,"Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies'",TA633,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,USTEKINUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
USTEKINUMAB,"Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies'",TA633,ulcerative colitis,445243001,Left sided ulcerative colitis,USTEKINUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
USTEKINUMAB ALONE OR IN COMBINATION WITH METHOTREXATE,Active psoriatic arthritis,TA313,psoriatic arthritis,156370009,Psoriatic arthritis,USTEKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
USTEKINUMAB ALONE OR IN COMBINATION WITH METHOTREXATE,Active psoriatic arthritis,TA313,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,USTEKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
USTEKINUMAB ALONE OR IN COMBINATION WITH METHOTREXATE,Active psoriatic arthritis,TA313,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,USTEKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
USTEKINUMAB ALONE OR IN COMBINATION WITH METHOTREXATE,Active psoriatic arthritis,TA313,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,USTEKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
USTEKINUMAB ALONE OR IN COMBINATION WITH METHOTREXATE,Active psoriatic arthritis,TA313,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,USTEKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
USTEKINUMAB ALONE OR IN COMBINATION WITH METHOTREXATE,Active psoriatic arthritis,TA313,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,USTEKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
"USTEKINUMAB, ALONE OR IN COMBINATION WITH METHOTREXATE",Active psoriatic arthritis,TA340,psoriatic arthritis,156370009,Psoriatic arthritis,USTEKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
"USTEKINUMAB, ALONE OR IN COMBINATION WITH METHOTREXATE",Active psoriatic arthritis,TA340,psoriatic arthritis,239802003,Juvenile psoriatic arthritis,USTEKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
"USTEKINUMAB, ALONE OR IN COMBINATION WITH METHOTREXATE",Active psoriatic arthritis,TA340,psoriatic arthritis,239803008,Juvenile psoriatic arthritis with psoriasis,USTEKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
"USTEKINUMAB, ALONE OR IN COMBINATION WITH METHOTREXATE",Active psoriatic arthritis,TA340,psoriatic arthritis,239812005,Psoriatic arthritis with distal interphalangeal joint involvement,USTEKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
"USTEKINUMAB, ALONE OR IN COMBINATION WITH METHOTREXATE",Active psoriatic arthritis,TA340,psoriatic arthritis,430543001,Family history of psoriasis with psoriatic arthritis,USTEKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
"USTEKINUMAB, ALONE OR IN COMBINATION WITH METHOTREXATE",Active psoriatic arthritis,TA340,psoriatic arthritis,1036471000000109,Psoriatic Arthritis Impact of Disease 9 questionnaire score,USTEKINUMAB,RHEUMATOLOGY,RHEUMATOLOGY|DERMATOLOGY
VALPROATE SEMISODIUM,Bipolar disorder,TA066,bipolar disorder,4441000,Severe bipolar disorder with psychotic features,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH
VALPROATE SEMISODIUM,Bipolar disorder,TA066,bipolar disorder,5703000,Bipolar disorder in partial remission,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH
VALPROATE SEMISODIUM,Bipolar disorder,TA066,bipolar disorder,13313007,Mild bipolar disorder,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH
VALPROATE SEMISODIUM,Bipolar disorder,TA066,bipolar disorder,41836007,Bipolar disorder in full remission,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH
VALPROATE SEMISODIUM,Bipolar disorder,TA066,bipolar disorder,53049002,Severe bipolar disorder without psychotic features,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH
VALPROATE SEMISODIUM,Bipolar disorder,TA066,bipolar disorder,79584002,Moderate bipolar disorder,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH
VALPROATE SEMISODIUM,Bipolar disorder,TA066,bipolar disorder,85248005,Bipolar disorder in remission,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH
VALPROATE SEMISODIUM,Bipolar disorder,TA066,bipolar disorder,160331005,Family history of bipolar disorder,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH
VALPROATE SEMISODIUM,Bipolar disorder,TA066,bipolar disorder,231444002,Organic bipolar disorder,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH
VALPROATE SEMISODIUM,Bipolar disorder,TA066,bipolar disorder,767632000,"Bipolar disorder, most recent episode manic",OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH
VALPROATE SEMISODIUM,Bipolar disorder,TA066,bipolar disorder,1365951000000107,Family intervention for psychosis and bipolar disorder,OLANZAPINE,MENTAL HEALTH,MENTAL HEALTH
VANDETANIB,Medullary thyroid cancer,TA550,thyroid cancer,94098005,Primary malignant neoplasm of thyroid gland,VANDETANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY
VANDETANIB,Medullary thyroid cancer,TA550,thyroid cancer,363478007,Malignant tumour of thyroid gland,VANDETANIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|ENDOCRINOLOGY|CLINICAL ONCOLOGY
VARENICLINE,Smoking cessation,TA123,smoking cessation,390900001,Smoking cessation milestones,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,395700008,Referral to smoking cessation advisor,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,401068004,Seen by smoking cessation advisor,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,401160008,Smoking cessation programme start date,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,710081004,Smoking cessation therapy,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,713700008,Smoking cessation drug therapy,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,765001003,Monitoring of smoking cessation therapy refused,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,771155005,Brief intervention for smoking cessation,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,1290027009,Consultation for smoking cessation,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,25261000000107,Did not attend smoking cessation clinic,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,200221000000105,Smoking cessation advice provided by community pharmacist,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,201931000000109,Attends practice smoking cessation clinic,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,201941000000100,Attends smoking cessation clinic not at practice,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,374361000000100,Smoking cessation enhanced services administration,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,374391000000106,Smoking cessation enhanced services administration monitoring template completed,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,506491000000102,Brief intervention for smoking cessation,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,527151000000107,Smoking cessation advice declined,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,712971000000108,Practice based smoking cessation programme start date,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,720401000000103,Smoking cessation,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,750821000000109,Consent given for follow-up evaluation after smoking cessation intervention,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,750851000000104,Consent given for smoking cessation data sharing,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,751101000000101,Declined consent for follow-up evaluation after smoking cessation intervention,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,751661000000106,Declined consent for smoking cessation data sharing,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,755721000000107,Consent given for follow-up by smoking cessation team,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,755741000000100,Declined consent for follow-up by smoking cessation team,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,767641000000109,Referral for smoking cessation service offered,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,768971000000109,Lost to smoking cessation follow-up,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,822591000000108,Smoking cessation drug therapy declined,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,850331000000104,Smoking cessation 12 week follow-up,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,871641000000105,Referral to smoking cessation service declined,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,871661000000106,Referral to smoking cessation service,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,966971000000103,Varenicline smoking cessation therapy declined,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,966991000000104,Varenicline smoking cessation therapy offered,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,1084381000000100,Signposting to smoking cessation service,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,1087441000000106,Smoking cessation programme declined,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VARENICLINE,Smoking cessation,TA123,smoking cessation,2140191000000108,Referral to Community Pharmacy Smoking Cessation Service,VARENICLINE,THORACIC MEDICINE,THORACIC MEDICINE|GENERAL MEDICINE
VEDOLIZUMAB,Chronic refractory pouchitis after surgery for ulcerative colitis,TA826,ulcerative colitis,64766004,UC - ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
VEDOLIZUMAB,Chronic refractory pouchitis after surgery for ulcerative colitis,TA826,ulcerative colitis,160383003,FH: Ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
VEDOLIZUMAB,Chronic refractory pouchitis after surgery for ulcerative colitis,TA826,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
VEDOLIZUMAB,Chronic refractory pouchitis after surgery for ulcerative colitis,TA826,ulcerative colitis,275129008,Family history of ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
VEDOLIZUMAB,Chronic refractory pouchitis after surgery for ulcerative colitis,TA826,ulcerative colitis,275549008,History of ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
VEDOLIZUMAB,Chronic refractory pouchitis after surgery for ulcerative colitis,TA826,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
VEDOLIZUMAB,Chronic refractory pouchitis after surgery for ulcerative colitis,TA826,ulcerative colitis,445243001,Left sided ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
VEDOLIZUMAB,Moderately to severely active ulcerative colitis,TA342,ulcerative colitis,64766004,UC - ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
VEDOLIZUMAB,Moderately to severely active ulcerative colitis,TA342,ulcerative colitis,160383003,FH: Ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
VEDOLIZUMAB,Moderately to severely active ulcerative colitis,TA342,ulcerative colitis,201727001,Arthropathy in ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
VEDOLIZUMAB,Moderately to severely active ulcerative colitis,TA342,ulcerative colitis,275129008,Family history of ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
VEDOLIZUMAB,Moderately to severely active ulcerative colitis,TA342,ulcerative colitis,275549008,History of ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
VEDOLIZUMAB,Moderately to severely active ulcerative colitis,TA342,ulcerative colitis,414156000,Exacerbation of ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
VEDOLIZUMAB,Moderately to severely active ulcerative colitis,TA342,ulcerative colitis,445243001,Left sided ulcerative colitis,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|COLORECTAL SURGERY
VEDOLIZUMAB,Treating moderately to severely active Crohn's disease after prior therapy,TA352,crohn's disease,196578009,Oral Crohn's disease,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
VEDOLIZUMAB,Treating moderately to severely active Crohn's disease after prior therapy,TA352,crohn's disease,196578009,Oral Crohn's disease,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
VEDOLIZUMAB,Treating moderately to severely active Crohn's disease after prior therapy,TA352,crohn's disease,273364009,Crohn's Disease Activity Index,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
VEDOLIZUMAB,Treating moderately to severely active Crohn's disease after prior therapy,TA352,crohn's disease,273364009,Crohn's Disease Activity Index,VEDOLIZUMAB,GASTROENTEROLOGY,GASTROENTEROLOGY|PAEDIATRIC GASTROENTEROLOGY|COLORECTAL SURGERY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,915007,Malignant melanoma in junctional naevus,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,39896009,"Malignant melanoma, regressing",VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,93209006,Malignant melanoma of perianal skin,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,93214005,Malignant melanoma of skin of back,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,93217003,Malignant melanoma of skin of cheek,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,93220006,Malignant melanoma of skin of ear,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,93221005,Malignant melanoma of skin of elbow,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,93228004,Malignant melanoma of skin of forearm,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,93642000,Malignant melanoma of skin of neck,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,93643005,Malignant melanoma of external surface of nose,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,93654000,Malignant melanoma of skin of wrist,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188030005,Malignant melanoma of lip,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188034001,Malignant melanoma of external auditory meatus,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188038003,Malignant melanoma of chin,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188042000,Malignant melanoma of temple,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188049009,Malignant melanoma of axilla,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188050009,Malignant melanoma of breast,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188054000,Malignant melanoma of perineum,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188062008,Malignant melanoma of forearm,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188069004,Malignant melanoma of thigh,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188070003,Malignant melanoma of knee,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188071004,Malignant melanoma of popliteal fossa area,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188072006,Malignant melanoma of lower leg,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,188076009,Malignant melanoma of toe,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,231834005,Malignant melanoma of eyelid,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,255004001,Malignant melanoma of conjunctiva,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,255012009,Malignant melanoma of iris,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,255015006,Malignant melanoma of ciliary body,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,255021005,Malignant melanoma of choroid,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,269578002,Malignant melanoma of head and neck,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,314976006,Local recurrence of malignant melanoma of skin,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,314987003,Metastasis from malignant melanoma of skin,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,1197324006,Metastatic malignant melanoma to skin,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,956371000000109,Malignant melanoma stage IIA,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,956391000000108,Malignant melanoma stage IIB,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,956451000000107,Malignant melanoma stage IIIB,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,956511000000107,Malignant melanoma stage IV M1a,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VEMURAFENIB,Locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma,TA269,malignant melanoma,956551000000106,Malignant melanoma stage IV M1c,VEMURAFENIB,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|DERMATOLOGY|CLINICAL ONCOLOGY
VENETOCLAX,Adults with chronic lymphocytic leukaemia who have received at least 1 prior therapy,TA561,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
VENETOCLAX,Adults with chronic lymphocytic leukaemia who have received at least 1 prior therapy,TA561,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
VENETOCLAX,Adults with chronic lymphocytic leukaemia who have received at least 1 prior therapy,TA561,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
VENETOCLAX,Adults with chronic lymphocytic leukaemia who have received at least 1 prior therapy,TA561,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
VENETOCLAX,Chronic lymphocytic leukaemia,TA487,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
VENETOCLAX,Chronic lymphocytic leukaemia,TA796,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
VENETOCLAX,Chronic lymphocytic leukaemia,TA487,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
VENETOCLAX,Chronic lymphocytic leukaemia,TA796,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
VENETOCLAX,Chronic lymphocytic leukaemia,TA487,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
VENETOCLAX,Chronic lymphocytic leukaemia,TA796,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
VENETOCLAX,Chronic lymphocytic leukaemia,TA487,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
VENETOCLAX,Chronic lymphocytic leukaemia,TA796,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
VENETOCLAX WITH AZACITIDINE,Untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable,TA765,acute myeloid leukaemia,91861009,"Acute myeloid leukaemia, disease",VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
VENETOCLAX WITH LOW DOSE CYTARABINE,Untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable,TA787,acute myeloid leukaemia,91861009,"Acute myeloid leukaemia, disease",VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|MEDICAL ONCOLOGY
VENETOCLAX WITH OBINUTUZUMAB,Untreated chronic lymphocytic leukaemia,TA663,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
VENETOCLAX WITH OBINUTUZUMAB,Untreated chronic lymphocytic leukaemia,TA663,chronic lymphocytic leukaemia,786855003,Monoclonal B-cell lymphocytosis chronic lymphocytic leukaemia-type,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
VENETOCLAX WITH OBINUTUZUMAB,Untreated chronic lymphocytic leukaemia,TA663,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
VENETOCLAX WITH OBINUTUZUMAB,Untreated chronic lymphocytic leukaemia,TA663,chronic lymphocytic leukaemia,863741000000108,Clinical stage A chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
VENETOCLAX WITH OBINUTUZUMAB,Untreated chronic lymphocytic leukaemia,TA663,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
VENETOCLAX WITH OBINUTUZUMAB,Untreated chronic lymphocytic leukaemia,TA663,chronic lymphocytic leukaemia,863761000000109,Clinical stage B chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
VENETOCLAX WITH OBINUTUZUMAB,Untreated chronic lymphocytic leukaemia,TA663,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
VENETOCLAX WITH OBINUTUZUMAB,Untreated chronic lymphocytic leukaemia,TA663,chronic lymphocytic leukaemia,863781000000100,Clinical stage C chronic lymphocytic leukaemia,VENETOCLAX,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,10335000,Chronic right-sided heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,10633002,Acute congestive heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,36315003,Malignant hypertensive heart disease without congestive heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,48447003,Chronic heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,56675007,Acute heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,77970009,Benign hypertensive heart disease without congestive heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,83105008,Malignant hypertensive heart disease with congestive heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,83291003,Right heart failure due to pulmonary hypertension,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,85232009,Left-sided heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,88805009,Chronic congestive heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,111283005,Chronic left-sided heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,128404006,Right heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,134378009,Congestive heart failure monitoring,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,134440006,Referral to heart failure clinic,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,161505003,History of heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,194779001,Hypertensive heart and renal disease with (congestive) heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,194781004,Hypertensive heart and renal disease with both (congestive) heart failure and renal failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,233924009,Heart failure as a complication of care,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,266308000,Right heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,309634009,History of heart failure in last year,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,314206003,Refractory heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,367363000,Right heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,390868005,Heart failure screen,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,390884006,Heart failure follow-up,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,390885007,Heart failure annual review,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,394887005,Suspected heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,394927007,Heart failure excluded,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,395105005,Heart failure confirmed,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,416683003,Emergency hospital admission for heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,416717003,Seen in heart failure clinic,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,417146007,Referral to heart failure nurse,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,417359009,Seen by community heart failure nurse,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,423475008,Heart failure education,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,424404003,Decompensated chronic heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,426263006,Congestive heart failure due to left ventricular systolic dysfunction,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,426611007,Congestive heart failure due to valvular disease,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,429959009,Family history of heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,441530006,Chronic diastolic heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,446221000,HFpEF - heart failure with preserved ejection fraction,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,473226007,Heart failure medication review,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,703272007,HFrEF - heart failure with reduced ejection fraction,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,703275009,Heart failure with reduced ejection fraction due to cardiomyopathy,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,704095000,Referral to heart failure exercise programme,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,704096004,Referral to heart failure exercise programme not indicated,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,704097008,Referral to heart failure exercise program declined,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,735984001,Heart failure self management plan,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,788950000,HFmEF - heart failure with mid range ejection fraction,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,1296659009,Acute on chronic heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,96311000119109,Exacerbation of congestive heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,143411000000100,QOF (Quality and Outcomes Framework) heart failure quality indicator-related care invitation using preferred method of communication,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,200171000000102,Referred by heart failure nurse specialist,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,200201000000101,Discharge from practice nurse heart failure clinic,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,200361000000106,Did not attend practice nurse heart failure clinic,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,202231000000106,Heart failure review completed,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,203791000000106,Referred to heart failure education group,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,247361000000100,Heart failure 6 month review,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,248571000000104,Did not attend heart failure clinic,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,374231000000104,High risk of heart failure screening invitation,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,521691000000100,Heart failure resolved,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,711461000000104,Heart failure monitoring invitation,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,713791000000101,Heart failure monitoring administration,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,715951000000107,Exception reporting - heart failure quality indicators,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,716621000000101,Heart failure monitoring third letter,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,716971000000109,Heart failure monitoring first letter,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,717191000000108,Heart failure monitoring second letter,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,717481000000104,Excepted from heart failure quality indicators - patient unsuitable,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,717491000000102,Excepted from heart failure quality indicators - informed dissent,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,717501000000108,Heart failure monitoring verbal invitation,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,717531000000102,Heart failure monitoring telephone invitation,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,760361000000100,Fast track heart failure referral for transthoracic two dimensional echocardiogram,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,763641000000102,Referral to heart failure education group declined,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,765661000000102,Discharge from heart failure nurse service,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,781051000000108,Has heart failure management plan,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,789621000000105,Preferred place of care for next exacerbation of heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,810971000000105,Heart failure self-management plan review,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,812001000000102,Heart failure self-management plan agreed,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,813991000000101,Education about deteriorating heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,835981000000108,Rehabilitation for heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,851071000000108,Heart failure initial assessment,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,851521000000102,Heart failure clinical pathway,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,871681000000102,Heart failure monitoring,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,872361000000105,Discussion about heart failure care plan,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,873881000000100,Referral to rapid access heart failure clinic,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,915571000000102,On optimal heart failure therapy,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,961881000000101,Provision of information about heart failure,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,1108711000000108,Excepted from heart failure quality indicators - service unavailable,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERICIGUAT,Chronic heart failure with reduced ejection fraction,TA731,heart failure,1110931000000103,QOF (Quality and Outcomes Framework) heart failure quality indicator-related care invitation,VERICIGUAT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,49436004,Atrial fibrillation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,134377004,Atrial fibrillation monitoring,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,195080001,Atrial fibrillation and flutter,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,233911009,Non-rheumatic atrial fibrillation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,282825002,Intermittent atrial fibrillation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,300996004,Controlled atrial fibrillation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,312442005,History of atrial fibrillation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,440028005,Permanent atrial fibrillation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,440059007,Persistent atrial fibrillation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,449863006,Insertion of pacemaker for control of atrial fibrillation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,699833006,Provision of written information about atrial fibrillation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,706923002,Longstanding persistent atrial fibrillation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,719008003,At increased risk of atrial fibrillation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,1010405004,Paroxysmal AF (atrial fibrillation) with RVR (rapid ventricular response),VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,120041000119109,Atrial fibrillation with rapid ventricular response,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,133111000000106,QOF (Quality and Outcomes Framework) atrial fibrillation quality indicator-related care invitation using preferred method of communication,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,196371000000102,Atrial fibrillation resolved,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,248411000000105,Atrial fibrillation annual review,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,711411000000101,Atrial fibrillation monitoring invitation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,713801000000102,Atrial fibrillation monitoring administration,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,715941000000109,Excepted from atrial fibrillation quality indicators - patient unsuitable,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,716181000000109,Atrial fibrillation monitoring third letter,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,716721000000107,Atrial fibrillation monitoring telephone invitation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,716871000000101,Exception reporting - atrial fibrillation quality indicators,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,716981000000106,Atrial fibrillation monitoring second letter,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,717011000000100,Atrial fibrillation monitoring verbal invite,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,717221000000101,Atrial fibrillation monitoring first letter,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,717381000000109,Excepted from atrial fibrillation quality indicators - informed dissent,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,816401000000105,Atrial fibrillation excluded,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,847611000000104,Atrial fibrillation care pathway,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,1025021000000107,High risk of atrial fibrillation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,1066831000000104,Atrial fibrillation detected,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,1067061000000104,Atrial fibrillation not detected,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VERNAKALANT,Rapid conversion of recent onset atrial fibrillation to sinus rhythm,TA675,atrial fibrillation,1110851000000100,QOF (Quality and Outcomes Framework) atrial fibrillation quality indicator-related care invitation,VERNAKALANT,CARDIOLOGY,CARDIOLOGY
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (adults),TA076,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,6204001,Juvenile myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,16873003,Musicogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,19598007,Generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,36803009,IGE - idiopathic generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,38281008,Self-limited neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,44145005,Benign epilepsy of childhood with centro-temporal spikes,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,50866000,CAE - childhood absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,65120008,Generalised convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,71831005,Secondary generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,75023009,Epilepsy due to and following traumatic brain injury,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,79745005,Sensory-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,84757009,Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,95208000,Photic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,160341008,Family history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,161480008,History of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,162658001,Epilepsy resolved,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,170702005,Epilepsy monitoring,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,170703000,Initial epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,170704006,Follow-up epilepsy assessment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,170706008,Epilepsy associated problems,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,170709001,Epilepsy drug side effect,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,170710006,Epilepsy treatment changed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,170711005,Epilepsy treatment started,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,170712003,Epilepsy treatment stopped,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,192979009,Generalized non-convulsive epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,192990004,Myoclonic epilepsy in infancy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,192999003,Partial epilepsy with impairment of consciousness,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,193000002,Temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,193002005,Psychosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,193007004,Focal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,193008009,Somatosensory epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,193009001,Partial epilepsy with autonomic symptoms,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,193011005,Unilateral epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,193021002,Running epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,193022009,Localization-related(focal)(partial)idiopathic epilepsy and epileptic syndromes with seizures of localized onset,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230381009,Localization-related epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230382002,Benign frontal epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230384001,Benign atypical partial epilepsy in childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230386004,Benign occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230387008,SeLEAS - self-limited epilepsy with autonomic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230388003,Late onset occipital epilepsy of childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230390002,Localisation-related symptomatic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230391003,Amygdalo-hippocampal temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230393000,Lateral temporal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230394006,Frontal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230403005,Parietal lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230404004,Occipital lobe epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230407006,Hemiplegia-hemiconvulsion-epilepsy syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230408001,Localisation-related cryptogenic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230410004,SeLFNE - self-limited familial neonatal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230412007,Myoclonic epilepsy of early childhood,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230413002,JAE - juvenile absence epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230414008,Epilepsy with generalized tonic-clonic seizures alone,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230415009,Cryptogenic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230421008,Epilepsy with myoclonic-atonic seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230422001,Epilepsy with myoclonic absence,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230426003,MERRF - myoclonic epilepsy with ragged red fibers,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230428002,Idiopathic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230430000,Symptomatic myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230435005,Epilepsy undetermined whether focal or generalized,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230438007,Aphasia co-occurrent with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230439004,Epilepsy with continuous spike wave during slow-wave sleep,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230440002,Secondary reading epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230441003,Drug-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230444006,Catamenial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230450001,Eating epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230452009,Toothbrushing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,230454005,Bathing epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,234639001,"Triple X syndrome, epilepsy, and hypogammaglobulinemia",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,243857008,Epilepsy monitoring status,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,267581004,Progressive myoclonic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,278510009,Localisation-related idiopathic epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,307356008,Motor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,307357004,"Jacksonian, focal or motor epilepsy",GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,314827004,Epilepsy control good,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,314828009,Epilepsy control poor,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,352818000,Grand mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,361123003,Psychomotor epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,361268000,Alcohol-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,401062003,Epilepsy medication review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,401178003,Epilepsy care arrangement,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,407616001,Epilepsy severity,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,407623000,Emergency epilepsy treatment since last appointment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,407625007,Suspected epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,407627004,Epilepsy confirmed,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,413101007,Stress-induced epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,414113005,Epilepsy leaflet given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,414860000,No epilepsy drug side effects,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,416090009,Epilepsy monitoring verbal invite,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,417568007,Epilepsy monitoring call,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,429279006,Seen in epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,699688008,Genetic epilepsy with febrile seizures plus,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,719425009,Sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,724992007,Epilepsy co-occurrent and due to dementia,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,771142009,CDFE (cortical dysplasia focal epilepsy) syndrome,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,784372002,Familial mesial temporal lobe epilepsy with febrile seizures,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,1260117009,Combined focal and generalized epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,1260407007,Genetic generalised epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,88491000000102,Epilepsy limits activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,93141000000105,Epilepsy restricts employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,93151000000108,Epilepsy prevents employment,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,93211000000101,Epilepsy does not limit activities,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,93401000000104,DNA (did not attend) epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,108211000000104,Epilepsy impairs education,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,109121000000109,Epilepsy society member,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,116401000119105,Recurrent complex partial epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,202061000000107,Epilepsy monitoring call first letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,202071000000100,Epilepsy monitoring call second letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,202081000000103,Epilepsy monitoring call third letter,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,248371000000106,Epilepsy monitoring telephone invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,509341000000107,Petit-mal epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,526921000000102,Contraceptive advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,526941000000109,Pre-conception advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,526961000000105,Pregnancy advice for patients with epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,527001000000105,Contraceptive advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,527021000000101,Pre-conception advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,527041000000108,Pregnancy advice for patients with epilepsy not indicated,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,527091000000103,Contraceptive advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,527111000000108,Pre-conception advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,527131000000100,Pregnancy advice for patients with epilepsy declined,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,711501000000104,Epilepsy screening invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,715091000000100,Epilepsy screening administration,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,715791000000102,Epilepsy screening second invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,716011000000103,Epilepsy screening first invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,716781000000108,Excepted from epilepsy quality indicators - informed dissent,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,716801000000109,Excepted from epilepsy quality indicators - patient unsuitable,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,716811000000106,Epilepsy screening third invitation,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,717681000000102,Exception reporting - epilepsy quality indicators,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,809381000000103,Referral for epilepsy review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,809551000000103,Referral to epilepsy clinic,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,810161000000101,Epilepsy monitoring in secondary care,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,811411000000104,Under care of epilepsy specialist nurse,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,840261000000103,Epilepsy management plan given,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,850201000000104,Epilepsy annual review,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,865371000000104,No history of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,876461000000101,No FH of epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,892181000000107,Referral to epilepsy service,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,968661000000102,At risk of sudden unexpected death in epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,1025681000000103,Provision of information about SUDEP (sudden unexpected death in epilepsy),GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VIGABATRIN,Epilepsy (children),TA079,epilepsy,2181251000000106,Topiramate Pregnancy Prevention Programme Annual Risk Awareness Form for Epilepsy,GABAPENTIN,NEUROLOGY,NEUROLOGY|PAEDIATRICS
VINFLUNINE,"Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, after failure of a prior platinum containing regimen",TA272,transitional cell carcinoma,53530009,Transitional cell carcinoma in situ,VINFLUNINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
VINFLUNINE,"Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, after failure of a prior platinum containing regimen",TA272,transitional cell carcinoma,255109008,TCC (transitional cell carcinoma) of urinary bladder,VINFLUNINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
VINFLUNINE,"Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, after failure of a prior platinum containing regimen",TA272,transitional cell carcinoma,300988009,Transitional cell carcinoma of ureter,VINFLUNINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
VINFLUNINE,"Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, after failure of a prior platinum containing regimen",TA272,transitional cell carcinoma,408642003,Transitional cell carcinoma of kidney,VINFLUNINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
VINFLUNINE,"Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, after failure of a prior platinum containing regimen",TA272,transitional cell carcinoma,1259423003,Primary transitional cell carcinoma of ureter,VINFLUNINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
VINFLUNINE,"Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, after failure of a prior platinum containing regimen",TA272,transitional cell carcinoma,1263659007,Secondary transitional cell carcinoma of renal pelvis,VINFLUNINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
VINFLUNINE,"Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, after failure of a prior platinum containing regimen",TA272,transitional cell carcinoma,689801000119101,Primary transitional cell carcinoma of lateral wall of urinary bladder,VINFLUNINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
VINFLUNINE,"Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, after failure of a prior platinum containing regimen",TA272,transitional cell carcinoma,754351000000100,Grade 1 (Stage pTa) papillary urothelial/transitional cell carcinoma,VINFLUNINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
VINFLUNINE,"Treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract, after failure of a prior platinum containing regimen",TA272,transitional cell carcinoma,754361000000102,Grade 2 (Stage pTa) papillary urothelial/transitional cell carcinoma,VINFLUNINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|UROLOGY|CLINICAL ONCOLOGY
VINORELBINE (1ST LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,254637007,Non-small cell lung cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
VINORELBINE (1ST LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,723301009,Squamous non-small cell lung cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
VINORELBINE (1ST LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,1259727001,Primary non-small cell lung cancer,DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
VINORELBINE (1ST LINE),Non-small cell lung cancer,TA026,non-small cell lung cancer,1259754003,Primary squamous NSCLC (non-small cell lung cancer),DOCETAXEL,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|THORACIC MEDICINE|CLINICAL ONCOLOGY
VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,134405005,Suspected breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,160287004,FH: Breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,268547008,Screening for breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,429740004,Family history of breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,431330007,Family history of breast cancer 1 gene mutation,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,431331006,Family history of breast cancer 2 gene mutation,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,706970001,TNBC - Triple-negative breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,94361000000105,Breast cancer detected by national screening programme,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,276341000000100,Fast track referral for suspected breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,838351000000107,Education about risk of breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,874291000000100,QCancer breast cancer risk,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE COMBINATION THERAPIES,Breast cancer,TA054,breast cancer,1035841000000108,Lymphoedema following breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,134405005,Suspected breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,160287004,FH: Breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,268547008,Screening for breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,405823003,"Breast cancer 1, early onset gene mutation carrier detection test",VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,429740004,Family history of breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,431330007,Family history of breast cancer 1 gene mutation,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,431331006,Family history of breast cancer 2 gene mutation,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,706970001,TNBC - Triple-negative breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,94361000000105,Breast cancer detected by national screening programme,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,143691000119102,Family history of breast cancer gene mutation in first degree relative,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,276341000000100,Fast track referral for suspected breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,382431000000103,Seen in fast track suspected breast cancer clinic,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,836761000000105,National Cancer Institute breast cancer risk assessment tool,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,838351000000107,Education about risk of breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,874291000000100,QCancer breast cancer risk,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,895171000000104,Meets NICE clinical guideline CG164 familial breast cancer referral criteria for assessment and management in secondary care,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,919701000000100,No FH of breast cancer meeting NICE CG164 referral criteria,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,1034381000000107,Discharge from secondary care breast cancer service,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VINORELBINE MONOTHERAPY,Breast cancer,TA054,breast cancer,1035841000000108,Lymphoedema following breast cancer,VINORELBINE,MEDICAL ONCOLOGY,MEDICAL ONCOLOGY|BREAST SURGERY|CLINICAL ONCOLOGY
VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,43369006,"Basal cell carcinoma, fibroepithelial",VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY
VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,56665009,"Infiltrating basal cell carcinoma, sclerosing",VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY
VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,128636006,"Basal cell carcinoma, nodular",VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY
VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,134152008,Basal cell carcinoma - morpheic,VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY
VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,254710004,Basal cell carcinoma with eccrine differentiation,VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY
VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,300025007,Excision of basal cell carcinoma,VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY
VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,300026008,Cryotherapy of basal cell carcinoma,VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY
VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,302821007,Basal cell carcinoma - sclerosing type,VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY
VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,400071004,"Basal cell carcinoma, micronodular",VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY
VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,402818009,Basal cell carcinoma of nose,VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY
VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,403914000,Multicentric basal cell carcinoma,VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY
VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,428796002,Excision biopsy of basal cell carcinoma,VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY
VISMODEGIB,Basal cell carcinoma,TA489,basal cell carcinoma,716274007,Nodular basal cell carcinoma of skin,VISMODEGIB,DERMATOLOGY,DERMATOLOGY|PLASTIC SURGERY|MEDICAL ONCOLOGY
VORTIOXETINE,Major depressive episodes,TA367,major depressive episodes,191610000,"Recurrent major depressive episodes, mild",VORTIOXETINE,MENTAL HEALTH,MENTAL HEALTH
VORTIOXETINE,Major depressive episodes,TA367,major depressive episodes,191611001,"Recurrent major depressive episodes, moderate",VORTIOXETINE,MENTAL HEALTH,MENTAL HEALTH
VORTIOXETINE,Major depressive episodes,TA367,major depressive episodes,191613003,"Recurrent major depressive episodes, severe, with psychosis",VORTIOXETINE,MENTAL HEALTH,MENTAL HEALTH
VORTIOXETINE,Major depressive episodes,TA367,major depressive episodes,268621008,Recurrent major depressive episodes,VORTIOXETINE,MENTAL HEALTH,MENTAL HEALTH
VORTIOXETINE,Major depressive episodes,TA367,major depressive episodes,755331000000108,"Recurrent major depressive episodes, severe, with psychosis, psychosis in remission",VORTIOXETINE,MENTAL HEALTH,MENTAL HEALTH
VORTIOXETINE,Major depressive episodes,TA367,major depressive episodes,764611000000100,"Recurrent major depressive episodes, severe",VORTIOXETINE,MENTAL HEALTH,MENTAL HEALTH
VORTIOXETINE,Major depressive episodes,TA367,major depressive episodes,764691000000109,"Recurrent major depressive episodes, in partial remission",VORTIOXETINE,MENTAL HEALTH,MENTAL HEALTH
VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,16573007,Wild-type transthyretin cardiac amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY
VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,17602002,Amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY
VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,23132008,Primary amyloidosis of light chain type,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY
VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,42295001,Familial neuropathic amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY
VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,45502001,Cerebrovascular amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY
VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,59017008,Conjunctival amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY
VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,193187004,Polyneuropathy due to amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY
VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,196135008,Pulmonary amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY
VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,197604006,Nephrotic syndrome in amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY
VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,201337008,Amyloidosis of skin,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY
VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,232459006,Laryngeal amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY
VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,234510005,Amyloidosis of spleen,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY
VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,237865009,Primary amyloidosis of light chain type,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY
VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,237868006,Nonneuropathic heredofamilial amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY
VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,237869003,Localised hereditary amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY
VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,237870002,Familial lichen amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY
VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,237875007,Localized non-hereditary amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY
VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,237876008,Arthritis secondary to amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY
VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,237877004,Wild type ATTR amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY
VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,274945004,Amyloid A amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY
VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,281034005,Secondary amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY
VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,398229007,Corino de Andrade paramyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY
VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,718105008,Lichen amyloidosis,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY
VUTRISIRAN,Hereditary transthyretin-related amyloidosis,TA868,amyloidosis,854071000000105,Amyloidosis of intestine,VUTRISIRAN,CLINICAL HAEMATOLOGY,CLINICAL HAEMATOLOGY|CARDIOLOGY|NEPHROLOGY
ZALEPLON,Insomnia,TA077,insomnia,3972004,Idiopathic insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZALEPLON,Insomnia,TA077,insomnia,41975002,Insomnia with sleep apnea,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZALEPLON,Insomnia,TA077,insomnia,162201008,Cannot sleep - insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZALEPLON,Insomnia,TA077,insomnia,162204000,Terminal insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZALEPLON,Insomnia,TA077,insomnia,191994005,Non-organic sleep disorders (& [hypersomnia] or [insomnia]),ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZALEPLON,Insomnia,TA077,insomnia,191997003,Persistent insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZALEPLON,Insomnia,TA077,insomnia,192454004,Nonorganic insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZALEPLON,Insomnia,TA077,insomnia,193462001,Insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZALEPLON,Insomnia,TA077,insomnia,198437004,Menopausal insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZALEPLON,Insomnia,TA077,insomnia,268652009,Transient insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZALEPLON,Insomnia,TA077,insomnia,272025006,Complaining of insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZALEPLON,Insomnia,TA077,insomnia,440313002,Education about stimulus control behaviour in insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZALEPLON,Insomnia,TA077,insomnia,762989006,Insomnia Severity Index score,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZALEPLON,Insomnia,TA077,insomnia,1107191000000102,Referral for dCBT (digital cognitive behaviour therapy) for insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZALEPLON,Insomnia,TA077,insomnia,1109721000000108,Digital CBT (cognitive behavioural therapy) for insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZANAMIVIR,Influenza,TA015,influenza,6142004,Influenza,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,24662006,Influenza caused by Influenza B virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,41269000,Influenzal bronchopneumonia,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,44470000,Haemophilus influenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,46233009,Influenza virus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,51593004,Haemophilus parainfluenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,64917006,Pneumonia due to parainfluenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,70036007,Haemophilus influenzae pneumonia,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,74644004,Influenza with encephalopathy,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,89117003,Parainfluenza virus type 4,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,91428005,Haemophilus influenzae infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,95891005,Influenza-like illness,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,120753009,Influenza A virus antibody,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,120843002,Influenza B virus Ab,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,120975003,Haemophilus influenzae type b antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,127787002,Haemophilus influenzae type b immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,170343007,First Haemophilus influenzae type b vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,170345000,Third Haemophilus influenzae type b vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,171272004,No consent - influenza immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,171282003,Influenza immunization advised at home,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,171290003,Influenza vaccination consent given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,171291004,No consent for Haemophilus influenzae type b immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,185900003,Has influenza vaccination at home,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,185901004,Has influenza vaccination at surgery,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,185902006,Has influenza vaccination at hospital,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,185903001,Needs influenza immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,192721000,Post influenza vaccination encephalitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,194946005,Acute myocarditis - influenzal,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,195726000,Acute parainfluenza virus bronchitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,195878008,Pneumonia and influenza,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,195923003,Influenza with laryngitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,195924009,Influenza with pharyngitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,195929004,Influenza with gastrointestinal tract involvement,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,195931008,Influenza like illness,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,266393000,Influenza-like illness,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,268561003,Influenza immunization advised in surgery,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,275983007,Influenza immunisation advised,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,291749008,Influenza vaccine poisoning,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,293112000,Influenza split virion vaccine adverse reaction,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,293113005,Influenza surface antigen vaccine adverse reaction,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,294647003,Allergy to influenza vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,294648008,Allergy to influenza split virion vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,294649000,Allergy to influenza surface antigen vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,294664000,Haemophilus influenzae type b vaccine allergy,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,308532005,Influenza vaccination status,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,309789002,Encephalitis caused by Influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,315640000,Influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,315641001,Influenza vaccination invitation letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,390796006,Influenza vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,396425006,FLU - Influenza vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,407479009,Influenza A virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,407480007,Influenza B virus(B/Lee/40),ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,407489008,Human parainfluenza virus 1,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,407491000,Parainfluenza virus type 2,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,407493002,Human parainfluenza virus 3,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,407498006,Human parainfluenza viruses,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,407573008,Influenza vaccination not indicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,414496007,Influenza vaccination telephone invite,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,416928007,Has influenza vaccination at work,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,441043003,Influenza A virus subtype H1 present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,441049004,Influenza A virus subtype H3 present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,441343005,Influenza A virus subtype H5 present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,441344004,Human parainfluenza virus present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,441345003,Influenza B virus present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,442438000,Influenza caused by Influenza A virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,442696006,Influenza A (H1N1) swine flu,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,444426005,Swine influenza contact,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,473169009,History of influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,698353005,Requires influenza virus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,709410003,Hib (Haemophilus influenzae type b) infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,711330007,Influenza A virus subtype H1N1 detected,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,711334003,Influenza A virus H1N1 subtype not detected,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,736818002,Influenza vaccination requested,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,737041000,Influenza immunisation telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,787016008,Administration of influenza vaccine via nasal route,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,73701000119109,Vaccination for influenza given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,135221000119101,Influenza A H1N1 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,199331000000106,Did not attend influenza vaccination appointment,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,200481000000107,Influenza vaccination invitation first letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,200491000000109,Influenza vaccination invitation second letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,200501000000103,Influenza vaccination invitation third letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,201391000000106,Booster influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,202301000000106,First pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,202311000000108,Second pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,380271000000101,Consent given for pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,380381000000108,Pandemic influenza vaccination refused,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,380631000000100,Pandemic influenza vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,380801000000105,Pandemic influenza vaccination not indicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,506751000000104,Possible influenza A virus H1N1 subtype,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,516101000000103,No response to influenza vaccination invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,540151000000108,Pneumonia or influenza NOS,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,761311000000109,Influenza vaccination verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,777791000000102,Influenza vaccination invitation first text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,822851000000102,Seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,822931000000100,Seasonal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,822951000000107,Seasonal influenza vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,822971000000103,Seasonal influenza vaccination not indicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,822991000000104,Consent given for seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,844941000000103,Influenza vaccination invitation email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,844961000000102,Influenza vaccination invitation first email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,844981000000106,Influenza vaccination invitation second email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,845001000000101,Influenza vaccination invitation third email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,860151000000103,Influenza vaccination first verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,860171000000107,Influenza vaccination second verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,860211000000105,Influenza vaccination second telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,860291000000101,Influenza vaccination third verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,868241000000109,Administration of intranasal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,868491000000103,No consent for seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,871521000000104,First intranasal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,871541000000106,Second intranasal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,871751000000104,Administration of first intranasal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,871781000000105,Administration of second intranasal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,873681000000101,Provision of information about seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,913961000000102,Education about influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,932221000000103,At risk of influenza related complication,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,935351000000106,Long term indication for seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,955641000000103,Influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,996211000000100,Influenza (A and B) serology,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,996761000000106,Haemophilus influenzae B IgG level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1001341000000106,Influenza A antigen level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1001351000000109,Influenza B antigen level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1005101000000108,Parainfluenza virus antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1005111000000105,Parainfluenza type 3 antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1008771000000107,Haemophilus influenzae B antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1014261000000103,Influenza A antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1014271000000105,Influenza B antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1020381000000100,Parainfluenza virus antigen assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1033051000000101,Influenza due to zoonotic influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1033071000000105,Influenza due to pandemic influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1033091000000109,Influenza due to seasonal influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1095821000000105,Influenza vaccination first telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1095831000000107,Influenza vaccination second telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1095841000000103,Influenza vaccination third telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1239861000000100,Seasonal influenza vaccination given in school,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza,TA015,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,6142004,Influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,24662006,Influenza caused by Influenza B virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,41269000,Influenzal bronchopneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,44470000,Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,46233009,Influenza virus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,51593004,Haemophilus parainfluenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,64917006,Pneumonia due to parainfluenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,70036007,Haemophilus influenzae pneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,74644004,Influenza with encephalopathy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,89117003,Parainfluenza virus type 4,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,91428005,Haemophilus influenzae infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,95891005,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,120753009,Influenza A virus antibody,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,120843002,Influenza B virus Ab,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,120975003,Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,127787002,Haemophilus influenzae type b immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170343007,First Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170345000,Third Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,171272004,No consent - influenza immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,171282003,Influenza immunization advised at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,171290003,Influenza vaccination consent given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,171291004,No consent for Haemophilus influenzae type b immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,185900003,Has influenza vaccination at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,185901004,Has influenza vaccination at surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,185902006,Has influenza vaccination at hospital,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,185903001,Needs influenza immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,192721000,Post influenza vaccination encephalitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,194946005,Acute myocarditis - influenzal,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195726000,Acute parainfluenza virus bronchitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195878008,Pneumonia and influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195923003,Influenza with laryngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195924009,Influenza with pharyngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195929004,Influenza with gastrointestinal tract involvement,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,195931008,Influenza like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,266393000,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,268561003,Influenza immunization advised in surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,275983007,Influenza immunisation advised,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,291749008,Influenza vaccine poisoning,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,293112000,Influenza split virion vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,293113005,Influenza surface antigen vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,294647003,Allergy to influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,294648008,Allergy to influenza split virion vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,294649000,Allergy to influenza surface antigen vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,294664000,Haemophilus influenzae type b vaccine allergy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,308532005,Influenza vaccination status,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,309789002,Encephalitis caused by Influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,315640000,Influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,315641001,Influenza vaccination invitation letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,390796006,Influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,396425006,FLU - Influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407479009,Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407480007,Influenza B virus(B/Lee/40),AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407489008,Human parainfluenza virus 1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407491000,Parainfluenza virus type 2,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407493002,Human parainfluenza virus 3,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407498006,Human parainfluenza viruses,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407573008,Influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,414496007,Influenza vaccination telephone invite,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,416928007,Has influenza vaccination at work,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,441043003,Influenza A virus subtype H1 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,441049004,Influenza A virus subtype H3 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,441343005,Influenza A virus subtype H5 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,441344004,Human parainfluenza virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,441345003,Influenza B virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,442438000,Influenza caused by Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,442696006,Influenza A (H1N1) swine flu,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,444426005,Swine influenza contact,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,473169009,History of influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,698353005,Requires influenza virus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,709410003,Hib (Haemophilus influenzae type b) infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,711330007,Influenza A virus subtype H1N1 detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,711334003,Influenza A virus H1N1 subtype not detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,736818002,Influenza vaccination requested,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,737041000,Influenza immunisation telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,787016008,Administration of influenza vaccine via nasal route,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,73701000119109,Vaccination for influenza given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,135221000119101,Influenza A H1N1 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,199331000000106,Did not attend influenza vaccination appointment,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,200481000000107,Influenza vaccination invitation first letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,200491000000109,Influenza vaccination invitation second letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,200501000000103,Influenza vaccination invitation third letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,201391000000106,Booster influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,202301000000106,First pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,202311000000108,Second pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,380271000000101,Consent given for pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,380381000000108,Pandemic influenza vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,380631000000100,Pandemic influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,380801000000105,Pandemic influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,506751000000104,Possible influenza A virus H1N1 subtype,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,516101000000103,No response to influenza vaccination invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,540151000000108,Pneumonia or influenza NOS,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,761311000000109,Influenza vaccination verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,777791000000102,Influenza vaccination invitation first text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,822851000000102,Seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,822931000000100,Seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,822951000000107,Seasonal influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,822971000000103,Seasonal influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,822991000000104,Consent given for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,844941000000103,Influenza vaccination invitation email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,844961000000102,Influenza vaccination invitation first email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,844981000000106,Influenza vaccination invitation second email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,845001000000101,Influenza vaccination invitation third email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,860151000000103,Influenza vaccination first verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,860171000000107,Influenza vaccination second verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,860211000000105,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,860291000000101,Influenza vaccination third verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,868241000000109,Administration of intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,868491000000103,No consent for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,871521000000104,First intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,871541000000106,Second intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,871751000000104,Administration of first intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,871781000000105,Administration of second intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,873681000000101,Provision of information about seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,913961000000102,Education about influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,932221000000103,At risk of influenza related complication,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,935351000000106,Long term indication for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955641000000103,Influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,996211000000100,Influenza (A and B) serology,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,996761000000106,Haemophilus influenzae B IgG level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1001341000000106,Influenza A antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1001351000000109,Influenza B antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1005101000000108,Parainfluenza virus antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1005111000000105,Parainfluenza type 3 antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1008771000000107,Haemophilus influenzae B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1014261000000103,Influenza A antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1014271000000105,Influenza B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1020381000000100,Parainfluenza virus antigen assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1033051000000101,Influenza due to zoonotic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1033071000000105,Influenza due to pandemic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1033091000000109,Influenza due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1095821000000105,Influenza vaccination first telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1095831000000107,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1095841000000103,Influenza vaccination third telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1239861000000100,Seasonal influenza vaccination given in school,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (post-exposure prophylaxis),TA158,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,6142004,Influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,6142004,Influenza,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,24662006,Influenza caused by Influenza B virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,24662006,Influenza caused by Influenza B virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,41269000,Influenzal bronchopneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,41269000,Influenzal bronchopneumonia,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,44470000,Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,44470000,Haemophilus influenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,46233009,Influenza virus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,46233009,Influenza virus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,51593004,Haemophilus parainfluenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,51593004,Haemophilus parainfluenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,64917006,Pneumonia due to parainfluenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,64917006,Pneumonia due to parainfluenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,70036007,Haemophilus influenzae pneumonia,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,70036007,Haemophilus influenzae pneumonia,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,74644004,Influenza with encephalopathy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,74644004,Influenza with encephalopathy,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,86198006,Administration of vaccine product containing only Influenza virus antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,89117003,Parainfluenza virus type 4,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,89117003,Parainfluenza virus type 4,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,91428005,Haemophilus influenzae infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,91428005,Haemophilus influenzae infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,95891005,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,95891005,Influenza-like illness,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,120753009,Influenza A virus antibody,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,120753009,Influenza A virus antibody,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,120843002,Influenza B virus Ab,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,120843002,Influenza B virus Ab,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,120975003,Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,120975003,Haemophilus influenzae type b antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,127787002,Haemophilus influenzae type b immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,127787002,Haemophilus influenzae type b immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,170343007,First Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,170343007,First Haemophilus influenzae type b vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,170344001,Administration of second dose of Haemophilus influenzae type b vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,170345000,Third Haemophilus influenzae type b vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,170345000,Third Haemophilus influenzae type b vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,170346004,Administration of booster dose of vaccine product containing only Haemophilus influenzae type b antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,170428009,"First Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,170429001,"Second Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,170430006,"Third Haemophilus influenzae type b and diphtheria, tetanus and pertussis vaccine given",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,171272004,No consent - influenza immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,171272004,No consent - influenza immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,171282003,Influenza immunization advised at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,171282003,Influenza immunization advised at home,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,171290003,Influenza vaccination consent given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,171290003,Influenza vaccination consent given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,171291004,No consent for Haemophilus influenzae type b immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,171291004,No consent for Haemophilus influenzae type b immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,185900003,Has influenza vaccination at home,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,185900003,Has influenza vaccination at home,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,185901004,Has influenza vaccination at surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,185901004,Has influenza vaccination at surgery,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,185902006,Has influenza vaccination at hospital,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,185902006,Has influenza vaccination at hospital,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,185903001,Needs influenza immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,185903001,Needs influenza immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,192721000,Post influenza vaccination encephalitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,192721000,Post influenza vaccination encephalitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,194946005,Acute myocarditis - influenzal,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,194946005,Acute myocarditis - influenzal,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,195721005,Acute bronchitis caused by Haemophilus influenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,195726000,Acute parainfluenza virus bronchitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,195726000,Acute parainfluenza virus bronchitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,195878008,Pneumonia and influenza,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,195878008,Pneumonia and influenza,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,195923003,Influenza with laryngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,195923003,Influenza with laryngitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,195924009,Influenza with pharyngitis,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,195924009,Influenza with pharyngitis,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,195929004,Influenza with gastrointestinal tract involvement,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,195929004,Influenza with gastrointestinal tract involvement,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,195931008,Influenza like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,195931008,Influenza like illness,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,234558001,Anti-Haemophilus influenzae type b capsular polysaccharide antibody deficiency,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,266393000,Influenza-like illness,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,266393000,Influenza-like illness,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,268561003,Influenza immunization advised in surgery,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,268561003,Influenza immunization advised in surgery,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,275983007,Influenza immunisation advised,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,275983007,Influenza immunisation advised,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,291749008,Influenza vaccine poisoning,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,291749008,Influenza vaccine poisoning,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,293112000,Influenza split virion vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,293112000,Influenza split virion vaccine adverse reaction,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,293113005,Influenza surface antigen vaccine adverse reaction,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,293113005,Influenza surface antigen vaccine adverse reaction,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,293127000,Adverse reaction to Haemophilus influenzae type b vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,294647003,Allergy to influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,294647003,Allergy to influenza vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,294648008,Allergy to influenza split virion vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,294648008,Allergy to influenza split virion vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,294649000,Allergy to influenza surface antigen vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,294649000,Allergy to influenza surface antigen vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,294664000,Haemophilus influenzae type b vaccine allergy,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,294664000,Haemophilus influenzae type b vaccine allergy,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,308532005,Influenza vaccination status,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,308532005,Influenza vaccination status,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,309789002,Encephalitis caused by Influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,309789002,Encephalitis caused by Influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,310306005,First diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,310307001,Administration of second dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,310308006,Administration of third dose of diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,312870000,Diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,313383003,Fourth diphtheria and Haemophilus influenzae type b and pertussis and poliomyelitis and tetanus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,315640000,Influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,315640000,Influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,315641001,Influenza vaccination invitation letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,315641001,Influenza vaccination invitation letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,390796006,Influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,390796006,Influenza vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,396425006,FLU - Influenza vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,396425006,FLU - Influenza vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,407479009,Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,407479009,Influenza A virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,407480007,Influenza B virus(B/Lee/40),AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,407480007,Influenza B virus(B/Lee/40),ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,407489008,Human parainfluenza virus 1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,407489008,Human parainfluenza virus 1,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,407491000,Parainfluenza virus type 2,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,407491000,Parainfluenza virus type 2,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,407493002,Human parainfluenza virus 3,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,407493002,Human parainfluenza virus 3,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,407498006,Human parainfluenza viruses,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,407498006,Human parainfluenza viruses,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,407573008,Influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,407573008,Influenza vaccination not indicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,407598009,No consent for third Haemophilus influenzae type b vaccine booster,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,413103005,"Did not attend diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,413105003,"Did not attend second diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,413106002,"Did not attend third diphtheria, tetanus and pertussis, Haemophilus influenzae type b and polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,414001002,Diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,414259000,First diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,414496007,Influenza vaccination telephone invite,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,414496007,Influenza vaccination telephone invite,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,415507003,Second diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,415712004,Administration of third dose of diphtheria and Haemophilus influenza type b and five component acellular pertussis and inactivated poliomyelitis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,416928007,Has influenza vaccination at work,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,416928007,Has influenza vaccination at work,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,420113004,Adverse reaction to component of vaccine product containing Influenza virus antigen,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,428975001,Haemophilus influenzae type b and meningitis C immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,441043003,Influenza A virus subtype H1 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,441043003,Influenza A virus subtype H1 present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,441049004,Influenza A virus subtype H3 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,441049004,Influenza A virus subtype H3 present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,441343005,Influenza A virus subtype H5 present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,441343005,Influenza A virus subtype H5 present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,441344004,Human parainfluenza virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,441344004,Human parainfluenza virus present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,441345003,Influenza B virus present,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,441345003,Influenza B virus present,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,442438000,Influenza caused by Influenza A virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,442438000,Influenza caused by Influenza A virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,442696006,Influenza A (H1N1) swine flu,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,442696006,Influenza A (H1N1) swine flu,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,444426005,Swine influenza contact,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,444426005,Swine influenza contact,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,447685007,Severe sepsis with acute organ dysfunction caused by Haemophilus influenzae,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,473169009,History of influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,473169009,History of influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,698353005,Requires influenza virus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,698353005,Requires influenza virus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,698950001,Influenza A virus subtype H1N1 vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,709410003,Hib (Haemophilus influenzae type b) infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,709410003,Hib (Haemophilus influenzae type b) infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,711330007,Influenza A virus subtype H1N1 detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,711330007,Influenza A virus subtype H1N1 detected,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,711334003,Influenza A virus H1N1 subtype not detected,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,711334003,Influenza A virus H1N1 subtype not detected,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,712833000,Second Haemophilus influenzae type b and meningitis C vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,712834006,First Haemophilus influenzae type b and meningitis C immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,719886001,Haemophilus influenzae type b vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,736818002,Influenza vaccination requested,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,736818002,Influenza vaccination requested,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,737041000,Influenza immunisation telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,737041000,Influenza immunisation telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,770608009,Diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,770616000,First diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunisation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,770617009,Second diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus immunization,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,770618004,Administration of third dose of diphtheria and Haemophilus influenzae type b and hepatitis B and pertussis and tetanus vaccine,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,787016008,Administration of influenza vaccine via nasal route,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,787016008,Administration of influenza vaccine via nasal route,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1162640003,Diphtheria and acellular pertussis and Haemophilus influenzae type b and hepatitis B and inactivated poliomyelitis and tetanus vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,61811000000102,Hib (haemophilus influenzae type B) and meningitis C vaccination not done,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,63281000000106,First intranasal seasonal influenza vaccination not done,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,73701000119109,Vaccination for influenza given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,73701000119109,Vaccination for influenza given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,88381000000109,No consent for 2nd HIB (haemophilus influenzae type B) booster,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,135221000119101,Influenza A H1N1 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,135221000119101,Influenza A H1N1 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,166311000000109,Influenza immunisation for those in the 65 years and over and other at risk groups enhanced services administration,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,199331000000106,Did not attend influenza vaccination appointment,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,199331000000106,Did not attend influenza vaccination appointment,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,200481000000107,Influenza vaccination invitation first letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,200481000000107,Influenza vaccination invitation first letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,200491000000109,Influenza vaccination invitation second letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,200491000000109,Influenza vaccination invitation second letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,200501000000103,Influenza vaccination invitation third letter sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,200501000000103,Influenza vaccination invitation third letter sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,201391000000106,Booster influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,201391000000106,Booster influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,202301000000106,First pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,202301000000106,First pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,202311000000108,Second pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,202311000000108,Second pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,299161000000100,Hib/MenC (Haemophilus influenzae type B and meningitis C) vaccination refused,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,310551000000106,"Booster diphtheria tetanus and five component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,335051000000104,"Booster diphtheria, tetanus, acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,379241000000107,"Booster diphtheria tetanus and three component acellular pertussis, haemophilus influenzae type b, inactivated polio vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,380271000000101,Consent given for pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,380271000000101,Consent given for pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,380381000000108,Pandemic influenza vaccination refused,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,380381000000108,Pandemic influenza vaccination refused,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,380631000000100,Pandemic influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,380631000000100,Pandemic influenza vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,380741000000101,First pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,380771000000107,Second pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,380801000000105,Pandemic influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,380801000000105,Pandemic influenza vaccination not indicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,505251000000100,Suspected influenza A virus subtype H1N1 infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,506751000000104,Possible influenza A virus H1N1 subtype,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,506751000000104,Possible influenza A virus H1N1 subtype,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,506901000000103,Close contact with Influenza A virus subtype H1N1,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,511571000000106,"Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, haemophilus influenzae type b vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,511781000000101,Advice given about Influenza A virus subtype H1N1 infection,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,515281000000108,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,515291000000105,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,515301000000109,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,515321000000100,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,515331000000103,CELVAPAN - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,515341000000107,PANDEMRIX - first influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,515351000000105,CELVAPAN - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,515361000000108,PANDEMRIX - second influenza A (H1N1v) 2009 vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,515371000000101,No consent for influenza A (H1N1v) 2009 vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,516101000000103,No response to influenza vaccination invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,516101000000103,No response to influenza vaccination invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,518961000000102,Consent given for influenza A subtype H1N1 vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,519421000000105,Did not attend Hib (haemophilus influenzae type B) and meningitis C vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,540151000000108,Pneumonia or influenza NOS,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,540151000000108,Pneumonia or influenza NOS,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,711301000000108,Influenza vaccination invitation SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,711831000000107,High priority for influenza A subtype H1N1 vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,761311000000109,Influenza vaccination verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,761311000000109,Influenza vaccination verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,764141000000106,Second Haemophilus influenzae type B and Neisseria meningitidis serotype C combination vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,774801000000105,Influenza A virus subtype H1N1 vaccination invitation short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,777791000000102,Influenza vaccination invitation first text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,777791000000102,Influenza vaccination invitation first text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,777831000000109,Influenza vaccination invitation second short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,777851000000102,Influenza vaccination invitation third SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,822851000000102,Seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,822851000000102,Seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,822931000000100,Seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,822931000000100,Seasonal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,822951000000107,Seasonal influenza vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,822951000000107,Seasonal influenza vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,822971000000103,Seasonal influenza vaccination not indicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,822971000000103,Seasonal influenza vaccination not indicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,822991000000104,Consent given for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,822991000000104,Consent given for seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,844941000000103,Influenza vaccination invitation email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,844941000000103,Influenza vaccination invitation email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,844961000000102,Influenza vaccination invitation first email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,844961000000102,Influenza vaccination invitation first email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,844981000000106,Influenza vaccination invitation second email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,844981000000106,Influenza vaccination invitation second email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,845001000000101,Influenza vaccination invitation third email,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,845001000000101,Influenza vaccination invitation third email,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,860151000000103,Influenza vaccination first verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,860151000000103,Influenza vaccination first verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,860171000000107,Influenza vaccination second verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,860171000000107,Influenza vaccination second verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,860211000000105,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,860211000000105,Influenza vaccination second telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,860291000000101,Influenza vaccination third verbal invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,860291000000101,Influenza vaccination third verbal invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,868241000000109,Administration of intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,868241000000109,Administration of intranasal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,868491000000103,No consent for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,868491000000103,No consent for seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,871521000000104,First intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,871521000000104,First intranasal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,871541000000106,Second intranasal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,871541000000106,Second intranasal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,871751000000104,Administration of first intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,871751000000104,Administration of first intranasal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,871781000000105,Administration of second intranasal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,871781000000105,Administration of second intranasal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,873681000000101,Provision of information about seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,873681000000101,Provision of information about seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,882141000000100,Did not attend second intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,882181000000108,Did not attend first intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,884821000000108,Administration of first intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,884841000000101,Administration of second intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,884861000000100,Administration of first intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,884881000000109,Administration of second intranasal seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,884901000000107,First intranasal pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,884921000000103,Second intranasal pandemic influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,885971000000103,First intranasal seasonal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,885991000000104,First intranasal pandemic influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,886011000000103,Second intranasal seasonal influenza vaccination declined,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,886071000000108,Did not attend first intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,886111000000102,Did not attend second intranasal pandemic influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,897331000000109,Hib (haemophilus influenzae type b) and meningitis C vaccination contraindicated,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,898291000000101,"DTaP/IPV/Hib (Diphtheria, tetanus, acellular pertussis, inactivated polio vaccine, Haemophilus influenzae type b) vaccination contraindicated",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,913961000000102,Education about influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,913961000000102,Education about influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,932221000000103,At risk of influenza related complication,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,932221000000103,At risk of influenza related complication,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,935351000000106,Long term indication for seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,935351000000106,Long term indication for seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,945831000000105,First intramuscular seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,955641000000103,Influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,955641000000103,Influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,955651000000100,Seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,955661000000102,First intranasal seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,955671000000109,Second intramuscular seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,955681000000106,Second intranasal seasonal influenza vaccination given by other healthcare provider,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,955691000000108,Seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,955701000000108,Seasonal influenza vaccination given while hospital inpatient,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,985151000000100,Administration of first inactivated seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,985171000000109,Administration of second inactivated seasonal influenza vaccination,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,996211000000100,Influenza (A and B) serology,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,996211000000100,Influenza (A and B) serology,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,996761000000106,Haemophilus influenzae B IgG level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,996761000000106,Haemophilus influenzae B IgG level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1001341000000106,Influenza A antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1001341000000106,Influenza A antigen level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1001351000000109,Influenza B antigen level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1001351000000109,Influenza B antigen level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1005101000000108,Parainfluenza virus antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1005101000000108,Parainfluenza virus antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1005111000000105,Parainfluenza type 3 antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1005111000000105,Parainfluenza type 3 antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1008161000000101,Parainfluenza virus type 3 RNA (ribonucleic acid detection) assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1008171000000108,Parainfluenza virus type 2 RNA (ribonucleic acid) detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1008181000000105,Parainfluenza virus type 1 RNA (ribonucleic acid) detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1008251000000105,Influenza B virus ribonucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1008261000000108,Influenza A virus ribonucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1008771000000107,Haemophilus influenzae B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1008771000000107,Haemophilus influenzae B antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1010721000000107,Avian influenza virus RNA (ribonucleic acid) detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1014261000000103,Influenza A antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1014261000000103,Influenza A antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1014271000000105,Influenza B antibody level,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1014271000000105,Influenza B antibody level,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1020381000000100,Parainfluenza virus antigen assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1020381000000100,Parainfluenza virus antigen assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1029731000000105,Parainfluenza type 1 nucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1031631000000102,Avian influenza virus nucleic acid detection assay,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1033051000000101,Influenza due to zoonotic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1033051000000101,Influenza due to zoonotic influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1033071000000105,Influenza due to pandemic influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1033071000000105,Influenza due to pandemic influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1033091000000109,Influenza due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1033091000000109,Influenza due to seasonal influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1033111000000104,Influenza with pneumonia due to seasonal influenza virus,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1037311000000106,First intranasal seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1037331000000103,Second intranasal seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1037351000000105,First inactivated seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1037371000000101,Second inactivated seasonal influenza vaccination given by pharmacist,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1066171000000108,Seasonal influenza vaccination given by midwife,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1066181000000105,First inactivated seasonal influenza vaccination given by midwife,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1066191000000107,Second inactivated seasonal influenza vaccination given by midwife,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1082431000000104,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1082441000000108,"First diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1082451000000106,"Second diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1082461000000109,"Third diphtheria, tetanus, whooping cough, Hib (Haemophilus influenzae type b), polio and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1082521000000100,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1083421000000107,"Diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination contraindicated",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1086431000000100,"First diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1086441000000109,"Second diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1086451000000107,"Third diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination declined",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1095821000000105,Influenza vaccination first telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1095821000000105,Influenza vaccination first telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1095831000000107,Influenza vaccination second telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1095831000000107,Influenza vaccination second telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1095841000000103,Influenza vaccination third telephone invitation,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1095841000000103,Influenza vaccination third telephone invitation,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1239861000000100,Seasonal influenza vaccination given in school,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1239861000000100,Seasonal influenza vaccination given in school,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1484821000000104,Influenza vaccination invitation short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1484831000000102,Influenza vaccination invitation first SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1484841000000106,Influenza vaccination invitation second SMS (short message service) text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,1484851000000109,Influenza vaccination invitation third short message service text message sent,ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,2427211000000109,"Fourth diphtheria, tetanus and acellular pertussis, inactivated polio, Haemophilus influenzae type b and hepatitis B vaccination",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA058,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",AMANTADINE,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZANAMIVIR,Influenza (treatment),TA168,influenza,3244411000001106,"Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (Sanofi Pasteur)",ZANAMIVIR,INFECTIOUS DISEASES,INFECTIOUS DISEASES|GENERAL MEDICINE
ZOLPIDEM,Insomnia,TA077,insomnia,3972004,Idiopathic insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOLPIDEM,Insomnia,TA077,insomnia,41975002,Insomnia with sleep apnea,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOLPIDEM,Insomnia,TA077,insomnia,162201008,Cannot sleep - insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOLPIDEM,Insomnia,TA077,insomnia,162204000,Terminal insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOLPIDEM,Insomnia,TA077,insomnia,191994005,Non-organic sleep disorders (& [hypersomnia] or [insomnia]),ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOLPIDEM,Insomnia,TA077,insomnia,191997003,Persistent insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOLPIDEM,Insomnia,TA077,insomnia,192454004,Nonorganic insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOLPIDEM,Insomnia,TA077,insomnia,193462001,Insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOLPIDEM,Insomnia,TA077,insomnia,198437004,Menopausal insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOLPIDEM,Insomnia,TA077,insomnia,268652009,Transient insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOLPIDEM,Insomnia,TA077,insomnia,272025006,Complaining of insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOLPIDEM,Insomnia,TA077,insomnia,440313002,Education about stimulus control behaviour in insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOLPIDEM,Insomnia,TA077,insomnia,762989006,Insomnia Severity Index score,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOLPIDEM,Insomnia,TA077,insomnia,1107191000000102,Referral for dCBT (digital cognitive behaviour therapy) for insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOLPIDEM,Insomnia,TA077,insomnia,1109721000000108,Digital CBT (cognitive behavioural therapy) for insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOPICLONE,Insomnia,TA077,insomnia,3972004,Idiopathic insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOPICLONE,Insomnia,TA077,insomnia,41975002,Insomnia with sleep apnea,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOPICLONE,Insomnia,TA077,insomnia,162201008,Cannot sleep - insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOPICLONE,Insomnia,TA077,insomnia,162204000,Terminal insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOPICLONE,Insomnia,TA077,insomnia,191994005,Non-organic sleep disorders (& [hypersomnia] or [insomnia]),ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOPICLONE,Insomnia,TA077,insomnia,191997003,Persistent insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOPICLONE,Insomnia,TA077,insomnia,192454004,Nonorganic insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOPICLONE,Insomnia,TA077,insomnia,193462001,Insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOPICLONE,Insomnia,TA077,insomnia,198437004,Menopausal insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOPICLONE,Insomnia,TA077,insomnia,268652009,Transient insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOPICLONE,Insomnia,TA077,insomnia,272025006,Complaining of insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOPICLONE,Insomnia,TA077,insomnia,440313002,Education about stimulus control behaviour in insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOPICLONE,Insomnia,TA077,insomnia,762989006,Insomnia Severity Index score,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOPICLONE,Insomnia,TA077,insomnia,1107191000000102,Referral for dCBT (digital cognitive behaviour therapy) for insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOPICLONE,Insomnia,TA077,insomnia,1109721000000108,Digital CBT (cognitive behavioural therapy) for insomnia,ZALEPLON,NEUROLOGY,NEUROLOGY|MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,4926007,Schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,12939007,Chronic disorganized schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,31373002,Hebephrenic schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,31658008,Chronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,35252006,Disorganised schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,39610001,Undifferentiated schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,58214004,Schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,63181006,"Paranoid schizophrenia, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,64905009,Paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,79866005,Subchronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,83746006,Chronic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,111482003,Subchronic schizophrenia with acute exacerbations,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,111483008,"Schizophrenia, catatonic, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,111484002,Undifferentiated schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,160328009,Family history of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,161103001,Schizophrenia association member,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,161468000,History of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,191527001,Simple schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,191531007,Acute exacerbation of chronic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,191548004,Chronic catatonic schizophrenia with acute exacerbation,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,191554003,Acute exacerbation of subchronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,191555002,Acute exacerbation of chronic paranoid schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,191559008,Latent schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,191565008,Latent schizophrenia in remission,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,191567000,Schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,191570001,Chronic schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,191572009,Acute exacerbation of chronic schizoaffective schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,191574005,"Schizophrenia, schizoaffective, in remission",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,247804008,Prodromal schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,274952002,Borderline schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,278853003,Acute schizophrenia-like psychotic disorder,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,444180005,History of schizophrenia in child of subject,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,712824002,Acute polymorphic psychotic disorder without symptoms of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,712850003,Acute polymorphic psychotic disorder with symptoms of schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,200951000000109,"Psychosis, schizophrenia and bipolar affective disorder resolved",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,285521000000103,Schizophrenia resolved,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,417601000000102,"[X]Schizophrenia, schizotypal and delusional disorders",AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,443791000000100,[X]Pseudopsychopathic schizophrenia,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,1062101000000104,Schizophrenia TOM (Therapy Outcome Measure) activity score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,1062121000000108,Schizophrenia TOM (Therapy Outcome Measure) impairment score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,1062131000000105,Schizophrenia TOM (Therapy Outcome Measure) participation score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
ZOTEPINE,Schizophrenia,TA043,schizophrenia,1062141000000101,Schizophrenia TOM (Therapy Outcome Measure) wellbeing score,AMISULPRIDE,MENTAL HEALTH,MENTAL HEALTH
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190388001,Type 2 diabetes mellitus with multiple complications,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190389009,Type 2 diabetes mellitus with ulcer,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,199230006,Pre-existing type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,237599002,Insulin treated type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,237627000,Pregnancy and type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421631007,Gangrene due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,422014003,Disorder due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,443694000,Uncontrolled type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,703138006,Type 2 diabetes mellitus in remission,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,46635009,T1DM - type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,290002008,Unstable type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,420825003,Gangrene due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,420868002,Disorder due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,429094000,Dietary advice for type 1 diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,444073006,Uncontrolled type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,703137001,Type 1 diabetes mellitus in remission,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,2751001,Fibrocalculous pancreatic diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,4855003,Retinopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,5368009,Drug-induced diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,5969009,Diabetes mellitus associated with genetic syndrome,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,6143009,Diabetes mellitus education,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,8801005,Secondary diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,9414007,Latent diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,11530004,Brittle diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,11687002,GDM - gestational diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,15771004,Diabetes insipidus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,21584002,Maternal diabetes syndrome,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,25093002,Disorder of eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,25412000,Microaneurysm of retinal artery due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,26298008,Ketoacidotic coma due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,39058009,Lumbosacral radiculoplexus neuropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,43959009,Cataract of eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,44054006,T2DM - diabetes mellitus type 2,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,48951005,Bullous disease due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,49455004,Polyneuropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,49817004,Neonatal diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,50620007,Autonomic neuropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,51002006,Pancreatogenic type 3c diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,59276001,Proliferative retinopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,61165007,Adiuretin-resistant diabetes insipidus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,62260007,Pretibial pigmental patches due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,70694009,"DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, deafness) syndrome",AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,73211009,Diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,74627003,Complication due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,75524006,MRDM - malnutrition related diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,111552007,Diabetes mellitus without complication,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,111556005,Ketoacidosis without coma due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,126534007,Mixed sensorimotor polyneuropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,127012008,Lipodystrophic diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,127013003,Disorder of kidney due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,160274005,No family history of diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,160303001,Family history of diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,160402005,Family history: Diabetes in pregnancy,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,161445009,History of diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,161641009,At increased risk of diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,166928007,Glucose tolerance test indicates diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,170745003,Diet controlled diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,170752001,Has seen dietitian - diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,170753006,Understands diet - diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,170766006,Loss of hypoglycaemic warning due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,170774007,Diabetes: practice program,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,170775008,Diabetes: shared care program,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,171183004,Diabetes mellitus screening,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,185753003,Attends diabetes monitoring,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,185754009,Diabetes monitoring declined,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,185755005,Diabetes monitoring default,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,185756006,Diabetes monitoring first letter,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,185757002,Diabetes monitoring second letter,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,185758007,Diabetes monitoring third letter,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,185759004,Diabetes monitoring verbal invite,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,185760009,Diabetes monitoring telephone invite,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,185761008,Diabetes monitoring deleted,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190323008,Non-insulin dependent diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190349003,Diabetes mellitus with neuropathy,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190354007,Diabetes with gangrene,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190368000,Insulin-dependent diabetes mellitus with ulcer,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190372001,Insulin-dependent diabetes maturity onset,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190406000,Ketoacidosis due to malnutrition related diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190411003,Multiple complications due to malnutrition related diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190412005,Malnutrition-related diabetes mellitus without complications,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190416008,Steroid-induced diabetes mellitus without complication,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190447002,Steroid-induced diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,190484000,Diabetes insipidus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,193141005,Mononeuritis multiplex due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,193183000,Acute painful neuropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,193184006,Chronic painful neuropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,193185007,Asymptomatic neuropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,193349004,Preproliferative retinopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,193350004,Advanced maculopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,193489006,Iritis due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,197605007,Nephrotic syndrome due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,199223000,"Diabetes mellitus during pregnancy, childbirth and the puerperium",AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,199225007,Diabetes mellitus during pregnancy - baby delivered,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,199226008,Diabetes mellitus in the puerperium - baby delivered during current episode of care,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,199227004,Diabetes mellitus during pregnancy - baby not yet delivered,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,200687002,Cellulitis of foot due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,201250006,Ischemic ulcer of foot due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,201251005,Neuropathic ulcer of foot due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,201723002,Cheiroarthropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,201724008,Neuropathic arthropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,230572002,Neuropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,230574001,Acute painful polyneuropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,230575000,Chronic painful polyneuropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,230577008,Mononeuropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,230579006,Thoracic radiculopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,232020009,Disorder of macula due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,232021008,Proliferative retinopathy with optic disc neovascularization due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,232022001,Proliferative retinopathy with neovascularisation elsewhere than the optic disc due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,232023006,Traction detachment of retina due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,236499007,Microalbuminuric nephropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,236500003,Proteinuric nephropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,237601000,Secondary endocrine diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,237604008,MODY2 (maturity onset diabetes of the young type 2),AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,237606005,Insulin receptor defect with insulin-resistant diabetes mellitus and acanthosis nigricans,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,237618001,Congenital insulin-dependent diabetes mellitus with fatal secretory diarrhea,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,237619009,Maternally-inherited diabetes and hearing loss,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,237620003,Abnormal metabolic state due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,237621004,Severe hyperglycemia due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,237632004,Hypoglycemic event due to diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,237633009,Hypoglycaemia due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,237635002,Nocturnal hypoglycemia due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,238981002,Disorder of soft tissue due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,238982009,Dermopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,238983004,Thick skin syndrome due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,267471001,Diabetes + eye manifestation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,268519009,Diabetes mellitus uncontrolled,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,270445003,Diabetes monitoring check done,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,273411009,Diabetes clinic satisfaction questionnaire,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,273412002,Diabetes treatment satisfaction questionnaire,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,273413007,Diabetes wellbeing questionnaire,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,284350006,Diabetes mellitus diet education,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,303059007,Postpancreatectomy diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,304752002,Perceived control of insulin-dependent diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,308505000,Diabetes monitoring call,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,309417009,Diabetes dietitian,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,309426007,Glomerulopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,309593006,Education score - diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,309596003,Retinal abnormality - non-diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,309598002,Foot abnormality - non-diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,309635005,History of admission in last year for diabetes foot problem,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,310425007,Diabetes monitoring invitation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,310505005,Hyperosmolar non-ketotic state due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,311782002,Advanced retinal disease due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,312856000,Referral to diabetes nurse,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,312888008,Attending diabetes clinic,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,312903003,Mild nonproliferative retinopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,312904009,Moderate nonproliferative retinopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,312905005,Severe nonproliferative retinopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,312909004,Proliferative retinopathy with iris neovascularisation due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,312910009,Vitreous hemorrhage due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,312912001,Macular oedema due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,313435000,Insulin-dependent diabetes without complication,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,313436004,Type II diabetes mellitus without complication,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,314010006,Diffuse exudative maculopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,314011005,Focal exudative maculopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,314014002,Ischemic maculopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,314015001,Mixed maculopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,314537004,Optic papillopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,314771006,Insulin dependent diabetes mellitus with hypoglycemic coma,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,315051004,Diabetes resolved,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,315216001,Diabetes mellitus excluded,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,361216007,Femoral mononeuropathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,371087003,Ulcer of foot due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,385805005,Health education - diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,390834004,Nonproliferative retinopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,394725008,Diabetes medication review,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,395123002,Urine screening test for diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,398140007,Post hypoglycaemic hyperglycaemia due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,399868002,Intraretinal microvascular anomaly due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,399871005,Visually threatening retinopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,405749004,Newly diagnosed diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,407569005,Patient on maximal tolerated therapy for diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,408290003,Diabetes key contact,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,408392008,Under care of diabetes specialist nurse,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,408540003,Diabetes mellitus induced by non-steroid drugs,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,413180006,Pan retinal photocoagulation for diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,413597006,Attended diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,414229005,Family/carer attended diabetes structured education program,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,414230000,Family/carer referral to diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,415269004,Referral to diabetes preconception counselling clinic,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,415270003,Referral to diabetes structured education program,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,415744000,Transition of diabetes care options discussed,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,416554009,Seen in community diabetes specialist clinic,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,416855002,Family history of diabetes mellitus in first degree relative,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,417467000,Discharged from care of diabetes specialist nurse,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,419100001,Infection of foot due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,420422005,Ketoacidosis due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,420756003,Cataract of eye due to diabetes mellitus type 2,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421895002,Peripheral vascular disorder due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,421920002,Cataract of eye due to diabetes mellitus type 1,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,422088007,Disorder of nervous system due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,422126006,Hyperosmolar coma due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,422183001,Skin ulcer due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,422275004,Gangrene due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,426875007,Latent autoimmune diabetes mellitus in adult,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,428274007,Dietary advice for type II diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,430678008,Family history of diabetes mellitus type 1,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,430679000,Family history of diabetes mellitus type 2,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,439051004,Dietary advice for gestational diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,441656006,Hyperglycaemic crisis due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,444094009,History of diabetes mellitus in child of subject,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,472969004,H/O diabetes mellitus type 2,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,472970003,H/O diabetes mellitus type 1,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,472971004,Past pregnancy history of gestational diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,473127005,Suspected diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,609561005,MODY - maturity onset diabetes of young,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,609572000,HNF1B (HNF1 homeobox B) monogenic diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,698610002,Education about self management of diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,699826006,Lifestyle education regarding risk of diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,700414001,Education about diabetes and driving,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,703040004,Agreeing on diabetes care plan,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,703136005,Diabetes mellitus in remission,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,704408003,Invitation for diabetes screening,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,705072004,Diabetes monitoring invitation by short message service text messaging,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,714628002,Prediabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,715159005,Referral to diabetes service,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,715759002,Provision of written information about diabetes and hypertension,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,715879000,Provision of written information about diabetes and high cholesterol,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,719943000,Provision of written information about diabetes and high haemoglobin A1c level,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,720504004,Not suitable for Diabetes Education and Self Management for Ongoing and Newly Diagnosed program,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,720685006,Seen by diabetes specialist nurse,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,720724003,Has diabetes identity card,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,724136006,Mastopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,735199000,History of diabetes related lower limb amputation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,735985000,Diabetes self management plan,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,736284000,Diabetes clinical management plan,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,762291006,Syndrome of infant of mother with gestational diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,762489000,Acute complication due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,763117005,FINDRISC (Finnish Diabetes Risk Score) score,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,763782001,Provision of patient held diabetes record declined,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,765147009,Diabetes Treatment Satisfaction Questionnaire status version score,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,768794008,Cataract of bilateral eyes due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,769182000,Preproliferative retinopathy of left eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,769218003,Macular oedema of left eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,769222008,Clinically significant macular edema of left eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,769244003,Disorder of right macula due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,769245002,Disorder of left macula due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,770096002,Erectile dysfunction due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,816177009,Nonproliferative retinopathy of left eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,816178004,Nonproliferative retinopathy of right eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,816961009,Stable treated proliferative retinopathy of right eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,816962002,Stable treated proliferative retinopathy of left eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,860709007,No disorder of macula of left eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,860710002,No maculopathy of right eye due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,860712005,Disorder of macula of both eyes due to diabetes mellitus present,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,878859007,Self management of diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,890171006,KPD - ketosis-prone diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,897238003,Diabetes management using closed-loop delivery system,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1196922005,Neovascular glaucoma due to type II diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1196923000,Neovascular glaucoma due to type I diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1258872006,Family referred to diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1258873001,Caregiver referred to diabetes structured education program,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1268646002,Gestational diabetes mellitus screening,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1296758008,Diabetes insipidus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1306699009,Stable treated proliferative retinopathy due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,701000119103,Mixed hyperlipidaemia due to type II diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,24451000000107,Diabetes: shared care in pregnancy - diabetologist and obstetrician,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,40801000119106,Gestational diabetes mellitus complicating pregnancy,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,113131000000107,Informed consent for diabetes national audit,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,113141000000103,Informed dissent for diabetes national audit,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,143401000000102,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation using preferred method of communication,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,143911000000105,Registration for access to online diabetes self-management application,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,143941000000106,Declined to register for access to online diabetes self-management application,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,199481000000100,Diabetes monitoring lower risk albumin excretion,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,199491000000103,Diabetes monitoring higher risk albumin excretion,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,276651000000107,Attended DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,279291000000109,Diabetes type 1 review,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,279321000000104,Diabetes type II review,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,279521000000108,Referral to community diabetes specialist nurse,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,300641000000105,Seen by general practitioner with special interest in diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306401000000106,Attended XPERT (expert patient education versus routine treatment) diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306441000000109,Attended DAFNE (dose adjustment for normal eating) diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306471000000103,DAFNE (dose adjustment for normal eating) diabetes structured education programme completed,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306501000000105,DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme completed,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306531000000104,XPERT (expert patient education versus routine treatment) diabetes structured education programme completed,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306591000000103,Diabetes structured education programme declined,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306701000000102,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306741000000104,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) diabetes structured programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306771000000105,Referral to XPERT (expert patient education versus routine treatment) diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306861000000107,Did not attend diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306931000000106,Did not complete diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306961000000101,Did not complete DAFNE (dose adjustment for normal eating) diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,306991000000107,Did not complete DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,307021000000105,Did not complete XPERT diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,307141000000102,Did not attend DAFNE (dose adjustment for normal eating) diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,307171000000108,Did not attend DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,307201000000109,Did not attend XPERT (expert patient education versus routine treatment) diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,334711000000100,Referral to diabetes special interest general practitioner,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,335621000000101,Maternally inherited diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,344061000000104,Referral to children's diabetes nurse specialist,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,368711000119106,Mild nonproliferative retinopathy due to secondary diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,385041000000108,Diabetes mellitus with multiple complications,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,385051000000106,Pre-existing diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,494961000000102,Discharged from diabetes shared care programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,512561000000108,Unsuitable for diabetes year of care programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,512581000000104,Declined consent for diabetes year of care programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,532411000000102,"Diabetes mellitus, adult onset, with no mention of complication",AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,658011000000104,Diabetes mellitus with other specified manifestation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,658061000000102,Diabetes mellitus NOS with other specified manifestation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,713671000000109,Diabetes monitoring administration,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,713691000000108,Diabetes clinic administration,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,715111000000105,Diabetes screening administration,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,716031000000106,Excepted from diabetes quality indicators - informed dissent,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,716911000000104,Exception reporting - diabetes quality indicators,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,717421000000100,Excepted from diabetes quality indicators - patient unsuitable,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,750721000000102,Excepted from diabetes quality indicators: service unavailable,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,754461000000105,Referral to type I diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,755491000000100,Diabetes structured education programme completed,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,762811000000109,DNA (did not attend) diabetes foot screening,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,764921000000102,Gestational diabetes information leaflet given,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,771571000000102,H/O: secondary diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,781161000000107,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme declined,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,787061000000100,Diabetes care plan declined,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,810961000000103,Diabetes self-management plan review,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,811391000000104,Referral to community diabetes service,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,811981000000102,Diabetes self-management plan agreed,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,816711000000104,Gestational diabetes mellitus annual review,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,819301000000105,Diabetes monitoring injection site check declined,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,819331000000104,Diabetes monitoring injection site not checked,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,828901000000109,Endocrinology and diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,829521000000104,Provision of diabetes clinical summary,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,837491000000107,High risk of diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,838731000000104,Referral to community diabetes specialist nurse declined,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,841221000000102,Referral to community diabetes clinic,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,850581000000106,High risk of diabetes mellitus annual review,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,851501000000106,Diabetes clinical pathway,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,851991000000108,Diabetes quality of life questionnaire score,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,857921000000103,Provision of written information about diabetes and driving,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,858301000000107,Pre-diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,860981000000106,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme declined,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,863501000000102,QDiabetes risk calculator,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,863521000000106,QDiabetes risk calculator score,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,867891000000101,Erectile dysfunction due to diabetes mellitus,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,876381000000100,Conversion to insulin by diabetes specialist nurse,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,885931000000100,Diabetes structured education programme not available,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,887861000000105,Diabetes Year of Care annual review,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,909421000000102,DDS2 (Diabetes Distress Scale 2) score,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,909441000000109,DDS17 - Diabetes Distress Scale 17,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,910931000000101,DDS17 (Diabetes Distress Scale 17) score,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,923461000000103,Lifestyle education for diabetes,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,927821000000100,Discharge from secondary care diabetes service,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,956781000000107,Joint consultation with practice nurse and community diabetes specialist nurse,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,956921000000109,Joint consultation with General Practitioner and community diabetes specialist nurse,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,961931000000109,Diabetes education care plan,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,977201000000107,Recommendation to self-refer for diabetes structured education,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1019431000000105,HbA1c level (Diabetes Control and Complications Trial aligned),AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1019551000000104,HbA1 level (Diabetes Control and Complications Trial aligned),AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1024551000000109,Under care of hospital-based diabetes specialist nurse,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1024571000000100,Under care of community-based diabetes specialist nurse,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1024941000000100,NHS Diabetes Prevention Programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1025211000000108,NHS Diabetes Prevention Programme not completed,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1025251000000107,NHS Diabetes Prevention Programme completed,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1025271000000103,NHS Diabetes Prevention Programme started,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1025301000000100,Referral to NHS Diabetes Prevention Programme declined,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1025321000000109,Referral to NHS Diabetes Prevention Programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1025601000000108,Leicester Diabetes Risk Score,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1054221000000100,Seen in hospital diabetes antenatal clinic,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1065461000000102,Type II diabetes mellitus risk assessment invitation first letter,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1065491000000108,Type II diabetes mellitus risk assessment verbal invitation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1065501000000102,Type II diabetes mellitus risk assessment telephone invitation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1066911000000100,Diabetes monitoring SMS (short message service) text message first invitation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1066921000000106,Diabetes monitoring SMS (short message service) text message second invitation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1066931000000108,Diabetes monitoring SMS (short message service) text message third invitation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1083111000000108,Diabetes monitoring invitation email,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1084661000000103,Diabetes UK Diabetes Risk Score,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1087971000000105,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) score",AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1089101000000109,UKPDS (United Kingdom Prospective Diabetes Study) risk engine score,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1090701000000104,NHS Diabetes Prevention Programme invitation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1092721000000109,Signposting to Diabetes UK,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1092731000000106,Signposting to Diabetes UK Learning Zone,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1097131000000105,Remote diabetes structured education and support programme commenced,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1097141000000101,Remote diabetes structured education and support programme completed,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1098011000000102,Did not commence remote structured diabetes education and support programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1103691000000102,Diabetes structured education programme offered,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1108731000000100,Referral to online diabetes structured education programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1108741000000109,Referral to HeLP-Diabetes (Healthy Living for People with Diabetes) online self-management programme,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1110921000000100,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,1362341000000103,Diabetes care plan,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
AFLIBERCEPT,Diabetic macular oedema,TA346,diabetes,12275391000119108,Diabetes screening declined,AFLIBERCEPT,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190388001,Type 2 diabetes mellitus with multiple complications,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190389009,Type 2 diabetes mellitus with ulcer,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,199230006,Pre-existing type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,237599002,Insulin treated type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,237627000,Pregnancy and type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421631007,Gangrene due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,422014003,Disorder due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,443694000,Uncontrolled type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,703138006,Type 2 diabetes mellitus in remission,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,46635009,T1DM - type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,290002008,Unstable type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,420825003,Gangrene due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,420868002,Disorder due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,429094000,Dietary advice for type 1 diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,444073006,Uncontrolled type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,703137001,Type 1 diabetes mellitus in remission,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,2751001,Fibrocalculous pancreatic diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,4855003,Retinopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,5368009,Drug-induced diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,5969009,Diabetes mellitus associated with genetic syndrome,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,6143009,Diabetes mellitus education,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,8801005,Secondary diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,9414007,Latent diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,11530004,Brittle diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,11687002,GDM - gestational diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,15771004,Diabetes insipidus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,21584002,Maternal diabetes syndrome,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,25093002,Disorder of eye due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,25412000,Microaneurysm of retinal artery due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,26298008,Ketoacidotic coma due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,39058009,Lumbosacral radiculoplexus neuropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,43959009,Cataract of eye due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,44054006,T2DM - diabetes mellitus type 2,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,48951005,Bullous disease due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,49455004,Polyneuropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,49817004,Neonatal diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,50620007,Autonomic neuropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,51002006,Pancreatogenic type 3c diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,59276001,Proliferative retinopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,61165007,Adiuretin-resistant diabetes insipidus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,62260007,Pretibial pigmental patches due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,70694009,"DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, deafness) syndrome",BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,73211009,Diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,74627003,Complication due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,75524006,MRDM - malnutrition related diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,111552007,Diabetes mellitus without complication,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,111556005,Ketoacidosis without coma due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,126534007,Mixed sensorimotor polyneuropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,127012008,Lipodystrophic diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,127013003,Disorder of kidney due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,160274005,No family history of diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,160303001,Family history of diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,160402005,Family history: Diabetes in pregnancy,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,161445009,History of diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,161641009,At increased risk of diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,166928007,Glucose tolerance test indicates diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,170745003,Diet controlled diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,170752001,Has seen dietitian - diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,170753006,Understands diet - diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,170766006,Loss of hypoglycaemic warning due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,170774007,Diabetes: practice program,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,170775008,Diabetes: shared care program,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,171183004,Diabetes mellitus screening,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,185753003,Attends diabetes monitoring,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,185754009,Diabetes monitoring declined,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,185755005,Diabetes monitoring default,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,185756006,Diabetes monitoring first letter,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,185757002,Diabetes monitoring second letter,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,185758007,Diabetes monitoring third letter,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,185759004,Diabetes monitoring verbal invite,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,185760009,Diabetes monitoring telephone invite,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,185761008,Diabetes monitoring deleted,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190323008,Non-insulin dependent diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190349003,Diabetes mellitus with neuropathy,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190354007,Diabetes with gangrene,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190368000,Insulin-dependent diabetes mellitus with ulcer,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190372001,Insulin-dependent diabetes maturity onset,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190406000,Ketoacidosis due to malnutrition related diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190411003,Multiple complications due to malnutrition related diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190412005,Malnutrition-related diabetes mellitus without complications,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190416008,Steroid-induced diabetes mellitus without complication,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190447002,Steroid-induced diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,190484000,Diabetes insipidus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,193141005,Mononeuritis multiplex due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,193183000,Acute painful neuropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,193184006,Chronic painful neuropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,193185007,Asymptomatic neuropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,193349004,Preproliferative retinopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,193350004,Advanced maculopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,193489006,Iritis due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,197605007,Nephrotic syndrome due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,199223000,"Diabetes mellitus during pregnancy, childbirth and the puerperium",BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,199225007,Diabetes mellitus during pregnancy - baby delivered,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,199226008,Diabetes mellitus in the puerperium - baby delivered during current episode of care,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,199227004,Diabetes mellitus during pregnancy - baby not yet delivered,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,200687002,Cellulitis of foot due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,201250006,Ischemic ulcer of foot due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,201251005,Neuropathic ulcer of foot due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,201723002,Cheiroarthropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,201724008,Neuropathic arthropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,230572002,Neuropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,230574001,Acute painful polyneuropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,230575000,Chronic painful polyneuropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,230577008,Mononeuropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,230579006,Thoracic radiculopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,232020009,Disorder of macula due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,232021008,Proliferative retinopathy with optic disc neovascularization due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,232022001,Proliferative retinopathy with neovascularisation elsewhere than the optic disc due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,232023006,Traction detachment of retina due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,236499007,Microalbuminuric nephropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,236500003,Proteinuric nephropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,237601000,Secondary endocrine diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,237604008,MODY2 (maturity onset diabetes of the young type 2),BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,237606005,Insulin receptor defect with insulin-resistant diabetes mellitus and acanthosis nigricans,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,237618001,Congenital insulin-dependent diabetes mellitus with fatal secretory diarrhea,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,237619009,Maternally-inherited diabetes and hearing loss,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,237620003,Abnormal metabolic state due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,237621004,Severe hyperglycemia due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,237632004,Hypoglycemic event due to diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,237633009,Hypoglycaemia due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,237635002,Nocturnal hypoglycemia due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,238981002,Disorder of soft tissue due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,238982009,Dermopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,238983004,Thick skin syndrome due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,267471001,Diabetes + eye manifestation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,268519009,Diabetes mellitus uncontrolled,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,270445003,Diabetes monitoring check done,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,273411009,Diabetes clinic satisfaction questionnaire,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,273412002,Diabetes treatment satisfaction questionnaire,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,273413007,Diabetes wellbeing questionnaire,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,284350006,Diabetes mellitus diet education,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,303059007,Postpancreatectomy diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,304752002,Perceived control of insulin-dependent diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,308505000,Diabetes monitoring call,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,309417009,Diabetes dietitian,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,309426007,Glomerulopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,309593006,Education score - diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,309596003,Retinal abnormality - non-diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,309598002,Foot abnormality - non-diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,309635005,History of admission in last year for diabetes foot problem,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,310425007,Diabetes monitoring invitation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,310505005,Hyperosmolar non-ketotic state due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,311782002,Advanced retinal disease due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,312856000,Referral to diabetes nurse,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,312888008,Attending diabetes clinic,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,312903003,Mild nonproliferative retinopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,312904009,Moderate nonproliferative retinopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,312905005,Severe nonproliferative retinopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,312909004,Proliferative retinopathy with iris neovascularisation due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,312910009,Vitreous hemorrhage due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,312912001,Macular oedema due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,313435000,Insulin-dependent diabetes without complication,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,313436004,Type II diabetes mellitus without complication,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,314010006,Diffuse exudative maculopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,314011005,Focal exudative maculopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,314014002,Ischemic maculopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,314015001,Mixed maculopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,314537004,Optic papillopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,314771006,Insulin dependent diabetes mellitus with hypoglycemic coma,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,315051004,Diabetes resolved,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,315216001,Diabetes mellitus excluded,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,361216007,Femoral mononeuropathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,371087003,Ulcer of foot due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,385805005,Health education - diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,390834004,Nonproliferative retinopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,394725008,Diabetes medication review,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,395123002,Urine screening test for diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,398140007,Post hypoglycaemic hyperglycaemia due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,399868002,Intraretinal microvascular anomaly due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,399871005,Visually threatening retinopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,405749004,Newly diagnosed diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,407569005,Patient on maximal tolerated therapy for diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,408290003,Diabetes key contact,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,408392008,Under care of diabetes specialist nurse,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,408540003,Diabetes mellitus induced by non-steroid drugs,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,413180006,Pan retinal photocoagulation for diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,413597006,Attended diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,414229005,Family/carer attended diabetes structured education program,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,414230000,Family/carer referral to diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,415269004,Referral to diabetes preconception counselling clinic,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,415270003,Referral to diabetes structured education program,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,415744000,Transition of diabetes care options discussed,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,416554009,Seen in community diabetes specialist clinic,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,416855002,Family history of diabetes mellitus in first degree relative,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,417467000,Discharged from care of diabetes specialist nurse,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,419100001,Infection of foot due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,420422005,Ketoacidosis due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,420756003,Cataract of eye due to diabetes mellitus type 2,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421895002,Peripheral vascular disorder due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,421920002,Cataract of eye due to diabetes mellitus type 1,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,422088007,Disorder of nervous system due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,422126006,Hyperosmolar coma due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,422183001,Skin ulcer due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,422275004,Gangrene due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,426875007,Latent autoimmune diabetes mellitus in adult,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,428274007,Dietary advice for type II diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,430678008,Family history of diabetes mellitus type 1,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,430679000,Family history of diabetes mellitus type 2,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,439051004,Dietary advice for gestational diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,441656006,Hyperglycaemic crisis due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,444094009,History of diabetes mellitus in child of subject,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,472969004,H/O diabetes mellitus type 2,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,472970003,H/O diabetes mellitus type 1,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,472971004,Past pregnancy history of gestational diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,473127005,Suspected diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,609561005,MODY - maturity onset diabetes of young,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,609572000,HNF1B (HNF1 homeobox B) monogenic diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,698610002,Education about self management of diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,699826006,Lifestyle education regarding risk of diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,700414001,Education about diabetes and driving,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,703040004,Agreeing on diabetes care plan,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,703136005,Diabetes mellitus in remission,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,704408003,Invitation for diabetes screening,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,705072004,Diabetes monitoring invitation by short message service text messaging,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,714628002,Prediabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,715159005,Referral to diabetes service,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,715759002,Provision of written information about diabetes and hypertension,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,715879000,Provision of written information about diabetes and high cholesterol,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,719943000,Provision of written information about diabetes and high haemoglobin A1c level,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,720504004,Not suitable for Diabetes Education and Self Management for Ongoing and Newly Diagnosed program,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,720685006,Seen by diabetes specialist nurse,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,720724003,Has diabetes identity card,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,724136006,Mastopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,735199000,History of diabetes related lower limb amputation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,735985000,Diabetes self management plan,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,736284000,Diabetes clinical management plan,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,762291006,Syndrome of infant of mother with gestational diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,762489000,Acute complication due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,763117005,FINDRISC (Finnish Diabetes Risk Score) score,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,763782001,Provision of patient held diabetes record declined,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,765147009,Diabetes Treatment Satisfaction Questionnaire status version score,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,768794008,Cataract of bilateral eyes due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,769182000,Preproliferative retinopathy of left eye due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,769218003,Macular oedema of left eye due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,769222008,Clinically significant macular edema of left eye due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,769244003,Disorder of right macula due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,769245002,Disorder of left macula due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,770096002,Erectile dysfunction due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,816177009,Nonproliferative retinopathy of left eye due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,816178004,Nonproliferative retinopathy of right eye due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,816961009,Stable treated proliferative retinopathy of right eye due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,816962002,Stable treated proliferative retinopathy of left eye due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,860709007,No disorder of macula of left eye due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,860710002,No maculopathy of right eye due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,860712005,Disorder of macula of both eyes due to diabetes mellitus present,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,878859007,Self management of diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,890171006,KPD - ketosis-prone diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,897238003,Diabetes management using closed-loop delivery system,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1196922005,Neovascular glaucoma due to type II diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1196923000,Neovascular glaucoma due to type I diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1258872006,Family referred to diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1258873001,Caregiver referred to diabetes structured education program,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1268646002,Gestational diabetes mellitus screening,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1296758008,Diabetes insipidus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1306699009,Stable treated proliferative retinopathy due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,701000119103,Mixed hyperlipidaemia due to type II diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,24451000000107,Diabetes: shared care in pregnancy - diabetologist and obstetrician,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,40801000119106,Gestational diabetes mellitus complicating pregnancy,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,113131000000107,Informed consent for diabetes national audit,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,113141000000103,Informed dissent for diabetes national audit,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,143401000000102,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation using preferred method of communication,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,143911000000105,Registration for access to online diabetes self-management application,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,143941000000106,Declined to register for access to online diabetes self-management application,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,199481000000100,Diabetes monitoring lower risk albumin excretion,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,199491000000103,Diabetes monitoring higher risk albumin excretion,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,276651000000107,Attended DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,279291000000109,Diabetes type 1 review,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,279321000000104,Diabetes type II review,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,279521000000108,Referral to community diabetes specialist nurse,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,300641000000105,Seen by general practitioner with special interest in diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306401000000106,Attended XPERT (expert patient education versus routine treatment) diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306441000000109,Attended DAFNE (dose adjustment for normal eating) diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306471000000103,DAFNE (dose adjustment for normal eating) diabetes structured education programme completed,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306501000000105,DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme completed,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306531000000104,XPERT (expert patient education versus routine treatment) diabetes structured education programme completed,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306591000000103,Diabetes structured education programme declined,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306701000000102,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306741000000104,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) diabetes structured programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306771000000105,Referral to XPERT (expert patient education versus routine treatment) diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306861000000107,Did not attend diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306931000000106,Did not complete diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306961000000101,Did not complete DAFNE (dose adjustment for normal eating) diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,306991000000107,Did not complete DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,307021000000105,Did not complete XPERT diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,307141000000102,Did not attend DAFNE (dose adjustment for normal eating) diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,307171000000108,Did not attend DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,307201000000109,Did not attend XPERT (expert patient education versus routine treatment) diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,334711000000100,Referral to diabetes special interest general practitioner,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,335621000000101,Maternally inherited diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,344061000000104,Referral to children's diabetes nurse specialist,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,368711000119106,Mild nonproliferative retinopathy due to secondary diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,385041000000108,Diabetes mellitus with multiple complications,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,385051000000106,Pre-existing diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,494961000000102,Discharged from diabetes shared care programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,512561000000108,Unsuitable for diabetes year of care programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,512581000000104,Declined consent for diabetes year of care programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,532411000000102,"Diabetes mellitus, adult onset, with no mention of complication",BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,658011000000104,Diabetes mellitus with other specified manifestation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,658061000000102,Diabetes mellitus NOS with other specified manifestation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,713671000000109,Diabetes monitoring administration,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,713691000000108,Diabetes clinic administration,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,715111000000105,Diabetes screening administration,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,716031000000106,Excepted from diabetes quality indicators - informed dissent,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,716911000000104,Exception reporting - diabetes quality indicators,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,717421000000100,Excepted from diabetes quality indicators - patient unsuitable,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,750721000000102,Excepted from diabetes quality indicators: service unavailable,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,754461000000105,Referral to type I diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,755491000000100,Diabetes structured education programme completed,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,762811000000109,DNA (did not attend) diabetes foot screening,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,764921000000102,Gestational diabetes information leaflet given,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,771571000000102,H/O: secondary diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,781161000000107,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme declined,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,787061000000100,Diabetes care plan declined,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,810961000000103,Diabetes self-management plan review,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,811391000000104,Referral to community diabetes service,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,811981000000102,Diabetes self-management plan agreed,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,816711000000104,Gestational diabetes mellitus annual review,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,819301000000105,Diabetes monitoring injection site check declined,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,819331000000104,Diabetes monitoring injection site not checked,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,828901000000109,Endocrinology and diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,829521000000104,Provision of diabetes clinical summary,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,837491000000107,High risk of diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,838731000000104,Referral to community diabetes specialist nurse declined,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,841221000000102,Referral to community diabetes clinic,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,850581000000106,High risk of diabetes mellitus annual review,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,851501000000106,Diabetes clinical pathway,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,851991000000108,Diabetes quality of life questionnaire score,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,857921000000103,Provision of written information about diabetes and driving,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,858301000000107,Pre-diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,860981000000106,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme declined,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,863501000000102,QDiabetes risk calculator,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,863521000000106,QDiabetes risk calculator score,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,867891000000101,Erectile dysfunction due to diabetes mellitus,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,876381000000100,Conversion to insulin by diabetes specialist nurse,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,885931000000100,Diabetes structured education programme not available,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,887861000000105,Diabetes Year of Care annual review,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,909421000000102,DDS2 (Diabetes Distress Scale 2) score,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,909441000000109,DDS17 - Diabetes Distress Scale 17,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,910931000000101,DDS17 (Diabetes Distress Scale 17) score,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,923461000000103,Lifestyle education for diabetes,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,927821000000100,Discharge from secondary care diabetes service,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,956781000000107,Joint consultation with practice nurse and community diabetes specialist nurse,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,956921000000109,Joint consultation with General Practitioner and community diabetes specialist nurse,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,961931000000109,Diabetes education care plan,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,977201000000107,Recommendation to self-refer for diabetes structured education,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1019431000000105,HbA1c level (Diabetes Control and Complications Trial aligned),BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1019551000000104,HbA1 level (Diabetes Control and Complications Trial aligned),BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1024551000000109,Under care of hospital-based diabetes specialist nurse,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1024571000000100,Under care of community-based diabetes specialist nurse,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1024941000000100,NHS Diabetes Prevention Programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1025211000000108,NHS Diabetes Prevention Programme not completed,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1025251000000107,NHS Diabetes Prevention Programme completed,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1025271000000103,NHS Diabetes Prevention Programme started,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1025301000000100,Referral to NHS Diabetes Prevention Programme declined,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1025321000000109,Referral to NHS Diabetes Prevention Programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1025601000000108,Leicester Diabetes Risk Score,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1054221000000100,Seen in hospital diabetes antenatal clinic,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1065461000000102,Type II diabetes mellitus risk assessment invitation first letter,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1065491000000108,Type II diabetes mellitus risk assessment verbal invitation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1065501000000102,Type II diabetes mellitus risk assessment telephone invitation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1066911000000100,Diabetes monitoring SMS (short message service) text message first invitation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1066921000000106,Diabetes monitoring SMS (short message service) text message second invitation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1066931000000108,Diabetes monitoring SMS (short message service) text message third invitation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1083111000000108,Diabetes monitoring invitation email,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1084661000000103,Diabetes UK Diabetes Risk Score,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1087971000000105,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) score",BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1089101000000109,UKPDS (United Kingdom Prospective Diabetes Study) risk engine score,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1090701000000104,NHS Diabetes Prevention Programme invitation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1092721000000109,Signposting to Diabetes UK,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1092731000000106,Signposting to Diabetes UK Learning Zone,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1097131000000105,Remote diabetes structured education and support programme commenced,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1097141000000101,Remote diabetes structured education and support programme completed,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1098011000000102,Did not commence remote structured diabetes education and support programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1103691000000102,Diabetes structured education programme offered,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1108731000000100,Referral to online diabetes structured education programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1108741000000109,Referral to HeLP-Diabetes (Healthy Living for People with Diabetes) online self-management programme,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1110921000000100,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,1362341000000103,Diabetes care plan,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
BROLUCIZUMAB,Diabetic macular oedema,TA820,diabetes,12275391000119108,Diabetes screening declined,BROLUCIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190388001,Type 2 diabetes mellitus with multiple complications,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190389009,Type 2 diabetes mellitus with ulcer,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,199230006,Pre-existing type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,237599002,Insulin treated type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,237627000,Pregnancy and type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421631007,Gangrene due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,422014003,Disorder due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,443694000,Uncontrolled type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,703138006,Type 2 diabetes mellitus in remission,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,46635009,T1DM - type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,290002008,Unstable type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,420825003,Gangrene due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,420868002,Disorder due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,429094000,Dietary advice for type 1 diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,444073006,Uncontrolled type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,703137001,Type 1 diabetes mellitus in remission,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,2751001,Fibrocalculous pancreatic diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,4855003,Retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,5368009,Drug-induced diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,5969009,Diabetes mellitus associated with genetic syndrome,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,6143009,Diabetes mellitus education,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,8801005,Secondary diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,9414007,Latent diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,11530004,Brittle diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,11687002,GDM - gestational diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,15771004,Diabetes insipidus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,21584002,Maternal diabetes syndrome,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,25093002,Disorder of eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,25412000,Microaneurysm of retinal artery due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,26298008,Ketoacidotic coma due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,39058009,Lumbosacral radiculoplexus neuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,43959009,Cataract of eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,44054006,T2DM - diabetes mellitus type 2,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,48951005,Bullous disease due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,49455004,Polyneuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,49817004,Neonatal diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,50620007,Autonomic neuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,51002006,Pancreatogenic type 3c diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,59276001,Proliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,61165007,Adiuretin-resistant diabetes insipidus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,62260007,Pretibial pigmental patches due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,70694009,"DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, deafness) syndrome",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,73211009,Diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,74627003,Complication due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,75524006,MRDM - malnutrition related diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,111552007,Diabetes mellitus without complication,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,111556005,Ketoacidosis without coma due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,126534007,Mixed sensorimotor polyneuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,127012008,Lipodystrophic diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,127013003,Disorder of kidney due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,160274005,No family history of diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,160303001,Family history of diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,160402005,Family history: Diabetes in pregnancy,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,161445009,History of diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,161641009,At increased risk of diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,166928007,Glucose tolerance test indicates diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,170745003,Diet controlled diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,170752001,Has seen dietitian - diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,170753006,Understands diet - diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,170766006,Loss of hypoglycaemic warning due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,170774007,Diabetes: practice program,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,170775008,Diabetes: shared care program,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,171183004,Diabetes mellitus screening,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,185753003,Attends diabetes monitoring,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,185754009,Diabetes monitoring declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,185755005,Diabetes monitoring default,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,185756006,Diabetes monitoring first letter,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,185757002,Diabetes monitoring second letter,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,185758007,Diabetes monitoring third letter,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,185759004,Diabetes monitoring verbal invite,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,185760009,Diabetes monitoring telephone invite,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,185761008,Diabetes monitoring deleted,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190323008,Non-insulin dependent diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190349003,Diabetes mellitus with neuropathy,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190354007,Diabetes with gangrene,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190368000,Insulin-dependent diabetes mellitus with ulcer,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190372001,Insulin-dependent diabetes maturity onset,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190406000,Ketoacidosis due to malnutrition related diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190411003,Multiple complications due to malnutrition related diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190412005,Malnutrition-related diabetes mellitus without complications,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190416008,Steroid-induced diabetes mellitus without complication,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190447002,Steroid-induced diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,190484000,Diabetes insipidus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,193141005,Mononeuritis multiplex due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,193183000,Acute painful neuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,193184006,Chronic painful neuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,193185007,Asymptomatic neuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,193349004,Preproliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,193350004,Advanced maculopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,193489006,Iritis due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,197605007,Nephrotic syndrome due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,199223000,"Diabetes mellitus during pregnancy, childbirth and the puerperium",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,199225007,Diabetes mellitus during pregnancy - baby delivered,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,199226008,Diabetes mellitus in the puerperium - baby delivered during current episode of care,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,199227004,Diabetes mellitus during pregnancy - baby not yet delivered,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,200687002,Cellulitis of foot due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,201250006,Ischemic ulcer of foot due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,201251005,Neuropathic ulcer of foot due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,201723002,Cheiroarthropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,201724008,Neuropathic arthropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,230572002,Neuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,230574001,Acute painful polyneuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,230575000,Chronic painful polyneuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,230577008,Mononeuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,230579006,Thoracic radiculopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,232020009,Disorder of macula due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,232021008,Proliferative retinopathy with optic disc neovascularization due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,232022001,Proliferative retinopathy with neovascularisation elsewhere than the optic disc due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,232023006,Traction detachment of retina due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,236499007,Microalbuminuric nephropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,236500003,Proteinuric nephropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,237601000,Secondary endocrine diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,237604008,MODY2 (maturity onset diabetes of the young type 2),DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,237606005,Insulin receptor defect with insulin-resistant diabetes mellitus and acanthosis nigricans,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,237618001,Congenital insulin-dependent diabetes mellitus with fatal secretory diarrhea,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,237619009,Maternally-inherited diabetes and hearing loss,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,237620003,Abnormal metabolic state due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,237621004,Severe hyperglycemia due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,237632004,Hypoglycemic event due to diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,237633009,Hypoglycaemia due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,237635002,Nocturnal hypoglycemia due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,238981002,Disorder of soft tissue due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,238982009,Dermopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,238983004,Thick skin syndrome due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,267471001,Diabetes + eye manifestation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,268519009,Diabetes mellitus uncontrolled,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,270445003,Diabetes monitoring check done,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,273411009,Diabetes clinic satisfaction questionnaire,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,273412002,Diabetes treatment satisfaction questionnaire,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,273413007,Diabetes wellbeing questionnaire,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,284350006,Diabetes mellitus diet education,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,303059007,Postpancreatectomy diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,304752002,Perceived control of insulin-dependent diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,308505000,Diabetes monitoring call,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,309417009,Diabetes dietitian,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,309426007,Glomerulopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,309593006,Education score - diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,309596003,Retinal abnormality - non-diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,309598002,Foot abnormality - non-diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,309635005,History of admission in last year for diabetes foot problem,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,310425007,Diabetes monitoring invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,310505005,Hyperosmolar non-ketotic state due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,311782002,Advanced retinal disease due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,312856000,Referral to diabetes nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,312888008,Attending diabetes clinic,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,312903003,Mild nonproliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,312904009,Moderate nonproliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,312905005,Severe nonproliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,312909004,Proliferative retinopathy with iris neovascularisation due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,312910009,Vitreous hemorrhage due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,312912001,Macular oedema due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,313435000,Insulin-dependent diabetes without complication,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,313436004,Type II diabetes mellitus without complication,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,314010006,Diffuse exudative maculopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,314011005,Focal exudative maculopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,314014002,Ischemic maculopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,314015001,Mixed maculopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,314537004,Optic papillopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,314771006,Insulin dependent diabetes mellitus with hypoglycemic coma,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,315051004,Diabetes resolved,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,315216001,Diabetes mellitus excluded,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,361216007,Femoral mononeuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,371087003,Ulcer of foot due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,385805005,Health education - diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,390834004,Nonproliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,394725008,Diabetes medication review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,395123002,Urine screening test for diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,398140007,Post hypoglycaemic hyperglycaemia due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,399868002,Intraretinal microvascular anomaly due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,399871005,Visually threatening retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,405749004,Newly diagnosed diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,407569005,Patient on maximal tolerated therapy for diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,408290003,Diabetes key contact,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,408392008,Under care of diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,408540003,Diabetes mellitus induced by non-steroid drugs,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,413180006,Pan retinal photocoagulation for diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,413597006,Attended diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,414229005,Family/carer attended diabetes structured education program,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,414230000,Family/carer referral to diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,415269004,Referral to diabetes preconception counselling clinic,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,415270003,Referral to diabetes structured education program,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,415744000,Transition of diabetes care options discussed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,416554009,Seen in community diabetes specialist clinic,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,416855002,Family history of diabetes mellitus in first degree relative,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,417467000,Discharged from care of diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,419100001,Infection of foot due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,420422005,Ketoacidosis due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,420756003,Cataract of eye due to diabetes mellitus type 2,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421895002,Peripheral vascular disorder due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,421920002,Cataract of eye due to diabetes mellitus type 1,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,422088007,Disorder of nervous system due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,422126006,Hyperosmolar coma due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,422183001,Skin ulcer due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,422275004,Gangrene due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,426875007,Latent autoimmune diabetes mellitus in adult,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,428274007,Dietary advice for type II diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,430678008,Family history of diabetes mellitus type 1,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,430679000,Family history of diabetes mellitus type 2,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,439051004,Dietary advice for gestational diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,441656006,Hyperglycaemic crisis due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,444094009,History of diabetes mellitus in child of subject,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,472969004,H/O diabetes mellitus type 2,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,472970003,H/O diabetes mellitus type 1,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,472971004,Past pregnancy history of gestational diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,473127005,Suspected diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,609561005,MODY - maturity onset diabetes of young,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,609572000,HNF1B (HNF1 homeobox B) monogenic diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,698610002,Education about self management of diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,699826006,Lifestyle education regarding risk of diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,700414001,Education about diabetes and driving,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,703040004,Agreeing on diabetes care plan,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,703136005,Diabetes mellitus in remission,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,704408003,Invitation for diabetes screening,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,705072004,Diabetes monitoring invitation by short message service text messaging,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,714628002,Prediabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,715159005,Referral to diabetes service,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,715759002,Provision of written information about diabetes and hypertension,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,715879000,Provision of written information about diabetes and high cholesterol,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,719943000,Provision of written information about diabetes and high haemoglobin A1c level,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,720504004,Not suitable for Diabetes Education and Self Management for Ongoing and Newly Diagnosed program,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,720685006,Seen by diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,720724003,Has diabetes identity card,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,724136006,Mastopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,735199000,History of diabetes related lower limb amputation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,735985000,Diabetes self management plan,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,736284000,Diabetes clinical management plan,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,762291006,Syndrome of infant of mother with gestational diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,762489000,Acute complication due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,763117005,FINDRISC (Finnish Diabetes Risk Score) score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,763782001,Provision of patient held diabetes record declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,765147009,Diabetes Treatment Satisfaction Questionnaire status version score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,768794008,Cataract of bilateral eyes due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,769182000,Preproliferative retinopathy of left eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,769218003,Macular oedema of left eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,769222008,Clinically significant macular edema of left eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,769244003,Disorder of right macula due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,769245002,Disorder of left macula due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,770096002,Erectile dysfunction due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,816177009,Nonproliferative retinopathy of left eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,816178004,Nonproliferative retinopathy of right eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,816961009,Stable treated proliferative retinopathy of right eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,816962002,Stable treated proliferative retinopathy of left eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,860709007,No disorder of macula of left eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,860710002,No maculopathy of right eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,860712005,Disorder of macula of both eyes due to diabetes mellitus present,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,878859007,Self management of diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,890171006,KPD - ketosis-prone diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,897238003,Diabetes management using closed-loop delivery system,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1196922005,Neovascular glaucoma due to type II diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1196923000,Neovascular glaucoma due to type I diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1258872006,Family referred to diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1258873001,Caregiver referred to diabetes structured education program,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1268646002,Gestational diabetes mellitus screening,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1296758008,Diabetes insipidus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1306699009,Stable treated proliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,701000119103,Mixed hyperlipidaemia due to type II diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,24451000000107,Diabetes: shared care in pregnancy - diabetologist and obstetrician,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,40801000119106,Gestational diabetes mellitus complicating pregnancy,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,113131000000107,Informed consent for diabetes national audit,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,113141000000103,Informed dissent for diabetes national audit,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,143401000000102,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation using preferred method of communication,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,143911000000105,Registration for access to online diabetes self-management application,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,143941000000106,Declined to register for access to online diabetes self-management application,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,199481000000100,Diabetes monitoring lower risk albumin excretion,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,199491000000103,Diabetes monitoring higher risk albumin excretion,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,276651000000107,Attended DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,279291000000109,Diabetes type 1 review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,279321000000104,Diabetes type II review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,279521000000108,Referral to community diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,300641000000105,Seen by general practitioner with special interest in diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306401000000106,Attended XPERT (expert patient education versus routine treatment) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306441000000109,Attended DAFNE (dose adjustment for normal eating) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306471000000103,DAFNE (dose adjustment for normal eating) diabetes structured education programme completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306501000000105,DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306531000000104,XPERT (expert patient education versus routine treatment) diabetes structured education programme completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306591000000103,Diabetes structured education programme declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306701000000102,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306741000000104,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) diabetes structured programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306771000000105,Referral to XPERT (expert patient education versus routine treatment) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306861000000107,Did not attend diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306931000000106,Did not complete diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306961000000101,Did not complete DAFNE (dose adjustment for normal eating) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,306991000000107,Did not complete DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,307021000000105,Did not complete XPERT diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,307141000000102,Did not attend DAFNE (dose adjustment for normal eating) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,307171000000108,Did not attend DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,307201000000109,Did not attend XPERT (expert patient education versus routine treatment) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,334711000000100,Referral to diabetes special interest general practitioner,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,335621000000101,Maternally inherited diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,344061000000104,Referral to children's diabetes nurse specialist,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,368711000119106,Mild nonproliferative retinopathy due to secondary diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,385041000000108,Diabetes mellitus with multiple complications,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,385051000000106,Pre-existing diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,494961000000102,Discharged from diabetes shared care programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,512561000000108,Unsuitable for diabetes year of care programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,512581000000104,Declined consent for diabetes year of care programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,532411000000102,"Diabetes mellitus, adult onset, with no mention of complication",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,658011000000104,Diabetes mellitus with other specified manifestation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,658061000000102,Diabetes mellitus NOS with other specified manifestation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,713671000000109,Diabetes monitoring administration,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,713691000000108,Diabetes clinic administration,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,715111000000105,Diabetes screening administration,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,716031000000106,Excepted from diabetes quality indicators - informed dissent,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,716911000000104,Exception reporting - diabetes quality indicators,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,717421000000100,Excepted from diabetes quality indicators - patient unsuitable,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,750721000000102,Excepted from diabetes quality indicators: service unavailable,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,754461000000105,Referral to type I diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,755491000000100,Diabetes structured education programme completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,762811000000109,DNA (did not attend) diabetes foot screening,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,764921000000102,Gestational diabetes information leaflet given,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,771571000000102,H/O: secondary diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,781161000000107,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,787061000000100,Diabetes care plan declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,810961000000103,Diabetes self-management plan review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,811391000000104,Referral to community diabetes service,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,811981000000102,Diabetes self-management plan agreed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,816711000000104,Gestational diabetes mellitus annual review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,819301000000105,Diabetes monitoring injection site check declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,819331000000104,Diabetes monitoring injection site not checked,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,828901000000109,Endocrinology and diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,829521000000104,Provision of diabetes clinical summary,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,837491000000107,High risk of diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,838731000000104,Referral to community diabetes specialist nurse declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,841221000000102,Referral to community diabetes clinic,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,850581000000106,High risk of diabetes mellitus annual review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,851501000000106,Diabetes clinical pathway,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,851991000000108,Diabetes quality of life questionnaire score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,857921000000103,Provision of written information about diabetes and driving,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,858301000000107,Pre-diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,860981000000106,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,863501000000102,QDiabetes risk calculator,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,863521000000106,QDiabetes risk calculator score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,867891000000101,Erectile dysfunction due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,876381000000100,Conversion to insulin by diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,885931000000100,Diabetes structured education programme not available,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,887861000000105,Diabetes Year of Care annual review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,909421000000102,DDS2 (Diabetes Distress Scale 2) score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,909441000000109,DDS17 - Diabetes Distress Scale 17,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,910931000000101,DDS17 (Diabetes Distress Scale 17) score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,923461000000103,Lifestyle education for diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,927821000000100,Discharge from secondary care diabetes service,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,956781000000107,Joint consultation with practice nurse and community diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,956921000000109,Joint consultation with General Practitioner and community diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,961931000000109,Diabetes education care plan,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,977201000000107,Recommendation to self-refer for diabetes structured education,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1019431000000105,HbA1c level (Diabetes Control and Complications Trial aligned),DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1019551000000104,HbA1 level (Diabetes Control and Complications Trial aligned),DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1024551000000109,Under care of hospital-based diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1024571000000100,Under care of community-based diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1024941000000100,NHS Diabetes Prevention Programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1025211000000108,NHS Diabetes Prevention Programme not completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1025251000000107,NHS Diabetes Prevention Programme completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1025271000000103,NHS Diabetes Prevention Programme started,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1025301000000100,Referral to NHS Diabetes Prevention Programme declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1025321000000109,Referral to NHS Diabetes Prevention Programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1025601000000108,Leicester Diabetes Risk Score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1054221000000100,Seen in hospital diabetes antenatal clinic,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1065461000000102,Type II diabetes mellitus risk assessment invitation first letter,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1065491000000108,Type II diabetes mellitus risk assessment verbal invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1065501000000102,Type II diabetes mellitus risk assessment telephone invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1066911000000100,Diabetes monitoring SMS (short message service) text message first invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1066921000000106,Diabetes monitoring SMS (short message service) text message second invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1066931000000108,Diabetes monitoring SMS (short message service) text message third invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1083111000000108,Diabetes monitoring invitation email,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1084661000000103,Diabetes UK Diabetes Risk Score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1087971000000105,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) score",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1089101000000109,UKPDS (United Kingdom Prospective Diabetes Study) risk engine score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1090701000000104,NHS Diabetes Prevention Programme invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1092721000000109,Signposting to Diabetes UK,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1092731000000106,Signposting to Diabetes UK Learning Zone,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1097131000000105,Remote diabetes structured education and support programme commenced,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1097141000000101,Remote diabetes structured education and support programme completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1098011000000102,Did not commence remote structured diabetes education and support programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1103691000000102,Diabetes structured education programme offered,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1108731000000100,Referral to online diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1108741000000109,Referral to HeLP-Diabetes (Healthy Living for People with Diabetes) online self-management programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1110921000000100,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,1362341000000103,Diabetes care plan,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA349,diabetes,12275391000119108,Diabetes screening declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190388001,Type 2 diabetes mellitus with multiple complications,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190389009,Type 2 diabetes mellitus with ulcer,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,199230006,Pre-existing type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,237599002,Insulin treated type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,237627000,Pregnancy and type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421631007,Gangrene due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,422014003,Disorder due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,443694000,Uncontrolled type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,703138006,Type 2 diabetes mellitus in remission,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,46635009,T1DM - type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,290002008,Unstable type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,420825003,Gangrene due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,420868002,Disorder due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,429094000,Dietary advice for type 1 diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,444073006,Uncontrolled type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,703137001,Type 1 diabetes mellitus in remission,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,2751001,Fibrocalculous pancreatic diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,4855003,Retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,5368009,Drug-induced diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,5969009,Diabetes mellitus associated with genetic syndrome,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,6143009,Diabetes mellitus education,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,8801005,Secondary diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,9414007,Latent diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,11530004,Brittle diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,11687002,GDM - gestational diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,15771004,Diabetes insipidus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,21584002,Maternal diabetes syndrome,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,25093002,Disorder of eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,25412000,Microaneurysm of retinal artery due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,26298008,Ketoacidotic coma due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,39058009,Lumbosacral radiculoplexus neuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,43959009,Cataract of eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,44054006,T2DM - diabetes mellitus type 2,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,48951005,Bullous disease due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,49455004,Polyneuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,49817004,Neonatal diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,50620007,Autonomic neuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,51002006,Pancreatogenic type 3c diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,59276001,Proliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,61165007,Adiuretin-resistant diabetes insipidus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,62260007,Pretibial pigmental patches due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,70694009,"DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, deafness) syndrome",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,73211009,Diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,74627003,Complication due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,75524006,MRDM - malnutrition related diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,111552007,Diabetes mellitus without complication,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,111556005,Ketoacidosis without coma due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,126534007,Mixed sensorimotor polyneuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,127012008,Lipodystrophic diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,127013003,Disorder of kidney due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,160274005,No family history of diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,160303001,Family history of diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,160402005,Family history: Diabetes in pregnancy,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,161445009,History of diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,161641009,At increased risk of diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,166928007,Glucose tolerance test indicates diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,170745003,Diet controlled diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,170752001,Has seen dietitian - diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,170753006,Understands diet - diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,170766006,Loss of hypoglycaemic warning due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,170774007,Diabetes: practice program,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,170775008,Diabetes: shared care program,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,171183004,Diabetes mellitus screening,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,185753003,Attends diabetes monitoring,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,185754009,Diabetes monitoring declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,185755005,Diabetes monitoring default,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,185756006,Diabetes monitoring first letter,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,185757002,Diabetes monitoring second letter,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,185758007,Diabetes monitoring third letter,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,185759004,Diabetes monitoring verbal invite,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,185760009,Diabetes monitoring telephone invite,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,185761008,Diabetes monitoring deleted,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190323008,Non-insulin dependent diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190349003,Diabetes mellitus with neuropathy,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190354007,Diabetes with gangrene,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190368000,Insulin-dependent diabetes mellitus with ulcer,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190372001,Insulin-dependent diabetes maturity onset,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190406000,Ketoacidosis due to malnutrition related diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190411003,Multiple complications due to malnutrition related diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190412005,Malnutrition-related diabetes mellitus without complications,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190416008,Steroid-induced diabetes mellitus without complication,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190447002,Steroid-induced diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,190484000,Diabetes insipidus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,193141005,Mononeuritis multiplex due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,193183000,Acute painful neuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,193184006,Chronic painful neuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,193185007,Asymptomatic neuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,193349004,Preproliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,193350004,Advanced maculopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,193489006,Iritis due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,197605007,Nephrotic syndrome due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,199223000,"Diabetes mellitus during pregnancy, childbirth and the puerperium",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,199225007,Diabetes mellitus during pregnancy - baby delivered,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,199226008,Diabetes mellitus in the puerperium - baby delivered during current episode of care,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,199227004,Diabetes mellitus during pregnancy - baby not yet delivered,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,200687002,Cellulitis of foot due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,201250006,Ischemic ulcer of foot due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,201251005,Neuropathic ulcer of foot due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,201723002,Cheiroarthropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,201724008,Neuropathic arthropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,230572002,Neuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,230574001,Acute painful polyneuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,230575000,Chronic painful polyneuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,230577008,Mononeuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,230579006,Thoracic radiculopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,232020009,Disorder of macula due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,232021008,Proliferative retinopathy with optic disc neovascularization due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,232022001,Proliferative retinopathy with neovascularisation elsewhere than the optic disc due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,232023006,Traction detachment of retina due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,236499007,Microalbuminuric nephropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,236500003,Proteinuric nephropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,237601000,Secondary endocrine diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,237604008,MODY2 (maturity onset diabetes of the young type 2),DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,237606005,Insulin receptor defect with insulin-resistant diabetes mellitus and acanthosis nigricans,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,237618001,Congenital insulin-dependent diabetes mellitus with fatal secretory diarrhea,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,237619009,Maternally-inherited diabetes and hearing loss,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,237620003,Abnormal metabolic state due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,237621004,Severe hyperglycemia due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,237632004,Hypoglycemic event due to diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,237633009,Hypoglycaemia due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,237635002,Nocturnal hypoglycemia due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,238981002,Disorder of soft tissue due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,238982009,Dermopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,238983004,Thick skin syndrome due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,267471001,Diabetes + eye manifestation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,268519009,Diabetes mellitus uncontrolled,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,270445003,Diabetes monitoring check done,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,273411009,Diabetes clinic satisfaction questionnaire,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,273412002,Diabetes treatment satisfaction questionnaire,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,273413007,Diabetes wellbeing questionnaire,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,284350006,Diabetes mellitus diet education,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,303059007,Postpancreatectomy diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,304752002,Perceived control of insulin-dependent diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,308505000,Diabetes monitoring call,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,309417009,Diabetes dietitian,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,309426007,Glomerulopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,309593006,Education score - diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,309596003,Retinal abnormality - non-diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,309598002,Foot abnormality - non-diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,309635005,History of admission in last year for diabetes foot problem,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,310425007,Diabetes monitoring invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,310505005,Hyperosmolar non-ketotic state due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,311782002,Advanced retinal disease due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,312856000,Referral to diabetes nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,312888008,Attending diabetes clinic,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,312903003,Mild nonproliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,312904009,Moderate nonproliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,312905005,Severe nonproliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,312909004,Proliferative retinopathy with iris neovascularisation due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,312910009,Vitreous hemorrhage due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,312912001,Macular oedema due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,313435000,Insulin-dependent diabetes without complication,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,313436004,Type II diabetes mellitus without complication,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,314010006,Diffuse exudative maculopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,314011005,Focal exudative maculopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,314014002,Ischemic maculopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,314015001,Mixed maculopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,314537004,Optic papillopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,314771006,Insulin dependent diabetes mellitus with hypoglycemic coma,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,315051004,Diabetes resolved,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,315216001,Diabetes mellitus excluded,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,361216007,Femoral mononeuropathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,371087003,Ulcer of foot due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,385805005,Health education - diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,390834004,Nonproliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,394725008,Diabetes medication review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,395123002,Urine screening test for diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,398140007,Post hypoglycaemic hyperglycaemia due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,399868002,Intraretinal microvascular anomaly due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,399871005,Visually threatening retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,405749004,Newly diagnosed diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,407569005,Patient on maximal tolerated therapy for diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,408290003,Diabetes key contact,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,408392008,Under care of diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,408540003,Diabetes mellitus induced by non-steroid drugs,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,413180006,Pan retinal photocoagulation for diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,413597006,Attended diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,414229005,Family/carer attended diabetes structured education program,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,414230000,Family/carer referral to diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,415269004,Referral to diabetes preconception counselling clinic,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,415270003,Referral to diabetes structured education program,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,415744000,Transition of diabetes care options discussed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,416554009,Seen in community diabetes specialist clinic,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,416855002,Family history of diabetes mellitus in first degree relative,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,417467000,Discharged from care of diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,419100001,Infection of foot due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,420422005,Ketoacidosis due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,420756003,Cataract of eye due to diabetes mellitus type 2,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421895002,Peripheral vascular disorder due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,421920002,Cataract of eye due to diabetes mellitus type 1,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,422088007,Disorder of nervous system due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,422126006,Hyperosmolar coma due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,422183001,Skin ulcer due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,422275004,Gangrene due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,426875007,Latent autoimmune diabetes mellitus in adult,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,428274007,Dietary advice for type II diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,430678008,Family history of diabetes mellitus type 1,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,430679000,Family history of diabetes mellitus type 2,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,439051004,Dietary advice for gestational diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,441656006,Hyperglycaemic crisis due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,444094009,History of diabetes mellitus in child of subject,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,472969004,H/O diabetes mellitus type 2,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,472970003,H/O diabetes mellitus type 1,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,472971004,Past pregnancy history of gestational diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,473127005,Suspected diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,609561005,MODY - maturity onset diabetes of young,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,609572000,HNF1B (HNF1 homeobox B) monogenic diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,698610002,Education about self management of diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,699826006,Lifestyle education regarding risk of diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,700414001,Education about diabetes and driving,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,703040004,Agreeing on diabetes care plan,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,703136005,Diabetes mellitus in remission,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,704408003,Invitation for diabetes screening,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,705072004,Diabetes monitoring invitation by short message service text messaging,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,714628002,Prediabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,715159005,Referral to diabetes service,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,715759002,Provision of written information about diabetes and hypertension,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,715879000,Provision of written information about diabetes and high cholesterol,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,719943000,Provision of written information about diabetes and high haemoglobin A1c level,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,720504004,Not suitable for Diabetes Education and Self Management for Ongoing and Newly Diagnosed program,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,720685006,Seen by diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,720724003,Has diabetes identity card,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,724136006,Mastopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,735199000,History of diabetes related lower limb amputation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,735985000,Diabetes self management plan,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,736284000,Diabetes clinical management plan,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,762291006,Syndrome of infant of mother with gestational diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,762489000,Acute complication due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,763117005,FINDRISC (Finnish Diabetes Risk Score) score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,763782001,Provision of patient held diabetes record declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,765147009,Diabetes Treatment Satisfaction Questionnaire status version score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,768794008,Cataract of bilateral eyes due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,769182000,Preproliferative retinopathy of left eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,769218003,Macular oedema of left eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,769222008,Clinically significant macular edema of left eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,769244003,Disorder of right macula due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,769245002,Disorder of left macula due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,770096002,Erectile dysfunction due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,816177009,Nonproliferative retinopathy of left eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,816178004,Nonproliferative retinopathy of right eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,816961009,Stable treated proliferative retinopathy of right eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,816962002,Stable treated proliferative retinopathy of left eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,860709007,No disorder of macula of left eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,860710002,No maculopathy of right eye due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,860712005,Disorder of macula of both eyes due to diabetes mellitus present,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,878859007,Self management of diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,890171006,KPD - ketosis-prone diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,897238003,Diabetes management using closed-loop delivery system,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1196922005,Neovascular glaucoma due to type II diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1196923000,Neovascular glaucoma due to type I diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1258872006,Family referred to diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1258873001,Caregiver referred to diabetes structured education program,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1268646002,Gestational diabetes mellitus screening,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1296758008,Diabetes insipidus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1306699009,Stable treated proliferative retinopathy due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,701000119103,Mixed hyperlipidaemia due to type II diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,24451000000107,Diabetes: shared care in pregnancy - diabetologist and obstetrician,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,40801000119106,Gestational diabetes mellitus complicating pregnancy,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,113131000000107,Informed consent for diabetes national audit,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,113141000000103,Informed dissent for diabetes national audit,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,143401000000102,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation using preferred method of communication,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,143911000000105,Registration for access to online diabetes self-management application,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,143941000000106,Declined to register for access to online diabetes self-management application,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,199481000000100,Diabetes monitoring lower risk albumin excretion,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,199491000000103,Diabetes monitoring higher risk albumin excretion,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,276651000000107,Attended DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,279291000000109,Diabetes type 1 review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,279321000000104,Diabetes type II review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,279521000000108,Referral to community diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,300641000000105,Seen by general practitioner with special interest in diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306401000000106,Attended XPERT (expert patient education versus routine treatment) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306441000000109,Attended DAFNE (dose adjustment for normal eating) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306471000000103,DAFNE (dose adjustment for normal eating) diabetes structured education programme completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306501000000105,DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306531000000104,XPERT (expert patient education versus routine treatment) diabetes structured education programme completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306591000000103,Diabetes structured education programme declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306701000000102,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306741000000104,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) diabetes structured programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306771000000105,Referral to XPERT (expert patient education versus routine treatment) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306861000000107,Did not attend diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306931000000106,Did not complete diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306961000000101,Did not complete DAFNE (dose adjustment for normal eating) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,306991000000107,Did not complete DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,307021000000105,Did not complete XPERT diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,307141000000102,Did not attend DAFNE (dose adjustment for normal eating) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,307171000000108,Did not attend DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,307201000000109,Did not attend XPERT (expert patient education versus routine treatment) diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,334711000000100,Referral to diabetes special interest general practitioner,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,335621000000101,Maternally inherited diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,344061000000104,Referral to children's diabetes nurse specialist,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,368711000119106,Mild nonproliferative retinopathy due to secondary diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,385041000000108,Diabetes mellitus with multiple complications,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,385051000000106,Pre-existing diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,494961000000102,Discharged from diabetes shared care programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,512561000000108,Unsuitable for diabetes year of care programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,512581000000104,Declined consent for diabetes year of care programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,532411000000102,"Diabetes mellitus, adult onset, with no mention of complication",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,658011000000104,Diabetes mellitus with other specified manifestation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,658061000000102,Diabetes mellitus NOS with other specified manifestation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,713671000000109,Diabetes monitoring administration,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,713691000000108,Diabetes clinic administration,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,715111000000105,Diabetes screening administration,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,716031000000106,Excepted from diabetes quality indicators - informed dissent,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,716911000000104,Exception reporting - diabetes quality indicators,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,717421000000100,Excepted from diabetes quality indicators - patient unsuitable,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,750721000000102,Excepted from diabetes quality indicators: service unavailable,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,754461000000105,Referral to type I diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,755491000000100,Diabetes structured education programme completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,762811000000109,DNA (did not attend) diabetes foot screening,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,764921000000102,Gestational diabetes information leaflet given,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,771571000000102,H/O: secondary diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,781161000000107,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,787061000000100,Diabetes care plan declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,810961000000103,Diabetes self-management plan review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,811391000000104,Referral to community diabetes service,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,811981000000102,Diabetes self-management plan agreed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,816711000000104,Gestational diabetes mellitus annual review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,819301000000105,Diabetes monitoring injection site check declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,819331000000104,Diabetes monitoring injection site not checked,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,828901000000109,Endocrinology and diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,829521000000104,Provision of diabetes clinical summary,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,837491000000107,High risk of diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,838731000000104,Referral to community diabetes specialist nurse declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,841221000000102,Referral to community diabetes clinic,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,850581000000106,High risk of diabetes mellitus annual review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,851501000000106,Diabetes clinical pathway,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,851991000000108,Diabetes quality of life questionnaire score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,857921000000103,Provision of written information about diabetes and driving,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,858301000000107,Pre-diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,860981000000106,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,863501000000102,QDiabetes risk calculator,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,863521000000106,QDiabetes risk calculator score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,867891000000101,Erectile dysfunction due to diabetes mellitus,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,876381000000100,Conversion to insulin by diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,885931000000100,Diabetes structured education programme not available,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,887861000000105,Diabetes Year of Care annual review,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,909421000000102,DDS2 (Diabetes Distress Scale 2) score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,909441000000109,DDS17 - Diabetes Distress Scale 17,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,910931000000101,DDS17 (Diabetes Distress Scale 17) score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,923461000000103,Lifestyle education for diabetes,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,927821000000100,Discharge from secondary care diabetes service,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,956781000000107,Joint consultation with practice nurse and community diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,956921000000109,Joint consultation with General Practitioner and community diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,961931000000109,Diabetes education care plan,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,977201000000107,Recommendation to self-refer for diabetes structured education,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1019431000000105,HbA1c level (Diabetes Control and Complications Trial aligned),DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1019551000000104,HbA1 level (Diabetes Control and Complications Trial aligned),DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1024551000000109,Under care of hospital-based diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1024571000000100,Under care of community-based diabetes specialist nurse,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1024941000000100,NHS Diabetes Prevention Programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1025211000000108,NHS Diabetes Prevention Programme not completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1025251000000107,NHS Diabetes Prevention Programme completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1025271000000103,NHS Diabetes Prevention Programme started,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1025301000000100,Referral to NHS Diabetes Prevention Programme declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1025321000000109,Referral to NHS Diabetes Prevention Programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1025601000000108,Leicester Diabetes Risk Score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1054221000000100,Seen in hospital diabetes antenatal clinic,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1065461000000102,Type II diabetes mellitus risk assessment invitation first letter,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1065491000000108,Type II diabetes mellitus risk assessment verbal invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1065501000000102,Type II diabetes mellitus risk assessment telephone invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1066911000000100,Diabetes monitoring SMS (short message service) text message first invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1066921000000106,Diabetes monitoring SMS (short message service) text message second invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1066931000000108,Diabetes monitoring SMS (short message service) text message third invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1083111000000108,Diabetes monitoring invitation email,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1084661000000103,Diabetes UK Diabetes Risk Score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1087971000000105,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) score",DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1089101000000109,UKPDS (United Kingdom Prospective Diabetes Study) risk engine score,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1090701000000104,NHS Diabetes Prevention Programme invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1092721000000109,Signposting to Diabetes UK,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1092731000000106,Signposting to Diabetes UK Learning Zone,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1097131000000105,Remote diabetes structured education and support programme commenced,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1097141000000101,Remote diabetes structured education and support programme completed,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1098011000000102,Did not commence remote structured diabetes education and support programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1103691000000102,Diabetes structured education programme offered,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1108731000000100,Referral to online diabetes structured education programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1108741000000109,Referral to HeLP-Diabetes (Healthy Living for People with Diabetes) online self-management programme,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1110921000000100,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,1362341000000103,Diabetes care plan,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
DEXAMETHASONE INTRAVITREAL IMPLANT,Diabetic macular oedema,TA824,diabetes,12275391000119108,Diabetes screening declined,DEXAMETHASONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,190388001,Type 2 diabetes mellitus with multiple complications,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,190389009,Type 2 diabetes mellitus with ulcer,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,199230006,Pre-existing type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,237599002,Insulin treated type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,237627000,Pregnancy and type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,421631007,Gangrene due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,422014003,Disorder due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,443694000,Uncontrolled type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,703138006,Type 2 diabetes mellitus in remission,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,46635009,T1DM - type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,290002008,Unstable type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,420825003,Gangrene due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,420868002,Disorder due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,429094000,Dietary advice for type 1 diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,444073006,Uncontrolled type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,703137001,Type 1 diabetes mellitus in remission,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,2751001,Fibrocalculous pancreatic diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,4855003,Retinopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,5368009,Drug-induced diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,5969009,Diabetes mellitus associated with genetic syndrome,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,6143009,Diabetes mellitus education,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,8801005,Secondary diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,9414007,Latent diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,11530004,Brittle diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,11687002,GDM - gestational diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,15771004,Diabetes insipidus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,21584002,Maternal diabetes syndrome,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,25093002,Disorder of eye due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,25412000,Microaneurysm of retinal artery due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,26298008,Ketoacidotic coma due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,39058009,Lumbosacral radiculoplexus neuropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,43959009,Cataract of eye due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,44054006,T2DM - diabetes mellitus type 2,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,48951005,Bullous disease due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,49455004,Polyneuropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,49817004,Neonatal diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,50620007,Autonomic neuropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,51002006,Pancreatogenic type 3c diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,59276001,Proliferative retinopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,61165007,Adiuretin-resistant diabetes insipidus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,62260007,Pretibial pigmental patches due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,70694009,"DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, deafness) syndrome",FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,73211009,Diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,74627003,Complication due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,75524006,MRDM - malnutrition related diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,111552007,Diabetes mellitus without complication,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,111556005,Ketoacidosis without coma due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,126534007,Mixed sensorimotor polyneuropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,127012008,Lipodystrophic diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,127013003,Disorder of kidney due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,160274005,No family history of diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,160303001,Family history of diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,160402005,Family history: Diabetes in pregnancy,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,161445009,History of diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,161641009,At increased risk of diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,166928007,Glucose tolerance test indicates diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,170745003,Diet controlled diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,170752001,Has seen dietitian - diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,170753006,Understands diet - diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,170766006,Loss of hypoglycaemic warning due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,170774007,Diabetes: practice program,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,170775008,Diabetes: shared care program,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,171183004,Diabetes mellitus screening,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,185753003,Attends diabetes monitoring,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,185754009,Diabetes monitoring declined,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,185755005,Diabetes monitoring default,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,185756006,Diabetes monitoring first letter,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,185757002,Diabetes monitoring second letter,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,185758007,Diabetes monitoring third letter,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,185759004,Diabetes monitoring verbal invite,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,185760009,Diabetes monitoring telephone invite,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,185761008,Diabetes monitoring deleted,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,190323008,Non-insulin dependent diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,190349003,Diabetes mellitus with neuropathy,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,190354007,Diabetes with gangrene,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,190368000,Insulin-dependent diabetes mellitus with ulcer,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,190372001,Insulin-dependent diabetes maturity onset,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,190406000,Ketoacidosis due to malnutrition related diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,190411003,Multiple complications due to malnutrition related diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,190412005,Malnutrition-related diabetes mellitus without complications,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,190416008,Steroid-induced diabetes mellitus without complication,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,190447002,Steroid-induced diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,190484000,Diabetes insipidus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,193141005,Mononeuritis multiplex due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,193183000,Acute painful neuropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,193184006,Chronic painful neuropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,193185007,Asymptomatic neuropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,193349004,Preproliferative retinopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,193350004,Advanced maculopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,193489006,Iritis due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,197605007,Nephrotic syndrome due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,199223000,"Diabetes mellitus during pregnancy, childbirth and the puerperium",FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,199225007,Diabetes mellitus during pregnancy - baby delivered,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,199226008,Diabetes mellitus in the puerperium - baby delivered during current episode of care,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,199227004,Diabetes mellitus during pregnancy - baby not yet delivered,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,200687002,Cellulitis of foot due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,201250006,Ischemic ulcer of foot due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,201251005,Neuropathic ulcer of foot due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,201723002,Cheiroarthropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,201724008,Neuropathic arthropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,230572002,Neuropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,230574001,Acute painful polyneuropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,230575000,Chronic painful polyneuropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,230577008,Mononeuropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,230579006,Thoracic radiculopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,232020009,Disorder of macula due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,232021008,Proliferative retinopathy with optic disc neovascularization due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,232022001,Proliferative retinopathy with neovascularisation elsewhere than the optic disc due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,232023006,Traction detachment of retina due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,236499007,Microalbuminuric nephropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,236500003,Proteinuric nephropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,237601000,Secondary endocrine diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,237604008,MODY2 (maturity onset diabetes of the young type 2),FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,237606005,Insulin receptor defect with insulin-resistant diabetes mellitus and acanthosis nigricans,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,237618001,Congenital insulin-dependent diabetes mellitus with fatal secretory diarrhea,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,237619009,Maternally-inherited diabetes and hearing loss,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,237620003,Abnormal metabolic state due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,237621004,Severe hyperglycemia due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,237632004,Hypoglycemic event due to diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,237633009,Hypoglycaemia due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,237635002,Nocturnal hypoglycemia due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,238981002,Disorder of soft tissue due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,238982009,Dermopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,238983004,Thick skin syndrome due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,267471001,Diabetes + eye manifestation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,268519009,Diabetes mellitus uncontrolled,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,270445003,Diabetes monitoring check done,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,273411009,Diabetes clinic satisfaction questionnaire,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,273412002,Diabetes treatment satisfaction questionnaire,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,273413007,Diabetes wellbeing questionnaire,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,284350006,Diabetes mellitus diet education,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,303059007,Postpancreatectomy diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,304752002,Perceived control of insulin-dependent diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,308505000,Diabetes monitoring call,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,309417009,Diabetes dietitian,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,309426007,Glomerulopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,309593006,Education score - diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,309596003,Retinal abnormality - non-diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,309598002,Foot abnormality - non-diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,309635005,History of admission in last year for diabetes foot problem,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,310425007,Diabetes monitoring invitation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,310505005,Hyperosmolar non-ketotic state due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,311782002,Advanced retinal disease due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,312856000,Referral to diabetes nurse,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,312888008,Attending diabetes clinic,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,312903003,Mild nonproliferative retinopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,312904009,Moderate nonproliferative retinopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,312905005,Severe nonproliferative retinopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,312909004,Proliferative retinopathy with iris neovascularisation due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,312910009,Vitreous hemorrhage due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,312912001,Macular oedema due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,313435000,Insulin-dependent diabetes without complication,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,313436004,Type II diabetes mellitus without complication,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,314010006,Diffuse exudative maculopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,314011005,Focal exudative maculopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,314014002,Ischemic maculopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,314015001,Mixed maculopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,314537004,Optic papillopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,314771006,Insulin dependent diabetes mellitus with hypoglycemic coma,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,315051004,Diabetes resolved,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,315216001,Diabetes mellitus excluded,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,361216007,Femoral mononeuropathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,371087003,Ulcer of foot due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,385805005,Health education - diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,390834004,Nonproliferative retinopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,394725008,Diabetes medication review,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,395123002,Urine screening test for diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,398140007,Post hypoglycaemic hyperglycaemia due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,399868002,Intraretinal microvascular anomaly due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,399871005,Visually threatening retinopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,405749004,Newly diagnosed diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,407569005,Patient on maximal tolerated therapy for diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,408290003,Diabetes key contact,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,408392008,Under care of diabetes specialist nurse,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,408540003,Diabetes mellitus induced by non-steroid drugs,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,413180006,Pan retinal photocoagulation for diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,413597006,Attended diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,414229005,Family/carer attended diabetes structured education program,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,414230000,Family/carer referral to diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,415269004,Referral to diabetes preconception counselling clinic,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,415270003,Referral to diabetes structured education program,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,415744000,Transition of diabetes care options discussed,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,416554009,Seen in community diabetes specialist clinic,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,416855002,Family history of diabetes mellitus in first degree relative,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,417467000,Discharged from care of diabetes specialist nurse,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,419100001,Infection of foot due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,420422005,Ketoacidosis due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,420756003,Cataract of eye due to diabetes mellitus type 2,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,421895002,Peripheral vascular disorder due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,421920002,Cataract of eye due to diabetes mellitus type 1,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,422088007,Disorder of nervous system due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,422126006,Hyperosmolar coma due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,422183001,Skin ulcer due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,422275004,Gangrene due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,426875007,Latent autoimmune diabetes mellitus in adult,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,428274007,Dietary advice for type II diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,430678008,Family history of diabetes mellitus type 1,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,430679000,Family history of diabetes mellitus type 2,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,439051004,Dietary advice for gestational diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,441656006,Hyperglycaemic crisis due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,444094009,History of diabetes mellitus in child of subject,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,472969004,H/O diabetes mellitus type 2,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,472970003,H/O diabetes mellitus type 1,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,472971004,Past pregnancy history of gestational diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,473127005,Suspected diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,609561005,MODY - maturity onset diabetes of young,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,609572000,HNF1B (HNF1 homeobox B) monogenic diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,698610002,Education about self management of diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,699826006,Lifestyle education regarding risk of diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,700414001,Education about diabetes and driving,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,703040004,Agreeing on diabetes care plan,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,703136005,Diabetes mellitus in remission,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,704408003,Invitation for diabetes screening,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,705072004,Diabetes monitoring invitation by short message service text messaging,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,714628002,Prediabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,715159005,Referral to diabetes service,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,715759002,Provision of written information about diabetes and hypertension,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,715879000,Provision of written information about diabetes and high cholesterol,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,719943000,Provision of written information about diabetes and high haemoglobin A1c level,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,720504004,Not suitable for Diabetes Education and Self Management for Ongoing and Newly Diagnosed program,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,720685006,Seen by diabetes specialist nurse,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,720724003,Has diabetes identity card,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,724136006,Mastopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,735199000,History of diabetes related lower limb amputation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,735985000,Diabetes self management plan,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,736284000,Diabetes clinical management plan,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,762291006,Syndrome of infant of mother with gestational diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,762489000,Acute complication due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,763117005,FINDRISC (Finnish Diabetes Risk Score) score,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,763782001,Provision of patient held diabetes record declined,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,765147009,Diabetes Treatment Satisfaction Questionnaire status version score,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,768794008,Cataract of bilateral eyes due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,769182000,Preproliferative retinopathy of left eye due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,769218003,Macular oedema of left eye due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,769222008,Clinically significant macular edema of left eye due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,769244003,Disorder of right macula due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,769245002,Disorder of left macula due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,770096002,Erectile dysfunction due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,816177009,Nonproliferative retinopathy of left eye due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,816178004,Nonproliferative retinopathy of right eye due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,816961009,Stable treated proliferative retinopathy of right eye due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,816962002,Stable treated proliferative retinopathy of left eye due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,860709007,No disorder of macula of left eye due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,860710002,No maculopathy of right eye due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,860712005,Disorder of macula of both eyes due to diabetes mellitus present,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,878859007,Self management of diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,890171006,KPD - ketosis-prone diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,897238003,Diabetes management using closed-loop delivery system,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1196922005,Neovascular glaucoma due to type II diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1196923000,Neovascular glaucoma due to type I diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1258872006,Family referred to diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1258873001,Caregiver referred to diabetes structured education program,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1268646002,Gestational diabetes mellitus screening,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1296758008,Diabetes insipidus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1306699009,Stable treated proliferative retinopathy due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,701000119103,Mixed hyperlipidaemia due to type II diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,24451000000107,Diabetes: shared care in pregnancy - diabetologist and obstetrician,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,40801000119106,Gestational diabetes mellitus complicating pregnancy,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,113131000000107,Informed consent for diabetes national audit,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,113141000000103,Informed dissent for diabetes national audit,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,143401000000102,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation using preferred method of communication,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,143911000000105,Registration for access to online diabetes self-management application,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,143941000000106,Declined to register for access to online diabetes self-management application,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,199481000000100,Diabetes monitoring lower risk albumin excretion,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,199491000000103,Diabetes monitoring higher risk albumin excretion,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,276651000000107,Attended DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,279291000000109,Diabetes type 1 review,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,279321000000104,Diabetes type II review,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,279521000000108,Referral to community diabetes specialist nurse,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,300641000000105,Seen by general practitioner with special interest in diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,306401000000106,Attended XPERT (expert patient education versus routine treatment) diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,306441000000109,Attended DAFNE (dose adjustment for normal eating) diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,306471000000103,DAFNE (dose adjustment for normal eating) diabetes structured education programme completed,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,306501000000105,DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme completed,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,306531000000104,XPERT (expert patient education versus routine treatment) diabetes structured education programme completed,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,306591000000103,Diabetes structured education programme declined,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,306701000000102,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,306741000000104,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) diabetes structured programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,306771000000105,Referral to XPERT (expert patient education versus routine treatment) diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,306861000000107,Did not attend diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,306931000000106,Did not complete diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,306961000000101,Did not complete DAFNE (dose adjustment for normal eating) diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,306991000000107,Did not complete DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,307021000000105,Did not complete XPERT diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,307141000000102,Did not attend DAFNE (dose adjustment for normal eating) diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,307171000000108,Did not attend DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,307201000000109,Did not attend XPERT (expert patient education versus routine treatment) diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,334711000000100,Referral to diabetes special interest general practitioner,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,335621000000101,Maternally inherited diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,344061000000104,Referral to children's diabetes nurse specialist,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,368711000119106,Mild nonproliferative retinopathy due to secondary diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,385041000000108,Diabetes mellitus with multiple complications,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,385051000000106,Pre-existing diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,494961000000102,Discharged from diabetes shared care programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,512561000000108,Unsuitable for diabetes year of care programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,512581000000104,Declined consent for diabetes year of care programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,532411000000102,"Diabetes mellitus, adult onset, with no mention of complication",FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,658011000000104,Diabetes mellitus with other specified manifestation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,658061000000102,Diabetes mellitus NOS with other specified manifestation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,713671000000109,Diabetes monitoring administration,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,713691000000108,Diabetes clinic administration,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,715111000000105,Diabetes screening administration,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,716031000000106,Excepted from diabetes quality indicators - informed dissent,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,716911000000104,Exception reporting - diabetes quality indicators,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,717421000000100,Excepted from diabetes quality indicators - patient unsuitable,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,750721000000102,Excepted from diabetes quality indicators: service unavailable,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,754461000000105,Referral to type I diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,755491000000100,Diabetes structured education programme completed,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,762811000000109,DNA (did not attend) diabetes foot screening,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,764921000000102,Gestational diabetes information leaflet given,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,771571000000102,H/O: secondary diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,781161000000107,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme declined,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,787061000000100,Diabetes care plan declined,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,810961000000103,Diabetes self-management plan review,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,811391000000104,Referral to community diabetes service,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,811981000000102,Diabetes self-management plan agreed,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,816711000000104,Gestational diabetes mellitus annual review,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,819301000000105,Diabetes monitoring injection site check declined,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,819331000000104,Diabetes monitoring injection site not checked,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,828901000000109,Endocrinology and diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,829521000000104,Provision of diabetes clinical summary,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,837491000000107,High risk of diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,838731000000104,Referral to community diabetes specialist nurse declined,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,841221000000102,Referral to community diabetes clinic,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,850581000000106,High risk of diabetes mellitus annual review,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,851501000000106,Diabetes clinical pathway,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,851991000000108,Diabetes quality of life questionnaire score,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,857921000000103,Provision of written information about diabetes and driving,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,858301000000107,Pre-diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,860981000000106,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme declined,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,863501000000102,QDiabetes risk calculator,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,863521000000106,QDiabetes risk calculator score,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,867891000000101,Erectile dysfunction due to diabetes mellitus,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,876381000000100,Conversion to insulin by diabetes specialist nurse,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,885931000000100,Diabetes structured education programme not available,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,887861000000105,Diabetes Year of Care annual review,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,909421000000102,DDS2 (Diabetes Distress Scale 2) score,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,909441000000109,DDS17 - Diabetes Distress Scale 17,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,910931000000101,DDS17 (Diabetes Distress Scale 17) score,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,923461000000103,Lifestyle education for diabetes,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,927821000000100,Discharge from secondary care diabetes service,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,956781000000107,Joint consultation with practice nurse and community diabetes specialist nurse,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,956921000000109,Joint consultation with General Practitioner and community diabetes specialist nurse,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,961931000000109,Diabetes education care plan,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,977201000000107,Recommendation to self-refer for diabetes structured education,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1019431000000105,HbA1c level (Diabetes Control and Complications Trial aligned),FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1019551000000104,HbA1 level (Diabetes Control and Complications Trial aligned),FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1024551000000109,Under care of hospital-based diabetes specialist nurse,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1024571000000100,Under care of community-based diabetes specialist nurse,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1024941000000100,NHS Diabetes Prevention Programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1025211000000108,NHS Diabetes Prevention Programme not completed,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1025251000000107,NHS Diabetes Prevention Programme completed,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1025271000000103,NHS Diabetes Prevention Programme started,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1025301000000100,Referral to NHS Diabetes Prevention Programme declined,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1025321000000109,Referral to NHS Diabetes Prevention Programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1025601000000108,Leicester Diabetes Risk Score,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1054221000000100,Seen in hospital diabetes antenatal clinic,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1065461000000102,Type II diabetes mellitus risk assessment invitation first letter,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1065491000000108,Type II diabetes mellitus risk assessment verbal invitation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1065501000000102,Type II diabetes mellitus risk assessment telephone invitation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1066911000000100,Diabetes monitoring SMS (short message service) text message first invitation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1066921000000106,Diabetes monitoring SMS (short message service) text message second invitation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1066931000000108,Diabetes monitoring SMS (short message service) text message third invitation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1083111000000108,Diabetes monitoring invitation email,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1084661000000103,Diabetes UK Diabetes Risk Score,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1087971000000105,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) score",FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1089101000000109,UKPDS (United Kingdom Prospective Diabetes Study) risk engine score,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1090701000000104,NHS Diabetes Prevention Programme invitation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1092721000000109,Signposting to Diabetes UK,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1092731000000106,Signposting to Diabetes UK Learning Zone,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1097131000000105,Remote diabetes structured education and support programme commenced,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1097141000000101,Remote diabetes structured education and support programme completed,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1098011000000102,Did not commence remote structured diabetes education and support programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1103691000000102,Diabetes structured education programme offered,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1108731000000100,Referral to online diabetes structured education programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1108741000000109,Referral to HeLP-Diabetes (Healthy Living for People with Diabetes) online self-management programme,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1110921000000100,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,1362341000000103,Diabetes care plan,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FARICIMAB,Diabetic macular oedema,TA799,diabetes,12275391000119108,Diabetes screening declined,FARICIMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190388001,Type 2 diabetes mellitus with multiple complications,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190389009,Type 2 diabetes mellitus with ulcer,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,199230006,Pre-existing type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,237599002,Insulin treated type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,237627000,Pregnancy and type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421631007,Gangrene due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,422014003,Disorder due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,443694000,Uncontrolled type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,703138006,Type 2 diabetes mellitus in remission,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,46635009,T1DM - type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,290002008,Unstable type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,420825003,Gangrene due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,420868002,Disorder due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,429094000,Dietary advice for type 1 diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,444073006,Uncontrolled type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,703137001,Type 1 diabetes mellitus in remission,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,2751001,Fibrocalculous pancreatic diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,4855003,Retinopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,5368009,Drug-induced diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,5969009,Diabetes mellitus associated with genetic syndrome,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,6143009,Diabetes mellitus education,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,8801005,Secondary diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,9414007,Latent diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,11530004,Brittle diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,11687002,GDM - gestational diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,15771004,Diabetes insipidus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,21584002,Maternal diabetes syndrome,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,25093002,Disorder of eye due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,25412000,Microaneurysm of retinal artery due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,26298008,Ketoacidotic coma due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,39058009,Lumbosacral radiculoplexus neuropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,43959009,Cataract of eye due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,44054006,T2DM - diabetes mellitus type 2,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,48951005,Bullous disease due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,49455004,Polyneuropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,49817004,Neonatal diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,50620007,Autonomic neuropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,51002006,Pancreatogenic type 3c diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,59276001,Proliferative retinopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,61165007,Adiuretin-resistant diabetes insipidus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,62260007,Pretibial pigmental patches due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,70694009,"DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, deafness) syndrome",FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,73211009,Diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,74627003,Complication due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,75524006,MRDM - malnutrition related diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,111552007,Diabetes mellitus without complication,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,111556005,Ketoacidosis without coma due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,126534007,Mixed sensorimotor polyneuropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,127012008,Lipodystrophic diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,127013003,Disorder of kidney due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,160274005,No family history of diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,160303001,Family history of diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,160402005,Family history: Diabetes in pregnancy,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,161445009,History of diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,161641009,At increased risk of diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,166928007,Glucose tolerance test indicates diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,170745003,Diet controlled diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,170752001,Has seen dietitian - diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,170753006,Understands diet - diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,170766006,Loss of hypoglycaemic warning due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,170774007,Diabetes: practice program,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,170775008,Diabetes: shared care program,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,171183004,Diabetes mellitus screening,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,185753003,Attends diabetes monitoring,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,185754009,Diabetes monitoring declined,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,185755005,Diabetes monitoring default,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,185756006,Diabetes monitoring first letter,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,185757002,Diabetes monitoring second letter,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,185758007,Diabetes monitoring third letter,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,185759004,Diabetes monitoring verbal invite,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,185760009,Diabetes monitoring telephone invite,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,185761008,Diabetes monitoring deleted,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190323008,Non-insulin dependent diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190349003,Diabetes mellitus with neuropathy,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190354007,Diabetes with gangrene,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190368000,Insulin-dependent diabetes mellitus with ulcer,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190372001,Insulin-dependent diabetes maturity onset,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190406000,Ketoacidosis due to malnutrition related diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190411003,Multiple complications due to malnutrition related diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190412005,Malnutrition-related diabetes mellitus without complications,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190416008,Steroid-induced diabetes mellitus without complication,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190447002,Steroid-induced diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,190484000,Diabetes insipidus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,193141005,Mononeuritis multiplex due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,193183000,Acute painful neuropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,193184006,Chronic painful neuropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,193185007,Asymptomatic neuropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,193349004,Preproliferative retinopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,193350004,Advanced maculopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,193489006,Iritis due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,197605007,Nephrotic syndrome due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,199223000,"Diabetes mellitus during pregnancy, childbirth and the puerperium",FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,199225007,Diabetes mellitus during pregnancy - baby delivered,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,199226008,Diabetes mellitus in the puerperium - baby delivered during current episode of care,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,199227004,Diabetes mellitus during pregnancy - baby not yet delivered,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,200687002,Cellulitis of foot due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,201250006,Ischemic ulcer of foot due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,201251005,Neuropathic ulcer of foot due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,201723002,Cheiroarthropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,201724008,Neuropathic arthropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,230572002,Neuropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,230574001,Acute painful polyneuropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,230575000,Chronic painful polyneuropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,230577008,Mononeuropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,230579006,Thoracic radiculopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,232020009,Disorder of macula due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,232021008,Proliferative retinopathy with optic disc neovascularization due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,232022001,Proliferative retinopathy with neovascularisation elsewhere than the optic disc due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,232023006,Traction detachment of retina due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,236499007,Microalbuminuric nephropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,236500003,Proteinuric nephropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,237601000,Secondary endocrine diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,237604008,MODY2 (maturity onset diabetes of the young type 2),FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,237606005,Insulin receptor defect with insulin-resistant diabetes mellitus and acanthosis nigricans,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,237618001,Congenital insulin-dependent diabetes mellitus with fatal secretory diarrhea,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,237619009,Maternally-inherited diabetes and hearing loss,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,237620003,Abnormal metabolic state due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,237621004,Severe hyperglycemia due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,237632004,Hypoglycemic event due to diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,237633009,Hypoglycaemia due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,237635002,Nocturnal hypoglycemia due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,238981002,Disorder of soft tissue due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,238982009,Dermopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,238983004,Thick skin syndrome due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,267471001,Diabetes + eye manifestation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,268519009,Diabetes mellitus uncontrolled,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,270445003,Diabetes monitoring check done,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,273411009,Diabetes clinic satisfaction questionnaire,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,273412002,Diabetes treatment satisfaction questionnaire,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,273413007,Diabetes wellbeing questionnaire,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,284350006,Diabetes mellitus diet education,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,303059007,Postpancreatectomy diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,304752002,Perceived control of insulin-dependent diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,308505000,Diabetes monitoring call,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,309417009,Diabetes dietitian,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,309426007,Glomerulopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,309593006,Education score - diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,309596003,Retinal abnormality - non-diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,309598002,Foot abnormality - non-diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,309635005,History of admission in last year for diabetes foot problem,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,310425007,Diabetes monitoring invitation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,310505005,Hyperosmolar non-ketotic state due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,311782002,Advanced retinal disease due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,312856000,Referral to diabetes nurse,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,312888008,Attending diabetes clinic,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,312903003,Mild nonproliferative retinopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,312904009,Moderate nonproliferative retinopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,312905005,Severe nonproliferative retinopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,312909004,Proliferative retinopathy with iris neovascularisation due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,312910009,Vitreous hemorrhage due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,312912001,Macular oedema due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,313435000,Insulin-dependent diabetes without complication,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,313436004,Type II diabetes mellitus without complication,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,314010006,Diffuse exudative maculopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,314011005,Focal exudative maculopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,314014002,Ischemic maculopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,314015001,Mixed maculopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,314537004,Optic papillopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,314771006,Insulin dependent diabetes mellitus with hypoglycemic coma,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,315051004,Diabetes resolved,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,315216001,Diabetes mellitus excluded,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,361216007,Femoral mononeuropathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,371087003,Ulcer of foot due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,385805005,Health education - diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,390834004,Nonproliferative retinopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,394725008,Diabetes medication review,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,395123002,Urine screening test for diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,398140007,Post hypoglycaemic hyperglycaemia due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,399868002,Intraretinal microvascular anomaly due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,399871005,Visually threatening retinopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,405749004,Newly diagnosed diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,407569005,Patient on maximal tolerated therapy for diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,408290003,Diabetes key contact,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,408392008,Under care of diabetes specialist nurse,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,408540003,Diabetes mellitus induced by non-steroid drugs,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,413180006,Pan retinal photocoagulation for diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,413597006,Attended diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,414229005,Family/carer attended diabetes structured education program,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,414230000,Family/carer referral to diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,415269004,Referral to diabetes preconception counselling clinic,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,415270003,Referral to diabetes structured education program,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,415744000,Transition of diabetes care options discussed,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,416554009,Seen in community diabetes specialist clinic,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,416855002,Family history of diabetes mellitus in first degree relative,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,417467000,Discharged from care of diabetes specialist nurse,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,419100001,Infection of foot due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,420422005,Ketoacidosis due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,420756003,Cataract of eye due to diabetes mellitus type 2,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421895002,Peripheral vascular disorder due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,421920002,Cataract of eye due to diabetes mellitus type 1,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,422088007,Disorder of nervous system due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,422126006,Hyperosmolar coma due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,422183001,Skin ulcer due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,422275004,Gangrene due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,426875007,Latent autoimmune diabetes mellitus in adult,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,428274007,Dietary advice for type II diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,430678008,Family history of diabetes mellitus type 1,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,430679000,Family history of diabetes mellitus type 2,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,439051004,Dietary advice for gestational diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,441656006,Hyperglycaemic crisis due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,444094009,History of diabetes mellitus in child of subject,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,472969004,H/O diabetes mellitus type 2,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,472970003,H/O diabetes mellitus type 1,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,472971004,Past pregnancy history of gestational diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,473127005,Suspected diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,609561005,MODY - maturity onset diabetes of young,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,609572000,HNF1B (HNF1 homeobox B) monogenic diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,698610002,Education about self management of diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,699826006,Lifestyle education regarding risk of diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,700414001,Education about diabetes and driving,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,703040004,Agreeing on diabetes care plan,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,703136005,Diabetes mellitus in remission,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,704408003,Invitation for diabetes screening,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,705072004,Diabetes monitoring invitation by short message service text messaging,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,714628002,Prediabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,715159005,Referral to diabetes service,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,715759002,Provision of written information about diabetes and hypertension,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,715879000,Provision of written information about diabetes and high cholesterol,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,719943000,Provision of written information about diabetes and high haemoglobin A1c level,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,720504004,Not suitable for Diabetes Education and Self Management for Ongoing and Newly Diagnosed program,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,720685006,Seen by diabetes specialist nurse,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,720724003,Has diabetes identity card,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,724136006,Mastopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,735199000,History of diabetes related lower limb amputation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,735985000,Diabetes self management plan,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,736284000,Diabetes clinical management plan,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,762291006,Syndrome of infant of mother with gestational diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,762489000,Acute complication due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,763117005,FINDRISC (Finnish Diabetes Risk Score) score,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,763782001,Provision of patient held diabetes record declined,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,765147009,Diabetes Treatment Satisfaction Questionnaire status version score,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,768794008,Cataract of bilateral eyes due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,769182000,Preproliferative retinopathy of left eye due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,769218003,Macular oedema of left eye due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,769222008,Clinically significant macular edema of left eye due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,769244003,Disorder of right macula due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,769245002,Disorder of left macula due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,770096002,Erectile dysfunction due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,816177009,Nonproliferative retinopathy of left eye due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,816178004,Nonproliferative retinopathy of right eye due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,816961009,Stable treated proliferative retinopathy of right eye due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,816962002,Stable treated proliferative retinopathy of left eye due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,860709007,No disorder of macula of left eye due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,860710002,No maculopathy of right eye due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,860712005,Disorder of macula of both eyes due to diabetes mellitus present,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,878859007,Self management of diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,890171006,KPD - ketosis-prone diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,897238003,Diabetes management using closed-loop delivery system,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1196922005,Neovascular glaucoma due to type II diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1196923000,Neovascular glaucoma due to type I diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1258872006,Family referred to diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1258873001,Caregiver referred to diabetes structured education program,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1268646002,Gestational diabetes mellitus screening,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1296758008,Diabetes insipidus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1306699009,Stable treated proliferative retinopathy due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,701000119103,Mixed hyperlipidaemia due to type II diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,24451000000107,Diabetes: shared care in pregnancy - diabetologist and obstetrician,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,40801000119106,Gestational diabetes mellitus complicating pregnancy,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,113131000000107,Informed consent for diabetes national audit,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,113141000000103,Informed dissent for diabetes national audit,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,143401000000102,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation using preferred method of communication,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,143911000000105,Registration for access to online diabetes self-management application,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,143941000000106,Declined to register for access to online diabetes self-management application,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,199481000000100,Diabetes monitoring lower risk albumin excretion,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,199491000000103,Diabetes monitoring higher risk albumin excretion,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,276651000000107,Attended DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,279291000000109,Diabetes type 1 review,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,279321000000104,Diabetes type II review,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,279521000000108,Referral to community diabetes specialist nurse,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,300641000000105,Seen by general practitioner with special interest in diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306401000000106,Attended XPERT (expert patient education versus routine treatment) diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306441000000109,Attended DAFNE (dose adjustment for normal eating) diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306471000000103,DAFNE (dose adjustment for normal eating) diabetes structured education programme completed,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306501000000105,DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme completed,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306531000000104,XPERT (expert patient education versus routine treatment) diabetes structured education programme completed,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306591000000103,Diabetes structured education programme declined,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306701000000102,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306741000000104,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) diabetes structured programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306771000000105,Referral to XPERT (expert patient education versus routine treatment) diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306861000000107,Did not attend diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306931000000106,Did not complete diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306961000000101,Did not complete DAFNE (dose adjustment for normal eating) diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,306991000000107,Did not complete DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,307021000000105,Did not complete XPERT diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,307141000000102,Did not attend DAFNE (dose adjustment for normal eating) diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,307171000000108,Did not attend DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,307201000000109,Did not attend XPERT (expert patient education versus routine treatment) diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,334711000000100,Referral to diabetes special interest general practitioner,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,335621000000101,Maternally inherited diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,344061000000104,Referral to children's diabetes nurse specialist,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,368711000119106,Mild nonproliferative retinopathy due to secondary diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,385041000000108,Diabetes mellitus with multiple complications,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,385051000000106,Pre-existing diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,494961000000102,Discharged from diabetes shared care programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,512561000000108,Unsuitable for diabetes year of care programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,512581000000104,Declined consent for diabetes year of care programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,532411000000102,"Diabetes mellitus, adult onset, with no mention of complication",FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,658011000000104,Diabetes mellitus with other specified manifestation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,658061000000102,Diabetes mellitus NOS with other specified manifestation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,713671000000109,Diabetes monitoring administration,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,713691000000108,Diabetes clinic administration,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,715111000000105,Diabetes screening administration,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,716031000000106,Excepted from diabetes quality indicators - informed dissent,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,716911000000104,Exception reporting - diabetes quality indicators,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,717421000000100,Excepted from diabetes quality indicators - patient unsuitable,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,750721000000102,Excepted from diabetes quality indicators: service unavailable,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,754461000000105,Referral to type I diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,755491000000100,Diabetes structured education programme completed,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,762811000000109,DNA (did not attend) diabetes foot screening,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,764921000000102,Gestational diabetes information leaflet given,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,771571000000102,H/O: secondary diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,781161000000107,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme declined,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,787061000000100,Diabetes care plan declined,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,810961000000103,Diabetes self-management plan review,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,811391000000104,Referral to community diabetes service,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,811981000000102,Diabetes self-management plan agreed,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,816711000000104,Gestational diabetes mellitus annual review,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,819301000000105,Diabetes monitoring injection site check declined,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,819331000000104,Diabetes monitoring injection site not checked,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,828901000000109,Endocrinology and diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,829521000000104,Provision of diabetes clinical summary,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,837491000000107,High risk of diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,838731000000104,Referral to community diabetes specialist nurse declined,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,841221000000102,Referral to community diabetes clinic,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,850581000000106,High risk of diabetes mellitus annual review,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,851501000000106,Diabetes clinical pathway,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,851991000000108,Diabetes quality of life questionnaire score,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,857921000000103,Provision of written information about diabetes and driving,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,858301000000107,Pre-diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,860981000000106,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme declined,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,863501000000102,QDiabetes risk calculator,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,863521000000106,QDiabetes risk calculator score,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,867891000000101,Erectile dysfunction due to diabetes mellitus,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,876381000000100,Conversion to insulin by diabetes specialist nurse,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,885931000000100,Diabetes structured education programme not available,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,887861000000105,Diabetes Year of Care annual review,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,909421000000102,DDS2 (Diabetes Distress Scale 2) score,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,909441000000109,DDS17 - Diabetes Distress Scale 17,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,910931000000101,DDS17 (Diabetes Distress Scale 17) score,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,923461000000103,Lifestyle education for diabetes,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,927821000000100,Discharge from secondary care diabetes service,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,956781000000107,Joint consultation with practice nurse and community diabetes specialist nurse,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,956921000000109,Joint consultation with General Practitioner and community diabetes specialist nurse,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,961931000000109,Diabetes education care plan,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,977201000000107,Recommendation to self-refer for diabetes structured education,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1019431000000105,HbA1c level (Diabetes Control and Complications Trial aligned),FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1019551000000104,HbA1 level (Diabetes Control and Complications Trial aligned),FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1024551000000109,Under care of hospital-based diabetes specialist nurse,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1024571000000100,Under care of community-based diabetes specialist nurse,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1024941000000100,NHS Diabetes Prevention Programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1025211000000108,NHS Diabetes Prevention Programme not completed,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1025251000000107,NHS Diabetes Prevention Programme completed,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1025271000000103,NHS Diabetes Prevention Programme started,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1025301000000100,Referral to NHS Diabetes Prevention Programme declined,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1025321000000109,Referral to NHS Diabetes Prevention Programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1025601000000108,Leicester Diabetes Risk Score,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1054221000000100,Seen in hospital diabetes antenatal clinic,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1065461000000102,Type II diabetes mellitus risk assessment invitation first letter,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1065491000000108,Type II diabetes mellitus risk assessment verbal invitation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1065501000000102,Type II diabetes mellitus risk assessment telephone invitation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1066911000000100,Diabetes monitoring SMS (short message service) text message first invitation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1066921000000106,Diabetes monitoring SMS (short message service) text message second invitation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1066931000000108,Diabetes monitoring SMS (short message service) text message third invitation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1083111000000108,Diabetes monitoring invitation email,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1084661000000103,Diabetes UK Diabetes Risk Score,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1087971000000105,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) score",FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1089101000000109,UKPDS (United Kingdom Prospective Diabetes Study) risk engine score,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1090701000000104,NHS Diabetes Prevention Programme invitation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1092721000000109,Signposting to Diabetes UK,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1092731000000106,Signposting to Diabetes UK Learning Zone,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1097131000000105,Remote diabetes structured education and support programme commenced,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1097141000000101,Remote diabetes structured education and support programme completed,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1098011000000102,Did not commence remote structured diabetes education and support programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1103691000000102,Diabetes structured education programme offered,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1108731000000100,Referral to online diabetes structured education programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1108741000000109,Referral to HeLP-Diabetes (Healthy Living for People with Diabetes) online self-management programme,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1110921000000100,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,1362341000000103,Diabetes care plan,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT,Chronic diabetic macular oedema in phakic eyes after inadequate response to available therapies,TA613,diabetes,12275391000119108,Diabetes screening declined,FLUOCINOLONE,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190388001,Type 2 diabetes mellitus with multiple complications,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190389009,Type 2 diabetes mellitus with ulcer,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,199230006,Pre-existing type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,237599002,Insulin treated type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,237627000,Pregnancy and type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421631007,Gangrene due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,422014003,Disorder due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,443694000,Uncontrolled type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,703138006,Type 2 diabetes mellitus in remission,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,46635009,T1DM - type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,290002008,Unstable type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,420825003,Gangrene due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,420868002,Disorder due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,429094000,Dietary advice for type 1 diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,444073006,Uncontrolled type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,703137001,Type 1 diabetes mellitus in remission,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,2751001,Fibrocalculous pancreatic diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,4855003,Retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,5368009,Drug-induced diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,5969009,Diabetes mellitus associated with genetic syndrome,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,6143009,Diabetes mellitus education,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,8801005,Secondary diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,9414007,Latent diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,11530004,Brittle diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,11687002,GDM - gestational diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,15771004,Diabetes insipidus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,21584002,Maternal diabetes syndrome,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,25093002,Disorder of eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,25412000,Microaneurysm of retinal artery due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,26298008,Ketoacidotic coma due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,39058009,Lumbosacral radiculoplexus neuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,43959009,Cataract of eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,44054006,T2DM - diabetes mellitus type 2,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,48951005,Bullous disease due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,49455004,Polyneuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,49817004,Neonatal diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,50620007,Autonomic neuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,51002006,Pancreatogenic type 3c diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,59276001,Proliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,61165007,Adiuretin-resistant diabetes insipidus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,62260007,Pretibial pigmental patches due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,70694009,"DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, deafness) syndrome",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,73211009,Diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,74627003,Complication due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,75524006,MRDM - malnutrition related diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,111552007,Diabetes mellitus without complication,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,111556005,Ketoacidosis without coma due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,126534007,Mixed sensorimotor polyneuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,127012008,Lipodystrophic diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,127013003,Disorder of kidney due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,160274005,No family history of diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,160303001,Family history of diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,160402005,Family history: Diabetes in pregnancy,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,161445009,History of diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,161641009,At increased risk of diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,166928007,Glucose tolerance test indicates diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,170745003,Diet controlled diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,170752001,Has seen dietitian - diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,170753006,Understands diet - diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,170766006,Loss of hypoglycaemic warning due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,170774007,Diabetes: practice program,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,170775008,Diabetes: shared care program,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,171183004,Diabetes mellitus screening,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,185753003,Attends diabetes monitoring,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,185754009,Diabetes monitoring declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,185755005,Diabetes monitoring default,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,185756006,Diabetes monitoring first letter,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,185757002,Diabetes monitoring second letter,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,185758007,Diabetes monitoring third letter,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,185759004,Diabetes monitoring verbal invite,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,185760009,Diabetes monitoring telephone invite,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,185761008,Diabetes monitoring deleted,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190323008,Non-insulin dependent diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190349003,Diabetes mellitus with neuropathy,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190354007,Diabetes with gangrene,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190368000,Insulin-dependent diabetes mellitus with ulcer,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190372001,Insulin-dependent diabetes maturity onset,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190406000,Ketoacidosis due to malnutrition related diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190411003,Multiple complications due to malnutrition related diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190412005,Malnutrition-related diabetes mellitus without complications,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190416008,Steroid-induced diabetes mellitus without complication,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190447002,Steroid-induced diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,190484000,Diabetes insipidus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,193141005,Mononeuritis multiplex due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,193183000,Acute painful neuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,193184006,Chronic painful neuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,193185007,Asymptomatic neuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,193349004,Preproliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,193350004,Advanced maculopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,193489006,Iritis due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,197605007,Nephrotic syndrome due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,199223000,"Diabetes mellitus during pregnancy, childbirth and the puerperium",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,199225007,Diabetes mellitus during pregnancy - baby delivered,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,199226008,Diabetes mellitus in the puerperium - baby delivered during current episode of care,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,199227004,Diabetes mellitus during pregnancy - baby not yet delivered,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,200687002,Cellulitis of foot due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,201250006,Ischemic ulcer of foot due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,201251005,Neuropathic ulcer of foot due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,201723002,Cheiroarthropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,201724008,Neuropathic arthropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,230572002,Neuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,230574001,Acute painful polyneuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,230575000,Chronic painful polyneuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,230577008,Mononeuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,230579006,Thoracic radiculopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,232020009,Disorder of macula due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,232021008,Proliferative retinopathy with optic disc neovascularization due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,232022001,Proliferative retinopathy with neovascularisation elsewhere than the optic disc due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,232023006,Traction detachment of retina due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,236499007,Microalbuminuric nephropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,236500003,Proteinuric nephropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,237601000,Secondary endocrine diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,237604008,MODY2 (maturity onset diabetes of the young type 2),RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,237606005,Insulin receptor defect with insulin-resistant diabetes mellitus and acanthosis nigricans,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,237618001,Congenital insulin-dependent diabetes mellitus with fatal secretory diarrhea,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,237619009,Maternally-inherited diabetes and hearing loss,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,237620003,Abnormal metabolic state due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,237621004,Severe hyperglycemia due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,237632004,Hypoglycemic event due to diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,237633009,Hypoglycaemia due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,237635002,Nocturnal hypoglycemia due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,238981002,Disorder of soft tissue due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,238982009,Dermopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,238983004,Thick skin syndrome due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,267471001,Diabetes + eye manifestation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,268519009,Diabetes mellitus uncontrolled,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,270445003,Diabetes monitoring check done,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,273411009,Diabetes clinic satisfaction questionnaire,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,273412002,Diabetes treatment satisfaction questionnaire,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,273413007,Diabetes wellbeing questionnaire,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,284350006,Diabetes mellitus diet education,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,303059007,Postpancreatectomy diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,304752002,Perceived control of insulin-dependent diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,308505000,Diabetes monitoring call,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,309417009,Diabetes dietitian,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,309426007,Glomerulopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,309593006,Education score - diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,309596003,Retinal abnormality - non-diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,309598002,Foot abnormality - non-diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,309635005,History of admission in last year for diabetes foot problem,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,310425007,Diabetes monitoring invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,310505005,Hyperosmolar non-ketotic state due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,311782002,Advanced retinal disease due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,312856000,Referral to diabetes nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,312888008,Attending diabetes clinic,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,312903003,Mild nonproliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,312904009,Moderate nonproliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,312905005,Severe nonproliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,312909004,Proliferative retinopathy with iris neovascularisation due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,312910009,Vitreous hemorrhage due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,312912001,Macular oedema due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,313435000,Insulin-dependent diabetes without complication,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,313436004,Type II diabetes mellitus without complication,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,314010006,Diffuse exudative maculopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,314011005,Focal exudative maculopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,314014002,Ischemic maculopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,314015001,Mixed maculopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,314537004,Optic papillopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,314771006,Insulin dependent diabetes mellitus with hypoglycemic coma,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,315051004,Diabetes resolved,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,315216001,Diabetes mellitus excluded,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,361216007,Femoral mononeuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,371087003,Ulcer of foot due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,385805005,Health education - diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,390834004,Nonproliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,394725008,Diabetes medication review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,395123002,Urine screening test for diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,398140007,Post hypoglycaemic hyperglycaemia due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,399868002,Intraretinal microvascular anomaly due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,399871005,Visually threatening retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,405749004,Newly diagnosed diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,407569005,Patient on maximal tolerated therapy for diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,408290003,Diabetes key contact,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,408392008,Under care of diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,408540003,Diabetes mellitus induced by non-steroid drugs,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,413180006,Pan retinal photocoagulation for diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,413597006,Attended diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,414229005,Family/carer attended diabetes structured education program,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,414230000,Family/carer referral to diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,415269004,Referral to diabetes preconception counselling clinic,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,415270003,Referral to diabetes structured education program,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,415744000,Transition of diabetes care options discussed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,416554009,Seen in community diabetes specialist clinic,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,416855002,Family history of diabetes mellitus in first degree relative,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,417467000,Discharged from care of diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,419100001,Infection of foot due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,420422005,Ketoacidosis due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,420756003,Cataract of eye due to diabetes mellitus type 2,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421895002,Peripheral vascular disorder due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,421920002,Cataract of eye due to diabetes mellitus type 1,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,422088007,Disorder of nervous system due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,422126006,Hyperosmolar coma due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,422183001,Skin ulcer due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,422275004,Gangrene due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,426875007,Latent autoimmune diabetes mellitus in adult,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,428274007,Dietary advice for type II diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,430678008,Family history of diabetes mellitus type 1,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,430679000,Family history of diabetes mellitus type 2,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,439051004,Dietary advice for gestational diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,441656006,Hyperglycaemic crisis due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,444094009,History of diabetes mellitus in child of subject,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,472969004,H/O diabetes mellitus type 2,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,472970003,H/O diabetes mellitus type 1,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,472971004,Past pregnancy history of gestational diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,473127005,Suspected diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,609561005,MODY - maturity onset diabetes of young,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,609572000,HNF1B (HNF1 homeobox B) monogenic diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,698610002,Education about self management of diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,699826006,Lifestyle education regarding risk of diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,700414001,Education about diabetes and driving,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,703040004,Agreeing on diabetes care plan,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,703136005,Diabetes mellitus in remission,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,704408003,Invitation for diabetes screening,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,705072004,Diabetes monitoring invitation by short message service text messaging,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,714628002,Prediabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,715159005,Referral to diabetes service,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,715759002,Provision of written information about diabetes and hypertension,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,715879000,Provision of written information about diabetes and high cholesterol,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,719943000,Provision of written information about diabetes and high haemoglobin A1c level,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,720504004,Not suitable for Diabetes Education and Self Management for Ongoing and Newly Diagnosed program,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,720685006,Seen by diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,720724003,Has diabetes identity card,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,724136006,Mastopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,735199000,History of diabetes related lower limb amputation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,735985000,Diabetes self management plan,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,736284000,Diabetes clinical management plan,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,762291006,Syndrome of infant of mother with gestational diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,762489000,Acute complication due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,763117005,FINDRISC (Finnish Diabetes Risk Score) score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,763782001,Provision of patient held diabetes record declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,765147009,Diabetes Treatment Satisfaction Questionnaire status version score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,768794008,Cataract of bilateral eyes due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,769182000,Preproliferative retinopathy of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,769218003,Macular oedema of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,769222008,Clinically significant macular edema of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,769244003,Disorder of right macula due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,769245002,Disorder of left macula due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,770096002,Erectile dysfunction due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,816177009,Nonproliferative retinopathy of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,816178004,Nonproliferative retinopathy of right eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,816961009,Stable treated proliferative retinopathy of right eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,816962002,Stable treated proliferative retinopathy of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,860709007,No disorder of macula of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,860710002,No maculopathy of right eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,860712005,Disorder of macula of both eyes due to diabetes mellitus present,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,878859007,Self management of diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,890171006,KPD - ketosis-prone diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,897238003,Diabetes management using closed-loop delivery system,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1196922005,Neovascular glaucoma due to type II diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1196923000,Neovascular glaucoma due to type I diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1258872006,Family referred to diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1258873001,Caregiver referred to diabetes structured education program,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1268646002,Gestational diabetes mellitus screening,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1296758008,Diabetes insipidus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1306699009,Stable treated proliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,701000119103,Mixed hyperlipidaemia due to type II diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,24451000000107,Diabetes: shared care in pregnancy - diabetologist and obstetrician,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,40801000119106,Gestational diabetes mellitus complicating pregnancy,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,113131000000107,Informed consent for diabetes national audit,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,113141000000103,Informed dissent for diabetes national audit,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,143401000000102,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation using preferred method of communication,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,143911000000105,Registration for access to online diabetes self-management application,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,143941000000106,Declined to register for access to online diabetes self-management application,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,199481000000100,Diabetes monitoring lower risk albumin excretion,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,199491000000103,Diabetes monitoring higher risk albumin excretion,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,276651000000107,Attended DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,279291000000109,Diabetes type 1 review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,279321000000104,Diabetes type II review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,279521000000108,Referral to community diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,300641000000105,Seen by general practitioner with special interest in diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306401000000106,Attended XPERT (expert patient education versus routine treatment) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306441000000109,Attended DAFNE (dose adjustment for normal eating) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306471000000103,DAFNE (dose adjustment for normal eating) diabetes structured education programme completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306501000000105,DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306531000000104,XPERT (expert patient education versus routine treatment) diabetes structured education programme completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306591000000103,Diabetes structured education programme declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306701000000102,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306741000000104,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) diabetes structured programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306771000000105,Referral to XPERT (expert patient education versus routine treatment) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306861000000107,Did not attend diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306931000000106,Did not complete diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306961000000101,Did not complete DAFNE (dose adjustment for normal eating) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,306991000000107,Did not complete DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,307021000000105,Did not complete XPERT diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,307141000000102,Did not attend DAFNE (dose adjustment for normal eating) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,307171000000108,Did not attend DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,307201000000109,Did not attend XPERT (expert patient education versus routine treatment) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,334711000000100,Referral to diabetes special interest general practitioner,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,335621000000101,Maternally inherited diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,344061000000104,Referral to children's diabetes nurse specialist,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,368711000119106,Mild nonproliferative retinopathy due to secondary diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,385041000000108,Diabetes mellitus with multiple complications,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,385051000000106,Pre-existing diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,494961000000102,Discharged from diabetes shared care programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,512561000000108,Unsuitable for diabetes year of care programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,512581000000104,Declined consent for diabetes year of care programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,532411000000102,"Diabetes mellitus, adult onset, with no mention of complication",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,658011000000104,Diabetes mellitus with other specified manifestation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,658061000000102,Diabetes mellitus NOS with other specified manifestation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,713671000000109,Diabetes monitoring administration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,713691000000108,Diabetes clinic administration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,715111000000105,Diabetes screening administration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,716031000000106,Excepted from diabetes quality indicators - informed dissent,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,716911000000104,Exception reporting - diabetes quality indicators,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,717421000000100,Excepted from diabetes quality indicators - patient unsuitable,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,750721000000102,Excepted from diabetes quality indicators: service unavailable,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,754461000000105,Referral to type I diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,755491000000100,Diabetes structured education programme completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,762811000000109,DNA (did not attend) diabetes foot screening,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,764921000000102,Gestational diabetes information leaflet given,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,771571000000102,H/O: secondary diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,781161000000107,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,787061000000100,Diabetes care plan declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,810961000000103,Diabetes self-management plan review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,811391000000104,Referral to community diabetes service,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,811981000000102,Diabetes self-management plan agreed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,816711000000104,Gestational diabetes mellitus annual review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,819301000000105,Diabetes monitoring injection site check declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,819331000000104,Diabetes monitoring injection site not checked,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,828901000000109,Endocrinology and diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,829521000000104,Provision of diabetes clinical summary,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,837491000000107,High risk of diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,838731000000104,Referral to community diabetes specialist nurse declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,841221000000102,Referral to community diabetes clinic,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,850581000000106,High risk of diabetes mellitus annual review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,851501000000106,Diabetes clinical pathway,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,851991000000108,Diabetes quality of life questionnaire score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,857921000000103,Provision of written information about diabetes and driving,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,858301000000107,Pre-diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,860981000000106,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,863501000000102,QDiabetes risk calculator,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,863521000000106,QDiabetes risk calculator score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,867891000000101,Erectile dysfunction due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,876381000000100,Conversion to insulin by diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,885931000000100,Diabetes structured education programme not available,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,887861000000105,Diabetes Year of Care annual review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,909421000000102,DDS2 (Diabetes Distress Scale 2) score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,909441000000109,DDS17 - Diabetes Distress Scale 17,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,910931000000101,DDS17 (Diabetes Distress Scale 17) score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,923461000000103,Lifestyle education for diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,927821000000100,Discharge from secondary care diabetes service,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,956781000000107,Joint consultation with practice nurse and community diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,956921000000109,Joint consultation with General Practitioner and community diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,961931000000109,Diabetes education care plan,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,977201000000107,Recommendation to self-refer for diabetes structured education,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1019431000000105,HbA1c level (Diabetes Control and Complications Trial aligned),RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1019551000000104,HbA1 level (Diabetes Control and Complications Trial aligned),RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1024551000000109,Under care of hospital-based diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1024571000000100,Under care of community-based diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1024941000000100,NHS Diabetes Prevention Programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1025211000000108,NHS Diabetes Prevention Programme not completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1025251000000107,NHS Diabetes Prevention Programme completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1025271000000103,NHS Diabetes Prevention Programme started,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1025301000000100,Referral to NHS Diabetes Prevention Programme declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1025321000000109,Referral to NHS Diabetes Prevention Programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1025601000000108,Leicester Diabetes Risk Score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1054221000000100,Seen in hospital diabetes antenatal clinic,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1065461000000102,Type II diabetes mellitus risk assessment invitation first letter,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1065491000000108,Type II diabetes mellitus risk assessment verbal invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1065501000000102,Type II diabetes mellitus risk assessment telephone invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1066911000000100,Diabetes monitoring SMS (short message service) text message first invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1066921000000106,Diabetes monitoring SMS (short message service) text message second invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1066931000000108,Diabetes monitoring SMS (short message service) text message third invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1083111000000108,Diabetes monitoring invitation email,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1084661000000103,Diabetes UK Diabetes Risk Score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1087971000000105,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) score",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1089101000000109,UKPDS (United Kingdom Prospective Diabetes Study) risk engine score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1090701000000104,NHS Diabetes Prevention Programme invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1092721000000109,Signposting to Diabetes UK,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1092731000000106,Signposting to Diabetes UK Learning Zone,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1097131000000105,Remote diabetes structured education and support programme commenced,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1097141000000101,Remote diabetes structured education and support programme completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1098011000000102,Did not commence remote structured diabetes education and support programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1103691000000102,Diabetes structured education programme offered,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1108731000000100,Referral to online diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1108741000000109,Referral to HeLP-Diabetes (Healthy Living for People with Diabetes) online self-management programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1110921000000100,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,1362341000000103,Diabetes care plan,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA237,diabetes,12275391000119108,Diabetes screening declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190331003,Hyperosmolar coma due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190388001,Type 2 diabetes mellitus with multiple complications,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190389009,Type 2 diabetes mellitus with ulcer,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,199230006,Pre-existing type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,237599002,Insulin treated type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,237627000,Pregnancy and type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,314902007,Peripheral angiopathy due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,314903002,Arthropathy due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,314904008,Type 2 diabetes mellitus with neuropathic arthropathy,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,395204000,Hyperosmolar non-ketotic state due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,420279001,Kidney disorder associated with type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,420436000,Mononeuropathy due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,420715001,Persistent microalbuminuria due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421326000,Disorder of nervous system due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421631007,Gangrene due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421750000,Ketoacidosis due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421779007,Exudative maculopathy due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421847006,Ketoacidotic coma due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421986006,Persistent proteinuria due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,422014003,Disorder due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,422034002,Retinopathy due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,422099009,Disorder of eye due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,422166005,Peripheral circulatory disorder due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,443694000,Uncontrolled type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,703138006,Type 2 diabetes mellitus in remission,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,713703005,Gastroparesis with type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,713706002,Polyneuropathy due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,719216001,Hypoglycaemic coma due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1332470007,Chronic renal disease stage 3A due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,71421000119105,Hypertension in chronic kidney disease due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,90781000119102,Microalbuminuria due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,137931000119102,Hyperlipidaemia due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,140381000119104,Neuropathic ulcer of toe due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,157141000119108,Proteinuria due to type 2 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1064541000000100,Type 2 diabetes mellitus risk assessment declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1065451000000100,Type 2 diabetes mellitus risk assessment invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1065471000000109,Type 2 diabetes mellitus risk assessment invitation second letter,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1065511000000100,Type 2 diabetes mellitus risk assessment invitation SMS (short message service) text message,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,2222151000000100,Type 2 Diabetes in the Young review offered,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,46635009,T1DM - type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,290002008,Unstable type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,314893005,Arthropathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,401110002,Type 1 diabetes mellitus with persistent microalbuminuria,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,420270002,Ketoacidosis due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,420486006,Exudative maculopathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,420514000,Persistent proteinuria due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,420789003,Retinopathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,420825003,Gangrene due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,420868002,Disorder due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,420918009,Mononeuropathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421075007,Ketoacidotic coma due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421305000,Persistent microalbuminuria due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421365002,Peripheral circulatory disorder due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421468001,Disorder of nervous system due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421893009,Renal disorder due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,422228004,Multiple complications due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,429094000,Dietary advice for type 1 diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,444073006,Uncontrolled type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,703137001,Type 1 diabetes mellitus in remission,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,713702000,Gastroparesis with type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,713705003,Polyneuropathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,739681000,Disorder of eye due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1290118005,Presymptomatic T1DM (type 1 diabetes mellitus),RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1571000119104,Mixed hyperlipidaemia due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,18521000119106,Microalbuminuria due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,31211000119101,Peripheral angiopathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,71771000119100,Neuropathic arthropathy due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,82581000119105,Rubeosis iridis with type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,90761000119106,Chronic kidney disease stage 5 due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,137941000119106,Hyperlipidemia due to type 1 diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1373581000000100,T1-DDS (Type 1 Diabetes Distress Scale) Negative Social Perceptions score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,2751001,Fibrocalculous pancreatic diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,4855003,Retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,5368009,Drug-induced diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,5969009,Diabetes mellitus associated with genetic syndrome,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,6143009,Diabetes mellitus education,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,8801005,Secondary diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,9414007,Latent diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,11530004,Brittle diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,11687002,GDM - gestational diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,15771004,Diabetes insipidus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,21584002,Maternal diabetes syndrome,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,25093002,Disorder of eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,25412000,Microaneurysm of retinal artery due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,26298008,Ketoacidotic coma due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,39058009,Lumbosacral radiculoplexus neuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,43959009,Cataract of eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,44054006,T2DM - diabetes mellitus type 2,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,48951005,Bullous disease due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,49455004,Polyneuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,49817004,Neonatal diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,50620007,Autonomic neuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,51002006,Pancreatogenic type 3c diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,59276001,Proliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,61165007,Adiuretin-resistant diabetes insipidus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,62260007,Pretibial pigmental patches due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,70694009,"DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, deafness) syndrome",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,73211009,Diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,74627003,Complication due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,75524006,MRDM - malnutrition related diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,111552007,Diabetes mellitus without complication,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,111556005,Ketoacidosis without coma due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,126534007,Mixed sensorimotor polyneuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,127012008,Lipodystrophic diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,127013003,Disorder of kidney due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,160274005,No family history of diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,160303001,Family history of diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,160402005,Family history: Diabetes in pregnancy,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,161445009,History of diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,161641009,At increased risk of diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,166928007,Glucose tolerance test indicates diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,170745003,Diet controlled diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,170752001,Has seen dietitian - diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,170753006,Understands diet - diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,170766006,Loss of hypoglycaemic warning due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,170774007,Diabetes: practice program,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,170775008,Diabetes: shared care program,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,171183004,Diabetes mellitus screening,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,185753003,Attends diabetes monitoring,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,185754009,Diabetes monitoring declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,185755005,Diabetes monitoring default,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,185756006,Diabetes monitoring first letter,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,185757002,Diabetes monitoring second letter,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,185758007,Diabetes monitoring third letter,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,185759004,Diabetes monitoring verbal invite,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,185760009,Diabetes monitoring telephone invite,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,185761008,Diabetes monitoring deleted,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190323008,Non-insulin dependent diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190349003,Diabetes mellitus with neuropathy,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190354007,Diabetes with gangrene,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190368000,Insulin-dependent diabetes mellitus with ulcer,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190372001,Insulin-dependent diabetes maturity onset,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190406000,Ketoacidosis due to malnutrition related diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190411003,Multiple complications due to malnutrition related diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190412005,Malnutrition-related diabetes mellitus without complications,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190416008,Steroid-induced diabetes mellitus without complication,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190447002,Steroid-induced diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,190484000,Diabetes insipidus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,193141005,Mononeuritis multiplex due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,193183000,Acute painful neuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,193184006,Chronic painful neuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,193185007,Asymptomatic neuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,193349004,Preproliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,193350004,Advanced maculopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,193489006,Iritis due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,197605007,Nephrotic syndrome due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,199223000,"Diabetes mellitus during pregnancy, childbirth and the puerperium",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,199225007,Diabetes mellitus during pregnancy - baby delivered,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,199226008,Diabetes mellitus in the puerperium - baby delivered during current episode of care,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,199227004,Diabetes mellitus during pregnancy - baby not yet delivered,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,200687002,Cellulitis of foot due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,201250006,Ischemic ulcer of foot due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,201251005,Neuropathic ulcer of foot due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,201723002,Cheiroarthropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,201724008,Neuropathic arthropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,230572002,Neuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,230574001,Acute painful polyneuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,230575000,Chronic painful polyneuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,230577008,Mononeuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,230579006,Thoracic radiculopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,232020009,Disorder of macula due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,232021008,Proliferative retinopathy with optic disc neovascularization due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,232022001,Proliferative retinopathy with neovascularisation elsewhere than the optic disc due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,232023006,Traction detachment of retina due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,236499007,Microalbuminuric nephropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,236500003,Proteinuric nephropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,237601000,Secondary endocrine diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,237604008,MODY2 (maturity onset diabetes of the young type 2),RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,237606005,Insulin receptor defect with insulin-resistant diabetes mellitus and acanthosis nigricans,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,237618001,Congenital insulin-dependent diabetes mellitus with fatal secretory diarrhea,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,237619009,Maternally-inherited diabetes and hearing loss,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,237620003,Abnormal metabolic state due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,237621004,Severe hyperglycemia due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,237632004,Hypoglycemic event due to diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,237633009,Hypoglycaemia due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,237635002,Nocturnal hypoglycemia due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,238981002,Disorder of soft tissue due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,238982009,Dermopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,238983004,Thick skin syndrome due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,267471001,Diabetes + eye manifestation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,268519009,Diabetes mellitus uncontrolled,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,270445003,Diabetes monitoring check done,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,273411009,Diabetes clinic satisfaction questionnaire,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,273412002,Diabetes treatment satisfaction questionnaire,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,273413007,Diabetes wellbeing questionnaire,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,284350006,Diabetes mellitus diet education,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,303059007,Postpancreatectomy diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,304752002,Perceived control of insulin-dependent diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,308505000,Diabetes monitoring call,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,309417009,Diabetes dietitian,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,309426007,Glomerulopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,309593006,Education score - diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,309596003,Retinal abnormality - non-diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,309598002,Foot abnormality - non-diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,309635005,History of admission in last year for diabetes foot problem,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,310425007,Diabetes monitoring invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,310505005,Hyperosmolar non-ketotic state due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,311782002,Advanced retinal disease due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,312856000,Referral to diabetes nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,312888008,Attending diabetes clinic,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,312903003,Mild nonproliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,312904009,Moderate nonproliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,312905005,Severe nonproliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,312909004,Proliferative retinopathy with iris neovascularisation due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,312910009,Vitreous hemorrhage due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,312912001,Macular oedema due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,313435000,Insulin-dependent diabetes without complication,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,313436004,Type II diabetes mellitus without complication,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,314010006,Diffuse exudative maculopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,314011005,Focal exudative maculopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,314014002,Ischemic maculopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,314015001,Mixed maculopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,314537004,Optic papillopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,314771006,Insulin dependent diabetes mellitus with hypoglycemic coma,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,315051004,Diabetes resolved,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,315216001,Diabetes mellitus excluded,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,361216007,Femoral mononeuropathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,371087003,Ulcer of foot due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,385805005,Health education - diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,390834004,Nonproliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,394725008,Diabetes medication review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,395123002,Urine screening test for diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,398140007,Post hypoglycaemic hyperglycaemia due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,399868002,Intraretinal microvascular anomaly due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,399871005,Visually threatening retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,405749004,Newly diagnosed diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,407569005,Patient on maximal tolerated therapy for diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,408290003,Diabetes key contact,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,408392008,Under care of diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,408540003,Diabetes mellitus induced by non-steroid drugs,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,413180006,Pan retinal photocoagulation for diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,413597006,Attended diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,414229005,Family/carer attended diabetes structured education program,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,414230000,Family/carer referral to diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,415269004,Referral to diabetes preconception counselling clinic,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,415270003,Referral to diabetes structured education program,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,415744000,Transition of diabetes care options discussed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,416554009,Seen in community diabetes specialist clinic,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,416855002,Family history of diabetes mellitus in first degree relative,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,417467000,Discharged from care of diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,419100001,Infection of foot due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,420422005,Ketoacidosis due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,420756003,Cataract of eye due to diabetes mellitus type 2,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421895002,Peripheral vascular disorder due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,421920002,Cataract of eye due to diabetes mellitus type 1,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,422088007,Disorder of nervous system due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,422126006,Hyperosmolar coma due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,422183001,Skin ulcer due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,422275004,Gangrene due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,426705001,Diabetes mellitus co-occurrent and due to cystic fibrosis,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,426875007,Latent autoimmune diabetes mellitus in adult,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,428274007,Dietary advice for type II diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,430678008,Family history of diabetes mellitus type 1,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,430679000,Family history of diabetes mellitus type 2,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,439051004,Dietary advice for gestational diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,441656006,Hyperglycaemic crisis due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,444094009,History of diabetes mellitus in child of subject,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,472969004,H/O diabetes mellitus type 2,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,472970003,H/O diabetes mellitus type 1,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,472971004,Past pregnancy history of gestational diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,473127005,Suspected diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,609561005,MODY - maturity onset diabetes of young,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,609572000,HNF1B (HNF1 homeobox B) monogenic diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,698610002,Education about self management of diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,699826006,Lifestyle education regarding risk of diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,700414001,Education about diabetes and driving,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,703040004,Agreeing on diabetes care plan,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,703136005,Diabetes mellitus in remission,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,704408003,Invitation for diabetes screening,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,705072004,Diabetes monitoring invitation by short message service text messaging,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,714628002,Prediabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,715159005,Referral to diabetes service,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,715759002,Provision of written information about diabetes and hypertension,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,715879000,Provision of written information about diabetes and high cholesterol,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,719943000,Provision of written information about diabetes and high haemoglobin A1c level,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,720504004,Not suitable for Diabetes Education and Self Management for Ongoing and Newly Diagnosed program,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,720685006,Seen by diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,720724003,Has diabetes identity card,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,724136006,Mastopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,735199000,History of diabetes related lower limb amputation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,735259005,"Congestive heart failure, hypertension, age 2, diabetes mellitus, stroke 2, vascular disease, age, sex category stroke risk score",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,735985000,Diabetes self management plan,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,736284000,Diabetes clinical management plan,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,762291006,Syndrome of infant of mother with gestational diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,762489000,Acute complication due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,763007002,"Assessment using CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,763008007,"CHADS2 (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus and previous stroke or transient ischemic attack) score",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,763117005,FINDRISC (Finnish Diabetes Risk Score) score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,763782001,Provision of patient held diabetes record declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,765147009,Diabetes Treatment Satisfaction Questionnaire status version score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,768794008,Cataract of bilateral eyes due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,769182000,Preproliferative retinopathy of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,769218003,Macular oedema of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,769221001,Clinically significant macular oedema of right eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,769222008,Clinically significant macular edema of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,769244003,Disorder of right macula due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,769245002,Disorder of left macula due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,770096002,Erectile dysfunction due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,774086001,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) stroke risk score",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,816177009,Nonproliferative retinopathy of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,816178004,Nonproliferative retinopathy of right eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,816961009,Stable treated proliferative retinopathy of right eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,816962002,Stable treated proliferative retinopathy of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,860709007,No disorder of macula of left eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,860710002,No maculopathy of right eye due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,860712005,Disorder of macula of both eyes due to diabetes mellitus present,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,878859007,Self management of diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,890171006,KPD - ketosis-prone diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,897238003,Diabetes management using closed-loop delivery system,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1196922005,Neovascular glaucoma due to type II diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1196923000,Neovascular glaucoma due to type I diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1258872006,Family referred to diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1258873001,Caregiver referred to diabetes structured education program,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1268646002,Gestational diabetes mellitus screening,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1296758008,Diabetes insipidus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1306699009,Stable treated proliferative retinopathy due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1332472004,Chronic kidney disease stage 3A due to type I diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,701000119103,Mixed hyperlipidaemia due to type II diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,24451000000107,Diabetes: shared care in pregnancy - diabetologist and obstetrician,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,40801000119106,Gestational diabetes mellitus complicating pregnancy,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,113131000000107,Informed consent for diabetes national audit,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,113141000000103,Informed dissent for diabetes national audit,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,143401000000102,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation using preferred method of communication,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,143911000000105,Registration for access to online diabetes self-management application,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,143941000000106,Declined to register for access to online diabetes self-management application,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,199481000000100,Diabetes monitoring lower risk albumin excretion,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,199491000000103,Diabetes monitoring higher risk albumin excretion,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,276651000000107,Attended DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,279291000000109,Diabetes type 1 review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,279321000000104,Diabetes type II review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,279521000000108,Referral to community diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,300641000000105,Seen by general practitioner with special interest in diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306401000000106,Attended XPERT (expert patient education versus routine treatment) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306441000000109,Attended DAFNE (dose adjustment for normal eating) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306471000000103,DAFNE (dose adjustment for normal eating) diabetes structured education programme completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306501000000105,DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306531000000104,XPERT (expert patient education versus routine treatment) diabetes structured education programme completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306591000000103,Diabetes structured education programme declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306701000000102,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306741000000104,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) diabetes structured programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306771000000105,Referral to XPERT (expert patient education versus routine treatment) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306861000000107,Did not attend diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306931000000106,Did not complete diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306961000000101,Did not complete DAFNE (dose adjustment for normal eating) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,306991000000107,Did not complete DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,307021000000105,Did not complete XPERT diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,307141000000102,Did not attend DAFNE (dose adjustment for normal eating) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,307171000000108,Did not attend DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,307201000000109,Did not attend XPERT (expert patient education versus routine treatment) diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,334711000000100,Referral to diabetes special interest general practitioner,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,335621000000101,Maternally inherited diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,344061000000104,Referral to children's diabetes nurse specialist,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,368711000119106,Mild nonproliferative retinopathy due to secondary diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,385041000000108,Diabetes mellitus with multiple complications,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,385051000000106,Pre-existing diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,494961000000102,Discharged from diabetes shared care programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,512561000000108,Unsuitable for diabetes year of care programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,512581000000104,Declined consent for diabetes year of care programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,532411000000102,"Diabetes mellitus, adult onset, with no mention of complication",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,658011000000104,Diabetes mellitus with other specified manifestation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,658061000000102,Diabetes mellitus NOS with other specified manifestation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,713671000000109,Diabetes monitoring administration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,713691000000108,Diabetes clinic administration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,715111000000105,Diabetes screening administration,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,716031000000106,Excepted from diabetes quality indicators - informed dissent,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,716911000000104,Exception reporting - diabetes quality indicators,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,717421000000100,Excepted from diabetes quality indicators - patient unsuitable,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,750721000000102,Excepted from diabetes quality indicators: service unavailable,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,754461000000105,Referral to type I diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,755491000000100,Diabetes structured education programme completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,762811000000109,DNA (did not attend) diabetes foot screening,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,764921000000102,Gestational diabetes information leaflet given,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,771571000000102,H/O: secondary diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,781161000000107,Referral to DESMOND (diabetes education and self management for ongoing and newly diagnosed) structured programme declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,787061000000100,Diabetes care plan declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,810961000000103,Diabetes self-management plan review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,811391000000104,Referral to community diabetes service,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,811981000000102,Diabetes self-management plan agreed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,816711000000104,Gestational diabetes mellitus annual review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,819301000000105,Diabetes monitoring injection site check declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,819331000000104,Diabetes monitoring injection site not checked,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,828901000000109,Endocrinology and diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,829521000000104,Provision of diabetes clinical summary,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,837491000000107,High risk of diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,838731000000104,Referral to community diabetes specialist nurse declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,841221000000102,Referral to community diabetes clinic,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,850581000000106,High risk of diabetes mellitus annual review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,851501000000106,Diabetes clinical pathway,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,851991000000108,Diabetes quality of life questionnaire score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,857921000000103,Provision of written information about diabetes and driving,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,858301000000107,Pre-diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,860981000000106,Referral to DAFNE (dose adjustment for normal eating) diabetes structured education programme declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,863501000000102,QDiabetes risk calculator,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,863521000000106,QDiabetes risk calculator score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,867891000000101,Erectile dysfunction due to diabetes mellitus,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,876381000000100,Conversion to insulin by diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,885931000000100,Diabetes structured education programme not available,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,887861000000105,Diabetes Year of Care annual review,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,909421000000102,DDS2 (Diabetes Distress Scale 2) score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,909441000000109,DDS17 - Diabetes Distress Scale 17,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,910931000000101,DDS17 (Diabetes Distress Scale 17) score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,923461000000103,Lifestyle education for diabetes,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,927821000000100,Discharge from secondary care diabetes service,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,956781000000107,Joint consultation with practice nurse and community diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,956921000000109,Joint consultation with General Practitioner and community diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,961931000000109,Diabetes education care plan,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,977201000000107,Recommendation to self-refer for diabetes structured education,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1019431000000105,HbA1c level (Diabetes Control and Complications Trial aligned),RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1019551000000104,HbA1 level (Diabetes Control and Complications Trial aligned),RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1024551000000109,Under care of hospital-based diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1024571000000100,Under care of community-based diabetes specialist nurse,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1024941000000100,NHS Diabetes Prevention Programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1025211000000108,NHS Diabetes Prevention Programme not completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1025251000000107,NHS Diabetes Prevention Programme completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1025271000000103,NHS Diabetes Prevention Programme started,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1025301000000100,Referral to NHS Diabetes Prevention Programme declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1025321000000109,Referral to NHS Diabetes Prevention Programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1025601000000108,Leicester Diabetes Risk Score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1054221000000100,Seen in hospital diabetes antenatal clinic,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1065461000000102,Type II diabetes mellitus risk assessment invitation first letter,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1065491000000108,Type II diabetes mellitus risk assessment verbal invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1065501000000102,Type II diabetes mellitus risk assessment telephone invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1066911000000100,Diabetes monitoring SMS (short message service) text message first invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1066921000000106,Diabetes monitoring SMS (short message service) text message second invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1066931000000108,Diabetes monitoring SMS (short message service) text message third invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1083111000000108,Diabetes monitoring invitation email,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1084661000000103,Diabetes UK Diabetes Risk Score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1087971000000105,"ABCD2 (Age, Blood pressure, Clinical features, Duration, Diabetes) score",RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1089101000000109,UKPDS (United Kingdom Prospective Diabetes Study) risk engine score,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1090701000000104,NHS Diabetes Prevention Programme invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1092721000000109,Signposting to Diabetes UK,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1092731000000106,Signposting to Diabetes UK Learning Zone,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1097131000000105,Remote diabetes structured education and support programme commenced,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1097141000000101,Remote diabetes structured education and support programme completed,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1098011000000102,Did not commence remote structured diabetes education and support programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1103691000000102,Diabetes structured education programme offered,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1108731000000100,Referral to online diabetes structured education programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1108741000000109,Referral to HeLP-Diabetes (Healthy Living for People with Diabetes) online self-management programme,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1110921000000100,QOF (Quality and Outcomes Framework) diabetes mellitus quality indicator-related care invitation,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,1362341000000103,Diabetes care plan,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
RANIBIZUMAB,Treatment of visual impairment due to diabetic macular oedema,TA274,diabetes,12275391000119108,Diabetes screening declined,RANIBIZUMAB,OPHTHALMOLOGY,OPHTHALMOLOGY
